Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases

ABSTRACT

Methods of diagnosing or monitoring an autoimmune or chronic inflammatory disease, particularly SLE in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring chronic inflammatory disease, particularly SLE infection and kits or systems containing the same are also described.

RELATED APPLICATIONS

[0001] This application is a Continuation-in-Part Application of Ser. No. 10/006,290 filed Oct. 22, 2002, which claims priority to U.S. provisional patent application No. 60/296,764 filed Jun. 8, 2001, both of which are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

[0002] This application is in the field of chronic inflammatory diseases. In particular, this invention relates to methods and compositions for diagnosing or monitoring chronic inflammatory diseases.

BACKGROUND OF THE INVENTION

[0003] Many of the current shortcomings in diagnosis, prognosis, risk stratification and treatment of disease can be approached through the identification of the molecular mechanisms underlying a disease and through the discovery of nucleotide sequences (or sets of nucleotide sequences) whose expression patterns predict the occurrence or progression of disease states, or predict a patient's response to a particular therapeutic intervention. In particular, identification of nucleotide sequences and sets of nucleotide sequences with such predictive value from cells and tissues that are readily accessible would be extremely valuable. For example, peripheral blood is attainable from all patients and can easily be obtained at multiple time points at low cost. This is a desirable contrast to most other cell and tissue types, which are less readily accessible, or accessible only through invasive and aversive procedures. In addition, the various cell types present in circulating blood are ideal for expression profiling experiments as the many cell types in the blood specimen can be easily separated if desired prior to analysis of gene expression. While blood provides a very attractive substrate for the study of diseases using expression profiling techniques, and for the development of diagnostic technologies and the identification of therapeutic targets, the value of expression profiling in blood samples rests on the degree to which changes in gene expression in these cell types are associated with a predisposition to, and pathogenesis and progression of a disease.

[0004] There is an extensive literature supporting the role of leukocytes, e.g., T-and B-lymphocytes, monocytes and granulocytes, including neutrophils, in a wide range of disease processes, including such broad classes as cardiovascular diseases, inflammatory, autoimmune and rheumatic diseases, infectious diseases, transplant rejection, cancer and malignancy, and endocrine diseases.

[0005] Of particular interest is the role of leukocytes and leukocyte gene expression in chronic inflammatory diseases such as Systemic Lupus Erythematosis and Rheumatoid Arthritis. Systemic lupus erythematosis (SLE) and Rheumatoid Arthritis (RA) are chonic autoimmune and inflammatory disorders characterized by dysregulation of the immune system, which causes damage to a variety of organs. These diseases clearly involve differential expression of genes in leukocytes. Diagnostic and disease monitoring tools are severly lacking for these patients and their physicians. Leukocyte expression profiling can be applied to discover expression markers for SLE and RA and apply them as patient management tools in the clinical setting. In addition, osteoarthirtis is a degenerative joint disease that can be confused with RA. This disease also involves leukocytes and expression profiling of leukocytes associated with osteoarthritis may lead to the discovery of new diagnostic and therapeutic approaches to the disease.

[0006] The accuracy of technologies based on expression profiling for the diagnosis, prognosis, and monitoring of disease would be dramatically increased if numerous differentially expressed nucleotide sequences, each with a measure of sensitivity and specificity for a disease in question, could be identified and assayed in a concerted manner. Using the expression of multiple genes (gene sets) for diagnostic applications helps overcome assay and population variability. In order to achieve this improved accuracy, the appropriate sets of nucleotide sequences need to be identified and validated against numerous samples in combination with relevant clinical data.

SUMMARY OF THE INVENTION

[0007] In order to meet these needs, the present invention identifies genes and gene sets that have clinical utility as diagnostic tools for the management of transplant recipients, lupus patients and patients with a variety of chronic inflammatory and autoimmune diseases. The present invention is thus directed to a method of diagnosing or monitoring chronic autoimmune or inflammatory disease in a patient. The method of the invention involves detecting in a patient expression of one or more genes such as those genes depicted in Table 8 and Table 10A and surrogates derived therefrom. Exemplary surrogates are provided in Table 10C. The present invention is further directed to a method of diagnosing or monitoring an autoimmune or chronic inflammatory disease in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in said patient to diagnose or monitor the autoimmune or chronic inflammatory disease in the patient wherein said genes include a nucleotide sequence selected from SEQ ID NO: 41; SEQ ID NO:328; SEQ ID NO:668; SEQ ID NO:855; SEQ ID NO:981; SEQ ID NO:1001; SEQ ID NO:1003; SEQ ID NO:1025; SEQ ID NO:1035; SEQ ID NO:1227; SEQ ID NO:1341; SEQ ID NO:1390; SEQ ID NO:1436; SEQ ID NO:1535; SEQ ID NO:1750; SEQ ID NO:2102; SEQ ID NO:2331; SEQ ID NO:2386; SEQ ID NO:2412; SEQ ID NO:2560; SEQ ID NO:2648; SEQ ID NO:2895, SEQ ID NO:3249; SEQ ID NO:3305; SEQ ID NO:3541;SEQ ID NO:3692; SEQ ID NO:3701; SEQ ID NO:3741; SEQ ID NO:3825; SEQ ID NO:3827; SEQ ID NO:3832; SEQ ID NO:4149; SEQ ID NO:4400; SEQ ID NO:4601; SEQ ID NO:4604; SEQ ID NO:4631; SEQ ID NO:4637; SEQ ID NO:5067; SEQ ID NO:5074; SEQ ID NO:5468; SEQ ID NO:5531; SEQ ID NO:5607; SEQ ID NO:6382; SEQ ID NO:6956; SEQ ID NO:7238; SEQ ID NO:7330; SEQ ID NO:7641; SEQ ID NO:8015 and SEQ ID NO:8095.

[0008] In the method of the invention, the chronic inflammatory disease or autoimmune disease may be systemic lupus erythematosis (SLE).

[0009] In one format, expression is detecting by measuring RNA levels or protein levels from the genes.

[0010] In the method of the invention, RNA may be isolated from the patient prior to detecting expression of a gene such as those depicted in Table 1 OA. RNA levels may be detected by PCR, hybridization, such as hybridization to an oligonucleotide. The nucleotide sequence may include comprises DNA, cDNA, PNA, genomic DNA, or synthetic oligonucleotides.

[0011] In the methods of the invention, the RNA may be detected by hybridization to an oligonucleotide having a nucleotide sequence selected from SEQ ID NO: 41; SEQ ID NO:328; SEQ ID NO:668; SEQ ID NO:855; SEQ ID NO:981; SEQ ID NO:1001; SEQ ID NO:1003; SEQ ID NO:1025; SEQ ID NO:1035; SEQ ID NO:1227; SEQ ID NO:1341; SEQ ID NO:1390; SEQ ID NO:1436; SEQ ID NO:1535; SEQ ID NO:1750; SEQ ID NO:2102; SEQ ID NO:2331; SEQ ID NO:2386; SEQ ID NO:2412; SEQ ID NO:2560; SEQ ID NO:2648; SEQ ID NO:2895, SEQ ID NO:3249; SEQ ID NO:3305; SEQ ID NO:3541;SEQ ID NO:3692; SEQ ID NO:3701; SEQ ID NO:3741; SEQ ID NO:3825; SEQ ID NO:3827; SEQ ID NO:3832; SEQ ID NO:4149; SEQ ID NO:4400; SEQ ID NO:4601; SEQ ID NO:4604; SEQ ID NO:4631; SEQ ID NO:4637; SEQ ID NO:5067; SEQ ID NO:5074; SEQ ID NO:5468; SEQ ID NO:5531; SEQ ID NO:5607; SEQ ID NO:6382; SEQ ID NO:6956; SEQ ID NO:7238; SEQ ID NO:7330; SEQ ID NO:7641; SEQ ID NO:8015 and SEQ ID NO:8095.

[0012] The present invention is further directed to a diagnostic oligonucleotide for detecting chronic or inflammatory disease wherein the oligonucleotide has a nucleotide sequence selected from SEQ ID NO: 4637, The diagnostic oligonucleotide of may include DNA, cDNA, PNA, genomic DNA, or synthetic oligonucleotides.

[0013] The present invention is further directed to a system or kit for diagnosing or monitoring chronic inflammatory or autoimmune disease in a patient comprising an isolated DNA molecule wherein the isolated DNA molecule detects expression of a gene listed in Table 10A. In the system of the invention, the DNA molecules may be synthetic DNA, genomic DNA, PNA or cDNA. The isolated DNA molecule may be immobilized on an array. Such arrays may include a chip array, a plate array, a bead array, a pin array, a membrane array, a solid surface array, a liquid array, an oligonucleotide array, polynucleotide array or a cDNA array, a microtiter plate, a membrane and a chip.

[0014] The present invention is further directed to a system or detecting differential gene expression. In one format, the system has one or more isolated DNA molecules wherein each isolated DNA molecule detects expression of a gene selected from the group of genes corresponding to the oligonucleotides depicted in the Sequence Listing. It is understood that the DNA sequences and oligonucleotides of the invention may have slightly different sequences than those identified herein. Such sequence variations are understood to those of ordinary skill in the art to be variations in the sequence which do not significantly affect the ability of the sequences to detect gene expression.

[0015] The sequences encompassed by the invention have at least 40-50, 50-60, 70-80, 80-85, 85-90, 90-95 or 95-100% sequence identity to the sequences disclosed herein. In some embodiments, DNA molecules are less than about any of the following lengths (in bases or base pairs): 10,000; 5,000; 2500; 2000; 1500; 1250; 1000; 750; 500; 300; 250; 200; 175; 150; 125; 100; 75; 50; 25; 10. In some embodiments, DNA molecule is greater than about any of the following lengths (in bases or base pairs): 10; 15; 20; 25; 30; 40; 50; 60; 75; 100; 125; 150; 175; 200; 250; 300; 350; 400; 500; 750; 1000; 2000; 5000; 7500; 10000; 20000; 50000. Alternately, a DNA molecule can be any of a range of sizes having an upper limit of 10,000; 5,000; 2500; 2000; 1500; 1250; 1000; 750; 500; 300; 250; 200; 175; 150; 125; 100; 75; 50; 25; or 10 and an independently selected lower limit of 10; 15; 20; 25; 30; 40; 50; 60; 75; 100; 125; 150; 175; 200; 250; 300; 350; 400; 500; 750; 1000; 2000; 5000; 7500 wherein the lower limit is less than the upper limit.

[0016] The gene expression system may be a candidate library, a diagnostic agent, a diagnostic oligonucleotide set or a diagnostic probe set. The DNA molecules may be genomic DNA, protein nucleic acid (PNA), cDNA or synthetic oligonucleotides.

[0017] In one format, the gene expression system is immobilized on an array. The array may be a chip array, a plate array, a bead array, a pin array, a membrane array, a solid surface array, a liquid array, an oligonucleotide array, a polynucleotide array, a cDNA array, a microfilter plate, a membrane or a chip.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

[0018] A brief description of the sequence listing is given below. There are 9090 entries. The Sequence Listing presents 50mer oligonucleotide sequences derived from human leukocyte, plant and viral genes. These are listed as SEQ IDs 1-8143. The 50mer sequences and their sources are also displayed in Table 8. Most of these 50mers were designed from sequences of genes in Tables 2, 3A, B and C and the Sequence listing.

[0019] SEQ IDs 8144-8766 are the cDNA sequences derived from human leukocytes that were not homologous to UniGene sequences or sequences found in dbEST at the time they were searched. Some of these sequences match human genomic sequences and are listed in Tables 3B and C. The remaining clones are putative cDNA sequences that contained less than 50% masked nucleotides when submitted to RepeatMasker, were longer than 147 nucleotides, and did not have significant similarity to the UniGene Unique database, dbEST, the NR nucleotide database of Genbank or the assembled human genome of Genbank.

[0020] SEQ IDs 8767-8770, 8828-8830 and 8832 are sequences that appear in the specification (primer, masked sequences, exemplary sequences, etc.).

[0021] SEQ IDs 8845-8893are the fall length gene sequences for the genes identified by an accession number in Table 10A.

[0022] SEQ IDs 8894-9085 are the primer sequences for lupus genes identified in Table lOB.

BRIEF DESCRIPTION OF THE FIGURES

[0023]FIG. 1: FIG. 1 is a schematic flow chart illustrating an instruction set for characterization of the nucleotide sequence and/or the predicted protein sequence of novel nucleotide sequences.

[0024]FIG. 2: FIG. 2 shows PCR Primer efficiency testing. A standard curve of Ct versus log of the starting RNA amount is shown for 2 genes.

[0025]FIG. 3: FIG. 3 describes kits useful for the practice of the invention. FIG. 3A describes the contents of a kit useful for the discovery of diagnostic nucleotide sets using microarrays. FIG. 3B describes the contents of a kit useful for the application of diagnostic nucleotide sets using microarrays. FIG. 3C describes contents of a kit useful for the application of diagnostic nucleotide sets using real-time PCR.

[0026]FIG. 4: FIG. 4 depicts a graph comparing the median background subtracted expression signals for various leukocyte reference RNAs.

[0027]FIG. 5: FIG. 5 depicts Diagnostic genes, gene sets and diagnostic algorithms for Systemic Lupus Erythematosis are identified. FIG. 5A shows the relative expression level of oligonucleotide and SEQ ID # 4637 (Sialyltransferase 4A) between Lupus and control samples is shown. The gene is identified as having a false detection rate for differential expression from the SAM algorithm of 0.5%. FIG. 5B shows the scaled ratios (non log) for Sialyltransferase (SEQ ID # 4637) are given for the samples in the analysis. The average ratio of each group along with the standard deviation of the ratio is shown. The average fold change from control to Lupus is 1.48. FIG. 5C shows CART gene expression models for diagnosis of SLE. For each model, the number of genes used, the relative cost with 10 fold cross validation, the SEQ ID, Locus accession number, the name and the position and values in the CART model are given. The CART values given are the expression level thresholds for classification of the sample as SLE after the node. For example, in the single gene model II, the first node of the decision tree asks if expression of gene 5067 is >0.103. If yes, the sample is placed in the lupus class. FIG. 5D shows the sensitivity and specificity of Model 1. The sensitivity and specificity are given for both the 2 and 3 gene models and both the training set and on cross validation. The relative cost is given for cross-validation. FIG. 5E shows the CART Model 1,2 genes. The model uses 2 genes in a single node to classify samples as Lupus (Class 1) or non-Lupus (Class 2). FIG. 5F shows CART Model 1,3 genes. The model uses a second node to classify all samples correctly as lupus (class 1) or non-lupus (class 2) for the training set.

[0028]FIG. 6: FIG. 6 shows endpoint testing of PCR primers. Electrophoresis and microfluidics are used to assess the product of gene specific PCR primers. FIG. 6A is a β-GUS gel image. Lane 3 is the image for primers F178 and R242. Lanes 2 and 1 correspond to the no-template control and −RT control, respectively. FIG. 6B shows the electropherogram of β-GUS primers F178 and R242, a graphical representation of Lane 3 from the gel image. FIG. 6C shows a β-Actin gel image. Lane 3 is the image for primers F75 and R178. Lanes 2 and 1 correspond to the no-template control and −RT control, respectively. FIG. 6D shows the electropherogram of P-Actin primers F75 and R178, a graphical representation of Lave 3 from the gel image.

[0029]FIG. 7: FIG. 7 shows the validation of differential expression of a gene discovered using microarrays using Real-time PCR. FIG. 7A shows the Ct for each patient sample on multiple assays is shown along with the Ct in the R50 control RNA. Triangles represent −RT (reverse transcriptase) controls. FIG. 7B shows the fold difference between the expression of Granzyme B and an Actin reference is shown for 3 samples from patients with and without CMV disease.

BRIEF DESCRIPTION OF THE TABLES

[0030] Table 1: Table 1 lists some of the diseases or conditions amenable to study by leukocyte profiling.

[0031] Table 2: Table 2 describes genes and other nucleotide sequences identified using data mining of publically available publication databases and nucleotide sequence databases. Corresponding Unigene (build 133) cluster numbers are listed with each gene or other nucleotide sequence.

[0032] Table 3A: Table 3A describes differentially expressed nucleotide sequences useful for the prediction of clinical outcomes. This table contains 4517 identified cDNAs and cDNA regions of genes that are members of a leukocyte candidate library, for use in measuring the expression of nucleotide sequences that could subsequently be correlated with human clinical conditions. The regions of similarity were found by searching three different databases for pair wise similarity using blastn. The three databases were UniGene Unique build 3/30/01, file Hs.seq.uniq.Z; the downloadable database located at the website ftp.ncbi.nlm.nih.com/blast/db/est human.Z with date 4/8/01 which is a section of Genbank version 122; and the non-redundant section of Genbank ver 123. The Hs.XXXXX numbers represent UniGene accession numbers from the Hs.seq.uniq.Z file of 3/30/01. The clone sequences are not in the sequence listing.

[0033] Table 3B: Table 3B describes Identified Genomic Regions that code for novel mRNAs. The table contains 591 identified genomic regions that are highly similar to the cDNA clones. Those regions that are within 100 to 200 Kb of each other on the same contig are likely to represent exons of the same gene. The indicated clone is exemplary of the cDNA clones that match the indicated genomic region. The “number clones” column indicates how many clones were isolated from the libraries that are similar to the indicated region of the chromosome. The probability number is the likelihood that region of similarity would occur by chance on a random sequence. The Accession numbers are from the Mar. 15, 2001 build of the human genome. The file date for the downloaded data was 4/17/01. These sequences may prove useful for the prediction of clinical outcomes.

[0034] Table 3C: Table 3C describes 48 clones whose sequences align to two or more non-contiguous sequences on the same assembled human contig of genomic sequence. The Accession numbers are from the Mar. 15, 2001 build of the human genome. The file date for the downloaded data was 4/17/01. The alignments of the clone and the contig are indicated in the table. The start and stop offset of each matching region is indicated in the table. The sequence of the clones themselves is included in the sequence listing. The alignments of these clones strongly suggest that they are novel nucleotide sequences. Furthermore, no EST or mRNA aligning to the clone was found in the database. These sequences may prove useful for the prediction of clinical outcomes.

[0035] Table 4: Database mining. The Library Browser at the NCBI UniGene web site was used to identify genes that are specifically expressed in leukocyte cell populations. The table lists the library name and type, the number of sequences in each library and the number used for the array.

[0036] Table 5: Table 5 describes the nucleotide sequence databases used in the sequence analysis described herein.

[0037] Table 6: Table 6 describes the algorithms and software packages used for exon and polypeptide prediction used in the sequence analysis described herein.

[0038] Table 7: Table 7 describes the databases and algorithms used for the protein sequence analysis described herein.

[0039] Table 8: Table 8 provides a listing of all oligonucleotides designed for the arrays and their associated genes. In this table, the sequence ID is given which corresponds to the sequence listing. The origin of the sequence for inclusion on the array is noted as coming from one of the cDNA libraries described in example 1, mining from databases as described in examples 2 and 11 or identification from the published literature. The unigene number, genebank accession and GI number are also given for each sequence when known. These data were obtained from the Unigene unique database, build 137. The name of the gene associated with the accession number is noted. The sequence of these genes as available from the databases are hereby incorporated by reference in their entirety. The strand is noted as −1 or 1, meaning that the probe was designed from the complement of the sequence (−1) or directly from the sequence (1). The nucleotide sequence of each probe is also given in the Sequence Listing.

[0040] Table 9: Table 9 shows viral genes for arrays. Viral genomes were used to design oligonucleotides for the microarrays. The accession numbers for the viral genomes used are given, along with the gene name and location of the region used for oligonucleotide design.

[0041] Table 10A. Table 10A shows Lupus gene expression markers. This table lists the oligonucleotides and associated genes identified as having value for the diagnosis and monitoring of lupus. The first column gives the SEQ ID that corresponds to the oligonuclotide in the sequence listing. The origin of the sequence for inclusion on the array is noted as coming from one of the cDNA libraries described in example 1, mining from databases as described in examples 2 and 11 or identification from the published literature. The unigene number, genebank accession and GI number are also given for each sequence when known. The SEQ ID for the sequence listing for the full-length genes corresponding to the accession numbers in the table are also given (SEQ ID ACC). These data were obtained from the Unigene unique database, build ###. The name of the gene associated with the accession number is noted. The strand is noted as −1 or 1, meaning that the probe was designed from the complement of the sequence (−1) or directly from the sequence (1). Next, the nucleotide sequence of each probe is also given. For each gene, the false detection rate (FDR) from the significance analsysis described in example 10 is given if applicable. Also, those genes that were identified by CART as a diagnostic gene are noted with the model and position in the model (see example IO and FIG. 5).

[0042] Table 10B. Table 10B shows primers for PCR. For each of the lupus gene expression markers identified in Table 10A, 2 sets of PCR primer pairs are shown that were derived by the methods described in example 15. The melting temperature (Tm) for each primer is shown, as is the corresponding SEQ ID number for the primer in the sequence listing.

[0043] Table 10C. Table 10C shows surrogates for the lupus gene expression markers disclosed herein. For some of the lupus marker genes identified in Table 10A, genes are identified by the SEQ ID number as surrogates. The surrogates are identified as such by the CART algorithm or by hierarchical clustering as detailed below.

DETAILED DESCRIPTION OF THE INVENTION

[0044] Definitions

[0045] Unless defined otherwise, all scientific and technical terms are understood to have the same meaning as commonly used in the art to which they pertain. For the purpose of the present invention, the following terms are defined below.

[0046] In the context of the invention, the term “gene expression system” refers to any system, device or means to detect gene expression and includes diagnostic agents, candidate libraries oligonucleotide, oligonucleotide sets or probe sets.

[0047] The terms “diagnostic oligonucleotide” or “diagnostic oligonucleotide set” generally refers to an oligonucleotide or to a set of two or more oligonucleotides that, when evaluated for differential expression their corresponding diagnostic genes, collectively yields predictive data. Such predictive data typically relates to diagnosis, prognosis, monitoring of therapeutic outcomes, and the like. In general, the components of a diagnostic oligonucleotide or a diagnostic oligonucleotide set are distinguished from oligonucleotide sequences that are evaluated by analysis of the DNA to directly determine the genotype of an individual as it correlates with a specified trait or phenotype, such as a disease, in that it is the pattern of expression of the components of the diagnostic oligonucleotide set, rather than mutation or polymorphism of the DNA sequence that provides predictive value. It will be understood that a particular component (or member) of a diagnostic oligonucleotide set can, in some cases, also present one or more mutations, or polymorphisms that are amenable to direct genotyping by any of a variety of well known analysis methods, e.g., Southern blotting, RFLP, AFLP, SSCP, SNP, and the like.

[0048] A “diagnostic gene” is a gene whose expression is detected by a diagnostic oligonucleotide or diagnostic oligonucleotide set.

[0049] A “disease specific target oligonucleotide sequence” is a gene or other oligonucleotide that encodes a polypeptide, most typically a protein, or a subunit of a multi-subunit protein that is a therapeutic target for a disease, or group of diseases.

[0050] A “candidate library” or a “candidate oligonucleotide library” refers to a collection of oligonucleotide sequences (or gene sequences) that by one or more criteria have an increased probability of being associated with a particular disease or group of diseases. The criteria can be, for example, a differential expression pattern in a disease state or in activated or resting leukocytes in vitro as reported in the scientific or technical literature, tissue specific expression as reported in a sequence database, differential expression in a tissue or cell type of interest, or the like. Typically, a candidate library has at least 2 members or components; more typically, the library has in excess of about 110, or about 100, or about 1000, or even more, members or components.

[0051] The term “disease criterion” is used herein to designate an indicator of a disease, such as a diagnostic factor, a prognostic factor, a factor indicated by a medical or family history, a genetic factor, or a symptom, as well as an overt or confirmed diagnosis of a disease associated with several indicators such as those selected from the above list. A disease criterian includes data describing a patient's health status, including retrospective or prospective health data, e.g. in the form of the patient's medical history, laboratory test results, diagnostic test result, clinical events, medications, lists, response(s) to treatment and risk factors, etc.

[0052] An autoimmune disorder is defined as a disease state in which a patient's immune system recognizes an antigen in that patient's organs or tissues as foreign and becomes activated. The activated immune cells can then cause damage to the inciting organ or tissue or can damage other organs or tissues. In some cases, the disorder may be caused by a dysregulation of the immune system cells, rather than by the recognition as a self-antigen as foreign. Dysregulated immune cells can secrete inflammatory cytokines that cause systemic inflammation or they can recognize self-antigens as foreign.

[0053] Examples of autoimmune diseases include: Autoimmune hepatitis, Multiple Sclerosis, Myasthenia Gravis, Type I diabetes, Rheumatoid Arthritis, Psoriasis, Systemic Lupus Erythematosis, Hashimoto's Thyroiditis, Grave's disease, Ankylosing Spondylitis Sjogrens Disease, CREST syndrome, Scleroderma and many more.

[0054] Most of the autoimmune diseases are also chronic inflammatory diseases. This is defined as a disease process associated with long-term (>6 months) activation of inflammatory cells (leukocytes). The chronic inflammation leads to damage of patient organs or tissues. Many diseases are chronic inflammatory disorders, but are not know to have an autoimmune basis. For example, Atherosclerosis, Congestive Heart Failure, Crohn's disease, Ulcerative Colitis, Polyarteritis nodosa, Whipple's Disease, Primary Sclerosing Cholangitis and many more.

[0055] The terms “molecular signature” or “expression profile” refers to the collection of expression values for a plurality (e.g., at least 2, but frequently about 10, about 100, about 1000, or more) of members of a candidate library. In many cases, the molecular signature represents the expression pattern for all of the nucleotide sequences in a library or array of candidate or diagnostic nucleotide sequences or genes. Alternatively, the molecular signature represents the expression pattern for one or more subsets of the candidate library. The term “oligonucleotide” refers to two or more nucleotides. Nucleotides may be DNA or RNA, naturally occurring or synthetic.

[0056] The term “healthy individual,” as used herein, is relative to a specified disease or disease criterion. That is, the individual does not exhibit the specified disease criterion or is not diagnosed with the specified disease. It will be understood, that the individual in question, can, of course, exhibit symptoms, or possess various indicator factors for another disease.

[0057] Similarly, an “individual diagnosed with a disease” refers to an individual diagnosed with a specified disease (or disease criterion). Such an individual may, or may not, also exhibit a disease criterion associated with, or be diagnosed with another (related or unrelated) disease.

[0058] The term “monitoring” is used herein to describe the use of gene sets to provide useful information about an individual or an individual's health or disease status. “Monitoring” can include, determination of prognosis, risk-stratification, selection of drug therapy, assessment of ongoing drug therapy, prediction of outcomes, determining response to therapy, diagnosis of a disease or disease complication, following progression of a disease or providing any information relating to a patients health status.

[0059] An “array” is a spatially or logically organized collection, e.g., of oligonucleotide sequences or nucleotide sequence products such as RNA or proteins encoded by an oligonucleotide sequence. In some embodiments, an array includes antibodies or other binding reagents specific for products of a candidate library.

[0060] When referring to a pattern of expression, a “qualitative” difference in gene expression refers to a difference that is not assigned a relative value. That is, such a difference is designated by an “all or nothing” valuation. Such an all or nothing variation can be, for example, expression above or below a threshold of detection (an on/off pattern of expression). Alternatively, a qualitative difference can refer to expression of different types of expression products, e.g., different alleles (e.g., a mutant or polymorphic allele), variants (including sequence variants as well as post-translationally modified variants), etc.

[0061] In contrast, a “quantitative” difference, when referring to a pattern of gene expression, refers to a difference in expression that can be assigned a value on a graduated scale, (e.g., a 0-5 or 1-10 scale, a +−+++scale, a grade 1-grade 5 scale, or the like; it will be understood that the numbers selected for illustration are entirely arbitrary and in no-way are meant to be interpreted to limit the invention).

[0062] Gene Expression Systems and Methods of Detecting Gene Expression

[0063] The invention is directed to methods of detecting gene expression with a gene expression system having one or more DNA molecules wherein the one or more DNA molecules has a nucleotide sequence which detects expression of a gene corresponding to the oligonucleotides depicted in the Sequence Listing. In one format, the oligonucleotide detects expression of a gene that is differentially expressed in leukocytes. The gene expression system may be a candidate library, a diagnostic agent, a diagnostic oligonucleotide set or a diagnostic probe set. The DNA molecules may be genomic DNA, RNA, protein nucleic acid (PNA), cDNA or synthetic oligonucleotides. Following the procedures taught herein, one can identity sequences of interest for analyzing gene expression in leukocytes. Such sequences may be predictive of a disease state.

[0064] Diagnostic Oligonucleotides of the Invention

[0065] The invention relates to diagnostic oligonucleotides and diagnostic oligonucleotide set(s) comprising members of the leukocyte candidate library listed in Table 2, Table 3 and Tables 8-10 in the Sequence Listing, for which a correlation exists between the health status of an individual, and the individual's expression of RNA or protein products corresponding to the nucleotide sequence. In some instances, only one oligonucleotide is necessary for such detection. Members of a diagnostic oligonucleotide set may be identified by any means capable of detecting expression of RNA or protein products, including but not limited to differential expression screening, PCR, RT-PCR, SAGE analysis, high-throughput sequencing, microarrays, liquid or other arrays, protein-based methods (e.g., western blotting, proteomics, and other methods described herein), and data mining methods, as further described herein.

[0066] In one embodiment, a diagnostic oligonucleotide set comprises at least two oligonucleotide sequences listed in Table 2, Table 3 and Tables 8-10 or the Sequence Listing which are differentially expressed in leukocytes in an individual with at least one disease criterion for at least one leukocyte-implicated disease relative to the expression in individual without the at least one disease criterion, wherein expression of the two or more nucleotide sequences is correlated with at least one disease criterion, as described below.

[0067] In another embodiment, a diagnostic oligonucleotide set comprises at least one oligonucleotide having an oligonucleotide sequence listed in Table 2, 3 and Tables 8-10, or the Sequence Listing which is differentially expressed, and further wherein the differential expression/correlation has not previously been described. In some embodiments, the diagnostic oligonucleotide set is immobilized on an array.

[0068] In another embodiment, diagnostic oligonucleotides (or oligonucleotide sets) are related to the members of the leukocyte candidate library listed in Table 2, Table 3, Tables 8-10 and in the Sequence Listing, for which a correlation exists between the health status (or disease criterion) of an individual. The diagnostic oligonucleotides are partially or totally contained in (or derived from) full-length gene sequences (or predicted full-length gene sequences) for the members of the candidate library listed in Table 2, 3 and the Sequence Listing. This includes sequences from accession numbers and unigene numbers from Table 8. Table 8 shows the accession and unigene number (when known) for each oligonucleotide used on the 8134 gene leukocyte array described in examples 11-13. In some cases, oligonucleotide sequences are designed from EST or Chromosomal sequences from a public database. In these cases the full-length gene sequences may not be known. Full-length sequences in these cases can be predicted using gene prediction algorithms (Examples 4-6). Alternatively the full-length can be determined by cloning and sequencing the full-length gene or genes that contain the sequence of interest using standard molecular biology approaches described here. The same is true for olignonucleotides designed from our sequencing of cDNA libraries (see Examples 1-4) where the cDNA does not match any sequence in the public databases.

[0069] The diagnostic oligonucleotides may also be derived from other genes that are coexpressed with the correlated sequence or full-length gene. Genes may share expression patterns because they are regulated in the same molecular pathway. Because of the similarity of expression, behavior genes are identified as surrogates in that they can substitute for a diagnostic gene in a diagnostic gene set. Example 10 demonstrates the discovery of surrogates from the data and Table 10C and the sequence listing identify and give the sequence for surrogates for lupus diagnostic genes. Surrogate oligonucleotide and surrogate oligonucleotide sets can be utilized to detect expression of surrogate genes and thereby diagnose or monitor patients with a disease.

[0070] As used herein the term “gene cluster” or “cluster” refers to a group of genes related by expression pattern. In other words, a cluster of genes is a group of genes with similar regulation across different conditions, such as a patient having a chronic autoimmune or inflammatory disease or a patient without chronic autoimmune or inflammatory disease. The expression profile for each gene in a cluster should be correlated with the expression profile of at least one other gene in that cluster. Correlation may be evaluated using a variety of statistical methods. As used herein the term “surrogate” refers to a gene with an expression profile such that it can substitute for a diagnostic gene in a diagnostic assay. Such genes are often members of the same gene cluster as the diagnostic gene. For each member of a diagnostic gene set, a set of potential surrogates can be identified through identification of genes with similar expression patterns as described below.

[0071] Many statistical analyses produce a correlation coefficient to describe the relatedness between two gene expression patterns. Patterns may be considered correlated if the correlation coefficient is greater than or equal to 0.8. In preferred embodiments, the correlation coefficient should be greater than 0.85, 0.9 or 0.95. Other statistical methods produce a measure of mutual information to describe the relatedness between two gene expression patterns. Patterns may be considered correlated if the normalized mutual information value is greater than or equal to 0.7. In preferred embodiments, the normalized mutual information value should be greater than 0.8, 0.9 or 0.95. Patterns may also be considered similar if they cluster closely upon hierarchical clustering of gene expression data (Eisen et al. 1998). Similar patterns may be those genes that are among the 1, 2, 5, 10, 20, 50 or 100 nearest neighbors in a hierarchical clustering or have a similarity score (Eisen et al. 1998) of >0.5, 0.7, 0.8, 0.9, 0.95 or 0.99. Similar patterns may also be identified as those genes found to be surrogates in a classification tree by CART (Breiman et al. 1994). Often, but not always, members of a gene cluster have similar biological functions in addition to similar gene expression patterns.

[0072] Correlated genes, clusters and surrogates are identified for the diagnostic genes of the invention. These surrogates may be used as diagnostic genes in an assay instead of, or in addition to, the diagnostic genes for which they are surrogates.

[0073] The invention also provides diagnostic probe sets. It is understood that a probe includes any reagent capable of specifically identifying a nucleotide sequence of the diagnostic nucleotide set, including but not limited to amplified DNA, amplified RNA, cDNA, synthetic oligonucleotide, partial or full-length nucleic acid sequences. In addition, the probe may identify the protein product of a diagnostic nucleotide sequence, including, for example, antibodies and other affinity reagents.

[0074] It is also understood that each probe can correspond to one gene, or multiple probes can correspond to one gene, or both, or one probe can correspond to more than one gene.

[0075] Homologs and variants of the disclosed nucleic acid molecules may be used in the present invention. Homologs and variants of these nucleic acid molecules will possess a relatively high degree of sequence identity when aligned using standard methods. The sequences encompassed by the invention have at least 40-50, 50-60, 70-80, 80-85, 85-90, 90-95 or 95-100% sequence identity to the sequences disclosed herein.

[0076] It is understood that for expression profiling, variations in the disclosed sequences will still permit detection of gene expression. The degree of sequence identity required to detect gene expression varies depending on the length of the oligomer. For a 60mer, (an oligonucleotide with 60 nucleotides) 6-8 random mutations or 6-8 random deletions in a 60 mer do not affect gene expression detection. Hughes, T R, et al. “Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nature Biotechnology, 19:343-347(2001). As the length of the DNA sequence is increased, the number of mutations or deletions permitted while still allowing gene expression detection is increased.

[0077] As will be appreciated by those skilled in the art, the sequences of the present invention may contain sequencing errors. That is, there may be incorrect nucleotides, frameshifts, unknown nucleotides, or other types of sequencing errors in any of the sequences; however, the correct sequences will fall within the homology and stringency definitions herein.

[0078] The minimum length of an oligonucleotide probe necessary for specific hybridization in the human genome can be estimated using two approaches. The first method uses a statistical argument that the probe will be unique in the human genome by chance. Briefly, the number of independent perfect matches (Po) expected for an oligonucleotide of length L in a genome of complexity C can be calculated from the equation (Laird CD, Chromosoma 32:378 (1971):

Po=({fraction (1/4)}) ^(L)*2C

[0079] In the case of mammalian genomes, 2C=˜3.6×10⁹, and an oligonucleotide of 14-15 nucleotides is expected to be represented only once in the genome. However, the distribution of nucleotides in the coding sequence of mammalian genomes is nonrandom (Lathe, R. J. Mol. Biol. 183:1 (1985) and longer oligonucleotides may be preferred in order to in increase the specificity of hybridization. In practical terms, this works out to probes that are 19-40 nucleotides long (Sambrook J et al., infra). The second method for estimating the length of a specific probe is to use a probe long enough to hybridize under the chosen conditions and use a computer to search for that sequence or close matches to the sequence in the human genome and choose a unique match. Probe sequences are chosen based on the desired hybridization properties as described in Chapter 11 of Sambrook et al, infra. The PRIMER3 program is useful for designing these probes (S. Rozen and H. Skaletsky 1996,1997; Primer3 code available at genome.wi.mit.edu/genome_software/other/primer3.html, the website). The sequences of these probes are then compared pair wise against a database of the human genome sequences using a program such as BLAST or MEGABLAST (Madden, T. L et al.(1996) Meth. Enzyrnol. 266:131-141). Since most of the human genome is now contained in the database, the number of matches will be determined. Probe sequences are chosen that are unique to the desired target sequence.

[0080] In some embodiments, a diagnostic oligonucleotide or oligonucleotide probe set is immobilized on an array. The array is optionally comprises one or more of: a chip array, a plate array, a bead array, a pin array, a membrane array, a solid surface array, a liquid array, an oligonucleotide array, a polynucleotide array or a cDNA array, a microtiter plate, a pin array, a bead array, a membrane or a chip.

[0081] In some embodiments, the leukocyte-implicated disease is selected from the diseases listed in Table 1. In other embodiments, the disease is atherosclerosis or cardiac allograft rejection. In other embodiments, the disease is congestive heart failure, angina, myocardial infarction, chronic autoimmune and inflammatory diseases, systemic lupus erythematosis (SLE) and rheumatoid arthritis.

[0082] In some embodiments, diagnostic oligonucleotides of the invention are used as a diagnostic gene set in combination with genes that are know to be associated with a disease state (“known markers”). The use of the diagnostic oligonucleotides in combination with the known markers can provide information that is not obtainable through the known markers alone. The known markers include those identified by the prior art listing provided.

[0083] General Molecular Biology References

[0084] In the context of the invention, nucleic acids and/or proteins are manipulated according to well known molecular biology techniques. Detailed protocols for numerous such procedures are described in, e.g., in Ausubel et al. Current Protocols in Molecular Biology (supplemented through 2000) John Wiley & Sons, New York (“Ausubel”); Sambrook et al. Molecular Cloning—A Laboratory Manual (2nd Ed.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989 (“Sambrook”), and Berger and Kimmel Guide to Molecular Cloning Techniques, Methods in Enzymology volume 152 Academic Press, Inc., San Diego, Calif. (“Berger”).

[0085] In addition to the above references, protocols for in vitro amplification techniques, such as the polymerase chain reaction (PCR), the ligase chain reaction (LCR), Q-replicase amplification, and other RNA polymerase mediated techniques (e.g., NASBA), useful e.g., for amplifying cDNA probes of the invention, are found in Mullis et al. (1987) U.S. Pat. No. 4,683,202; PCR Protocols A Guide to Methods and Applications (Innis et al. eds) Academic Press Inc. San Diego, Calif. (1990) (“Innis”); Arnheim and Levinson (1990) C&EN 36; The Journal Of NIH Research (1991) 3:81; Kwoh et al. (1989) Proc Natl Acad Sci USA 86, 1173; Guatelli et al. (1990) Proc Natl Acad Sci USA 87:1874; Lomell et al. (1989) J Clin Chem 35:1826; Landegren et al. (1988) Science 241:1077; Van Brunt (1990) Biotechnology 8:291; Wu and Wallace (1989) Gene 4: 560; Barringer et al. (1990) Gene 89:117, and Sooknanan and Malek (1995) Biotechnology 13:563. Additional methods, useful for cloning nucleic acids in the context of the present invention, include Wallace et al. U.S. Pat. No. 5,426,039. Improved methods of amplifying large nucleic acids by PCR are summarized in Cheng et al. (1994) Nature 369:684 and the references therein.

[0086] Certain polynucleotides of the invention, e.g., oligonucleotides can be synthesized utilizing various solid-phase strategies involving mononucleotide- and/or trinucleotide-based phosphoramidite coupling chemistry. For example, nucleic acid sequences can be synthesized by the sequential addition of activated monomers and/or trimers to an elongating polynucleotide chain. See e.g., Caruthers, M. H. et al. (1992) Meth Enzymol 211:3.

[0087] In lieu of synthesizing the desired sequences, essentially any nucleic acid can be custom ordered from any of a variety of commercial sources, such as The Midland Certified Reagent Company (mcrc@oligos.com), The Great American Gene Company (genco.com), ExpressGen, Inc. (expressgen.com), Operon Technologies, Inc. (operon.com), and many others.

[0088] Similarly, commercial sources for nucleic acid and protein microarrays are available, and include, e.g., Agilent Technologies, Palo Alto, Calif. and Affymetrix, Santa Clara, Calif.

[0089] Candidate library

[0090] Libraries of candidate genes that are differentially expressed in leukocytes are substrates for the identification and evaluation of diagnostic oligonucleotides and oligonucleotide sets and disease specific target nucleotide sequences.

[0091] The term leukocyte is used generically to refer to any nucleated blood cell that is not a nucleated erythrocyte. More specifically, leukocytes can be subdivided into two broad classes. The first class includes granulocytes, including, most prevalently, neutrophils, as well as eosinophils and basophils at low frequency. The second class, the non-granular or mononuclear leukocytes, includes monocytes and lymphocytes (e.g., T cells and B cells). There is an extensive literature in the art implicating leukocytes, e.g., neutrophils, monocytes and lymphocytes in a wide variety of disease processes, including inflammatory and rheumatic diseases, neurodegenerative diseases (such as Alzheimer's dementia), cardiovascular disease, endocrine diseases, transplant rejection, malignancy and infectious diseases, and other diseases listed in Table 1. Mononuclear cells are involved in the chronic immune response, while granulocytes, which make up approximately 60% of the leukocytes, have a non-specific and stereotyped response to acute inflammatory stimuli and often have a life span of only 24 hours.

[0092] In addition to their widespread involvement and/or implication in numerous disease related processes, leukocytes are particularly attractive substrates for clinical and experimental evaluation for a variety of reasons. Most importantly, they are readily accessible at low cost from essentially every potential subject. Collection is minimally invasive and associated with little pain, disability or recovery time. Collection can be performed by minimally trained personnel (e.g., phlebotomists, medical technicians, etc.) in a variety of clinical and non-clinical settings without significant technological expenditure. Additionally, leukocytes are renewable, and thus available at multiple time points for a single subject.

[0093] Assembly of Candidate Libraries

[0094] At least two conceptually distinct approaches to the assembly of candidate libraries exist. Either, or both, or other, approaches can be favorably employed. The method of assembling, or identifying, candidate libraries is secondary to the criteria utilized for selecting appropriate library members. Most importantly, library members are assembled based on differential expression of RNA or protein products in leukocyte populations. More specifically, candidate nucleotide sequences are induced or suppressed, or expressed at increased or decreased levels in leukocytes from a subject with one or more disease or disease state (a disease criterion) relative to leukocytes from a subject lacking the specified disease criterion. Alternatively, or in addition, library members can be assembled from among nucleotide sequences that are differentially expressed in activated or resting leukocytes relative to other cell types.

[0095] Firstly, publication and sequence databases can be “mined” using a variety of search strategies. For example, currently available scientific and medical publication databases such as Medline, Current Contents, OMIM (online Mendelian inheritance in man) various Biological and Chemical Abstracts, Journal indexes, and the like can be searched using term or key-word searches, or by author, title, or other relevant search parameters. Many such databases are publicly available, and one of skill is well versed in strategies and procedures for identifying publications and their contents, e.g., genes, other nucleotide sequences, descriptions, indications, expression pattern, etc. Numerous databases are available through the internet for free or by subscription, see, e.g., the websites, ncbi.nlm.nih.gov/PubMed/; 3.infotrieve.com/; isinet.com/; sciencemag.org/. Additional or alternative publication or citation databases are also available that provide identical or similar types of information, any of which are favorably employed in the context of the invention. These databases can be searched for publications describing differential gene expression in leukocytes between patients with and without diseases or conditions listed in Table 1. We identified the nucleotide sequences listed in Table 2 and some of the sequences used to design oligonucleotides for microarrays (sequence listing), using data mining methods.

[0096] Alternatively, a variety of publicly available and proprietary sequence databases (including Genlank, dbEST, UniGene, and TIGR and SAGE databases) including sequences corresponding to expressed nucleotide sequences, such as expressed sequence tags (ESTs) are available. For example, the Genbank™ website located at ncbi.nlm.nih.gov/Genbank/among others, can be readily accessed and searched via the internet. These and other sequence and clone database resources are currently available; however, any number of additional or alternative databases comprising nucleotide sequence sequences, EST sequences, clone repositories, PCR primer sequences, and the like corresponding to individual nucleotide sequence sequences are also suitable for the purposes of the invention. Nucleotide sequences can be identified that are only found in libraries derived from leukocytes or sub-populations of leukocytes, for example see Table 2 and Example 2.

[0097] Alternatively, the representation, or relative frequency, of a nucleotide sequence may be determined in a leukocyte-derived nucleic acid library and compared to the representation of the sequence in non-leukocyte derived libraries. The representation of a nucleotide sequence correlates with the relative expression level of the nucleotide sequence in leukocytes and non-leukocytes. An oligonucleotide sequence that has increased or decreased representation in a leukocyte-derived nucleic acid library relative to a non-leukocyte-derived libraries is a candidate for a leukocyte-specific gene.

[0098] Nucleotide sequences identified as having specificity to activated or resting leukocytes or to leukocytes from patients or patient samples with a variety of disease types can be isolated for use in a candidate library for leukocyte expression profiling through a variety of mechanisms. These include, but are not limited to, the amplification of the nucleotide sequence from RNA or DNA using nucleotide sequence specific primers for PCR or RT-PCR, isolation of the nucleotide sequence using conventional cloning methods, the purchase of an IMAGE consortium cDNA clone (EST) with complimentary sequence or from the same expressed nucleotide sequence, design of oligonucleotides, preparation of synthetic nucleic acid sequence, or any other nucleic-acid based method. In addition, the protein product of the nucleotide sequence can be isolated or prepared, and represented in a candidate library, using standard methods in the art, as described further below.

[0099] While the above discussion related primarily to “genomics” approaches, it is appreciated that numerous, analogous “proteomics” approaches are suitable to the present invention. For example, a differentially expressed protein product can, for example, be detected using western analysis, two-dimensional gel analysis, chromatographic separation, mass spectrometric detection, protein-fusion reporter constructs, colorometric assays, binding to a protein array, or by characterization of polysomal mRNA. The protein is further characterized and the nucleotide sequence encoding the protein is identified using standard techniques, e.g. by screening a cDNA library using a probe based on protein sequence information.

[0100] The second approach involves the construction of a differential expression library by any of a variety of means. Any one or more of differential screening, differential display or subtractive hybridization procedures, or other techniques that preferentially identify, isolate or amplify differentially expressed nucleotide sequences can be employed to produce a library of differentially expressed candidate nucleotide sequences, a subset of such a library, a partial library, or the like. Such methods are well known in the art. For example, peripheral blood leukocytes, (i.e., a mixed population including lymphocytes, monocytes and neutrophils), from multiple donor samples are pooled to prevent bias due to a single-donor's unique genotype. The pooled leukocytes are cultured in standard medium and stimulated with individual cytokines or growth factors e.g., with IL-2, IL-1, MCP1, TNFα, and/or IL8 according to well known procedures (see, e.g., Tough et al. (1999); Winston et al. (1999); Hansson et al. (1989)). Typically, leukocytes are recovered from Buffy coat preparations produced by centrifugation of whole blood. Alternatively, mononuclear cells (monocytes and lymphocytes) can be obtained by density gradient centrifugation of whole blood, or specific cell types (such as a T lymphocyte) can be isolated using affinity reagents to cell specific surface markers. When affinity reagents are used to isolate specific cell types, it is desirable to isolate the cells using negative selection to avoid activation of the desired cell type by binding of the antibody. Leukocytes may also be stimulated by incubation with ionomycin, and phorbol myristate acetate (PMA). This stimulation protocol is intended to non-specifically mimic “activation” of numerous pathways due to variety of disease conditions rather than to simulate any single disease condition or paradigm.

[0101] Using well-known subtractive hybridization procedures (as described in, e.g., U.S. Pat. Nos. 5,958,738; 5589,339; 5,827,658; 5,712,127; 5,643,761) each of which are hereby incorporated by reference, a library is produced that is enriched for RNA species (messages) that are differentially expressed between test and control leukocyte populations. In some embodiments, the test population of leukocytes are simply stimulated as described above to emulate non-specific activation events, while in other embodiments the test population can be selected from subjects (or patients) with a specified disease or class of diseases. Typically, the control leukocyte population lacks the defining test condition, e.g., stimulation, disease state, diagnosis, genotype, etc. Alternatively, the total RNA from control and test leukocyte populations are prepared by established techniques, treated with DNAseI, and selected for messenger RNA with an intact 3′ end (i.e., polyA(+) messenger RNA) e.g., using commercially available kits according to the manufacturer's instructions e.g. Clontech. Double stranded cDNA is synthesized utilizing reverse transcriptase. Double stranded cDNA is then cut with a first restriction enzyme (e.g., NlaIII, that cuts at the recognition site: CATG, and cuts the cDNA sequence at approximately 256 bp intervals) that cuts the cDNA molecules into conveniently sized fragments.

[0102] The cDNAs prepared from the test population of leukocytes are divided into (typically 2) “tester” pools, while cDNAs prepared from the control population of leukocytes are designated the “driver” pool. Typically, pooled populations of cells from multiple individual donors are utilized and in the case of stimulated versus unstimulated cells, the corresponding tester and driver pools for any single subtraction reaction are derived from the same donor pool.

[0103] A unique double-stranded adapter is ligated to each of the tester cDNA populations using unphosphorylated primers so that only the sense strand is covalently linked to the adapter. An initial hybridization is performed consisting of each of the tester pools of cDNA (each with its corresponding adapter) and an excess of the driver cDNA. Typically, an excess of about 10-100 fold driver relative to tester is employed, although significantly lower or higher ratios can be empirically determined to provide more favorable results. The initial hybridization results in an initial normalization of the cDNAs such that high and low abundance messages become more equally represented following hybridization due to a failure of driver/tester hybrids to amplify.

[0104] A second hybridization involves pooling un-hybridized sequences from initial hybridizations together with the addition of supplemental driver cDNA. In this step, the expressed sequences enriched in the two tester pools following the initial hybridization can hybridize. Hybrids resulting from the hybridization between members of each of the two tester pools are then recovered by amplification in a polymerase chain reaction (PCR) using primers specific for the unique adapters. Again, sequences originating in a tester pool that form hybrids with components of the driver pool are not amplified. Hybrids resulting between members of the same tester pool are eliminated by the formation of “panhandles” between their common 5′ and 3′ ends. For additional details, see, e.g., Lukyanov et al. (1997) Biochem Biophys Res Commun 230:285-8.

[0105] Typically, the tester and driver pools are designated in the alternative, such that the hybridization is performed in both directions to ensure recovery of messenger RNAs that are differentially expressed in either a positive or negative manner (i.e., that are turned on or turned off, up-regulated or down-regulated). Accordingly, it will be understood that the designation of test and control populations is to some extent arbitrary, and that a test population can just as easily be compared to leukocytes derived from a patient with the same of another disease of interest.

[0106] If so desired, the efficacy of the process can be assessed by such techniques as semi-quantitative PCR of known (i.e., control) nucleotide sequences, of varying abundance such as β-actin. The resulting PCR products representing partial cDNAs of differentially expressed nucleotide sequences are then cloned (i.e., ligated) into an appropriate vector (e.g., a commercially available TA cloning vector, such as pGEM from Promega) and, optionally, transformed into competent bacteria for selection and screening.

[0107] Either of the above approaches, or both in combination, or indeed, any procedure, which permits the assembly of a collection of nucleotide sequences that are expressed in leukocytes, is favorably employed to produce the libraries of candidates useful for the identification of diagnostic nucleotide sets and disease specific target nucleotides of the invention. Additionally, any method that permits the assembly of a collection of nucleotides that are expressed in leukocytes and preferentially associated with one or more disease or condition, whether or not the nucleotide sequences are differentially expressed, is favorably employed in the context of the invention. Typically, libraries of about 2,000-10,000 members are produced (although libraries in excess of 10,000 are not uncommon). Following additional evaluation procedures, as described below, the proportion of unique clones in the candidate library can approximate 100%.

[0108] A candidate oligonucleotide sequence may be represented in a candidate library by a full-length or partial nucleic acid sequence, deoxyribonucleic acid (DNA) sequence, cDNA sequence, RNA sequence, synthetic oligonucleotides, etc. The nucleic acid sequence can be at least 19 nucleotides in length, at least 25 nucleotides, at least 40 nucleotides, at least 100 nucleotides, or larger. Alternatively, the protein product of a candidate nucleotide sequence may be represented in a candidate library using standard methods, as further described below.

[0109] Characterization of Candidate Oligonucleotide Sequences

[0110] The sequence of individual members (e.g., clones, partial sequence listing in a database such as an EST, etc.) of the candidate oligonucleotide libraries is then determined by conventional sequencing methods well known in the art, e.g., by the dideoxy-chain termination method of Sanger et al. (1977) Proc Natl Acad Sci USA 74:5463-7; by chemical procedures, e.g., Maxam and Gilbert (1977) Proc Natl Acad Sci USA 74:560-4; or by polymerase chain reaction cycle sequencing methods, e.g., Olsen and Eckstein (1989) Nuc Acid Res 17:9613-20, DNA chip based sequencing techniques or variations, including automated variations (e.g., as described in Hunkapiller et al. (1991) Science 254:59-67; Pease et al. (1994) Proc Natl Acad Sci USA 91:5022-6), thereof. Numerous kits for performing the above procedures are commercially available and well known to those of skill in the art. Character strings corresponding to the resulting nucleotide sequences are then recorded (i.e., stored) in a database. Most commonly the character strings are recorded on a computer readable medium for processing by a computational device.

[0111] Generally, to facilitate subsequent analysis, a custom algorithm is employed to query existing databases in an ongoing fashion, to determine the identity, expression pattern and potential function of the particular members of a candidate library. The sequence is first processed, by removing low quality sequence. Next the vector sequences are identified and removed and sequence repeats are identified and masked. The remaining sequence is then used in a Blast algorithm against multiple publicly available, and/or proprietary databases, e.g., NCBI nucleotide, EST and protein databases, Unigene, and Human Genome Sequence. Sequences are also compared to all previously sequenced members of the candidate libraries to detect redundancy.

[0112] In some cases, sequences are of high quality, but do not match any sequence in the NCBI nr, human EST or Unigene databases. In this case the sequence is queried against the human genomic sequence. If a single chromosomal site is matched with a high degree of confidence, that region of genomic DNA is identified and subjected to further analysis with a gene prediction program such as GRAIL. This analysis may lead to the identification of a new gene in the genomic sequence. This sequence can then be translated to identify the protein sequence that is encoded and that sequence can be further analyzed using tools such as Pfam, Blast P, or other protein structure prediction programs, as illustrated in Table 7. Typically, the above analysis is directed towards the identification of putative coding regions, e.g., previously unidentified open reading frames, confirming the presence of known coding sequences, and determining structural motifs or sequence similarities of the predicted protein (i.e., the conceptual translation product) in relation to known sequences. In addition, it has become increasingly possible to assemble “virtual cDNAs” containing large portions of coding region, simply through the assembly of available expressed sequence tags (ESTs). In turn, these extended nucleic acid and amino acid sequences allow the rapid expansion of substrate sequences for homology searches and structural and functional motif characterization. The results of these analysis permits the categorization of sequences according to structural characteristics, e.g., as structural proteins, proteins involved in signal transduction, cell surface or secreted proteins etc.

[0113] It is understood that full-length nucleotide sequences may also be identified using conventional methods, for example, library screening, RT-PCR, chromosome walking, etc., as described in Sambrook and Ausubel, infra.

[0114] Candidate Nucleotide Library of the Invention

[0115] We identified members of a candidate nucleotide library that are differentially expressed in activated leukocytes and resting leukocytes. Accordingly, the invention provides the candidate leukocyte nucleotide library comprising the nucleotide sequences listed in Table 2, Table 3, Tables 8-10 and in the Sequence Listing. In another embodiment, the invention provides a candidate library comprising at least two nucleotide sequences listed in Table 2, Table 3, Tables 8-10 and the Sequence Listing. In another embodiment, at least two nucleotide sequences are 18 nucleotides in length, at least 35 nucleotides, at least 40 nucleotides or at least 100 nucleotides. In some embodiments, the nucleotide sequences comprises deoxyribonucleic acid (DNA) sequence, ribonucleic acid (RNA) sequence, synthetic oligonucleotide sequence, or genomic DNA sequence. It is understood that the nucleotide sequences may each correspond to one gene, or that several nucleotide sequences may correspond to one gene, or that a single nucleotide sequence may correspond to multiple genes.

[0116] The invention also provides probes to the candidate nucleotide library. In one embodiment of the invention, the probes comprise at least two nucleotide sequences listed in Table 2, Table 3, Tables 8-10, or the Sequence Listing which are differentially expressed in leukocytes in an individual with a least one disease criterion for at least one leukocyte-related disease and in leukocytes in an individual without the at least one disease criterion, wherein expression of the two or more nucleotide sequences is correlated with at least one disease criterion. It is understood that a probe may detect either the RNA expression or protein product expression of the candidate nucleotide library. Alternatively, or in addition, a probe can detect a genotype associated with a candidate nucleotide sequence, as further described below. In another embodiment, the probes for the candidate nucleotide library are immobilized on an array.

[0117] The candidate nucleotide library of the invention is useful in identifying diagnostic nucleotide sets of the invention, as described below. The candidate nucleotide sequences may be further characterized, and may be identified as a disease target nucleotide sequence and/or a novel nucleotide sequence, as described below. The candidate nucleotide sequences may also be suitable for use as imaging reagents, as described below.

[0118] Generation of Expression Patterns

[0119] RNA, DNA or Protein Sample Procurement

[0120] Following identification or assembly of a library of differentially expressed candidate nucleotide sequences, leukocyte expression profiles corresponding to multiple members of the candidate library are obtained. Leukocyte samples from one or more subjects are obtained by standard methods. Most typically, these methods involve transcutaneous venous sampling of peripheral blood. While sampling of circulating leukocytes from whole blood from the peripheral vasculature is generally the simplest, least invasive, and lowest cost alternative, it will be appreciated that numerous alternative sampling procedures exist, and are favorably employed in some circumstances. No pertinent distinction exists, in fact, between leukocytes sampled from the peripheral vasculature, and those obtained, e.g., from a central line, from a central artery, or indeed from a cardiac catheter, or during a surgical procedure which accesses the central vasculature. In addition, other body fluids and tissues that are, at least in part, composed of leukocytes are also desirable leukocyte samples. For example, fluid samples obtained from the lung during bronchoscopy may be rich in leukocytes, and amenable to expression profiling in the context of the invention, e.g., for the diagnosis, prognosis, or monitoring of lung transplant rejection, inflammatory lung diseases or infectious lung disease. Fluid samples from other tissues, e.g., obtained by endoscopy of the colon, sinuses, esophagus, stomach, small bowel, pancreatic duct, biliary tree, bladder, ureter, vagina, cervix or uterus, etc., are also suitable. Samples may also be obtained other sources containing leukocytes, e.g., from urine, bile, cerebrospinal fluid, feces, gastric or intestinal secretions, semen, or solid organ or joint biopsies.

[0121] Most frequently, mixed populations of leukocytes, such as are found in whole blood are utilized in the methods of the present invention. A crude separation, e.g., of mixed leukocytes from red blood cells, and/or concentration, e.g., over a sucrose, percoll or ficoll gradient, or by other methods known in the art, can be employed to facilitate the recovery of RNA or protein expression products at sufficient concentrations, and to reduce non-specific background. In some instances, it can be desirable to purify sub-populations of leukocytes, and methods for doing so, such as density or affinity gradients, flow cytometry, Fluorescence Activated Cell Sorting (FACS), immuno-magnetic separation, “panning,” and the like, are described in the available literature and below.

[0122] Obtaining DNA, RNA and Protein Samples for Expression Profiling

[0123] A variety of techniques are available for the isolation of RNA from whole blood. Any technique that allows isolation of mRNA from cells (in the presence or absence of rRNA and tRNA) can be utilized. In brief, one method that allows reliable isolation of total RNA suitable for subsequent gene expression analysis is described as follows. Peripheral blood (either venous or arterial) is drawn from a subject, into one or more sterile, endotoxin free, tubes containing an anticoagulant (e.g., EDTA, citrate, heparin, etc.). Typically, the sample is divided into at least two portions. One portion, e.g., of 5-8 ml of whole blood is frozen and stored for future analysis, e.g., of DNA or protein. A second portion, e.g., of approximately 8 ml whole blood is processed for isolation of total RNA by any of a variety of techniques as described in, e.g, Sambook, Ausubel, below, as well as U.S. Pat. Nos. 5,728,822 and 4,843,155.

[0124] Typically, a subject sample of mononuclear leukocytes obtained from about 8 ml of whole blood, a quantity readily available from an adult human subject under most circumstances, yields 5-20 μg of total RNA. This amount is ample, e.g., for labeling and hybridization to at least two probe arrays. Labeled probes for analysis of expression patterns of nucleotides of the candidate libraries are prepared from the subject's sample of RNA using standard methods. In many cases, cDNA is synthesized from total RNA using a polyT primer and labeled, e.g., radioactive or fluorescent, nucleotides. The resulting labeled cDNA is then hybridized to probes corresponding to members of the candidate nucleotide library, and expression data is obtained for each nucleotide sequence in the library. RNA isolated from subject samples (e.g., peripheral blood leukocytes, or leukocytes obtained from other biological fluids and samples) is next used for analysis of expression patterns of nucleotides of the candidate libraries.

[0125] In some cases, however, the amount of RNA that is extracted from the leukocyte sample is limiting, and amplification of the RNA is desirable. Amplification may be accomplished by increasing the efficiency of probe labeling, or by amplifying the RNA sample prior to labeling. It is appreciated that care must be taken to select an amplification procedure that does not introduce any bias (with respect to gene expression levels) during the amplification process.

[0126] Several methods are available that increase the signal from limiting amounts of RNA, e.g. use of the Clontech (Glass Fluorescent Labeling Kit) or Stratagene (Fairplay Microarray Labeling Kit), or the Micromax kit (New England Nuclear, Inc.). Alternatively, cDNA is synthesized from RNA using a T7-polyT primer, in the absence of label, and DNA dendrimers from Genisphere (3DNA Submicro) are hybridized to the poly T sequence on the primer, or to a different “capture sequence” which is complementary to a fluorescently labeled sequence. Each 3DNA molecule has 250 fluorescent molecules and therefore can strongly label each cDNA.

[0127] Alternatively, the RNA sample is amplified prior to labeling. For example, linear amplification may be performed, as described in U.S. Pat. No. 6,132,997. A T7-polyT primer is used to generate the cDNA copy of the RNA. A second DNA strand is then made to complete the substrate for amplification. The T7 promoter incorporated into the primer is used by a T7 polymerase to produce numerous antisense copies of the original RNA. Fluorescent dye labeled nucleotides are directly incorporated into the RNA. Alternatively, amino allyl labeled nucleotides are incorporated into the RNA, and then fluorescent dyes are chemically coupled to the amino allyl groups, as described in Hughes et al. 2001. Other exemplary methods for amplification are described below.

[0128] It is appreciated that the RNA isolated must contain RNA derived from leukocytes, but may also contain RNA from other cell types to a variable degree. Additionally, the isolated RNA may come from subsets of leukocytes, e.g. monocytes and/or T-lymphocytes, as described above. Such consideration of cell type used for the derivation of RNA depends on the method of expression profiling used.

[0129] DNA samples may be obtained for analysis of the presence of DNA mutations, single nucleotide polymorphisms (SNPs), or other polymorphisms. DNA is isolated using standard techniques, e.g. Maniatus, supra.

[0130] Expression of products of candidate nucleotides may also be assessed using proteomics. Protein(s) are detected in samples of patient serum or from leukocyte cellular protein. Serum is prepared by centrifugation of whole blood, using standard methods. Proteins present in the serum may have been produced from any of a variety of leukocytes and non-leukocyte cells, and may include secreted proteins from leukocytes. Alternatively, leukocytes or a desired sub-population of leukocytes are prepared as described above. Cellular protein is prepared from leukocyte samples using methods well known in the art, e.g., Trizol (Invitrogen Life Technologies, cat # 15596108; Chomczynski, P. and Sacchi, N. (1987) Anal. Biochem. 162, 156; Simms, D., Cizdziel, P. E., and Chomczynski, P. (1993) Focus® 15, 99; Chomczynski, P., Bowers-Finn, R., and Sabatini, L. (1987) J. of NIH Res. 6, 83; Chomczynski, P. (1993) Bio/Techniques 15, 532; Bracete, A. M., Fox, D. K., and Simms, D. (1998) Focus 20, 82; Sewall, A. and McRae, S. (1998) Focus 20, 36; Anal Biochem April 1984; 138(1):141-3, A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids; Wessel D, Flugge Ul. (1984) Anal Biochem. April 1984;138(1):141-143.

[0131] Obtaining Expression Patterns

[0132] Expression patterns, or profiles, of a plurality of nucleotides corresponding to members of the candidate library are then evaluated in one or more samples of leukocytes. Typically, the leukocytes are derived from patient peripheral blood samples, although, as indicated above, many other sample sources are also suitable. These expression patterns constitute a set of relative or absolute expression values for some number of RNAs or protein products corresponding to the plurality of nucleotide sequences evaluated, which is referred to herein as the subject's “expression profile” for those nucleotide sequences. While expression patterns for as few as one independent member of the candidate library can be obtained, it is generally preferable to obtain expression patterns corresponding to a larger number of nucleotide sequences, e.g., about 2, about 5, about 10, about 20, about 50, about 100, about 200, about 500, or about 1000, or more. The expression pattern for each differentially expressed component member of the library provides a finite specificity and sensitivity with respect to predictive value, e.g., for diagnosis, prognosis, monitoring, and the like.

[0133] Clinical Studies, Data and Patient Groups

[0134] For the purpose of discussion, the term subject, or subject sample of leukocytes, refers to an individual regardless of health and/or disease status. A subject can be a patient, a study participant, a control subject, a screening subject, or any other class of individual from whom a leukocyte sample is obtained and assessed in the context of the invention. Accordingly, a subject can be diagnosed with a disease, can present with one or more symptom of a disease, or a predisposing factor, such as a family (genetic) or medical history (medical) factor, for a disease, or the like. Alternatively, a subject can be healthy with respect to any of the aforementioned factors or criteria. It will be appreciated that the term “healthy” as used herein, is relative to a specified disease, or disease factor, or disease criterion, as the term “healthy” cannot be defined to correspond to any absolute evaluation or status. Thus, an individual defined as healthy with reference to any specified disease or disease criterion, can in fact be diagnosed with any other one or more disease, or exhibit any other one or more disease criterion.

[0135] Furthermore, while the discussion of the invention focuses, and is exemplified using human sequences and samples, the invention is equally applicable, through construction or selection of appropriate candidate libraries, to non-human animals, such as laboratory animals, e.g., mice, rats, guinea pigs, rabbits; domesticated livestock, e.g., cows, horses, goats, sheep, chicken, etc.; and companion animals, e.g., dogs, cats, etc.

[0136] Methods for Obtaining Expression Data

[0137] Numerous methods for obtaining expression data are known, and any one or more of these techniques, singly or in combination, are suitable for determining expression profiles in the context of the present invention. For example, expression patterns can be evaluated by northern analysis, PCR, RT-PCR, Taq Man analysis, FRET detection, monitoring one or more molecular beacon, hybridization to an oligonucleotide array, hybridization to a cDNA array, hybridization to a polynucleotide array, hybridization to a liquid microarray, hybridization to a microelectric array, molecular beacons, cDNA sequencing, clone hybridization, cDNA fragment fingerprinting, serial analysis of gene expression (SAGE), subtractive hybridization, differential display and/or differential screening (see, e.g., Lockhart and Winzeler (2000) Nature 405:827-836, and references cited therein).

[0138] For example, specific PCR primers are designed to a member(s) of a candidate nucleotide library. cDNA is prepared from subject sample RNA by reverse transcription from a poly-dT oligonucleotide primer, and subjected to PCR. Double stranded cDNA may be prepared using primers suitable for reverse transcription of the PCR product, followed by amplification of the cDNA using in vitro transcription. The product of in vitro transcription is a sense-RNA corresponding to the original member(s) of the candidate library. PCR product may be also be evaluated in a number of ways known in the art, including real-time assessment using detection of labeled primers, e.g. TaqMan or molecular beacon probes. Technology platforms suitable for analysis of PCR products include the ABI 7700, 5700, or 7000 Sequence Detection Systems (Applied Biosystems, Foster City, Calif.), the MJ Research Opticon (MJ Research, Waltham, Mass.), the Roche Light Cycler (Roche Diagnositics, Indianapolis, Ind.), the Stratagene MX4000 (Stratagene, La Jolla, Calif.), and the Bio-Rad iCycler (Bio-Rad Laboratories, Hercules, Calif.). Alternatively, molecular beacons are used to detect presence of a nucleic acid sequence in an unamplified RNA or cDNA sample, or following amplification of the sequence using any method, e.g. IVT (In Vitro transcription) or NASBA (nucleic acid sequence based amplification). Molecular beacons are designed with sequences complementary to member(s) of a candidate nucleotide library, and are linked to fluorescent labels. Each probe has a different fluorescent label with non-overlapping emission wavelengths. For example, expression of ten genes may be assessed using ten different sequence-specific molecular beacons.

[0139] Alternatively, or in addition, molecular beacons are used to assess expression of multiple nucleotide sequences at once. Molecular beacons with sequence complimentary to the members of a diagnostic nucleotide set are designed and linked to fluorescent labels. Each fluorescent label used must have a non-overlapping emission wavelength. For example, 10 nucleotide sequences can be assessed by hybridizing 10 sequence specific molecular beacons (each labeled with a different fluorescent molecule) to an amplified or un-amplified RNA or cDNA sample. Such an assay bypasses the need for sample labeling procedures.

[0140] Alternatively, or in addition bead arrays can be used to assess expression of multiple sequences at once (See, e.g, LabMAP 100, Luminex Corp, Austin, Tex.). Alternatively, or in addition electric arrays are used to assess expression of multiple sequences, as exemplified by the e-Sensor technology of Motorola (Chicago, Ill.) or Nanochip technology of Nanogen (San Diego, Calif.)

[0141] Of course, the particular method elected will be dependent on such factors as quantity of RNA recovered, practitioner preference, available reagents and equipment, detectors, and the like. Typically, however, the elected method(s) will be appropriate for processing the number of samples and probes of interest. Methods for high-throughput expression analysis are discussed below.

[0142] Alternatively, expression at the level of protein products of gene expression is performed. For example, protein expression, in a sample of leukocytes, can be evaluated by one or more method selected from among: western analysis, two-dimensional gel analysis, chromatographic separation, mass spectrometric detection, protein-fusion reporter constructs, colorimetric assays, binding to a protein array and characterization of polysomal mRNA. One particularly favorable approach involves binding of labeled protein expression products to an array of antibodies specific for members of the candidate library. Methods for producing and evaluating antibodies are widespread in the art, see, e.g., Coligan, supra; and Harlow and Lane (1989) Antibodies: A Laboratory Manual, Cold Spring Harbor Press, NY (“Harlow and Lane”). Additional details regarding a variety of immunological and immunoassay procedures adaptable to the present invention by selection of antibody reagents specific for the products of candidate nucleotide sequences can be found in, e.g., Stites and Terr (eds.)(1991) Basic and Clinical Immunology, 7^(th) ed., and Paul, supra. Another approach uses systems for performing desorption spectrometry. Commercially available systems, e.g., from Ciphergen Biosystems, Inc. (Fremont, Calif.) are particularly well suited to quantitative analysis of protein expression. Indeed, Protein Chip® arrays (see, e.g., the website, ciphergen.com) used in desorption spectrometry approaches provide arrays for detection of protein expression. Alternatively, affinity reagents, (e.g., antibodies, small molecules, etc.) are developed that recognize epitopes of the protein product. Affinity assays are used in protein array assays, e.g. to detect the presence or absence of particular proteins. Alternatively, affinity reagents are used to detect expression using the methods described above. In the case of a protein that is expressed on the cell surface of leukocytes, labeled affinity reagents are bound to populations of leukocytes, and leukocytes expressing the protein are identified and counted using fluorescent activated cell sorting (FACS).

[0143] It is appreciated that the methods of expression evaluation discussed herein, although discussed in the context of discovery of diagnostic nucleotide sets, are also applicable for expression evaluation when using diagnostic nucleotide sets for, e.g. diagnosis of diseases, as further discussed below.

[0144] High Throughput Expression Assays

[0145] A number of suitable high throughput formats exist for evaluating gene expression. Typically, the term high throughput refers to a format that performs at least about 100 assays, or at least about 500 assays, or at least about 1000 assays, or at least about 5000 assays, or at least about 10,000 assays, or more per day. When enumerating assays, either the number of samples or the number of candidate nucleotide sequences evaluated can be considered. For example, a northern analysis of, e.g., about 100 samples performed in a gridded array, e.g., a dot blot, using a single probe corresponding to a candidate nucleotide sequence can be considered a high throughput assay. More typically, however, such an assay is performed as a series of duplicate blots, each evaluated with a distinct probe corresponding to a different member of the candidate library. Alternatively, methods that simultaneously evaluate expression of about 100 or more candidate nucleotide sequences in one or more samples, or in multiple samples, are considered high throughput.

[0146] Numerous technological platforms for performing high throughput expression analysis are known. Generally, such methods involve a logical or physical array of either the subject samples, or the candidate library, or both. Common array formats include both liquid and solid phase arrays. For example, assays employing liquid phase arrays, e.g., for hybridization of nucleic acids, binding of antibodies or other receptors to ligand, etc., can be performed in multiwell, or microtiter, plates. Microtiter plates with 96, 384 or 1536 wells are widely available, and even higher numbers of wells, e.g, 3456 and 9600 can be used. In general, the choice of microtiter plates is determined by the methods and equipment, e.g., robotic handling and loading systems, used for sample preparation and analysis. Exemplary systems include, e.g., the ORCA™ system from Beckman-Coulter, Inc. (Fullerton, Calif.) and the Zymate systems from Zymark Corporation (Hopkinton, Mass.).

[0147] Alternatively, a variety of solid phase arrays can favorably be employed in to determine expression patterns in the context of the invention. Exemplary formats include membrane or filter arrays (e.g, nitrocellulose, nylon), pin arrays, and bead arrays (e.g., in a liquid “slurry”). Typically, probes corresponding to nucleic acid or protein reagents that specifically interact with (e.g., hybridize to or bind to) an expression product corresponding to a member of the candidate library are immobilized, for example by direct or indirect cross-linking, to the solid support. Essentially any solid support capable of withstanding the reagents and conditions necessary for performing the particular expression assay can be utilized. For example, functionalized glass, silicon, silicon dioxide, modified silicon, any of a variety of polymers, such as (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, polystyrene, polycarbonate, or combinations thereof can all serve as the substrate for a solid phase array.

[0148] In a preferred embodiment, the array is a “chip” composed, e.g., of one of the above-specified materials. Polynucleotide probes, e.g., RNA or DNA, such as cDNA, synthetic oligonucleotides, and the like, or binding proteins such as antibodies, that specifically interact with expression products of individual components of the candidate library are affixed to the chip in a logically ordered manner, i.e., in an array. In addition, any molecule with a specific affinity for either the sense or anti-sense sequence of the marker nucleotide sequence (depending on the design of the sample labeling), can be fixed to the array surface without loss of specific affinity for the marker and can be obtained and produced for array production, for example, proteins that specifically recognize the specific nucleic acid sequence of the marker, ribozymes, peptide nucleic acids (PNA), or other chemicals or molecules with specific affinity.

[0149] Detailed discussion of methods for linking nucleic acids and proteins to a chip substrate, are found in, e.g., U.S. Pat. No. 5,143,854 “Large Scale Photolithographic Solid Phase Synthesis Of Polypeptides And Receptor Binding Screening Thereof” to Pirrung et al., issued, Sep. 1, 1992; U.S. Pat. No. 5,837,832 “Arrays Of Nucleic Acid Probes On Biological Chips” to Chee et al., issued Nov. 17, 1998; U.S. Pat. No. 6,087,112 “Arrays With Modified Oligonucleotide And Polynucleotide Compositions” to Dale, issued Jul. 11, 2000; U.S. Pat. No. 5,215,882 “Method Of Immobilizing Nucleic Acid On A Solid Substrate For Use In Nucleic Acid Hybridization Assays” to Bahl et al., issued Jun. 1, 1993; U.S. Pat. No. 5,707,807 “Molecular Indexing For Expressed Gene Analysis” to Kato, issued Jan. 13, 1998; U.S. Pat. No. 5,807,522 “Methods For Fabricating Microarrays Of Biological Samples” to Brown et al., issued Sep. 15, 1998; U.S. Pat. No. 5,958,342 “Jet Droplet Device” to Gamble et al., issued Sep. 28, 1999; U.S. Pat. No. 5,994,076 “Methods Of Assaying Differential Expression” to Chenchik et al., issued Nov. 30, 1999; U.S. Pat. No. 6,004,755 “Quantitative Microarray Hybridization Assays” to Wang, issued Dec. 21, 1999; U.S. Pat. No. 6,048,695 “Chemically Modified Nucleic Acids And Method For Coupling Nucleic Acids To Solid Support” to Bradley et al., issued Apr. 11, 2000; U.S. Pat. No. 6,060,240 “Methods For Measuring Relative Amounts Of Nucleic Acids In A Complex Mixture And Retrieval Of Specific Sequences Therefrom” to Kamb et al., issued May 9, 2000; U.S. Pat. No. 6,090,556 “Method For Quantitatively Determining The Expression Of A Gene” to Kato, issued Jul. 18, 2000; and U.S. Pat. No. 6,040,138 “Expression Monitoring By Hybridization To High Density Oligonucleotide Arrays” to Lockhart et al., issued Mar. 21, 2000 each of which are hereby incorporated by reference in their entirety.

[0150] For example, cDNA inserts corresponding to candidate nucleotide sequences, in a standard TA cloning vector are amplified by a polymerase chain reaction for approximately 30-40 cycles. The amplified PCR products are then arrayed onto a glass support by any of a variety of well-known techniques, e.g., the VSLIPS™ technology described in U.S. Pat. No. 5,143,854. RNA, or cDNA corresponding to RNA, isolated from a subject sample of leukocytes is labeled, e.g., with a fluorescent tag, and a solution containing the RNA (or cDNA) is incubated under conditions favorable for hybridization, with the “probe” chip. Following incubation, and washing to eliminate non-specific hybridization, the labeled nucleic acid bound to the chip is detected qualitatively or quantitatively, and the resulting expression profile for the corresponding candidate nucleotide sequences is recorded. It is appreciated that the probe used for diagnostic purposes may be identical to the probe used during diagnostic nucleotide sequence discovery and validation. Alternatively, the probe sequence may be different than the sequence used in diagnostic nucleotide sequence discovery and validation. Multiple cDNAs from a nucleotide sequence that are non-overlapping or partially overlapping may also be used.

[0151] In another approach, oligonucleotides corresponding to members of a candidate nucleotide library are synthesized and spotted onto an array. Alternatively, oligonucleotides are synthesized onto the array using methods known in the art, e.g. Hughes, et al. supra. The oligonucleotide is designed to be complementary to any portion of the candidate nucleotide sequence. In addition, in the context of expression analysis for, e.g. diagnostic use of diagnostic nucleotide sets, an oligonucleotide can be designed to exhibit particular hybridization characteristics, or to exhibit a particular specificity and/or sensitivity, as further described below.

[0152] Oligonucleotide probes are also prepared using the DNA sequence information for the candidate genes identified by differential hybridization screening (listed in Tables 3, 8-10 and the Sequence Listing) and/or the sequence information for the genes identified by database mining (listed in Table 2) is used to design complimentary oligonucleotide probes. Oligo probes are designed on a contract basis by various companies (for example, Compugen, Mergen, Affymetrix, Telechem), or designed from the candidate sequences using a variety of parameters and algorithms as indicated at the website genome.wi.mit.edu/cgi-bin/prtmer/primer3.cgi. Briefly, the length of the oligonucleotide to be synthesized is determined, preferably at least 16 nucleotides, generally 18-24 nucleotides, 24-70 nucleotides and, in some circumstances, more than 70 nucleotides. The sequence analysis algorithms and tools described above are applied to the sequences to mask repetitive elements, vector sequences and low complexity sequences. Oligonucleotides are selected that are specific to the candidate nucleotide sequence (based on a Blast n search of the oligonucleotide sequence in question against gene sequences databases, such as the Human Genome Sequence, UniGene, dbEST or the non-redundant database at NCBI), and have <50% G content and 25-70% G+C content. Desired oligonucleotides are synthesized using well-known methods and apparatus, or ordered from a company (for example Sigma). Oligonucleotides are spotted onto microarrays. Alternatively, oligonucleotides are synthesized directly on the array surface, using a variety of techniques (Hughes et al. 2001, Yershov et al. 1996, Lockhart et al 1996).

[0153] Hybridization signal may be amplified using methods known in the art, and as described herein, for example use of the Clontech kit (Glass Fluorescent Labeling Kit), Stratagene kit (Fairplay Microarray Labeling Kit), the Micromax kit (New England Nuclear, Inc.), the Genisphere kit (3DNA Submicro), linear amplification, e.g. as described in U.S. Pat. No. 6,132,997 or described in Hughes, T R, et al., Nature Biotechnology, 19:343-347 (2001) and/or Westin et al. Nat Biotech. 18:199-204. In some cases, amplification techniques do not increase signal intensity, but allow assays to be done with small amounts of RNA.

[0154] Alternatively, fluorescently labeled cDNA are hybridized directly to the microarray using methods known in the art. For example, labeled cDNA are generated by reverse transcription using Cy3- and Cy5-conjugated deoxynucleotides, and the reaction products purified using standard methods. It is appreciated that the methods for signal amplification of expression data useful for identifying diagnostic nucleotide sets are also useful for amplification of expression data for diagnostic purposes.

[0155] Microarray expression may be detected by scanning the microarray with a variety of laser or CCD-based scanners, and extracting features with numerous software packages, for example, Imagene (Biodiscovery), Feature Extraction Software (Agilent), Scanalyze (Eisen, M. 1999. SCANALYZE User Manual; Stanford Univ., Stanford, Calif. Ver 2.32.), GenePix (Axon Instruments).

[0156] In another approach, hybridization to microelectric arrays is performed, e.g. as described in Umek et al (2001) J Mol Diagn. 3:74-84. An affinity probe, e.g. DNA, is deposited on a metal surface. The metal surface underlying each probe is connected to a metal wire and electrical signal detection system. Unlabelled RNA or cDNA is hybridized to the array, or alternatively, RNA or cDNA sample is amplified before hybridization, e.g. by PCR. Specific hybridization of sample RNA or cDNA results in generation of an electrical signal, which is transmitted to a detector. See Westin (2000) Nat Biotech. 18:199-204 (describing anchored multiplex amplification of a microelectronic chip array); Edman (1997) NAR 25:4907-14; Vignali (2000) J Immunol Methods 243:243-55.

[0157] In another approach, a microfluidics chip is used for RNA sample preparation and analysis. This approach increases efficiency because sample preparation and analysis are streamlined. Briefly, microfluidics may be used to sort specific leukocyte sub-populations prior to RNA preparation and analysis. Microfluidics chips are also useful for, e.g., RNA preparation, and reactions involving RNA (reverse transcription, RT-PCR). Briefly, a small volume of whole, anti-coagulated blood is loaded onto a microfluidics chip, for example chips available from Caliper (Mountain View, Calif.) or Nanogen (San Diego, Calif.) A microfluidics chip may contain channels and reservoirs in which cells are moved and reactions are performed. Mechanical, electrical, magnetic, gravitational, centrifugal or other forces are used to move the cells and to expose them to reagents. For example, cells of whole blood are moved into a chamber containing hypotonic saline, which results in selective lysis of red blood cells after a 20-minute incubation. Next, the remaining cells (leukocytes) are moved into a wash chamber and finally, moved into a chamber containing a lysis buffer such as guanidine isothyocyanate. The leukocyte cell lysate is further processed for RNA isolation in the chip, or is then removed for further processing, for example, RNA extraction by standard methods. Alternatively, the microfluidics chip is a circular disk containing ficoll or another density reagent. The blood sample is injected into the center of the disc, the disc is rotated at a speed that generates a centrifugal force appropriate for density gradient separation of mononuclear cells, and the separated mononuclear cells are then harvested for further analysis or processing.

[0158] It is understood that the methods of expression evaluation, above, although discussed in the context of discovery of diagnostic nucleotide sets, are also applicable for expression evaluation when using diagnostic nucleotide sets for, e.g. diagnosis of diseases, as further discussed below.

[0159] Evaluation of Expression Patterns

[0160] Expression patterns can be evaluated by qualitative and/or quantitative measures. Certain of the above described techniques for evaluating gene expression (as RNA or protein products) yield data that are predominantly qualitative in nature. That is, the methods detect differences in expression that classify expression into distinct modes without providing significant information regarding quantitative aspects of expression. For example, a technique can be described as a qualitative technique if it detects the presence or absence of expression of a candidate nucleotide sequence, i.e., an on/off pattern of expression. Alternatively, a qualitative technique measures the presence (and/or absence) of different alleles, or variants, of a gene product.

[0161] In contrast, some methods provide data that characterize expression in a quantitative manner. That is, the methods relate expression on a numerical scale, e.g., a scale of 0-5, a scale of 1-10, a scale of +−+++, from grade 1 to grade 5, a grade from a to z, or the like. It will be understood that the numerical, and symbolic examples provided are arbitrary, and that any graduated scale (or any symbolic representation of a graduated scale) can be employed in the context of the present invention to describe quantitative differences in nucleotide sequence expression. Typically, such methods yield information corresponding to a relative increase or decrease in expression.

[0162] Any method that yields either quantitative or qualitative expression data is suitable for evaluating expression of candidate nucleotide sequence in a subject sample of leukocytes. In some cases, e.g., when multiple methods are employed to determine expression patterns for a plurality of candidate nucleotide sequences, the recovered data, e.g., the expression profile, for the nucleotide sequences is a combination of quantitative and qualitative data.

[0163] In some applications, expression of the plurality of candidate nucleotide sequences is evaluated sequentially. This is typically the case for methods that can be characterized as low- to moderate-throughput. In contrast, as the throughput of the elected assay increases, expression for the plurality of candidate nucleotide sequences in a sample or multiple samples of leukocytes, is assayed simultaneously. Again, the methods (and throughput) are largely determined by the individual practitioner, although, typically, it is preferable to employ methods that permit rapid, e.g. automated or partially automated, preparation and detection, on a scale that is time-efficient and cost-effective.

[0164] It is understood that the preceding discussion, while directed at the assessment of expression of the members of candidate libraries, is also applies to the assessment of the expression of members of diagnostic nucleotide sets, as further discussed below. Genotyping

[0165] In addition to, or in conjunction with the correlation of expression profiles and clinical data, it is often desirable to correlate expression patterns with the subject's genotype at one or more genetic loci or to correlate both expression profiles and genetic loci data with clinical data. The selected loci can be, for example, chromosomal loci corresponding to one or more member of the candidate library, polymorphic alleles for marker loci, or alternative disease related loci (not contributing to the candidate library) known to be, or putatively associated with, a disease (or disease criterion). Indeed, it will be appreciated, that where a (polymorphic) allele at a locus is linked to a disease (or to a predisposition to a disease), the presence of the allele can itself be a disease criterion.

[0166] Numerous well known methods exist for evaluating the genotype of an individual, including southern analysis, restriction fragment length polymorphism (RFLP) analysis, polymerase chain reaction (PCR), amplification length polymorphism (AFLP) analysis, single stranded conformation polymorphism (SSCP) analysis, single nucleotide polymorphism (SNP) analysis (e.g., via PCR, Taqman or molecular beacons), among many other useful methods. Many such procedures are readily adaptable to high throughput and/or automated (or semi-automated) sample preparation and analysis methods. Most, can be performed on nucleic acid samples recovered via simple procedures from the same sample of leukocytes as yielded the material for expression profiling. Exemplary techniques are described in, e.g., Sambrook, and Ausubel, supra.

[0167] Identification of the Diagnostic Oligonucleotides and Oligonucleotide Sets of the Invention

[0168] Identification of diagnostic nucleotides and nucleotide sets and disease specific target nucleotide sequence proceeds by correlating the leukocyte expression profiles with data regarding the subject's health status to produce a data set designated a “molecular signature.” Examples of data regarding a patient's health status, also termed “disease criteria(ion)”, is described below and in the Section titled “selected diseases,” below. Methods useful for correlation analysis are further described elsewhere in the specification.

[0169] Generally, relevant data regarding the subject's health status includes retrospective or prospective health data, e.g., in the form of the subject's medical history, as provided by the subject, physician or third party, such as, medical diagnoses, laboratory test results, diagnostic test results, clinical events, or medication lists, as further described below. Such data may include information regarding a patient's response to treatment and/or a particular medication and data regarding the presence of previously characterized “risk factors.” For example, cigarette smoking and obesity are previously identified risk factors for heart disease. Further examples of health status information, including diseases and disease criteria, is described in the section titled Selected diseases, below.

[0170] Typically, the data describes prior events and evaluations (i.e., retrospective data). However, it is envisioned that data collected subsequent to the sampling (i.e., prospective data) can also be correlated with the expression profile. The tissue sampled, e.g., peripheral blood, bronchial lavage, etc., can be obtained at one or more multiple time points and subject data is considered retrospective or prospective with respect to the time of sample procurement.

[0171] Data collected at multiple time points, called “longitudinal data”, is often useful, and thus, the invention encompasses the analysis of patient data collected from the same patient at different time points. Analysis of paired samples, such as samples from a patient at different times, allows identification of differences that are specifically related to the disease state since the genetic variability specific to the patient is controlled for by the comparison. Additionally, other variables that exist between patients may be controlled for in this way, for example, the presence or absence of inflammatory diseases (e.g., rheumatoid arthritis) the use of medications that may effect leukocyte gene expression, the presence or absence of co-morbid conditions, etc. Methods for analysis of paired samples are further described below. Moreover, the analysis of a pattern of expression profiles (generated by collecting multiple expression profiles) provides information relating to changes in expression level over time, and may permit the determination of a rate of change, a trajectory, or an expression curve. Two longitudinal samples may provide information on the change in expression of a gene over time, while three longitudinal samples may be necessary to determine the “trajectory” of expression of a gene. Such information may be relevant to the diagnosis of a disease. For example, the expression of a gene may vary from individual to individual, but a clinical event, for example, a heart attack, may cause the level of expression to double in each patient. In this example, clinically interesting information is gleaned from the change in expression level, as opposed to the absolute level of expression in each individual.

[0172] When a single patient sample is obtained, it may still be desirable to compare the expression profile of that sample to some reference expression profile. In this case, one can determine the change of expression between the patient's sample and a reference expression profile that is appropriate for that patient and the medical condition in question. For example, a reference expression profile can be determined for all patients without the disease criterion in question who have similar characteristics, such as age, sex, race, diagnoses etc.

[0173] Generally, small sample sizes of 10-40 samples from 10-20 individuals are used to identify a diagnostic nucleotide set. Larger sample sizes are generally necessary to validate the diagnostic nucleotide set for use in large and varied patient populations, as further described below. For example, extension of gene expression correlations to varied ethnic groups, demographic groups, nations, peoples or races may require expression correlation experiments on the population of interest.

[0174] Expression Reference Standards

[0175] Expression profiles derived from a patient (i.e., subjects diagnosed with, or exhibiting symptoms of, or exhibiting a disease criterion, or under a doctor's care for a disease) sample are compared to a control or standard expression RNA to facilitate comparison of expression profiles (e.g. of a set of candidate nucleotide sequences) from a group of patients relative to each other (i.e., from one patient in the group to other patients in the group, or to patients in another group).

[0176] The reference RNA used should have desirable features of low cost and simplicity of production on a large scale. Additionally, the reference RNA should contain measurable amounts of as many of the genes of the candidate library as possible.

[0177] For example, in one approach to identifying diagnostic nucleotide sets, expression profiles derived from patient samples are compared to a expression reference “standard.”Standard expression reference can be, for example, RNA derived from resting cultured leukocytes or commercially available reference RNA, such as Universal reference RNA from Stratagene. See Nature, V406, 8-17-00, p. 747-752. Use of an expression reference standard is particularly useful when the expression of large numbers of nucleotide sequences is assayed, e.g. in an array, and in certain other applications, e.g. qualitative PCR, RT-PCR, etc., where it is desirable to compare a sample profile to a standard profile, and/or when large numbers of expression profiles, e.g. a patient population, are to be compared. Generally, an expression reference standard should be available in large quantities, should be a good substrate for amplification and labeling reactions, and should be capable of detecting a large percentage of candidate nucleic acids using suitable expression profiling technology.

[0178] Alternatively, or in addition, the expression profile derived from a patient sample is compared with the expression of an internal reference control gene, for example, β-actin or CD4. The relative expression of the profiled genes and the internal reference control gene (from the same individual) is obtained. An internal reference control may also be used with a reference RNA. For example, an expression profile for “gene 1” and the gene encoding CD4 can be determined in a patient sample and in a reference RNA. The expression of each gene can be expressed as the “relative” ratio of expression the gene in the patient sample compared with expression of the gene in the reference RNA. The expression ratio (sample/reference) for gene 1 may be divided by the expression ration for CD4 (sample/reference) and thus the relative expression of gene 1 to CD4 is obtained.

[0179] The invention also provides a buffy coat control RNA useful for expression profiling, and a method of using control RNA produced from a population of buffy coat cells, the white blood cell layer derived from the centrifugation of whole blood. Buffy coat contains all white blood cells, including granulocytes, mononuclear cells and platelets. The invention also provides a method of preparing control RNA from buffy coat cells for use in expression profile analysis of leukocytes. Buffy coat fractions are obtained, e.g. from a blood bank or directly from individuals, preferably from a large number of individuals such that bias from individual samples is avoided and so that the RNA sample represents an average expression of a healthy population. Buffy coat fractions from about 50 or about 100, or more individuals are preferred. 10 ml buffy coat from each individual is used. Buffy coat samples are treated with an erthythrocyte lysis buffer, so that erthythrocytes are selectively removed. The leukocytes of the buffy coat layer are collected by centrifugation. Alternatively, the buffy cell sample can be further enriched for a particular leukocyte sub-populations, e.g. mononuclear cells, T-lymphocytes, etc. To enrich for mononuclear cells, the buffy cell pellet, above, is diluted in PBS (phosphate buffered saline) and loaded onto a non-polystyrene tube containing a polysucrose and sodium diatrizoate solution adjusted to a density of 1.077+/−0.001 g/ml. To enrich for T-lymphocytes, 45 ml of whole blood is treated with RosetteSep (Stem Cell Technologies), and incubated at room temperature for 20 minutes. The mixture is diluted with an equal volume of PBS plus 2% FBS and mixed by inversion. 30 ml of diluted mixture is layered on top of 15 ml DML medium (Stem Cell Technologies). The tube is centrifuged at 1200× g, and the enriched cell layer at the plasma: medium interface is removed, washed with PBS +2% FBS, and cells collected by centrifugation at 1200× g. The cell pellet is treated with 5 ml of erythrocyte lysis buffer (EL buffer, Qiagen) for 10 minutes on ice, and enriched T-lymphoctes are collected by centrifugation.

[0180] In addition or alternatively, the buffy cells (whole buffy coat or sub-population, e.g. mononuclear fraction) can be cultured in vitro and subjected to stimulation with cytokines or activating chemicals such as phorbol esters or ionomycin. Such stimuli may increase expression of nucleotide sequences that are expressed in activated immune cells and might be of interest for leukocyte expression profiling experiments.

[0181] Following sub-population selection and/or further treatment, e.g. stimulation as described above, RNA is prepared using standard methods. For example, cells are pelleted and lysed with a phenol/guanidinium thiocyanate and RNA is prepared. RNA can also be isolated using a silica gel-based purification column or the column method can be used on RNA isolated by the phenol/guanidinium thiocyanate method. RNA from individual buffy coat samples can be pooled during this process, so that the resulting reference RNA represents the RNA of many individuals and individual bias is minimized or eliminated. In addition, a new batch of buffy coat reference RNA can be directly compared to the last batch to ensure similar expression pattern from one batch to another, using methods of collecting and comparing expression profiles described above/below. One or more expression reference controls are used in an experiment. For example, RNA derived from one or more of the following sources can be used as controls for an experiment: stimulated or unstimulated whole buffy coat, stimulated or unstimulated peripheral mononuclear cells, or stimulated or unstimulated T-lymphocytes.

[0182] Alternatively, the expression reference standard can be derived from any subject or class of subjects including healthy subjects or subjects diagnosed with the same or a different disease or disease criterion. Expression profiles from subjects in two or more distinct classes are compared to determine which subset of nucleotide sequences in the candidate library can best distinguish between the subject classes, as further discussed below. It will be appreciated that in the present context, the term “distinct classes” is relevant to at least one distinguishable criterion relevant to a disease of interest, a “disease criterion.” The classes can, of course, demonstrate significant overlap (or identity) with respect to other disease criteria, or with respect to disease diagnoses, prognoses, or the like. The mode of discovery involves, e.g., comparing the molecular signature of different subject classes to each other (such as patient to control, patients with a first diagnosis to patients with a second diagnosis, etc.) or by comparing the molecular signatures of a single individual taken at different time points. The invention can be applied to a broad range of diseases, disease criteria, conditions and other clinical and/or epidemiological questions, as further discussed above/below.

[0183] It is appreciated that while the present discussion pertains to the use of expression reference controls while identifying diagnostic nucleotide sets, expression reference controls are also useful during use of diagnostic nucleotide sets, e.g. use of a diagnostic nucleotide set for diagnosis of a disease, as further described below.

[0184] Analysis of Expression Profiles

[0185] In order to facilitate ready access, e.g., for comparison, review, recovery, and/or modification, the molecular signatures/expression profiles are typically recorded in a database. Most typically, the database is a relational database accessible by a computational device, although other formats, e.g., manually accessible indexed files of expression profiles as photographs, analogue or digital imaging readouts, spreadsheets, etc. can be used. Further details regarding preferred embodiments are provided below. Regardless of whether the expression patterns initially recorded are analog or digital in nature and/or whether they represent quantitative or qualitative differences in expression, the expression patterns, expression profiles (collective expression patterns), and molecular signatures (correlated expression patterns) are stored digitally and accessed via a database. Typically, the database is compiled and maintained at a central facility, with access being available locally and/or remotely.

[0186] As additional samples are obtained, and their expression profiles determined and correlated with relevant subject data, the ensuing molecular signatures are likewise recorded in the database. However, rather than each subsequent addition being added in an essentially passive manner in which the data from one sample has little relation to data from a second (prior or subsequent) sample, the algorithms optionally additionally query additional samples against the existing database to further refine the association between a molecular signature and disease criterion. Furthermore, the data set comprising the one (or more) molecular signatures is optionally queried against an expanding set of additional or other disease criteria. The use of the database in integrated systems and web embodiments is further described below.

[0187] Analysis of Expression Profile Data from Arrays

[0188] Expression data is analyzed using methods well known in the art, including the software packages Imagene (Biodiscovery, Marina del Rey, Calif.), Feature Extraction Software (Agilent, Palo Alto, Calif.), and Scanalyze (Stanford University). In the discussion that follows, a “feature” refers to an individual spot of DNA on an array. Each gene may be represented by more than one feature. For example, hybridized microarrays are scanned and analyzed on an Axon Instruments scanner using GenePix 3.0 software (Axon Instruments, Union City, Calif.). The data extracted by GenePix is used for all downstream quality control and expression evaluation. The data is derived as follows. The data for all features flagged as “not found” by the software is removed from the dataset for individual hybridizations. The “not found” flag by GenePix indicates that the software was unable to discriminate the feature from the background. Each feature is examined to determine the value of its signal. The median pixel intensity of the background (B,) is subtracted from the median pixel intensity of the feature (F,) to produce the background-subtracted signal (hereinafter, “BGSS”). The BGSS is divided by the standard deviation of the background pixels to provide the signal-to-noise ratio (hereinafter, “S/N”). Features with a S/N of three or greater in both the Cy3 channel (corresponding to the sample RNA) and Cy5 channel (corresponding to the reference RNA) are used for further analysis (hereinafter denoted “useable features”). Alternatively, different S/Ns are used for selecting expression data for an analysis. For example, only expression data with signal to noise ratios >3 might be used in an analysis. Alternatively, features with S/N values <3 may be flagged as such and included in the analysis. Such flagged data sets include more values and may allow one to discover expression markers that would be missed otherwise. However, such data sets may have a higher variablilty than filtered data, which may decrease significance of findings or performance of correlation statistics.

[0189] For each usable feature (i), the expression level (e) is expressed as the logarithm of the ratio (R) of the Background Subtracted Signal (hereinafter “BGSS”) for the Cy3 (sample RNA) channel divided by the BGSS for the Cy5 channel (reference RNA). This “log ratio” value is used for comparison to other experiments. $\begin{matrix} {R_{i} = \frac{{BGSS}_{sample}}{{BGSS}_{reference}}} & (0.1) \end{matrix}$

e _(i) =log r _(i)  (0.2)

[0190] Variation in signal across hybridizations may be caused by a number of factors affecting hybridization, DNA spotting, wash conditions, and labeling efficiency.

[0191] A single reference RNA may be used with all of the experimental RNAs, permitting multiple comparisons in addition to individual comparisons. By comparing sample RNAs to the same reference, the gene expression levels from each sample are compared across arrays, permitting the use of a consistent denominator for our experimental ratios.

[0192] Scaling

[0193] The data may be scaled (normalized) to control for labeling and hybridization variability within the experiment, using methods known in the art. Scaling is desirable because it facilitates the comparison of data between different experiments, patients, etc. Generally the BGSS are scaled to a factor such as the median, the mean, the trimmed mean, and percentile. Additional methods of scaling include: to scale between 0 and 1, to subtract the mean, or to subtract the median.

[0194] Scaling is also performed by comparison to expression patterns obtained using a common reference RNA, as described in greater detail above. As with other scaling methods, the reference RNA facilitates multiple comparisons of the expression data, e.g., between patients, between samples, etc. Use of a reference RNA provides a consistent denominator for experimental ratios.

[0195] In addition to the use of a reference RNA, individual expression levels may be adjusted to correct for differences in labeling efficiency between different hybridization experiments, allowing direct comparison between experiments with different overall signal intensities, for example. A scaling factor (a) may be used to adjust individual expression levels as follows. The median of the scaling factor (a), for example, BGSS, is determined for the set of all features with a SIN greater than three. Next, the BGSS, (the BGSS for each feature “i”) is divided by the median for all features (a), generating a scaled ratio. The scaled ration is used to determine the expression value for the feature (e_(i)), or the log ratio. $\begin{matrix} {S_{i} = \frac{{BGSS}_{i}}{a}} & (0.3) \\ {e_{i} = {\log \left( \frac{{Cy3S}_{i}}{C_{y}5S_{i}} \right)}} & (0.4) \end{matrix}$

[0196] In addition, or alternatively, control features are used to normalize the data for labeling and hybridization variability within the experiment. Control feature may be cDNA for genes from the plant, Arabidopsis thaliana, that are included when spotting the mini-array. Equal amounts of RNA complementary to control cDNAs are added to each of the samples before they were labeled. Using the signal from these control genes, a normalization constant (L) is determined according to the following formula: $L_{j} = \frac{\frac{\sum\limits_{i = 1}^{N}{BGSS}_{j,i}}{N}}{\frac{\sum\limits_{j = 1}^{K}\frac{\sum\limits_{i = 1}^{N}{BGSS}_{j,i}}{N}}{K}}$

[0197] where BGSS₁ is the signal for a specific feature, N is the number of A. thaliana control features, K is the number of hybridizations, and L_(j) is the normalization constant for each individual hybridization.

[0198] Using the formula above, the mean for all control features of a particular hybridization and dye (e.g., Cy3) is calculated. The control feature means for all Cy3 hybridizations are averaged, and the control feature mean in one hybridization divided by the average of all hybridizations to generate a normalization constant for that particular Cy3 hybridization (L_(j)), which is used as a in equation (0.3). The same normalization steps may be performed for Cy3 and Cy5 values.

[0199] Many additional methods for normalization exist and can be applied to the data. In one method, the average ratio of Cy3 BGSS/Cy5 BGSS is determined for all features on an array. This ratio is then scaled to some arbitrary number, such as I or some other number. The ratio for each probe is then multiplied by the scaling factor required to bring the average ratio to the chosen level. This is performed for each array in an analysis. Alternatively, the ratios are normalized to the average ratio across all arrays in an analysis.

[0200] If multiple features are used per gene sequence or oligonucleotide, these repeats can be used to derive an average expression value for each gene. If some of the replicate features are of poor qualitay and don't meet requirements for analysis, the remaining features can be used to represent the gene or gene sequence.

[0201] Correlation Analysis

[0202] Correlation analysis is performed to determine which array probes have expression behavior that best distinguishes or serves as markers for relevant groups of samples representing a particular clinical condition. Correlation analysis, or comparison among samples representing different disease criteria (e.g., clinical conditions), is performed using standard statistical methods. Numerous algorithms are useful for correlation analysis of expression data, and the selection of algorithms depends in part on the data analysis to be performed. For example, algorithms can be used to identify the single most informative gene with expression behavior that reliably classifies samples, or to identify all the genes useful to classify samples. Alternatively, algorithms can be applied that determine which set of 2 or more genes have collective expression behavior that accurately classifies samples. The use of multiple expression markers for diagnostics may overcome the variability in expression of a gene between individuals, or overcome the variability intrinsic to the assay. Multiple expression markers may include redundant markers (surrogates), in that two or more genes or probes may provide the same information with respect to diagnosis. This may occur, for example, when two or more genes or gene probes are coordinately expressed. For diagnostic application, it may be appropriate to utilize a gene and one or more of its surrogates in the assay. This redundancy may overcome failures (technical or biological) of a single marker to distinguish samples. Alternatively, one or more surrogates may have properties that make them more suitable for assay development, such as a higher baseline level of expression, better cell specificity, a higher fold change between sample groups or more specific sequence for the design of PCR primers or complimentary probes. It will be appreciated that while the discussion above pertains to the analysis of RNA expression profiles the discussion is equally applicable to the analysis of profiles of proteins or other molecular markers.

[0203] Prior to analysis, expression profile data may be formatted or prepared for analysis using methods known in the art. For example, often the log ratio of scaled expression data for every array probe is calculated using the following formula:

[0204] log (Cy 3 BGSS/Cy5 BGSS), where Cy 3 signal corresponds to the expression of the gene in the clinical sample, and Cy5 signal corresponds to expression of the gene in the reference RNA.

[0205] Data may be further filtered depending on the specific analysis to be done as noted below. For example, filtering may be aimed at selecting only samples with expression above a certain level, or probes with variability above a certain level between sample sets.

[0206] The following non-limiting discussion consider several statistical methods known in the art. Briefly, the t-test and ANOVA are used to identify single genes with expression differences between or among populations, respectively. Multivariate methods are used to identify a set of two or more genes for which expression discriminates between two disease states more specifically than expression of any single gene.

[0207] t-test

[0208] The simplest measure of a difference between two groups is the Student's t test. See, e.g., Welsh et al. (2001) Proc Natl Acad Sci USA 98:1176-81 (demonstrating the use of an unpaired Student's t-test for the discovery of differential gene expression in ovarian cancer samples and control tissue samples). The t-test assumes equal variance and normally distributed data. This test identifies the probability that there is a difference in expression of a single gene between two groups of samples. The number of samples within each group that is required to achieve statistical significance is dependent upon the variation among the samples within each group. The standard formula for a t-test is: $\begin{matrix} {{{t\left( e_{i} \right)} = \frac{{\overset{\_}{e}}_{i,c} - {\overset{\_}{e}}_{i,t}}{\sqrt{\left( {s_{i,c}^{2}/n_{c}} \right) + \left( {s_{i,t}^{2}\text{/}n_{t}} \right)}}},} & (0.5) \end{matrix}$

[0209] where {overscore (e)}_(i) is the difference between the mean expression level of gene i in groups c and t, s_(i,c) is the variance of gene x in group c and s_(i,t) is the variance of gene x in group t. n_(c) and nt are the numbers of samples in groups c and t.

[0210] The combination of the t statistic and the degrees of freedom [min(n_(t), n_(c))−1] provides a p value, the probability of rejecting the null hypothesis. A p-value of ≦0.01, signifying a 99 percent probability the mean expression levels are different between the two groups (a 1% chance that the mean expression levels are in fact not different and that the observed difference occurred by statistical chance), is often considered acceptable.

[0211] When performing tests on a large scale, for example, on a large dataset of about 8000 genes, a correction factor must be included to adjust for the number of individual tests being performed. The most common and simplest correction is the Bonferroni correction for multiple tests, which divides the p-value by the number of tests run. Using this test on an 8000 member dataset indicates that a p value of ≦0.00000125 is required to identify genes that are likely to be truly different between the two test conditions.

[0212] Significance Analysis for Microarrays (SAM)

[0213] Significance analysis for microarrays (SAM) (Tusher 2001) is a method through which genes with a correlation between their expression values and the response vector are statistically discovered and assigned a statistical significance. The ratio of false significant to significant genes is the False Discovery Rate (FDR). This means that for each threshold there are a set of genes which are called significant, and the FDR gives a confidence level for this claim. If a gene is called differentially expressed between 2 classes by SAM, with a FDR of 5%, there is a 95% chance that the gene is actually differentially expressed between the classes. SAM takes into account the variability and large number of variables of microarrays. SAM will identiy genes that are most globally differentially expressed between the classes. Thus, important genes for identifying and classifying outlier samples or patients may not be identified by SAM.

[0214] Wilcoxon's Signed Ranks Test

[0215] This method is non-parametric and is utilized for paired comparisons. See e.g., Sokal and Rohlf (1987) Introduction to Biostatistics 2^(nd) edition, WH Freeman, New York. At least 6 pairs are necessary to apply this statistic. This test is useful for analysis of paired expression data (for example, a set of patients who have had samples taken before and after administration of a pharmacologic agent).

[0216] ANOVA

[0217] Differences in gene expression across multiple related groups may be assessed using an Analysis of Variance (ANOVA), a method well known in the art (Michelson and Schofield, 1996).

[0218] Multivariate analysis

[0219] Many algorithms suitable for multivariate analysis are known in the art (Katz 1999). Generally, a set of two or more genes for which expression discriminates between two disease states more specifically than expression of any single gene is identified by searching through the possible combinations of genes using a criterion for discrimination, for example the expression of gene X must increase from normal 300 percent, while the expression of genes Y and Z must decrease from normal by 75 percent. Ordinarily, the search starts with a single gene, then adds the next best fit at each step of the search. Alternatively, the search starts with all of the genes and genes that do not aid in the discrimination are eliminated step-wise.

[0220] Paired Samples

[0221] Paired samples, or samples collected at different time-points from the same patient, are often useful, as described above. For example, use of paired samples permits the reduction of variation due to genetic variation among individuals. In addition, the use of paired samples has a statistical significance in that data derived from paired samples can be calculated in a different manner that recognizes the reduced variability. For example, the formula for a t-test for paired samples is: $\begin{matrix} {{t\left( e_{x} \right)} = \frac{{\overset{\_}{D}}_{{\overset{\_}{e}}_{x}}}{\sqrt{\frac{{\sum D^{2}} - {\left( {\sum D} \right)^{2}\text{/}b}}{b - 1}}}} & (0.5) \end{matrix}$

[0222] where D is the difference between each set of paired samples and b is the number of sample pairs. {overscore (D)} is the mean of the differences between the members of the pairs. In this test, only the differences between the paired samples are considered, then grouped together (as opposed to taking all possible differences between groups, as would be the case with an ordinary t-test). Additional statistical tests useful with paired data, e.g., ANOVA and Wilcoxon's signed rank test, are discussed above.

[0223] Diagnostic Classification

[0224] Once a discriminating set of genes is identified, the diagnostic classifier (a mathematical function that assigns samples to diagnostic categories based on expression data) is applied to unknown sample expression levels.

[0225] Methods that can be used for this analysis include the following non-limiting list:

[0226] CLEAVER is an algorithm used for classification of useful expression profile data. See Raychaudhuri et al. (2001) Trends Biotechnol 19:189-193. CLEAVER uses positive training samples (e.g., expression profiles from samples known to be derived from a particular patient or sample diagnostic category, disease or disease criteria), negative training samples (e.g., expression profiles from samples known not to be derived from a particular patient or sample diagnostic category, disease or disease criteria) and test samples (e.g., expression profiles obtained from a patient), and determines whether the test sample correlates with the particular disease or disease criteria, or does not correlate with a particular disease or disease criteria. CLEAVER also generates a list of the 20 most predictive genes for classification.

[0227] Artificial neural networks (hereinafter, “ANN”) can be used to recognize patterns in complex data sets and can discover expression criteria that classify samples into more than 2 groups. The use of artificial neural networks for discovery of gene expression diagnostics for cancers using expression data generated by oligonucleotide expression microarrays is demonstrated by Khan et al. (2001) Nature Med. 7:673-9. Khan found that 96 genes provided 0% error rate in classification of the tumors. The most important of these genes for classification was then determined by measuring the sensitivity of the classification to a change in expression of each gene. Hierarchical clustering using the 96 genes results in correct grouping of the cancers into diagnostic categories.

[0228] Golub uses cDNA microarrays and a distinction calculation to identify genes with expression behavior that distinguishes myeloid and lymphoid leukemias. See Golub et al. (1999) Science 286:531-7. Self organizing maps were used for new class discovery. Cross validation was done with a “leave one out” analysis. 50 genes were identified as useful markers. This was reduced to as few as 10 genes with equivalent diagnostic accuracy.

[0229] Hierarchical and non-hierarchical clustering methods are also useful for identifying groups of genes that correlate with a subset of clinical samples such as those with and without Lupus. Alizadeh used hierarchical clustering as the primary tool to distinguish different types of diffuse B-cell lymphomas based on gene expression profile data. See Alizadeh et al. (2000) Nature 403:503-11. Alizadeh used hierarchical clustering as the primary tool to distinguish different types of diffuse B-cell lymphomas based on gene expression profile data. A cDNA array carrying 17856 probes was used for these experiments, 96 samples were assessed on 128 arrays, and a set of 380 genes was identified as being useful for sample classification.

[0230] Perou demonstrates the use of hierarchical clustering for the molecular classification of breast tumor samples based on expression profile data. See Perou et al. (2000) Nature 406:747-52. In this work, a cDNA array carrying 8102 gene probes was used. 1753 of these genes were found to have high variation between breast tumors and were used for the analysis.

[0231] Hastie describes the use of gene shaving for discovery of expression markers. Hastie et al. (2000) Genome Biol. 1(2):RESEARCH 0003.1-0003.21. The gene shaving algorithm identifies sets of genes with similar or coherent expression patterns, but large variation across conditions (RNA samples, sample classes, patient classes). In this manner, genes with a tight expression pattern within a diagnostic group, but also with high variability across the diagnoses are grouped together. The algorithm takes advantage of both characteristics in one grouping step. For example, gene shaving can identify useful marker genes with co-regulated expression. Sets of useful marker genes can be reduced to a smaller set, with each gene providing some non-redundant value in classification. This algorithm was used on the data set described in Alizadeh et al., supra, and the set of 380 informative gene markers was reduced to 234.

[0232] Supervised harvesting of expression trees (Hastie 2001) identifies genes or clusters that best distinguish one class from all the others on the data set. The method is used to identify the genes/clusters that can best separate one class versus all the others for datasets that include two or more classes or all classes from each other. This algorithm can be used for discovery or testing of a diagnostic gene set.

[0233] CART is a decision tree classification algorithm (Breiman 1984). From gene expression and or other data, CART can develop a decision tree for the classification of samples. Each node on the decision tree involves a query about the expression level of one or more genes or variables. Samples that are above the threshold go down one branch of the decision tree and samples that are not go down the other branch. See examples 10 and 16 for further description of its use in classification analysis and examples of its usefulness in discovering and implementing a diagnostic gene set. CART identifies surrogates for each splitter (genes that are the next best substitute for a useful gene in classification.

[0234] Once a set of genes and expression criteria for those genes have been established for classification, cross validation is done. There are many approaches, including a 10 fold cross validation analysis in which 10% of the training samples are left out of the analysis and the classification algorithm is built with the remaining 90%. The 10% are then used as a test set for the algorithm. The process is repeated 10 times with 10% of the samples being left out as a test set each time. Through this analysis, one can derive a cross validation error which helps estimate the robustness of the algorithm for use on prospective (test) samples.

[0235] Clinical data are gathered for every patient sample used for expression analysis. Clinical variables can be quantitative or non-quantitative. A clinical variable that is quantitiative can be used as a variable for significance or classification analysis. Non-quantitative clinical variables, such as the sex of the patient, can also be used in a significance analysis or classification analysis with some statistical tool. It is appreciated that the most useful diagnostic gene set for a condition may be optimal when considered along with one or more predictive clinical variables. Clinical data can also be used as supervising vectors for a correlation analysis. That is to say that the clinical data associated with each sample can be used to divide the samples into meaningful diagnostic categories for analysis. For example, samples can be divided into 2 or more groups based on the presence or absence of some diagnostic criterion (a). In addition, clinical data can be utilized to select patients for a correlation analysis or to exclude them based on some undesirable characteristic, such as an ongoing infection, a medicine or some other issue. Clincial data can also be used to assess the pre-test probability of an outcome. For example, patients who are female are much more likely to be diagnosed as having systemic lupus erythematosis than patients who are male.

[0236] Once a set of genes are identified that classify samples with acceptable accuracy. These genes are validated as a set using new samples that were not used to discover the gene set. These samples can be taken from frozen archieves from the discovery clinical study or can be taken from new patients prospectively. Validation using a “test set” of samples can be done using expression profiling of the gene set with microarrays or using real-time PCR for each gene on the test set samples. Alternatively, a different expression profiling technology can be used.

[0237] Validation and Accuracy of Diagnostic Nucleotide Sets

[0238] Prior to widespread application of the diagnostic probe sets of the invention the predictive value of the probe set is validated. When the diagnostic probe set is discovered by microarray based expression analysis, the differential expression of the member genes may be validated by a less variable and more quantitive and accurate technology such as real time PCR. In this type of experiment the amplification product is measured during the PCR reaction. This enables the researcher to observe the amplification before any reagent becomes rate limiting for amplification. In kinetic PCR the measurement is of C_(T) (threshold cycle) or C_(P) (crossing point). This measurement (C_(T)=C_(P)) is the point at which an amplification curve crosses a threshold fluorescence value. The threshold is set to a point within the area where all of the reactions were in their linear phase of amplification. When measuring C_(T), a lower C_(T) value is indicative of a higher amount of starting material since an earlier cycle number means the threshold was crossed more quickly.

[0239] Several fluorescence methodologies are available to measure amplification product in real-time PCR. Taqman (Applied BioSystems, Foster City, Calif.) uses fluorescence resonance energy transfer (FRET) to inhibit signal from a probe until the probe is degraded by the sequence specific binding and Taq 3′ exonuclease activity. Molecular Beacons (Stratagene, La Jolla, Calif.) also use FRET technology, whereby the fluorescence is measured when a hairpin structure is relaxed by the specific probe binding to the amplified DNA. The third commonly used chemistry is Sybr Green, a DNA-binding dye (Molecular Probes, Eugene, Oreg.). The more amplified product that is produced, the higher the signal. The Sybr Green method is sensitive to non-specific amplification products, increasing the importance of primer design and selection. Other detection chemistries can also been used, such as ethedium bromide or other DNA-binding dyes and many modifications of the fluorescent dye/quencher dye Taqman chemistry, for example scorpions.

[0240] Real-time PCR validation can be done as described in Example 15.

[0241] Typically, the oligonucleotide sequence of each probe is confirmed, e.g. by DNA sequencing using an oligonucleotide-specific primer. Partial sequence obtained is generally sufficient to confirm the identity of the oligonucleotide probe. Alternatively, a complementary polynucleotide is fluorescently labeled and hybridized to the array, or to a different array containing a resynthesized version of the oligo nucleotide probe, and detection of the correct probe is confumed.

[0242] Typically, validation is performed by statistically evaluating the accuracy of the correspondence between the molecular signature for a diagnostic probe set and a selected indicator. For example, the expression differential for a nucleotide sequence between two subject classes can be expressed as a simple ratio of relative expression. The expression of the nucleotide sequence in subjects with selected indicator can be compared to the expression of that nucleotide sequence in subjects without the indicator, as described in the following equations.

Σ_(x) ai/N=E _(x)A the average expression of nucleotide sequence x in the members of group A;

Σ_(x) bi/M=E _(x)B the average expression of nucleotide sequence x in the members of group B;

E _(x) A/ExB=ΔE _(x)AB the average differential expression of nucleotide sequence x between groups A and B:

[0243] where Σ indicates a sum; Ex is the expression of nucleotide sequence x relative to a standard; ai are the individual members of group A, group A has N members; bi are the individual members of group B, group B has M members.

[0244] Individual components of a diagnostic probe set each have a defined sensitivity and specificity for distinguishing between subject groups. Such individual nucleotide sequences can be employed in concert as a diagnostic probe set to increase the sensitivity and specificity of the evaluation. The database of molecular signatures is queried by algorithms to identify the set of nucleotide sequences (i.e., corresponding to members of the probe set) with the highest average differential expression between subject groups. Typically, as the number of nucleotide sequences in the diagnostic probe set increases, so does the predictive value, that is, the sensitivity and specificity of the probe set. When the probe sets are defined they may be used for diagnosis and patient monitoring as discussed below. The diagnostic sensitivity and specificity of the probe sets for the defined use can be determined for a given probe set with specified expression levels as demonstrated above. By altering the expression threshold required for the use of each nucleotide sequence as a diagnostic, the sensitivity and specificity of the probe set can be altered by the practitioner. For example, by lowering the magnitude of the expression differential threshold for each nucleotide sequence in the set, the sensitivity of the test will increase, but the specificity will decrease. As is apparent from the foregoing discussion, sensitivity and specificity are inversely related and the predictive accuracy of the probe set is continuous and dependent on the expression threshold set for each nucleotide sequence. Although sensitivity and specificity tend to have an inverse relationship when expression thresholds are altered, both parameters can be increased as nucleotide sequences with predictive value are added to the diagnostic nucleotide set. In addition a single or a few markers may not be reliable expression markers across a population of patients. This is because of the variability in expression and measurement of expression that exists between measurements, individuals and individuals over time. Inclusion of a large number of candidate nucleotide sequences or large numbers of nucleotide sequences in a diagnostic nucleotide set allows for this variability as not all nucleotide sequences need to meet a threshold for diagnosis. Generally, more markers are better than a single marker. If many markers are used to make a diagnosis, the likelihood that all expression markers will not meet some thresholds based upon random variability is low and thus the test will give fewer false negatives. Surrogate markers are useful for these purposes. These are markers or genes that are coordinately expressed. Surrogate markers essential provide redundant information, but this redundancy can improve accuracy by decreasing errors due to assay variability.

[0245] It is appreciated that the desired diagnostic sensitivity and specificity of the diagnostic nucleotide set may vary depending on the intended use of the set. For example, in certain uses, high specificity and high sensitivity are desired. For example, a diagnostic nucleotide set for predicting which patient population may experience side effects may require high sensitivity so as to avoid treating such patients. In other settings, high sensitivity is desired, while reduced specificity may be tolerated. For example, in the case of a beneficial treatment with few side effects, it may be important to identify as many patients as possible (high sensitivity) who will respond to the drug, and treatment of some patients who will not respond is tolerated. In other settings, high specificity is desired and reduced sensitivity may be tolerated. For example, when identifying patients for an early-phase clinical trial, it is important to identify patients who may respond to the particular treatment. Lower sensitivity is tolerated in this setting as it merely results in reduced patients who enroll in the study or requires that more patients are screened for enrollment.

[0246] To discover and validate a gene set that can be applied to accurately diagnose or classify patients across the country or around the world, it is necessary to ensure that the gene set was developed and validated using samples that represent the types of patients that will be encountered in the clinical setting. For example, diverse ethnicity, drug usage and clinical practice patterns must all be represented in the discovery and validation to ensure that the test works on this variety of patients.

[0247] Selected Diseases

[0248] In principle, individual oligonucleotides and diagnostic oligonucleotide sets of the invention may be developed and applied to essentially any disease, or disease criterion, as long as at least one subset of oligonucleotide sequences is differentially expressed in samples derived from one or more individuals with a disease criteria or disease and one or more individuals without the disease criteria or disease, wherein the individual may be the same individual sampled at different points in time, or the individuals may be different individuals (or populations of individuals). For example, the subset of oligonucleotide sequences may be differentially expressed in the sampled tissues of subjects with the disease or disease criterion (e.g., a patient with a disease or disease criteria) as compared to subjects without the disease or disease criterion (e.g., patients without a disease (control patients)). Alternatively, or in addition, the subset of oligonucleotide sequence(s) may be differentially expressed in different samples taken from the same patient, e.g at different points in time, at different disease stages, before and after a treatment, in the presence or absence of a risk factor, etc.

[0249] Expression profiles corresponding to oligonucleotides and sets of oligonucleotide sequences that correlate not with a diagnosis, but rather with a particular aspect of a disease can also be used to identify the diagnostic oligonucleotide sets and disease specific target oligonucleotide sequences of the invention. For example, such an aspect, or disease criterion, can relate to a subject's medical or family history, e.g., occurance of an autoimmune disease, childhood illness, cause of death of a parent or other relative, prior surgery or other intervention, medications, laboratory values and results of diagnostic testing (radiology, pathology, etc.), symptoms (including onset and/or duration of symptoms), etc. Alternatively, the disease criterion can relate to a diagnosis, e.g., chronic inflammatory disease such as lupus, rheumatoid arthritis, osteoarthritis, or prognosis (e.g., prediction of future diagnoses, events or complications), e.g., renal failure from lupus, joint replacement surgery for rheumatoid arthritis, rheumatoid arthritis or systemic lupus erythematosis disease activity or the like. In other cases, the disease criterion corresponds to a therapeutic outcome, e.g., response to a medication, response to a surgery or physical therapy for a joint. Alternatively, the disease criteria correspond with previously identified or classic risk factors and may correspond to prognosis or future disease diagnosis. As indicated above, a disease criterion can also correspond to genotype for one or more loci. Disease criteria (including patient data) may be collected (and compared) from the same patient at different points in time, from different patients, between patients with a disease (criterion) and patients respresenting a control population, etc. Longitudinal data, i.e., data collected at different time points from an individual (or group of individuals) may be used for comparisons of samples obtained from an individual (group of individuals) at different points in time, to permit identification of differences specifically related to the disease state, and to obtain information relating to the change in expression over time, including a rate of change or trajectory of expression over time. The usefulness of longitudinal data is further discussed in the section titled “Identification of diagnostic nucleotide sets of the invention”.

[0250] It is further understood that diagnostic oligonucleotides and oligonucleotide sets may be developed for use in diagnosing conditions for which there is no present means of diagnosis. For example, in rheumatoid arthritis, joint destruction is often well under way before a patient experience symptoms of the condition. A diagnostic nucleotide or nucleotide set may be developed that diagnoses rheumatic joint destruction at an earlier stage than would be possible using present means of diagnosis, which rely in part on the presentation of symptoms by a patient. Diagnostic nucleotide sets may also be developed to replace or augment current diagnostic procedures. For example, the use of a diagnostic nucleotide or nucleotide set to diagnose lupus may replace or supplement the current diagnostic tests and strategies.

[0251] It is understood that the following discussion of diseases is exemplary and non-limiting, and further that the general criteria discussed above, e.g. use of family medical history, are generally applicable to the specific diseases discussed below.

[0252] In addition to leukocytes, as described throughout, the general method is applicable to oligonucleotide sequences that are differentially expressed in any subject tissue or cell type, by the collection and assessment of samples of that tissue or cell type. However, in many cases, collection of such samples presents significant technical or medical problems given the current state of the art.

[0253] Systemic Lupus Erythematosis (SLE)

[0254] SLE is a chronic, systemic inflammatory disease characterized by dysregulation of the immune system, which effects up to 2 million patients in the US. Symptoms of SLE include rashes, joint pain, abnormal blood counts, renal dysfunction and damage, infections, CNS disorders, arthralgias and autoimmunity. Patients may also have early onset atherosclerosis. The diagnosis of SLE is difficult to make with certainty using current diagnostic tests and algorithms. Antibody tests can be specific for the disease, but often lack sensitivity. Clinical diagnosis may lack both high sensisivity and specificity. SLE is a disease that clearly involves differential gene expression in leukocytes compared to patients without the disease.

[0255] Diagnostic oligonucleotides and oligonucleotide sets are identified and validated for use in diagnosis and monitoring of SLE activity and progression. Disease criteria correspond to clinical data, e.g. symptom rash, joint pain, malaise, rashes, blood counts (white and red), tests of renal function e.g. creatinine, blood urea nitrogen (hereinafter, “bun”) creative clearance, data obtained from laboratory tests, including complete blood counts with differentials, CRP, ESR, ANA, Serum IL6, Soluble CD40 ligand, LDL, HDL, Anti-DNA antibodies, rheumatoid factor, C3, C4, serum creatinine and any medication levels, the need for pain medications, cumulative doses or immunosuppressive therapy, symptoms or any manifestation of carotid atherosclerosis (e.g. ultrasound diagnosis or any other manifestations of the disease), data from surgical procedures such as gross operative findings and pathological evaluation of resected tissues and biopsies (e.g., renal, CNS), information on pharmacological therapy and treatment changes, clinical diagnoses of disease “flare”, hospitalizations, death, response to medications, quantitative joint exams, results from health assessment questionnaires (HAQs), and other clinical measures of patient symptoms and disability. In addition, disease criteria correspond to the clinical score known as SLEDAI (Bombadier C, Gladman D D, Urowitz M B, Caron D, Chang C H and the Committee on Prognosis Studies in SLE: Derivation of the SLEDAI for Lupus Patients. Arthritis Rheum 35:630-640, 1992.). Diagnostic nucleotide sets may be useful for diagnosis of SLE, monitoring disease progression including progressive renal dysfunction, carotid atherosclerosis and CNS dysfunction, and predicting occurrence of side-effects, for example.

[0256] Rheumatoid Arthritis

[0257] Rheumatoid arthritis (RA) effects about two million patients in the US and is a chronic and debilitating inflammatory arthritis, particularly involving pain and destruction of the joints. RA often goes undiagnosed because patients may have no pain, but the disease is actively destroying the joint. Other patients are known to have RA, and are treated to alleviate symptoms, but the rate of progression of joint destruction can't easily be monitored. Drug therapy is available, but the most effective medicines are toxic (e.g., steroids, methotrexate) and thus need to be used with caution. A new class of medications (TNF blockers) is very effective, but the drugs are expensive, have side effects, and not all patients respond. Side-effects are common and include immune suppression, toxicity to organ systems, allergy and metabolic disturbances.

[0258] Diagnostic oligonucleotides and oligonucleotide sets of the invention are developed and validated for use in diagnosis and treatment of RA. Disease criteria correspond to disease symptoms (e.g., joint pain, joint swelling and joint stiffness and any of the American College for Rheumatology criteria for the diagnosis of RA, see Arnett et al (1988) Arthr. Rheum. 31:315-24), progression of joint destruction (e.g. as measured by serial hand radiographs, assessment of joint function and mobility), surgery, need for medication, additional diagnoses of inflammatory and non-inflammatory conditions, and clinical laboratory measurements including complete blood counts with differentials, CRP, ESR, ANA, Serum IL6, Soluble CD40 ligand, LDL, HDL, Anti-DNA antibodies, rheumatoid factor, C3, C4, serum creatinine, death, hospitalization and disability due to joint destruction. In addition, or alternatively, disease criteria correspond to response to drug therapy and presence or absence of side-effects or measures of improvement exemplified by the American College of Rheumatology “20%” and “50%” response/improvement rates. See Felson et al (1995) Arthr Rheum 38:531-37. Diagnostic nucleotide sets are identified that monitor and predict disease progression including flaring (acute worsening of disease accompanied by joint pain or other symptoms), response to drug treatment and likelihood of side-effects.

[0259] In addition to peripheral leukocytes, surgical specimens of rheumatoid joints can be used for leukocyte expression profiling experiments. Members of diagnostic nucleotide sets are candidates for leukocyte target nucleotide sequences, e.g. as a candidate drug target for rheumatoid arthritis. Synovial specimens can be used for expression profiling or cells derived and sorted from that tissue (such as subsets of leukocytes) can be used. Cells can be separated by fluorescence activated cell sorting or magnetic affinity reagent techniques or some other technique. Synovial specimens and blood can be obtained from the same patient and gene expression can be compared between these 2 sample types.

[0260] Osteoarthritis

[0261] 20-40 million patients in the US have osteoarthritis. Patient groups are heterogeneous, with a subset of patients having earlier onset, more aggressive joint damage, involving more inflammation (leukocyte infiltration). Leukocyte diagnostics can be used to distinguish osteoarthritis from rheumatoid arthritis and other differential diagnoses, define likelihood and degree of response to NSAID therapy (non-steroidal anti-inflammatory drugs) or other anti-inflammatory therapies. Rate of progression of joint damage can also be assessed. Diagnostic nucleotide sets may be developed for use in selection and titration of treatment therapies. Disease criteria correspond to response to therapy, and disease progression using certain therapies, response to medications, need for joint surgery, joint pain and disability.

[0262] In addition to peripheral leukocytes, surgical specimens of osteoarthritic joints can be used for leukocyte expression profiling experiments. Diagnostic oligonucleotides and diagnostic oligonucleotide sets are candidates for leukocyte target nucleotide sequences, e.g. as a candidate drug target for osteoarthritis. Synovial specimens can be used for expression profiling or cells derived and sorted from that tissue (such as subsets of leukocytes) can be used. Cells can be separated by fluorescence activated cell sorting or magnetic affinity reagent techniques or some other technique. Synovial specimens and blood can be obtained from the same patient and gene expression can be compared between these 2 sample types.

[0263] In another example, diagnostic nucleotide sets are developed and validated for use in diagnosis and therapy of peri-prosthetic osteolysis. In this disease, a prosthetic joint such as a knee or hip is found to loosen over time and requires repeat surgery. Loosening may occur in some patients due to an inflammatory response incited by the foreign material of the prosthesis. Disease criteria include joint loosening, radiographic evidence of peri-prosthetic osteolysis, need for repeat surgery, response to pharmacological therapy, and/or histological (from biopsy or surgery) or biochemical (markers of bone metabolism such as alkaline phosphatase) evidence of osteolysis. Tissues used for expression profiling can include peripheral leukocytes or leukocyte subsets, periprosthetic tissue, or synovial fluid. In addition, gene sets can be discovered using an in vitromodel of the disease in which immune cells are exposed to prosthesis materials such as cement or titanium.

[0264] Pharmacogenomics

[0265] Pharmocogenomics is the study of the individual propensity to respond to a particular drug therapy (combination of therapies). In this context, response can mean whether a particular drug will work on a particular patient, e.g. some patients respond to one drug but not to another drug. Response can also refer to the likelihood of successful treatment or the assessment of progress in treatment. Titration of drug therapy to a particular patient is also included in this description, e.g. different patients can respond to different doses of a given medication. This aspect may be important when drugs with side-effects or interactions with other drug therapies are contemplated.

[0266] Diagnostic oligonucleotides and oligonucleotide sets are developed and validated for use in assessing whether a patient will respond to a particular therapy and/or monitoring response of a patient to drug therapy(therapies). Disease criteria correspond to presence or absence of clinical symptoms or clinical endpoints, presence of side-effects or interaction with other drug(s). The diagnostic nucleotide set may further comprise nucleotide sequences that are targets of drug treatment or markers of active disease.

[0267] Diagnostic oligonucleotides and oligonucleotide sets are developed and validated for use in assessing whether a patient has a particular drug toxicity or toxicity due to an environmental, work-related or other agent. Such exposures of the patient may also be related to biological or biochemical agents used in warfare. Diagnostic oligonucleotides and oligonucleotide sets may allow early diagnosis of a toxicity or exposure or may monitor the severity and course of toxic responses.

[0268] Methods of Using Diagnostic Oligonucleotides and Oligonucleotide Sets.

[0269] The invention also provide methods of using the diagnostic oligonucleotides and oligonucleotide sets to: diagnose or monitor disease; assess severity of disease; predict future occurrence of disease; predict future complications of disease; determine disease prognosis; evaluate the patient's risk, or “stratify” a group of patients; assess response to current drug therapy; assess response to current non-pharmacological therapy; determine the most appropriate medication or treatment for the patient; predict whether a patient is likely to respond to a particular drug; and determine most appropriate additional diagnostic testing for the patient, among other clinically and epidemiologically relevant applications.

[0270] The oligonucleotides and oligonucleotide sets of the invention can be utilized for a variety of purposes by physicians, healthcare workers, hospitals, laboratories, patients, companies and other institutions. As indicated previously, essentially any disease, condition, or status for which at least one nucleotide sequence is differentially expressed in leukocyte populations (or sub-populations) can be evaluated, e.g., diagnosed, monitored, etc. using the diagnostic nucleotide sets and methods of the invention. In addition to assessing health status at an individual level, the diagnostic nucleotide sets of the present invention are suitable for evaluating subjects at a “population level,” e.g., for epidemiological studies, or for population screening for a condition or disease.

[0271] Collection and Preparation of Sample

[0272] RNA, protein and/or DNA are prepared using methods well-known in the art, as further described herein. It is appreciated that subject samples collected for use in the methods of the invention are generally collected in a clinical setting, where delays may be introduced before RNA samples are prepared from the subject samples of whole blood, e.g. the blood sample may not be promptly delivered to the clinical lab for further processing. Further delay may be introduced in the clinical lab setting where multiple samples are generally being processed at any given time. For this reason, methods that feature lengthy incubations of intact leukocytes at room temperature are not preferred, because the expression profile of the leukocytes may change during this extended time period. For example, RNA can be isolated from whole blood using a phenol/guanidine isothiocyanate reagent or another direct whole-blood lysis method, as described in, e.g., U.S. Pat. Nos. 5,346,994 and 4,843,155. This method may be less preferred under certain circumstances because the large majority of the RNA recovered from whole blood RNA extraction comes from erythrocytes since these cells outnumber leukocytes 1000:1. Care must be taken to ensure that the presence of erythrocyte RNA and protein does not introduce bias in the RNA expression profile data or lead to inadequate sensitivity or specificity of probes.

[0273] Alternatively, intact leukocytes may be collected from whole blood using a lysis buffer that selectively lyses erythrocytes, but not leukocytes, as described, e.g., in (U.S. Pat. Nos. 5,973,137, and 6,020,186). Intact leukocytes are then collected by centrifugation, and leukocyte RNA is isolated using standard protocols, as described herein. However, this method does not allow isolation of sub-populations of leukocytes, e.g. mononuclear cells, which may be desired. In addition, the expression profile may change during the lengthy incubation in lysis buffer, especially in a busy clinical lab where large numbers of samples are being prepared at any given time.

[0274] Alternatively, specific leukocyte cell types can be separated using density gradient reagents (Boyum, A, 1968.). For example, mononuclear cells may be separated from whole blood using density gradient centrifugation, as described, e.g., in U.S. Pat. Nos. 4,190,535, 4,350,593, 4,751,001, 4,818,418, and 5053134. Blood is drawn directly into a tube containing an anticoagulant and a density reagent (such as Ficoll or Percoll). Centrifugation of this tube results in separation of blood into an erythrocyte and granulocyte layer, a mononuclear cell suspension, and a plasma layer. The mononuclear cell layer is easily removed and the cells can be collected by centrifugation, lysed, and frozen. Frozen samples are stable until RNA can be isolated. Density centrifugation, however, must be conducted at room temperature, and if processing is unduly lengthy, such as in a busy clinical lab, the expression profile may change.

[0275] The quality and quantity of each clinical RNA sample is desirably checked before amplification and labeling for array hybridization, using methods known in the art. For example, one microliter of each sample may be analyzed on a Bioanalyzer (Agilent 2100 Palo Alto, Calif. USA) using an RNA 6000 nano LabChip (Caliper, Mountain View, Calif. USA). Degraded RNA is identified by the reduction of the 28S to 18S ribosomal RNA ratio and/or the presence of large quantities of RNA in the 25-100 nucleotide range.

[0276] It is appreciated that the RNA sample for use with a diagnostic oligonucleotide or oligonucleotide set may be produced from the same or a different cell population, sub-population and/or cell type as used to identify the diagnostic nucleotide set. For example, a diagnostic oligonucleotide or oligonucleotide set identified using RNA extracted from mononuclear cells may be suitable for analysis of RNA extracted from whole blood or mononuclear cells, depending on the particular characteristics of the members of the diagnostic nucleotide set. Generally, diagnostic oligonucleotides or oligonucleotide sets must be tested and validated when used with RNA derived from a different cell population, sub-population or cell type than that used when obtaining the diagnostic gene set. Factors such as the cell-specific gene expression of diagnostic nucleotide set members, redundancy of the information provided by members of the diagnostic nucleotide set, expression level of the member of the diagnostic nucleotide set, and cell-specific alteration of expression of a member of the diagnostic nucleotide set will contribute to the usefullness of a different RNA source than that used when identifying the members of the diagnostic nucleotide set. It is appreciated that it may be desirable to assay RNA derived from whole blood, obviating the need to isolate particular cell types from the blood.

[0277] Assessing Expression for Diagnostics

[0278] Expression profiles for the oligonucleotides or the set of diagnostic oligonucleotide sequences in a subject sample can be evaluated by any technique that determines the expression of each component oligonucleotide sequence. Methods suitable for expression analysis are known in the art, and numerous examples are discussed in the Sections titled “Methods of obtaining expression data” and “high throughput expression Assays”, above.

[0279] In many cases, evaluation of expression profiles is most efficiently, and cost effectively, performed by analyzing RNA expression. Alternatively, the proteins encoded by each component of the diagnostic nucleotide set are detected for diagnostic purposes by any technique capable of determining protein expression, e.g., as described above. Expression profiles can be assessed in subject leukocyte sample using the same or different techniques as those used to identify and validate the diagnostic oligonucleotide or oligonucleotide set. For example, a diagnostic nucleotide set identified as a subset of sequences on a cDNA microarray can be utilized for diagnostic (or prognostic, or monitoring, etc.) purposes on the same array from which they were identified. Alternatively, the diagnostic nucleotide sets for a given disease or condition can be organized onto a dedicated sub-array for the indicated purpose. It is important to note that if diagnostic nucleotide sets are discovered using one technology, e.g. RNA expression profiling, but applied as a diagnostic using another technology, e.g. protein expression profiling, the nucleotide (or gene, or protein) sets must generally be validated for diagnostic purposes with the new technology. In addition, it is appreciated that diagnostic nucleotide sets that are developed for one use, e.g. to diagnose a particular disease, may later be found to be useful for a different application, e.g. to predict the likelihood that the particular disease will occur. Generally, the diagnostic nucleotide set will need to be validated for use in the second circumstance. As discussed herein, the sequence of diagnostic nucleotide set members may be amplified from RNA or cDNA using methods known in the art providing specific amplification of the nucleotide sequences.

[0280] Identification of Novel Nucleotide Sequences That are Differentially Expressed in Leukocytes

[0281] Novel nucleotide sequences that are differentially expressed in leukocytes are also part of the invention. Previously unidentified open reading frames may be identified in a library of differentially expressed candidate nucleotide sequences, as described above, and the DNA and predicted protein sequence may be identified and characterized as noted above. We identified unnamed (not previously described as corresponding to a gene, or an expressed gene) nucleotide sequences in our candidate nucleotide library, depicted in Table 3A, 3B AND 3C and the sequence listing. Accordingly, further embodiments of the invention are the isolated nucleic acids described in Tables 3A and 3B AND 3C and in the sequence listing. The novel differentially expressed nucleotide sequences of the invention are useful in the diagnostic nucleotide set of the invention described above, and are further useful as members of a diagnostic nucleotide set immobilized on an array. The novel partial nucleotide sequences may be further characterized using sequence tools and publically or privately accessible sequence databases, as is well known in the art: Novel differentially expressed nucleotide sequences may be identified as disease target nucleotide sequences, described below. Novel nucleotide sequences may also be used as imaging reagent, as further described below.

[0282] As used herein, “novel nucleotide sequence” refers to (a) a nucleotide sequence containing at least one of the DNA sequences disclosed herein (as shown in FIGS. Table 3A, 3B and the sequence listing); (b) any DNA sequence that encodes the amino acid sequence encoded by the DNA sequences disclosed herein; (c) any DNA sequence that hybridizes to the complement of the coding sequences disclosed herein, contained within the coding region of the nucleotide sequence to which the DNA sequences disclosed herein (as shown in Table 3A, 3B AND 3C and the sequence listing) belong, under highly stringent conditions, e.g., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and washing in 0.1× SSC/0.1% SDS at 68° C. (Ausubel F. M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. 1, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3), (d) any DNA sequence that hybridizes to the complement of the coding sequences disclosed herein, (as shown in Table 3A, 3B AND 3C and the sequence listing) contained within the coding region of the nucleotide sequence to which DNA sequences disclosed herein (as shown in TABLES 3A, 3B and the sequence listing) belong, under less stringent conditions, such as moderately stringent conditions, e.g., washing in 0.2× SSC/0.1% SDS at 42° C. (Ausubel et al., 1989, supra), yet which still encodes a functionally equivalent gene product; and/or (e) any DNA sequence that is at least 90% identical, at least 80% identical or at least 70% identical to the coding sequences disclosed herein (as shown in TABLES 3A, 3B AND 3C and the sequence listing), wherein % identity is determined using standard algorithms known in the art.

[0283] The invention also includes nucleic acid molecules, preferably DNA molecules, that hybridize to, and are therefore the complements of, the DNA sequences (a) through (c), in the preceding paragraph. Such hybridization conditions may be highly stringent or less highly stringent, as described above. In instances wherein the nucleic acid molecules are deoxyoligonucleotides (“oligos”), highly stringent conditions may refer, e.g., to washing in 6× SSC/0.05% sodium pyrophosphate at 37° C. (for 14-base oligos), 48° C. (for 17-base oligos), 55° C. (for 20-base oligos), and 60° C. (for 23-base oligos). These nucleic acid molecules may act as target nucleotide sequence antisense molecules, useful, for example, in target nucleotide sequence regulation and/or as antisense primers in amplification reactions of target nucleotide sequence nucleic acid sequences. Further, such sequences may be used as part of ribozyme and/or triple helix sequences, also useful for target nucleotide sequence regulation. Still further, such molecules may be used as components of diagnostic methods whereby the presence of a disease-causing allele, may be detected.

[0284] The Invention Also Encompasses Nucleic Acid Molecules Contained in Full-Length Gene Sequences That Are Related to Or Derived From Sequences In Tables 2, 3, 8-10 and the Sequence Listing. One Sequence May Map to More Than One Full-Length Gene.

[0285] The invention also encompasses (a) DNA vectors that contain any of the foregoing coding sequences and/or their complements (i.e., antisense); (b) DNA expression vectors that contain any of the foregoing coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences; and (c) genetically engineered host cells that contain any of the foregoing coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences in the host cell. As used herein, regulatory elements include but are not limited to inducible and non-inducible promoters, enhancers, operators and other elements known to those skilled in the art that drive and regulate expression. The invention includes fragments of any of the DNA sequences disclosed herein. Fragments of the DNA sequences may be at least 5, at least 10, at least 15, at least 19 nucleotides, at least 25 nucleotides, at least 50 nucleotides, at least 100 nucleotides, at least 200, at least 500, or larger.

[0286] In addition to the oligonucleotide sequences described above, homologues and orthologs of such sequences, as may, for example be present in other species, may be identified and may be readily isolated, without undue experimentation, by molecular biological techniques well known in the art, as well as use of gene analysis tools described above, and e.g., in Example 4. Further, there may exist nucleotide sequences at other genetic loci within the genome that encode proteins, which have extensive homology to one or more domains of such gene products. These nucleotide sequences may also be identified via similar techniques.

[0287] For example, the isolated differentially expressed nucleotide sequence may be labeled and used to screen a cDNA library constructed from mRNA obtained from the organism of interest. Hybridization conditions will be of a lower stringency when the cDNA library was derived from an organism different from the type of organism from which the labeled sequence was derived. Alternatively, the labeled fragment may be used to screen a genomic library derived from the organism of interest, again, using appropriately stringent conditions. Such low stringency conditions will be well known to those of skill in the art, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Springs Harbor Press, N.Y.; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

[0288] Protein Products

[0289] Novel nucleotide products include those proteins encoded by the novel nucleotide sequences described, above. Specifically, novel gene products may include polypeptides encoded by the novel nucleotide sequences contained in the coding regions of the nucleotide sequences to which DNA sequences disclosed herein (in TABLES 3A, 3B and the sequence listing).

[0290] In addition, novel protein products of novel nucleotide sequences may include proteins that represent functionally equivalent gene products. Such an equivalent novel gene product may contain deletions, additions or substitutions of amino acid residues within the amino acid sequence encoded by the novel nucleotide sequences described, above, but which result in a silent change, thus producing a functionally equivalent novel nucleotide sequence product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.

[0291] For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid. “Functionally equivalent”, as utilized herein, refers to a protein capable of exhibiting a substantially similar in vivo activity as the endogenous novel gene products encoded by the novel nucleotide described, above.

[0292] The novel gene products (protein products of the novel nucleotide sequences) may be produced by recombinant DNA technology using techniques well known in the art. Methods which are well known to those skilled in the art can be used to construct expression vectors containing novel nucleotide sequence protein coding sequences and appropriate transcriptional/translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. See, for example, the techniques described in Sambrook et al., 1989, supra, and Ausubel et al., 1989, supra. Alternatively, RNA capable of encoding novel nucleotide sequence protein sequences may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in “Oligonucleotide Synthesis”, 1984, Gait, M. J. ed., IRL Press, Oxford, which is incorporated by reference herein in its entirety. A variety of host-expression vector systems may be utilized to express the novel nucleotide sequence coding sequences of the invention. (Ruther et al., 1983, EMBO J. 2:1791; Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503; Smith et al., 1983, J. Virol. 46: 584; Smith, U.S. Pat. No. 4,215,051; Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659; Bittner et al., 1987, Methods in Enzymol. 153:516-544; Wigler, et al., 1977, Cell 11:223; Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026; Lowy, et al., 1980, Cell 22:817; Wigler, et al., 1980, Natl. Acad. Sci. USA 77:3567; O'Hare, et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527; Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072; Colberre-Garapin, et al., 1981, J. Mol. Biol. 150:1; Santerre, et al., 1984, Gene 30:147; Janknecht, et al., 1991, Proc. Natl. Acad. Sci. USA 88: 8972-8976

[0293] Where recombinant DNA technology is used to produce the protein encoded by the novel nucleotide sequence for such assay systems, it may be advantageous to engineer fusion proteins that can facilitate labeling, immobilization and/or detection.

[0294] Indirect labeling involves the use of a protein, such as a labeled antibody, which specifically binds to the protein encoded by the novel nucleotide sequence. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments and fragments produced by an Fab expression library.

[0295] Antibodies

[0296] The invention also provides for antibodies to the protein encoded by the novel nucleotide sequences. Described herein are methods for the production of antibodies capable of specifically recognizing one or more novel nucleotide sequence epitopes. Such antibodies may include, but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab′)₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Such antibodies may be used, for example, in the detection of a novel nucleotide sequence in a biological sample, or, alternatively, as a method for the inhibition of abnormal gene activity, for example, the inhibition of a disease target nucleotide sequence, as further described below. Thus, such antibodies may be utilized as part of cardiovascular or other disease treatment method, and/or may be used as part of diagnostic techniques whereby patients may be tested for abnormal levels of novel nucleotide sequence encoded proteins, or for the presence of abnormal forms of the such proteins.

[0297] For the production of antibodies to a novel nucleotide sequence, various host animals may be immunized by injection with a novel protein encoded by the novel nucleotide sequence, or a portion thereof. Such host animals may include but are not limited to rabbits, mice, and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum.

[0298] Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as novel gene product, or an antigenic functional derivative thereof. For the production of polyclonal antibodies, host animals such as those described above, may be immunized by injection with novel gene product supplemented with adjuvants as also described above.

[0299] Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to the hybridoma technique of Kohler and Milstein, (1975, Nature 256:495-497; and U.S. Pat. No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, Immunology Today 4:72; Cole et al., 1983, Proc. Natl. Acad. Sci. USA 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo.

[0300] In addition, techniques developed for the production of “chimeric antibodies” (Morrison et al., 1984, Proc. Natl. Acad. Sci., 81:6851-6855; Neuberger et al., 1984, Nature, 312:604-608; Takeda et al., 1985, Nature, 314:452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.

[0301] Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778; Bird, 1988, Science 242:423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward et al., 1989, Nature 334:544-546) can be adapted to produce novel nucleotide sequence-single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

[0302] Antibody fragments which recognize specific epitopes may be generated by known techniques For example, such fragments include but are not limited to: the F(ab′)₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab′)₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

[0303] Disease specific Target Oligonucleotide Sequences

[0304] The invention also provides disease specific target oligonucleotide sequences, and sets of disease specific target oligonucleotide sequences. The diagnostic oligonucleotide sets, subsets thereof, novel oligonucleotide sequences, and individual members of the diagnostic oligonucleotide sets identified as described above are also disease specific target oligonucleotide sequences. In particular, individual oligonucleotide sequences that are differentially regulated or have predictive value that is strongly correlated with a disease or disease criterion are especially favorable as disease specific target oligonucleotide sequences. Sets of genes that are co-regulated may also be identified as disease specific target oligonucleotide sets. Such oligonucleotide sequences and/or oligonucleotide sequence products are targets for modulation by a variety of agents and techniques. For example, disease specific target oligonucleotide sequences (or the products of such oligonucleotide sequences, or sets of disease specific target oligonucleotide sequences) can be inhibited or activated by, e.g., target specific monoclonal antibodies or small molecule inhibitors, or delivery of the oligonucleotide sequence or gene product of the oligonucleotide sequence to patients. Also, sets of genes can be inhibited or activated by a variety of agents and techniques. The specific usefulness of the target oligonucleotide sequence(s) depends on the subject groups from which they were discovered, and the disease or disease criterion with which they correlate.

[0305] Kits

[0306] The present invention is optionally provided to a user as a kit. Typically, a kit contains one or more diagnostic nucleotide sets of the invention. Alternatively, the kit contains the candidate nucleotide library of the invention. Most often, the kit contains a diagnostic nucleotide probe set, or other subset of a candidate library, (e.g., as a cDNA, oligonucleotide or antibody microarray or reagents for performing an assay on a diagnostic gene set using any expression profiling technology), packaged in a suitable container. The kit may further comprise, one or more additional reagents, e.g., substrates, labels, primers, for labeling expression products, tubes and/or other accessories, reagents for collecting blood samples, buffers, e.g., erythrocyte lysis buffer, leukocyte lysis buffer, hybridization chambers, cover slips, etc., as well as a software package, e.g., including the statistical methods of the invention, e.g., as described above, and a password and/or account number for accessing the compiled database. The kit optionally further comprises an instruction set or user manual detailing preferred methods of using the diagnostic nucleotide sets in the methods of the invention.

[0307] This invention will be better understood by reference to the following non-limiting Examples:

EXAMPLES

[0308] Example 1: Generation of Subtracted Leukocyte Candidate Nucleotide Library

[0309] Example 2: Identification of Nucleotide Sequences for Candidate Library Using Data Mining Techniques

[0310] Example 3: DNA Sequencing and Processing of Raw Sequence Data.

[0311] Example 4: Further Sequence Analysis of Novel Nucleotide Sequences Identified by Subtractive Hybridization Screening

[0312] Example 5: Further Sequence Analysis of Novel Clone 596H6

[0313] Example 6: Further Sequence Analysis of Novel Clone 486E11

[0314] Example 7: Preparation of RNA from Mononuclear Cells for Expression Profiling

[0315] Example 8: Preparation of Universal Control RNA for Use in Leukocyte Expression Profiling

[0316] Example 9: Identification of Diagnostic Oligonucleotide Sets for Use in Diagnosis of Rheumatoid Arthritis.

[0317] Example 10: Identification of Diagnostic Oligonucleotide Sets for Diagnosis of Systemic Lupus Erythematosis

[0318] Example 11: Probe Selection for a 24,000 Feature Array.

[0319] Example 12: Design of Oligonucleotide Probes.

[0320] Example 13: Production of an Array of 8,000 Spotted 50 Mer Oligonucleotides.

[0321] Example 14: Amplification, Labeling and Hybridization of Total RNA to an Oligonucleotide Microarray.

[0322] Example 15: Real-Time PCR Validation of Array Expression Results

[0323] Example 16: Correlation and Classification Analysis Examples

Example 1 Generation of Subtracted Leukocyte Candidate Nucleotide Library

[0324] To produce a candidate nucleotide library with representatives from the spectrum of nucleotide sequences that are differentially expressed in leukocytes, subtracted hybridization libraries were produced from the following cell types and conditions:

[0325] 1. Buffy Coat leukocyte fractions—stimulated with ionomycin and PMA

[0326] 2. Buffy Coat leukocyte fractions—un-stimulated

[0327] 3. Peripheral blood mononuclear cells—stimulated with ionomycin and PMA

[0328] 4. Peripheral blood mononuclear cells—un-stimulated

[0329] 5. T lymphocytes—stimulated with PMA and ionomycin

[0330] 6. T lymphocytes—resting

[0331] Cells were obtained from multiple individuals to avoid introduction of bias by using only one person as a cell source.

[0332] Buffy coats (platelets and leukocytes that are isolated from whole blood) were purchased from Stanford Medical School Blood Center. Four buffy coats were used, each of which was derived from about 350 ml of whole blood from one donor individual 10 ml of buffy coat sample was drawn from the sample bag using a needle and syringe. 40 ml of Buffer EL (Qiagen) was added per 10 ml of buffy coat to lyse red blood cells. The sample was placed on ice for 15 minutes, and cells were collected by centrifugation at 2000 rpm for 10 minutes. The supernatant was decanted and the cell pellet was re-suspended in leukocyte growth media supplemented with DNase (LGM-3 from Clonetics supplemented with Dnase at a final concentration of 30 U/ml). Cell density was determined using a hemocytometer. Cells were plated in media at a density of 1×10⁶ cells/ml in a total volume of 30 ml in a T-75 flask (Coming). Half of the cells were stimulated with ionomycin and phorbol myristate acetate (PMA) at a final concentration of 1μg/ml and 62 ng/ml, respectively. Cells were incubated at 37° C. and at 5% CO₂ for 3 hours, then cells were scraped off the flask and collected into 50 ml tubes. Stimulated and resting cell populations were kept separate. Cells were centrifuged at 2000 rpm for 10 minutes and the supernatant was removed. Cells were lysed in 6 ml of phenol/guanidine isothyocyanate (Trizol reagent, GibcoBRL), homogenized using a rotary homogenizer, and frozen at 80°. Total RNA and mRNA were isolated as described below.

[0333] Two frozen vials of 5×10⁶ pooled human peripheral blood mononuclear cells (PBMCs) were purchased from Clonetics (catalog number α-2702). The cells were rapidly thawed in a 37° C. water bath and transferred to a 15 ml tube containing 10 ml of leukocyte growth media supplemented with DNase (prepared as described above). Cells were centrifuged at 2000 μg for 10 minutes. The supernatant was removed and the cell pellet was resuspended in LGM-3 media supplemented with DNase. Cell density was determined using a hemocytometer. Cells were plated at a density of 1×10⁶ cells/ml in a total volume of 30 ml in a T-75 flask (Coming). Half of the cells were stimulated with ionomycin and PMA at a final concentration of 1 μg/ml and 62 ng/ml, respectively. Cells were incubated at 37° C. and at 5% CO₂ for 3 hours, then cells were scraped off the flask and collected into 50 ml tubes. Stimulated and resting cell populations were kept separate. Cells were centrifuged at 2000 rpm and the supernatant was removed. Cells were lysed in 6 ml of phenol/guanidine isothyocyanate solution (TRIZOL reagent, GibcoBRL)), homogenized using a rotary homogenizer, and frozen at 80°. Total RNA and mRNA were isolated from these samples using the protocol described below.

[0334] 45 ml of whole blood was drawn from a peripheral vein of four healthy human subjects into tubes containing anticoagulant. 50 μl RosetteSep (Stem Cell Technologies) T-cell isolation cocktail per ml of blood was added, mixed well, and incubated for 20 minutes at room temperature. The mixture was diluted with an equal volume of PBS +2% fetal bovine serum (FBS) and mixed by inversion. 30 ml of diluted mixture sample was layered on top of 15 ml DML medium (Stem Cell Technologies). The sample tube was centrifuged for 20 minutes at 1200× g at room temperature. The enriched T-lymphocyte cell layer at the plasma: medium interface was removed. Enriched cells were washed with PBS +2% FBS and centrifuged at 1200× g. The cell pellet was treated with 5 ml of erythrocyte lysis buffer (EL buffer, Qiagen) for 10 minutes on ice. The sample was centrifuged for 5 min at 1200 g. Cells were plated at a density of 1×10⁶ cells/ml in a total volume of 30 ml in a T-75 flask (Coming). Half of the cells were stimulated with ionomycin and PMA at a final concentration of 1 μg/ml and 62 ng/ml, respectively. Cells were incubated at 37° C. and at 5% CO₂ for 3 hours, then cells were scraped off the flask and collected into 50 ml tubes. Stimulated and resting cell populations were kept separate. Cells were centrifuged at 2000 rpm and the supernatant was removed. Cells were lysed in 6 ml of phenol/guanidine isothyocyanate solution (TRIZOL reagent, GibcoBRL), homogenized using a rotary homogenizer, and frozen at 80°. Total RNA and mRNA were isolated as described below.

[0335] Total RNA and mRNA were isolated using the following procedure: the homogenized samples were thawed and mixed by vortexing. Samples were lysed in a 1:0.2 mixture of Trizol and chloroform, respectively. For some samples, 6 ml of Trizol-chloroform was added. Variable amounts of Trizol-chloroform was added to other samples. Following lysis, samples were centrifuged at 3000 g for 15 min at 4° C. The aqueous layer was removed into a clean tube and 4 volumes of Buffer RLT Qiagen) was added for every volume of aqueous layer. The samples were mixed thoroughly and total RNA was prepared from the sample by following the Qiagen Rneasy midi protocol for RNA cleanup (October 1999 protocol, Qiagen). For the final step, the RNA was eluted from the column twice with 250 μl Rnase-free water. Total RNA was quantified using a spectrophotometer. Isolation of mRNA from total RNA sample was done using The Oligotex mRNA isolation protocol (Qiagen) was used to isolate mRNA from total RNA, according to the manufacturer's instructions (Qiagen, 7/99 version). mRNA was quantified by spectrophotometry.

[0336] Subtracted cDNA libraries were prepared using Clontech's PCR-Select cDNA Subtraction Kit (protocol number PT-1117-1) as described in the manufacturer's protocol. The protocol calls for two sources of RNA per library, designated “Driver” and “Tester.” The following 6 libraries were made: Library Driver RNA Tester RNA Buffy Coat Un-stimulated Buffy Stimulated Buffy Coat Stimulated Coat Buffy Coat Resting Stimulated Buffy Coat Un-stimulated Buffy Coat PBMC Stimulated Un-stimulated PBMCs Stimulated PBMCs PBMC Resting Stimulated PBMCs Un-stimulated PBMCs T-cell Stimulated Un-stimulated T-cells Stimulated T-cells T-cell Resting Stimulated T-cells Un-stimulated T-cells

[0337] The Clontech protocol results in the PCR amplification of cDNA products. The PCR products of the subtraction protocol were ligated to the pGEM T-easy bacterial vector as described by the vector manufacturer (Promega 6/99 version). Ligated vector was transformed into competent bacteria using well-known techniques, plated, and individual clones are picked, grown and stored as a glycerol stock at −80C. Plasmid DNA was isolated from these bacteria by standard techniques and used for sequence analysis of the insert. Unique cDNA sequences were searched in the Unigene database (build 133), and Unigene cluster numbers were identified that corresponded to the DNA sequence of the cDNA. Unigene cluster numbers were recorded in an Excel spreadsheet.

Example 2 Identification of Nucleotide Sequences for Candidate Library Using Data Mining Techniques

[0338] Existing and publicly available gene sequence databases were used to identify candidate nucleotide sequences for leukocyte expression profiling. Genes and nucleotide sequences with specific expression in leukocytes, for example, lineage specific markers, or known differential expression in resting or activated leukocytes were identified. Such nucleotide sequences are used in a leukocyte candidate nucleotide library, alone or in combination with nucleotide sequences isolated through cDNA library construction, as described above.

[0339] Leukocyte candidate nucleotide sequences were identified using three primary methods. First, the publically accessible publication database PubMed was searched to identify nucleotide sequences with known specific or differential expression in leukocytes. Nucleotide sequences were identified that have been demonstrated to have differential expression in peripheral blood leukocytes between subjects with and without particular disease(s) selected from Table 1. Additionally, genes and gene sequences that were known to be specific or selective for leukocytes or sub-populations of leukocytes were identified in this way.

[0340] Next, two publicly available databases of DNA sequences, Unigene located on the website at ncbi.nlm.nih.gov/UniGene and BodyMap located on the website at bodymap.ims.u-tokyo.acjp, were searched for sequenced DNA clones that showed specificity to leukocyte lineages, or subsets of leukocytes, or resting or activated leukocytes.

[0341] The human Unigene database (build 133) was used to identify leukocyte candidate nucleotide sequences that were likely to be highly or exclusively expressed in leukocytes. We used the Library Differential Display utility of Unigene located on the website at ncbi.nlm.nih.gov/UniGene/info/ddd.html, which uses statistical methods (The Fisher Exact Test) to identify nucleotide sequences that have relative specificity for a chosen library or group of libraries relative to each other. We compared the following human libraries from Unigene release 133:

[0342] 546 NCI_CGAP_HSCl (399)

[0343] 848 Human_mRNA_from_cd34+_stem_cells (122)

[0344] 105 CD34+DIRECTIONAL (150)

[0345] 3587 KRIBB_Human_CD4_intrathymicT-cell_cDNAibrary (134)

[0346] 3586 KRIBB_Human_DP_intrathymicT-cell_cDNAibrary (179)

[0347] 3585 KRIBB_Human_TN_intrathymicT-cell_cDNAlibrary (127)

[0348] 3568 323 ActivatedT-cells_(—)1(740)

[0349] 376 Activated_T-cellsXX (1727)

[0350] 327 Monocytes,_stimulated_II (110)

[0351] 824 Proliferating Erythroid_Cells (LCB adjibrary) (665)

[0352] 825 429 MacrophageII (105)

[0353] 387 MacrophageI (137)

[0354] 669 NCI_CGAP_CLL1 (11626)

[0355] 129 HumanWhiteblood_cells (922)

[0356] 1400 NIH_MGC_(—)2 (422)

[0357] 55 Human_promyelocyte (1220)

[0358] 1010 NCI_CGAP_CML1 (2541)

[0359] 2217 NCI_CGAP_Sub7 (218)

[0360] 1395 NCI_CGAP_Sub6 (2764)

[0361] 4874 NIH_MGC 48 (2524)

[0362] Sequences from these libraries were compared to sequences from non-leukocyte derived libraries in the Unigene database to identify genes that had some specificity for the leukcoyte-derived libraries.

[0363] BodyMap, like Unigene, contains cell-specific libraries that contain potentially useful information about genes that may serve as lineage-specific or leukocyte specific markers (Okubo et al. 1992). We compared three leukocyte specific libraries, Granulocyte CD4 T cell, and CD8 T cell, with the other libraries. Nucleotide sequences that were found in one or more of the leukocyte-specific libraries, but absent in the others, were identified. Clones that were found exclusively in one of the three leukocyte libraries were also included in a list of nucleotide sequences that could serve as lineage-specific markers.

[0364] Next, the sequence of the nucleotide sequences identified in PubMed or BodyMap were searched in Unigene (version 133), and a human Unigene cluster number was identified for each nucleotide sequence. The cluster number was recorded in a Microsoft Excel™ spreadsheet, and a non-redundant list of these clones was made by sorting the clones by UniGene number, and removing all redundant clones using Microsoft Excel™ tools. The non-redundant list of UniGene cluster numbers was then compared to the UniGene cluster numbers of the cDNAs identified using subtractive cDNA hybridization, as described above in Example 1 (listed in Table 3 and the sequence listing). Only UniGene clusters that were not contained in the cDNA libraries were retained. Unigene clusters corresponding to 1911 candidate nucleotide sequences for leukocyte expression profiling were identified in this way and are listed in Table 3 and the sequence listing.

[0365] DNA clones corresponding to each UniGene cluster number are obtained in a variety of ways. First, a cDNA clone with identical sequence to part of, or all of the identified UniGene cluster is bought from a commercial vendor or obtained from the IMAGE consortium located on the web at image.llnl.gov/, the Integrated Molecular Analysis of Genomes and their Expression. Alternatively, PCR primers are designed to amplify and clone any portion of the nucleotide sequence from cDNA or genomic DNA using well-known techniques. Alternatively, the sequences of the identified UniGene clusters are used to design and synthesize oligonucleotide probes for use in oligonucleotide microarray based expression profiling.

Example 3 DNA Sequencing and Processing of Raw Sequence Data

[0366] Clones of differentially expressed cDNAs (identified by subtractive hybridization, described above) were sequenced on an MJ Research BaseStation™ slab gel based fluorescent detection system, using BigDye™ (Applied Biosystems, Foster City, Calif.) terminator chemistry was used (Heiner et al., Genome Res May 1998; 8(5):557-61).

[0367] The fluorescent profiles were analyzed using the Phred sequence analysis program (Ewing et al, (1998), Genome Research 8: 175-185). Analysis of each clone results in a one pass nucleotide sequence and a quality file containing a number for each base pair with a score based on the probability that the determined base is correct. Each of the sequence files and its respective quality files were initially combined into single fasta format (Pearson, WR. Methods Mol. Biol. 2000;132:185-219), multi-sequence file with the appropriate labels for each clone in the headers for subsequent automated analysis.

[0368] Initially, known sequences were analyzed by pair wise similarity searching using the blastn option of the blastall program obtained from the National Center for Biological Information, National Library of Medicine, National Institutes of Health (NCBI) to determine the quality score that produced accurate matching (Altschul SF, et al. J. Mol. Biol. 1990 Oct 5;215(3):403-10.). Empirically, it was determined that a raw score of 8 was the minimum that contained useful information. Using a sliding window average for 16 base pairs, an average score was determined. The sequence was removed (trimmed) when the average score fell below 8. Maximum reads were 950 nucleotides long.

[0369] Next, the sequences were compared by similarity matching against a database file containing the flanking vector sequences used to clone the cDNA, using the blastall program with the blastn option. All regions of vector similarity were removed, or “trimmed” from the sequences of the clones using scripts in the GAWK programming language, a variation of AWK (Aho AV et al, The Awk Programming Language (Addison-Wesley, Reading MA, 1988); Robbins, AD, “Effective AWK Programming” (Free Software Foundation, Boston Mass., 1997). It was found that the first 45 base pairs of all the sequences were related to vector; these sequences were also trimmed and thus removed from consideration. The remaining sequences were then compared against the NCBI vector database (Kitts, P. A. et al. National Center for Biological Information, National Library of Medicine, National Institutes of Health, Manuscript in preparation (2001) using blastall with the blastn option. Any vector sequences that were found were removed from the sequences.

[0370] Messenger RNA contains repetitive elements that are found in genomic DNA. These repetitive elements lead to false positive results in similarity searches of query mRNA sequences versus known mRNA and EST databases. Additionally, regions of low information content (long runs of the same nucleotide, for example) also result in false positive results. These regions were masked using the program RepeatMasker2 found on the website at repeatmasker.genome.washington.edu (Smit, A F A & Green, P “RepeatMasker” at the website at genome.washington.edu/RM/RepeatMasker.html. The trimmed and masked files were then subjected to further sequence analysis.

Example 4 Further Sequence Analysis of Novel Nucleotide Sequences Identified by Subtractive Hybridization Screening

[0371] cDNA sequences were further characterized using BLAST analysis. The BLASTN program was used to compare the sequence of the fragment to the UniGene, dbEST, and nr databases at NCBI (GenBark release 123.0; see Table 5). In the BLAST algorithm, the expect value for an alignment is used as the measure of its significance. First, the cDNA sequences were compared to sequences in Unigene on the web at ncbi.nlm.nih.gov/UniGene. If no alignments were found with an expect value less than 10³¹ ²⁵, the sequence was compared to the sequences in the dbEST database using BLASTN. If no alignments were found with an expect value less than 10-25, the sequence was compared to sequences in the nr database.

[0372] The BLAST analysis produced the following categories of results: a) a significant match to a known or predicted human gene, b) a significant match to a nonhuman DNA sequence, such as vector DNA or E. coli DNA, c) a significant match to an unidentified GenBank entry (a sequence not previously identified or predicted to be an expressed sequence or a gene), such as a cDNA clone, mRNA, or cosmid, or d) no significant alignments. If a match to a known or predicted human gene was found, analysis of the known or predicted protein product was performed as described below. If a match to an unidentified GenBank entry was found, or if no significant alignments were found, the sequence was searched against all known sequences in the human genome database located on the web at ncbi.nlm.nih.gov/genome/seq/page.cgi?F=HsBlast.html&&ORG=Hs, see Table 5.

[0373] If many unknown sequences were to be analyzed with BLASTN, the clustering algorithm CAP2 (Contig Assembly Program, version 2) was used to cluster them into longer, contiguous sequences before performing a BLAST search of the human genome. Sequences that can be grouped into contigs are likely to be cDNA from expressed genes rather than vector DNA, E. coli DNA or human chromosomal DNA from a noncoding region, any of which could have been incorporated into the library. Clustered sequences provide a longer query sequence for database comparisons with BLASTN, increasing the probability of finding a significant match to a known gene. When a significant alignment was found, further analysis of the putative gene was performed, as described below. Otherwise, the sequence of the original cDNA fragment or the CAP2 contig is used to design a probe for expression analysis and further approaches are taken to identify the gene or predicted gene that corresponds to the cDNA sequence, including similarity searches of other databases, molecular cloning, and Rapid Amplification of cDNA Ends (RACE).

[0374] In some cases, the process of analyzing many unknown sequences with BLASTN was automated by using the BLAST network-client program blastc13, which was downloaded from ftp://ncbi.nlm.nih.gov/blast/network/netblast.

[0375] When a cDNA sequence aligned to the sequence of one or more chromosomes, a large piece of the genomic region around the loci was used to predict the gene containing the cDNA. To do this, the contig corresponding to the mapped locus, as assembled by the RefSeq project at NCBI, was downloaded and cropped to include the region of alignment plus 100,000 bases preceding it and 100,000 bases following it on the chromosome. The result was a segment 200 kb in length, plus the length of the alignment. This segment, designated a putative gene, was analyzed using an exon prediction algorithm to determine whether the alignment area of the unknown sequence was contained within a region predicted to be transcribed (see Table 6).

[0376] This putative gene was characterized as follows: all of the exons comprising the putative gene and the introns between them were taken as a unit by noting the residue numbers on the 200 kb+ segment that correspond to the first base of the first exon and the last base of the last exon, as given in the data returned by the exon prediction algorithm. The truncated sequence was compared to the UniGene, dbEST, and nr databases to search for alignments missed by searching with the initial fragment.

[0377] The predicted amino acid sequence of the gene was also analyzed. The peptide sequence of the gene predicted from the exons was used in conjunction with numerous software tools for protein analysis (see Table 7). These were used to classify or identify the peptide based on similarities to known proteins, as well as to predict physical, chemical, and biological properties of the peptides, including secondary and tertiary structure, flexibility, hydrophobicity, antigenicity (hydrophilicity), common domains and motifs, and localization within the cell or tissues. The peptide sequence was compared to protein databases, including SWISS-PROT, TrEMBL, GenPept, PDB, PIR, PROSITE, ProDom, PROSITE, Blocks, PRINTS, and Pfam, using BLASTP and other algorithms to determine similarities to known proteins or protein subunits.

Example 5 Further Sequence Analysis of Novel Clone 596H6

[0378] The sequence of clone 596H6 is provided below: (SEQ ID NO:8767) ACTATATTTA GGCACCACTG CCATAAACTA CCAAAAAAAA AATGTAATTC 50 CTAGAAGCTG TGAAGAATAG TAGTGTAGCT AAGCACGGTG TGTGGACAGT 100 GGGACATCTG CCACCTGCAG TAGGTCTCTG CACTCCCAAA AGCAAATTAC 150 ATTGGCTTGA ACTTCAGTAT GCCCGGTTCC ACCCTCCAGA AACTTTTGTG 200 TTCTTTGTAT AGAATTTAGG AACTTCTGAG GGCCACAAAT ACACACATTA 250 AAAAAGGTAG AATTTTTGAA GATAAGATTC TTCTAAAAAA GCTTCCCAAT 300 GCTTGAGTAG AAAGTATCAG TAGAGGTATC AAGGGAGGAG AGACTAGGTG 350 ACCACTAAAC TCCTTCAGAC TCTTAAAATT ACGATTCTTT TCTCAAAGGG 400 GAAGAACGTC AGTGCAGCGA TCCCTTCACC TTTAGCTAAA GAATTGGACT 450 GTGCTGCTCA AAATAAAGAT CAGTTGGAGG TANGATGTCC AAGACTGAAG 500 GTAAAGGACT AGTGCAAACT GAAAGTGATG GGGAAACAGA CCTACGTATG 550 GAAGCCATGT AGTGTTCTTC ACAGGCTGCT GTTGACTGAA ATTCCTATCC 600 TCAAATTACT CTAGACTGAA GCTGCTTCCC TTCAGTGAGC AGCCTCTCCT 650 TCCAAGATTC TGGAAAGCAC ACCTGACTCC AAACAAAGAC TTAGAGCCCT 700 GTGTCAGTGC TGCTGCTGCT TTTACCAGAT TCTCTAACCT TCCGGGTAGA 750 AGAG

[0379] This sequence was used as input for a series of BLASTN searches. First, it was used to search the UniGene database, build 132 located on the web at ncbi.nlm.nih.gov/BLAST. No alignments were found with an expect value less than the threshold value of 10⁻²⁵. A BLASTN search of the database dbEST, release 041001, was then performed on the sequence and 21 alignments were found (http://www.ncbi.nlm.nih.gov/BLAST/). Ten of these had expect values less than 1025, but all were matches to unidentified cDNA clones. Next, the sequence was used to run a BLASTN search of the nr database, release 123.0. No significant alignment to any sequence in nr was found. Finally, a BLASTN search of the human genome was performed on the sequence located on the web at ncbi.nlm.nih. gov/genome/seq/page.cgi?F=HsBlast.html&&ORG=Hs.

[0380] A single alignment to the genome was found on contig NT_(—)004698.3 (e=0.0). The region of alignment on the contig was from base 1,821,298 to base 1,822,054, and this region was found to be mapped to chromosome 1, from base 105,552,694 to base 105,553,450. The sequence containing the aligned region, plus 100 kilobases on each side of the aligned region, was downloaded. Specifically, the sequence of chromosome 1 from base105,452,694 to 105,653,450 was downloaded from the website at ncbi.nlm.nih.gov/cgi-bin/Entrez/seq_reg.cgi?chr=1 &from=105452694&to=105653450.

[0381] This 200,757 bp segment of the chromosome was used to predict exons and their peptide products as follows. The sequence was used as input for the Genscan algorithm located on the web at genes.mit.edu/GENSCAN.html, using the following Genscan settings:

[0382] Organism: vertebrate

[0383] Suboptimal exon cutoff: 1.00 (no suboptimal exons)

[0384] Print options: Predicted CDS and peptides

[0385] The region matching the sequence of clone 596H6 was known to span base numbers 100,001 to 100,757 of the input sequence. An exon was predicted by the algorithm, with a probability of 0.695, covering bases 100,601 to 101,094 (designated exon 4.14 of the fourth predicted gene). This exon was part of a predicted cistron that is 24,195 bp in length. The sequence corresponding to the cistron was noted and saved separately from the 200,757 bp segment. BLASTN searches of the Unigene, dbEST, and nr databases were performed on it.

[0386] At least 100 significant alignments to various regions of the sequence were found in the dbEST database, although most appeared to be redundant representations of a few exons. All matches were to unnamed cDNAs and mRNAs (unnamed cDNAs and mRNAs are cDNAs and mRNAs not previously identified, or shown to correspond to a known or predicted human gene) from various tissue types. Most aligned to a single region on the sequence and spanned 500 bp or less, but several consisted of five or six regions separated by gaps, suggesting the locations of exons in the gene. Several significant matches to entries in the UniGene database were found, as well, even after masking low-complexity regions and short repeats in the sequence. All matches were to unnamed cDNA clones.

[0387] At least 100 significant alignments were found in the nr database, as well. A similarity to hypothetical protein FLJ22457 (UniGene cluster Hs.238707) was found (e=0.0). The cDNA of this predicted protein has been isolated from B lymphocytes located on the web at ncbi.nlm.nih.gov/entrez/viewer.cgi?save—0&cmd=&cfm=on&f=1 &view=gp&txt=0&val=13637988.

[0388] Other significant alignments were to unnamed cDNAs and mRNAs.

[0389] Using Genscan, the following 730 residue peptide sequence was predicted from the putative gene: +TR,1(SEQ ID NO:8768) MDGLGRRLRA SLRLKRGHGG HWRLNEMPYM KHEFDGGPPQ DNSGEALKEP 50 ERAQEHSLPN FAGGQHFFEY LLVVSLKKKR SEDDYEPIIT YQFPKRENLL 100 RGQQEEEERL LKAIPLFCFP DGNEWASLTE YPSLSCKTPG LLAALVVEKA 150 QPRTCCHASA PSAAPQARGP DAPSPAAGQA LPAGPGPRLP KVYCIISCIG 200 CFGLFSKILD EVEKRHQISM AVIYPFMQGL REAAFPAPGK TVTLKSFIPD 250 SGTEFISLTR PLDSHLEHVD FSSLLHCLSF EQILQIFASA VLERKIIFLA 300 EGLREEEKDV RDSTEVRGAG ECHGFQRKGN LGKQWGLCVE DSVKMGDNQR 350 GTSCSTLSQC IHAAAALLYP FSWAHTYIPV VPESLLATVC CPTPFMVGVQ 400 MRFQQEVMDS PMEEIQPQAE IKTVNPLGVY EERGPEKASL CLFQVLLVNL 450 CEGTFLMSVG DEKDILPPKL QDDILDSLGQ GINELKTAEQ INEHVSGPFV 500 QFFVKIVGHY ASYIKREANG QGHFQERSFC KALTSKTNRR FVKKFVKTQL 550 FSLFIQEAEK SKNPPAEVTQ VGNSSTCVVD TWLEAAATAL SHHYNIFNTE 600 HTLWSKGSAS LHEVCGHVRT RVKRKILFLY VSLAFTMGKS IFLVENKAMN 650 MTIKWTTSGR PGHGDMFGVI ESWGAAALLL LTGRVRDTGK SSSSTGHRAS 700 KSLVWSQVCF PESWEERLLT EGKQLQSRVI

[0390] Multiple analyses were performed using this prediction. First, a pairwise comparison of the sequence above and the sequence of FLJ22457, the hypothetical protein mentioned above, using BLASTP version 2.1.2 located on the web at ncbi.nlm.nih.gov/BLAST, resulted in a match with an expect value of 0.0. The peptide sequence predicted from clone 596H6 was longer and 19% of the region of alignment between the two resulted from gaps in hypothetical protein FLJ22457. The cause of the discrepancy might be alternative mRNA splicing, alternative post-translational processing, or differences in the peptide-predicting algorithms used to create the two sequences, but the homology between the two is significant.

[0391] BLASTP and TBLASTN were also used to search for sequence similarities in the SWISS-PROT, TrEMBL, GenBank Translated, and PDB databases. Matches to several proteins were found, among them a tumor cell suppression protein, HTS1. No matches aligned to the full length of the peptide sequence, however, suggesting that similarity is limited to a few regions of the peptide.

[0392] TBLASTN produced matches to several proteins—both identified and theoretical—but again, no matches aligned to the full length of the peptide sequence. The best alignment was to the same hypothetical protein found in GenBank before (FLJ22457).

[0393] To discover similarities to protein families, comparisons of the domains (described above) were carried out using the Pfam and Blocks databases. A search of the Pfam database identified two regions of the peptide domains as belonging the DENN protein family (e=2.1×10⁻³³). The human DENN protein possesses an RGD cellular adhesion motif and a leucine-zipper-like motif associated with protein dimerization, and shows partial homology to the receptor binding domain of tumor necrosis factor alpha. DENN is virtually identical to MADD, a human MAP kinase-activating death domain protein that interacts with type I tumor necrosis factor receptor located on the web at srs.ebi. ac.uk/srs6bin/cgi-bin/wgetz?-id+fS 5n1GQsHf+-e+[INTERPRO:‘IPROO 1194’]. The search of the Blocks database also revealed similarities between regions of the peptide sequence and known protein groups, but none with a satisfactory degree of confidence. In the Blocks scoring system, scores over 1,I00 are likely to be relevant. The highest score of any match to the predicted peptide was 1,058.

[0394] The Prosite, ProDom, PRINTS databases (all publicly available) were used to conduct further domain and motif analysis. The Prosite search generated many recognized protein domains. A BLASTP search was performed to identify areas of similarity between the protein query sequence and PRINTS, a protein database of protein fingerprints, groups of motifs that together form a characteristic signature of a protein family. In this case, no groups were found to align closely to any section of the submitted sequence. The same was true when the ProDom database was searched with BLASTP.

[0395] A prediction of protein structure was done by performing a BLAST search of the sequence against PDB, a database in which every member has tertiary structure information. No significant alignments were found by this method. Secondary and super-secondary structure was examined using the Gamier algorithm. Although it is only considered to be 60-65% accurate, the algorithm provided information on the locations and lengths of alpha-helices, beta-sheets, turns and coils.

[0396] The antigenicity of the predicted peptide was modeled by graphing hydrophilicity vs. amino acid number. This produced a visual representation of trends in hydrophilicity along the sequence. Many locations in the sequence showed antigenicity and five sites had antigenicity greater than 2. This information can be used in the design of affinity reagents to the protein.

[0397] Membrane-spanning regions were predicted by graphing hydrophobicity vs. amino acid number. Thirteen regions were found to be somewhat hydrophobic. The algorithm TMpred predicted a model with 6 strong transmembrane helices located on the web at ch.embnet.org/software/TMPRED_form.html.

[0398] NNPSL is a neural network algorithm developed by the Sanger Center. It uses amino acid composition and sequence to predict cellular location. For the peptide sequence submitted, its first choice was mitochondrial (51.1% expected accuracy). Its second choice was cytoplasmic (91.4% expected accuracy).

Example 6 Further Sequence Analysis of Novel Clone 486E11

[0399] The sequence of clone 486E11 is provided below: (SEQ ID NO:8769) TAAAAGCAGG CTGTGCACTA GGGACCTAGT GACCTTACTA GAAAAAACTC 50 AAATTCTCTG AGCCACAAGT CCTCATGGGC AAAATGTAGA TACCACCACC 100 TAACCCTGCC AATTTCCTAT CATTGTGACT ATCAAATTAA ACCACAGGCA 150 GGAAGTTGCC TTGAAAACTT TTTATAGTGT ATATTACTGT TCACATAGAT 200 NAGCAATTAA CTTTACATAT ACCCGTTTTT AAAAGATCAG TCCTGTGATT 250 AAAAGTCTGG CTGCCCTAAT TCACTTCGAT TATACATTAG GTTAAAGCCA 300 TATAAAAGAG GCACTACGTC TTCGGAGAGA TGAATGGATA TTACAAGCAG 350 TAATGTTGGC TTTGGAATAT ACACATAATG TCCACTTGAC CTCATCTATT 400 TGACACAAAA TGTAAACTAA ATTATGAGCA TCATTAGATA CCTTGGCCTT 450 TTCAAATCAC ACAGGGTCCT AGATCTNNNN NNNNNNNNNN NNNNNNNNNN 500 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN TTTGGGATTC 550 CTATATCTTT GTCAGCTGTC AACTTCAGTG TTTTCAGGTT AAATTCTATC 600 CATAGTCATC CCAATATACC TGCTTTAGAT GATACAACCT TCAAAAGATC 650 CGCTCTTCCT CGTAAAAAGT GGAG

[0400] The BLASTN program was used to compare the sequence to the UniGene and dbEST databases. No significant alignments were found in either. It was then searched against the nr database and only alignments to unnamed genomic DNA clones were found.

[0401] CAP2 was used to cluster a group of unknowns, including clone 486E11. The sequence for 486E11 was found to overlap others. These formed a contig of 1,010 residues, which is shown below: (SEQ ID NO:8832) CGGACAGGTA CCTAAAAGCA GGCTGTGCAC TAGGGACCTA GTGACCTTAC 50 TAGAAAAAAC TCAAATTCTC TGAGCCACAA GTCCTCATGG GCAAAATGTA 100 GATACCACCA CCTAACCCTG CCAATTTCCT ATCATTGTGA CTATCAAATT 150 AAACCACAGG CAGGAAGTTG CCTTGAAAAC TTTTTATAGT GTATATTACT 200 GTTCACATAG ATNAGCAATT AACTTTACAT ATACCCGTTT TTAAAAGATC 250 AGTCCTGTGA TTAAAAGTCT GGCTGCCCTA ATTCACTTCG ATTATACATT 300 AGGTTAAAGC CATATAAAAG AGGCACTACG TCTTCGGAGA GATGAATGGA 350 TATTACAAGC AGTAATTTTG GCTTTGGAAT ATACACATAA TGTCCACTTG 400 ACCTCATCTA TTTGACACAA AATGTAAACT AAATTATGAG CATCATTAGA 450 TACCTTGGGC CTTTTCAAAT CACACAGGGT CCTAGATCTG NNNNNNNNNN 500 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN 550 NACTTTGGAT TCTTATATCT TTGTCAGCTG TCAACTTCAG TGTTTTCAGG 600 NTAAATTCTA TCCATAGTCA TCCCAATATA CCTGCTTTAG ATGATACAAA 650 CTTCAAAAGA TCCGGCTCTC CCTCGTAAAA CGTGGAGGAC AGACATCAAG 700 GGGGTTTTCT GAGTAAAGAA AGGCAACCGC TCGGCAAAAA CTCACCCTGG 750 CACAACAGGA NCGAATATAT ACAGACGCTG ATTGAGCGTT TTGCTCCATC 800 TTCACTTCTG TTAAATGAAG ACATTGATAT CTAAAATGCT ATGAGTCTAA 850 CTTTGTAAAA TTAAAATAGA TTTGTAGTTA TTTTTCAAAA TGAAATCGAA 900 AAGATACAAG TTTTGAAGGC AGTCTCTTTT TCCACCCTGC CCCTCTAGTG 950 TGTTTTACAC ACTTCTCTGG CCACTCCAAC AGGGAAGCTG GTCCAGGGCC 1000 ATTATACAGG

[0402] The sequence of the CAP2 contig was used in a BLAST search of the human genome. 934 out of 1,010 residues aligned to a region of chromosome 21. A gap of 61 residues divided the aligned region into two smaller fragments. The sequence of this region, plus 100 kilobases on each side of it, was downloaded and analyzed using the Genscan site at MIT located on the web at genes.mit.edu/GENSCAN.html, with the following settings:

[0403] Organism: vertebrate

[0404] Suboptimal exon cutoff: 1.00 (no suboptimal exons)

[0405] Print options: Predicted CDS and peptides

[0406] The fragment was found to fall within one of several predicted genes in the chromosome region. The bases corresponding to the predicted gene, including its predicted introns, were saved as a separate file and used to search GenBank again with BLASTN to find any ESTs or UniGene clusters identified by portions of the sequence not included in the original unknown fragment. The nr database contained no significant matches. At least 100 significant matches to various parts of the predicted gene were found in the dbEST database, but all of them were to unnamed cDNA clones. Comparison to UniGene produced fewer significant matches, but all matches were to unnamed cDNAs.

[0407] The peptide sequence predicted by Genscan was also saved. Multiple types of analyses were performed on it using the resources mentioned in Table 3. BLASTP and TBLASTN were used to search the TrEMBL protein database located on the web at expasy.ch/sprot/) and the GenBank nr database located on the web at ncbi.nlm.hih.gov/BLAST, which includes data from the SwissProt, PIR, PRF, and PDB databases. No significant matches were found in any of these, so no gene identity or tertiary structure was discovered.

[0408] The peptide sequence was also searched for similarity to known domains and motifs using BLASTP with the Prosite, Blocks, Pfam, and ProDom databases. The searches produced no significant alignments to known domains. BLASTP comparison to the PRINTS database produced an alignment to the P450 protein family, but with a low probability of accuracy (e=6.9).

[0409] Two methods were used to predict secondary structure—the Gamier/Osguthorpe/Robson model and the Chou-Fasman model. The two methods differed somewhat in their results, but both produced representations of the peptide sequence with helical and sheet regions and locations of turns.

[0410] Antigenicity was plotted as a graph with amino acid number in the sequence on the x-axis and hydrophilicity on the y-axis. Several areas of antigenicity were observed, but only one with antigenicity greater than 2. Hydrophobicity was plotted in the same way. Only one region, from approximately residue 135 to residue 150, had notable hydrophobicity. TMpred, accessed through ExPASy, was used to predict transmembrane helices. No regions of the peptide sequence were predicted with reasonable confidence to be membrane-spanning helices.

[0411] NNPSL predicted that the putative protein would be found either in the nucleus (expected prediction accuracy =51.1%) or secreted from the cell (expected prediction accuracy =91.4%).

Example 7 Preparation of RNA from Mononuclear Cells for Expression Profiling

[0412] Blood was isolated from the subject for leukocyte expression profiling using the following methods:

[0413] Two tubes were drawn per patient. Blood was drawn from either a standard peripheral venous blood draw or directly from a large-bore intra-arterial or intravenous catheter inserted in the femoral artery, femoral vein, subdlavian vein or internal jugular vein. Care was taken to avoid sample contamination with heparin from the intravascular catheters, as heparin can interfere with subsequent RNA reactions.

[0414] For each tube, 8 ml of whole blood was drawn into a tube (CPT, Becton-Dickinson order #362753) containing the anticoagulant Citrate, 25° C. density gradient solution (e.g. Ficoll, Percoll) and a polyester gel barrier that upon centrifugation was permeable to RBCs and granulocytes but not to mononuclear cells. The tube was inverted several times to mix the blood with the anticoagulant. The tubes were centrifuged at 1750× g in a swing-out rotor at room temperature for 20 minutes. The tubes were removed from the centrifuge and inverted 5-10 times to mix the plasma with the mononuclear cells, while trapping the RBCs and the granulocytes beneath the gel barrier. The plasma/mononuclear cell mix was decanted into a 15 ml tube and 5 ml of phosphate-buffered saline (PBS) is added. The 15 ml tubes were spun for 5 minutes at 1750× g to pellet the cells. The supernatant was discarded and 1.8 ml of RLT lysis buffer is added to the mononuclear cell pellet. The buffer and cells were pipetted up and down to ensure complete lysis of the pellet. The cell lysate was frozen and stored until it is convenient to proceed with isolation of total RNA.

[0415] Total RNA was purified from the lysed mononuclear cells using the Qiagen Rneasy Miniprep kit, as directed by the manufacturer (10/99 version) for total RNA isolation, including homogenization (Qiashredder columns) and on-column DNase treatment. The purified RNA was eluted in 50 μl of water.

[0416] Some samples were prepared by a different protocol, as follows:

[0417] Two 8 ml blood samples were drawn from a peripheral vein into a tube (CPT, Becton-Dickinson order #362753) containing anticoagulant (Citrate), 25° C. density gradient solution (Ficoll) and a polyester gel barrier that upon centrifugation is permeable to RBCs and granulocytes but not to mononuclear cells. The mononuclear cells and plasma remained above the barrier while the RBCs and granulocytes were trapped below. The tube was inverted several times to mix the blood with the anticoagulant, and the tubes were subjected to centrifugation at 1750× g in a swing-out rotor at room temperature for 20 min. The tubes were removed from the centrifuge, and the clear plasma layer above the cloudy mononuclear cell layer was aspirated and discarded. The cloudy mononuclear cell layer was aspirated, with care taken to rinse all of the mononuclear cells from the surface of the gel barrier with PBS (phosphate buffered saline). Approximately 2 mls of mononuclear cell suspension was transferred to a 2 ml microcentrifuge tube, and centrifuged for 3 min. at 16,000 rpm in a microcentrifuge to pellet the cells. The supernatant was discarded and 1.8 ml of RLT lysis buffer (Qiagen) were added to the mononuclear cell pellet, which lysed the cells and inactivated Rnases. The cells and lysis buffer were pipetted up and down to ensure complete lysis of the pellet. Cell lysate was frozen and stored until it was convenient to proceed with isolation of total RNA.

[0418] RNA samples were isolated from 8 mL of whole blood. Yields ranged from 2 ug to 20 ug total RNA for 8 mL blood. A260/A280 spectrophotometric ratios were between 1.6 and 2.0, indicating purity of sample. 2 ul of each sample were run on an agarose gel in the presence of ethidium bromide. No degradation of the RNA sample and no DNA contamination were visible.

[0419] In some cases, specific subsets of mononuclear cells were isolated from peripheral blood of human subjects. When this was done, the StemSep cell separation kits (manual version 6.0.0) were used from StemCell Technologies (Vancouver, Canada). This same protocol can be applied to the isolation of T cells, CD4 T cells, CD8 T cells, B cells, monocytes, NK cells and other cells. Isolation of cell types using negative selection with antibodies may be desirable to avoid activation of target cells by antibodies.

Example 8 Preparation of Universal Control RNA for use in Leukocyte Expression Profiling

[0420] Control RNA was prepared using total RNA from Buffy coats and/or total RNA from enriched mononuclear cells isolated from Buffy coats, both with and without stimulation with ionomycin and PMA. The following control RNAs were prepared:

[0421] Control 1: Buffy Coat Total RNA

[0422] Control 2: Mononuclear cell Total RNA

[0423] Control 3: Stimulated buffy coat Total RNA

[0424] Control 4: Stimulated mononuclear Total RNA

[0425] Control 5: 50% Buffy coat Total RNA/50% Stimulated buffy coat Total RNA

[0426] Control 6: 50% Mononuclear cell Total RNA/50% Stimulated Mononuclear Total RNA.

[0427] Some samples were prepared using the following protocol: Buffy coats from 38 individuals were obtained from Stanford Blood Center. Each buffy coat is derived from ˜350 mL whole blood from one individual. 10 ml buffy coat was removed from the bag, and placed into a 50 ml tube. 40 ml of Buffer EL (Qiagen) was added, the tube was mixed and placed on ice for 15 minutes, then cells were pelleted by centrifugation at 2000× g for 10 minutes at 4° C. The supernatant was decanted and the cell pellet was re-suspended in 10 ml of Qiagen Buffer EL. The tube was then centrifuged at 2000× g for 10 minutes at 4° C. The cell pellet was then re-suspended in 20 ml TRIZOL (GibcoBRL) per Buffy coat sample, the mixture was shredded using a rotary homogenizer, and the lysate was then frozen at −80° C. prior to proceeding to RNA isolation.

[0428] Other control RNAs were prepared from enriched mononuclear cells prepared from Buffy coats. Buffy coats from Stanford Blood Center were obtained, as described above. 10 ml buffy coat was added to a 50 ml polypropylene tube, and 10 ml of phosphate buffer saline (PBS) was added to each tube. A polysucrose (5.7 g/dL) and sodium diatrizoate (9.0 g/dL) solution at a 1.077+/−0.0001 g/ml density solution of equal volume to diluted sample was prepared (Histopaque 1077, Sigma cat. no 1077-1). This and all subsequent steps were performed at room temperature. 15 ml of diluted buffy coat/PBS was layered on top of 15 ml of the histopaque solution in a 50 ml tube. The tube was centrifuged at 400× g for 30 minutes at room temperature. After centrifugation, the upper layer of the solution to within 0.5 cm of the opaque interface containing the mononuclear cells was discarded. The opaque interface was transferred into a clean centrifuge tube. An equal volume of PBS was added to each tube and centrifuged at 350× g for 10 minutes at room temperature. The supernatant was discarded. 5 ml of Buffer EL (Qiagen) was used to resuspend the remaining cell pellet and the tube was centrifuged at 2000× g for 10 minutes at room temperature. The supernatant was discarded. The pellet was resuspended in 20 ml of TRIZOL (GibcoBRL) for each individual buffy coat that was processed. The sample was homogenized using a rotary homogenizer and frozen at −80C until RNA was isolated.

[0429] RNA was isolated from frozen lysed Buffy coat samples as follows: frozen samples were thawed, and 4 ml of chloroform was added to each buffy coat sample. The sample was mixed by vortexing and centrifuged at 2000× g for 5 minutes. The aqueous layer was moved to new tube and then repurified by using the RNeasy Maxi RNA clean up kit, according to the manufacturer's instruction (Qiagen, PN 75162). The yield, purity and integrity were assessed by spectrophotometer and gel electrophoresis.

[0430] Some samples were prepared by a different protocol, as follows. The further use of RNA prepared using this protocol is described in Example 14.

[0431] 50 whole blood samples were randomly selected from consented blood donors at the Stanford Medical School Blood Center. Each buffy coat sample was produced from 350 mL of an individual's donated blood. The whole blood sample was centrifuged at 4,400× g for 8 minutes at room temperature, resulting in three distinct layers: a top layer of plasma, a second layer of buffy coat, and a third layer of red blood cells. 25 ml of the buffy coat fraction was obtained and diluted with an equal volume of PBS (phosphate buffered saline). 30 ml of diluted buffy coat was layered onto 15 ml of sodium diatrizoate solution adjusted to a density of 1.077+/−0.001 g/ml (Histopaque 1077, Sigma) in a 50 mL plastic tube. The tube was spun at 800 g for 10 minutes at room temperature. The plasma layer was removed to the 30 ml mark on the tube, and the mononuclear cell layer removed into a new tube and washed with an equal volume of PBS, and collected by centrifugation at 2000 g for 10 minutes at room temperature. The cell pellet was resuspended in 10 ml of Buffer EL (Qiagen) by vortexing and incubated on ice for 10 minutes to remove any remaining erthythrocytes. The mononuclear cells were spun at 2000 g for 10 minutes at 4 degrees Celsius. The cell pellet was lysed in 25 ml of a phenol/guanidinium thiocyanate solution (TRIZOL Reagent, Invitrogen). The sample was homogenized using a PowerGene 5 rotary homogenizer (Fisher Scientific) and Omini disposable generator probes (Fisher Scientific). The Trizol lysate was frozen at −80 degrees C. until the next step.

[0432] The samples were thawed out and incubated at room temperature for 5 minutes. 5 ml chloroform was added to each sample, mixed by vortexing, and incubated at room temperature for 3 minutes. The aqueous layers were transferred to new 50 ml tubes. The aqueous layer containing total RNA was further purified using the Qiagen RNeasy Maxi kit (PN 75162), per the manufacturer's protocol (October 1999). The columns were eluted twice with 1 ml Rnase-free water, with a minute incubation before each spin. Quantity and quality of RNA was assessed using standard methods. Generally, RNA was isolated from batches of 10 buffy coats at a time, with an average yield per buffy coat of 870 μg, and an estimated total yield of 43.5 mg total RNA with a 260/280 ratio of 1.56 and a 28S/18S ratio of 1.78.

[0433] Quality of the RNA was tested using the Agilent 2100 Bioanalyzer using RNA 6000 microfluidics chips. Analysis of the electrophorgrams from the Bioanalyzer for five different batches demonstrated the reproducibility in quality between the batches.

[0434] Total RNA from all five batches were combined and mixed in a 50 ml tube, then aliquoted as follows: 2×10 ml aliquots in 15 ml tubes, and the rest in 100 μl aliquots in 1.5 ml microcentrifuge tubes. The aliquots gave highly reproducible results with respect to RNA purity, size and integrity. The RNA was stored at −80° C. Test hybridization of Reference RNA.

[0435] When compared with BC38 and Stimulated mononuclear reference samples, the R50 performed as well, if not better than the other reference samples as shown in FIG. 4.

[0436] In an analysis of hybridizations, where the R50 targets were fluorescently labeled with Cy-5 using methods described herein and the amplified and labeled aRNA was hybridized (as in example 14) to the olignoucleotide array described in example 13. The R50 detected 97.3% of probes with a Signal to Noise ratio (S/N) of greater than three and 99.9% of probes with SIN greater one.

Example 9 Identification of Diagnostic Oligonucleotides and Oligonuldeotide Sets for Use in Monitoring Treatment and/or Progression of Rheumatoid Arthritis

[0437] Rheumatoid arthritis (hereinafter, “RA”) is a chronic and debilitating inflammatory arthritis. The diagnosis of RA is made by clinical criteria and radiographs. A new class of medication, TNF blockers, are effective, but the drugs are expensive, have side effects and not all patients respond to treatment. In addition, relief of disease symptoms does not always correlate with inhibition of joint destruction. For these reasons, an alternative mechanism for the titration of therapy is needed.

[0438] An observational study was conducted in which a cohort of patients meeting American College of Rheumatology (hereinafter “ARC”) criteria for the diagnosis of RA was identified. Arnett et al. (1988) Arthritis Rheum 31:315-24. Patients gave informed consent and a peripheral blood mononuclear cell RNA sample was obtained by the methods as described herein. When available, RNA samples were also obtained from surgical specimens of bone or synovium from effected joints, and synovial fluid. Also, T-cells were isolated from the peripheral blood for some patients for expression analysis. This was done using the protocol given in Example 7.

[0439] From each patient, the following clinical information was obtained if available: Demographic information; information relating to the ACR criteria for RA; presence or absence of additional diagnoses of inflammatory and non-inflammatory conditions; data from laboratory test, including complete blood counts with differentials, CRP, ESR, ANA, Serum IL6, Soluble CD40 ligand, LDL, HDL, Anti-DNA antibodies, rheumatoid factor, C3, C4, serum creatinine and any medication levels; data from surgical procedures such as gross operative findings and pathological evaluation of resected tissues and biopsies; information on pharmacological therapy and treatment changes; clinical diagnoses of disease “flare”; hospitalizations; quantitative joint exams; results from health assessment questionnaires (HAQs); other clinical measures of patient symptoms and disability; physical examination results and radiographic data assessing joint involvement, synovial thickening, bone loss and erosion and joint space narrowing and deformity. In some cases, data includes pathological evaluation of synovial memebranes and joint tissues from RA and control patients. Pathology scoring systems were used to determine disease category, inflammation, type of inflammatory infiltrate, cellular and makeup of the synovial inflammation.

[0440] For some specimens of synovium, mononuclear cells or subsets of mononuclear cells (such as T cells) can be isolated for expression profiling. The relative number of lyphocyte subsets for some specimens can be determined by fluorescence activated cell sorting. Examples are determination of the CD4/CD8 T-cell ratio for a specimen. This information can be used as a variable to correlate to other outcomes or as an outcome for correlation analysis.

[0441] From these data, measures of improvement in RA are derived as exemplified by the ACR 20% and 50% response/improvement rates (Felson et al. 1996). Measures of disease activity over some period of time is derived from these data as are measures of disease progression. Serial radiography of effected joints is used for objective determination of progression (e.g., joint space narrowing, peri-articular osteoporosis, synovial thickening). Disease activity is determined from the clinical scores, medical history, physical exam, lab studies, surgical and pathological findings.

[0442] The collected clinical data (disease criteria) is used to define patient or sample groups for correlation of expression data. Patient groups are identified for comparison, for example, a patient group that possesses a useful or interesting clinical distinction, verses a patient group that does not possess the distinction. Examples of useful and interesting patient distinctions that can be made on the basis of collected clinical data are listed here:

[0443] Samples from patients during a clinically diagnosed RA flare versus samples from these same or different patients while they are asymptomatic.

[0444] Samples from patients who subsequently have high measures of disease activity versus samples from those same or different patients who have low subsequent disease activity.

[0445] Samples from patients who subsequently have high measures of disease progression versus samples from those same or different patients who have low subsequent disease progression.

[0446] Samples from patients who subsequently respond to a given medication or treatment regimen versus samples from those same or different patients who subsequently do not respond to a given medication or treatment regimen (for example, TNF pathway blocking medications).

[0447] Samples from patients with a diagnosis of osteoarthritis versus patients with rheumatoid arthritis.

[0448] Samples from patients with tissue biopsy results showing a high degree of inflammation versus samples from patients with lesser degrees of histological evidence of inflammation on biopsy.

[0449] Expression profiles correlating with progression of RA are identified. Subsets of the candidate library (or a previously identified diagnostic nucleotide set) are identified, according to the above procedures, that have predictive value for the progression of RA.

[0450] Diagnostic nucleotide set(s) are identified which predict respond to TNF blockade. Patients are profiled before and during treatment with these medications. Patients are followed for relief of symptoms, side effects and progression of joint destruction, e.g., as measured by hand radiographs. Expression profiles correlating with response to TNF blockade are identified. Subsets of the candidate library (or a previously identified diagnostic nucleotide set) are identified, according to the above procedures that have predictive value for response to TNF blockade.

Example 10 Identification of Diagnostic Oligonucleotide and Oligonucleotide Sets for Diagnosis of Systemic Lupus Erythematosis

[0451] SLE is a chronic, systemic inflammatory disease characterized by dysregulation of the immune system. Clinical manifestations affect every organ system and include skin rash, renal dysfunction, CNS disorders, arthralgias and hematologic abnormalities. SLE clinical manifestations tend to both recur intermittently (or “flare”) and progress over time, leading to permanent end-organ damage.

[0452] An observational study was conducted in which a cohort of patients meeting American College of Rheumatology (hereinafter “ACR”) criteria for the diagnosis of SLE were identified. See Tan et al. (1982) Arthritis Rheum 25:1271-7. Patients gave informed consent and a peripheral blood mononuclear cell RNA sample or a peripheral T cell sample was obtained by the methods as described in example 7.

[0453] From each patient, the following clinical information was obtained if available: Demographic information, ACR criteria for SLE, additional diagnoses of inflammatory and non-inflammatory conditions, data from laboratory testing including complete blood counts with differentials, CRP, ESR, ANA, Serum IL6, Soluble CD40 ligand, LDL, HDL, Anti-DNA antibodies, rheumatoid factor, C3, C4, serum creatinine (and other measures of renal dysfunction), medication levels, data from surgical procedures such as gross operative findings and pathological evaluation of resected tissues and biopsies (e.g., renal, CNS), information on pharmacological therapy and treatment changes, clinical diagnoses of disease “flare”, hospitalizations, quantitative joint exams, results from health assessment questionnaires (HAQs), SLEDAIs (a clinical score for SLE activity that assess many clinical variables; Bombadier C, Gladman DD, Urowitz MB, Caron D, Chang CH and the Committee on Prognosis Studies in SLE: Derivation of the SLEDAI for Lupus Patients. Arthritis Rheum 35:630-640, 1992), other clinical measures of patient symptoms and disability, physical examination results and carotid ultrasonography.

[0454] The collected clinical data (disease criteria) is used to define patient or sample groups for correlation of expression data. Patient groups are identified for comparison, for example, a patient group that possesses a useful or interesting clinical distinction, verses a patient group that does not possess the distinction. Measures of disease activity in SLE are derived from the clinical data described above to divide patients (and patient samples) into groups with higher and lower disease activity over some period of time or at any one point in time. Such data are SLEDAI scores and other clinical scores, levels of inflammatory markers or complement, number of hospitalizations, medication use and changes, biopsy results and data measuring progression of end-organ damage or end-organ damage, including progressive renal failure, carotid atherosclerosis, and CNS dysfunction.

[0455] Expression profiles correlating with progression of SLE are identified, including expression profiles corresponding to end-organ damage and progression of end-organ damage. Expression profiles are identified predicting disease progression or disease “flare”, response to treatment or likelihood of response to treatment, predict likelihood of “low” or “high” disease measures (optionally described using the SLEDAI score), and presence or likelihood of developing premature carotid atherosclerosis. Subsets of the candidate library (or a previously identified diagnostic nucleotide set) are identified, according to the above procedures that have predictive value for the progression of SLE.

[0456] Further examples of useful and interesting patient distinctions that can be made on the basis of collected clinical data are listed here. Samples can be grouped and groups are compared to discover diagnostic gene sets:

[0457] 1. Samples from patients during a clinically diagnosed SLE flare versus samples from these same or different patients while they are asymptomatic or while they have a documented infection.

[0458] 2. Samples from patients who subsequently have high measures of disease activity versus samples from those same or different patients who have low subsequent disease activity.

[0459] 3. Samples from patients who subsequently have high measures of disease progression versus samples from those same or different patients who have low subsequent disease progression.

[0460] 4. Samples from patients who subsequently respond to a given medication or treatment regimen versus samples from those same or different patients who subsequently do not respond to a given medication or treatment regimen.

[0461] 5. Samples from patients with premature carotid atherosclerosis on ultrasonography versus patients with SLE without premature atherosclerosis. Identification of a diagnostic oligonucleotide or oligonucleotide set for diagnosis of lupus

[0462] Mononuclear RNA samples were collected from patients with SLE and patients with Rheumatoid or Osteoarthritis (RA and OA) or controls using the protocol described in example 7. The patient diagnoses were determined using standard diagnostic algorithms such as those that are employed by the American College of Rheumatology (see example See Tan et al. (1982) Arthritis Rheum 25:1271-7; Arnett et al. (1988) Arthritis Rheum 31:315-24).

[0463] 32 samples were included in the analysis. 15 samples were derived from, patients with a clinical diagnosis of SLE and the remainder were derived from patients with RA (9), OA (4) and subjects without known disease (4) who served as controls. Samples from patients with SLE or RA were classified as “Active” or “Controlled” (with respect to disease activity) by the patient's physician based on objective and subjective criteria, such as patient history, physical exam and lab studies. An attempt was made to match SLE patients and controls with respect to important variables such as medication use, sex, age and secondary diagnoses.

[0464] After preparation of RNA (example 7), amplification, labeling, hybridization, scanning, feature extraction and data processing were done as described in Example 14 using the oligonucleotide microarrays described in Example 13. The resulting log ratio of expression of Cy3 (patient sample)/Cy5 (R50 reference RNA) was used for analysis.

[0465] Initially, significance analysis for microarrays (SAM, Tusher 2001, Example 16) was used to discover that were differentially expressed between 7 of the Lupus samples and 17 control samples. 1 gene was identified that was expressed at a higher level in the lupus patients than in all controls. This gene had a 0.5% false detection rate using SAM. This means that there is statistically, a 99.5% chance that the gene is truly differentially expressed between the Lupus and control samples. This gene was oligonucleotide and SEQ ID # 4637. The oligonucleotide: GCCTCTTGCTTGGCGTGATAACCCTGTCATCTTCCCAAAGCTCATTTATG detects a specific human gene: sialyltransferase (SIAT4A), Unigene: Hs.301698 Locus: NM_(—)003033, GI: 4506950. Expression ratios for the gene are given for each sample in FIGS. 5A-B. The average fold change in expression between SLE and controls was 1.48.

[0466] When a larger data set was used, 15 SLE samples were compared to 17 controls. Using SAM, genes were identified as significantly differentially expressed between Lupus and controls. These genes and their FDRs are given in Table 10A. Supervised harvesting classification (X-Mine, Brisbane, Calif.) and CART (Salford Systems, San Diego Calif.) were also used on the same data to determine which set of genes best distinguish SLE from control samples (Example 16).

[0467] CART was used to build a decision tree for classification of samples as lupus or not lupus using the gene expression data from the arrays. The analysis identitifies sets of genes that can be used together to accurately identify samples derived from lupus patients. The set of genes and the identified threshold expression levels for the decision tree are referred to as “models”. Multiple models for diagnosis of Lupus were derived by using different settings and parameters for the CART algorithm and using different sets of genes in the analysis. When using CART, it may be desirable to limit the number of independent variables. In the case of the genes on the arrays, a subset of 8000 can be selected for analysis in CART based on significant differential expression discovered by using SAM or some other algorithm.

[0468] Model I was based on a data set consisting of thirty-two samples (fifteen SLE and seventeen non-SLE). These samples were used to derive the model and are referred to a the “training set”. Model I used the expression values for twenty-nine genes, which were found to be most significant in differentiating SLE and non-SLE samples in the analysis using SAM described above. SLE samples were designated as Class 1 and non-SLE samples were designated as Class 2. For this analysis, the following settings were used in the MODEL SETUP (CART, Salford Systems, San Diego, Calif.). In the Model settings, the tree type selected for the analysis was classification. In the Categorical settings, the default values were used. In the Testing settings, V-fold cross-validation was selected with a value of 10. In the Select Cases settings, the default values were used. In the Best Tree settings, the default values were used. In the Combine settings, the default values were used. In the Method settings, Symmetric Gini was selected as the type of classification tree and Linear combinations for splitting was also selected. The default values were used for the linear combinations. In the Advance Settings, the default values were used. In the Costs settings, the default values were used. In the Priors settings, Equal was selected as the priors for Class. In the penalty settings, the default values were used.

[0469] From this analysis, CART built two models, a two-gene model and a three-gene model (FIGS. 5C-E). The sensitivity and specificity for the identification of lupus in the training set samples of the two genes model were 100% and 94%, respectively. The sensitivity and specificity for the 10-fold cross validation set of the two-gene model were 100% and 88%, respectively, with a relative cost of 0.118. The sensitivity and specificity for the training set of the three genes model were 100% and 100%, respectively. The sensitivity and specificity for the 10-fold cross validation set of the three genes model were 93% and 94%, respectively, with a relative cost of 0.125.

[0470] Model II was based on a data set consisted of thirty-two samples, fifteen SLE and seventeen non-SLE (training set) and six thousand forty-four genes with expression values for at least 80% of the samples. The MODEL SETUP for the analysis of this data set was the same as for the analysis above, except for the following correction. In the Method settings, Linear combination for splitting was unchecked after the analysis yielded no classification tree. The change in the linear combination setting resulted in the following.

[0471] The sensitivity and specificity for the training set of the one gene model were 87% and 82%, respectively. The sensitivity and specificity for the 10-fold cross validation set of the one gene model were 80% and 59%, respectively, with a relative cost of 0.612. The sensitivity and specificity for the training set of the three genes model were 100% and 88%, respectively. The sensitivity and specificity for the 10-fold cross validation set of the three genes model were 67% and 65%, respectively, with a relative cost of 0.686. The sensitivity and specificity for the training set of the five genes model were 100% and 94%, respectively. The sensitivity and specificity for the 10-fold cross validation set of the five genes model were 67% and 59%, respectively, with a relative cost of 0.745. Results and models are summarized in FIG. 5C and F.

[0472] Those genes that were found to be useful for classification are noted in Table 10A.

[0473] These genes can be used alone or in association with other genes or variables to build a diagnostic gene set or a classification algorithm. These genes can be used in association with known gene markers for lupus (such as those identified in the prior art) to provide a diagnostic algorithm.

[0474] Primers for real-time PCR validation were designed for each of the genes as described in Example 15 and are listed in Table 10B.

[0475] Surrogates for some of the most useful genes were identified and are listed in Table 10C. Surrogates can be used in addition to or in place of a diagnostic gene in a method of detecting lupus or in diagnostic gene set. For genes that were splitters in CART, surrogates were identified and reported by the software. In these cases, the best available surrogates are listed. For other genes, hierarchical clustering of the data was performed with default settings α-miner, X-mine, Brisbane, Calif.) and members of gene expression clusters were noted. A cluster was selected that included the gene of interest and the members of that cluster were recorded in Table 10C.

Example 11 Probe Selection for a 24,000 Feature Array

[0476] This Example describes the compilation of almost 8,000 unique genes and ESTs using sequences identified from the sources described below. The sequences of these genes and ESTs were used to design probes, as described in the following Example.

[0477] Tables 3A, 3B and 3C list the sequences identified in the subtracted leukocyte expression libraries. All sequences that were identified as corresponding to a known RNA transcript were represented at least once, and all unidentified sequences were represented twice—once by the sequence on file and again by the complementary sequence—to ensure that the sense (or coding) strand of the gene sequence was included.

[0478] Table 3A. Table 3A contained all those sequences in the subtracted libraries of example 1 that matched sequences in GenBank's nr, EST_Human, and UniGene databases with an acceptable level of confidence. All the entries in the table representing the sense strand of their genes were grouped together and all those representing the antisense strand were grouped. A third group contained those entries whose strand could not be determined. Two complementary probes were designed for each member of this third group.

[0479] Table 3B and 3C. Table 3B and 3C contained all those sequences in the leukocyte expression subtracted libraries of example 1 that did not match sequences in GenBank's nr, EST_Human, and UniGene databases with an acceptable level of confidence, but which had a high probability of representing real mRNA sequences. Sequences in Table 3B did not match anything in the databases above but matched regions of the human genome draft and were spatially clustered along it, suggesting that they were exons, rather than genomic DNA included in the library by chance. Sequences in Table 3C also aligned well to regions of the human genome draft, but the aligned regions were interrupted by genomic DNA, meaning they were likely to be spliced transcripts of multiple exon genes.

[0480] Table 3B lists 510 clones and Table 3C lists 48 clones that originally had no similarity with any sequence in the public databases. Blastn searches conducted after the initial filing have identified sequences in the public database with high similarity (E values less than le-40) to the sequences determined for these clones. Table 3B contained 272 clones and Table 3C contained 25 clones that were found to have high similarity to sequences in dbEST. The sequences of the similar dbEST clones were used to design probes. Sequences from clones that contained no similar regions to any sequence in the database were used to design a pair of complementary probes.

[0481] Probes were designed from database sequences that had the highest similarity to each of the sequenced clones in Tables 3A, 3B, and 3C. Based on BLAST™ searches the most similar database sequence was identified by locus number and the locus number was submitted to GenBank using batch Entrez (located at the website ncbi.nlm.nih.gov/entrezibatchentrez.cgi?db=Nucleotide) to obtain the sequence for that locus. The GenBank entry sequence was used because in most cases it was more complete or was derived from multi-pass sequencing and thus would likely have fewer errors than the single pass cDNA library sequences. When only UniGene cluster IDs were available for genes of interest, the respective sequences were extracted from the UniGene_unique database, build 137, downloaded from NCBI (ftp://ncbi.nlm.nih.gov/repository/UniGene/). This database contains one representative sequence for each cluster in UniGene.

[0482] Summary of Library Clones Used in Array Probe Design Table Sense Strand Antisnese Strand Strand Undetermined 3A 3621 763 124 3B 142 130 238 3C 19 6 23 Totals 3782 899 385

[0483] Literature Searches

[0484] Example 2 describes searches of literature databases. We also searched for research articles discussing genes expressed only in leukocytes or involved in inflammation and particular disease conditions, including genes that were specifically expressed or down-regulated in a disease state. Searches included, but were not limited to, the following terms and various combinations of theses terms: inflammation, atherosclerosis, rheumatoid arthritis, osteoarthritis, lupus, SLE, allograft, transplant, rejection, leukocyte, monocyte, lymphocyte, mononuclear, macrophage, neutrophil, eosinophil, basophil, platelet, congestive heart failure, expression, profiling, microarray, inflammatory bowel disease, asthma, RNA expression, gene expression, granulocyte.

[0485] A UniGene cluster ID or GenBank accession number was found for each gene in the list. The strand of the corresponding sequence was determined, if possible, and the genes were divided into the three groups: sense (coding) strand, anti-sense strand, or strand unknown. The rest of the probe design process was carried out as described above for the sequences from the leukocyte subtracted expression library.

[0486] Database Mining

[0487] Database mining was performed as described in Example 2. In addition, the Library Browser at the NCBI UniGene web site (located on the web at ncbi.nlm.nih.goviUniGene/lbrowse.cgi?ORG=Hs&DISPLAY=ALL) was used to identify genes that are specifically expressed in leukocyte cell populations. All expression libraries available at the time were examined and those derived from leukocytes were viewed individually. Each library viewed through the Library Browser at the UniGene web site contains a section titled “Shown below are UniGene clusters of special interest only” that lists genes that are either highly represented or found only in that library. Only the genes in this section were downloaded from each library. Alternatively, every sequence in each library is downloaded and then redundancy between libraries is reduced by discarding all UniGene cluster IDs that are represented more than once. A total of 439 libraries were downloaded, containing 35,819 genes, although many were found in more than one library. The most important libraries from the remaining set were separated and 3,914 genes remained. After eliminating all redundancy between these libraries and comparing the remaining genes to those listed in Tables 3A, 3B and 3C, the set was reduced to 2,573 genes in 35 libraries as shown in Table 4. From these, all genes in first 30 libraries were used to design probes. A random subset of genes was used from Library Lib.376, “Activated_T-cells_XX”. From the last four libraries, a random subset of sequences listed as “ESTs, found only in this library” was used.

[0488] Angiogenesis Markers

[0489] 215 sequences derived from an angiogenic endothelial cell subtracted cDNA library obtained from Stanford University were used for probe design. Briefly, using well known subtractive hybridization procedures, (as described in, e.g., U.S. Pat. Nos. 5,958,738; 5,589,339; 5,827,658; 5,712,127; 5,643,761; 5,565,340) modified to normalize expression by suppressing over-representation of abundant RNA species while increasing representation of rare RNA species, a library was produced that is enriched for RNA species (messages) that are differentially expressed between test (stimulated) and control (resting) HUVEC populations. The subtraction/suppression protocol was performed as described by the kit manufacturer (Clontech, PCR-select cDNA Subtraction Kit).

[0490] Pooled primary HuvECs (Clonetics) were cultured in 15% FCS, M199 (GibcoBRL) with standard concentrations of Heparin, Penicillin, Streptomycin, Glutamine and Endothelial Cell Growth Supplement. The cells were cultured on 1% gelatin coated 10 cm dishes. Confluent HUVECs were photographed under phase contrast microscopy. The cells formed a monolayer of flat cells without gaps. Passage 2-5 cells were used for all experiments. Confluent HUVECs were treated with trypsin/EDTA and seeded onto collagen gels. Collagen gels were made according to the protocol of the Collagen manufacturer (Becton Dickinson Labware). Collagen gels were prepared with the following ingredients: Rat tail collagen type I (Collaborative Biomedical) 1.5 mg/mL, mouse laminin (Collaborative Biomedical) 0.5 mg/mL, 10% 10× media 199 (Gibco BRL). 1N NaOH, 10× PBS and sterile water were added in amounts recommended in the protocol. Cell density was measured by microscopy. 1.2×10⁶ cells were seeded onto gels in 6-well, 35 mm dishes, in 5% FCS M199 media. The cells were incubated for 2 hrs at 37 C with 5% CO₂. The media was then changed to the same media with the addition of VEGF (Sigma) at 30 ng/mL media. Cells were cultured for 36 hrs. At 12, 24 and 36 hrs, the cells were observed with phase contrast microscopy. At 36 hours, the cells were observed elongating, adhering to each other and forming lumen structures. At 12 and 24 hrs media was aspirated and refreshed. At 36 hrs, the media was aspirated, the cells were rinsed with PBS and then treated with Collagenase (Sigma) 2.5 mg/mL PBS for 5 min with active agitation until the collagen gels were liquefied. The cells were then centrifuged at 4C, 2000 g for 10 min. The supernatant was removed and the cells were lysed with 1 mL Trizol Reagent (Gibco) per 5×10⁶ cells. Total RNA was prepared as specified in the Trizol instructions for use. mRNA was then isolated as described in the micro-fast track mRNA isolation protocol from Invitrogen. This RNA was used as the tester RNA for the subtraction procedure.

[0491] Ten plates of resting, confluent, p4 HUVECs, were cultured with 15% FCS in the M199 media described above. The media was aspirated and the cells were lysed with 1 mL Trizol and total RNA was prepared according to the Trizol protocol. mRNA was then isolated according to the micro-fast track mRNA isolation protocol from Invitrogen. This RNA served as the control RNA for the subtraction procedure.

[0492] The entire subtraction cloning procedure was carried out as per the user manual for the Clontech PCR Select Subtraction Kit. The cDNAs prepared from the test population of HUVECs were divided into “tester” pools, while cDNAs prepared from the control population of HTVECs were designated the “driver” pool. cDNA was synthesized from the tester and control RNA samples described above. Resulting cDNAs were digested with the restriction enzyme Rsal. Unique double-stranded adapters were ligated to the tester cDNA. An initial hybridization was performed consisting of the tester pools of cDNA (with its corresponding adapter) and an excess of the driver cDNA. The initial hybridization results in a partial normalization of the cDNAs such that high and low abundance messages become more equally represented following hybridization due to a failure of driver/tester hybrids to amplify.

[0493] A second hybridization involved pooling unhybridized sequences from the first hybridization together with the addition of supplemental driver cDNA. In this step, the expressed sequences enriched in the two tester pools following the initial hybridization can hybridize. Hybrids resulting from the hybridization between members of each of the two tester pools are then recovered by amplification in a polymerase chain reaction (PCR) using primers specific for the unique adapters. Again, sequences originating in a tester pool that form hybrids with components of the driver pool are not amplified. Hybrids resulting between members of the same tester pool are eliminated by the formation of “panhandles” between their common 5′ and 3′ ends. The subtraction was done in both directions, producing two libraries, one with clones that are upregulated in tube-formation and one with clones that are down-regulated in the process.

[0494] The resulting PCR products representing partial cDNAs of differentially expressed genes were then cloned (i.e., ligated) into an appropriate vector according to the manufacturer's protocol (pGEM-Teasy from Promega) and transformed into competent bacteria for selection and screening. Colonies (2180) were picked and cultured in LB broth with 50 μg/mL ampicillin at 37C overnight. Stocks of saturated LB +50 ug/mL ampicillin and 15% glycerol in 96-well plates were stored at −80C. Plasmid was prepared from 1.4 mL saturated LB broth containing 50 ug/mL ampicillin. This was done in a 96 well format using commercially available kits according to the manufacturer's recommendations (Qiagen 96-turbo prep).

[0495] 2 probes to represent 22 of these sequences required, therefore, a total of 237 probes were derived from this library.

[0496] Viral Genes

[0497] Several viruses may play a role in a host of disease including inflammatory disorders, atherosclerosis, and transplant rejection. Table 12 lists the viral genes represented by oligonucleotide probes on the microarray. Low-complexity regions in the sequences were masked using RepeatMasker before using them to design probes.

[0498] Strand Selection

[0499] It was necessary to design sense oligonucleotide probes because the labeling and hybridization protocol to be used with the microarray results in fluorescently-labeled antisense cRNA. All of the sequences we selected to design probes could be divided into three categories:

[0500] (1) Sequences known to represent the sense strand

[0501] (2) Sequences known to represent the antisense strand

[0502] (3) Sequences whose strand could not be easily determined from their descriptions

[0503] It was not known whether the sequences from the leukocyte subtracted expression library were from the sense or antisense strand. GenBank sequences are reported with sequence given 5′ to 3′, and the majority of the sequences we used to design probes came from accession numbers with descriptions that made it clear whether they represented sense or antisense sequence. For example, all sequences containing “mRNA” in their descriptions were understood to be the sequences of the sense mRNA, unless otherwise noted in the description, and all IMAGE Consortium clones are directionally cloned and so the direction (or sense) of the reported sequence can be determined from the annotation in the GenBank record.

[0504] For accession numbers representing the sense strand, the sequence was downloaded and masked and a probe was designed directly from the sequence. These probes were selected as close to the 3′ end as possible. For accession numbers representing the antisense strand, the sequence was downloaded and masked, and a probe was designed complementary to this sequence. These probes were designed as close to the 5′ end as possible (i.e., complementary to the 3′ end of the sense strand).

[0505] Minimizing Probe Redundancy.

[0506] Multiple copies of certain genes or segments of genes were included in the sequences from each category described above, either by accident or by design. Reducing redundancy within each of the gene sets was necessary to maximize the number of unique genes and ESTs that could be represented on the microarray.

[0507] Three methods were used to reduce redundancy of genes, depending on what information was available. First, in gene sets with multiple occurrences of one or more UniGene numbers, only one occurrence of each UniGene number was kept. Next, each gene set was searched by GenBank accession numbers and only one occurrence of each accession number was conserved. Finally, the gene name, description, or gene symbol were searched for redundant genes with no UniGene number or different accession numbers. In reducing the redundancy of the gene sets, every effort was made to conserve the most information about each gene.

[0508] We note, however, that the UniGene system for clustering submissions to GenBank is frequently updated and UniGene cluster IDs can change. Two or more clusters may be combined under a new cluster ID or a cluster may be split into several new clusters and the original cluster ID retired. Since the lists of genes in each of the gene sets discussed were assembled at different times, the same sequence may appear in several different sets with a different UniGene ID in each.

[0509] Sequences from Table 3A were treated differently. In some cases, two or more of the leukocyte subtracted expression library sequences aligned to different regions of the same GenBank entry, indicating that these sequences were likely to be from different exons in the same gene transcript. In these cases, one representative library sequence corresponding to each presumptive exon was individually listed in Table 3A.

[0510] Compilation.

[0511] After redundancy within a gene set was sufficiently reduced, a table of approximately 8,000 unique genes and ESTs was compiled in the following manner. All of the entries in Table 3A were transferred to the new table. The list of genes produced by literature and database searches was added, eliminating any genes already contained in Table 3A. Next, each of the remaining sets of genes was compared to the table and any genes already contained in the table were deleted from the gene sets before appending them to the table. Probes Subtracted Leukocyte Expression Library Table 3A 4,872 Table 3B 796 Table 3C 85 Literature Search Results 494 Database Mining 1,607 Viral genes a. CMV 14 b. EBV 6 c. HHV 6 14 d. Adenovirus 8 Angiogenesis markers: 215, 22 of which needed two probes 237 Arabidopsis thaliana genes 10 Total sequences used to design probes 8,143

Example 12 Design of Oligonucleotide Probes

[0512] By way of example, this section describes the design of four oligonucleotide probes using Array Designer Ver 1.1 (Premier Biosoft International, Palo Alto, Calif.). The major steps in the process are given first.

[0513] 1) Obtain best possible sequence of mRNA from GenBank. If a full-length sequence reference sequence is not available, a partial sequence is used, with preference for the 3′ end over the 5′ end. When the sequence is known to represent the antisense strand, the reverse complement of the sequence is used for probe design. For sequences represented in the subtracted leukocyte expression library that have no significant match in GenBank at the time of probe design, our sequence is used.

[0514] 2) Mask low complexity regions and repetitive elements in the sequence using an algorithm such as RepeatMasker.

[0515] 3) Use probe design software, such as Array Designer, version 1. 1, to select a sequence of 50 residues with specified physical and chemical properties. The 50 residues nearest the 3′ end constitute a search frame. The residues it contains are tested for suitability. If they don't meet the specified criteria, the search frame is moved one residue closer to the 5′ end, and the 50 residues it now contains are tested. The process is repeated until a suitable 50-mer is found.

[0516] 4) If no such 50-mer occurs in the sequence, the physical and chemical criteria are adjusted until a suitable 50-mer is found.

[0517] 5) Compare the probe to dbEST, the UniGene cluster set, and the assembled human genome using the BLASTn search tool at NCBI to obtain the pertinent identifying information and to verify that the probe does not have significant similarity to more than one known gene.

[0518] Clone 40H12

[0519] Clone 40H12 was sequenced and compared to the nr, dbEST, and UniGene databases at NCBI using the BLAST search tool. The sequence matched accession number NM_(—)002310, a ‘curated RefSeq project’ sequence, see Pruitt et al. (2000) Trends Genet. 16:44-47, encoding leukemia inhibitory factor receptor (LIFR) mRNA with a reported E value of zero. An E value of zero indicates there is, for all practical purposes, no chance that the similarity was random based on the length of the sequence and the composition and size of the database. This sequence, cataloged by accession number NM_(—)002310, is much longer than the sequence of clone 40H12 and has a poly-A tail. This indicated that the sequence cataloged by accession number NM_(—)002310 is the sense strand and a more complete representation of the mRNA than the sequence of clone 40H12, especially at the 3′ end. Accession number “NM_(—)002310” was included in a text file of accession numbers representing sense strand mRNAs, and sequences for the sense strand mRNAs were obtained by uploading a text file containing desired accession numbers as an Entrez search query using the Batch Entrez web interface and saving the results locally as a FASTA file. The following sequence was obtained, and the region of alignment of clone 40H 12 is outlined: CTCTCTCCCAGAACGTGTCTCTGCTGCAAGGCACCGGGCCCTTTCGCTCTGCAGAACTGC (SEQ ID NO: 8827) ACTTGCAAGACCATTATCAACTCCTAATCCCAGCTCAGAAAGGGAGCCTCTGCGACTCAT TCATCGCCCTCCAGGACTGACTGCATTGCACAGATGATGGATATTTACGTATGTTTGAAA CGACCATCCTGGATGGTGGACAATAAAAGAATGAGGACTGCTTCAAATTTCCAGTGGCTG TTATCAACATTTATTCTTCTATATCTAATGAATCAAGTAAATAGCCACAAAAAGGGGGCT CCTCATGATTTGAAGTGTGTAACTAACAATTTGCAAGTGTGGAACTGTTCTTGGAAAGCA CCCTCTGGAACAGGCCGTGGTACTGATTATGAAGTTTGCATTGAAAACAGGTCCCGTTCT TGTTATCAGTTGGAGAAAACCAGTATTAAAATTCCAGCTCTTTCACATGGTGATTATCAA ATAACAATAAATTCTCTACATGATTTTGGAAGTTCTACAAGTAAATTCACACTAAATGAA CAAAACGTTTCCTTAATTCCAGATACTCCAGAGATCTTGAATTTGTCTGCTGATTTCTCA ACCTCTACATTATACCTAAAGTGGAACGACAGGGGTTCAGTTTTTCCACACCGCTCAAAT GTTATCTGGGAAATTAAAGTTCTACGTAAAGAGAGTATGGAGCTCGTAAAATTAGTGACC CACAACACAACTCTGAATGGCAAAGATACACTTCATCACTGGAGTTGGGCCTCAGATATG CCCTTGGAATGTGCCATTCATTTTGTGGAAATTAGATGCTACATTGACAATCTTCATTTT TCTGGTCTCGAAGAGTGGAGTGACTGGAGCCCTGTGAAGAACATTTCTTGGATACCTGAT TCTCAGACTAAGGTTTTTCCTCAAGATAAAGTGATACTTGTAGGCTCAGACATAACATTT TGTTGTGTGAGTCAAGAAAAAGTGTTATCAGCACTGATTGGCCATACAAACTGCCCCTTG ATCCATCTTGATGGGGAAAATGTTGCAATCAAGATTCGTAATATTTCTGTTTCTGCAAGT AGTGGAACAAATGTAGTTTTTACAACCGAAGATAACATATTTGGAACCGTTATTTTTGCT GGATATCCACCAGATACTCCTCAACAACTGAATTGTGAGACACATGATTTAAAAGAAATT ATATGTAGTTGGAATCCAGGAAGGGTGACAGCGTTGGTGGGCCCACGTGCTACAAGCTAC ACTTTAGTTGAAAGTTTTTCAGGAAAATATGTTAGACTTAAAAGAGCTGAAGCACCTACA AACGAAAGCTATCAATTATTATTTCAAATGCTTCCAAATCAAGAAATATATAATTTTACT TTGAATGCTCACAATCCGCTGGGTCGATCACAATCAACAATTTTAGTTAATATAACTGAA AAAGTTTATCCCCATACTCCTACTTCATTCAAAGTGAAGGATATTAATTCAACAGCTGTT AAACTTTCTTGGCATTTACCAGGCAACTTTGCAAAGATTAATTTTTTATGTGAAATTGAA ATTAAGAAATCTAATTCAGTACAAGAGCAGCGGAATGTCACAATCAAAGGAGTAGAAAAT TCAAGTTATCTTGTTGCTCTGGACAAGTTAAATCCATACACTCTATATACTTTTCGGATT CGTTGTTCTACTGAAACTTTCTGGAAATGGAGCAAATGGAGCAATAAAAAACAACATTTA ACAACAGAAGCCAGTCCTTCAAAGGGGCCTGATACTTGGAGAGAGTGGAGTTCTGATGGA AAAAATTTAATAATCTATTGGAAGCCTTTACCCATTAATGAAGCTAATGGAAAAATACTT TCCTACAATGTATCGTGTTCATCAGATGAGGAAACACAGTCCCTTTCTGAAATCCCTGAT CCTCAGCACAAAGCAGAGATACGACTTGATAAGAATGACTACATCATCAGCGTAGTGGCT AAAAATTCTGTGGGCTCATCACCACCTTCCAAAATAGCGAGTATGGAAATTCCAAATGAT GATCTCAAAATAGAACAAGTTGTTGGGATGGGAAAGGGGATTCTCCTCACCTGGCATTAC GACCCCAACATGACTTGCGACTACGTCATTAAGTGGTGTAACTCGTCTCGGTCGGAACCA TGCCTTATGGACTGGAGAAAAGTTCCCTCAAACAGCACTGAAACTGTAATAGAATCTGAT GAGTTTCGACCAGGTATAAGATATAATTTTTTCCTGTATGGATGCAGAAATCAAGGATAT CAATTATTACGCTCCATGATTGGATATATAGAAGAATTGGCTCCCATTGTTGCACCAAAT TTTACTGTTGAGGATACTTCTGCAGATTCGATATTAGTAAAATGGGAAGACATTCCTGTG GAAGAACTTAGAGGCTTTTTAAGAGGATATTTGTTTTACTTTGGAAAAGGAGAAAGAGAC ACATCTAAGATGAGGGTTTTAGAATCAGGTCGTTCTGACATAAAAGTTAAGAATATTACT GACATATCCCAGAAGACACTGAGAATTGCTGATCTTCAAGGTAAAACAAGTTACCACCTG GTCTTGCGAGCCTATACAGATGGTGGAGTGGGCCCGGAGAAGAGTATGTATGTGGTGACA AAGGAAAATTCTGTGGGATTAATTATTGCCATTCTCATCCCAGTGGCAGTGGCTGTCATT GTTGGAGTGGTGACAAGTATCCTTTGCTATCGGAAACGAGAATGGATTAAAGAAACCTTC TACCCTGATATTCCAAATCCAGAAAACTGTAAAGCATTACAGTTTCAAAAGAGTGTCTGT GAGGGAAGCAGTGCTCTTAAAACATTGGAAATGAATCCTTGTACCCCAAATAATGTTGAG GTTCTGGAAACTCGATCAGCATTTCCTAAAATAGAAGATACAGAAATAATTTCCCCAGTA GCTGAGCGTCCTGAAGATCGCTCTGATGCAGAGCCTGAAAACCATGTGGTTGTGTCCTAT TGTCCACCCATCATTGAGGAAGAAATACCAAACCCAGCCGCAGATGAAGCTGGAGGGACT GCACAGGTTATTTACATTGATGTTCAGTCGATGTATCAGCCTCAAGCAAAACCAGAAGAA GAACAAGAAAATGACCCTGTAGGAGGGGCAGGCTATAAGCCACAGATGCACCTCCCCATT AATTCTACTGTGGAAGATATAGCTGCAGAAGAGGACTTAGATAAAACTGCGGGTTACAGA CCTCAGGCCAATGTAAATACATGGAATTTAGTGTCTCCAGACTCTCCTAGATCCATAGAC AGCAACAGTGAGATTGTCTCATTTGGAAGTCCATGCTCCATTAATTCCCGACAATTTTTG ATTCCTCCTAAAGATGAAGACTCTCCTAAATCTAATGGAGGAGGGTGGTCCTTTACAAAC TTTTTTCAGAACAAACCAAACGATTAACAGTGTCACCGTGTCACTTCAGTCAGCCATCTC AATAAGCTCTTACTGCTAGTGTTGCTACATCAGCACTGGGCATTCTTGGAGGGATCCTGT GAAGTATTGTTAGGAGGTGAACTTCACTACATGTTAAGTTACACTGAAAGTTCATGTGCT TTTAATGTAGTCTAAAAGCCAAAGTATAGTGACTCAGAATCCTCAATCCACAAAACTCAA GATTGGGAGCTCTTTGTGATCAAGCCAAAGAATTCTCATGTACTCTACCTTCAAGAAGCA TTTCAAGGCTAATACCTACTTGTACGTACATGTAAAACAAATCCCGCCGCAACTGTTTTC TGTTCTGTTGTTTGTGGTTTTCTCATATGTATACTTGGTGGAATTGTAAGTGGATTTGCA GGCCAGGGAGAAAATGTCCAAGTAACAGGTGAAGTTTATTTGCCTGACGTTTACTCCTTT CTAGATGAAAACCAAGCACAGATTTTAAAACTTCTAAGATTATTCTCCTCTATCCACAGC ATTCACAAAAATTAATATAATTTTTAATGTAGTGACAGCGATTTAGTGTTTTGTTTGATA AAGTATGCTTATTTCTGTGCCTACTGTATAATGGTTATCAAACAGTTGTCTCAGGGGTAC AAACTTTGAAAACAAGTGTGACACTGACCAGCCCAAATCATAATCATGTTTTCTTGCTGT GATAGGTTTTGCTTGCCTTTTCATTATTTTTTAGCTTTTATGCTTGCTTCCATTATTTCA GTTGGTTGCCCTAATATTTAAAATTTACACTTCTAAGACTAGAGACCCACATTTTTTAAA AATCATTTTATTTTGTGATACAGTGACAGCTTTATATGAGCAAATTCAATATTATTCATA AGCATGTAATTCCAGTGACTTACTATGTGAGATGACTACTAAGCAATATCTAGCAGCGTT AGTTCCATATAGTTCTGATTGGATTTCGTTCCTCCTGAGGAGACCATGCCGTTGAGCTTG GCTACCCAGGCAGTGGTGATCTTTGACACCTTCTGGTGGATGTTCCTCCCACTCATGAGT CTTTTCATCATGCCACATTATCTGATCCAGTCCTCACATTTTTAAATATAAAACTAAAGA GAGAATGCTTCTTACAGGAACAGTTACCCAAGGGCTGTTTCTTAGTAACTGTCATAAACT GATCTGGATCCATGGGCATACCTGTGTTCGAGGTGCAGCAATTGCTTGGTGAGCTGTGCA GAATTGATTGCCTTCAGCACAGCATCCTCTGCCCACCCTTGTTTCTCATAAGCGATGTCT GGAGTGATTGTGGTTCTTGGAAAAGCAGAAGGAAAAACTAAAAAGTGTATCTTGTATTTT CCCTGCCCTCAGGTTGCCTATGTATTTTACCTTTTCATATTTAAGGCAAAAGTACTTGAA AATTTTAAGTGTCCGAATAAGATATGTCTTTTTTGTTTGTTTTTTTTGGTTGGTTGTTTG TTTTTTATCATCTGAGATTCTGTAATGTATTTGCAAATAATGGATCAATTAATTTTTTTT GAAGCTCATATTGTATCTTTTTAAAAACCATGTTGTGGAAAAAAGCCAGAGTGACAAGTG ACAAAATCTATTTAGGAACTCTGTGTATGAATCCTGATTTTAACTGCTAGGATTCAGCTA AATTTCTGAGCTTTATGATCTGTGGAAATTTGGAATGAAATCGAATTCATTTTGTACATA CATAGTATATTAAAACTATATAATAGTTCATAGAAATGTTCAGTAATGAAAAAATATATC CAATCAGAGCCATCCCGAAAAAAAAAAAAAAA

[0520] The FASTA file, including the sequence of NM_(—)0023 10, was masked using the RepeatMasker web interface (Smit, AFA & Green, P RepeatMasker at genome.washington.edu/RM/RepeatMasker.html, Smit and Green). Specifically, during masking, the following types of sequences were replaced with “N's”: SINE/MIR & LINE/L2, LINE/L1, LTR/MaLR, LTR/Retroviral, Alu, and other low informational content sequences such as simple repeats. Below is the sequence following masking: CTCTCTCCCAGAACGTGTCTCTGCTGCAAGGCACCGGGCCCTTTCGCTCTGCAGAACTG (SEQ ID NO: 8828) CACTTGCAAGACCATTATCAACTCCTAATCCCAGCTCAGAAAGGGAGCCTCTGCGACTC ATTCATCGCCCTCCAGGACTGACTGCATTGCACAGATGATGGATATTTACGTATGTTTG AAACGACCATCCTGGATGGTGGACAATAAAAGAATGAGGACTGCTTCAAATTTCCAGTG GCTGTTATCAACATTTATTCTTCTATATCTAATGAATCAAGTAAATAGCCAGAAAAAGG GGGCTCCTCATGATTTGAAGTGTGTAACTAACAATTTGCAAGTGTGGAACTGTTCTTGG AAAGCACCCTCTGGAACAGGCCGTGGTACTGATTATGAAGTTTGCATTGAAAACAGGTC CCGTTCTTGTTATCAGTTGGAGAAAACCAGTATTAAAATTCCAGCTCTTTCACATGGTG ATTATGAAATAACAATAAATTCTCTACATGATTTTGGAAGTTCTACAAGTAAATTCACA CTAAATGAACAAAACGTTTCCTTAATTCCAGATACTCCAGAGATCTTGAATTTGTCTGC TGATTTCTCAACCTCTACATTATACCTAAAGTGGAACGACAGGGGTTCAGTTTTTCCAC ACCGCTCAAATGTTATCTGGGAAATTAAAGTTCTACGTAAAGAGAGTATGGAGCTCGTA AAATTAGTGACCCACAACACAACTCTGAATGGCAAAGATACACTTCATCACTGGAGTTG GGCCTCAGATATGCCCTTGGAATGTGCCATTCATTTTGTGGAAATTAGATGCTACATTG ACAATCTTCATTTTTCTGGTCTCGAAGAGTGGAGTGACTGGAGCCCTGTGAAGAACATT TCTTGGATACCTGATTCTCAGACTAAGGTTTTTCCTCAAGATAAAGTGATACTTGTAGG CTCAGACATAACATTTTGTTGTGTGAGTCAAGAAAAAGTGTTATCAGCACTGATTGGCC ATACAAACTGCCCCTTGATCCATCTTGATGGGGAAAATGTTGCAATCAAGATTCGTAAT ATTTCTGTTTCTGCAAGTAGTGGAACAAATGTAGTTTTTACAACCGAAGATAACATATT TGGAACCGTTATTTTTGCTGGATATCCACCAGATACTCCTCAACAACTGAATTGTGAGA CACATGATTTAAAAGAAATTATATGTAGTTGGAATCCAGGAAGGGTGACAGCGTTGGTG GGCCCACGTGCTACAAGCTACACTTTAGTTGAAAGTTTTTCAGGAAAATATGTTAGACT TAAAAGAGCTGAAGCACCTACAAACGAAAGCTATCAATTATTATTTCAAATGCTTCCAA ATCAAGAAATATATAATTTTACTTTGAATGCTCACAATCCGCTGGGTCGATCACAATCA ACAATTTTAGTTAATATAACTGAAAAAGTTTATCCCCATACTCCTACTTCATTCAAAGT GAAGGATATTAATTCAACAGCTGTTAAACTTTCTTGGCATTTACCAGGCAACTTTGCAA AGATTAATTTTTTATGTGAAATTGAAATTAAGAAATCTAATTCAGTACAAGAGCAGCGG AATGTCACAATCAAAGGAGTAGAAAATTCAAGTTATCTTGTTGCTCTGGACAAGTTAAA TCCATACACTCTATATACTTTTCGGATTCGTTGTTCTACTGAAACTTTCTGGAAATGGA GCAAATGGAGCAATAAAAAACAACATTTAACAACAGAAGCCAGTCCTTCAAAGGGGCCT GATACTTGGAGAGAGTGGAGTTCTGATGGAAAAAATTTAATAATCTATTGGAAGCCTTT ACCCATTAATGAAGCTAATGGAAAAATACTTTCCTACAATGTATCGTGTTCATCAGATG AGGAAACACAGTCCCTTTCTGAAATCCCTGATCCTCAGCACAAAGCAGAGATACGACTT GATAAGAATGACTACATCATCAGCGTAGTGGCTAAAAATTCTGTGGGCTCATCACCACC TTCCAAAATAGCGAGTATGGAAATTCCAAATGATGATCTCAAAATAGAACAAGTTGTTG GGATGGGAAAGGGGATTCTCCTCACCTGGCATTACGACCCCAACATGACTTGCGACTAC GTCATTAAGTGGTGTAACTCGTCTCGGTCGGAACCATGCCTTATGGACTGGAGAAAAGT TCCCTCAAACAGCACTGAAACTGTAATAGAATCTGATGAGTTTCGACCAGGTATAAGAT ATAATTTTTTCCTGTATGGATGCAGAAATCAAGGATATCAATTATTACGCTCCATGATT GGATATATAGAAGAATTGGCTCCCATTGTTGCACCAAATTTTACTGTTGAGGATACTTC TGCAGATTCGATATTAGTAAAATGGGAAGACATTCCTGTGGAAGAACTTAGAGGCTTTT TAAGAGGATATTTGTTTTACTTTGGAAAAGGAGAAAGAGACACATCTAAGATGAGGGTT TTAGAATCAGGTCGTTCTGACATAAAAGTTAAGAATATTACTGACATATCCCAGAAGAC ACTGAGAATTGCTGATCTTCAAGGTAAAACAAGTTACCACCTGGTCTTGCGAGCCTATA CAGATGGTGGAGTGGGCCCGGAGAAGAGTATGTATGTGGTGACAAAGGAAAATTCTGTG GGATTAATTATTGCCATTCTCATCCCAGTGGCAGTGGCTGTCATTGTTGGAGTGGTGAC AAGTATCCTTTGCTATCGGAAACGAGAATGGATTAAAGAAACCTTCTACCCTGATATTC CAAATCCAGAAAACTGTAAAGCATTACAGTTTCAAAAGAGTGTCTGTGAGGGAAGCAGT GCTCTTAAAACATTGGAAATGAATCCTTGTACCCCAAATAATGTTGAGGTTCTGGAAAC TCGATCAGCATTTCCTAAAATAGAAGATACAGAAATAATTTCCCCAGTAGCTGAGCGTC CTGAAGATCGCTCTGATGCAGAGCCTGAAAACCATGTGGTTGTGTCCTATTGTCCACCC ATCATTGAGGAAGAAATACCAAACCCAGCCGCAGATGAAGCTGGAGGGACTGCACAGGT TATTTACATTGATGTTCAGTCGATGTATCAGCCTCAAGCAAAACCAGAAGAAGAACAAG AAAATGACCCTGTAGGAGGGGCAGGCTATAAGCCACAGATGCACCTCCCCATTAATTCT ACTGTGGAAGATATAGCTGCAGAAGAGGACTTAGATAAAACTGCGGGTTACAGACCTCA GGCCAATGTAAATACATGGAATTTAGTGTCTCCAGACTCTCCTAGATCCATAGACAGCA ACAGTGAGATTGTCTCATTTGGAAGTCCATGCTCCATTAATTCCCGACAATTTTTGATT CCTCCTAAAGATGAAGACTCTCCTAAATCTAATGGAGGAGGGTGGTCCTTTACAAACTT TTTTCAGAACAAACCAAACGATTAACAGTGTCACCGTGTCACTTCAGTCAGCCATCTCA ATAAGCTCTTACTGCTAGTGTTGCTACATCAGCACTGGGCATTCTTGGAGGGATCCTGT GAAGTATTGTTAGGAGGTGAACTTCACTACATGTTAAGTTACACTGAAAGTTCATGTGC TTTTAATGTAGTCTAAAAGCCAAAGTATAGTGACTCAGAATCCTCAATCCACAAAACTC AAGATTGGGAGCTCTTTGTGATCAAGCCAAAGAATTCTCATGTACTCTACCTTCAAGAA GCATTTCAAGGCTAATACCTACTTGTACGTACATGTAAAACAAATCCCGCCGCAACTGT TTTCTGTTCTGTTGTTTGTGGTTTTCTCATATGTATACTTGGTGGAATTGTAAGTGGAT TTGCAGGCCAGGGAGAAAATGTCCAAGTAACAGGTGAAGTTTATTTGCCTGACGTTTAC TCCTTTCTAGATGAAAACCAAGCACAGATTTTAAAACTTCTAAGATTATTCTCCTCTAT CCACAGCATTCACNNNNNNNNNNNNNNNNNNNNNNGTAGTGACAGCGATTTAGTGTTTT GTTTGATAAAGTATGCTTATTTCTGTGCCTACTGTATAATGGTTATCAAACAGTTGTCT CAGGGGTACAAACTTTGAAAACAAGTGTGACACTGACCAGCCCAAATCATAATCATGTT TTCTTGCTGTGATAGGTTTTGCTTGCCTTTTCATTATTTTTTAGCTTTTATGCTTGCTT CCATTATTTCAGTTGGTTGCCCTAATATTTAAAATTTACACTTCTAAGACTAGAGACCC ACATTTTTTAAAAATCATTTTATTTTGTGATACAGTGACAGCTTTATATGAGCAAATTC AATATTATTCATAAGCATGTAATTCCAGTGACTTACTATGTGAGATGACTACTAAGCAA TATCTAGCAGCGTTAGTTCCATATAGTTCTGATTGGATTTCGTTCCTCCTGAGGAGACC ATGCCGTTGAGCTTGGCTACCCAGGCAGTGGTGATCTTTGACACCTTCTGGTGGATGTT CCTCCCACTCATGAGTCTTTTCATCATGCCACATTATCTGATCCAGTCCTCACATTTTT AAATATAAAACTAAAGAGAGAATGCTTCTTACAGGAACAGTTACCCAAGGGCTGTTTCT TAGTAACTGTCATAAACTGATCTGGATCCATGGGCATACCTGTGTTCGAGGTGCAGCAA TTGCTTGGTGAGCTGTGCAGAATTGATTGCCTTCAGCACAGCATCCTCTGCCCACCCTT GTTTCTCATAAGCGATGTCTGGAGTGATTGTGGTTCTTGGAAAAGCAGAAGGAAAAACT AAAAAGTGTATCTTGTATTTTCCCTGCCCTCAGGTTGCCTATGTATTTTACCTTTTCAT ATTTAAGGCAAAAGTACTTGAAAATTTTAAGTGTCCGAATAAGATATGTCTTTTTTGTT TGTTTTTTTTGGTTGGTTGTTTGTTTTTTATCATCTGAGATTCTGTAATGTATTTGCAA ATAATGGATCAATTAATTTTTTTTGAAGCTCATATTGTATCTTTTTAAAAACCATGTTG TGGAAAAAAGCCAGAGTGACAAGTGACAAAATCTATTTAGGAACTCTGTGTATGAATCC TGATTTTAACTGCTAGGATTCAGCTAAATTTCTGAGCTTTATGATCTGTGGAAATTTGG AATGAAATCGAATTCATTTTGTACATACATAGTATATTAAAACTATATAATAGTTCATA GAAATGTTCAGTAATGAAAAAATATATCCAATCAGAGCCATCCCGAAAAAAAAAAAAAA A.

[0521] The length of this sequence was determined using batch, automated computational methods and the sequence, as sense strand, its length, and the desired location of the probe sequence near the 3′ end of the mRNA was submitted to Array Designer Ver 1.1 (Premier Biosoft International, Palo Alto, Calif.). Search quality was set at 100%, number of best probes set at 1, length range set at 50 base pairs, Target Tm set at 75 C. degrees plus or minus 5 degrees, Hairpin max deltaG at 6.0-kcal/mol., Self dimmer max deltaG at 6.0-kcal/mol, Run/repeat (dinucleotide) max length set at 5, and Probe site minimum overlap set at 1. When none of the 49 possible probes met the criteria, the probe site would be moved 50 base pairs closer to the 5′ end of the sequence and resubmitted to Array Designer for analysis. When no possible probes met the criteria, the variation on melting temperature was raised to plus and minus 8 degrees and the number of identical basepairs in a run increased to 6 so that a probe sequence was produced.

[0522] In the sequence above, using the criteria noted above, Array Designer Ver 1.1 designed a probe corresponding to oligonucleotide number 2280 in Table 8 and is indicated by underlining in the sequence above. It has a melting temperature of 68.4 degrees Celsius and a max run of 6 nucleotides and represents one of the cases where the criteria for probe design in Array Designer Ver 1.1 were relaxed in order to obtain an oligonucleotide near the 3′ end of the mRNA (Low melting temperature was allowed).

[0523] Clone 463D12

[0524] Clone 463D12 was sequenced and compared to the nr, dbEST, and UniGene databases at NCBI using the BLAST search tool. The sequence matched accession number All 84553, an EST sequence with the definition line “qd60a05.x1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:1733840 3′ similar to gb:M29550 PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT 1 (HUMAN);, mRNA sequence.” The E value of the alignment was 1.00×10¹¹⁸. The GenBank sequence begins with a poly-T region, suggesting that it is the antisense strand, read 5′ to 3′. The beginning of this sequence is complementary to the 3′ end of the mRNA sense strand. The accession number for this sequence was included in a text file of accession numbers representing antisense sequences. Sequences for antisense strand mRNAs were obtained by uploading a text file containing desired accession numbers as an Entrez search query using the Batch Entrez web interface and saving the results locally as a FASTA file. The following sequence was obtained, and the region of alignment of clone 463D12 is outlined: (SEQ ID NO: 8829) TTTTTTTTTTTTTTCTTAAATAGCATTTATTTTCTCTCAAAAAGCCTATT ATGTACTAACAAGTGTTCCTCTAAATTAGAAAGGCATCACTACTAAAATT TTATACATATTTTTTATATAAGAGAAGGAATATTGGGTTACAATCTGAAT TTCTCTTTATGATTTCTCTTAAAGTATAGAACAGCTATTAAAATGACTAA TATTGCTAAAATGAAGGCTACTAAATTTCCCCAAGAATTTCGGTGGAATG CCCAAAAATGGTGTTAAGATATGCAGAAGGGCCCATTTCAAGCAAAGCAA TCTCTCCACCCCTTCATAAAAGATTTAAGCTAAAAAAAAAAAAAAAAGAA {overscore (|GAAAATCCAACAGCTGAAGACATTGGGCTATTTATAAATCTTCTCCCAG)} {overscore (TCCCCCAGACAGCCTCACATGGGGGCTGTAAACAGCTAACTAAAATATCT)} {overscore (TTGAGACTCTTATGTCCACACCCACTGACACAAGGAGAGCTGTAACCACA)} {overscore (GTGAAACTAGACTTTGCTTTCCTTTAGCAAGTATGTGCCTATGATAGTAA)} {overscore (ACTGGAGTAAATGTAACA|)}GTAATAAAACAAATTTTTTTTAAAAATAAAA ATTATACCTTTTTCTCCAACAAACGGTAAAGACCACGTGAAGACATCCAT AAAATTAGGCAACCAGTAAAGATGTGGAGAACCAGTAAACTGTCGAAATT CATCACATTATTTTCATACTTTAATACAGCAGCTTTAATTATTGGAGAAC ATCAAAGTAATTAGGTGCCGAAAAACATTGTTATTAATGAAGGGAACCCC TGACGTTTGACCTTTTCTGTACCATCTATAGCCCTGGACTTGA

[0525] The FASTA file, including the sequence of AA184553, was then masked using the RepeatMasker web interface, as shown below. The region of alignment of clone 463D12 is outlined. (SEQ ID NO: 8830) TTTTTTTTTTTTTTCTTAAATAGCATTTATTTTCTCTCAAAAAGCCTATT ATGTACTAACAAGTGTTCCTCTAAATTAGAAAGGCATCACTACNNNNNNN NNNNNNNNNNNNNNNNNNNNNGAGAAGGAATATTGGGTTACAATCTGAAT TTCTCTTTATGATTTCTCTTAAAGTATAGAACAGCTATTAAAATGACTAA TATTGCTAAAATGAAGGCTACTAAATTTCCCCAAGAATTTCGGTGGAATG CCCAAAAATGGTGTTAAGATATGCAGAAGGGCCCATTTCAAGCAAAGCAA TCTCTCCACCCCTTCATAAAAGATTTAAGCTAAAAAAAAAAAAAAAAGAA {overscore (|GAAAATCCAACAGCTGAAGACATTGGGCTATTTATAAATCTTCTCCCAG)} {overscore (TCCCCCAGACAGCCTCACATGGGGGCTGTAAACAGCTAACTAAAATATCT)} {overscore (TTGAGACTCTTATGTCCACACCCACTGACACAAGGAGAGCTGTAACCACA)} {overscore (GTGAAACTAGACTTTGCTTTCCTTTAGCAAGTATGTGCCTATGATAGTAA)} {overscore (ACTGGAGTAAATGTAACA|)}GNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNNCCTTTTTCTCCAACAAACGGTAAAGACCACGTGAAGACATCCAT AAAATTAGGCAACCAGTAAAGATGTGGAGAACCAGTAAACTGTCGAAATT CATCACATTATTTTCATACTTTAATACAGCAGCTTTAATTATTGGAGAAC ATCAAAGTAATTAGGTGCCGAAAAACATTGTTATTAATGAAGGGAACCCC TGACGTTTGACCTTTTCTGTACCATCTATAGCCCTGGACTTGA Masked version of 463D12 sequence.

[0526] The sequence was submitted to Array Designer as described above, however, the desired location of the probe was indicated at base pair 50 and if no probe met the criteria, moved in the 3′ direction. The complementary sequence from Array Designer was used, because the original sequence was antisense. The oligonucleotide designed by Array Designer corresponds to oligonucleotide number 4342 in Table 8 and is complementary to the underlined sequence above. The probe has a melting temperature of 72.7 degrees centigrade and a max run of 4 nucleotides.

[0527] Clone 72D4

[0528] Clone 72D4 was sequenced and compared to the nr, dbEST, and UniGene databases at NCBI using the BLAST search tool. No significant matches were found in any of these databases. When compared to the human genome draft, significant alignments were found to three consecutive regions of the reference sequence NT_(—)008060, as depicted below, suggesting that the insert contains three spliced exons of an unidentified gene.

[0529] Residue Numbers on Matching Residue clone 72D4 sequence numbers on NT_008060  1-198 478646-478843 197-489 479876-480168 491-585 489271-489365

[0530] Because the reference sequence contains introns and may represent either the coding or noncoding strand for this gene, BioCardia's own sequence file was used to design the oligonucleotide. Two complementary probes were designed to ensure that the sense strand was represented. The sequence of the insert in clone 72D4 is shown below, with the three putative exons outlined.

[0531] The sequence was submitted to RepeatMasker, but no repetitive sequences were found. The sequence shown above was used to design the two 50-mer probes using Array Designer as described above. The probes are shown in bold typeface in the sequence depicted below. The probe in the sequence is oligonucleotide number 6415 (SEQ ID NO: 6415) in Table 8 and the complementary probe is oligonucleotide number 6805 (SEQ ID NO:6805). CAGGTCACACAGCACATCAGTGGCTACATGTGAGCTCAGACCTGGGTCTGCTGCTGTCT GTCTTCCCAATATCCATGACCTTGACTGATGCAGGTGTCTAGGGATACGTCCATCCCCG TCCTGCTGGAGCCCAGAGCACGGAAGCCTGGCCCTCCGAGGAGACAGAAGGGAGTGTCG GACACCATGACGAGAGCTTGGCAGAATAAATAACTTCTTTAAACAATTTTACGGCATGA AGAAATCTGGACCAGTTTATTAAATGGGATTTCTGCCACAAACCTTGGAAGAATCACAT CATCTTANNCCCAAGTGAAAACTGTGTTGCGTAACAAAGAACATGACTGCGCTCCACAC ATACATCATTGCCCGGCGAGGCGGGACACAAGTCAACGACGGAACACTTGAGACAGGCC TACAACTGTGCACGGGTCAGAAGCAAGTTTAAGCCATACTTGCTGCAGTGAGACTACAT TTCTGTCTATAGAAGATACCTGACTTGATCTGTTTTTCAGCTCCAGTTCCCAGATGTGC                                      ←----GTCAAGGGTCTACACG GTGTTGTGGTCCCCAAGTATCACCTTCCAATTTCTGGGAG--→ CACAACACCAGGGGTTCATAGTGGAAGGTTAAAG-5′ CAGTGCTCTGGCCGGATCCTTGCCGCGCGGATAAAAACT---→

[0532] Confirmation of Probe Sequence

[0533] Following probe design, each probe sequence was confirmed by comparing the sequence against dbEST, the UniGene cluster set, and the assembled human genome using BLASTn at NCBI. Alignments, accession numbers, gi numbers, UniGene cluster numbers and names were examined and the most common sequence used for the probe. The final probe set was compiled into Table 8. In this table, the sequence ID is given which corresponds to the sequence listing. The origin of the sequence for inclusion on the array is noted as coming from one of the cDNA libraries described in example 1, mining from databases as described in examples 2 and 11 or identification from the published literature. The unigene number, genebank accession and GI number are also given for each sequence when known. The name of the gene associated with the accession number is noted. The strand is noted as −1 or 1, meaning that the probe was designed from the complement of the sequence (-1) or directly from the sequence (1). Finally, the nucleotide sequence of each probe is also given.

Example 13 Production of an Array of 8000 Spotted 50mer Oligonucleotides

[0534] We produced an array of 8000 spotted 50mer oligonucleotides. Examples 11 and 12 exemplify the design and selection of probes for this array.

[0535] Sigma-Genosys (The Woodlands, Tex.) synthesized unmodified 50-mer oligonucleotides using standard phosphoramidite chemistry, with a starting scale of synthesis of 0.05 μmole (see, e.g., R. Meyers, ed. (1995) Molecular Biology and Biotechnology: A Comprehensive Desk Reference). Briefly, to begin synthesis, a 3′ hydroxyl nucleoside with a dimethoxytrityl (DMT) group at the 5′ end was attached to a solid support. The DMT group was removed with trichloroacetic acid (TCA) in order to free the 5′-hydroxyl for the coupling reaction. Next, tetrazole and a phosphoramidite derivative of the next nucleotide were added. The tetrazole protonates the nitrogen of the phosphoramidite, making it susceptible to nucleophilic attack. The DMT group at the 5′-end of the hydroxyl group blocks further addition of nucleotides in excess. Next, the inter-nucleotide linkage was converted to a phosphotriester bond in an oxidation step using an oxidizing agent and water as the oxygen donor. Excess nucleotides were filtered out and the cycle for the next nucleotide was started by the removal of the DMT protecting group. Following the synthesis, the oligo was cleaved from the solid support. The oligonucleotides were desalted, resuspended in water at a concentration of 100 or 200 μM, and placed in 96-deep well format. The oligonucleotides were re-arrayed into Whatman Uniplate 384-well polyproylene V bottom plates. The oligonucleotides were diluted to a final concentration 30 μM in 1× Micro Spotting Solution Plus (Telechem/arrayit.com, Sunnyvale, Calif.) in a total volume of 15 μl. In total, 8,031 oligonucleotides were arrayed into twenty-one 384-well plates.

[0536] Arrays were produced on Telechem/arrayit.com Super amine glass substrates (Telechem/arrayit.com), which were manufactured in 0.1 mm filtered clean room with exact dimensions of 25×76×0.96 mm. The arrays were printed using the Virtek Chipwriter with a Telechem 48 pin Micro Spotting Printhead. The Printhead was loaded with 48 Stealth SMP3B TeleChem Micro Spotting Pins, which were used to print oligonucleotides onto the slide with the spot size being 110-115 microns in diameter.

Example 14 Amplification, Labeling, and Hybridization of Total RNA to an Oligonucleotide Microarray

[0537] Amplification, Labeling, Hybridization and Scanning

[0538] Samples consisting of at least 2 μg of intact total RNA were further processed for array hybridization. Amplification and labeling of total RNA samples was performed in three successive enzymatic reactions. First, a single-stranded DNA copy of the RNA was made (hereinafter, “ss-cDNA”). Second, the ss-cDNA was used as a template for the complementary DNA strand, producing double-stranded cDNA (hereinafter, “ds-cDNA, or cDNA”). Third, linear amplification was performed by in vitro transcription from a bacterial T₇ promoter. During this step, fluorescent-conjugated nucleotides were incorporated into the amplified RNA (hereinafter, “aRNA”).

[0539] The first strand cDNA was produced using the Invitrogen kit (Superscript II). The first strand cDNA was produced in a reaction composed of 50 mM Tris-HCl (pH 8.3), 75 mM KCl, and 3 mM MgCl₂ (1× First Strand Buffer, Invitrogen), 0.5 mM dGTP, 0.5 mM dATP, 0.5 mM dTTP, 0.5 mM dCTP, 10 mM DTT, 10 U reverse transcriptase (Superscript II, Invitrogen, #18064014), 15 U RNase inhibitor (RNAGuard, Amersham Pharmacia, #27-0815-01), δ 1M T7T24 primer (5′-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGGTTTTTTTTTTTT TTTTTTTTTTTT-3′), (SEQ ID NO:8831) and 2 μg of selected sample total RNA. Several purified, recombinant control mRNAs from the plant Arabidopsis thaliana were added to the reaction mixture: 2-20 μg of the following genes CAB, RCA, LTP4, NACI, RCPI, XCP2, RBCL, LTP6, TIM, and PRKase (Stratagene, #252201, #252202, #252204, #252208, #252207, #252206, #252203, #252205, #252209, #252210 respectively). The control RNAs allow the estimate of copy numbers for individual mRNAs in the clinical sample because corresponding sense oligonucleotide probes for each of these plant genes are present on the microarray. The final reaction volume of 20 μl was incubated at 42° C. for 60 min.

[0540] For synthesis of the second cDNA strand, DNA polymerase and RNase were added to the previous reaction, bringing the final volume to 150 μl. The previous contents were diluted and new substrates were added to a final concentration of 20 mM Tris-HCl (pH 7.0) (Fisher Scientific, Pittsburgh, Pa. #BP1756-100), 90 mMKCl (Teknova, Half Moon Bay, CA, #0313-500), 4.6 mM MgCl₂ (Teknova, Half Moon Bay, CA, #0304-500), 10 mM(NH₄)₂SO₄ (Fisher Scientific #A702-500)(1× Second Strand buffer, Invitrogen), 0.266 mM dGTP, 0.266 mM dATP, 0.266 mM dTTP, 0.266 mM dCTP, 40 U E. coli DNA polymerase (Invitrogen, #18010-025), and 2 U RNaseH (Invitrogen, #18021-014). The second strand synthesis took place at 16° C. for 120 minutes.

[0541] Following second-strand synthesis, the ds-cDNA was purified from the enzymes, dNTPs, and buffers before proceeding to amplification, using phenol-chloroform extraction followed by ethanol precipitation of the cDNA in the presence of glycogen.

[0542] Alternatively, a silica-gel column is used to purify the cDNA (e.g. Qiaquick PCR cleanup from Qiagen, #28104). The cDNA was collected by centrifugation at >10,000 μg for 30 minutes, the supernatant is aspirated, and 150 μl of 70% ethanol, 30% water was added to wash the DNA pellet. Following centrifugation, the supernatant was removed, and residual ethanol was evaporated at room temperature.

[0543] Linear amplification of the cDNA was performed by in vitro transcription of the cDNA. The cDNA pellet from the step described above was resuspended in 7.4 μl of water, and in vitro transcription reaction buffer was added to a final volume of 20 μl containing 7.5 mM GTP, 7.5 mM ATP, 7.5 mM TTP, 2.25 mM CTP, 1.025 mM Cy3-conjugated CTP (Perkin Elmer; Boston, Mass., #NEL-580), lx reaction buffer (Ambion, Megascript Kit, Austin, Tex. and #1334) and 1% T₇ polymerase enzyme mix (Ambion, Megascript Kit, Austin, Tex. and #1334). This reaction was incubated at 37° C. overnight. Following in vitro transcription, the RNA was purified from the enzyme, buffers, and excess NTPs using the RNeasy kit from Qiagen (Valencia, Calif.; # 74106) as described in the vendor's protocol. A second elution step was performed and the two eluates were combined for a final volume of 60μl. RNA is quantified using an Agilent 2100 bioanalyzer with the RNA 6000 nano LabChip.

[0544] Reference RNA was prepared as described above, except Cy5-CTP was incorporated instead of Cy3CTP. Reference RNA from five reactions, each reaction started with 2 μg total RNA, was pooled together and quantitated as described above.

[0545] Hybridization to an Array

[0546] RNA was prepared for hybridization as follows: for an 18 mm×55 mm array, 20 μg of amplified RNA (aRNA) was combined with 20 μg of reference aRNA. The combined sample and reference aRNA was concentrated by evaporating the water to 10 μl in a vacuum evaporator. The sample was fragmented by heating the sample at 95° C. for 30 minutes to fragment the RNA into 50-200 bp pieces. Alternatively, the combined sample and reference aRNA was concentrated by evaporating the water to 5μl in a vacuum evaporator. Five μl of 20 mM zinc acetate was added to the aRNA and the mix incubated at 60° C. for 10 minutes. Following fragmentation, 40 μl of hybridization buffer was added to achieve final concentrations of 5× SSC and 0.20%SDS with 0.1 μg/ul of Cot-i DNA (Invitrogen) as a competitor DNA. The final hybridization mix was heated to 98° C., and then reduced to 50C at 0.1° C. per second.

[0547] Alternatively, formamide is included in the hybridization mixture to lower the hybridization temperature.

[0548] The hybridization mixture was applied to a pre-heated 65° C. microarray, surface, covered with a glass coverslip (Corning, #2935-246), and placed on a pre-heated 65° C. hybridization chamber (Telechem, AHC-10). 15 ul of 5× SSC was placed in each of the reservoir in the hybridization chamber and the chamber was sealed and placed in a water bath at 62° C. for overnight (16-20 hrs). Following incubation, the slides were washed in 2× SSC, 0.1% SDS for five minutes at 30° C., then in 2× SSC for five minutes at 30° C., then in 2× SSC for another five minutes at 30° C., then in 0.2× SSC for two minutes at room temperature. The arrays were spun at 1000× g for 2 minutes to dry them. The dry microarrays are then scanned by methods described above.

[0549] The microarrays were imaged on the Agilent (Palo Alto, Calif.) scanner G2565AA. The scan settings using the Agilent software were as follows: for the PMT Sensitivity (100% Red and 100% Green); Scan Resolution (10 microns); red and green dye channels; used the default scan region for all slides in the carousel; using the largest scan region; scan date for Instrument ID; and barcode for Slide ID. The full image produced by the Agilent scanner was flipped, rotated, and split into two images (one for each signal channel) using TIFFSplitter (Agilent, Palo Alto, Calif.). The two channels are the output at 532 nm (Cy3-labeled sample) and 633 nm (Cy5-labeled R50). The individual images were loaded into GenePix 3.0 (Axon Instruments, Union City, Calif.) for feature extraction, each image was assigned an excitation wavelength corresponding the file opened; Red equals 633 nm and Green equals 532 nm. The setting file (gal) was opened and the grid was laid onto the image so that each spot in the grid overlaped with >50% of the feature. Then the GenePix software was used to find the features without setting minimum threshold value for a feature. For features with low signal intensity, GenePix reports “not found”. For all features, the diameter setting was adjusted to include only the feature if necessary.

[0550] The GenePix software determined the median pixel intensity for each feature (F_(i)) and the median pixel intensity of the local background for each feature (B_(i)) in both channels. The standard deviation (SDF_(i and) SDB_(i)) for each is also determined. Features for which GenePix could not discriminate the feature from the background were “flagged” as described below.

[0551] Following feature extraction into a .gpr file, the header information of the .gpr file was changed to carry accurate information into the database. An Excel macro was written to change the headers. The steps in that macro were:

[0552] 1. Open .gpr file.

[0553] 2. Check the value in the first row, first column. If it is “ATF”, then the header has likely already been reformatted. The file is skipped and the user is alerted. Otherwise, proceed through the following steps.

[0554] 3. Store the following values in variables.

[0555] a. Name of.tif image file: parsed from row 11.

[0556] b. SlideID: parsed from name of .tif image file.

[0557] c. Version of the feature extraction software: parsed from row 25

[0558] d. GenePix Array List file: parsed from row 6

[0559] e. GenePix Settings file: parsed from row 5

[0560] 4. Delete rows 1-8, 10-12, 20, 22, and 25.

[0561] 5. Arrange remaining values in rows 15-29.

[0562] 6. Fill in rows 1-14 with the following:

[0563] Row 1: ScanID (date image file was last modified, formatted as yyyy.mm.dd-hh.mm.ss)

[0564] Row 2: SlideID, from stored value

[0565] Row 3: Name of person who scanned the slide, from user input

[0566] Row 4: Image file name, from stored value

[0567] Row 5: Green PMT setting, from user input

[0568] Row 6: Red PMT setting, from user input

[0569] Row 7: ExtractID (date .gpr file was created, formatted as yyyy.mm.dd-hh.mm.ss)

[0570] Row 8: Name of person who performed the feature extraction, from user input

[0571] Row 9: Feature extraction software used, from stored value

[0572] Row 10: Results file name (same as the .gpr file name)

[0573] Row 11: GenePix Array List file, from stored value

[0574] Row 12: GenePix Settings file, from stored value

[0575] Row 13: StorageCD, currently left blank

[0576] Row 14: Extraction comments, from user input (anything about the scanning or feature extraction of the image the user feels might be relevant when selecting which hybridizations to include in an analysis)

[0577] Pre-processing with Excel Templates

[0578] Following analysis of the image and extraction of the data, the data from each hybridization was pre-processed to extract data that was entered into the database and subsequently used for analysis. The complete GPR file produced by the feature extraction in GenePix was imported into an excel file pre-processing template. The same excel template was used to process each GPR file. The template performs a series of calculations on the data to differentiate poor features from others and to combine triplicate feature data into a single data point for each probe.

[0579] Each GPR file contained 31 rows of header information, followed by rows of data for 24093 features. The last of these rows was retained with the data. Rows 31 through the end of the file were imported into the excel template. Each row contained 43 columns of data. The only columns used in the pre-processing were: Oligo ID, F633 Median (median value from all the pixels in the feature for the Cy5 dye), B633 Median (the median value of all the pixels in the local background of the selected feature for Cy5), B633 SD (the standard deviation of the values for the pixels in the local background of the selected feature for Cy5), F532 Median (median value from all the pixels in the feature for the Cy3 dye), B532 Median (the median value of all the pixels in the local background of the selected feature for Cy3), B532 SD (the standard deviation of the values for the pixels in the local background of the selected feature for Cy3), and Flags. The GenePix Flags column contains the flags set during feature extraction. “-75” indicates there were no features printed on the array in that position, “-50” indicates that GenePix could not differentiate the feature signal from the local background, and “-100” indicates that the user marked the feature as bad.

[0580] Once imported, the rows with −75 flags were deleted. Then the median of B633 SD and B532 SD were calculated over all features with a flag value of “0”. The minimum values of B633 Median and B532 Median were identified, considering only those values associated with a flag value of “0”. For each feature, the signal to noise ratio (S/N) was calculated for both dyes by taking the fluorescence signal minus the local background (BGSS) and dividing it by the standard deviation of the local background: ${S\text{/}N} = \frac{F_{i} - B_{i}}{{SDB}_{i}}$

[0581] If the S/N was less than 3, then an adjusted background-subtracted signal was calculated as the fluorescence minus the minimum local background on the slide. An adjusted S/N was then calculated as the adjusted background subtracted signal divided by the median noise over all features for that channel. If the adjusted S/N was greater than three and the original S/N were less than three, a flag of 25 was set for the Cy5 channel, a flag of 23 was set for the Cy3 channel, and if both met these criteria, then a flag of 20 was set. If both the adjusted S/N and the original S/N were less than three, then a flag of 65 was set for Cy5, 63 set for Cy3, and 60 set if both dye channels had an adjusted S/N less than three. All signal to noise calculations, adjusted background-subtracted signal, and adjusted S/N were calculated for each dye channel. If the BGSS value was greater than or equal to 64000, a flag was set to indicate saturation; 55 for Cy5, 53 for Cy3, 50 for both.

[0582] The BGSS used for further calculations was the original BGSS if the original S/N was greater than or equal to three. If the original S/N ratio was less than three and the adjusted SIN ratio was greater than or equal to three, then the adjusted BGSS was used. If the adjusted S/N ratio was less than three, then the adjusted BGSS was used, but with knowledge of the flag status.

[0583] To facilitate comparison among arrays, the Cy3 and CyS data were scaled to have a median of 1. For each dye channel, the median value of all features with flags=0,20,23, or 25 was calculated. The BGSS for each dye in each feature was then divided by this median value. The Cy3/Cy5 ratio was calculated for each feature using the scaled $R_{n\quad} = \frac{{Cy3S}_{i}}{{Cy5S}_{i}}$

[0584] The flag setting for each feature was used to determine the expression ratio for each probe, a combination of three features. If all three features had flag settings in the same category (categories=negatives, 0 to 25, 50-55, and 60-65), then the average and CV of the three feature ratios was calculated. If the CV of all three features was less than 15, the average was used. If the CV was greater than 15, then the CV of each combination of two of the features was calculated and the two features with the lowest CV were averaged. If none of the combinations of two features had a CV less than 15, then the median ratio of the three features was used as the probe feature.

[0585] If the three features do not have flags in the same category, then the features with the best quality flags were used (0>25>23>20>55>53>50>65>63>60). Features with negative flags were never used. When the best flags were two features in the same category, the average was used. If a single feature had a better flag category than the other two then that feature was used.

[0586] Once the probe expression ratio was calculated from the three features, the log of the ratio was taken as described below and stored for use in analyzing the data. Whichever features were used to calculate the probe value, the worst of the flags from those features was carried forward and stored as the flag value for that probe. 2 different data sets can be used for analysis. Flagged data uses all values, including those with flags. Filtered data sets are created by removing flagged data from the set before analysis.

Example 15 Real-Time PCR Validation of Array Expression Results

[0587] In example 10, leukocyte gene expression was used to discover expression markers and diagnostic gene sets for clinical outcomes. It is desirable to validate the gene expression results for each gene using a more sensitive and quantitative technology such as real-time PCR. Further, it is possible for the diagnostic nucleotide sets to be implemented as a diagnostic test as a real-time PCR panel. Alternatively, the quantitative information provided by real-time PCR validation can be used to design a diagnostic test using any alternative quantitative or semi-quantitative gene expression technology.

[0588] To validate the results of the microarray experiments we used real-time, or kinetic, PCR. In this type of experiment the amplification product is measured during the PCR reaction. This enables the researcher to observe the amplification before any reagent becomes rate limiting for amplification. In kinetic PCR the measurement is of C_(T) (threshold cycle) or C_(P) (crossing point). This measurement (C_(T)=C_(P)) is the point at which an amplification curve crosses a threshold fluorescence value. The threshold is set to a point within the area where all of the reactions were in their linear phase of amplification. When measuring C_(T), a lower C_(T) value is indicative of a higher amount of starting material since an earlier cycle number means the threshold was crossed more quickly.

[0589] Several fluorescence methodologies are available to measure amplification product in real-time PCR. Taqman (Applied BioSystems, Foster City, Calif.) uses fluorescence resonance energy transfer (FRET) to inhibit signal from a probe until the probe is degraded by the sequence specific binding and Taq 3′ exonuclease activity. Molecular Beacons (Stratagene, La Jolla, Calif.) also use FRET technology, whereby the fluorescence is measured when a hairpin structure is relaxed by the specific probe binding to the amplified DNA. The third commonly used chemistry is Sybr Green, a DNA-binding dye (Molecular Probes, Eugene, Oreg.). The more amplified product that is produced, the higher the signal. The Sybr Green method is sensitive to non-specific amplification products, increasing the importance of primer design and selection. Other detection chemistries can also been used, such as ethedium bromide or other DNA-binding dyes and many modifications of the fluorescent dye/quencher dye Taqman chemistry, for example scorpions.

[0590] Initially, samples are chosen for validation, which have already been used for microarray based expression analysis. They are also chosen to represent important disease classes or disease criteria. For the first steps of this example (primer design, primer endpoint testing, and primer efficiency testing) we examined M-actin and P-GUS. These genes are considered “housekeeping” genes because they are required for maintenance in all cells. They are commonly used as a reference that is expected to not change with experimental treatment. We chose these two particular genes as references because they varied the least in expression across 5 mRNA samples examined by real-time PCR.

[0591] The inputs for real time PCR reaction are gene-specific primers, cDNA from specific patient samples, and the standard reagents. The cDNA was produced from mononuclear RNA (prepared as in example 7) by reverse transcription using OligodT primers (Invitrogen, 18418-012) and random hexamers (Invitrogen, 48190-011) at a final concentration of 0.5 ng/μl and 3 ng/μl respectively. For the first strand reaction mix, 1.451 μg/μl of total RNA (R50, universal leukocyte reference RNA as described in Example 8) and 1 μl of the Oligo dT/Random Hexamer Mix, were added to water to a final volume of 11.5 μl. The sample mix was then placed at 70° C. for 10 minutes. Following the 70° C. incubation, the samples were chilled on ice, spun down, and 88.5 μl of first strand buffer mix dispensed into the reaction tube. The final first strand buffer mix produced final concentrations of IX first strand buffer (Invitrogen, Y00146, Carlsbad, Calif.), 0.01 mM DTT (Invitrogen, Y00147), 0.1 mM dATP (NEB, NO₄₄₀S, Beverly, Mass.), 0.1 mM dGTP (NEB, NO₄₄₂S), 0.1 mM dTTP (NEB, NO₄₄₃S), 0.1 mM dCTP (NEB, NO₄₄₁S), 2U of reverse transcriptase (Superscript II, Invitrogen, 18064-014), and 0.18U of RNase inhibitor (RNAGaurd Amersham Pharmacia, 27-0815-01, Piscataway, N.J.). The reaction was incubated at 42° C. for 1 hour. After incubation the enzyme was heat inactivated at 70° C. for 15 minutes, 1 III of RNAse H added to the reaction tube, and incubated at 37° C. for 20 minutes.

[0592] Primer Design

[0593] Two methods were used to design primers. The first was to use the software, Primer Express™ and recommendations for primer design that are provided with the GeneAmp®b 7700 Sequence Detection System supplied by Applied BioSystems (Foster City, Calif.). The second method used to design primers was the PRIMER3 ver 0.9 program that is available from the Whitehead Research Institute, Cambridge, Mass. The program can also be accessed on the World Wide Web at: genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi. Primers and Taqman/hybridization probes were designed as described below using both programs.

[0594] The Primer Express literature explains that primers should be designed with a melting temperature between 58 and 60 degrees C. while the Taqman probes should have a melting temperature of 68 to 70 under the salt conditions of the supplied reagents. The salt concentration is fixed in the software. Primers should be between 15 and 30 basepairs long. The primers should produce and amplicon in size between 50 and 150 base pairs, have a C-G content between 20% and 80%, have no more than 4 identical base pairs next to one another, and no more than 2 C's and G's in the last 5 bases of the 3′ end. The probe cannot have a G on the 5′ end and the strand with the fewest G's should be used for the probe.

[0595] Primer3 has a large number of parameters. The defaults were used for all except for melting temperature and the optimal size of the amplicon was set at 100 bases. One of the most critical is salt concentration as it affects the melting temperature of the probes and primers. In order to produce primers and probes with melting temperatures equivalent to Primer Express, a number of primers and probes designed by Primer Express were examined using PRIMER3. Using a salt concentration of 50 mM these primers had an average melting temperature of 3.7 degrees higher than predicted by Primer Express. In order to design primers and probes with equivalent melting temperatures as Primer Express using PRIMER3, a melting temperature of 62.7 plus/minus 1.0 degree was used in PRIMER3 for primers and 72.7 plus/minus 1.0 degrees for probes with a salt concentration of 50 mM.

[0596] The C source code for Primer3 was downloaded and complied on a Sun Enterprise 250 server using the GCC complier. The program was then used from the command line using a input file that contained the sequence for which we wanted to design primers and probes along with the input parameters as described by help files that accompany the software. Using scripting it was possible to input a number of sequences and automatically generate a number of possible probes and primers.

[0597] Primers for p-Actin (Beta Actin, Genbank Locus: NM001 101)and B-GUS: glucuronidase, beta, (GUSB, Genbank Locus: NM_(—)000181), two reference genes, were designed using both methods and are shown here as examples. The first step was to mask out repetitive sequences found in the mRNA sequences using RepeatMasker program that can be accessed at the web site located at repeatmasker.genome.washington.edu/cgi-bin/RepeatMasker (Smit, AFA & Green, P “RepeatMasker” at the web site located at ftp.genome.washington.edu/RM/RepeatMasker.html). The last 500 basepairs on the last 3′ end of masked sequence was then submitted to PRIMER3 using the following exemplary input file:

[0598] PRIMER_SEQUENCE_ID=>ACTB Beta Actin

[0599] PRIMER_EXPLAIN FLAG=L

[0600] PRIMER_MISPRIMING_LIBRARY= (SEQ ID NO: 8833) SEQUENCE = TTGGCTTGACTCAGGATTTAAAAACTGGAACGGTGAAGGTGACAGCAGTCGGTTGGACGAGC ATCCCCCAAAGTTCACAATGTGGCCGAGGACTTTGATTGCACATTGTTGTTTTTTAATAGTCATTCCAAAT ATGAGATGCATTGTTACAGGAAGTCCCTTGCCATCCTAAAAGCACCCCACTTCTCTCTAAGGAGAATGGCC CAGTCCTCTCCCAAGTCCACACAGGGGAGGGATAGCATTGCTTTCGTGTAAATTATGTAATGCAAAATTTT TTTAATCTTCGCCTTAATCTTTTTTATTTTGTTTTATTTTGAATGATGAGCCTTCGTGCCCCCCCTTCCCC CTTTTTTCCCCCAACTTGAGATGTATGAAGGCTTTTGGTCTCCCTGGGAGTGGGTGGAGGCAGCCGGGCTT ACCTGTACACTGACTTGAGACCAGTTGAATAAAAGTGCACACCTTA

[0601] PRIMER_PRODUCT_OPT_SIZE=100

[0602] PRIMER_NUM_RETURN=100

[0603] PRIMER_MAX_END_STABILITY=9.0

[0604] PRIMER_MAX_MISPRIMING=12.00

[0605] PRIMER_PAIR_MAX_MISPRIMING=24.00

[0606] PRIMER_MINSIZE=18

[0607] PRIMER_OPT_SIZE=20

[0608] PRIMER_MAX_SIZE=32

[0609] PRIMER_MIN_TM=61.7

[0610] PRIMER_OPT_TM=62.7

[0611] PRIMER_MAX_TM=63.7

[0612] PRIMER_MAX_DIFF_TM=100.0

[0613] PRIMER_MIN_GC=20.0

[0614] PRIMER_MAX_GC=80.0

[0615] PRIMER_SELF_ANY=8.00

[0616] PRIMER_SELF_END=3.00

[0617] PRIMER_NUM_NS_ACCEPTED=0

[0618] PRIMER_MAX_POLY_X=4

[0619] PRIMER_OUTSIDE PENALTY=0

[0620] PRIMER GC_CLAMP=0

[0621] PRIMER_SALT_CONC=50.0

[0622] PRIMER_DNA_CONC=50.0

[0623] PRIMER_LIBERAL_BASE=1

[0624] PRIMER_MIN_QUALITY=0

[0625] PRIMER_MIN_END_QUALITY=0

[0626] PRIMER_QUALITY_RANGE_MIN=0

[0627] PRIMER_QUALITY_RANGE_MAX=100

[0628] PRIMER_WT_TM_LT=1.0

[0629] PRIMER_WT_TM_GT=1.0

[0630] PRIMER_WT_SIZE_LT=1.0

[0631] PRIMER_WT_SIZE_GT=1.0

[0632] PRIMER_WT_GC_PERCENT_LT=0.0

[0633] PRIMER_WT_GC_PERCENT_GT=0.0

[0634] PRIMER_WT_COMPL ANY=0.0

[0635] PRIMER_WT_COMPL_END=0.0

[0636] PRIMER_WT_NUM_NS=0.0

[0637] PRIMER_WT_REP_SIM=0.0

[0638] PRIMER_WT_SEQQUAL=0.0

[0639] PRIMER_WT_END_QUAL=0.0

[0640] PRIMER_WT_POS_PENALTY=0.0

[0641] PRIMER_WT_END_STABILITY=1

[0642] PRIMER_PAIR_WT_PRODUCT_SIZE_LT=0.05

[0643] PRIMER_PAIR_WT_PRODUCT_SIZE_GT=0.05

[0644] PRIMER_PAIRWT_PRODUCT_TM_LT=0.0

[0645] PRIMER_PAIR WT_PRODUCT_TM_GT=0.0

[0646] PRIMER_PAIR_WT_DIFF_TM=0.0

[0647] PRIMER_PAIR_WT_COMPL ANY=0.0

[0648] PRIMER_PAIR_WT_COMPL_END=0.0

[0649] PRIMER_PAIR_WT_REP_SIM=0.0

[0650] PRIMER_PAIR_WT_PR_PENALTY=1.0

[0651] PRIMER_PAIR_WT_IO_PENALTY=0.0

[0652] PRIMER_INTERNALOLIGOMINSIZE=18

[0653] PRIMER_INTERNAL_OLIGO_OPT_SIZE=20

[0654] PRIMER_INTERNAL_OLIGO_MAX_SIZE=35

[0655] PRIMER_INTERNAL_OLIGO_MIN_TM=71.7

[0656] PRIMER_INTERNAL_OLIGO_OPT_TM=72.7

[0657] PRIMER_INTERNAL_OLIGO_MAX_TM=73.7

[0658] PRIMER_INTERNAL_OLIGO_MIN_GC=20.0

[0659] PRIMER_INTERNAL_OLIGO_MAX_GC=80.0

[0660] PRIMER_INTERNAL_OLIGO_SELF_ANY=12.00

[0661] PRIMER_INTERNAL_OLIGO_SELF_END=12.00

[0662] PRIMER_INTERNAL_OLIGO_NUM_NS=0

[0663] PRIMER_INTERNAL_OLIGO_MAX_POLY_X=5

[0664] PRIMER_INTERNAL_OLIGO_MISHYB_LIBRARY=

[0665] PRIMER_INTERNAL_OLIGO_MAX_MISHYB=12.00

[0666] PRIMER_INTERNAL_OLIGO_MIN_QUALITY=O

[0667] PRIMER_INTERNAL_OLIGO_SALT_CONC=50.0.

[0668] PRIMER_INTERNAL_OLIGO_DNA_CONC=50.0

[0669] PRIMER_IO_WT_TM_LT=1.0

[0670] PRIMER_IO_WT_TM_GT=1.0

[0671] PRIMER_IO_WT_SIZE_LT=1.0

[0672] PRIMER_IO_WT_SIZE_GT=1.0

[0673] PRIMER_IO_WT_GC_PERCENT_LT=0.0

[0674] PRIMER_IO_WT_GC_PERCENT_GT=0.0

[0675] PRIMER_IO_WT_COMPL_ANY=0.0

[0676] PRIMER_IO_WT_NUM_NS=0.0

[0677] PRIMER_IO_WT_REP_SIM=0.0

[0678] PRIMER_IO_WT_SEQ_QUAL=0.0

[0679] PRIMER_TASK=pick_pcr_primers_and_hyb_probe

[0680] PRIMER_PRODUCT_SIZE_RANGE=50-150

[0681] PRIMER_FIRST_BASE_INDEX=1

[0682] PRIMER_PICK_ANYWAY=1

[0683] PRIMER_SEQUENCE_ID=>GUSB

[0684] PRIMER_EXPLAIN_FLAG=1

[0685] PRIMER_MISPRIMING_LIBRARY= (SEQ ID NO: 8834) SEQUENCE = GAAGAGTACCAGAAAAGTCTGCTAGAGCAGTACCATCTGGGTCTGGATCAAAAACGCAGAAA ATATGTGGTTGGAGAGCTCATTTGGAATTTTGCCGATTTCATGACTGAACAGTCACCGACGAGAGTGCTGG GGAATAAAAAGGGGATCTTCACTCGGCAGAGACAACCAAAAAGTGCAGCGTTCCTTTTGCGAGAGAGATAC TGGAAGATTGCCAATGAAACCAGGTATCCCCACTCAGTAGCCAAGTCACAATGTTTGGAAAACAGCCCGTT TACTTGAGCAAGACTGATACCACCTGCGTGTCCCTTCCTCCCCGAGTCAGGGCGACTTCCACAGCAGCAGA ACAAGTGCCTCCTGGACTGTTCACGGCAGACCAGAACGTTTCTGGCCTGGGTTTTGTGGTCATCTATTCTA GCAGGGAACACTAAAGGTGGAAATAAAAGATTTTCTATTATGGAAATAAAGAGTTGGCATGAAAGTCGCTA CTG

[0686] CTG (SEQ ID NO: 8834)

[0687] PRIMER_PRODUCT_OPT_SIZE=100

[0688] PRIMER_NUM_RETURN=100

[0689] PRIMER_MAX ENDSTABILITY=9.

[0690] PRIMER_MAX_MISPRIMING=12.00

[0691] PRIMER_PAIR_MAX_MISPRIMING=24.00

[0692] PRIMER_MIN_SIZE=18

[0693] PRIMER_OPT_SIZE=20

[0694] PRIMER_MAX_SIZE=32

[0695] PRIMER_MIN_TM=61.7

[0696] PRIMER_OPT_TM=62.7

[0697] PRIMER_MAX_TM=63.7

[0698] PRIMER_MAX_DIFF_TM=100.0

[0699] PRIMER_MIN_GC=20.0

[0700] PRIMER_MAX_GC=80.0

[0701] PRIMER_SELF ANY=8.00

[0702] PRIMER_SELF_END=3.00

[0703] PRIMER_NUM_NS_ACCEPTED=0

[0704] PRIMER_MAX_POLY_X=4

[0705] PRIMER_OUTSIDE_PENALTY=0

[0706] PRIMER_GC_CLAMP=0

[0707] PRIMER_SALT_CONC=50.0

[0708] PRIMER_DNA_CONC=50.0

[0709] PRIMER_LIBERAL_BASE=1

[0710] PRIMER_MIN_QUALITY=0

[0711] PRIMER_MIN_END_QUALITY=0

[0712] PRIMER_QUALITY_RANGE_MIN=0

[0713] PRIMER_QUALITY_RANGE_MAX=100

[0714] PRIMER_WT_TM_LT=1.0

[0715] PRIMER_WT_TM_GT=1.0

[0716] PRIMER_WT_SIZE_LT=1.0

[0717] PRIMER_WT_SIZE_GT=1.0

[0718] PRIMER_WT_GC_PERCENT_LT=0.0

[0719] PRIMER_WT_GC_PERCENT_GT=0.0

[0720] PRIMER_WT_COMPL_ANY=0.0

[0721] PRIMER_WT_COMPL_END=0.0

[0722] PRIMER_WT_NUM_NS=0.0

[0723] PRIMER_WT_REP_SIM=0.0

[0724] PRIMER_WT_SEQ_QUAL=0.0

[0725] PRIMER_WT_END_QUAL=0.0

[0726] PRIMER_WT_POS_PENALTY=0.0

[0727] PRIMER_WT_END_STABILITY=0.0

[0728] PRIMER_PAIR_WT _PRODUCT_SIZE_LT0.05

[0729] PRIMER_PAIR_WT_PRODUCT_SIZE_GT=0.05

[0730] PRIMER_PAIR_WT_PRODUCT_TM_LT=0.0

[0731] PRIMER_PAIR_WT_PRODUCT_TM_GT=0.0

[0732] PRIMER_PAIR_WT_DIFF_TM=0.0

[0733] PRIMER_PAIR_WT_COMPL_ANY=0.0

[0734] PRIMER_PAIR_WT_COMPL_END=0.0

[0735] PRIMER_PAIR_(—WT)_REP_SIM=0.0

[0736] PRIMER_PAIR_WT_PR_PENALTY=1.0.

[0737] PRIMER_PAIR_WT_IO_PENALTY=0.0

[0738] PRIMER_INTERNAL_OLIGO_MIN_SIZE=18

[0739] PRIMER_INTERNAL_OLIGO_OPT_SIZE=20

[0740] PRIMER_INTERNAL_OLIGO_MAX_SIZE=35

[0741] PRIMER_INTERNAL_OLIGO_MIN_TM=71.7

[0742] PRIMER_INTERNAL_OLIGO_OPT_TM=72.7

[0743] PRIMER_INTERNAL_OLIGO_MAX_TM=73.7

[0744] PRIMER_INTERNAL_OLIGO_MIN_GC=20.0

[0745] PRIMER_INTERNAL_OLIGO_MAX_GC=80.0

[0746] PRIMER_INTERNAL_OLIGO_SELF_ANY=12.00

[0747] PRIMER_INTERNAL_OLIGO_SELF_END=12.00

[0748] PRIMER_INTERNAL_OLIGO_NUM_NS=0

[0749] PRIMER_INTERNAL_OLIGO_MAX_POLY_X=5

[0750] PRIMER_INTERNAL_OLIGO_MISHYB_LIBRARY=

[0751] PRIMER_INTERNAL_OLIGO_MAX_MISHYB=12.00

[0752] PRIMER_INTERNAL_OLIGO_MIN_QUALITY=0

[0753] PRIMER_INTERNAL_OLIGO_SALT_CONC=50.0

[0754] PRIMER_INTERNAL_OLIGO_DNA_CONC=50.0

[0755] PRIMER_IO_WT_TM_LT=1.0

[0756] PRIMER_IO_WT_TM_GT=1.0

[0757] PRIMER_IO_WT_SIZE_LT=1.0.

[0758] PRIMER_IO_WT_SIZE_GT=1.0.

[0759] PRIMER_IO_WT_GC_PERCENT_LT=0.0

[0760] PRIMER_IO_WT_GC_PERCENT_GT=0.0

[0761] PRIMER_IO_WT_COMPL_ANY=0.0

[0762] PRIMER_IO_WT_NUM_NS=0.0

[0763] PRIMER_IO_WT_REP_SIM=0.0

[0764] PRIMER_IO_WT_SEQ_QUAL=0.0

[0765] PRIMER_TASK=pick crprimers_and_hybprobe

[0766] PRIMER_PRODUCT_SIZE_RANGE=50-150

[0767] PRIMER_FIRST_BASEINDEX=1

[0768] PRIMER_PICK_ANYWAY=1

[0769] After running PRIMER3, 100 sets of primers and probes were generated for ACTB and GUSB. From this set, nested primers were chosen based on whether both left primers could be paired with both right primers and a single Taqman probe could be used on an insert of the correct size. With more experience we have decided not use the mix and match approach to primer selection and just use several of the top pairs of predicted primers.

[0770] For ACTB this turned out to be: Forward  75 CACAATGTGGCCGAGGACTT, (SEQ ID NO: 8835) Forward  80 TGTGGCCGAGGACTTTGATT, (SEQ ID NO: 8836) Reverse 178 TGGCTTTTAGGATGGCAAGG, (SEQ ID NO: 8837) and Reverse 168 GGGGGCTTAGTTTGCTTCCT. (SEQ ID NO: 8838)

[0771] Upon testing, the F75 and R178 pair worked best.

[0772] For GUSB the following primers were chosen: Forward  59 AAGTGCAGCGTTCCTTTTGC, (SEQ ID NO: 8839) Forward  65 AGCGTTCCTTTTGCGAGAGA, (SEQ ID NO: 8840) Reverse 158 CGGGCTGTTTTCCAAACATT (SEQ ID NO: 8841) and Reverse 197 GAAGGGACACGCAGGTGGTA. (SEQ ID NO: 8842)

[0773] No combination of these GUSB pairs worked well.

[0774] In addition to the primer pairs above, Primer Express predicted the following primers for GUSB: Forward 178 TACCACCTGCGTGTCCCTTC (SEQ ID NO: 8843) and Reverse 242 GAGGCACTTGTTCTGCTGCTG (SEQ ID NO: 8844). This pair of primers worked to amplify the GUSB mRNA.

[0775] The parameters used to predict these primers in Primer Express were:

[0776] Primer Tm: min 58, Max=60, opt 59, max difference=2 degrees

[0777] Primer GC: min—20% Max =80% no 3′ G/C clamp

[0778] Primer: Length: min=9 max=40 opt=20

[0779] Amplicon:

[0780] min T_(m)=0 max T_(m)=85

[0781] min=50 bpmax=150 bp

[0782] Probe:

[0783] Tm 10 degrees >primers, do not begin with a G on 5′ end

[0784] Other:

[0785] max base pair repeat=3

[0786] max number of ambiguous residues=0

[0787] secondary structure: max consec bp=4, max total bp=8

[0788] Uniqueness:

[0789] max consec match=9

[0790] max % match=75

[0791] max 3′ consecutive match=7

[0792] Using this approach, multiple primers were designed for genes that were shown to have expression patterns that correlated with clinical data in example 10. These primer pairs are shown in Table 10B and are added to the sequence listing. Primers can be designed from any region of a target gene using this approach.

[0793] Granzyme B is an important marker of CMV infection and transplant rejection. For Granzyme B the following sequence (NM 004131) was used as input for Primer3: (SEQ ID No: 9086) GGGGACTCTGGAGGCCCTCTTGTGTGTAACAAGGTGGCCCAGGGCATTGT CTCCTATGGACGAAACAATGGCATGCCTCCACGAGCCTGCACCAAAGTCT CAAGCTTTGTACACTGGATAAAGAAAACCATGAAACGCTACTAACTACAG GAAGCAAACTAAGCCCCCGCTGTAATGAAACACCTTCTCTGGAGCCAAGT CCAGATTTACACTGGGAGAGGTGCCAGCAACTGAATAAATACCTCTCCCA GTGTAAATCTGGAGCCAAGTCCAGATTTACACTGGGAGAGGTGCCAGCAA CTGAATAAATACCTCTTAGCTGAGTGG

[0794] For Granzyme B the following primers were chosen for testing: Forward  81 ACGAGCCTGCACCAAAGTCT (SEQ ID No: 9087) Forward  63 AAACAATGGCATGCCTCCAC (SEQ ID No: 9088) Reverse 178 TCATTACAGCGGGGGCTTAG (SEQ ID No: 9089) Reverse 168 GGGGGCTTAGTTTGCTTCCT (SEQ ID No: 9090)

[0795] Testing demonstrated that F81 and R178 worked well in amplifying a product.

[0796] Primer Endpoint Testing

[0797] Primers were first tested to examine whether they would produce the correct size product without non-specific amplification. The standard real-time PCR protocol was used with out the Rox and Sybr green dyes. Each primer pair was tested on cDNA made from universal mononuclear leukocyte reference RNA that was produced from 50 individuals as described in Example 8 (R50).

[0798] The PCR reaction consisted of I X RealTime PCR Buffer (Ambion, Austin, Tex.), 3 mM MgCl2 (Applied BioSystems, B02953), 0.2 mM dATP (NEB), 0.2 mM dTTP (NEB), 0.2 mM dCTP (NEB), 0.2 mM dGTP (NEB), 1.25U AmpliTaq Gold (Applied BioSystems, Foster City, Calif.), 0.3 μM of each primer to be used (Sigma Genosys, The Woodlands, Tex.), 5 μl of the R50 reverse-transcription reaction and water to a final volume of 19 μl.

[0799] Following 40 cycles of PCR, one microliter of the product was examined by agarose gel electrophoresis and on an Agilent Bioanalyzer, DNA1000 chip (Palo Alto, Calif.). Results for 2 genes are shown in FIG. 6. From the primer design and the sequence of the target gene, one can calculate the expected size of the amplified DNA product. Only primer pairs with amplification of the desired product and minimal amplification of contaminants were used for real-time PCR. Primers that produced multiple products of different sizes are likely not specific for the gene of interest and may amplify multiple genes or chromosomal loci.

[0800] Primer Optimization/Efficiency

[0801] Once primers passed the end-point PCR, the primers were tested to determine the efficiency of the reaction in a real-time PCR reaction. cDNA was synthesized from starting total RNA as described above. A set of 5 serial dilutions of the R50 reverse-transcribed cDNA (as described above) were made in water: 1:10, 1:20, 1:40, 1:80, and 1:160.

[0802] The Sybr Green real-time PCR reaction was performed using the Taqman PCR Reagent kit (Applied BioSystems, Foster City, Calif., N₈O₈-0228). A master mix was made that consisted of all reagents except the primes and template. The final concentration of all ingredients in the reaction was 1× Taqman Buffer A (Applied BioSystems), 2 mM MgCl2 (Applied BioSystems), 200 μM dATP (Applied BioSystems), 200 μM dCTP (Applied BioSystems), 200 μM dGTP (Applied BioSystems), 400 μM dUTP (Applied BioSystems), 1:400,000 diluted Sybr Green dye (Molecular Probes), 1.25U AmpliTaq Gold (Applied BioSystems). The master mix for 92 reactions was made to a final volume of 2112 μl. 1012 μl of PCR master mix was dispensed into two, light-tight tubes. Each β-Actin primer F75 and R178 (Genosys), was added to one tube of PCR master mix and Each β-GUS primer F178 and R242 (Genosys), was added to the other tube of PCR master mix to a final primer concentration of 300 nM, and a final volume of 1035 μl per reaction tube. 45 μl of the β-Actin master mix was dispensed into 23 wells, in a 96well plate (Applied BioSystems). 451 μl of the β-GUS master mix was dispensed into 23 wells, in a 96well plate (Applied BioSystems). 5 μl of the template dilution series was dispensed into triplicate wells for each primer. The reaction was run on an ABI 7700 Sequence Detector (Applied BioSystems).

[0803] The Sequence Detector v1.7 software was used to analyze the fluorescent signal from each well. A threshold value was selected that allowed most of the amplification curves to cross the threshold during the linear phase of amplification. The cycle number at which each amplification curve crossed the threshold (C_(T)) was recorded and the file transferred to MS Excel for further analysis. The C_(T) values for triplicate wells were averaged. The data were plotted as a function of the log₁₀ of the calculated starting concentration of RNA. The starting RNA concentration for each cDNA dilution was determined based on the original amount of RNA used in the RT reaction, the dilution of the RT reaction, and the amount used (5 μl) in the real-time PCR reaction. For each gene, a linear regression line was plotted through all of the dilutions series points. The slope of the line was used to calculate the efficiency of the reaction for each primer set using the equation:

E=10^((−1/slope))

[0804] Using this equation (Pfaffl 2001), the efficiency for these β-actin primers is 2.28 and the efficiency for these β-GUS primers is 2.14 (FIG. 2). This efficiency was used when comparing the expression levels among multiple genes and multiple samples. This same method was used to calculate reaction efficiency for primer pairs for each gene we studied.

[0805] Assay and Results

[0806] Once primers were designed and tested and efficiency analysis was completed, primers were used examine expression of a single gene among many clinical samples. The basic design was to examine expression of both the experimental gene and a reference gene in each sample and, at the same time, in a control sample. The control sample we used was the universal mononuclear leukocyte reference RNA described in example 8 (R50).

[0807] In this example, three patient samples from patients with known CMV infection were compared to three patient samples from patients with no diagnosis of CMV infection based on standard diagnostic algorithms for active CMV infection (including viral PCR assays, serologies, culture and other tests). cDNA was made from all six RNA samples and the R50 control as described above. The cDNA was diluted 1:10 in water and 5 μl of this dilution was used in the 50 μl PCR reaction. Each 96-well plate consisted of 32 reactions, each done in triplicate. There were 17 templates and 3 primer sets. The three primer sets were β-GUS, β-Actin, and Granzyme B AS described above. Each of the three primer sets was used to measure template levels in 8 templates: the six experimental samples, R50, and water (no-template control). The β-GUS primers were also used to measure template levels a set of 8 templates identical except for the absence of the reverse transcriptase enzyme in the cDNA synthesis reaction (−RT). The real-time PCR reactions were performed as described above in “primer optimization/efficiency”.

[0808] The β-GUS amplification with +RT and −RT cDNA synthesis reaction templates were compared to measure the amount of genomic DNA contamination of the patient RNA sample (FIG. 7A). The only source of amplifiable material in the −RT cDNA synthesis reaction is contaminating genomic DNA. Separation by at least four C_(T) between the −RT and +RT for each sample was required to consider the sample useful for analysis of RNA levels. Since a C_(T) decrease of one is a two-fold increase in template, a difference of four C_(T) would indicate that genomic DNA contamination level in the +RT samples was 6.25% of the total signal. Since we used these reactions to measure 30% or greater differences, a 6% contamination would not change the result.

[0809] For samples with sufficiently low genomic DNA contamination the data were used to identify differences in gene expression by measuring RNA levels. CT values from the triplicate wells for each reaction were averaged and the coefficient of variation (CV) determined. Samples with high CV (>2%) were examined and outlier reaction wells were discarded from further analysis. The average of the wells for each sample was taken as the C_(T) value for each sample. For each gene, the ΔC_(T) was the R50 control C_(T) minus the sample C_(T). The equation below was then used to identify an expression ratio compared to a reference gene (β-Actin) and control sample (R50) for Granzyme B expression in each experimental sample (Pfaffl, M. W. 2001). E is the amplification efficiency determined above. ${ratio} = \frac{\left( E_{target} \right)^{\Delta \quad C_{T}{{target}{({{control} - {sample}})}}}}{\left( E_{ref} \right)^{\Delta \quad C_{T}{{ref}{({{control} - {sample}})}}}}$

[0810] The complete experiment was performed in duplicate and the average of the two ratios taken for each gene. When β-Actin was used as the reference gene, the data show that Granzyme B is expressed at 25-fold higher levels in mononuclear cell RNA from patients with CMV than from patients without CMV (FIG. 7B). In this graph, each circle represents a patient sample and the black bars are the average of the three samples in each category.

Example 16 Correlation and Classification Analysis

[0811] After generation and processing of expression data sets from microarrays as described in Example 14, a log ratio value is used for most subsequent analysis. This is the logarithm of the expression ratio for each gene between sample and universal reference. The processing algorithm assigns a number of flags to data that are of low signal to noise or are in some other way of uncertain quality. Correlation analysis can proceed with all the data (including the flagged data) or can be done on filtered data sets where the flagged data is removed from the set. Filtered data should have less variability and may result in more significant results. Flagged data contains all information available and may allow discovery of genes that are missed with the filtered data set.

[0812] In addition to expression data, clinical data are included in the analysis. Continuous variables, such as the ejection fraction of the heart measured by echocardiography or the white blood cell count can be used for correlation analysis. In some cases, it may be desirable to take the logarithm of the values before analysis. These variables can be included in an analysis along with gene expression values, in which case they are treated as another “gene”. Sets of markers can be discovered that work to diagnose a patient condition and these can include both genes and clinical parameters. Categorical variables such as male or female can also be used as variables for correlation analysis. For example, the sex of a patient may be an important splitter for a classification tree.

[0813] Clinical data are used as supervising vectors for the significance or classification analysis. In this case, clinical data associated with the samples are used to divide samples in to clinically meaningful diagnostic categories for correlation or classification analsysis. For example, pathologic specimens from kidney biopsies can be used to divide lupus patients into groups with and without kidney disease. A third or more categories can also be included (for example “unknown” or “not reported”). After generation of expression data and definition of using supervising vectors, correlation, significance and classification analysis is used to determine which set of genes are most appropriate for diagnosis and classification of patients and patient samples.

[0814] Significance Analysis for Microarrays (SAM)

[0815] Significance analysis for microarrays (SAM) (Tusher 2001) is a method through which genes with a correlation between their expression values and the response vector are statistically discovered and assigned a statistical significance. The ratio of false significant to significant genes is the False Discovery Rate (FDR). This means that for each threshold there are a set of genes which are called significant, and the FDR gives a confidence level for this claim. If a gene is called differentially expressed between 2 classes by SAM, with a FDR of 5%, there is a 95% chance that the gene is actually differentially expressed between the classes. SAM takes into account the variability and large number of variables of microarrays. SAM will identify genes that are most globally differentially expressed between the classes. Thus, important genes for identifying and classifying outlier samples or patients may not be identified by SAM.

[0816] After generation of data from patient samples and definition of categories using clinical data as supervising vectors, SAM is used to detect genes that are likely to be differentially expressed between the groupings. Those genes with the highest significance can be validated by real-time PCR (Example 15) or can be used to build a classification algorithm as described here.

[0817] Classification

[0818] Supervised harvesting of expression trees (Hastie 2001) identifies genes or clusters that best distinguish one class from all the others on the data set. The method is used to identify the genes/clusters that can best separate one class versus all the others for datasets that include two or more classes from each other. This algorithm can be used to identify genes that are used to create a diagnostic algorithm. Genes that are identified can be used to build a classification tree with algorithms such as CART.

[0819] CART is a decision tree classification algorithm (Breiman 1984). From gene expression and or other data, CART can develop a decision tree for the classification of samples. Each node on the decision tree involves a query about the expression level of one or more genes or variables. Samples that are above the threshold go down one branch of the decision tree and samples that are not go down the other branch. Genes from expression data sets can be selected for classification building using CART by significant differential expression in SAM analysis (or other significance test), identification by supervised tree-harvesting analysis, high fold change between sample groups, or known relevance to classification of the target diseases. In addition, clinical data can also be used as variables for CART that are of know importance to the clinical question or are found to be significant predictors by multivariate analysis or some other technique. CART identifies surrogates for each splitter (genes that are the next best substitute for a useful gene in classification). Analysis is performed in CART by weighting misclassification costs to optimize desired performance of the assay. For example, it may be most important the sensitivity of a test for a given diagnosis be near 100% while specificity is less important.

[0820] Once a set of genes and expression criteria for those genes have been established for classification, cross validation is done. There are many approaches, including a 10 fold cross validation analysis in which 10% of the training samples are left out of the analysis and the classification algorithm is built with the remaining 90%. The 10% are then used as a test set for the algorithm. The process is repeated 10 times with 10% of the samples being left out as a test set each time. Through this analysis, one can derive a cross validation error which helps estimate the robustness of the algorithm for use on prospective (test) samples. When a gene set is established for a diagnosis with a low cross validation error, this set of genes is tested using samples that were not included in the initial analysis (test samples). These samples may be taken from archives generated during the clinical study. Alternatively, a new prospective clinical study can be initiated, where samples are obtained and the gene set is used to predict patient diagnoses. TABLE 1 Disease Classification Disease/Patient Group Cardiovascular Disease Atherosclerosis Unstable angina Myocardial Infarction Restenosis after angioplasty Congestive Heart Failure Myocarditis Endocarditis Endothelial Dysfunction Cardiomyopathy Cardiovascular drug use Endocrine Disease Diabetes Mellitus I and II Thyroiditis Addisson's Disease Infectious Disease Hepatitis A, B, C, D, E, G Malaria Tuberculosis HIV Pneumocystis Carinii Giardia Toxoplasmosis Lyme Disease Rocky Mountain Spotted Fever Cytomegalovirus Epstein Barr Virus Herpes Simplex Virus Clostridium Dificile Colitis Meningitis (all organisms) Pneumonia (all organisms) Urinary Tract Infection (all organisms) Infectious Diarrhea (all organisms) Anti-infectious drug use Angiogenesis Pathologic angiogenesis Physiologic angiogenesis Treatment induced angiogenesis Pro or anti-angiogenic drug use Inflammatory/Rheumatic Rheumatoid Arthritis Systemic Lupus Erythematosis Sjogrens Disease CREST syndrome Scleroderma Ankylosing Spondylitis Crohn's Ulcerative Colitis Primary Sclerosing Cholangitis Appendicitis Diverticulitis Primary Biliary Sclerosis Wegener's Granulomatosis Polyarteritis nodosa Whipple's Disease Psoriasis Microscopic Polyanngiitis Takayasu's Disease Kawasaki's Disease Autoimmune hepatitis Asthma Churg-Strauss Disease Beurger's Disease Raynaud's Disease Cholecystitis Sarcoidosis Asbestosis Pneumoconioses Antinflammatory drug use Transplant Rejection Heart Lung Liver Pancreas Bowel Bone Marrow Stem Cell Graft versus host disease Transplant vasculopathy Skin Cornea Immunosupressive drug use Malignant Disorders Leukemia Lymphoma Carcinoma Sarcoma Neurological Disease Alzheimer's Dementia Pick's Disease Multiple Sclerosis Guillain Barre Syndrome Peripheral Neuropathy

[0821] TABLE 2 Candidate genes, Database mining Unigene clusters are listed. Cluster numbers are defined as in Unigene build #133 uploaded on: Fri Apr 20 2001 CD50 Hs.99995 Homo sapiens cAMP responsive element Hs.79194 binding protein 1 (CREB1) mRNA. CD70 = CD27L Hs.99899 Nucleolin (NCL) Hs.79110 MDC Hs.97203 MAPK14 Hs.79107 CD3z Hs.97087 CD100 Hs.79089 CD19 Hs.96023 OX-2 Hs.79015 Hs.95388 PCNA Hs.78996 CD3d Hs.95327 Hs.78909 Hs.9456 GRO-a Hs.789 interleukin 6 Hs.93913 CDw32A Hs.78864 phospholipaseA2 Hs.93304 H. sapiens mRNA for herpesvirus associated Hs.78683 ubiquitin-specific protease (HAUSP). Human mRNA for KIAA0128 gene, partial Hs.90998 CD41b = LIBS1 Hs.785 cds. CD48 Hs.901 ANXA1 (LPC1) Hs.78225 heat shock 70 kD protein 1A Hs.8997 CD31 Hs.78146 TxA2 receptor Hs.89887 Homo sapiens TERF1 (TRF1)-interacting Hs.7797 nuclear factor 2 (TINF2), mRNA. fragile X mental retardation protein (FMR- Hs.89764 major histocompatibility complex, class I, B Hs.77961 1) CD20 Hs.89751 LOX1 Hs.77729 ENA-78 Hs.89714 major histocompatibility complex, class II, Hs.77522 DM alpha IL-2 Hs.89679 CD64 Hs.77424 CD79b Hs.89575 CD71 Hs.77356 CD2 Hs.89476 Hs.77054 SDF-1 = CXCR4 Hs.89414 HLA-DRA Hs.76807 CD61 Hs.87149 CD105 Hs.76753 IFN-g Hs.856 Hs.76691 CD34 Hs.85289 TNF-alpha Hs.76507 CD104 Hs.85266 LCP1 Hs.76506 CD8 Hs.85258 TMSB4X Hs.75968 IGF-1 Hs.85112 PAI2 Hs.75716 CD103 Hs.851 MIP-1b Hs.75703 IL-13 Hs.845 CD58 Hs.75626 RPA1 Hs.84318 CD36 Hs.75613 CD74 Hs.84298 hnRNP A2/hnRNP B1 Hs.75598 CD132 Hs.84 CD124 Hs.75545 CD18 Hs.83968 MIP-3a Hs.75498 Cathepsin K Hs.83942 beta-2-microglobulin Hs.75415 CD80 Hs.838 FPR1 Hs.753 CD46 Hs.83532 Topo2B Hs.75248 NFKB1 Hs.83428 interleukin enhancer binding factor 2, 45 kD Hs.75117 IL-18 Hs.83077 chloride intracellular channel 1 Hs.74276 interleukin 14 Hs.83004 EGR3 Hs.74088 L-selectin = CD62L Hs.82848 MIP-1a Hs.73817 CD107b Hs.8262 CD62P = p-selectin Hs.73800 CD69 Hs.82401 CD21 Hs.73792 CD95 Hs.82359 APE Hs.73722 CD53 Hs.82212 IL12Rb2 Hs.73165 Human lymphocyte specific interferon Hs.82132 NFKB2 Hs.73090 regulatory factor/interferon regulatory factor 4 (LSIRF/IRF4) mRNA, complete cds. IL-16 Hs.82127 I-309 Hs.72918 DUT Hs.82113 immunoglobulin superfamily, member 4 Hs.70337 CDw121a Hs.82112 IL-3 Hs.694 PAI-1 Hs.82085 Hs.6895 TGF-bR2 Hs.82028 NTH1 Hs.66196 CD117 Hs.81665 CD40L Hs.652 HLA-DPB1 Hs.814 IL-11R Hs.64310 NFKBIA Hs.81328 Homo sapiens toll-like receptor 2 (TLR2) Hs.63668 mRNA. CD6 Hs.81226 ferritin H chain Hs.62954 IL-1 RA Hs.81134 IL8 Hs.624 UBE2B (RAD6B) Hs.811 Tissue Factor Hs.62192 Lyn Hs.80887 F-box only protein 7 Hs.5912 STAT4 Hs.80642 CD5 Hs.58685 UBE2A (RAD6A) Hs.80612 guanine nucleotide binding protein (G Hs.5662 protein), beta polypeptide 2-like 1 Fractalkine Hs.80420 SCYA11 Hs.54460 IK cytokine, down-regulator of HLA II Hs.8024 IK1 Hs.54452 Hs.79933 CCR1 Hs.516 CD79a Hs.79630 Homo sapiens TRAIL receptor 2 mRNA, Hs.51233 complete cds. Hs.7942 CD11c Hs.51077 nuclear factor, interleukin 3 regulated Hs.79334 CD66a Hs.50964 CD83 Hs.79197 JAK1 Hs.50651 DC-CK1 Hs.16530 Homo sapiens programmed cell death 4 Hs.100407 (PDCD4), mRNA. CCR7 Hs.1652 SCYB13 (CXCL13) Hs.100431 TLR4 Hs.159239 SMAD7 Hs.100602 EST Hs.158975 RAD51L1 (RAD51B) Hs.100669 EST Hs.158966 PPARG Hs.100724 EST Hs.158965 transcription factor 3 (E2A immunoglobulin Hs.101047 enhancer binding factors E12/E47) EST Hs.158943 major histocompatibility complex, class I- Hs.101840 like sequence EST Hs.158894 immunoglobulin superfamily containing Hs.102171 leucine-rich repeat EST Hs.158877 CD166 Hs.10247 EST Hs.157815 fibroblast tropomyosin TM30 (pl) Hs.102824 EST Hs.157813 interleukin 1 receptor-like 2 Hs.102865 ESTs Hs.157569 GTF2H4 Hs.102910 immunoglobulin kappa constant Hs.156110 Hs.10326 INPP5D Hs.155939 Human ITAC (IBICK) Hs.103982 C3AR1 Hs.155935 novel protein with MAM domain Hs.104311 PRKDC Hs.155637 ESTs, Weakly similar to interleukin Hs.105125 enhancer binding factor 2 [H. sapiens] MHC class II HLA-DRw53-associated Hs.155122 Homo sapiens clone 24686 mRNA Hs.105509 glycoprotein sequence. CD73 Hs.153952 Hs.105532 CD37 Hs.153053 Homo sapiens granulysin (GNLY), Hs.105806 transcript variant 519, mRNA. IFNAR1 Hs.1513 CD77 Hs.105956 Homo sapiens solute carrier family 21 Hs.14805 RD RNA-binding protein Hs.106061 (organic anion transporter), member 11 (SLC21A11), mRNA. EST Hs.146627 Hs.106673 SET translocation (myeloid leukemia- Hs.145279 Hs.10669 associated) EST Hs.144119 Homo sapiens clone 24818 mRNA Hs.106823 sequence. ESTs Hs.143534 Hs.106826 STAT3 Hs.142258 Hs.10712 CD96 Hs.142023 Hs.107149 CD23 Hs.1416 hypothetical protein Hs.10729 EGR2 Hs.1395 Tachykinin Receptor 1 Hs.1080 CDw84 Hs.137548 glycophorin A Hs.108694 CD55 Hs.1369 Histone H1x Hs.109804 EST Hs.135339 CD66d Hs.11 GM-CSF Hs.1349 interleukin 17 Hs.110040 EST Hs.133175 Hs.110131 CD1a Hs.1309 major histocompatibility complex, class I, F Hs.110309 CD10 Hs.1298 REV1 Hs.110347 HVEM Hs.129708 HCR Hs.110746 C9 Hs.1290 VWF Hs.110802 C6 Hs.1282 high affinity immunoglobulin epsilon Hs.11090 receptor beta subunit C1R Hs.1279 interleukin 22 receptor Hs.110915 IL-1b Hs.126256 Hs.110978 CD9 Hs.1244 Homo sapiens ubiquitin specific protease 6 Hs.111065 (Tre-2 oncogene) (USP6), mRNA. Hs.12305 Hs.111128 Homo sapiens Vanin 2 (VNN2) mRNA. Hs.121102 MMP2 Hs.111301 Hsp10 Hs.1197 major histocompatibility complex, class II, Hs.11135 DN alpha CD59 Hs.119663 LTBR Hs.1116 CD51 Hs.118512 ESTs, Weakly similar to A41285 Hs.111941 interleukin enhancer-binding factor ILE-1 [H. sapiens] CD49a Hs.116774 Homo sapiens STRIN protein (STRIN), Hs.112144 mRNA. CD72 Hs.116481 MSH5 Hs.112193 HLA-DMB Hs.1162 TCRg Hs.112259 MCP-4 Hs.11383 Hs.11307 Hs.111554 CMKRL2 Hs.113207 ferritin L chain Hs.111334 CCR8 Hs.113222 TGF-b Hs.1103 LILRA3 Hs.113277 Homo sapiens ras homolog gene family, Hs.109918 Human CXCR-5 (BLR-1) Hs.113916 member H (ARHH), mRNA. lysosomal alpha-mannosidase (MANB) Hs.108969 RAD51C Hs.11393 Hs.108327 myosin, heavy polypeptide 8, skeletal Hs.113973 muscle, perinatal granzyme B Hs.1051 CD42a Hs.1144 HCC-4 Hs.10458 TNFRSF11A Hs.114676 Hs.10362 Hs.114931 Hs.102630 MSH4 Hs.115246 Hs.101382 Homo sapiens dendritic cell Hs.115515 immunoreceptor (DCIR), mRNA. C4BPA Hs.1012 REV3L (POLZ) Hs.115521 CD125 Hs.100001 JAK2 Hs.115541 TERF2 Hs.100030 OPG ligand Hs.115770 LIG3 Hs.100299 PCDH12 Hs.115897 Hs.157489 Hs.166235 EST Hs.157560 POLE1 Hs.166846 EST Hs.157808 regulatory factor X, 5 (influences HLA class Hs.166891 II expression) EST Hs.157811 PIG-F (phosphatidyl-inositol-glycan class Hs.166982 F) Hs.158127 ESTs, Moderately similar to Hs.167154 ILF1_HUMAN INTERLEUKIN ENHANCER-BINDING FACTOR 1 [H. sapiens] interleukin 18 receptor accessory protein Hs.158315 HLA-DRB6 Hs.167385 CCR3 Hs.158324 ret finger protein-like 3 Hs.167751 Human DNA sequence from clone CTA- Hs.158352 CD56 Hs.167988 390C10 on chromosome 22q11.21-12.1 Contains an Immunoglobulin-like gene and a pseudogene similar to Beta Crystallin, ESTs, STSs, GSSs and taga and tat repeat polymorphisms ESTs Hs.158576 RBT1 Hs.169138 Hs.158874 APOE Hs.169401 EST Hs.158875 Hs.16944 EST Hs.158876 Hs.169470 EST Hs.158878 MMP12 Hs.1695 EST Hs.158956 CD161 Hs.169824 EST Hs.158967 tenascin XB Hs.169886 EST Hs.158969 Hs.170027 EST Hs.158971 Hs.170150 EST Hs.158988 C4A Hs.170250 CD120a = TNFR-1 Hs.159 TP53BP1 Hs.170263 EST Hs.159000 ESTs Hs.170274 Hs.159013 ESTs, Weakly similar to ALU1_HUMAN Hs.170338 ALU SUBFAMILY J SEQUENCE CONTAMINATION WARNING ENTRY□ [H. sapiens] EST Hs.159025 ESTs Hs.170578 EST Hs.159059 EST Hs.170579 IL18R1 Hs.159301 ESTs Hs.170580 ftp-3 Hs.159494 EST Hs.170581 CASP8 Hs.159651 ESTs Hs.170583 EST Hs.159655 EST Hs.170586 EST Hs.159660 EST Hs.170588 EST Hs.159678 EST Hs.170589 kallikrein 12 (KLK12) Hs.159679 Hs.170772 EST Hs.159682 ESTs Hs.170786 EST Hs.159683 EST Hs.170909 EST Hs.159693 EST Hs.170912 EST Hs.159706 EST Hs.170933 EST Hs.159718 ESTs Hs.171004 SPO11 Hs.159737 EST Hs.171095 EST Hs.159754 EST Hs.171098 EST Hs.160401 ESTs Hs.171101 EST Hs.160405 EST Hs.171108 EST Hs.160408 ESTs Hs.171110 EST Hs.160410 ESTs Hs.171113 EST Hs.160423 ESTs Hs.171117 RPA3 Hs.1608 EST Hs.171119 ESTs Hs.160946 ESTs Hs.171120 EST Hs.160956 EST Hs.171122 ESTs Hs.160978 EST Hs.171123 EST Hs.160980 EST Hs.171124 EST Hs.160981 EST Hs.171140 EST Hs.160982 EST Hs.171216 EST Hs.160983 EST Hs.171260 Tachykinin Receptor 2 Hs.161305 ESTs Hs.171264 RAD17 (RAD24) Hs.16184 RIP Hs.171545 Human phosphatidylinositol 3-kinase Hs.162808 ESTs, Weakly similar to immunoglobulin Hs.171697 catalytic subunit p110delta mRNA, superfamily member [D. melanogaster] complete cds. Human alpha-1 Ig germline C-region Hs.163271 CD22 Hs.171763 membrane-coding region, 3′ end GCP-2 Hs.164021 Hs.171776 Hs.164284 sema domain, immunoglobulin domain (Ig), Hs.171921 short basic domain, secreted, (semaphorin) 3C EST Hs.164331 interleukin 11 Hs.1721 Hs.164427 CD11b Hs.172631 Hs.165568 EST, Highly similar to APS [H. sapiens] Hs.172656 ER Hs.1657 ALK1 Hs.172670 EST, Highly similar to JM26 [H. sapiens] Hs.165701 Hs.172674 EST Hs.165702 CD123 Hs.172689 EST Hs.165704 ESTs Hs.172822 EST Hs.165732 CollaI Hs.172928 regulatory factor X, 3 (influences HLA class Hs.166019 Hs.172998 II expression) LIG4 Hs.166091 Hs.173081 TNFSF18 Hs.248197 myosin, heavy polypeptide 3, skeletal Hs.173084 muscle, embryonic EST Hs.248228 Hs.173201 H. sapiens rearranged gene for kappa Hs.248756 Mediterranean fever (MEFV) Hs.173730 immunoglobulin subgroup V kappa IV caspase 1, apoptosis-related cysteine Hs.2490 Hs.173749 protease (interleukin 1, beta, convertase) EST Hs.249031 interleukin 1 receptor accessory protein Hs.173880 TNFRSF10A Hs.249190 EST, Weakly similar to RL13_HUMAN Hs.174231 60S RIBOSOMAL PROTEIN L13 [H. sapiens] immunoglobulin lambda variable 3-10 Hs.249208 EST Hs.174242 Homo sapiens mRNA for single-chain Hs.249245 EST Hs.174300 antibody, complete cds EST Hs.250473 EST Hs.174634 ESTs Hs.250591 EST Hs.174635 ESTs Hs.250605 EST Hs.174650 Hs.25063 EST Hs.174673 Human DNA sequence from clone RP1- Hs.250675 EST Hs.174716 149A16 on chromosome 22 Contains an IGLC (Immunoglobulin Lambda Chain C) pseudogene, the RFPL3 gene for Ret finger protein-like 3, the RFPL3S gene for Ret finger protein-like 3 antisense, the gene for a novel Immunoglobulin Lambda Chain V family protein, the gene for a novel protein similar to mouse RGDS (RALGDS, RALGEF, Guanine Nucleotide Dissociation Stimulator A) and rabbit oncogene RSC, the gene for a novel protein (ortholog of worm F16A11.2 and bacterial and archea-bacterial predicted proteins), the gene for a novel protein similar to BPI (Bacterial Permeability-Increasing Protein) and rabbit LBP (Liposaccharide-Binding Protein) and the 5′ part of a novel gene. Contains ESTs, STSs, GSSs and three putative CpG islands ACE Hs.250711 EST Hs.174740 TREX2 Hs.251398 EST Hs.174778 Human DNA sequence from clone 1170K4 Hs.251417 EST Hs.174779 on chromosome 22q12.2-13.1. Contains three novel genes, one of which codes for a Trypsin family protein with class A LDL receptor domains, and the IL2RB gene for Interleukin 2 Receptor, Beta (IL-2 Receptor, CD122 antigen). Contains a putative CpG island, ESTs, and GSSs EST Hs.251539 EST, Weakly similar to RL13_HUMAN Hs.174780 60S RIBOSOMAL PROTEIN L13 [H. sapiens] EST Hs.251540 (KIAA0033) for ORF, partial cds. Hs.174905 C3 Hs.251972 Hs.175270 EST Hs.252273 EST Hs.175281 EST Hs.252359 EST Hs.175300 ESTs, Moderately similar to Hs.252867 EST Hs.175336 T2DT_HUMAN TRANSCRIPTION INITIATION FACTOR TFIID 105 KDA SUBUNIT [H. sapiens] EST, Moderately similar to RS2_HUMAN Hs.253150 EST Hs.175388 40S RIBOSOMAL PROTEIN S2 [H. sapiens] EST Hs.253151 Hs.175437 EST Hs.253154 EST, Weakly similar to salivary proline-rich Hs.175777 protein precursor [H. sapiens] EST Hs.253165 EST Hs.175803 EST Hs.253166 ESTs Hs.176337 EST Hs.253167 EST Hs.176374 EST Hs.253168 EST Hs.176380 EST Hs.253169 EST Hs.176404 interleukin 1 receptor, type II Hs.25333 EST Hs.176406 Hs.25361 LCK Hs.1765 EST Hs.253742 LIG1 Hs.1770 EST Hs.253743 EST Hs.177012 EST, Weakly similar to AF161429_1 Hs.253744 PERB11 family member in MHC class I Hs.17704 HSPC311 [H. sapiens] region EST Hs.253747 EST Hs.177146 EST Hs.253748 EST Hs.177209 EST Hs.253753 Hs.177376 EST, Moderately similar to Hs.254108 Hs.177461 ALU5_HUMAN ALU SUBFAMILY SC SEQUENCE CONTAMINATION WARNING ENTRY□ [H. sapiens] ESTs Hs.254948 CD99 Hs.177543 ESTs Hs.255011 PMS2 Hs.177548 EST Hs.255118 human calmodulin Hs.177656 EST Hs.255119 Hs.177712 EST Hs.255123 Homo sapiens immunoglobulin lambda Hs.178665 gene locus DNA, clone: 288A10 EST Hs.255129 Hs.178743 EST Hs.255134 EST Hs.179008 EST Hs.255135 EST Hs.179070 EST Hs.255139 EST Hs.179130 EST Hs.255140 EST Hs.179132 ESTs Hs.255142 Hs.179149 EST Hs.255150 EST Hs.179490 EST Hs.255152 EST Hs.179492 ESTs Hs.255153 promyelocytic leukemia cell mRNA, clones Hs.179735 pHH58 and pHH81. ESTs Hs.255157 Hs.179817 ESTs Hs.255171 major histocompatibility complex, class II, Hs.1802 DO beta EST Hs.255172 HLA-DRB1 Hs.180255 EST, Moderately similar to Hs.255174 TNFRSF12 Hs.180338 PGTA_HUMAN RAB GERANYLGERANYLTRANSFERASE ALPHA SUBUNIT [H. sapiens] EST Hs.255177 RAD23A (HR23A) Hs.180455 EST Hs.255178 MKK3 Hs.180533 EST Hs.255245 EST Hs.180637 EST Hs.255246 CD27 Hs.180841 EST Hs.255249 STAT6 Hs.181015 EST Hs.255251 TNFSF4 Hs.181097 EST Hs.255253 immunoglobulin lambda locus Hs.181125 EST Hs.255254 Hs.181368 EST Hs.255255 CD3 Hs.181392 ESTs Hs.255256 EST Hs.255745 EST Hs.255330 EST Hs.255746 EST, Weakly similar to putative G protein- Hs.255333 EST Hs.255747 coupled Receptor [H. sapiens] EST Hs.255336 EST Hs.255749 EST Hs.255337 EST Hs.255754 EST Hs.255339 ESTs, Moderately similar to KIAA1271 Hs.255759 protein [H. sapiens] EST Hs.255340 EST Hs.255762 EST Hs.255341 EST Hs.255763 ESTs Hs.255343 EST Hs.255764 EST Hs.255347 EST Hs.255766 EST Hs.255349 EST Hs.255767 EST Hs.255350 EST Hs.255768 EST Hs.255354 EST Hs.255769 ESTs Hs.255359 EST Hs.255770 ESTs Hs.255387 EST Hs.255772 EST Hs.255388 EST Hs.255777 EST Hs.255389 EST Hs.255778 ESTs Hs.255390 EST Hs.255779 EST Hs.255392 EST Hs.255782 EST Hs.255444 EST Hs.255783 EST Hs.255446 EST Hs.255784 EST Hs.255448 EST Hs.255785 ESTs Hs.255449 EST, Weakly similar to Con1 [H. sapiens] Hs.255788 EST Hs.255454 EST Hs.255791 EST Hs.255455 EST Hs.255794 EST Hs.255457 EST Hs.255796 EST Hs.255459 EST Hs.255797 EST Hs.255462 EST Hs.255799 EST Hs.255464 ESTs Hs.255877 EST Hs.255492 EST Hs.255880 EST Hs.255494 EST Hs.255920 EST Hs.255495 EST Hs.255927 EST Hs.255497 CD40 Hs.25648 EST Hs.255498 interleukin enhancer binding factor 3, 90 kD Hs.256583 EST Hs.255499 ESTs Hs.256810 EST Hs.255501 EST Hs.256956 EST Hs.255502 EST Hs.256957 EST Hs.255505 EST Hs.256959 EST Hs.255541 EST Hs.256961 EST Hs.255543 EST Hs.256970 ESTs Hs.255544 EST Hs.256971 EST Hs.255546 ESTs Hs.256979 EST Hs.255549 ESTs Hs.257572 EST Hs.255552 EST Hs.257579 EST Hs.255554 EST Hs.257581 EST Hs.255556 EST Hs.257582 EST Hs.255558 EST Hs.257630 EST Hs.255559 EST Hs.257632 EST Hs.255560 EST Hs.257633 EST Hs.255561 EST Hs.257636 EST Hs.255569 EST Hs.257640 EST Hs.255572 ESTs Hs.257641 EST Hs.255573 EST Hs.257644 EST Hs.255575 EST Hs.257645 EST Hs.255577 EST Hs.257646 EST Hs.255578 EST Hs.257647 EST Hs.255579 EST Hs.257667 EST Hs.255580 EST Hs.257668 EST Hs.255590 EST Hs.257677 EST Hs.255591 EST Hs.257679 EST Hs.255598 EST Hs.257680 TNFRSF17 Hs.2556 ESTs Hs.257682 EST Hs.255600 ESTs Hs.257684 EST Hs.255601 EST Hs.257687 ESTs, Highly similar to KIAA1039 protein Hs.255603 EST Hs.257688 [H. sapiens] EST Hs.255614 EST Hs.257690 EST Hs.255615 EST Hs.257695 ESTs Hs.255617 EST Hs.257697 EST Hs.255618 EST Hs.257705 EST Hs.255621 EST Hs.257706 EST Hs.255622 EST Hs.257709 ESTs Hs.255625 ESTs, Moderately similar to Hs.257711 ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION WARNING ENTRY□ [H. sapiens] EST Hs.255626 EST Hs.257713 ESTs Hs.255627 EST Hs.257716 ESTs Hs.255630 EST Hs.257719 EST Hs.255632 EST Hs.257720 EST Hs.255633 EST Hs.257727 EST Hs.255634 EST Hs.257730 EST Hs.255635 EST Hs.257738 EST Hs.255637 EST Hs.257743 ESTs Hs.255639 ESTs Hs.258513 EST Hs.255641 EST Hs.258820 EST Hs.255644 EST Hs.258864 EST Hs.255645 sema domain, immunoglobulin domain (Ig), Hs.25887 transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4F EST Hs.255646 EST Hs.258898 EST Hs.255647 EST Hs.258933 EST Hs.255648 interleukin 13 receptor, alpha 2 Hs.25954 EST Hs.255649 Homo sapiens HSPC101 mRNA, partial cds Hs.259683 EST Hs.255650 EST Hs.263695 EST Hs.255653 ESTs Hs.263784 EST Hs.255657 TNFSF12 Hs.26401 EST Hs.255661 EST Hs.264154 ESTs Hs.255664 EST Hs.264654 EST Hs.255665 CDw116b Hs.265262 EST Hs.255666 MHC binding factor, beta Hs.2654 EST Hs.255668 EST Hs.265634 EST Hs.255671 EST Hs.266387 EST Hs.255672 ESTs Hs.268027 EST Hs.255673 ATHS (LDLR?) Hs.268571 EST Hs.255674 ESTs, Highly similar to AAD18086 BAT2 Hs.270193 [H. sapiens] EST Hs.255675 ESTs Hs.270198 EST Hs.255677 ESTs Hs.270294 EST Hs.255679 ESTs, Weakly similar to alternatively Hs.270542 spliced product using exon 13A [H. sapiens] EST Hs.255681 ESTs, Moderately similar to Hs.270561 ALU2_HUMAN ALU SUBFAMILY SB SEQUENCE CONTAMINATION WARNING ENTRY□ [H. sapiens] EST Hs.255682 ESTs, Weakly similar to pro alpha 1(I) Hs.270564 collagen [H. sapiens] EST Hs.255686 ESTs, Weakly similar to ALU1_HUMAN Hs.270578 ALU SUBFAMILY J SEQUENCE CONTAMINATION WARNING ENTRY□ [H. sapiens] ESTs Hs.255687 ESTs, Moderately similar to brain-derived Hs.270588 immunoglobulin superfamily molecule [M. musculus] EST Hs.255688 TALL1 Hs.270737 ESTs Hs.255689 ESTs Hs.271206 EST Hs.255691 MYH Hs.271353 EST Hs.255692 POLI (RAD30B) Hs.271699 ESTs Hs.255693 ADPRTL3 Hs.271742 EST Hs.255695 ESTs, Moderately similar to Hs.272075 ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION WARNING ENTRY□ [H. sapiens] EST, Highly similar to transmembrane Hs.255697 Human DNA sequence from clone RP5- Hs.272271 chloride conductor protein [H. sapiens] 1170K4 on chromosome 22q12.2-13.1 Contains three novel genes, one of which codes for a Trypsin family protein with class A LDL receptor domains, and the IL2RB gene for Interleukin 2 Receptor, Beta (IL-2 Receptor, CD122 antigen), a putative CpG island, ESTs, and GSSs EST Hs.255698 interleukin 1 receptor accessory protein-like 2 Hs.272354 EST Hs.255699 Homo sapiens partial IGVH3 V3-20 gene Hs.272355 for immunoglobulin heavy chain V region, case 1, clone 2 EST Hs.255705 Homo sapiens partial IGVH3 gene for Hs.272356 immunoglobulin heavy chain V region, case 1, clone 16 EST Hs.255706 Homo sapiens partial IGVH3 gene for Hs.272357 immunoglobulin heavy chain V region, case 1, clone 19 EST Hs.255708 Homo sapiens partial IGVH3 gene for Hs.272358 immunoglobulin heavy chain V region, case 1, cell Mo IV 72 EST Hs.255710 Homo sapiens partial IGVH1 gene for Hs.272359 immunoglobulin heavy chain V region, case 1, cell Mo V 94 EST Hs.255713 Homo sapiens partial IGVL2 gene for Hs.272360 immunoglobulin lambda light chain V region, case 1, cell Mo V 94 EST Hs.255717 Homo sapiens partial IGVH3 gene for Hs.272361 immunoglobulin heavy chain V region, case 1, cell Mo VI 7 EST Hs.255718 Homo sapiens partial IGVL1 gene for Hs.272362 immunoglobulin lambda light chain V region, case 1, cell Mo VI 65 EST Hs.255721 Homo sapiens partial IGVH3 gene for Hs.272363 immunoglobulin heavy chain V region, case 1, cell Mo VI 162 ESTs Hs.255723 Homo sapiens partial IGVH3 DP29 gene Hs.272364 for immunoglobulin heavy chain V region, case 1, cell Mo VII 116 EST Hs.255725 Homo sapiens partial IGVH4 gene for Hs.272365 immunoglobulin heavy chain V region, case 2, cell D 56 EST Hs.255726 Homo sapiens partial IGVH3 gene for Hs.272366 immunoglobulin heavy chain V region, case 2, cell E 172 EST Hs.255727 interleukin 20 Hs.272373 EST Hs.255736 Human DNA sequence from clone RP1- Hs.272521 149A16 on chromosome 22 Contains an IGLC (Immunoglobulin Lambda Chain C) pseudogene, the RFPL3 gene for Ret finger protein-like 3, the RFPL3S gene for Ret finger protein-like 3 antisense, the gene for a novel Immunoglobulin Lambda Chain V family protein, the gene for a novel protein similar to mouse RGDS (RALGDS, RALGEF, Guanine Nucleotide Dissociation Stimulator A) and rabbit oncogene RSC, the gene for a novel protein (ortholog of worm F16A11.2 and bacterial and archea-bacterial predicted proteins), the gene for a novel protein similar to BPI (Bacterial Permeability-Increasing Protein) and rabbit LBP (Liposaccharide-Binding Protein) and the 5′ part of a novel gene. Contains ESTs, STSs, GSSs and three putative CpG islands EST Hs.255740 TdT Hs.272537 EST Hs.255742 ret finger protein-like 3 antisense Hs.274285 EST Hs.255743 PRKR Hs.274382 EST Hs.7569 H. sapiens immunoglobulin epsilon chain Hs.274600 SMAD4 Hs.75862 EST, Weakly similar to HLA-DQ alpha Hs.275720 chain [H. sapiens] Homo sapiens splicing factor, Hs.76122 EST, Weakly similar to RL13_HUMAN Hs.276279 arginine/serine-rich 4 (SFRS4) mRNA. 60S RIBOSOMAL PROTEIN L13 [H. sapiens] thymosin beta-10 Hs.76293 EST Hs.276341 CD63 Hs.76294 EST Hs.276342 AIF1 Hs.76364 EST, Weakly similar to RL13_HUMAN Hs.276353 60S RIBOSOMAL PROTEIN L13 [H. sapiens] phospholipase A2, group IIA (platelets, Hs.76422 EST Hs.276774 synovial fluid), CES1 Hs.76688 EST Hs.276819 ubiquitin conjugating enzyme Hs.76932 EST Hs.276871 Homo sapiens KIAA0963 protein Hs.7724 EST, Weakly similar to FBRL_HUMAN Hs.276872 (KIAA0963), mRNA. FIBRILLARIN [H. sapiens] Homo sapiens fragile histidine triad gene Hs.77252 EST Hs.276887 (FHIT) mRNA. PAF-AH Hs.77318 EST Hs.276902 Mig Hs.77367 EST Hs.276917 DDB2 Hs.77602 EST Hs.276918 ATR Hs.77613 EST, Weakly similar to RL13_HUMAN Hs.276938 60S RIBOSOMAL PROTEIN L13 [H. sapiens] XPB (ERCC3) Hs.77929 EST Hs.277051 PNKP Hs.78016 EST Hs.277052 C7 Hs.78065 EST, Moderately similar to RL13_HUMAN Hs.277236 60S RIBOSOMAL PROTEIN L13 [H. sapiens] Homo sapiens small nuclear RNA activating Hs.78403 EST, Moderately similar to DEAD Box Hs.277237 complex, polypeptide 2, 45 kD (SNAPC2) Protein 5 [H. sapiens] mRNA. Hs.78465 EST Hs.277238 sphingolipid activator protein/cerebroside Hs.78575 EST Hs.277286 sulfate activator protein Homo sapiens aminolevulinate, delta-, Hs.78712 major histocompatibility complex, class I, C Hs.277477 synthase 1 (ALAS1), nuclear gene encoding mitochondrial protein, mRNA. tyrosine kinase with immunoglobulin and Hs.78824 EST, Weakly similar to AF150959 1 Hs.277591 epidermal growth factor homology domains immunoglobulin G1 Fc fragment [H. sapiens] Hsp72 Hs.78846 EST Hs.277714 UNG Hs.78853 EST Hs.277715 CX3CR1 Hs.78913 EST Hs.277716 MSH2 Hs.78934 EST Hs.277717 CRHR1 Hs.79117 EST Hs.277718 BCL2 Hs.79241 EST, Weakly similar to BAT3_HUMAN Hs.277774 LARGE PROLINE-RICH PROTEIN BAT3 [H. sapiens] P-selectin Hs.79283 EST Hs.277975 UBE2VE (MMS2) Hs.79300 EST Hs.278060 retinoid X receptor, beta Hs.79372 cytochrome P450, subfamily XXIA (steroid Hs.278430 21-hydroxylase, congenital adrenal hyperplasia), polypeptide 2 MPG Hs.79396 KIAA0015 gene product Hs.278441 RPA2 Hs.79411 CD32B Hs.278443 heat shock 70 kD protein-like 1 Hs.80288 KIR2DL1 Hs.278453 FANCG (XRCC9) Hs.8047 CD158a Hs.278455 CD43 Hs.80738 CD24 Hs.278667 POLG Hs.80961 HLA class II region expressed gene KE4 Hs.278721 Human CB-4 transcript of unrearranged Hs.81220 IL-17C Hs.278911 immunoglobulin V(H)5 gene Human L2-9 transcript of unrearranged Hs.81221 HSPC048 protein (HSPC048) Hs.278944 immunoglobulin V(H)5 pseudogene immunoglobulin superfamily, member 3 Hs.81234 HSPC054 protein (HSPC054) Hs.278946 UBL1 Hs.81424 HSPC073 protein (HSPC073) Hs.278948 PF4 Hs.81564 ESTs Hs.279066 palmitoyl-protein thioesterase 2 Hs.81737 ESTs Hs.279067 natural killer cell receptor, immunoglobulin Hs.81743 ESTs Hs.279068 superfamily member TNFRSF11B Hs.81791 ESTs Hs.279069 interleukin 6 signal transducer (gp130, Hs.82065 ESTs Hs.279070 oncostatin M receptor) CD138 Hs.82109 ESTs Hs.279071 Human monocytic leukaemia zinc finger Hs.82210 ESTs Hs.279072 protein (MOZ) mRNA, complete cds. sema domain, immunoglobulin domain (Ig), Hs.82222 ESTs, Weakly similar to KIAA0052 protein Hs.279073 short basic domain, secreted, (semaphorin) [H. sapiens] 3B HPRT Hs.82314 ESTs Hs.279074 Human RNA binding protein Etr-3 mRNA, Hs.82321 ESTs Hs.279075 complete cds. MNAT1 Hs.82380 ESTs Hs.279076 SMAD2 Hs.82483 ESTs Hs.279077 CD47 Hs.82685 EST Hs.279078 CETN2 Hs.82794 EST Hs.279079 protein phosphatase 1, regulatory (inhibitor) Hs.82887 ESTs Hs.279080 subunit 11 MMP1 Hs.83169 EST Hs.279081 D3-type cyclin (CCND3) Hs.83173 ESTs Hs.279082 MMP3 Hs.83326 ESTs Hs.279083 TNFSF10 Hs.83429 ESTs Hs.279084 CD33 Hs.83731 ESTs Hs.279085 CD102 Hs.83733 ESTs Hs.279086 Hs.84153 ESTs, Weakly similar to AF201422_1 Hs.279087 splicing coactivator subunit SRm300 [H. sapiens] interleukin 8 receptor, beta Hs.846 ESTs Hs.279088 titin immunoglobulin domain protein Hs.84665 ESTs Hs.279089 (myotilin) KU80 (XRCC5) Hs.84981 Hs.86437 Raf-1 Hs.85181 Hs.86761 major histocompatibility complex, class I, J Hs.85242 CD118 = IFNAR-2 Hs.86958 (pseudogene) RELB Hs.858 Hs.87113 Hs.85923 PGHS-1 Hs.88474 ERK1 Hs.861 Hs.8882 FADD Hs.86131 LT-b Hs.890 MHC class I polypeptide-related sequence A Hs.90598 EST Hs.92440 TNF receptor-associated factor 6 Hs.90957 Hs.92460 Topo3A Hs.91175 myosin-binding protein H Hs.927 PARG Hs.91390 IFN-b Hs.93177 HLA-DPA1 Hs.914 C8A Hs.93210 SEEK1 Hs.91600 pre-B-cell leukemia transcription factor 2 Hs.93728 POLD1 Hs.99890 Tachykinin Receptor 3 Hs.942 ALK4 Hs.99954 Homo sapiens cDNA FLJ12242 fis, clone Hs.94810 MAMMA1001292 XPD (ERCC2) Hs.99987 CD29 Hs.287797 SCYA25 (CCL25) Hs.50404 LIF Hs.2250 SCYA19 (CCL19) Hs.50002 Human IP-10 Hs.2248 TCIRG1 Hs.46465 IL-5 Hs.2247 PAF-Receptor Hs.46 G-CSF Hs.2233 CD26 Hs.44926 TGF-bR Hs.220 Hs.44865 G-CSFR Hs.2175 REL Hs.44313 CD15 Hs.2173 IL-17 Hs.41724 STAT1 Hs.21486 CD49d Hs.40034 CD85 Hs.204040 CCR2 Hs.395 HCC-1 Hs.20144 Hs.3688 Fas ligand Hs.2007 TNF-b Hs.36 CD28 Hs.1987 lactoferrin Hs.347 HLA-DQA1 Hs.198253 MCP-1 Hs.340 Ku70 (G22P1) Hs.197345 CD150 Hs.32970 PGHS-2 Hs.196384 IL-10Ra Hs.327 CDw128 Hs.194778 EGR1 Hs.326035 IL-10 Hs.193717 SCYC1 (XCL1) Hs.3195 CD126 Hs.193400 HLA-DR Hs.318720 Hs.1880 Topo I (TOP1) Hs.317 CD98 Hs.184601 SCYA2 (MCP1) Hs.303649 Hs.184542 HuRNPD Hs.303627 MHC class I region ORF Hs.1845 Human C mu gene for IgM heavy chain Hs.302063 CDw116a Hs.182378 exons CH1-4, secretory P1 Hs.297681 HLA-DRB5 Hs.181366 immunoglobulin lambda joining 3 Hs.289110 major histocompatibility complex, class I, A Hs.181244 major histocompatibility complex, class II, Hs.289095 elongation factor 1-alpha (clone CEF4) Hs.181165 DQ alpha 2 HSPCA Hs.289088 CD119 Hs.180866 interleukin 22 Hs.287369 Hs.180804 ribosomal protein L4 Hs.286 Hs.180532 IgM Hs.285823 POLB Hs.180107 EST Hs.283267 CD1d Hs.1799 TREM1 Hs.283022 CD87 Hs.179657 HLA-DRB3 Hs.279930 minichromosome maintenance deficient (S. Hs.179565 cerevisiae) 3 LIFR Hs.2798 RAD23B (HR23B) Hs.178658 C4B Hs.278625 Hs.178391 EST Hs.276907 Hs.177781 CDw52 Hs.276770 ADPRT Hs.177766 CD16b Hs.274467 IFNGR2 Hs.177559 heat shock 70 kD protein 1B Hs.274402 CD16a Hs.176663 Th1 Hs.273385 CD4 Hs.17483 MIP-5/HCC-2 Hs.272493 SCYC2 (XCL2) Hs.174228 TBX21 Hs.272409 CD115 Hs.174142 Homo sapiens mRNA; cDNA Hs.272307 CD11a Hs.174103 DKFZp434O2417 (from clone DKFZp434O2417); partial cds Human DNA sequence from clone RP1- Hs.272295 IL-10Rb Hs.173936 108C2 on chromosome 6p12.1-21.1. Contains the MCM3 gene for minichromosome maintenance deficient (S. cerevisiae) 3 (DNA replication licensing factor, DNA polymerase alpha holoenzyme- associated protein P1, RLF beta subunit), a CACT (carnitine/acylcarnitine translocase) pseudogene, part of the gene for a PUTATIVE novel protein similar to IL17 (interleukin 17 (cytotoxic T-lymphocyte- associated serine esterase 8)) (cytotoxic T lymphocyte-associated antigen 8, CTLA8), ESTs, STSs, GSSs and a putative CpG island CD49b Hs.271986 MSCF Hs.173894 MCP-2 Hs.271387 TDG Hs.173824 CD49c Hs.265829 RAC1 Hs.173737 NBS1 Hs.25812 integrin cytoplasmic domain-associated Hs.173274 protein 1 CD120b = TNFRSF1B Hs.256278 IL2R Hs.1724 CDw75 Hs.2554 IL-1a Hs.1722 CD82 Hs.25409 Hs.171872 MCP-3 Hs.251526 Hs.171118 xanthine oxidase Hs.250 EST Hs.171009 Human Ig rearranged lambda-chain mRNA, Hs.247947 EST Hs.170934 subgroup VL3, V-J region, partial cds Eotaxin-2/MPIF-2 Hs.247838 EST Hs.170587 CTLA-4 Hs.247824 IL-9R Hs.1702 immunoglobulin kappa variable 1-9 Hs.247792 CD45 Hs.170121 CD68 Hs.246381 TGF-a Hs.170009 OSMR Hs.238648 CD44 Hs.169610 CDw127 Hs.237868 Fyn Hs.169370 transcription factor 8 (represses interleukin Hs.232068 MPIF-1 Hs.169191 2 expression) CD8b Hs.2299 ICAM-1 Hs.168383 EST Hs.229374 IL-15 Hs.168132 TRF4-1 Hs.225951 STAT5A Hs.167503 CD3g Hs.2259 ESTs Hs.167208 C2 Hs.2253 ESTs Hs.165693 Hs.116834 Hs.135750 Hs.117741 DINB1 (POLK) Hs.135756 Human MHC Class I region proline rich Hs.118354 Human DNA sequence from clone RP1- Hs.136141 protein mRNA, complete cds 238O23 on chromosome 6. Contains part of the gene for a novel protein similar to PIGR (polymeric immunoglobulin receptor), part of the gene for a novel protein similar to rat SAC (soluble adenylyl cyclase), ESTs, STSs and GSS ESTs, Weakly similar to FCE2 MOUSE Hs.118392 Hs.136254 LOW AFFINITY IMMUNOGLOBULIN EPSILON FC RECEPTOR [M. musculus] MKK6 Hs.118825 Hs.13646 Hs.118895 Hs.136537 H. sapiens mRNA for ITBA4 gene. Hs.119018 Histone H1 (F3) Hs.136857 Hs.119057 MGMT Hs.1384 TNFRSF10c Hs.119684 Hs.138563 Hs.12064 IgG Hs.140 Hs.120907 Hs.140478 acid phosphatase 5, tartrate resistant Hs.1211 Hs.14070 Hs.121297 Hs.141153 Human immunoglobulin (mAb59) light Hs.121508 Hs.143954 chain V region mRNA, partial sequence IL12Rb1 Hs.121544 ESTs, Moderately similar to Hs.144814 I1BC_HUMAN INTERLEUKIN-1 BETA CONVERTASE PRECURSOR [H. sapiens] Human MHC class II DO-alpha mRNA, Hs.123041 CHK2 (Rad53) Hs.146329 partial cds Histone H4 (H4F2) Hs.123053 EST Hs.146591 TSHR Hs.123078 Hs.147040 Hs.123445 CD42b Hs.1472 regulatory factor X, 1 (influences HLA class Hs.123638 Hs.149235 II expression) CD13 Hs.1239 AICD Hs.149342 IL-15R Hs.12503 Homo sapiens putative tumor suppressor Hs.149443 protein (101F6) mRNA, complete cds. RAD51L3 (RAD51D) Hs.125244 CD49e Hs.149609 CDw90 Hs.125359 heparan sulfate proteoglycan (HSPG) core Hs.1501 protein LYPLA1 Hs.12540 CD107a Hs.150101 ESTs, Weakly similar to AF201951 1 high Hs.126580 ESTs, Weakly similar to 157587 MHC HLA Hs.150175 affinity immunoglobulin epsilon receptor SX-alpha [H. sapiens] beta subunit [H. sapiens] Hs.127128 ALK2 Hs.150402 Hs.127444 WRN Hs.150477 C5 Hs.1281 EST Hs.150708 C8G Hs.1285 XRCC4 Hs.150930 RAD54B Hs.128501 IFN-a Hs.1510 Hs.129020 MAPK Hs.151051 Hs.129268 Hs.15200 Hs.129332 immunoglobulin mu binding protein 2 Hs.1521 XRCC2 Hs.129727 4-1BBL Hs.1524 potassium voltage-gated channel, Shaw- Hs.129738 Hs.152818 related subfamily, member 3 (KCNC3) interleukin 17 receptor Hs.129751 HUS1 Hs.152983 CD134 Hs.129780 SWAP70 Hs.153026 TNFRSF10d Hs.129844 DOM-3 (C. elegans) homolog Z Hs.153299 POLL Hs.129903 Hs.153551 GADD153 = growth arrest and DNA-damage Hs.129913 Hs.15370 inducible gene/fus-chop fusion protein solute carrier family 5 (neutral amino acid Hs.130101 SMAD6 Hs.153863 transporters, system A), member 4 Hs.130232 APEXL2 Hs.154149 Hs.13034 Hs.154198 CD30L Hs.1313 Hs.154366 SCYA26 (CCL26) Hs.131342 BCL6 Hs.155024 CD30 Hs.1314 Hs.155150 Hs.131885 Hs.155402 Hs.131887 RAIDD Hs.155566 Hs.13256 POLH Hs.155573 ESTs Hs.132775 Hs.15589 Homo sapiens (clone 3.8-1) MHC class I Hs.132807 Homo sapiens mRNA for KIAA0695 Hs.155976 mRNA fragment protein complete cds. Hs.13288 SNM1 (P502) Hs.1560 Hs.132943 Topo2A Hs.156346 EST Hs.133261 ESTs, Highly similar to MHC class II Hs.156811 antigen [H. sapiens] Hs.133388 Histamine H1 receptor Hs.1570 EST Hs.133393 Hs.157118 EST Hs.133930 Hs.157267 ESTs Hs.133947 EST Hs.157279 ESTs Hs.133949 EST Hs.157280 EST Hs.134017 EST Hs.157308 EST Hs.134018 EST Hs.157309 EST Hs.134590 EST Hs.157310 Hs.135135 EST Hs.157311 immunoglobulin superfamily, member 6 Hs.135194 ESTs Hs.157344 Hs.135570 ret finger protein-like 2 Hs.157427 Homo sapiens arrestin, beta 2 (ARRB2) Hs.18142 Hs.214956 mRNA. myeloperoxidase Hs.1817 WASP Hs.2157 APO-1 Hs.182359 CD88 Hs.2161 TRAP1 Hs.182366 Hs.21618 Hs.182594 ring finger protein 5 Hs.216354 TNFRSF16 Hs.1827 class II cytokine receptor ZCYTOR7 Hs.21814 Hs.182817 Hs.219149 regulatory factor X, 4 (influences HLA class Hs.183009 cyclophilin-related protein Hs.219153 II expression) Homo sapiens killer cell lectin-like receptor Hs.183125 Homo sapiens mannosyl (alpha-1,6-)- Hs.219479 F1 (KLRF1), mRNA. glycoprotein beta-1,2-N- acetylglucosaminyltransferase (MGAT2) mRNA. Hs.183171 perforin Hs.2200 EST Hs.183386 Hs.220154 Hs.183656 ESTs, Weakly similar to FCE2 MOUSE Hs.220649 LOW AFFINITY IMMUNOGLOBULIN EPSILON FC RECEPTOR [M. musculus] Hs.18368 Hs.220868 advanced glycosylation end product-specific Hs.184 Hs.220960 receptor CDK7 Hs.184298 immunoglobulin superfamily, member 1 Hs.22111 Hs.184376 Hs.221539 CCR4 Hs.184926 ESTs Hs.221694 EST, Weakly similar to A27307 proline- Hs.185463 Hs.222921 rich phosphoprotein [H. sapiens] EST Hs.185498 Hs.222942 EST, Weakly similar to B39066 proline- Hs.186243 EST Hs.223520 rich protein 15 - rat [R. norvegicus] EST, Weakly similar to salivary proline-rich Hs.186265 EST Hs.223935 protein [R. norvegicus] EST Hs.187200 EST, Moderately similar to SMO_HUMAN Hs.224178 SMOOTHENED HOMOLOG PRECURSOR [H. sapiens] Hs.188048 Blk Hs.2243 EST Hs.188075 EST Hs.224344 EST Hs.188194 EST Hs.224408 EST Hs.188300 EST Hs.224409 Hs.190251 CPN1 Hs.2246 Hs.19056 MMP7 Hs.2256 EST Hs.190831 MMP10 Hs.2258 MAPK8 Hs.190913 CCR9 Hs.225946 EST Hs.190921 toll-like receptor 6 (TLR6) Hs.227105 EST, Weakly similar to S39206 Hs.190924 XPR1 Hs.227656 hypothetical protein 1 - rat□ [R. norvegicus] GTF2H2 Hs.191356 CD49f Hs.227730 Hs.191367 Hs.22790 Hs.191914 EST Hs.228337 ESTs, Weakly similar to immunoglobulin Hs.192078 EST, Highly similar to 1409218A elastase Hs.228525 superfamily member [D. melanogaster] [H. sapiens] XPA Hs.192803 EST Hs.228528 CD89 Hs.193122 EST, Moderately similar to Hs.228874 R37A_HUMAN 60S RIBOSOMAL PROTEIN L37A□ [H. sapiens] DFFRY Hs.193145 EST Hs.228891 CD35 Hs.193716 EST Hs.228926 REV7 (MAD2L2) Hs.19400 EST Hs.229071 Hs.194082 EST Hs.229405 Hs.194110 EST Hs.229494 BRCA1 Hs.194143 EST, Weakly similar to ALU1_HUMAN Hs.229560 ALU SUBFAMILY J SEQUENCE CONTAMINATION WARNING ENTRY□ [H. sapiens] ESTs, Moderately similar to MHC Class I Hs.194249 EST, Moderately similar to AAD18086 Hs.229901 region proline rich protein [H. sapiens] BAT2 [H. sapiens] Hs.194534 EST Hs.229902 Topo3B Hs.194685 EST, Highly similar to 1409218A elastase Hs.230053 [H. sapiens] Human DNA sequence from clone 1170K4 Hs.194750 RAD51 Hs.23044 on chromosome 22q12.2-13.1. Contains three novel genes, one of which codes for a Trypsin family protein with class A LDL receptor domains, and the IL2RB gene for Interleukin 2 Receptor, Beta (IL-2 Receptor, CD122 antigen). Contains a putative CpG island, ESTs, and GSSs major histocompatibility complex, class II, Hs.194764 EST, Moderately similar to A54746 adhalin Hs.230485 DP alpha 2 (pseudogene) precursor - human□ [H. sapiens] Human DNA sequence from clone RP11- Hs.194976 EST Hs.230691 367J7 on chromosome 1. Contains (part of) two or more genes for novel Immunoglobulin domains containing proteins, a SON DNA binding protein (SON) pseudogene, a voltage-dependent anion channel 1 (VDAC1) (plasmalemmal porin) pseudogene, ESTs, STSs and GSSs Hs.195447 EST Hs.230775 PDGF-B Hs.1976 EST Hs.230805 CXCR3 Hs.198252 EST Hs.230848 Hs.198694 EST Hs.230862 Hs.198738 EST Hs.230874 MAR/SAR DNA binding protein (SATB1) Hs.198822 EST Hs.230931 CHUK Hs.198998 EST Hs.231031 hemochromatosis Hs.20019 EST Hs.231261 T-cell receptor active beta-chain Hs.2003 EST Hs.231284 APO-1 Hs.2007, EST Hs.231285 RXRA Hs.20084 EST Hs.231292 EST Hs.200876 EST, Weakly similar to putative Hs.231512 mitochondrial outer membrane protein import receptor [H. sapiens] Hs.201194 Homo sapiens mRNA for KIAA0529 Hs.23168 protein, partial cds. TCRd Hs.2014 EST Hs.235042 ESTs, Highly similar to TNF-alpha Hs.202407 EST Hs.235826 converting enzyme [H. sapiens] Hs.202608 TREX1 (Dnase III) Hs.23595 Integrin b1 = CD29 Hs.202661 EST Hs.237126 thrombomodulin Hs.2030 Hs.23860 Hs.203064 RAD9 Hs.240457 Hs.203184 1-acylglycerol-3-phosphate O- Hs.240534 acyltransferase 1 (lysophosphatidic acid acyltransferase, alpha) Hs.203584 EST Hs.240635 EST Hs.204477 EST, Weakly similar to ALU8_HUMAN Hs.241136 ALU SUBFAMILY SX SEQUENCE CONTAMINATION WARNING ENTRY□ [H. sapiens] EST Hs.204480 TNFSF15 Hs.241382 EST, Weakly similar to CA13_HUMAN Hs.204483 interleukin 1 receptor accessory protein-like 1 Hs.241385 COLLAGEN ALPHA 1(III) CHAIN PRECURSOR□ [H. sapiens] ESTs Hs.204588 RANTES Hs.241392 EST, Weakly similar to salivary proline-rich Hs.204598 sema domain, immunoglobulin domain (Ig), Hs.2414 protein 1 [H. sapiens] short basic domain, secreted, (semaphorin) 3A EST Hs.204610 POLQ Hs.241517 ESTs Hs.204703 TNF-a Hs.241570 ESTs Hs.204751 Homo sapiens genes encoding RNCC Hs.241586 protein, DDAH protein, Ly6-C protein, Ly6- D protein and immunoglobulin receptor EST Hs.204760 megakaryocyte-enhanced gene transcript 1 Hs.241587 protein EST Hs.204771 EST, Moderately similar to 1409218A Hs.241981 elastase [H. sapiens] ESTs Hs.204873 EST Hs.241982 ESTs Hs.204932 EST Hs.241983 EST Hs.204954 EST Hs.242605 EST Hs.205158 ADPRT2 Hs.24284 ESTs Hs.205159 EST Hs.243284 ESTs Hs.205327 EST Hs.243286 CD39 Hs.205353 ESTs Hs.243288 ESTs Hs.205435 SCYB14 Hs.24395 EST Hs.205438 EST Hs.244046 EST, Highly similar to elastic titin Hs.205452 EST Hs.244048 [H. sapiens] EST Hs.205456 EST Hs.244049 MRE11A Hs.20555 EST Hs.244050 HLA class II region expressed gene KE2 Hs.205736 RFXAP Hs.24422 EST Hs.205788 Hs.24435 ESTs Hs.205789 STAT5B Hs.244613 EST Hs.205803 EST Hs.244666 EST Hs.205815 EST Hs.245586 ESTs Hs.206160 CDw108 Hs.24640 Hs.206654 ESTs Hs.246796 EST Hs.207060 dimethylarginine dimethylaminohydrolase 2 Hs.247362 EST Hs.207062 Homo sapiens clone mcg53-54 Hs.247721 immunoglobulin lambda light chain variable region 4a mRNA, partial cds EST Hs.207063 Homo sapiens ELK1 pseudogene (ELK2) Hs.247775 and immunoglobulin heavy chain gamma pseudogene (IGHGP) EST Hs.207473 immunoglobulin kappa variable 1/OR2-108 Hs.247804 ESTs Hs.207474 butyrophilin-like 2 (MHC class II Hs.247808 associated) ESTs Hs.207971 Homo sapiens genes encoding RNCC Hs.247879 protein, DDAH protein, Ly6-C protein, Ly6- D protein and immunoglobulin receptor EST Hs.207993 Histamine H2 receptor Hs.247885 EST Hs.208153 Human anti-streptococcal/anti-myosin Hs.247898 immunoglobulin lambda light chain variable region mRNA, partial cds EST, Weakly similar to S10889 proline-rich Hs.208667 Homo sapiens isolate donor Z clone Z55K Hs.247907 protein - human□ [H. sapiens] immunoglobulin kappa light chain variable region mRNA, partial cds ESTs Hs.209142 Homo sapiens isolate donor D clone D103L Hs.247908 immunoglobulin lambda light chain variable region mRNA, partial cds EST Hs.209261 Homo sapiens isolate 459 immunoglobulin Hs.247909 lambda light chain variable region (IGL) gene, partial cds ESTs Hs.209306 Homo sapiens isolate donor N clone N88K Hs.247910 immunoglobulin kappa light chain variable region mRNA, partial cds Hs.209362 Homo sapiens isolate donor N clone N8K Hs.247911 immunoglobulin kappa light chain variable region mRNA, partial cds EST, Weakly similar to FCEB MOUSE Hs.209540 Human Ig rearranged mu-chain V-region Hs.247923 HIGH AFFINITY IMMUNOGLOBULIN gene, subgroup VH-III, exon 1 and 2 EPSILON RECEPTOR BETA-SUBUNIT [M. musculus] EST Hs.209913 Epsilon, IgE = membrane-bound IgE, Hs.247930 epsilon m/s isoform {alternative splicing} [human, mRNA Partial, 216 nt] EST Hs.209989 H. sapiens (T1.1) mRNA for IG lambda light Hs.247949 chain EST Hs.210049 H. sapiens mRNA for Ig light chain, variable Hs.247950 region (ID: CLL001VL) EST, Moderately similar to probable Hs.210276 Human interleukin 2 gene, clone pATtacIL- Hs.247956 sodium potassium ATPase gamma chain 2C/2TT, complete cds, clone pATtacIL- [H. sapiens] 2C/2TT EST, Weakly similar to N-WASP Hs.210306 pre-B lymphocyte gene 1 Hs.247979 [H. sapiens] EST Hs.210307 Human immunoglobulin heavy chain Hs.247987 variable region (V4-31) gene, partial cds EST Hs.210385 Human immunoglobulin heavy chain Hs.247989 variable region (V4-30.2) gene, partial cds interleukin 21 receptor Hs.210546 Human DNA sequence from phage LAW2 Hs.247991 from a contig from the tip of the short arm of chromosome 16, spanning 2Mb of 16p13.3 Contains Interleukin 9 receptor pseudogene EST Hs.210727 Homo sapiens HLA class III region Hs.247993 containing NOTCH4 gene, partial sequence, homeobox PBX2 (HPBX) gene, receptor for advanced glycosylation end products (RAGE) gene, complete cds, and 6 unidentified cds Hs.211266 Homo sapiens immunoglobulin lambda Hs.248010 gene locus DNA, clone: 61D6 SMAD3 Hs.211578 immunoglobulin lambda variable 9-49 Hs.248011 MHC class I polypeptide-related sequence B Hs.211580 immunoglobulin lambda variable 4-3 Hs.248012 ESTs, Weakly similar to CA1B_MOUSE Hs.211744 H. sapiens mRNA for IgG lambda light Hs.248030 COLLAGEN ALPHA 1(XI) CHAIN chain V-J-C region (clone Tgl11) PRECURSOR□ [M. musculus] sema domain, immunoglobulin domain (Ig), Hs.212414 Human immunoglobulin (mAb56) light Hs.248043 short basic domain, secreted, (semaphorin) chain V region mRNA, partial sequence 3E TNFRSF18 Hs.212680 Homo sapiens lymphocyte-predominant Hs.248077 Hodgkin's disease case #4 immunoglobulin heavy chain gene, variable region, partial cds Homo sapiens general transcription factor 2- Hs.212939 Homo sapiens lymphocyte-predominant Hs.248078 I pseudogene 1 (GTF2IP1) mRNA. Hodgkin's disease case #7 immunoglobulin heavy chain gene, variable region, partial cds RAD 18 Hs.21320 Homo sapiens clone ASMneg1-b3 Hs.248083 immunoglobulin lambda chain VJ region, (IGL) mRNA, partial cds Hs.213226 OSM Hs.248156 ESTs Hs.279090 Hs.29128 ESTs Hs.279091 Homo sapiens clone 24659 mRNA Hs.29206 sequence. ESTs Hs.279092 EST Hs.292235 EST Hs.279093 EST Hs.292450 ESTs Hs.279094 EST, Moderately similar to Ewing sarcoma Hs.292455 breakpoint region 1, isoform EWS [H. sapiens] ESTs Hs.279095 EST Hs.292461 ESTs, Weakly similar to AF279265_1 Hs.279096 ESTs Hs.292501 putative anion transporter 1 [H. sapiens] ESTs Hs.279097 EST Hs.292516 EST Hs.279098 EST Hs.292517 ESTs Hs.279099 EST Hs.292520 ESTs Hs.279100 EST, Moderately similar to RL13_HUMAN Hs.292540 60S RIBOSOMAL PROTEIN L13 [H. sapiens] ESTs Hs.279101 EST Hs.292545 ESTs Hs.279102 EST, Weakly similar to ORFII [H. sapiens] Hs.292704 ESTs Hs.279103 EST Hs.292761 ESTs Hs.279104 ESTs Hs.292803 ESTs Hs.279105 ESTs Hs.293183 ESTs Hs.279106 ESTs Hs.293280 EST Hs.279107 ESTs Hs.293281 ESTs Hs.279108 ESTs, Moderately similar to 0501254A Hs.293441 protein Tro alpha1 H,myeloma [H. sapiens] EST Hs.279109 MMP13 Hs.2936 ESTs Hs.279110 major histocompatibility complex, class II, Hs.293934 DR beta 4 ESTs Hs.279111 Human MHC class III serum complement Hs.294163 factor B, mRNA ESTs Hs.279112 EST Hs.294315 EST Hs.279113 EST Hs.294316 ESTs Hs.279114 EST, Highly similar to Y196_HUMAN Hs.295582 HYPOTHETICAL PROTEIN KIAA0196□ [H. sapiens] ESTs Hs.279115 EST Hs.295583 ESTs Hs.279116 EST, Highly similar to ZN07_HUMAN Hs.295584 ZINC FINGER PROTEIN 7 [H. sapiens] ESTs Hs.279117 EST Hs.295585 ESTs Hs.279118 EST Hs.295586 ESTs Hs.279119 EST, Moderately similar to angiotensin Hs.295595 converting enzyme [H. sapiens] ESTs Hs.279120 EST Hs.295621 ESTs Hs.279121 EST Hs.295622 ESTs Hs.279122 EST, Moderately similar to RL13_HUMAN Hs.295629 60S RIBOSOMAL PROTEIN L13 [H. sapiens] ESTs Hs.279123 EST Hs.295724 ESTs Hs.279124 EST Hs.296064 ESTs Hs.279125 EST, Moderately similar to IDS_HUMAN Hs.296070 IDURONATE 2-SULFATASE PRECURSOR□ [H. sapiens] ESTs Hs.279126 EST Hs.296073 ESTs Hs.279127 interleukin enhancer binding factor 1 Hs.296281 EST Hs.279128 similar to rat integral membrane Hs.296429 glycoprotein POM121 ESTs, Weakly similar to aconitase Hs.279129 Human histocompatibility antigen mrna Hs.296476 [H. sapiens] clone phla-1 ESTs Hs.279130 immunoglobulin lambda-like polypeptide 3 Hs.296552 ESTs Hs.279131 RFXANK Hs.296776 ESTs Hs.279132 Hs.29826 ESTs Hs.279133 Hs.29871 ESTs, Weakly similar to PYRG_HUMAN Hs.279134 MEKK1 Hs.298727 CTP SYNTHASE [H. sapiens] ESTs, Weakly similar to RIR1_HUMAN Hs.279135 Hs.30029 RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE M1 CHAIN [H. sapiens] ESTs Hs.279136 CD3e Hs.3003 ESTs Hs.279137 ESTs, Weakly similar to CA13_HUMAN Hs.300697 COLLAGEN ALPHA 1(III) CHAIN PRECURSOR [H. sapiens] ESTs Hs.279138 Homo sapiens clone BCSynL38 Hs.300865 immunoglobulin lambda light chain variable region mRNA, partial cds ESTs Hs.279139 FCGR3A Hs.300983 ESTs Hs.279140 Homo sapiens DP47 gene for Hs.301365 immunoglobulin heavy chain, partial cds ESTs Hs.279141 PMS2L9 Hs.301862 EST Hs.279142 CCR1 Hs.301921 ESTs Hs.279143 FANCE Hs.302003 ESTs Hs.279144 interleukin 21 Hs.302014 ESTs Hs.279145 interleukin 17E Hs.302036 ESTs Hs.279146 Hs.30446 EST Hs.279147 EST Hs.30709 ESTs Hs.279148 EST Hs.30731 ESTs Hs.279149 MHC class II transactivator Hs.3076 ESTs Hs.279150 EST Hs.30766 ESTs, Weakly similar to PUR2_HUMAN Hs.279151 EST Hs.30793 TRIFUNCTIONAL PURINE BIOSYNTHETIC PROTEIN ADENOSINE 3 [H. sapiens] ESTs Hs.279152 Hs.30818 ESTs Hs.279153 CD97 Hs.3107 ESTs Hs.279154 RAR-beta2 Hs.31408 ESTs Hs.279155 RECQL4 Hs.31442 ESTs Hs.279156 XPC Hs.320 ESTs Hs.279157 ERK2 Hs.324473 ESTs Hs.279158 Hs.32456 ESTs Hs.279159 MSH6 Hs.3248 ESTs Hs.279160 ribosomal protein L23-related Hs.3254 ESTs, Weakly similar to IDHA_HUMAN Hs.279161 PI3CG Hs.32942 ISOCITRATE DEHYDROGENASE [H. sapiens] ESTs Hs.279162 CSA (CKN1) Hs.32967 ESTs Hs.279163 sema domain, immunoglobulin domain (Ig), Hs.32981 short basic domain, secreted, (semaphorin) 3F ESTs Hs.279164 BRCA2 Hs.34012 ESTs Hs.279165 MEK1 Hs.3446 ESTs Hs.279166 STRL33 (CXCR6) Hs.34526 ESTs Hs.279167 MBD4 Hs.35947 ESTs Hs.279168 immunoglobulin (CD79A) binding protein 1 Hs.3631 EST Hs.279169 CD7 Hs.36972 ESTs Hs.279170 IFNA1 Hs.37026 ESTs Hs.279171 PDGF-A Hs.37040 EST Hs.279172 immunoglobulin kappa variable 1-13 Hs.37089 ESTs Hs.279174 DMC1 Hs.37181 ESTs Hs.279175 Hs.37892 CD86 Hs.27954 Homo sapiens suppressor of variegation 3-9 Hs.37936 (Drosophila) homolog (SUV39H) mRNA, and translated products. CGI-81 protein Hs.279583 C8B Hs.38069 ESTs Hs.279821 MTH1 (NUDT1) Hs.388 ESTs Hs.279823 Adrenomedullin Hs.394 ESTs, Weakly similar to IRE1_HUMAN Hs.279824 Hs.39441 IRON-RESPONSIVE ELEMENT BINDING PROTEIN 1 [H. sapiens] ESTs Hs.279825 CD66b Hs.41 ESTs Hs.279826 RAD50 Hs.41587 MLH3 Hs.279843 CD94 Hs.41682 TNFRSF14 Hs.279899 HLJ1 Hs.41693 RPA4 Hs.283018 ESM1 Hs.41716 EST Hs.283165 MSH3 Hs.42674 EST Hs.283166 cAMP responsive element binding protein- Hs.42853 like 1 EST Hs.283167 IKBKG Hs.43505 EST Hs.283168 Homo sapiens suppressor of white apricot Hs.43543 homolog 2 (SWAP2), mRNA. ESTs Hs.283169 LEU2 Hs.43628 EST Hs.283245 Homo sapiens immunoglobulin lambda Hs.43834 gene locus DNA, clone: 288A10 EST Hs.283247 SIRT2 Hs.44017 ESTs Hs.283248 Hs.44087 EST Hs.283249 TREM2 Hs.44234 EST Hs.283250 serine/threonine kinase 19 Hs.444 EST Hs.283251 Hs.44512 EST Hs.283252 Hs.44628 EST Hs.283253 Hs.45063 EST Hs.283254 LTC4 synthase Hs.456 EST Hs.283255 FUT2 Hs.46328 EST Hs.283256 CCR6 Hs.46468 EST Hs.283257 POLM Hs.46964 EST Hs.283258 EXO1 (HEX1) Hs.47504 ESTs Hs.283259 FEN1 (Dnase IV) Hs.4756 EST Hs.283261 Hs.4863 EST Hs.283262 golgin-165 Hs.4953 EST Hs.283263 Hs.50102 EST Hs.283264 ATP-binding cassette, sub-family B Hs.502 (MDR/TAP), member 3 EST Hs.283266 Hs.5057 ESTs Hs.283268 corneodesmosin Hs.507 EST Hs.283269 Histone H2 (H2AFP) Hs.51011 EST, Weakly similar to AF189011_1 Hs.283270 CCNH Hs.514 ribonuclease III [H. sapiens] EST Hs.283271 EST Hs.5146 EST Hs.283272 SMUG1 Hs.5212 EST Hs.283274 ABH (ALKB) Hs.54418 EST Hs.283275 CCR5 Hs.54443 EST Hs.283276 CD81 Hs.54457 ESTs, Weakly similar to S32605 collagen Hs.283392 TNFSF13 Hs.54673 alpha 3(VI) chain - mouse [M. musculus] ESTs Hs.283433 PRPS1 Hs.56 ESTs Hs.283434 Hs.56156 ESTs Hs.283438 Hs.56265 ESTs Hs.283442 killer cell immunoglobulin-like receptor, Hs.56328 three domains, long cytoplasmic tail, 2 ESTs Hs.283443 EST Hs.5656 ESTs Hs.283456 Hs.56845 ESTs Hs.283457 MLH1 Hs.57301 ESTs, Weakly similar to similar to collagen Hs.283458 testis specific basic protein Hs.57692 [C. elegans] ESTs Hs.283459 ESTs Hs.57841 ESTs Hs.283460 Human 6Ckine Hs.57907 ESTs Hs.283462 EST Hs.5816 ESTs Hs.283463 Homo sapiens cell growth regulatory with Hs.59106 ring finger domain (CGR19) mRNA. ESTs Hs.283496 ERCC1 Hs.59544 ESTs Hs.283497 Hs.61558 ESTs Hs.283499 Homo sapiens GPI transamidase mRNA, Hs.62187 complete cds. ESTs Hs.283500 Hs.62699 ESTs, Weakly similar to ORF YDL014w Hs.283504 Hs.63913 [S. cerevisiae] ESTs, Weakly similar to S09646 collagen Hs.283505 Homo sapiens chloride intracellular channel Hs.64746 alpha 2(VI) chain precursor, medium splice 3 (CLIC3), mRNA. form - human□ [H. sapiens] ESTs Hs.283608 FANCF Hs.65328 CD42c Hs.283743 Hs.6544 tenascin XA Hs.283750 interleukin 1 receptor-like 1 Hs.66 immunoglobulin kappa variable 1D-8 Hs.283770 CD38 Hs.66052 protocadherin gamma subfamily A, 2 Hs.283801 Hs.6607 (PCDHGA2) Homo sapiens mRNA; cDNA Hs.283849 RAD54L Hs.66718 DKFZp762F0616 (from clone DKFZp762F0616) Homo sapiens clone bsmneg3-t7 Hs.283876 SCYA17 (CCL17) Hs.66742 immunoglobulin lambda light chain VJ region, (IGL) mRNA, partial cds Homo sapiens transgenic-JHD mouse #2357 Hs.283878 IL-12 Hs.673 immunoglobulin heavy chain variable region (IgG VH251) mRNA, partial cds Homo sapiens clone N97 immunoglobulin Hs.283882 Human IL-12 p40 Hs.674 heavy chain variable region mRNA, partial cds Homo sapiens clone case06H1 Hs.283924 LILRB4 Hs.67846 immunoglobulin heavy chain variable region gene, partial cds Homo sapiens HSPC077 mRNA, partial cds Hs.283929 interleukin 5 receptor, alpha Hs.68876 Homo sapiens HSPC088 mRNA, partial cds Hs.283931 Hs.6891 Homo sapiens HSPC097 mRNA, partial cds Hs.283933 Hs.69233 Homo sapiens HSPC102 mRNA, partial cds Hs.283934 FUT1 Hs.69747 Homo sapiens HSPC107 mRNA, partial cds Hs.283935 B-factor, properdin Hs.69771 CMKRL1 Hs.28408 Hs.70333 FANCA Hs.284153 Hs.71618 Homo sapiens immunoglobulin mu chain Hs.284277 RAD1 Hs.7179 antibody MO30 (IgM) mRNA, complete cds gamma-glutamyltransferase 1 Hs.284380 interleukin 19 Hs.71979 putative human HLA class II associated Hs.285013 MEK2 Hs.72241 protein I interleukin 13 receptor, alpha 1 Hs.285115 IL-7 Hs.72927 CDw131 Hs.285401 STAT2 Hs.72988 Homo sapiens VH2-D3.10-JH5b gene for Hs.287403 CD42d Hs.73734 immunoglobulin heavy chain variable region Homo sapiens cDNA: FLJ22546 fis, clone Hs.287697 MIF Hs.73798 HSI00290 Homo sapiens cDNA: FLJ23140 fis, clone Hs.287728 ECP Hs.73839 LNG09065 H. sapiens mRNA for HLA-C alpha chain Hs.287811 CPN2 Hs.73858 (Cw*1701) Homo sapiens clone ASMneg1-b1 Hs.287815 MMP8 Hs.73862 immunoglobulin lambda chain VJ region, (IGL) mRNA, partial cds Homo sapiens clone CPRF1-T2 Hs.287816 HLA-G histocompatibility antigen, class I, G Hs.73885 immunoglobulin lambda chain VJ region, (IGL) mRNA, partial cds EST Hs.287817 TNFRSF9 Hs.73895 myelin protein zero-like 1 Hs.287832 IL-4 Hs.73917 immunoglobulin lambda-like polypeptide 1 Hs.288168 HLA-DQB1 Hs.73931 cathepsinB Hs.288181 RAG1 Hs.73958 G18.2 protein Hs.288316 LAG-3 Hs.74011 ESTs Hs.288403 Hs.7402 EST Hs.288431 CD163 Hs.74076 Homo sapiens partial IGVH2 gene for Hs.288553 immunoglobulin superfamily, member 2 Hs.74115 immunoglobulin heavy chain V region, case 2, cell B 45 polymeric immunoglobulin receptor Hs.288579 CD158b Hs.74134 Human immunoglobulin heavy chain Hs.288711 Hs.7434 variable region (V4-4) gene, partial cds Human immunoglobulin heavy chain Hs.289036 TCRa Hs.74647 variable region (V4-4b) gene, partial cds Hs.28921 human immunodeficiency virus type I Hs.75063 enhancer-binding protein 2 EST Hs.289577 MLN50 Hs.75080 EST Hs.289836 lysyl hydroxylase (PLOD) Hs.75093 EST Hs.289878 TAK1 Hs.7510 GSN Hs.290070 Homo sapiens transcription factor 6-like 1 Hs.75133 (mitochondrial transcription factor 1-like) (TCF6L1) mRNA. EST, Weakly similar to unnamed protein Hs.290133 UBE2N (UBC13, BTG1) HS.75355 product [H. sapiens] EST Hs.290227 Hs.75450 ESTs Hs.290315 HSPA2 Hs.75452 EST Hs.290339 CD151 Hs.75564 EST Hs.290340 RELA Hs.75569 Hs.29055 CD122 Hs.75596 EST Hs.291125 CD14 Hs.75627 EST Hs.291126 nuclear factor erythroid 2 isoform f = basic Hs.75643 leucine zipper protein {alternatively spliced CD91 = LRP Hs.89137 C1QB Hs.8986 XPF (ERCC4) Hs.89296 superkiller viralicidic activity 2 (S. Hs.89864 cerevisiae homolog)-like Carbonic anhydrase IV Hs.89485 EST Hs.90165 CETP Hs.89538 EST Hs.90171 RAD52 Hs.89571 GTF2H3 Hs.90304 GTF2H1 Hs.89578 protein tyrosine kinase related sequence Hs.90314 Fc fragment of IgE, high affinity I, receptor Hs.897 Hs.90463 for; alpha polypeptide transcript ch138 Hs.94881 SGRF protein, Interleukin 23 p19 subunit Hs.98309 Hs.9578 XRCC1 Hs.98493 IL-9 Hs.960 Homo sapiens mRNA for KIAA0543 Hs.98507 protein, partial cds. NFATC1 Hs.96149 Hs.9893 OGG1 Hs.96398 DIR1 protein Hs.99134 Hs.96499 XRCC3 Hs.99742 NFKBIB Hs.9731 Elastase(leukocyte) Hs.99863 XAB2 (HCNP) Hs.9822 JAK3 Hs.99877 CD40 Hs.652

[0822] TABLE 3A Candidate nucleotide sequences identified using differential cDNA hybridization analysis Offset Example on Acc Accession Number Clone Start End Number UniGene Signif Clones Genbank Description 56D1 1521 1685 D00022 Hs.25 1.00E−84 1 for F1 beta subunit, complete 586E3 1227 1448 NM_001686 Hs.25 1.00E−89 1 ATP synthase, H+ transporting, mitochondrial 459F4 1484 2522 NM_002832 Hs.35 0 3 protein tyrosine phosphatase, non-receptor t 41A11 885 1128 D12614 Hs.36 1.00E−125 1 lymphotoxin (TNF-beta), complete 41G12 442 1149 D10202 Hs.46 0 1 for platelet-activating factor receptor, 98E12 1928 2652 NM_002835 Hs.62 0 1 protein tyrosine phosphatase, non-receptor t 170E1 473 1071 U13044 Hs.78 0 1 nuclear respiratory factor-2 subunit alpha mRNA, com 40C6 939 1357 D11086 Hs.84 0 1 interleukin 2 receptor gamma chain 521F9 283 1176 NM_000206 Hs.84 0 8 interleukin 2 receptor, gamma (severe combined 60A11 989 1399 L08069 Hs.94 0 2 heat shock protein, E. coli DnaJ homologue complete cd 520B9 545 1438 NM_001539 Hs.94 0 3 heat shock protein, DNAJ-like 2 (HSJ2), mRNA/ 460H9 626 1104 NM_021127 Hs.96 0 1 phorbol-12-myristate-13-acetate-induced p 127G12 651 1223 NM_004906 Hs.119 0 2 Wilms' tumor 1-associating protein (KIAA0105 586A7 438 808 NM_000971 Hs.153 0 3 ribosomal protein L7 (RPL7), mRNA/cds = (10,756 99H12 2447 4044 NM_002600 Hs.188 0 2 phosphodiesterase 4B, cAMP-specific (dunce ( 464D4 2317 2910 NM_002344 Hs.210 0 1 leukocyte tyrosine kinase (LTK), mRNA/cds = (17 464B3 10 385 NM_002515 Hs.214 1.00E−164 1 neuro-oncological ventral antigen 1 (NOVA1), 40A12 296 1153 L11695 Hs.220 0 1 activin receptor-like kinase (ALK-5) mRNA, complete 129A2 4138 4413 NM_000379 Hs.250 1.00E−155 1 xanthene dehydrogenase (XDH), mRNA 36B10 80 1475 AF068836 Hs.270 0 3 cytohesin binding protein HE mRNA, complete cd 45C11 58 1759 NM_004288 Hs.270 0 2 pleckstrin homology, Sec7 and coiled/coil dom 128C12 2555 3215 NM_000153 Hs.273 0 4 galactosylceramidase (Krabbe disease) (GALC) 67H2 259 1418 D23660 Hs.286 0 8 ribosomal protein, complete cds 151E6 624 1170 AF052124 Hs.313 0 1 clone 23810 osteopontin mRNA, complete cds/c 45A7 4 262 NM_000582 Hs.313 1.00E−136 1 secreted phosphoprotein 1 (osteopontin, bone 44C10 2288 2737 J03250 Hs.317 0 1 topoisomerase I mRNA, complete cds/ cds = (211,2508)/ 99H9 2867 3246 NM_001558 Hs.327 0 2 interleukin 10 receptor, alpha (IL10RA), mRNA 41B4 2867 3315 U00672 Hs.327 0 6 interleukin-10 receptor mRNA, complete 144E1 283 989 M26683 Hs.340 0 36 interferon gamma treatment inducible/cds = (14,1 41A12 1854 2590 X53961 Hs.347 0 1 lactoferrin/cds = (294,2429)/gb = X53961/gi = 40F1 1377 1734 U95626 Hs.395 0 1 ccr2b (ccr2), ccr2a (ccr2), ccr5 (ccr5) and cc 463H4 55 434 NM_001459 Hs.428 0 1 fms-related tyrosine kinase 3 ligand (FLT3LG) 127E1 552 1048 NM_005180 Hs.431 0 1 murine leukemia viral (bmi-1) oncogene homolo 73G12 189 1963 NM_004024 Hs.460 0 17 activating transcription factor 3 (ATF3), ATF 524A4 1361 2136 NM_004168 Hs.469 0 2 succinate dehydrogenase complex, subunit A, 41C7 1554 2097 D10925 Hs.516 0 1 HM145/cds = (22,1089)/gb = D10925/gi = 219862 588A2 48 163 NM_001032 Hs.539 1.00E−59 1 ribosomal protein S29 (RPS29), mRNA/cds = (30,2 177B4 1 1674 AF076465 Hs.550 2.00E−37 2 PhLOP2 mRNA, complete cds/cds = (5,358)/gb = AF 68G5 2 1454 M26383 Hs.624 0 17 monocyte-derived neutrophil-activating protein (M 45F10 1 1454 NM_000584 Hs.624 0 11 interleukin 8 (IL8), mRNA/cds = (74,373)/gb = N 59F11 59 1822 X68550 Hs.652 0 14 TRAP mRNA for ligand of CD40/cds = (56,841)/gb = X6 471C9 3115 3776 NM_000492 Hs.663 0 1 cystic fibrosis transmembrane conductance re 68D1 228 866 M20137 Hs.694 0 3 interleukin 3 (IL-3) mRNA, complete cds, clone pcD- SR 49H3 42 665 NM_000588 Hs.694 0 1 interleukin 3 (colony-stimulating factor, mu 147H3 110 340 BF690338 Hs.695 1.00E−102 1 602186730T1 cDNA, 3′ end/clone = IMAGE: 4299006 483E4 310 846 NM_000942 Hs.699 0 1 peptidylprolyl isomerase B (cyclophilin B) ( 522B12 349 755 NM_000788 Hs.709 0 2 deoxycytidine kinase (DCK), mRNA/cds = (159,94 331E5 1293 1470 J03634 Hs.727 9.00E−75 1 erythroid differentiation protein mRNA (EDF), comple 514D12 1164 1579 NM_004907 Hs.737 1.00E−169 3 immediate early protein (ETR101), mRNA/cds = ( 73H7 1953 3017 AJ243425 Hs.738 0 8 EGR1 gene for early growth response protein 1/ 592A8 10 454 NM_003973 Hs.738 0 5 ribosomal protein L14 (RPL14), mRNA 519A1 116 1527 NM_000801 Hs.752 1.00E−163 2 FK506-binding protein 1A (12 kD) (FKBP1A), mRN 109H11 1 1206 M60626 Hs.753 0 10 N-formylpeptide receptor (fMLP-R98) mRNA, complete 99C5 1 1175 NM_002029 Hs.753 0 25 formyl peptide receptor 1 (FPR1), mRNA 103C1 2285 2890 NM_002890 Hs.758 0 1 RAS p21 protein activator (GTPase activating p 41H4 3142 3332 NM_000419 Hs.785 1.00E−84 1 integrin, alpha 2b (platelet glycoprotein IIb 171D2 198 748 X54489 Hs.789 1.00E−132 2 melanoma growth stimulatory activity (MGSA) 458H7 2165 2818 NM_001656 Hs.792 0 1 ADP-ribosylation factor domain protein 1, 64 62B3 833 1241 M60278 Hs.799 0 2 heparin-binding EGF-like growth factor mRNA, complet 53G4 1299 2166 AK001364 Hs.808 0 6 FLJ10502 fis, clone NT2RP2000414, highly 597F3 1136 1797 NM_004966 Hs.808 0 2 heterogeneous nuclear ribonucleoprotein F ( 143F7 575 985 M74525 Hs.811 0 3 HHR6B (yeast RAD 6 homologue) mRNA, complete 518H8 580 974 NM_003337 Hs.811 0 1 ubiquitin-conjugating enzyme E2B (RAD6 homol 45G8 277 833 NM_002121 Hs.814 0 1 major histocompatibility complex, class II, 41H11 719 1534 NM_005191 Hs.838 0 1 CD80 antigen (CD28 antigen ligand 1, B7-1 antig 41G1 117 557 U31120 Hs.845 0 1 interleukin-13 (IL-13) precursor gene, complete cds 75E1 693 862 J05272 Hs.850 2.00E−58 4 IMP dehydrogenase type 1 mRNA complete 129B11 3361 3883 L25851 Hs.851 0 1 integrin alpha E precursor, mRNA, complete cds 481E9 3361 3742 NM_002208 Hs.851 1.00E−173 1 integrin, alpha E (antigen CD103, human mucosa 71G7 1 1193 NM_000619 Hs.856 0 111 interferon, gamma (IFNG), mRNA/cds = (108,608) 75H5 1 1193 X13274 Hs.856 0 314 interferon IFN-gamma/cds = (108,608)/gb = X13 525B12 672 894 NM_002341 Hs.890 1.00E−121 1 lymphotoxin beta (TNF superfamily, member 3) 40E8 75 999 AL121985 Hs.901 0 6 DNA sequence RP11-404F10 on chromosome 1q2 48H4 680 933 NM_001778 Hs.901 1.00E−130 2 CD48 antigen (B-cell membrane protein) (CD48) 179G8 1652 2181 AL163285 Hs.926 0 1 chromosome 21 segment HS21C085 48G11 1049 2092 NM_002463 Hs.926 0 3 myxovirus (influenza) resistance 2, homolog o 110B12 209 1734 M32011 Hs.949 0 8 neutrophil oxidase factor (p67-phox) mRNA, complete 99C9 207 1733 NM_000433 Hs.949 0 11 neutrophil cytosolic factor 2 (65 kD, chronic g 125D2 958 1645 NM_004645 Hs.966 0 1 coilin (COIL), mRNA/cds = (22,1752)/gb = NM_004 458C1 1649 2285 NM_006025 Hs.997 0 1 protease, serine, 22 (P11), mRNA/cds = (154,126 40H11 621 864 L26953 Hs.1010 1.00E−135 1 chromosomal protein mRNA, complete cds/cds = (7 116D10 513 858 NM_002932 Hs.1010 0 1 regulator of mitotic spindle assembly 1 (RMSA 40G11 1565 2151 M31452 Hs.1012 0 1 proline-rich protein (PRP) mRNA, complete 192A6 321 908 NM_000284 Hs.1023 0 1 pyruvate dehydrogenase (lipoamide) alpha 1 ( 460H11 2158 2402 NM_004762 Hs.1050 2.00E−91 1 pleckstrin homology, Sec7 and coiled/coil dom 41F12 291 565 M57888 Hs.1051 1.00E−112 1 (clone lambda B34) cytotoxic T-lymphocyte-associate 41A5 1311 1852 M55654 Hs.1100 0 1 TATA-binding protein mRNA, complete 461D7 999 1277 NM_002698 Hs.1101 1.00E−92 1 POU domain, class 2, transcription factor 2 (P 597H9 1083 1224 NM_000660 Hs.1103 3.00E−75 1 transforming growth factor, beta 1 (TGFB1), mR 40B5 1433 2010 X02812 Hs.1103 0 1 transforming growth factor-beta (TGF-beta) 106A10 1977 2294 M73047 Hs.1117 1.00E−176 1 tripeptidyl peptidase II mRNA, complete cds/c 165E8 4273 4582 NM_003291 Hs.1117 1.00E−173 1 tripeptidyl peptidase II (TPP2), mRNA/cds = (23 63G12 1114 2339 D49728 Hs.1119 0 7 NAK1 mRNA for DNA binding protein, complete 45B10 1317 1857 NM_002135 Hs.1119 0 1 nuclear receptor subfamily 4, group A, member 37H3 568 783 M24069 Hs.1139 1.00E−119 1 DNA-binding protein A (dbpA) gene, 3′ end 476F9 209 608 NM_000174 Hs.1144 0 1 glycoprotein IX (platelet) (GP9), mRNA/cds = ( 43A10 1105 1357 U15085 Hs.1162 3.00E−41 1 HLA-DMB mRNA, complete cds 139D6 1345 1680 L11329 Hs.1183 1.00E−102 1 protein tyrosine phosphatase (PAC-1) mRNA, co 134B12 1233 1675 NM_004418 Hs.1183 0 1 dual specificity phosphatase 2 (DUSP2), mRNA 58F1 17 341 NM_002157 Hs.1197 0 1 heat shock 10 kD protein 1 (chaperonin 10) (HSP 158G5 20 341 U07550 Hs.1197 1.00E−180 2 chaperonin 10 mRNA, complete cds 167C8 813 1453 NM_000022 Hs.1217 0 4 adenosine deaminase (ADA), mRNA/cds = (95,1186 179H1 730 1452 X02994 Hs.1217 0 6 adenosine deaminase (adenosine aminohydrola 40E10 594 792 M38690 Hs.1244 1.00E−109 1 CD9 antigen mRNA, complete cds 41C5 1280 1438 AK024951 Hs.1279 2.00E−80 1 FLJ21298 fis, clone COL02040, highly sim 40E3 1002 1735 NM_000065 Hs.1282 0 1 complement component 6 (C6) mRNA/cd 40A11 1638 1821 K02766 Hs.1290 3.00E−98 1 complement component C9 mRNA, complete 40B12 4639 5215 NM_007289 Hs.1298 0 1 membrane metallo-endopeptidase (neutral end 41G2 1576 1870 M28825 Hs.1309 1.00E−115 1 thymocyte antigen CD1a mRNA, complete cds 41F8 1171 1551 AX023365 Hs.1349 0 1 Sequence 36 from Patent WO0006605 40E1 673 1147 M30142 Hs.1369 0 1 decay-accelerating factor mRNA, complete cds 118B12 1129 1719 NM_000574 Hs.1369 0 1 decay accelerating factor for complement (CD5 75F8 830 2979 NM_000399 Hs.1395 0 48 early growth response 2 (Krox-20 (Drosophila) 41F11 973 1428 M15059 Hs.1416 0 1 Fc-epsilon receptor (IgE receptor) mRNA, complete cd 110G12 1931 2071 AL031729 Hs.1422 2.00E−70 1 DNA seq RP1-159A19 on chromosome 1p36 113D10 1718 2066 NM_005248 Hs.1422 6.00E−76 2 Gardner-Rasheed feline sarcoma viral (v-fgr) 477C2 3292 3842 NM_000152 Hs.1437 0 1 glucosidase, alpha; acid (Pompe disease, glyc 124D1 795 1127 NM_000167 Hs.1466 0 1 glycerol kinase (GK), mRNA/cds = (66,1640)/gb 41B9 2231 2447 J03171 Hs.1513 1.00E−108 1 interferon-alpha receptor (HuIFN-alpha-Rec) mRNA, 99F7 927 1889 NM_014882 Hs.1528 0 2 KIAA0053 gene product (KIAA0053), mRNA/cds = ( 469G9 1220 1507 NM_005082 Hs.1579 1.00E−117 1 zinc finger protein 147 (estrogen-responsive 195B7 190 1801 BC002971 Hs.1600 0 3 clone IMAGE: 3543711, mRNA, partial cds/cds = 195F10 3676 3856 NM_000110 Hs.1602 1.00E−85 1 dihydropyrimidine dehydrogenase (DPYD), mRN 129E7 648 1827 L08176 Hs.1652 0 2 Epstein-Barr virus induced G-protein coupled recepto 478H5 1839 2050 NM_002056 Hs.1674 7.00E−79 1 glutamine-fructose-6-phosphate transaminas 39H1 436 865 L35249 Hs.1697 0 1 vacuolar H+-ATPase Mr 56,000 subunit (HO57) mR 183H8 972 1183 NM_001693 Hs.1697 1.00E−106 1 ATPase, H+ transporting, lysosomal (vacuolar 481A4 1594 1785 NM_001420 Hs.1701 2.00E−79 1 ELAV (embryonic lethal, abnormal vision, Dros 40B3 3846 4009 L39064 Hs.1702 4.00E−70 1 interleukin 9 receptor precursor (IL9R) gene, 176G8 1033 1400 NM_006084 Hs.1706 0 1 interferon-stimulated transcription factor 589C11 1 1347 NM_005998 Hs.1708 0 2 chaperonin containing TCP1, subunit 3 (gamma) 70H5 1 494 X74801 Hs.1708 0 1 Cctg mRNA for chaperonin/cds = (0,1634)/gb = X7480 460C12 3310 3809 NM_012089 Hs.1710 0 1 ATP-binding cassette, sub-family B (MDR/TAP), 41D5 484 1862 M28983 Hs.1722 0 3 interleukin 1 alpha (IL 1) mRNA, complete cds/ 119E8 493 904 NM_000575 Hs.1722 1.00E−151 2 interleukin 1, alpha (IL1A), mRNA/cds = (36,851 479E11 5 268 NM_000417 Hs.1724 1.00E−145 1 interleukin 2 receptor, alpha (IL2RA), mRNA/ 62C8 85 1887 X01057 Hs.1724 0 2 interleukin-2 receptor/cds = (180,998)/gb = X 466A3 2166 2675 NM_000889 Hs.1741 0 1 integrin, beta 7 (ITGB7), mRNA/cds = (151,2547) 107A4 4960 5610 L33075 Hs.1742 0 1 ras GTPase-activating-like protein (IQGAP1) 189A5 4318 7450 NM_003870 Hs.1742 0 3 IQ motif containing GTPase activating protein 597D1 1230 1737 NM_005356 Hs.1765 1.00E−127 5 lymphocyte-specific protein tyrosine kinase 41C10 1057 1602 J04142 Hs.1799 0 1 (lambda-gt11ht-5) MHC class I antigen-like gl 104H1 1854 2023 L06175 Hs.1845 4.00E−54 1 P5-1 mRNA, complete cds/cds = (304,735)/gb = L06 98F7 34 2041 NM_006674 Hs.1845 4.00E−63 5 MHC class I region ORF (P5-1),/cds = (304,735)/ 104F1 1390 1756 NM_002436 Hs.1861 0 2 membrane protein, palmitoylated 1 (55 kD) (MPP 171F7 1760 2192 M55284 Hs.1880 0 1 protein kinase C-L (PRKCL) mRNA, complete cds 134B2 123 1182 NM_002727 Hs.1908 0 10 proteoglycan 1, secretory granule (PRG1), mRN 61C11 126 902 X17042 Hs.1908 0 11 hematopoetic proteoglycan core protein/cds 458G1 1 475 NM_001885 Hs.1940 0 1 crystallin, alpha B (CRYAB), mRNA 520E10 71 343 NM_001024 Hs.1948 1.00E−142 3 ribosomal protein S21 (RPS21), mRNA 459D6 2435 3055 NM_001761 Hs.1973 0 1 cyclin F (CCNF), mRNA/cds = (43,2403) 41H3 184 1620 NM_006139 Hs.1987 0 2 CD28 antigen (Tp44) (CD28), mRNA/cds = (222,884 71C5 721 1329 NM_000639 Hs.2007 0 2 tumor necrosis factor (ligand) superfamily, m 73C1 721 1603 X89102 Hs.2007 0 8 fasligand/cds = (157,1002) 135G3 940 1352 NM_002852 Hs.2050 6.00E−96 1 pentaxin-related gene, rapidly induced by IL 44A10 1562 1748 M58028 Hs.2055 7.00E−69 1 ubiquitin-activating enzyme E1 (UBE1) mRNA, complete 155G5 973 2207 AL133415 Hs.2064 0 7 DNA sequence from clone RP11-124N14 on chromosome 10. 599H7 48 3022 AK025306 Hs.2083 0 12 cDNA: FLJ21653 fis, clone COL08586, 71H1 1598 2163 NM_004419 Hs.2128 0 5 dual specificity phosphatase 5 (DUSP5), mRNA 69H7 1595 2161 U15932 Hs.2128 0 11 dual-specificity protein phosphatase mRNA, complete 458C4 1928 2356 NM_005658 Hs.2134 0 1 TNF receptor-associated factor 1 (TRAF1), mRN 192E11 6 414 NM_002704 Hs.2164 0 1 pro-platelet basic protein (includes platele 40D12 1935 2645 M58597 Hs.2173 0 2 ELAM-1 ligand fucosyltransferase (ELFT) mRNA, comple 40E5 2834 3024 M59820 Hs.2175 1.00E−104 1 granulocyte colony-stimulating factor receptor (CSF 482D8 2521 2943 NM_000760 Hs.2175 0 2 colony stimulating factor 3 receptor (granuloc 60H6 918 1723 AF119850 Hs.2186 0 6 PRO1608 mRNA, complete cds/cds = (1221,2174)/ 597F11 99 1267 NM_001404 Hs.2186 0 29 eukaryotic translation elongation factor 1 g 595G4 6 570 L40410 Hs.2210 0 1 thyroid receptor interactor (TRIP3) mRNA, 3′ 41H12 970 1353 X03656 Hs.2233 0 1 granulocyte colony-stimulating factor (G-C 461A9 287 730 Z29067 Hs.2236 0 1 H. sapiens nek3 mRNA for protein kinase 493E11 212 608 NM_000879 Hs.2247 1.00E−141 2 interleukin 5 (colony-stimulating factor, eo 150B5 363 815 X04688 Hs.2247 0 1 T-cell replacing factor (interleukin-5)/cd 461E12 255 342 NM_001565 Hs.2248 8.00E−34 1 small inducible cytokine subfamily B (Cys-X-C 129A8 1790 1970 NM_002309 Hs.2250 2.00E−94 1 leukemia inhibitory factor (cholinergic diff 40G10 2152 2560 X04481 Hs.2253 0 1 complement component C2/cds = (36,2294)/gb = X 479A2 95 610 NM_000073 Hs.2259 0 2 CD3G antigen, gamma polypeptide (TiT3 complex 592G6 783 1163 NM_002950 Hs.2280 0 2 ribophorin I (RPN1), mRNA/cds = (137,1960)/gb 459G11 673 1316 NM_004931 Hs.2299 0 1 CD8 antigen, beta polypeptide 1 (p37) (CD8B1), 129B8 1159 1316 X13444 Hs.2299 1.00E−74 1 CD8 beta-chain glycoprotein (CD8 beta. 1)/cd 467F12 2928 3239 NM_000346 Hs.2316 3.00E−85 1 SRY (sex determining region Y)-box 9 (campomeli 44A6 1506 1629 U23028 Hs.2437 7.00E−62 1 eukaryotic initiation factor 2B-epsilon mRNA, partia 127B8 1814 2405 NM_003816 Hs.2442 0 1 a disintegrin and metalloproteinase domain 9 36G6 1361 2019 D13645 Hs.2471 0 2 KIAA0020 gene, complete cds/cds = (418,1944) 458D6 396 961 NM_021966 Hs.2484 0 1 T-cell leukemia/lymphoma 1A (TCL1A), mRNA/c 124G1 966 1473 NM_005565 Hs.2488 0 1 lymphocyte cytosolic protein 2 (SH2 domain-con 107A6 1962 2031 U20158 Hs.2488 2.00E−22 1 76 kDa tyrosine phosphoprotein SLP-76 mRNA, complete 592E12 2175 2458 NM_002741 Hs.2499 1.00E−158 1 protein kinase C-like 1 (PRKCL1), mRNA/cds = (8 106A11 1455 2219 U34252 Hs.2533 0 2 gamma-aminobutyraldehyde dehydrogenase mRNA, compl 40F8 2201 2694 NM_003032 Hs.2554 0 1 sialyltransferase 1 (beta-galactoside alpha- 460G6 565 2052 NM_002094 Hs.2707 0 2 G1 to S phase transition 1 mRNA 60G5 35 184 X92518 Hs.2726 7.00E−27 2 HMGI-C protein/cds = UNKNOWN 461F10 1034 1520 NM_002145 Hs.2733 0 2 homeo box B2 (HOXB2), mRNA 69G2 408 1369 AK026515 Hs.2795 0 4 FLJ22862 fis, clone KAT01966, highly sim 71D8 13 541 NM_005566 Hs.2795 0 1 lactate dehydrogenase A (LDHA), mRNA/cds = (97 40H12 4119 4807 NM_002310 Hs.2798 0 1 leukemia inhibitory factor receptor (LIFR) mR 189C12 696 1287 NM_006196 Hs.2853 0 2 poly(rC)-binding protein 1 (PCBP1), mRNA/cds 111E8 1298 1938 NM_003566 Hs.2864 0 1 early endosome antigen 1, 162 kD (EEA1), mRNA/ 127F12 34 248 NM_001033 Hs.2934 1.00E−109 1 ribonucleotide reductase M1 polypeptide (RRM 74G6 11 241 AK023088 Hs.2953 1.00E−128 38 FLJ13026 fis, clone NT2RP3000968, modera 128D8 178 518 NM_000117 Hs.2985 1.00E−173 1 emerin (Emery-Dreifuss muscular dystrophy) ( 169G7 2406 3112 AL136593 Hs.3059 0 1 DKFZp761K102 (from clone DKFZp761K1 193A3 2405 3017 NM_016451 Hs.3059 0 5 coatomer protein complex, subunit beta (COPB) 53F12 486 1007 L11066 Hs.3069 0 3 sequence/cds = UNKNOWN/gb = L11066/gi = 307322/u 71E8 1623 2131 NM_004134 Hs.3069 0 2 heat shock 70 kD protein 9B (mortalin-2) (HSPA9 458A5 2236 2874 NM_014877 Hs.3085 0 1 KIAA0054 gene product; Helicase (KIAA0054), m 69E8 1752 1916 D31884 Hs.3094 7.00E−68 1 KIAA0063 gene, complete cds/cds = (279,887)/ 66B3 251 1590 D32053 Hs.3100 0 2 for Lysyl tRNA Synthetase, complete cds/ 458E1 1645 1964 NM_001666 Hs.3109 1.00E−178 1 Rho GTPase activating protein 4 (ARHGAP4), mRN 331D8 2882 3585 U26710 Hs.3144 0 1 cbl-b mRNA, complete cds/cds = (322,3270)/ gb = U26710 73D9 1 613 AL031736 Hs.3195 0 18 DNA sequence clone 738P11 on chromosome 1q24.1-2 58B1 1 607 NM_002995 Hs.3195 0 17 small inducible cytokine subfamily C, member 98F11 145 588 NM_003172 Hs.3196 0 1 surfeit 1 (SURF1), mRNA/cds = (14,916)/gb = NM_(—) 124E9 1258 2414 NM_007318 Hs.3260 0 2 presenilin 1 (Alzheimer disease 3) (PSEN1), tr 64G7 1040 1569 NM_002155 Hs.3268 0 1 heat shock 70 kD protein 6 (HSP70B') (HSPA6), mR 36D4 1116 1917 X51757 Hs.3268 0 4 heat-shock protein HSP70B' gene/cds = (0,1931)/ gb = X5 39H11 1 507 BE895166 Hs.3297 1.00E−152 4 601436095F1 cDNA, 5′ end/clone = IMAGE: 3921239 103G4 16 540 NM_002954 Hs.3297 0 4 ribosomal protein S27a (RPS27A), mRNA/cds = (3 127H7 1391 1806 AB037752 Hs.3355 0 1 mRNA for KIAA1331 protein, partial cds/cds = (0 107D3 1932 2517 AK027064 Hs.3382 0 1 FLJ23411 fis, clone HEP20452, highly sim 121B3 1270 3667 NM_005134 Hs.3382 0 4 protein phosphatase 4, regulatory subunit 1 ( 58H1 104 573 NM_001122 Hs.3416 0 6 adipose differentiation-related protein (AD 75G1 104 1314 X97324 Hs.3416 0 16 adipophilin/cds = (0,1313)/gb = X97324/ 182A4 147 334 NM_001867 Hs.3462 1.00E−102 1 cytochrome c oxidase subunit VIIc (COX7C), mRN 134D7 36 270 NM_001025 Hs.3463 1.00E−127 3 ribosomal protein S23 (RPS23), mRNA/cds = (13,4 192B10 129 1135 AL357536 Hs.3576 0 3 mRNA full length insert cDNA clone EUROIMAGE 37 112G12 56 687 NM_003001 Hs.3577 0 1 succinate dehydrogenase complex, subunit C, 526H6 143 537 BF666961 Hs.3585 0 1 602121608F1 cDNA, 5′ end/clone = IMAGE: 4278768 599F10 2098 2351 NM_004834 Hs.3628 1.00E−118 2 mitogen-activated protein kinase kinase kina 594F1 239 1321 NM_001551 Hs.3631 0 4 immunoglobulin (CD79A) binding protein 1 (IG 463E7 911 1033 AL359940 Hs.3640 1.00E−63 1 mRNA; cDNA DKFZp762P1915 (from clone DKFZp762P 182A9 657 1179 AL050268 Hs.3642 0 2 mRNA; cDNA DKFZp564B163 (from clone DKFZp564B1 38B4 257 568 AB034205 Hs.3688 1.00E−151 3 for cisplatin resistance-associated ove 185H6 769 995 NM_006003 Hs.3712 2.00E−88 1 ubiquinol-cytochrome c reductase, Rieske iro 587A1 716 1609 NM_006007 Hs.3776 0 2 zinc finger protein 216 (ZNF216), mRNA/cds = (2 473B5 46 531 NM_021633 Hs.3826 0 1 kelch-like protein C3IP1 (C3IP1), mRNA/cds = ( 194G5 2456 2984 AB002366 Hs.3852 0 1 mRNA for KIAA0368 gene, partial cds/cds = (0,4327)/ gb 589B4 526 1337 NM_000310 Hs.3873 0 3 palmitoyl-protein thioesterase 1 (ceroid-lip 515A10 1618 2130 NM_002267 Hs.3886 0 1 karyopherin alpha 3 (importin alpha 4) (KPNA3) 186A8 1160 1632 NM_002807 Hs.3887 0 1 proteasome (prosome, macropain) 26S subunit, 102F7 4226 4531 AB023163 Hs.4014 1.00E−158 1 for KIAA0946 protein, partial cds/cds = (0 50B8 1 166 AL117595 Hs.4055 3.00E−89 2 cDNA DKFZp564C2063 (from clone DKFZp564 473A10 1064 1709 NM_006582 Hs.4069 0 1 glucocorticoid modulatory element binding pr 524A12 2863 3386 AL136105 Hs.4082 0 1 DNA sequence from clone RP4-670F13 on chromosome 1q42 525E1 521 974 BC002435 Hs.4096 0 1 clone IMAGE: 3346451, mRNA, partial cds/cds = t-complex 163G12 1130 1630 X52882 Hs.4112 0 6 polypeptide 1 gene/cds = (21,1691)/ gb = X528 176A7 515 892 BC000687 Hs.4147 0 1 translocating chain-associating membrane p 185B5 3480 3707 AB023216 Hs.4278 1.00E−86 1 mRNA for KIAA0999 protein, partial cds/cds = (0 154E12 1731 2531 AF079566 Hs.4311 0 2 ubiquitin-like protein activating enzyme (UB 331C9 1595 1966 AF067008 Hs.4747 0 1 dyskerin (DKC1) mRNA, complete cds/cds = (60,16 182C8 1676 1966 NM_001363 Hs.4747 1.00E−148 2 dyskeratosis congenita 1, dyskerin (DKC1), mR 178C4 1623 2162 AL136610 Hs.4750 0 3 mRNA; cDNA DKFZp564K0822 (from clone DKFZp564K 107F9 3857 4266 AB032976 Hs.4779 0 1 for KIAA1150 protein, partial cds/cds = (0 191C11 1945 2618 AF240468 Hs.4788 0 3 nicastrin mRNA, complete cds/cds = (142,2271) 143G11 869 2076 AK022974 Hs.4859 0 2 FLJ12912 fis, clone NT2RP2004476, highly 127H11 977 1666 NM_020307 Hs.4859 0 1 cyclin L ania-6a (LOC57018), mRNA/cds = (54,163 479A11 215 544 AK001942 Hs.4863 1.00E−173 1 cDNA FLJ11080 fis, clone PLACE1005181/cds = UN 73C5 2314 2851 AF105366 Hs.4876 0 1 K-CI cotransporter KCC3a mRNA, alternatively 525F9 1059 1764 NM_006513 Hs.4888 0 3 seryl-tRNA synthetase (SARS), mRNA/cds = (75,1 114D8 931 1061 Z24724 Hs.4934 4.00E−52 1 H. sapiens polyA site DNA/cds = UNKNOWN/ gb = Z24724/gi = 50503 587C10 1104 1343 NM_006787 Hs.4943 3.00E−94 1 hepatocellular carcinoma associated protein; 174F12 1749 2291 NM_018107 Hs.4997 0 3 hypothetical protein FLJ10482 (FLJ10482), mR 514C11 899 1489 AK021776 Hs.5019 0 1 cDNA FLJ11714 fis, clone HEMBA1005219, weakly 126H9 25 397 BE379724 Hs.5027 1.00E−118 1 601159415T1 cDNA, 3′ end/clone = IMAGE: 3511107 599B5 801 970 NM_017840 Hs.5080 5.00E−73 1 hypothetical protein FLJ20484 (FLJ20484), mR 47E5 4 720 AL034553 Hs.5085 0 2 DNA sequence from clone 914P20 on chromosome 20q13.13 122C11 492 860 NM_003859 Hs.5085 0 1 dolichyl-phosphate mannosyltransferase pol 116H6 1644 2902 NM_014868 Hs.5094 1.00E−102 2 ring finger protein 10 (RNF10), mRNA/cds = (698, 187G7 700 1268 NM_004710 Hs.5097 0 1 synaptogyrin 2 (SYNGR2), mRNA/cds = (29,703)/ 174G3 240 500 NM_003746 Hs.5120 1.00E−144 4 dynein, cytoplasmic, light polypeptide (PIN) 145B6 199 695 BE539096 Hs.5122 1.00E−165 2 601061641F1 cDNA, 5′ end/clone = IMAGE: 3447850 486C1 1 529 BG028906 Hs.5122 0 2 602293015F1 cDNA, 5′ end/clone = IMAGE: 4387778 69F6 62 455 BF307213 Hs.5174 0 1 601891365F1 cDNA, 5′ end/clone = IMAGE: 4136752 583F4 82 477 NM_001021 Hs.5174 0 1 ribosomal protein S17 (RPS17), mRNA/cds = (25,4 74C4 1955 2373 AK025367 Hs.5181 1.00E−179 1 FLJ21714 fis, clone COL10256, highly sim 73E12 702 987 AL109840 Hs.5184 1.00E−161 1 DNA sequence from clone RP4-543J19 on chromosome 20 C 180G4 26 639 NM_002212 Hs.5215 0 2 integrin beta 4 binding protein (ITGB4BP), mRN 98F1 17 636 NM_014165 Hs.5232 0 5 HSPC125 protein (HSPC125), mRNA/cds = (79,606) 525A8 479 992 NM_006698 Hs.5300 0 1 bladder cancer associated protein (BLCAP), mR 99C1 19 507 NM_003333 Hs.5308 0 3 ubiquitin A-52 residue ribosomal protein fusi 172D11 714 1805 NM_005721 Hs.5321 0 3 ARP3 (actin-related protein 3, yeast) homolog 591F6 475 970 NM_015702 Hs.5324 0 1 hypothetical protein (CL25022), mRNA/cds = (1 68H8 724 1190 NM_014106 Hs.5327 0 2 PRO1914 protein (PRO1914), mRNA/cds = (1222,14 194D12 2128 2499 AB018305 Hs.5378 0 1 mRNA for KIAA0762 protein, partial cds/cds = (0 501G11 823 1322 NM_020122 Hs.5392 0 3 potassium channel modulatory factor (DKFZP434 74B4 502 1257 AF008442 Hs.5409 0 7 RNA polymerase I subunit hRPA39 mRNA, complete 134H7 543 916 NM_004875 Hs.5409 0 1 RNA polymerase I subunit (RPA40), mRNA/cds = (2 168A3 1909 2379 AF090891 Hs.5437 0 1 clone HQ0105 PRO0105 mRNA, complete cds/cds = ( 145C10 2375 2564 AF016270 Hs.5464 1.00E−104 2 thyroid hormone receptor coactivating protein 587H7 1857 2563 NM_006696 Hs.5464 0 4 thyroid hormone receptor coactivating protein 183D10 1199 1347 NM_006495 Hs.5509 9.00E−40 1 ecotropic viral integration site 2B (EVI2B), m 181D7 1385 1752 AK002173 Hs.5518 0 1 cDNA FLJ11311 fis, clone PLACE1010102/cds = UNK 173B1 1 642 NM_003315 Hs.5542 0 2 tetratricopeptide repeat domain 2 (TTC2), mRN 120F8 1782 2430 AF157323 Hs.5548 0 2 p45SKP2-like protein mRNA, complete cds/cds = ribosomal 464H2 46 357 NM_000998 Hs.5566 1.00E−163 2 protein L37a (RPL37A), mRNA/cds = (1 75F5 1252 2194 AK027192 Hs.5615 0 9 FLJ23539 fis, clone LNG08101, highly sim 56E8 27 205 AI570531 Hs.5637 2.00E−95 1 tm77g04.x1 cDNA, 3′ end/clone = IMAGE: 2164182 524G2 2 926 NM_006098 Hs.5662 0 9 guanine nucleotide binding protein (G protein 39F6 2311 2902 AB014579 Hs.5734 0 1 for KIAA0679 protein, partial cds/cds = (0 587G2 2883 4606 NM_012215 Hs.5734 0 11 meningioma expressed antigen 5 (hyaluronidase 469E5 5041 5393 NM_014864 Hs.5737 3.00E−75 2 KIAA0475 gene product (KIAA0475), mRNA/cds = ( 120H3 1022 1553 NM_016230 Hs.5741 0 1 flavohemoprotein b5+b5R (LOC51167), mRNA/cd 63H8 1049 1507 AK025729 Hs.5798 0 1 FLJ22076 fis, clone HEP12479, highly sim 590D9 1015 1470 NM_015946 Hs.5798 0 1 pelota (Drosophila) homolog (PELO), mRNA/cds 102E3 665 1027 AK000474 Hs.5811 0 1 FLJ20467 fis, clone KAT06638/cds = (360,77 187E5 665 1028 NM_017835 Hs.5811 0 1 chromosome 21 open reading frame 59 (C21ORF59), 39F9 1402 1728 AK025773 Hs.5822 0 3 FLJ22120 fis, clone HEP18874/cds = UNKNOW 39E12 1064 1843 AF208844 Hs.5862 0 1 BM-002 mRNA, complete cds/cds = (39,296)/gb = A 173H9 906 1684 NM_016090 Hs.5887 0 2 RNA binding motif protein 7 (LOC51120), mRNA/ 120E8 1702 2055 NM_012179 Hs.5912 1.00E−146 1 F-box only protein 7 (FBXO7), mRNA/cds = (205,17 195D1 1309 2656 AK025620 Hs.5985 0 8 cDNA: FLJ21967 fis, clone HEP05652, highly sim 116A6 1451 2073 AK024941 Hs.6019 0 1 cDNA: FLJ21288 fis, clone COL01927/cds = UNKNOW 113F9 1232 1598 NM_002896 Hs.6106 1.00E−126 1 RNA binding motif protein 4 (RBM4), mRNA/cds = ( 520H1 563 1007 NM_018285 Hs.6118 0 2 hypothetical protein FLJ10968 (FLJ10968), mR 180H12 5224 5568 AF315591 Hs.6151 1.00E−135 1 Pumilio 2 (PUMH2) mRNA, complete cds/cds = (23,3 185A7 612 1558 NM_016001 Hs.6153 0 6 CGI-48 protein (LOC51096), mRNA/cds = (107,167 595G2 3207 4752 Z97056 Hs.6179 0 10 DNA seq from clone RP3-434P1 on chromosome 22 592B11 234 4611 AI745230 Hs.6187 1.00E−130 6 wg10e05.x1 cDNA, 3′ end/clone = IMAGE: 2364704 590F2 994 1625 NM_004517 Hs.6196 0 3 integrin-linked kinase (ILK), mRNA/cds = (156, 188A3 1550 2929 M61906 Hs.6241 0 3 P13-kinase associated p85 mRNA sequence 103C12 502 1129 AF246238 Hs.6289 0 1 HT027 mRNA, complete cds/cds = (260,784)/gb = A 100C2 804 1111 AK024539 Hs.6289 1.00E−122 1 FLJ20886 fis, clone ADKA03257/cds = (359, 480A11 1149 1242 AB032977 Hs.6298 1.00E−46 1 mRNA for KIAA1151 protein, partial cds/cds = (0 473C8 3944 4149 NM_014859 Hs.6336 1.00E−106 1 KIAA0672 gene product (KIAA0672), mRNA/cds = ( 125A10 1293 1766 NM_006791 Hs.6353 0 1 MORF-related gene 15 (MRG15), mRNA/cds = (131,1 182F5 143 2118 NM_018471 Hs.6375 0 3 uncharacterized hypothalamus protein HT010 587E8 398 2287 NM_016289 Hs.6406 0 7 MO25 protein (LOC51719), mRNA/cds = (53,1078) 135C3 2519 3084 AF130110 Hs.6456 0 2 clone FLB6303 PRO1633 mRNA, complete cds/cds = DNA 178B5 1744 2425 AL117352 Hs.6523 0 2 seq from clone RP5-876B10 on chromosome 1q42 522F10 2392 2591 NM_001183 Hs.6551 1.00E−110 2 ATPase, H+ transporting, lysosomal (vacuolar 595C4 1676 2197 NM_021008 Hs.6574 0 4 suppressin (nuclear deformed epidermal autor 481F3 745 904 AL117565 Hs.6607 9.00E−82 1 mRNA; cDNA DKFZp566F164 (from clone DKFZp566F1 124A3 1046 1575 NM_017792 Hs.6631 0 1 hypothetical protein FLJ20373 (FLJ20373), mR 177F11 1966 2281 AB046844 Hs.6639 1.00E−152 1 for KIAA1624 protein, partial cds/cds = (0 521G7 4600 5210 NM_014856 Hs.6684 0 2 KIAA0476 gene product (KIAA0476), mRNA/cds = ( 54C6 265 756 AB037801 Hs.6685 0 1 for KIAA1380 protein, partial cds/cds = (0 75F7 95 3507 AB014560 Hs.6727 0 4 for KIAA0660 protein, complete cds/cds = ( 477H12 2 457 BF976590 Hs.6749 0 1 602244267F1 cDNA, 5′ end/clone = IMAGE: 4335353 60A1 1028 1307 AB026908 Hs.6790 1.00E−155 1 for microvascular endothelial differenti 100G9 341 454 BE875609 Hs.6820 2.00E−58 1 601487048F1 cDNA, 5′ end/clone = IMAGE: 3889762 184F7 1259 1633 AF056717 Hs.6856 0 5 ash2l2 (ASH2L2) mRNA, complete cds/cds = (295,1 195E7 1250 1711 NM_004674 Hs.6856 0 3 ash2 (absent, small, or homeotic, Drosophila, 135F11 328 600 NM_020188 Hs.6879 1.00E−151 1 DC13 protein (DC13), mRNA/cds = (175,414)/gb = DKFZP434D156 172G2 1477 1782 NM_015530 Hs.6880 1.00E−169 1 protein (DKFZP434D156), mRNA/c 483G5 3712 3947 AL031681 Hs.6891 3.00E−72 1 DNA sequence from clone 862K6 on chromosome 20q12-13.1 184B1 1 622 AF006086 Hs.6895 0 3 Arp2/3 protein complex subunit p21-Arc (ARC21 599C12 1 622 NM_005719 Hs.6895 0 24 actin related protein 2/3 complex, subunit 3 ( 43A1 2111 2312 AF037204 Hs.6900 9.00E−78 1 RING zinc finger protein (RZF) mRNA, complete c 105F6 638 1209 AK026850 Hs.6906 0 1 FLJ23197 fis, clone REC00917/cds = UNKNOW 178G10 5939 6469 AJ238403 Hs.6947 0 1 mRNA for huntingtin interacting protein 1/cd 72A2 178 2992 AF001542 Hs.6975 0 9 AF001542/clone = alpha_est218/52C1/gb = FLJ12506 37F2 1757 2397 AK022568 Hs.7010 0 1 fis, clone NT2RM2001700, weakly 598D3 1153 1299 NM_004637 Hs.7016 8.00E−56 1 RAB7, member RAS oncogene family (RAB7), mRNA 524C11 5542 5678 AB033034 Hs.7041 3.00E−72 1 mRNA for KIAA1208 protein, partial cds/cds = (2 109E10 452 1093 AF104921 Hs.7043 0 1 succinyl-CoA synthetase alpha subunit (SUCLA1 595F7 449 1150 NM_003849 Hs.7043 0 2 succinate-CoA ligase, GDP-forming, alpha sub 104H2 644 992 NM_020194 Hs.7045 1.00E−156 1 GL004 protein (GL004), mRNA/cds = (72,728)/gb 155C1 3322 3779 AK024478 Hs.7049 0 2 FLJ00071 protein, partial cds/cds = (3 473B1 3029 3439 AB051492 Hs.7076 1.00E−152 1 mRNA for KIAA1705 protein, partial cds/cds = (1 125E3 3612 3948 AL390127 Hs.7104 0 1 mRNA; cDNA DKFZp761P06121 (from clone DKFZp761 499B11 1451 1852 NM_021188 Hs.7137 0 2 clones 23667 and 23775 zinc finger protein (LOC 52B12 1850 2178 U90919 Hs.7137 1.00E−174 1 clones 23667 and 23775 zinc finger protein mRNA, compl 486A11 855 1186 NM_003904 Hs.7165 1.00E−132 1 zinc finger protein 259 (ZNF259), mRNA/cds = (2 460B6 2514 3182 NM_021931 Hs.7174 0 1 hypothetical protein FLJ22759 (FLJ22759), mR 592H8 3999 4524 AB051544 Hs.7187 0 2 mRNA for KIAA1757 protein, partial cds/cds = (3 180A10 102 468 AL117502 Hs.7200 1.00E−141 3 mRNA; cDNA DKFZp434D0935 (from clone DKFZp434 127A12 1503 2688 AL035661 Hs.7218 0 2 DNA sequence from clone RP4-568C11 on chromosome 20p1 592G9 12 263 NM_015953 Hs.7236 1.00E−138 2 CGI-25 protein (LOC51070), mRNA/cds = (44,949) 127E3 2624 4554 AB028980 Hs.7243 0 3 mRNA for KIAA1057 protein, partial cds/cds = (0 135F2 5029 5175 AB033050 Hs.7252 3.00E−78 1 mRNA for KIAA1224 protein, partial cds/cds = (0 57G1 2299 2723 NM_014319 Hs.7256 0 1 integral inner nuclear membrane protein (MAN1 122D11 2920 3123 AB014558 Hs.7278 5.00E−74 1 mRNA for KIAA0658 protein, partial cds/cds = (0 471H6 1 449 AV702692 Hs.7312 0 1 AV702692 cDNA 5′ end/clone = ADBBQC12/clone_(—) 104G12 4314 4797 AF084555 Hs.7351 0 2 okadaic acid-inducible and cAMP-regulated ph 590G7 771 1259 NM_005662 Hs.7381 0 5 voltage-dependent anion channel 3 (VDAC3), mR 159H2 355 1252 AL137423 Hs.7392 0 3 mRNA; cDNA DKFZp761E0323 (from clone DKFZp761E 161F3 1708 2371 NM_024045 Hs.7392 0 1 hypothetical protein MGC3199 (MGC3199), mRNA 195E1 1107 1362 NM_022736 Hs.7503 1.00E−129 1 hypothetical protein FLJ14153 (FLJ14153), mR 137F5 59 666 NM_018491 Hs.7535 0 2 COBW-like protein (LOC55871), mRNA/cds = (64,9 597E1 2302 2893 AF126028 Hs.7540 0 2 unknown mRNA/cds = (0,1261)/gb = AF126028/gi = cDNA: 473B6 3006 3302 AK025615 Hs.7567 1.00E−158 1 FLJ21962 fis, clone HEP05564/cds = UNKNOW 519H1 232 720 BG112505 Hs.7589 0 2 602282107F1 cDNA, 5′ end/clone = IMAGE: 4369729 73A9 106 3912 M20681 Hs.7594 0 8 glucose transporter-like protein-III (GLUT3), compl 51D3 106 3200 NM_006931 Hs.7594 0 2 solute carrier family 2 (facilitated glucose t 596E8 1512 1748 M94046 Hs.7647 1.00E−129 2 zinc finger protein (MAZ) mRNA/cds = UNKNOWN/ gb = M9404 472A8 1575 1983 NM_004576 Hs.7688 0 1 protein phosphatase 2 (formerly 2A), regulator 191A10 386 889 NM_007278 Hs.7719 0 3 GABA(A) receptor-associated protein (GABARAP 459C4 5636 5897 AB002323 Hs.7720 2.00E−87 1 mRNA for KIAA0325 gene, partial cds/cds = (0,6265)/ gb 99A12 606 1253 NM_018453 Hs.7731 0 1 uncharacterized bone marrow protein BM036 (BM 72G8 5806 6409 AB007938 Hs.7764 0 5 for KIAA0469 protein, complete cds/cds = ( 45G2 6168 6404 NM_014851 Hs.7764 1.00E−132 1 KIAA0469 gene product (KIAA0469), mRNA/cds = ( 172A4 371 588 NM_007273 Hs.7771 1.00E−107 1 B-cell associated protein (REA), mRNA/cds = (9 177B8 2055 2431 AK023166 Hs.7797 0 1 FLJ13104 fis, clone NT2RP3002343/cds = (28 99B6 865 1244 NM_012461 Hs.7797 0 1 TERF1 (TRF1)-interacting nuclear factor 2 (T 160G8 727 860 U94855 Hs.7811 5.00E−66 1 translation initiation factor 3 47 kDa subunit 54G6 1 1007 AK001319 Hs.7837 1.00E−148 3 FLJ10457 fis, clone NT2RP1001424/cds = UN 594A7 1295 1793 NM_013446 Hs.7838 0 4 makorin, ring finger protein, 1 (MKRN1), mRNA 188A12 1 2013 NM_017761 Hs.7862 0 3 hypothetical protein FLJ20312 (FLJ20312), mR 594A2 3060 3588 AK023813 Hs.7871 0 2 cDNA FLJ13751 fis, clone PLACE3000339, weakly 124C12 472 1251 NM_001550 Hs.7879 0 1 interferon-related developmental regulator 147A8 1381 1711 Y10313 Hs.7879 1.00E−134 1 for PC4 protein (IFRD1 gene)/cds = (219,158 74H3 4430 4978 AF302505 Hs.7886 0 2 pellino 1 (PELI1) mRNA, complete cds/cds = (4038 71G3 473 1112 NM_016224 Hs.7905 0 2 SH3 and PX domain-containing protein SH3PX1 (S 52C7 1637 2231 AB029551 Hs.7910 0 1 YEAF1 mRNA for YY1 and E4TF1 associated factor 177H5 5411 6045 AB002321 Hs.7911 0 1 KIAA0323 gene, partial cds/cds = (0,2175)/gb 114C8 1678 3078 NM_017657 Hs.7942 1.00E−149 2 hypothetical protein FLJ20080 (FLJ20080), mR 169D8 1453 2158 AK001437 Hs.7943 0 1 FLJ10575 fis, clone NT2RP2003295, highly 599G8 618 1204 NM_003796 Hs.7943 0 1 RPB5-mediating protein (RMP), mRNA/cds = (465, 127E11 107 796 NM_016099 Hs.7953 0 3 HSPC041 protein (LOC51125), mRNA/cds = (141,45 98D6 4769 6506 NM_001111 Hs.7957 0 20 adenosine deaminase, RNA-specific (ADAR), tr 37H10 2479 6594 X79448 Hs.7957 0 8 IFI-4 mRNA for type I protein/cds = (1165,3960)/g 178G4 4209 5132 AB028981 Hs.8021 0 4 mRNA for KIAA1058 protein, partial cds/cds = (0 118E9 630 1688 NM_006083 Hs.8024 0 2 IK cytokine, down-regulator of HLA II (IK), mRN 171A8 1658 1973 AK002026 Hs.8033 1.00E−151 1 FLJ11164 fis, clone PLACE1007226, weakly 103G5 1504 1977 NM_018346 Hs.8033 0 1 hypothetical protein FLJ11164 (FLJ11164), mR 179G7 2860 3032 AK022497 Hs.8068 6.00E−46 1 FLJ12435 fis, clone NT2RM1000059/cds = (88 594A11 2327 2658 NM_018210 Hs.8083 1.00E−167 1 hypothetical protein FLJ10769 (FLJ10769), mR 103B5 1968 2448 AF267856 Hs.8084 0 1 HT033 mRNA, complete cds/cds = (203,931)/gb = A 98E4 1367 1808 AF113008 Hs.8102 0 7 clone FLB0708 mRNA sequence/cds = UNKNOWN/ gb = erbb2-interacting 191H10 4581 5819 NM_018695 Hs.8117 0 3 protein ERBIN (LOC55914), 99F1 550 2672 AB014550 Hs.8118 0 4 mRNA for KIAA0650 protein, partial cds/cds = (0 165H11 488 663 NM_024408 Hs.8121 3.00E−93 1 Notch (Drosophila) homolog 2 (NOTCH2), mRNA/ 515C7 2188 2514 AL050371 Hs.8128 1.00E−114 1 mRNA; cDNA DKFZp566G2246 (from clone DKFZp566G 166A12 234 1196 AF131856 Hs.8148 1.00E−155 2 clone 24856 mRNA sequence, complete cds/cds = ( 520H8 512 712 NM_016275 Hs.8148 1.00E−110 1 selenoprotein T (LOC51714), mRNA/cds = (138,62 592D4 1 735 NM_014886 Hs.8170 1.00E−152 3 hypothetical protein (YR-29), mRNA/cds = (82,8 105F12 349 760 AK001665 Hs.8173 0 1 FLJ10803 fis, clone NT2RP4000833/cds = (1 75A7 737 1458 AF000652 Hs.8180 0 1 syntenin (sycl) mRNA, complete cds/cds = (148,1 64H5 105 618 NM_005625 Hs.8180 0 3 syndecan binding protein (syntenin) (SDCBP), 61G9 3147 3660 AB018339 Hs.8182 0 2 for KIAA0796 protein, partial cds/cds = (0 39G2 255 1675 AF042284 Hs.8185 0 4 unknown mRNA/cds = (76,1428)/gb = AF042284/gi 192G5 1054 1580 NM_021199 Hs.8185 0 8 CGI-44 protein; sulfide dehydrogenase like (y 109D3 1463 2503 AF269150 Hs.8203 0 2 transmembrane protein TM9SF3 (TM9SF3) mRNA, c 115H4 1251 3187 NM_020123 Hs.8203 0 12 endomembrane protein emp70 precursor isolog ( 113F12 2349 3576 AL355476 Hs.8217 4.00E−35 2 DNA sequence from clone RP11-517O1 on chromosome X Co 125D5 582 1050 NM_005006 Hs.8248 0 1 NADH dehydrogenase (ubiquinone) Fe-S protein 460D3 4851 5043 AF035947 Hs.8257 7.00E−76 1 cytokine-inducible inhibitor of signalling t 111E7 729 3182 NM_013995 Hs.8262 0 2 lysosomal-associated membrane protein 2 (LAM 590F10 3012 4133 AK022790 Hs.8309 0 6 cDNA FLJ12728 fis, clone NT2RP2000040, highly 109B1 138 476 AW973507 Hs.8360 1.00E−161 1 EST385607/gb = AW973507/gi = 8164686/ug = for 61A3 1137 1649 AB033017 Hs.8594 0 1 KIAA1191 protein, partial cds/cds = (0 523E12 905 2998 NM_007271 Hs.8724 0 4 serine threonine protein kinase (NDR), mRNA/ 590G2 3618 3932 NM_018031 Hs.8737 1.00E−166 3 WD repeat domain 6 (WDR6), mRNA/cds = (39,3404) 464C3 2299 2494 NM_018255 Hs.8739 1.00E−107 1 hypothetical protein FLJ10879 (FLJ10879), mR 128H8 1580 1711 NM_018450 Hs.8740 2.00E−64 1 uncharacterized bone marrow protein BM029 (BM 179D3 921 1457 AF083255 Hs.8765 0 1 RNA helicase-related protein complete c 195H11 1247 1481 NM_007269 Hs.8813 1.00E−100 1 syntaxin binding protein 3 (STXBP3), mRNA/cds 460F1 68 308 AA454036 Hs.8832 1.00E−105 1 zx48b04.r1 cDNA, 5′ end/clone = IMAGE: 795439/ 110E10 3672 5371 AB032252 Hs.8858 0 3 BAZ1A mRNA for bromodomain adjacent to zinc fi 113D1 4814 5890 NM_013448 Hs.8858 0 2 bromodomain adjacent to zinc finger domain, 1A 120H7 373 633 NM_017748 Hs.8928 1.00E−143 1 hypothetical protein FLJ20291 (FLJ20291), mR 470F10 1670 2260 NM_003917 Hs.8991 0 2 adaptor-related protein complex 1, gamma 2 su 72H11 1785 2418 M11717 Hs.8997 1.00E−147 23 heat shock protein (hsp 70) gene, complete cds/ cds = (2 49H4 1769 2243 NM_005345 Hs.8997 1.00E−145 12 heat shock 70 kD protein 1A (HSPA1A), mRNA/cds = VAMP 519E7 270 729 NM_003574 Hs.9006 0 1 (vesicle-associated membrane protein)-a 142E2 1265 1518 AK022215 Hs.9043 1.00E−107 1 FLJ12153 fis, clone MAMMA1000458/cds = UNK 108B9 1160 1823 AJ002030 Hs.9071 0 1 for putative progesterone binding protein 47C7 452 795 AB011420 Hs.9075 0 1 for DRAK1, complete cds/cds = (117,1361)/ 590A4 791 1377 NM_004760 Hs.9075 0 4 serine/threonine kinase 17a (apoptosis-induc 168D11 1000 1641 NM_017426 Hs.9082 0 1 nucleoporin p54 (NUP54), mRNA/cds = (25,1542) 63H9 799 1163 Y17829 Hs.9192 0 1 for Homer-related protein Syn47/cds = (75, 167B11 1466 1863 NM_006251 Hs.9247 0 1 protein kinase, AMP-activated, alpha 1 cataly 196D5 1021 1492 AK024327 Hs.9343 0 1 cDNA FLJ14265 fis, clone PLACE1002256/cds = UNK 192F3 245 790 NM_017983 Hs.9398 0 1 hypothetical protein FLJ10055 (FLJ10055), mR 121C3 3381 3567 AF217190 Hs.9414 3.00E−90 1 MLEL1 protein (MLEL1) mRNA, complete cds/cds = SWI/SNF 196B6 959 1551 NM_003601 Hs.9456 0 1 related, matrix associated, actin dep 331B5 2624 2950 AF027302 Hs.9573 1.00E−179 1 TNF-alpha stimulated ABC protein (ABC50) mRNA 592E11 1 479 NM_002520 Hs.9614 1.00E−139 7 nucleophosmin (nucleolar phosphoprotein B23 515D6 1739 2091 AB037796 Hs.9663 1.00E−160 1 mRNA for KIAA1375 protein, partial cds/cds = (0 124A5 1387 1762 NM_012068 Hs.9754 0 2 activating transcription factor 5 (ATF5), mRN 122A7 1484 1928 AB028963 Hs. 9846 1.00E−154 1 mRNA for KIAA1040 protein, partial cds/cds = (0 591E2 1626 2194 AF123073 Hs. 9851 0 5 C/EBP-induced protein mRNA, complete cds/cds 111G2 4208 5361 AB033076 Hs. 9873 0 2 mRNA for KIAA1250 protein, partial cds/cds = (0 469D5 932 3551 AK022758 Hs. 9908 1.00E−178 6 cDNA FLJ12696 fis, clone NT2RP1000513, highly 590D5 172 742 NM_001425 Hs. 9999 2.00E−94 2 epithelial membrane protein 3 (EMP3), mRNA/c 112E7 1065 1753 NM_001814 Hs. 10029 0 1 cathepsin C (CTSC), mRNA/cds = (33,1424)/gb = N 106C7 1066 1641 X87212 Hs. 10029 0 1 cathepsin C/cds = (33,1424)/gb = X87212/ 127B1 1003 1429 NM_014959 Hs. 10031 0 1 KIAA0955 protein (KIAA0955), mRNA/cds = (313,1 462E5 332 487 AW293461 Hs. 10041 3.00E−46 1 UI-H-BI2-ahm-e-02-0-UI.s1 cDNA, 3′ end/clon 190E3 101 356 NM_016551 Hs. 10071 6.00E−98 1 seven transmembrane protein TM7SF3 (TM7SF3), 61B6 2571 2764 AL163249 Hs. 10175 7.00E−94 1 chromosome 21 segment HS21C049/cds = (128,2599 110F6 5310 5808 D87432 Hs. 10315 0 1 KIAA0245 gene, complete cds/cds = (261,1808) 196E10 5312 5753 NM_003983 Hs. 10315 0 1 solute carrier family 7 (cationic amino acid t 49D8 315 2207 AK024597 Hs. 10362 0 3 cDNA: FLJ20944 fis, clone ADSE01780/cds = UNKNO 129C7 1000 1364 AB018249 Hs. 10458 0 1 CC chemokine LEC, complete cds/cds = (1 62F11 1239 2034 AL031685 Hs. 10590 0 2 DNA sequence from clone RP5-963K23 on chromosome 20q1 460D5 86 815 AL357374 Hs. 10600 0 4 DNA sequence from clone RP11-353C18 on chromosome 20 179C12 3765 4300 AK000005 Hs. 10647 0 2 FLJ00005 protein, partial cds/cds = (0 482D12 1753 2359 NM_004848 Hs. 10649 0 1 basement membrane-induced gene (ICB-1), mRNA 184F4 2686 3194 AL137721 Hs. 10702 0 1 mRNA; cDNA DKFZp761H221 (from clone DKFZp761H2 186F10 2688 3084 NM_017601 Hs. 10702 1.00E−137 2 hypothetical protein DKFZp761H221 (DKFZp761H 461E3 593 1110 NM_021821 Hs. 10724 0 1 MDS023 protein (MDS023), mRNA/cds = (335,1018) 598D5 660 1191 NM_014306 Hs. 10729 0 2 hypothetical protein (HSPC117), mRNA/cds = (75 125D9 104 397 NM_002495 Hs. 10758 1.00E−165 1 NADH dehydrogenase (ubiquinone) Fe-S protein 36A7 172 1114 NM_006325 Hs. 10842 0 11 RAN, member RAS oncogene familyRAN, member RAS 54H1 240 1467 NM_012257 Hs. 10882 0 2 HMG-box containing protein 1 (HBP1), mRNA/cds 596B8 1186 1895 AK025212 Hs. 10888 0 17 cDNA: FLJ21559 fis, clone COL06406/cds = UNKNOW 458G7 989 1492 Z78330 Hs. 10927 0 1 HSZ78330 cDNA/clone = 2.49-(CEPH)/gb = Z78330 115D2 308 638 BF793378 Hs. 10957 1.00E−102 1 602254823F1 cDNA, 5′ end/clone = IMAGE: 4347076 148H9 226 863 AF021819 Hs. 10958 0 1 RNA-binding protein regulatory subunit mRNA, 173D5 356 816 NM_007262 Hs. 10958 0 1 RNA-binding protein regulatory subunit (DJ-1 39B7 1553 2256 AF063605 Hs. 11000 0 1 brain my047 protein mRNA, complete cds/cds = (8 592H5 1553 2257 NM_015344 Hs. 11000 0 3 MY047 protein (MY047), mRNA/cds = (84,479)/gb 112G3 2591 3180 AB046813 Hs. 11123 0 1 mRNA for KIAA1593 protein, partial cds/cds = (4 592E8 251 725 NM_014041 Hs. 11125 0 2 HSPC033 protein (HSPC033), mRNA/cds = (168,443 477A2 1610 1697 NM_003100 Hs. 11183 8.00E−43 2 sorting nexin 2 (SNX2), mRNA/cds = (29,1588)/g 41G4 6498 6751 AB014522 Hs. 11238 1.00E−142 1 for KIAA0622 protein, partial cds/cds = (0 519A3 759 987 NM_018371 Hs. 11260 1.00E−127 1 hypothetical protein FLJ11264 (FLJ11264), mR 175B4 404 688 BE788546 Hs. 11355 4.00E−75 1 601476186F1 cDNA, 5′ end/clone = IMAGE: 3878948 114F11 245 401 BF665055 Hs. 11356 4.00E−55 1 602119656F1 cDNA, 5′ end/clone = IMAGE: 4276860 40D2 96 824 U59808 Hs. 11383 0 1 monocyte chemotactic protein-4 precursor (MCP-4) mR 109C3 767 2345 M74002 Hs. 11482 0 2 arginine-rich nuclear protein mRNA, complete cds/cds 117G9 408 2345 NM_004768 Hs. 11482 0 8 splicing factor, arginine/serine-rich 11 (SF 458G6 2053 2164 AK022628 Hs. 11556 1.00E−54 1 cDNA FLJ12566 fis, clone NT2RM4000852/cds = UNK 181E7 644 1004 AK021632 Hs. 11571 1.00E−167 1 cDNA FLJ11570 fis, clone HEMBA1003309/cds = UNK 458B3 85 522 R12665 Hs. 11594 1.00E−137 1 yf40a04.s1 cDNA, 3′ end/clone = IMAGE: 129294/ 146B6 498 677 BE794595 Hs. 11607 5.00E−82 1 601590368F1 5′ end/clone = IMAGE: 3944489 516F12 388 711 BG288429 Hs. 11637 1.00E−132 1 602388093F1 cDNA, 5′ end/clone = IMAGE: 4517086 60B1 1291 1882 NM_005121 Hs. 11861 0 1 thyroid hormone receptor-associated protein, 44C6 2613 2834 NM_000859 Hs. 11899 9.00E−72 1 3-hydroxy-3-methylglutaryl-Coenzyme A reduc 39F10 1 221 BF668230 Hs. 12035 1.00E−120 2 602122419F1 cDNA, 5′ end/clone = IMAGE: 4279300 596D8 234 849 U72514 Hs. 12045 0 2 C2f mRNA, complete cds 481E7 1902 2190 AB028986 Hs. 12064 1.00E−151 1 mRNA for KIAA1063 protein, partial cds/cds = (0 465D9 2529 2699 NM_004003 Hs. 12068 8.00E−91 1 carnitine acetyltransferase (CRAT), nuclear 116H8 283 738 NM_003321 Hs. 12084 0 1 Tu translation elongation factor, mitochondri 44A4 319 836 S75463 Hs. 12084 0 1 P43 = mitochondrial elongation factor homolog [human, live 114F7 4254 4495 AL137753 Hs. 12144 1.00E−115 1 mRNA; cDNA DKFZp434K1412 (from clone DKFZp434K 123F12 1 219 NM_021203 Hs. 12152 1.00E−114 1 APMCF1 protein (APMCF1), mRNA/cds = (82,225)/ 519H7 166 753 AK025775 Hs. 12245 0 1 cDNA: FLJ22122 fis, clone HEP19214/cds = UNKNOW 70E3 953 4720 AB014530 Hs. 12259 0 3 for KIAA0630 protein, partial cds/cds = (0 107H1 680 1078 AK024756 Hs. 12293 0 1 FLJ21103 fis, clone CAS04883/cds = (107,1 71E5 4750 5283 NM_003170 Hs. 12303 0 1 suppressor of Ty (S. cerevisiae) 6 homolog (SUP 106F3 977 1490 AL050272 Hs. 12305 0 1 cDNA DKFZp566B183 (from clone DKFZp566B1 481F4 1859 2403 NM_015509 Hs. 12305 0 1 DKFZP566B183 protein (DKFZP566B183), mRNA/c 114D3 1271 1520 AF038202 Hs. 12311 1.00E−118 1 clone 23570 mRNA sequence/cds = UNKNOWN/ gb = AF0 463B9 1006 1224 AK021670 Hs. 12315 1.00E−121 1 cDNA FLJ11608 fis, clone HEMBA1003976/cds = (56 167A8 71 723 BG034192 Hs. 12396 0 2 602302446F1 cDNA, 5′ end/clone = IMAGE: 4403866 460E9 3808 4166 D83776 Hs. 12413 1.00E−176 1 mRNA for KIAA0191 gene, partial cds/cds = (0,4552)/ gb 157E1 1887 3154 NM_020403 Hs. 12450 0 3 cadherin superfamily protein VR4-11 (LOC57123 69F11 2715 3447 AK001676 Hs. 12457 0 1 FLJ10814 fis, clone NT2RP4000984/cds = (92 118B8 5781 6374 AB032973 Hs. 12461 0 1 mRNA for KIAA1147 protein, partial cds/cds = (0 193G12 2069 2368 NM_005993 Hs. 12570 1.00E−169 1 tubulin-specific chaperone d (TBCD), mRNA/cd 459D11 2828 3122 NM_021151 Hs. 12743 1.00E−147 1 carnitine octanoyltransferase (COT), mRNA/c 196H4 1 5439 AB046785 Hs. 12772 0 2 mRNA for KIAA1565 protein, partial cds/cds = (0 56G11 458 1088 AL080156 Hs. 12813 0 1 cDNA DKFZp434J214 (from clone DKFZp434J2 476E6 1221 1638 NM_006590 Hs. 12820 0 1 SnRNP assembly defective 1 homolog (SAD1), mRN 109E7 1 180 AF208855 Hs. 12830 3.00E−79 1 BM-013 mRNA, complete cds/cds = (67,459)/gb = A 458A2 1818 2276 AK026747 Hs. 12969 0 1 cDNA: FLJ23094 fis, clone LNG07379, highly sim 466D10 1469 1745 AK001822 Hs. 12999 9.00E−39 1 cDNA FLJ10960 fis, clone PLACE1000564/cds = UNK 187A11 1866 2555 NM_003330 Hs. 13046 0 2 thioredoxin reductase 1 (TXNRD1), mRNA/cds = ( 60D9 1757 3508 X91247 Hs. 13046 0 3 thioredoxin reductase/cds = (439,1932) 75D7 2071 2550 AF055581 Hs. 13131 0 1 adaptor protein Lnk mRNA, complete cds/cds = (3 196C2 190 845 AK026239 Hs. 13179 0 2 cDNA: FLJ22586 fis, clone HSI02774/cds = UNKNOW 480G6 11 380 AL570416 Hs. 13256 1.00E−161 1 AL570416 cDNA/clone = CS0DI020YK05-(3-prime) 196H3 2814 3382 AB020663 Hs. 13264 0 1 mRNA for KIAA0856 protein, partial cds/cds = (0 460H3 127 431 BF029796 Hs. 13268 1.00E−151 1 601556721F1 cDNA, 5′ end/clone = IMAGE: 3826637 170B2 1487 1635 AB011164 Hs. 13273 1.00E−69 1 for KIAA0592 protein, partial cds/cds = (0, 115E6 2153 2376 AK025707 Hs. 13277 1.00E−124 1 cDNA: FLJ22054 fis, clone HEP09634/cds = (144,9 110F10 119 648 BE537908 Hs. 13328 0 1 601067373F1 cDNA, 5′ end/clone = IMAGE: 3453594 36C2 427 4137 AF054284 Hs. 13453 0 5 spliceosomal protein SAP 155 mRNA, complete cd 594C3 5 4229 NM_012433 Hs. 13453 0 10 splicing factor 3b, subunit 1, 155 kD (SF3B1), m 110C6 4 1853 AF131753 Hs. 13472 0 5 clone 24859 mRNA sequence/cds = UNKNOWN/ gb = AF 173B6 1156 1672 NM_013236 Hs. 13493 0 1 like mouse brain protein E46 (E46L), mRNA/cds = 462C4 794 1093 BC001909 Hs. 13580 1.00E−115 1 clone IMAGE: 3537447, mRNA, partial cds/cds = 597H11 412 936 NM_014174 Hs. 13645 0 1 HSPC144 protein (HSPC144), mRNA/cds = (446,112 107F8 429 821 AK025767 Hs. 13755 0 1 FLJ22114 fis, clone HEP18441/cds = UNKNOW 102D12 3153 4764 AF000993 Hs. 13980 0 2 ubiquitous TPR motif, X isoform (UTX) mRNA, alt 515G12 1710 2120 AK025425 Hs. 14040 0 2 cDNA: FLJ21772 fis, clone COLF7808/ cds = UNKNOW 480H5 1945 2259 AK024228 Hs. 14070 1.00E−119 1 cDNA FLJ14166 fis, clone NT2RP1000796/cds = (20 61D1 73 499 NM_014245 Hs. 14084 0 1 ring finger protein 7 (RNF7), mRNA/cds = (53,394 122E4 2162 2685 NM_014454 Hs. 14125 0 1 p53 regulated PA26 nuclear protein (PA26), mRN 123D9 22 722 NM_001161 Hs. 14142 0 1 nudix (nucleoside diphosphate linked moiety 460F11 1084 1322 NM_017827 Hs. 14220 4.00E−74 1 hypothetical protein FLJ20450 (FLJ20450), mR 458D2 127 536 NM_018648 Hs. 14317 0 1 nucleolar protein family A, member 3 (H/ACA sm 167G1 30 198 AK022939 Hs. 14347 3.00E−91 1 cDNA FLJ12877 fis, clone NT2RP2003825/cds = (3 117H10 975 1721 NM_003022 Hs. 14368 0 1 SH3 domain binding glutamic acid-rich protein 591B12 1082 1801 NM_001614 Hs. 14376 0 9 actin, gamma 1 (ACTG1), mRNA/cds = (74,1201)/g 179H3 1160 1791 X04098 Hs. 14376 1.00E−178 5 cytoskeletal gamma-actin/cds = (73,1200)/g 116D9 5818 6073 NM_012199 Hs. 14520 5.00E−84 1 eukaryotic translation initiation factor 2C, 64D11 1901 2506 NM_003592 Hs. 14541 0 1 cullin 1 (CUL1), mRNA/cds = (124,2382)/gb = NM_0 516F4 750 1331 AK025166 Hs. 14555 0 1 cDNA: FLJ21513 fis, clone COL05778/cds = UNKNOW 459G5 1 260 AK025269 Hs. 14562 5.00E−88 1 cDNA: FLJ21616 fis, clone COL07477/cds = (119,1 521B7 7 1825 NM_005335 Hs. 14601 0 8 hematopoietic cell-specific Lyn substrate 1 110D7 7 1295 X16663 Hs. 14601 0 3 HS1 gene for heamatopoietic lineage cell specific pro 114D11 1460 1559 NM_003584 Hs. 14611 1.00E−45 1 dual specificity phosphatase 11 (RNA/RNP comp 589A3 1665 2197 NM_016293 Hs. 14770 0 2 bridging integrator 2 (BIN2), mRNA/cds = (38,17 104C8 2113 2380 AB031050 Hs. 14805 1.00E−135 2 for organic anion transporter OATP-D, com 481D10 2466 2694 NM_013272 Hs. 14805 1.00E−68 1 solute carrier family 21 (organic anion transp 125B2 2704 3183 NM_001455 Hs. 14845 0 1 forkhead box O3A (FOXO3A), mRNA/cds = (924,2945 500D7 2174 2379 AL050021 Hs. 14846 1.00E−100 1 mRNA; cDNA DKFZp564D016 (from clone DKFZp564D0 123B5 1793 2195 NM_016598 Hs. 14896 0 1 DHHC1 protein (LOC51304), mRNA/cds = (214,1197 499E2 1266 1549 AB020644 Hs. 14945 1.00E−155 3 mRNA for KIAA0837 protein, partial cds/cds = (0 123H6 2980 3652 NM_007192 Hs. 14963 0 3 chromatin-specific transcription elongation 61G10 264 528 D13627 Hs. 15071 1.00E−144 1 KIAA0002 gene, complete cds/cds = (28,1674)/ 460D10 2162 4305 NM_014837 Hs. 15087 0 4 KIAA0250 gene product (KIAA0250), mRNA/cds = ( 176E12 9289 9739 NM_022473 Hs. 15220 0 1 zinc finger protein 106 (ZFP106), mRNA/cds = (3 487E11 1561 1989 NM_006170 Hs. 15243 0 1 nucleolar protein 1 (120 kD) (NOL1), mRNA/cds = 75E11 1628 2201 AF127139 Hs. 15259 0 20 Bcl-2-binding protein BIS (BIS) mRNA, complete 71H9 1656 2532 NM_004281 Hs. 15259 0 12 BCL2-associated athanogene 3 (BAG3), mRNA/cd 484G9 465 1006 NM_005826 Hs. 15265 0 1 heterogeneous nuclear ribonucleoprotein R ( 480H8 2013 2635 AB037828 Hs. 15370 0 1 mRNA for KIAA1407 protein, partial cds/cds = (0 587G9 2436 2769 AK024088 Hs. 15423 1.00E−167 1 cDNA FLJ14026 fis, clone HEMBA1003679, weakly 483D6 5239 5810 NM_004774 Hs. 15589 0 1 PPAR binding protein (PPARBP), mRNA/cds = (235, 514A7 673 942 NM_006833 Hs. 15591 1.00E−151 1 COP9 subunit 6 (MOV34 homolog, 34 kD) (MOV34-34 125A2 522 746 NM_024348 Hs. 15961 1.00E−112 1 dynactin 3 (p22) (DCTN3), transcript variant 591A5 295 704 NM_005005 Hs. 15977 0 3 NADH dehydrogenase (ubiquinone) 1 beta subcom 39H12 1641 1993 X74262 Hs. 16003 1.00E−180 1 RbAp48 mRNA encoding retinoblastoma binding prot 113A9 1328 1891 NM_016334 Hs. 16085 0 1 putative G-protein coupled receptor (SH120), 45C2 765 1674 NM_006461 Hs. 16244 0 2 mitotic spindle coiled-coil related protein ( 494H10 113 2576 NM_016312 Hs. 16420 0 3 Npw38-binding protein NpwBP (LOC51729), mRNA 40D8 52 246 Y13710 Hs. 16530 1.00E−107 1 for alternative activated macrophage spe 597E7 244 524 AL523085 Hs. 16648 1.00E−147 1 AL523085 cDNA/clone = CS0DC001YF21-(5-prime) 458D11 232 319 AY007106 Hs. 16773 1.00E−42 1 clone TCCCIA00427 mRNA sequence/ cds = UNKNOWN 70F2 824 991 AL021786 Hs. 17109 2.00E−90 2 DNA sequence from PAC 696H22 on chromosome Xq21.1-21.2 167C5 5768 5905 D86964 Hs. 17211 3.00E−62 1 mRNA for KIAA0209 gene, partial cds/cds = (0,5530)/ gb 460H2 3424 3624 AL162070 Hs. 17377 1.00E−103 1 mRNA; cDNA DKFZp762H186 (from clone DKFZp762H1 70G11 1384 1885 AK023680 Hs. 17448 0 2 FLJ13618 fis, clone PLACE1010925/cds = UNK 129C11 2458 3044 U47924 Hs. 17483 0 2 chromosome 12p13 sequence/cds = (194,1570)/ gb = U4792 467H3 4713 4908 NM_014521 Hs. 17667 1.00E−61 1 SH3-domain binding protein 4 (SH3BP4), mRNA/ 71A11 100 370 BG035218 Hs. 17719 1.00E−142 1 602324727F1 cDNA, 5′ end/clone = IMAGE: 4412910 598C7 513 902 NM_021622 Hs. 17757 1.00E−178 1 pleckstrin homology domain-containing, fami 595A7 3296 5680 AB046774 Hs. 17767 0 5 mRNA for KIAA1554 protein, partial cds/cds = (0 58D12 5225 5857 AB007861 Hs. 17803 0 1 KIAA0401 mRNA, partial cds/cds = (0,1036)/gb = 524G8 357 809 NM_014350 Hs. 17839 0 1 TNF-induced protein (GG2-1), mRNA/cds = (197,7 521B10 1008 1476 NM_002707 Hs. 17883 0 2 protein phosphatase 1G (formerly 2C), magnesiu 69B12 1014 1490 Y13936 Hs. 17883 0 1 for protein phosphatase 2C gamma/cds = (24, 178E6 1903 4365 NM_014827 Hs. 17969 0 3 KIAA0663 gene product (KIAA0663), mRNA/cds = ( 173H3 481 2362 AK001630 Hs. 18063 0 4 cDNA FLJ10768 fis, clone NT2RP4000150/cds = UN 113A8 1285 1393 NM_005606 Hs. 18069 5.00E−48 1 protease, cysteine, 1 (legumain) (PRSC1), mRN 118H9 3709 3950 AB020677 Hs. 18166 1.00E−125 1 mRNA for KIAA0870 protein, partial cds/cds = (0 513H7 2204 2757 NM_005839 Hs. 18192 1.00E−112 3 Ser/Arg-related nuclear matrix protein (plen 523G9 507 768 AB044661 Hs. 18259 1.00E−147 1 XAB1 mRNA for XPA binding protein 1, complete c 105B9 695 1115 AJ010842 Hs. 18259 0 1 for putative ATP(GTP)-binding protein, p 589D12 335 715 NM_016565 Hs. 18552 0 2 E2IG2 protein (LOC51287), mRNA/cds = (131,421) 170C8 414 737 AF072860 Hs. 18571 0 2 protein activator of the interferon-induced p 189A12 414 736 NM_003690 Hs. 18571 0 1 protein kinase, interferon-inducible double 134B9 2751 3057 AB046808 Hs. 18587 1.00E−165 1 mRNA for KIAA1588 protein, partial cds/cds = (2 519G5 1291 1581 NM_012332 Hs. 18625 1.00E−157 2 Mitochondrial Acyl-CoA Thioesterase (MT-ACT4 526H2 827 1205 NM_004208 Hs. 18720 0 1 programmed cell death 8 (apoptosis-inducing f 462F12 409 556 NM_017899 Hs. 18791 2.00E−78 1 hypothetical protein FLJ20607 (FLJ20607), mR 138B2 388 995 AF003938 Hs. 18792 0 1 thioredoxin-like protein complete cds 36G12 935 1272 AJ250014 Hs. 18827 0 2 for Familial Cylindromatosis cyld gene/ 194D3 924 2123 NM_018253 Hs. 18851 0 2 hypothetical protein FLJ10875 (FLJ10875), mR 523E1 3653 4056 NM_012290 Hs. 18895 0 1 tousled-like kinase 1 (TLK1), mRNA/cds = (212,2 587G5 1 350 NM_016302 Hs. 18925 1.00E−166 1 protein × 0001 (LOC51185), mRNA/cds = (33,1043) 595C10 161 1281 AC006042 Hs. 18987 0 4 BAC clone RP11-505D17 from 7p22-p21/cds = (0,12 125G10 54 752 NM_002492 Hs. 19236 0 3 NADH dehydrogenase (ubiquinone) 1 beta subcom 478G7 1 193 NM_021603 Hs. 19520 9.00E−51 1 FXYD domain-containing ion transport regulat 595F11 3623 3736 AB051481 Hs. 19597 3.00E−49 1 mRNA for KIAA1694 protein, partial cds/cds = (0 177C6 284 671 AF161339 Hs. 19807 0 2 HSPC076 mRNA, partial cds/cds = (0,301)/gb = AF 37E12 3485 3919 AB018298 Hs. 19822 0 1 for KIAA0755 protein, complete cds/cds = ( 64G8 962 1311 NM_001902 Hs. 19904 0 1 cystathionase (cystathionine gamma-lyase) ( 499D5 2829 3183 AB011169 Hs. 20141 0 1 mRNA for KIAA0597 protein, partial cds/cds = (0, 40D11 62 684 NM_004166 Hs. 20144 0 1 small inducible cytokine subfamily A (Cys-Cys 66C10 1240 2240 U76248 Hs. 20191 0 12 hSIAH2 mRNA, complete cds/cds = (526,1500)/ gb = U76248 586B12 1686 4288 AB040922 Hs. 20237 0 2 mRNA for KIAA1489 protein, partial cds/cds = (1 173G8 2578 3197 AL096776 Hs. 20252 0 1 DNA sequence from clone RP4-646B12 on chromosome 1q42 98C6 3303 4699 AB051487 Hs. 20281 0 6 mRNA for KIAA1700 protein, partial cds/cds = (1 107H11 781 1380 AK022103 Hs. 20281 0 1 FLJ12041 fis, clone HEMBB1001945/cds = UNK 121B8 778 1264 NM_001548 Hs. 20315 0 1 interferon-induced protein with tetratricope 110C4 1050 1431 AF244137 Hs. 20597 0 1 hepatocellular carcinoma-associated antigen 99H6 899 1412 NM_014315 Hs. 20597 0 2 host cell factor homolog (LCP), mRNA/cds = (316, 152B12 69 424 AK025446 Hs. 20760 0 1 FLJ21793 fis, clone HEP00466/cds = UNKNOW 459A8 1858 2143 AL021366 Hs. 20830 1.00E−155 1 DNA sequence from cosmid ICK0721Q on chromosome 587A11 720 1080 AL137576 Hs. 21015 0 1 mRNA; cDNA DKFZp564L0864 (from clone DKFZp564L 191E12 1688 2235 AK025019 Hs. 21056 0 2 cDNA: FLJ21366 fis, clone COL03012, highly sim 52G3 225 1652 NM_005880 Hs. 21189 0 6 HIRA interacting protein 4 (dnaJ-like) (HIRIP 181B7 3176 3316 AB018325 Hs. 21264 3.00E−72 1 mRNA for KIAA0782 protein, partial cds/cds = (0 45E11 1378 1518 NM_003115 Hs. 21293 1.00E−72 1 UDP-N-acteylglucosamine pyrophosphorylase 109G1 2989 3487 AB032948 Hs. 21356 0 1 for KIAA1122 protein, partial cds/cds = (0 116D4 5522 5741 NM_016936 Hs. 21479 1.00E−107 1 ubinuclein 1 (UBN1), mRNA/cds = (114,3518)/gb 37G10 294 3960 M97935 Hs. 21486 0 4 transcription factor ISGF-3 mRNA, complete cd 599E8 329 3568 NM_007315 Hs. 21486 0 6 signal transducer and activator of transcripti 592D10 2223 3204 NM_002709 Hs. 21537 0 3 protein phosphatase 1, catalytic subunit, bet 68A7 1327 1612 AB028958 Hs. 21542 1.00E−161 1 for KIAA1035 protein, partial cds/cds = (0 72B3 2519 2862 L03426 Hs. 21595 1.00E−179 1 XE7 mRNA, complete alternate coding regions/ cds = (166 592E6 2520 2854 NM_005088 Hs. 21595 1.00E−161 1 DNA segment on chromosome X and (unique) 155 ex 589G6 190 522 AL573787 Hs. 21732 1.00E−141 1 AL573787 cDNA/clone = CS0DI055YM17-(3-prime) 593H1 452 899 NM_005875 Hs. 21756 0 2 translation factor sui1 homolog (GC20), mRNA 59B8 2893 3273 NM_012406 Hs. 21807 0 1 PR domain containing 4 (PRDM4), mRNA/cds = (122, 196A9 12 543 AL562895 Hs. 21812 0 1 AL562895 cDNA/clone = CS0DC021YO20-(3-prime) 67D8 62 631 AW512498 Hs. 21879 1.00E−150 3 xx75e03.x1 cDNA, 3′ end/clone = IMAGE: 2849500 477B6 1969 2520 D84454 Hs. 21899 0 1 mRNA for UDP-galactose translocator, complete cds/c 515D1 2232 2647 NM_007067 Hs. 21907 0 2 histone acetyltransferase (HBOA), mRNA/cds = 100F8 1082 1508 AK022554 Hs. 21938 0 1 FLJ12492 fis, clone NT2RM2001632, weakly 470E4 1135 1244 NM_020239 Hs. 22065 4.00E−45 2 small protein effector 1 of Cdc42 (SPEC1), mRNA 68G4 1391 2013 AK022057 Hs. 22265 0 2 FLJ11995 fis, clone HEMBB1001443, highly 193H6 922 1328 NM_022494 Hs. 22353 1.00E−178 1 hypothetical protein FLJ21952 (FLJ21952), mR 151D2 1492 1694 AL049951 Hs.22370 4.00E−88 1 cDNA DKFZp564O0122 (from clone DKFZp564O 497E8 1581 4794 D83781 Hs.22559 0 3 mRNA for KIAA0197 gene, partial cds/cds = (0,3945)/gb 182D10 999 1830 AL117513 Hs.22583 0 5 mRNA; cDNA DKFZp434K2235 (from clone DKFZp434K 75B5 1775 2380 AF006513 Hs.22670 0 1 CHD1 mRNA, complete cds/cds = (163,5292)/gb = A 126H8 1776 2377 NM_001270 Hs.22670 0 1 chromodomain helicase DNA binding protein 1 ( 73D5 1599 1696 AK025485 Hs.22678 2.00E−42 1 FLJ21832 fis, clone HEP01571/cds = (32,15 481D11 128 562 BF968270 Hs.22790 1.00E−172 1 602269653F1 cDNA, 5′ end/clone = lMAGE: 4357740 74E4 724 1195 NM_012124 Hs.22857 0 1 chord domain-containing protein 1 (CHP1), mRN 459C6 813 1472 NM_012244 Hs.22891 0 1 solute carrier family 7 (cationic amino acid t 462G7 2972 3144 AB037784 Hs.22941 2.00E−93 1 mRNA for KIAA1363 protein, partial cds/cds = (0 70F12 37 846 AB020623 Hs.22960 0 3 DAM1 mRNA, complete cds/cds = (48,725)/gb = AB0 585H10 91 748 NM_005872 Hs.22960 0 1 breast carcinoma amplified sequence 2 (BCAS2) 142C8 1359 1597 AK024023 Hs.23170 1.00E−103 1 FLJ13961 fis, clone Y79AA1001236, highly 164F2 1220 1474 NM_012280 Hs.23170 1.00E−135 1 homolog of yeast SPB1 (JM23), mRNA/cds = (300,12 127F11 682 806 AL046016 Hs.23247 2.00E−58 1 DKFZp434P246_r1 cDNA, 5′ end/clone = DKFZp434P 98G7 760 1368 NM_022496 Hs.23259 0 1 hypothetical protein FLJ13433 (FLJ13433), mR 470C9 2 538 AL574514 Hs.23294 0 2 AL574514 cDNA/clone = CS0DI056YA07-(3-prime) 458F12 4293 4917 AB002365 Hs.23311 0 1 mRNA for KIAA0367 gene, partial cds/cds = (0,2150)/gb 57D8 460 566 BF439063 Hs.23349 3.00E−54 1 nab70e03.x1 cDNA/clone = IMAGE/gb = BF439063/ 599G12 352 983 NM_014814 Hs.23488 0 2 KIAA0107 gene product (KIAA0107), mRNA/cds = ( 112B3 2400 2715 NM_014887 Hs.23518 1.00E−172 1 hypothetical protein from BCRA2 region (CG005 167C10 1771 2107 NM_004380 Hs.23598 1.00E−175 1 CREB binding protein (Rubinstein-Taybi syndr 196G9 114 307 BF970427 Hs.23703 1.00E−101 1 602272760F1 cDNA, 5′ end/clone = IMAGE: 4360767 184B3 2488 2882 AK026983 Hs.23803 0 1 FLJ23330 fis, clone HEP12654/cds = (69,13 480H4 4871 5467 AB023227 Hs.23860 0 1 mRNA for KIAA1010 protein, partial cds/cds = (0 479C12 4 190 NM_005556 Hs.23881 4.00E−91 1 keratin 7 (KRT7), mRNA/cds = (56,1465)/gb = NM_(—) 36E7 742 1126 AL360135 Hs.23964 0 1 full length insert cDNA clone EUROIMAGE 12 598B5 544 1271 NM_005870 Hs.23964 0 12 sin3-associated polypeptide, 18 kD (SAP18), m 462D8 1205 1653 NM_004790 Hs.23965 0 1 solute carrier family 22 (organic anion transp 479A5 1817 2164 NM_002967 Hs.23978 0 1 scaffold attachment factor B (SAFB), mRNA/cds 188E2 1762 2160 NM_014950 Hs.24083 0 1 KIAA0997 protein (KIAA0997), mRNA/cds = (262,2 67D2 1304 1856 AK024240 Hs.24115 0 2 FLJ14178 fis, clone NT2RP2003339/cds = UNK 177D8 4674 5185 AF251039 Hs.24125 0 1 putative zinc finger protein mRNA, complete cd 190E1 5222 5394 NM_016604 Hs.24125 8.00E−73 1 putative zinc finger protein (LOC51780), mRNA 192A5 1517 1985 NM_003387 Hs.24143 1.00E−135 2 Wiskott-Aldrich syndrome protein interacting 170A4 1666 3280 X86019 Hs.24143 4.00E−23 1 PRPL-2 protein/cds = (204,1688)/gb = X860 480B6 1517 1937 NM_012155 Hs.24178 1.00E−133 1 microtubule-associated protein like echinode 143H11 177 656 BE877357 Hs.24181 0 2 601485590F1 cDNA, 5′ end/clone = IMAGE: 3887951 473D10 146 491 AW960486 Hs.24252 0 1 EST372557 cDNA/gb = AW960486/gi = 8150170/ug = 98H1 23 562 NM_003945 Hs.24322 0 1 ATPase, H+ transporting, lysosomal (vacuolar 169G2 391 638 BE612847 Hs.24349 4.00E−75 2 601452239F1 5′ end/clone = IMAGE: 3856304 479B12 1132 1599 AY007126 Hs.24435 0 1 clone CDABP0028 mRNA sequence/cds = UNKNOWN/g 480H9 4716 5012 NM_006048 Hs.24594 1.00E−145 1 ubiquitination factor E4B (homologous to yeas 110B10 520 1171 AL163206 Hs.24633 0 1 chromosome 21 segment HS21C006/cds = (82,1203) 99A3 519 1000 NM_022136 Hs.24633 0 2 SAM domain, SH3 domain and nuclear localisation 109G7 2024 2350 AB037797 Hs.24684 1.00E−141 1 for KIAA1376 protein, partial cds/cds = (1 61B7 485 1656 AK024029 Hs.24719 0 4 FLJ13967 fis, clone Y79AA1001402, weakly 166C11 1216 1509 AF006516 Hs.24752 1.00E−165 1 eps8 binding protein e3B1 mRNA, complete cds/ 464D12 166 764 NM_002882 Hs.24763 0 1 RAN binding protein 1 (RANBP1), mRNA/cds = (149 98C12 6523 8023 AB051512 Hs.25127 0 3 mRNA for KIAA1725 protein, partial cds/cds = (0 63F7 2164 2802 AL133611 Hs.25362 0 1 cDNA DKFZp434O1317 (from clone DKFZp434O 41D11 45 463 X53795 Hs.25409 0 1 R2 mRNA for an inducible membrane protein/ cds = (156,95 62G6 1452 1827 V01512 Hs.25647 0 3 cellular oncogene c-fos (complete sequence)/cds = (15 593D12 1135 2111 NM_015832 Hs.25674 0 8 methyl-CpG binding domain protein 2 (MBD2), tr 172G9 2014 2371 NM_021211 Hs.25726 0 1 transposon-derived Buster1 transposase-like 106D6 432 1878 AF058696 Hs.25812 0 2 cell cycle regulatory protein p95 (NBS1) mRNA, 98A4 533 3758 NM_002485 Hs.25812 0 2 Nijmegen breakage syndrome 1 (nibrin) (NBS1), 477H5 6320 6599 NM_004638 Hs.25911 1.00E−111 3 HLA-B associated transcript-2 (D6S51E), mRNA 71F11 2070 2931 NM_019555 Hs.25951 0 3 Rho guanine nucleotide exchange factor (GEF) 164B9 2163 2502 AK023999 Hs.26039 1.00E−159 1 cDNA FLJ13937 fis, clone Y79AA1000805/cds = UNK 100A3 2043 2620 M34668 Hs.26045 0 1 protein tyrosine phosphatase (PTPase-alpha) mRNA/c 123A5 2046 2638 NM_002836 Hs.26045 0 1 protein tyrosine phosphatase, receptor type, 466E5 7817 8241 NM_014112 Hs.26102 0 2 trichorhinophalangeal syndrome I gene (TRPS1) 588A1 361 857 AF070582 Hs.26118 0 1 clone 24766 mRNA sequence/cds = UNKNOWN/ gb = AF 526H12 176 1809 NM_018384 Hs.26194 0 5 hypothetical protein FLJ11296 (FLJ11296), mR 149G7 96 1123 AK027016 Hs.26198 0 3 FLJ23363 fis, clone HEP15507/cds = (206,1 122A4 1196 1332 AL050166 Hs.26295 3.00E−72 1 mRNA; cDNA DKFZp586D1122 (from clone DKFZp586D 122D5 1936 2435 AB029006 Hs.26334 0 1 mRNA for KIAA1083 protein, complete cds/cds = ( 137G5 137 452 AK025778 Hs.26367 1.00E−145 1 FLJ22125 fis, clone HEP19410/cds = (119,5 595D2 1 372 NM_022488 Hs.26367 3.00E−89 3 PC3-96 protein (PC3-96), mRNA/cds = (119,586) 64D12 1024 1135 NM_017746 Hs.26369 2.00E−57 1 hypothetical protein FLJ20287 (FLJ20287), mR 39E4 2132 2750 AK000367 Hs.26434 0 1 FLJ20360 fis, clone HEP16677/cds = (79,230 473C10 4318 4623 AF051782 Hs.26584 1.00E−154 1 diaphanous 1 (HDIA1) mRNA, complete cds/cds = ( 590C4 1740 2198 AL050205 Hs.26613 0 1 mRNA; cDNA DKFZp586F1323 (from clone DKFZp586F 523F3 454 792 AC002073 Hs.26670 1.00E−164 1 PAC clone RP3-515N1 from 22q11.2-q22/cds = (0,791)/g 587E11 1226 1876 NM_004779 Hs.26703 0 2 CCR4-NOT transcription complex, subunit 8 (C 110G4 191 685 BE868389 Hs.26731 0 1 601444360F1 cDNA, 5′ end/clone = IMAGE: 3848487 110E11 1001 3955 AL117448 Hs.26797 0 2 cDNA DKFZp586B14I7 (from clone DKFZp586B 152A8 12 112 AI760224 Hs.26873 2.00E−48 1 wh62g06.x1 cDNA, 3′ end/clone = IMAGE: 2385370 467G11 528 858 NM_016106 Hs.27023 1.00E−174 1 vesicle transport-related protein (KIAA0917) 465E11 634 1065 AL136656 Hs.27181 3.00E−83 1 mRNA; cDNA DKFZp564C1664 (from clone DKFZp564C 58E11 1 551 AJ238243 Hs.27182 0 1 mRNA for phospholipase A2 activating protein 590H2 398 1016 NM_014412 Hs.27258 0 1 calcyclin binding protein (CACYBP), mRNA/cds 179E9 1039 1905 AK025586 Hs.27268 0 4 FLJ21933 fis, clone HEP04337/cds = UNKNOW 459D7 1293 1936 AL050061 Hs.27371 0 1 mRNA; cDNA DKFZp566J123 (from clone DKFZp566J1 54A11 709 1542 AK022811 Hs.27475 0 1 FLJ12749 fis, clone NT2RP2001149/cds = UNK 111A5 42 686 NM_022485 Hs.27556 0 1 hypothetical protein FLJ22405 (FLJ22405), mR 123D4 879 1005 NM_016059 Hs.27693 3.00E−49 1 peptidylprolyl isomerase (cyclophilin)-like 518E11 1245 2235 AF332469 Hs.27721 0 5 putative protein WHSC1L1 (WHSG1L1) mRNA, comp 103B11 631 1343 NM_014805 Hs.28020 0 1 KIAA0766 gene product (KIAA0766), mRNA/cds = ( 479H3 4 100 AB007928 Hs.28169 7.00E−37 1 mRNA for KIAA0459 protein, partial cds/cds = (0 526B3 1901 1995 NM_007218 Hs.28285 4.00E−47 1 patched related protein translocated in renal 480E4 4088 4596 AB046766 Hs.28338 0 1 mRNA for KIAA1546 protein, partial cds/cds = (0 164D10 651 970 NM_002970 Hs.28491 1.00E−163 2 spermidine/spermine N1-acetyltransferase ( 69E10 729 1588 AB007888 Hs.28578 0 2 KIAA0428 mRNA, complete cds/cds = (1414,2526) 49B1 632 4266 NM_021038 Hs.28578 0 4 muscleblind (Drosophila)-like (MBNL), mRNA/ 173A10 2105 2391 AL034548 Hs.28608 1.00E−161 2 DNA sequence from clone RP5-1103G7 on chromosome 20p1 156H8 467 585 AV691642 Hs.28739 8.00E−43 1 AV691642 5′ end/clone = GKCDJG11/clone_(—) 588D3 444 909 NM_004800 Hs.28757 1.00E−123 1 transmembrane 9 superfamily member 2 (TM9SF2) 493B12 500 930 NM_003512 Hs.28777 0 1 H2A histone family, member L (H2AFL), mRNA/cd 115C5 63 661 BF341640 Hs.28788 0 1 602016073F1 cDNA, 5′ end/clone = IMAGE: 4151706 524C10 37 412 NM_007217 Hs.28866 1.00E−179 1 programmed cell death 10 (PDCD10), mRNA/cds = ( 39A8 1380 1873 AK000196 Hs.29052 0 1 FLJ20189 fis, clone COLF0657/cds = (122,84 477H7 690 1047 NM_005859 Hs.29117 1.00E−163 1 purine-rich element binding protein A (PURA), 134C8 2462 2789 NM_002894 Hs.29287 1.00E−173 1 retinoblastoma-binding protein 8 (RBBP8), mR 108A11 182 992 M31165 Hs.29352 0 9 tumor necrosis factor-inducible (TSG-6) mRNA fragme 99E8 179 992 NM_007115 Hs.29352 0 7 tumor necrosis factor, alpha-induced protein 169B3 2219 2683 AF039942 Hs.29417 0 1 HCF-binding transcription factor Zhangfei (Z 526A7 2219 2670 NM_021212 Hs.29417 0 1 HCF-binding transcription factor Zhangfei (Z 184H12 2380 4852 AB033042 Hs.29679 0 2 KIAA1216 protein, partial cds/cds = (0 125G9 1169 1814 AB037791 Hs.29716 0 1 mRNA for KIAA1370 protein, partial cds/cds = (4 68F3 1011 1892 AK027197 Hs.29797 0 5 FLJ23544 fis, clone LNG08336/cds = (125,5 72H12 2103 2564 L27071 Hs.29877 0 2 tyrosine kinase (TXK) mRNA, complete cds/ cds = (86,166 588D5 793 1321 NM_003328 Hs.29877 0 1 TXK tyrosine kinase (TXK), mRNA/cds = (86,1669) 127C3 1 1424 AK024961 Hs.29977 0 4 cDNA: FLJ21308 fis, clone COL02131/cds = (287,1 128H7 351 977 NM_014188 Hs.30026 0 1 HSPC182 protein (HSPC182), mRNA/cds = (65,649) 521G4 502 1260 NM_004593 Hs.30035 0 4 splicing factor, arginine/serine-rich (trans 47A2 503 1265 U61267 Hs.30035 0 4 putative splice factor transformer2-beta mRN 37G9 1287 1763 M16967 Hs.30054 0 2 coagulation factor V mRNA, complete cds/ cds = (90,6764 459E1 43 536 NM_015919 Hs.30303 0 1 Kruppel-associated box protein (LOC51595), m 465F6 256 573 NM_005710 Hs.30570 7.00E−75 1 polyglutamine binding protein 1 (PQBP1), mRNA 120H1 5305 5634 NM_012296 Hs.30687 1.00E−172 2 GRB2-associated binding protein 2 (GAB2), mRN 189G2 1 147 BG260954 Hs.30724 2.00E−68 1 602372562F1 cDNA, 5′ end/clone = IMAGE: 4480647 482E6 3086 3254 AK023743 Hs.30818 4.00E−91 1 cDNA FLJ13681 fis, clone PLACE2000014, weakly 179H5 20 1232 AK001972 Hs.30822 0 2 FLJ11110 fis, clone PLACE1005921, weakly 598B6 1 1169 NM_018326 Hs.30822 0 19 hypothetical protein FLJ11110 (FLJ11110), mR 126G10 1309 2463 AK000689 Hs.30882 0 18 cDNA FLJ20682 fis, clone KAIA3543, highly simi 126G7 5221 5904 NM_019081 Hs.30909 1.00E−163 2 KIAA0430 gene product (KIAA0430), mRNA/cds = ( 483D1 1481 2098 NM_003098 Hs.31121 0 1 syntrophin, alpha 1(dystrophin-associated p 464C9 1188 1755 NM_003273 Hs.31130 0 1 transmembrane 7 superfamily member 2 (TM7SF2), 478A6 3024 3837 NM_012238 Hs.31176 1.00E−176 2 sir2-like 1 (SIRT1), mRNA/cds = (53,2296)/gb = 122E5 1060 1294 NM_002893 Hs.31314 1.00E−113 1 retinoblastoma-binding protein 7 (RBBP7), mR 117B1 2056 2489 AF153419 Hs.31323 0 1 IkappaBkinase complex-associated protein (I 462E10 337 569 AV752358 Hs.31409 1.00E−108 1 AV752358 cDNA, 5′ end/clone = NPDBHG03/clone_(—) 126E7 1962 2748 AB014548 Hs.31921 0 2 mRNA for KIAA0648 protein, partial cds/cds = (0 186G11 729 954 BC000152 Hs.31989 1.00E−125 1 Similar to DKFZP586G1722 protein, clone MGC: 67H7 1705 2336 AJ400877 Hs.32017 0 2 ASCL3 gene, CEGP1 gene, C11orf14 gene, C11orf1 102B11 175 874 AK026455 Hs.32148 0 1 FLJ22802 fis, clone KAIA2682, highly sim 458D4 46 449 H14103 Hs.32149 1.00E−167 1 ym62a02.r1 cDNA, 5′ end/clone = IMAGE: 163466/ 99A2 3991 4532 AB007902 Hs.32168 0 1 KIAA0442 mRNA, partial cds/cds = (0,3519)/gb = 458G5 27 540 N30152 Hs.32250 0 1 yx81f03.s1 cDNA, 3′ end/clone = IMAGE: 268157/ 112D11 4399 5040 NM_005922 Hs.32353 0 1 mitogen-activated protein kinase kinase kina 48C8 3278 3988 AB002377 Hs.32556 0 2 mRNA for KIAA0379 protein, partial cds/cds = (0, 515F9 761 989 NM_003193 Hs.32675 1.00E−116 1 tubulin-specific chaperone e (TBCE), mRNA/c 158C12 342 809 NM_016063 Hs.32826 0 1 CGI-130 protein (LOC51020),/cds = (63,575 585E6 128 512 NM_005594 Hs.32916 0 3 nascent-polypeptide-associated complex alp 459B5 1271 1972 NM_017632 Hs.32922 0 1 hypothetical protein FLJ20036 (FLJ20036), mR 469G12 2711 2978 NM_001566 Hs.32944 1.00E−136 1 inositol polyphosphate-4-phosphatase, type 71B7 483 1787 NM_003037 Hs.32970 0 29 signaling lymphocytic activation molecule (S 74G1 1 1780 U33017 Hs.32970 0 33 signaling lymphocytic activation molecule (SLAM) mR 473B11 2993 3361 NM_006784 Hs.33085 1 .00E−111 1 WD repeat domain 3 (WDR3), mRNA/cds = (47,2878) 56B5 23 578 AB019571 Hs.33190 0 1 expressed only in placental villi, clone 469D12 187 394 AL359654 Hs.33756 1.00E−110 1 mRNA full length insert cDNA clone EUROIMAGE 19 98H8 371 618 AI114652 Hs.33757 3.00E−98 1 HA1247 cDNA/gb = AI114652/gi = 6359997/ug = Hs. 594E7 2134 2320 NM_012123 Hs.33979 5.00E−93 1 CGI-02 protein (CGI-02), mRNA/cds = (268,2124) 110D1 1158 1349 NM_018579 Hs.34401 1.00E−105 1 hypothetical protein PRO1278 (PRO1278), mRNA 596A6 1950 2144 NM_022766 Hs.34516 1.00E−102 2 hypothetical protein FLJ23239 (FLJ23239), mR 37B10 237 563 AI123826 Hs.34549 1.00E−145 1 ow61c10.x1 cDNA, 3′ end/clone = IMAGE: 1651314 458H4 3656 4415 AB040929 Hs.35089 0 1 mRNA for KIAA1496 protein, partial cds/cds = (0 100D1 3563 3777 D25215 Hs.35804 1.00E−105 1 KIAA0032 gene, complete cds/cds = (166,3318) 519A12 402 623 AW960004 Hs.36475 3.00E−48 1 EST372075 cDNA/gb = AW960004/gi = 8149688/ug = 498H2 11143 11490 NM_000081 Hs.36508 0 1 Chediak-Higashi syndrome 1 (CHS1), mRNA/cds = ( 521D6 304 791 NM_002712 Hs.36587 0 2 protein phosphatase 1, regulatory subunit 7 ( 460E1 1200 1542 AF319476 Hs.36752 0 2 GKAP42 (FKSG21) mRNA, complete cds/cds = (174,1 184G9 498 1191 AF082569 Hs.36794 0 2 D-type cyclin-interacting protein 1 (DIP1) mR 462D3 493 1517 NM_012142 Hs.36794 0 3 D-type cyclin-interacting protein 1 (DIP1), m 74E12 659 3054 D86956 Hs.36927 0 23 KIAA0201 gene, complete cds/cds = (347,2923) 58G5 1268 2888 NM_006644 Hs.36927 0 12 heat shock 105 kD (HSP105B), mRNA/cds = (313,275 52C10 1479 2588 AK022546 Hs.37747 0 2 FLJ12484 fis, clone NT2RM1001102, weakly 479F9 2066 2322 AL136932 Hs.37892 1.00E−119 1 mRNA; cDNA DKFZp586H1322 (from clone DKFZp586H 483C2 2222 2723 NM_003173 Hs.37936 0 1 suppressor of variegation 3-9 (Drosophila) ho 593G6 673 1213 NM_004510 Hs.38125 0 1 interferon-induced protein 75, 52 kD (IFI75), 101G12 118 436 N39230 Hs.38218 1.00E−173 1 yy50c03.s1 cDNA, 3′ end/clone = IMAGE: 276964/ 107E5 238 525 AW188135 Hs.38664 1.00E−158 1 xj92g04.x1 cDNA, 3′ end/clone = IMAGE: 2664726 596F2 9 504 BF892532 Hs.38664 0 9 IL0-MT0152-061100-501-e04 cDNA/gb = BF892532 469D7 47 474 NM_014343 Hs.38738 0 1 claudin 15 (CLDN15), mRNA/cds = (254,940)/gb = 166H8 1 81 BF103848 Hs.39457 9.00E−34 1 601647352F1 cDNA, 5′ end/clone = IMAGE: 3931452 465F3 157 296 NM_017859 Hs.39850 2.00E−47 1 hypothetical protein FLJ20517 (FLJ20517), mR 195C12 2684 2944 NM_000885 Hs.4C034 1.00E−146 1 integrin, alpha 4 (antigen CD49D, alpha 4 subu 151F11 1393 1661 AL031427 Hs.40094 6.00E−81 1 DNA sequence from clone 167A19 on chromosome 1p32.1-33 134C12 4532 4802 NM_004973 Hs.40154 1.00E−114 1 jumonji (mouse) homolog (JMJ), mRNA/cds = (244, 115C9 5279 5614 AB033085 Hs.40193 1.00E−157 1 mRNA for KIAA1259 protein, partial cds/cds = (1 119A8 862 2087 NM_006152 Hs.40202 0 3 lymphoid-restricted membrane protein (LRMP), 104D4 924 1398 U10485 Hs.40202 0 2 lymphoid-restricted membrane protein (Jaw1) mRNA, c 155G3 226 530 AF047472 Hs.40323 1.00E−114 1 spleen mitotic checkpoint BUB3 (BUB3) mRNA, c 521C2 233 710 NM_004725 Hs.40323 0 1 BUB3 (budding uninhibited by benzimidazoles 3 107B8 187 545 AI927454 Hs.40328 0 1 wo90a02.x1 cDNA, 3′ end/clone = IMAGE: 2462570 458F10 1 436 BE782824 Hs.40334 0 1 601472323F1 cDNA, 5′ end/clone = IMAGE: 3875501 463G6 16 496 AI266255 Hs.40411 0 1 qx69f01.x1 cDNA, 3′ end/clone = IMAGE: 2006617 162F1 2711 2895 D87468 Hs.40888 4.00E−96 1 KIAA0278 gene, partial cds/cds = (0,1383)/gb 463E1 70 272 AL137067 Hs.40919 1.00E−109 1 DNA sequence from clone RP11-13B9 on chromosome 9q22. 458E7 107 774 AK024474 Hs.41045 0 1 mRNA for FLJ00067 protein, partial cds/cds = (1 185G12 1051 2315 AL050141 Hs.41569 1.00E−140 11 mRNA; cDNA DKFZp586O031 (from clone DKFZp586O0 593F5 2106 2490 NM_006190 Hs.41694 0 1 origin recognition complex, subunit 2 (yeast h 513H4 739 1249 NM_002190 Hs.41724 0 6 interleukin 17 (cytotoxic T-lymphocyte-assoc 155F4 739 1247 U32659 Hs.41724 0 1 IL-17 mRNA, complete cds/cds = (53,520)/gb = U32659/g 108H12 892 1227 L40377 Hs.41726 1.00E−170 1 cytoplasmic antiproteinase 2 (CAP2) mRNA, com 477E7 249 404 BG033294 Hs.41989 6.00E−75 1 602298548F1 cDNA, 5′ end/clone = IMAGE: 4393186 143E2 5775 6018 A8033112 Hs.42179 1.00E−136 2 for KIAA1286 protein, partial cds/cds = (1 586B10 720 1225 NM_001952 Hs.42287 0 1 E2F transcription factor 6 (E2F6), mRNA/cds = ( 583A10 346 883 NM_012097 Hs.42500 0 1 ADP-ribosylation factor-like 5 (ARL5), mRNA 459A7 152 251 BC003525 Hs.42712 2.00E−50 1 Similar to Max, clone MGC: 10775, mRNA, comple 37B7 43 2687 AF006082 Hs.42915 1.00E−130 2 actin-related protein Arp2 (ARP2) mRNA, compl 120E3 512 2426 NM_005722 Hs.42915 0 3 ARP2 (actin-related protein 2, yeast) homolog 99D1 3298 3761 NM_014939 Hs.42959 0 1 KIAA1012 protein (KIAA1012), mRNA/cds = (57,43 473B2 3025 3425 AK023647 Hs.43047 1.00E−164 1 cDNA FLJ13585 fis, clone PLACE1009150/cds = UNK 460E6 2988 3184 AB033093 Hs.43141 1.00E−105 1 mRNA for KIAA1267 protein, partial cds/cds = (9 471F7 232 575 AW993524 Hs.43148 0 1 RC3-BN0034-120200-011-h06 cDNA/gb = AW993524 460B10 402 706 BE781009 Hs.43273 1.00E−78 1 601469768F1 cDNA, 5′ end/clone = IMAGE: 3872704 36F6 2815 3403 AK024439 Hs.43616 0 1 for FLJ00029 protein, partial cds/cds = (0 471G3 43 454 NM_006021 Hs.43628 1.00E−165 1 deleted in lymphocytic leukemia, 2 (DLEU2), mR 184H3 1819 2128 D14043 Hs.43910 1.00E−168 2 MGC-24, complete cds/cds = (79,648)/gb = D1404 195F4 511 2370 NM_006016 Hs.43910 0 7 CD164 antigen, sialomucin (CD164), mRNA/cds = 188H9 1573 2277 NM_006346 Hs.43913 0 3 PIBF1 gene product (PIBE1), mRNA/cds = (0,2276) 177H6 1575 2272 Y09631 Hs.43913 0 2 PIBF1 protein, complete/cds = (0,2276)/ 481E6 2529 2873 AB032952 Hs.44087 1.00E−159 1 mRNA for KIAA1126 protein, partial cds/cds = (0 112F5 1105 1701 AF197569 Hs.44143 0 1 BAF180 (BAF180) mRNA, complete cds/cds = (96,48 146F5 2620 3147 AL117452 Hs.44155 0 1 DKFZp586G1517 (from clone DKFZp586G 514C5 166 431 NM_018838 Hs.44163 1.00E−149 3 13 kDa differentiation-associated protein (L 71D9 1117 1800 AF263613 Hs.44198 0 2 membrane-associated calcium-independent ph 68E1 289 527 AA576946 Hs.44242 4.00E−83 1 nm82b03.s1 cDNA, 3′ end/clone = IMAGE: 1074701 53H12 1925 2112 X75042 Hs.44313 4.00E−84 1 rel proto-oncogene mRNA/cds = (177,2036)/gb = X75 595D4 21 402 NM_017867 Hs.44344 0 1 hypothetical protein FLJ20534 (FLJ20534), mR 165B10 250 658 BC000758 Hs.44468 0 1 clone MGC: 2698, mRNA, complete cds/cds = (168, 592E9 37 2422 NM_002687 Hs.44499 0 5 pinin, desmosome associated protein (PNN), mR 69F10 14 1152 Y09703 Hs.44499 0 3 MEMA protein/cds = (406,2166)/gb = Y09703 458H6 1 352 NM_015697 Hs.44563 0 1 hypothetical protein (CL640), mRNA/cds = (0,39 182C11 690 1324 AB046861 Hs.44566 0 4 mRNA for KIAA1641 protein, partial cds/cds = (6 115G3 318 731 BG288837 Hs.44577 0 1 602388170F1 cDNA, 5′ end/clone = IMAGE: 4517129 70B11 1879 4363 U58334 Hs.44585 0 3 Bcl2, p53 binding protein Bbp/53BP2 (BBP/53BP2) mRNA 165F10 265 496 AV726117 Hs.44656 6.00E−66 1 AV726117 cDNA, 5′ end/clone = HTCAXB05/clone_(—) 36F1 444 1176 AK001332 Hs.44672 0 1 FLJ10470 fis, clone NT2RP2000032, weakly 596H1 1073 2711 AF288571 Hs.44865 0 14 lymphoid enhancer factor-1 (LEF1) mRNA, compl 41C4 2876 3407 X60708 Hs.44926 0 1 pcHDP7 mRNA for liver dipeptidyl peptidase IV/ cds = (75 588A7 7564 7849 AL031667 Hs.45207 1.00E−158 1 DNA sequence from clone RP4-620E11 on chromosome 20q1 183G6 3967 4942 AB020630 Hs.45719 0 5 mRNA for KIAA0823 protein, partial cds/cds = (0 465C9 700 1325 BC002796 Hs.46446 0 1 lymphoblastic leukemia derived sequence 1, 464B1 1519 1997 NM_006019 Hs.46465 0 1 T-cell, immune regulator 1 (TCIRG1), mRNA/cds 466F10 455 518 AW974756 Hs.46476 6.00E−26 1 EST386846 cDNA/gb = AW974756/gi = 8165944/ug = 110E7 620 1153 AF223469 Hs.46847 0 1 AD022 protein (AD022) mRNA, complete cds/cds = 112D5 618 1197 NM_016614 Hs.46847 0 4 TRAF and TNF receptor-associated protein (AD0 172G6 4157 4527 NM_003954 Hs.47007 0 1 mitogen-activated protein kinase kinase kina 177C8 4217 4469 Y10256 Hs.47007 1.00E−96 1 serine/threonine protein kinase, NIK/c 458H9 18 457 AW291458 Hs.47325 0 1 UI-H-BI2-agh-c-02-0-UI.s1 cDNA, 3′ end/clon 62B6 562 697 BE872760 Hs.47334 7.00E−54 1 601450902F1 cDNA, 5′ end/clone = IMAGE: 3854544 178F12 169 2413 AF307339 Hs.47783 0 2 B aggressive lymphoma short isoform (BAL) mRNA 460G4 598 1081 NM_005985 Hs.48029 0 1 snail 1 (drosophila homolog), zinc finger prot 70D12 1 2038 AK027070 Hs.48320 0 13 FLJ23417 fis, clone HEP20868/cds = (59,12 41G5 6587 7128 NM_014345 Hs.48433 0 1 endocrine regulator (HRIHFB2436), mRNA/cds = 516H2 1 212 NM_017948 Hs.48712 2.00E−90 2 hypothetical protein FLJ20736 (FLJ20736), mR 517G9 665 1649 NM_004462 Hs.48876 0 2 farnesyl-diphosphate farnesyltransferase 1 146A2 88 440 X76770 Hs.49007 0 1 PAP/cds = UNKNOWN/gb = X76770/gi = 556782/ug 174H4 2612 3200 AF189011 Hs.49163 0 1 ribonuclease III (RN3) mRNA, complete cds/cds 121G3 463 829 NM_017917 Hs.49376 0 1 hypothetical protein FLJ20644 (FLJ20644), mR 170B9 2260 2948 AK023825 Hs.49391 0 1 FLJ13763 fis, clone PLACE4000089/cds = (56 65E2 629 1798 AF062075 Hs.49587 0 4 leupaxin mRNA, complete cds/cds = (93,1253)/g 518B2 26 1798 NM_004811 Hs.49587 0 12 leupaxin (LPXN), mRNA/cds = (93,1253)/gb = NM_0 472E8 1182 1516 AL390132 Hs.49822 0 1 mRNA; cDNA DKFZp547E107 (from clone DKFZp547E1 41B12 57 576 AB000887 Hs.50002 0 1 for EBI1-ligand chemokine, complete cds 41D1 1 310 U86358 Hs.50404 1.00E−135 1 chemokine (TECK) mRNA, complete cds/cds = (0,452)/gb 107C9 2861 3541 M64174 Hs.50651 0 3 protein-tyrosine kinase (JAK1) mRNA, complete cds/c 599H12 202 3541 NM_002227 Hs.50651 0 11 Janus kinase 1 (a protein tyrosine kinase) (JAK 105E3 621 1101 AF047442 Hs.50785 0 1 vesicle trafficking protein sec22b mRNA, comp 129B5 2489 2919 X16354 Hs.50964 0 2 transmembrane carcinoembryonic antigen BGPa 587H2 748 1673 NM_000521 Hs.51043 0 2 hexosaminidase B (beta polypeptide) (HEXB), m 458H12 4043 4561 NM_000887 Hs.51077 0 1 integrin, alpha X (antigen CD11C (p150), alpha 129C9 4055 4567 Y00093 Hs.51077 0 1 leukocyte adhesion glycoprotein p150,95 125D8 2502 3966 AF016266 Hs.51233 0 3 TRAIL receptor 2 mRNA, complete cds/cds = (117,1 179E1 17 343 M22538 Hs.51299 1.00E−179 1 nuclear-encoded mitochondrial NADH-ubiquinone redu 165D7 35 754 NM_021074 Hs.51299 0 4 NADH dehydrogenase (ubiquinone) flavoprotein 107F10 2632 2993 Y11251 Hs.51957 0 2 novel member of serine-arginine domain p 195B12 1344 1590 NM_017903 Hs.52184 3.00E−96 1 hypothetical protein FLJ20618 (FLJ20618), mR 69D7 3046 3568 AB014569 Hs.52526 0 4 for KIAA0669 protein, complete cds/cds = ( 55D1 2607 2847 NM_014779 Hs.52526 1.00E−130 1 KIAA0669 gene product (KIAA0669), mRNA/cds = ( 480B8 1943 2062 AL080213 Hs.52792 8.00E−44 1 mRNA; cDNA DKFZp586I1823 (from clone DKFZp586I 72G7 1236 1348 NM_018607 Hs.52891 2.00E−55 1 hypothetical protein PRO1853 (PRO1853), mRNA 526D1 1 256 NM_004597 Hs.53125 1.00E−114 1 small nuclear ribonucleoprotein D2 polypeptid 458E8 1182 1701 NM_002621 Hs.53155 0 1 properdin P factor, complement (PFC), mRNA/cd 458G2 2171 2836 NM_001204 Hs.53250 0 1 bone morphogenetic protein receptor, type II 458F7 30 650 NM_002200 Hs.54434 0 1 interferon regulatory factor 5 (IRF5), mRNA/ 459F12 2023 3325 NM_006060 Hs.54452 0 2 zinc finger protein, subfamily 1A, 1 (lkaros) ( 41A6 498 755 U46573 Hs.54460 1.00E−140 1 eotaxin precursor mRNA, complete cds/cds = (53,346)/ 590A10 243 659 NM_004688 Hs.54483 0 2 N-myc (and STAT) interactor (NMI), mRNA/cds = ( 461C11 872 1415 NM_014291 Hs.54609 0 1 glycine C-acetyltransferase (2-amino-3-keto 170H5 412 1630 AJ243721 Hs.54642 0 3 for dTDP-4-keto-6-deoxy-D-glucose 4-re 521F5 270 1491 NM_013283 Hs.54642 0 8 methionine adenosyltransferase II, beta (MAT 189H5 737 1049 X76302 Hs.54649 1.00E−131 2 H. sapiens RY-1 mRNA for putative nucleic acid binding protei 599D10 2614 3035 AB029015 Hs.54886 0 5 mRNA for KIAA1092 protein, partial cds/cds = (0 458D5 1026 1676 AK027243 Hs.54890 0 1 cDNA: FLJ23590 fis, clone LNG14491/cds = (709,1 37A10 1633 2040 AK026024 Hs.55024 0 1 FLJ22371 fis, clone HRC06680/cds = (77,12 121A8 799 1217 NM_018053 Hs.55024 1.00E−160 1 hypothetical protein FLJ10307 (FLJ10307), mR 460B1 11195 11326 AF231023 Hs.55173 1.00E−45 1 protocadherin Flamingo 1 (FMI1) mRNA, complete 57F1 1450 2070 NM_003447 Hs.55481 0 2 zinc finger protein 165 (ZNF165), mRNA/cds = (5 68D10 979 2070 U78722 Hs.55481 0 4 zinc finger protein 165 (Zpf165) mRNA, complete 584G7 268 1674 NM_003753 Hs.55682 0 4 eukaryotic translation initiation factor 3, 161C8 63 394 NM_017897 Hs.55781 1.00E−177 1 hypothetical protein FLJ20604 (FLJ20604), mR 588F6 1 387 NM_016497 Hs.55847 0 1 hypothetical protein (LOC51258), mRNA/cds = ( 597E10 334 2073 NM_004446 Hs.55921 0 5 glutamyl-prolyl-tRNA synthetase (EPRS), mRN 138H10 3603 4112 X54326 Hs.55921 0 1 glutaminyl-tRNA synthetase/cds = (58,43 121D5 3959 4192 AB018348 Hs.55947 1.00E−130 1 mRNA for KIAA0805 protein, partial cds/cds = (0 473D12 1428 1866 AJ245539 Hs.55968 0 2 partial mRNA for GaINAc-T5 (GALNT5 gene)/cds = 71E3 843 1724 NM_005542 Hs.56205 0 30 insulin induced gene 1 (INSIG1), mRNA/cds = (414 73F4 843 2495 U96876 Hs.56205 0 32 insulin induced protein 1 (INSIG1) gene, compl 75C8 180 2439 AJ277832 Hs.56247 0 13 for inducible T-cell co-stimulator (ICOS 187A6 2073 2255 AF195530 Hs.56542 2.00E−99 1 soluble aminopeptidase P (XPNPEP1) mRNA, comp 584H5 1496 1889 NM_001494 Hs.56845 1.00E−151 1 GDP dissociation inhibitor 2 (GDI2), mRNA/cds 460C5 2395 2860 AK022936 Hs.56847 0 1 cDNA FLJ12874 fis, clone NT2RP2003769/cds = UNK 460B5 164 741 BC003581 Hs.56851 0 1 Similar to RIKEN cDNA 2900073H19 gene, clone 54G4 1359 1761 AK027232 Hs.57209 0 2 FLJ23579 fis, clone LNG13017/cds = UNKNOW 192D8 1576 2872 AL136703 Hs.57209 0 3 mRNA; cDNA DKFZp566J091 (from clone DKFZp566J0 66F9 618 1056 U41654 Hs.57304 0 1 adenovirus protein E3-14.7k interacting protein 1 ( 183A1 2093 2334 NM_003751 Hs.57783 1.00E−132 1 eukaryotic translation initiation factor 3, 117B3 6933 7225 NM_022898 Hs.57987 1.00E−154 3 B-cell lymphoma/leukaemia 11B (BCL11B), mRNA 74C11 273 359 BE739287 Hs.58066 7.00E−21 1 601556492F1 cDNA, 5′ end/clone = IMAGE: 3826247 174H2 5591 5977 AJ131693 Hs.58103 0 1 mRNA for AKAP450 protein/cds = (222,11948)/gb 599H8 26 993 NM_003756 Hs.58189 0 3 eukaryotic translation initiation factor 3, 168F12 295 593 U54559 Hs.58189 1.00E−166 1 translation initiation factor elF3 p40 subuni 68B11 1 297 BE867841 Hs.58297 1.00E−146 1 601443614F1 cDNA, 5′ end/clone = IMAGE: 3847827 104A6 376 2578 AF001862 Hs.58435 0 3 FYN binding protein mRNA, complete cds/cds = (67 192E3 230 648 NM_001465 Hs.58435 0 4 FYN-binding protein (FYB-120/130) (FYB), mRN 73B4 1287 1763 AK022834 Hs.58488 0 1 FLJ12772 fis, clone NT2RP2001634, highly 100G3 1568 1786 NM_004850 Hs.58617 1.00E−108 1 Rho-associated, coiled-coil containing prot 116G9 1997 2464 NM_013352 Hs.58636 0 1 squamous cell carcinoma antigen recognized by 178C6 5 710 AV760147 Hs.58643 1.00E−111 5 AV760147 cDNA, 5′ end/clone = MDSEPB12/clone_(—) 519B1 2203 2320 NM_014207 Hs.58685 1.00E−56 1 CD5 antigen (p56-62) (CD5), mRNA/cds = (72,1559 40B6 1655 2283 X04391 Hs.58685 0 1 lymphocyte glycoprotein T1/Leu-1/cds = (72,1 466B9 262 534 AI684437 Hs.58774 1.00E−107 1 wa82a04.x1 cDNA, 3′ end/clone = IMAGE: 2302638 480H7 86 234 NM_006568 Hs.59106 1.00E−54 1 cell growth regulatory with ring finger domain 44A7 2229 2703 X17094 Hs.59242 0 1 fur mRNA for furin/cds = (216,2600)/gb = X17094/ gi = 314 106D12 21 380 M96982 Hs.59271 0 2 U2 snRNP auxiliary factor small subunit, compl 39C5 1821 2653 AB011098 Hs.59403 0 1 for KIAA0526 protein, complete cds/cds = ( 185H7 1826 2352 NM_004863 Hs.59403 0 1 serine palmitoyltransferase, long chain base 459C5 126 443 AA889552 Hs.59459 1.00E−158 1 ak20d12.s1 cDNA, 3′ end/clone = IMAGE: 1406519 108B8 2760 3079 AJ132592 Hs.59757 1.00E−138 1 for zinc finger protein, 3115/cds = (107,27 194F7 2074 2461 NM_018227 Hs.59838 0 1 hypothetical protein FLJ10808 (FLJ10808), mR 465D4 2 132 AI440512 Hs.59844 7.00E−67 1 tc83f09.x1 cDNA, 3′ end/clone = IMAGE: 2072777 161H10 1 381 AA004799 Hs.60088 1.00E−169 1 zh96b05.s1 cDNA, 3′ end/clone IMAGE: 429105/ 465B6 228 383 NM_018986 Hs.61053 1.00E−66 1 hypothetical protein (FLJ20356), mRNA/cds = ( 102G9 359 725 D11094 Hs.61153 0 1 MSS1, complete cds/cds = (66,1367)/gb = D11094 193C6 359 725 NM_002803 Hs.61153 1.00E−174 2 proteasome (prosome, macropain) 26S subunit, 99E7 1768 2339 AL023653 Hs.61469 0 10 DNA sequence from clone 753P9 on chromosome Xq25-26.1. 462B9 5 411 BE779284 Hs.61472 1.00E−152 1 601464557F1 cDNA, 5′ end/clone = IMAGE: 3867566 594F11 220 569 NM_003905 Hs.61828 1.00E−159 2 amyloid beta precursor protein-binding prote 102E7 1216 1921 AF046001 Hs.62112 0 3 zinc finger transcription factor (ZNF207) mRN 192B4 754 934 NM_003457 Hs.62112 2.00E−98 2 zinc finger protein 207 (ZNF207), mRNA/cds = (2 41G9 1664 2096 J02931 Hs.62192 0 1 placental tissue factor (two forms) mRNA, complete cd 482E12 1857 2149 NM_001993 Hs.62192 5.00E−87 1 coagulation factor III (thromboplastin, tiss 459C10 1548 1845 AB011114 Hs.62209 1.00E−166 1 mRNA for KIAA0542 protein, partial cds/cds = (39 114D6 2251 2712 NM_002053 Hs.62661 0 1 guanylate binding protein 1, interferon-induc 590C9 83 760 NM_002032 Hs.62954 0 43 ferritin, heavy polypeptide 1 (FTH1), mRNA/c 458C5 1798 2407 AB033118 Hs.63128 0 1 mRNA for KIAA1292 protein, partial cds/cds = (0 109E5 4661 5114 AB002369 Hs.63302 0 1 KIAA0371 gene, complete cds/cds = (247,3843) 589G9 250 5650 NM_021090 Hs.63302 0 6 myotubularin related protein 3 (MTMR3), mRNA 182E4 1751 2144 NM_002831 Hs.63489 0 1 protein tyrosine phosphatase, non-receptor t 589C8 1787 2222 AK023529 Hs.63525 0 2 cDNA FLJ13467 fis, clone PLACE1003519, highly 458D7 1595 1912 NM_022727 Hs.63609 1.00E−180 1 Hpall tiny fragments locus 9C (HTF9C), mRNA/c 193A2 144 2588 NM_003264 Hs.63668 0 5 toll-like receptor 2 (TLR2), mRNA/cds = (129,24 117C3 1504 2366 AF131762 Hs.64001 0 3 clone 25218 mRNA sequence/cds = UNKNOWN/ gb = AF 109F1 568 2157 AL031602 Hs.64239 0 3 DNA sequence from clone RP5-1174N9 on chromosome 1p34 40D5 698 1192 U32324 Hs.64310 0 1 interleukin-11 receptor alpha chain mRNA, complete c 522F4 12 504 NM_006356 Hs.64593 0 1 ATP synthase, H+ transporting, mitochondrial 462E9 215 891 NM_015423 Hs.64595 0 1 aminoadipate-semialdehyde dehydrogenase-ph 164G10 37 889 NM_006851 Hs.64639 0 2 glioma pathogenesis-related protein (RTVP1), 155G10 1 601 U16307 Hs.64639 0 1 glioma pathogenesis-related protein (GliPR) mRNA, c 110D11 341 712 S60099 Hs.64797 0 1 APPH = amyloid precursor protein homolog [human, placenta, 513E8 3411 3986 AF148537 Hs.65450 0 7 reticulon 4a mRNA, complete cds/cds = (141,3719 460F4 1415 1749 NM_018174 Hs.66048 1.00E−163 1 hypothetical protein FLJ10669 (FLJ10669), mR 478H8 486 1037 NM_001775 Hs.66052 0 1 CD38 antigen (p45) (CD38), mRNA/cds = (69,971) 461A6 2977 3516 AB051540 Hs.66053 0 1 mRNA for KIAA1753 protein, partial cds/cds = (0 191E7 1 494 AL157438 Hs.66151 0 6 mRNA; cDNA DKFZp434A115 (from clone DKFZp434A1 464B6 76 623 NM_002528 Hs.66196 0 1 nth (E. coli endonuclease III)-like 1 (NTHL1), 473C6 149 517 BE673759 Hs.66357 0 1 7d69d02.x1 cDNA, 3′ end/clone = IMAGE: 3278211 171G11 1001 1385 Z98884 Hs.66708 0 1 DNA sequence from clone RP3-467L1 on chromosome 1p36. 169H3 15 1800 X82200 Hs.68054 0 4 Staf50/cds = (122,1450)/gb = X82200/gi = 8992 167G9 747 1104 NM_005932 Hs.68583 1.00E−101 1 mitochondrial intermediate peptidase (MIPEP) 170H3 747 1104 U80034 Hs.68583 6.00E−99 1 mitochondrial intermediate peptidase precurs 69F9 321 1348 U78027 Hs.69089 0 5 Bruton's tyrosine kinase (BTK), alpha-D-galac 586D6 16 676 NM_006360 Hs.69469 1.00E−173 2 dendritic cell protein (GA17), mRNA/cds = (51,1 591E3 74 189 NM_002385 Hs.69547 2.00E−59 1 myelin basic protein (MBP), mRNA/cds = (10,570) 597H2 482 2702 NM_007158 Hs.69855 0 8 NRAS-related gene (D15155E), mRNA/cds = (420,2 515C5 3257 3421 NM_003169 Hs.70186 8.00E−45 1 suppressor of Ty (S.cerevisiae) 5 homolog (SUP 461B9 44 425 H06786 Hs.70258 0 1 yl83g05.r1 cDNA, 5′ end/clone = IMAGE: 44737/c 525H4 2834 2978 NM_014933 Hs.70266 4.00E−77 1 yeast Sec31p homolog (KIAA0905), mRNA/cds = (53 521C3 1 1165 NM_016628 Hs.70333 1.00E−176 2 hypothetical protein (LOC51322), mRNA/cds = ( 460E5 414 994 AF138903 Hs.70337 0 1 immunoglobulin superfamily protein beta-like 190C7 1406 1788 D50926 Hs.70359 0 1 mRNA for KIAA0136 gene, partial cds/cds = (0,2854)/gb 497F10 653 1096 NM_014210 Hs.70499 0 3 ecotropic viral integration site 2A (EVI2A), m 37C11 820 1523 AB002368 Hs.70500 0 4 KIAA0370 gene, partial cds/cds = (0,2406)/gb 464B2 496 721 BG283002 Hs.71243 3.00E−99 1 602406192F1 cDNA, 5′ end/clone = IMAGE: 4518214 69G4 1292 2708 AL161991 Hs.71252 0 4 cDNA DKFZp761C169 (from clone DKFZp761C1 485E4 176 485 AA131524 Hs.71433 1.00E−151 1 zl31h02.s1 cDNA, 3′ end/clone = IMAGE: 503571/ 161G2 1338 1877 NM_003129 Hs.71465 0 1 squalene epoxidase (SQLE), mRNA/cds(214,193 188D6 328 597 NM_016630 Hs.71475 1.00E−129 1 hypothetical protein (LOC51324), mRNA/cds = ( 483B5 12 384 NM_021128 Hs.71618 0 1 polymerase (RNA) II (DNA directed) polypeptide 161F6 675 1114 U79277 Hs.71848 0 1 clone 23548 mRNA sequence/cds = UNKNOWN/ gb = U79277/g 473F8 377 729 BE889075 Hs.71941 1.00E−146 1 601513514F1 cDNA, 5′ end/clone = IMAGE: 3915003 102A6 1129 1560 AK023183 Hs.72782 0 1 FLJ13121 fis, clone NT2RP3002687/cds = (39 41E2 56 539 M57506 Hs.72918 0 1 secreted protein (I-309) gene, complete cds/cds = (72, 476E12 1790 2311 S76638 Hs.73090 0 2 p50-NF-kappa B homolog [human, peripheral blood T cells, mR 41G7 3116 3469 U64198 Hs.73165 1.00E−173 1 II-12 receptor beta2 mRNA, complete cds/ cds = (640,322 51C9 1721 2339 NM_005263 Hs.73172 0 4 growth factor independent 1 (GFI1), mRNA/cds = 67H6 1723 2342 U67369 Hs.73172 0 1 growth factor independence-1 (Gfi-1) mRNA, complete 179E7 211 610 M92444 Hs.73722 0 1 apurinic/apyrimidinic endonuclease (HAP1) g 585G3 174 589 NM_001641 Hs.73722 0 8 APEX nuclease (multifunctional DNA repair enz 138A11 1360 1717 M72709 Hs.73737 1.00E−151 1 alternative splicing factor mRNA, complete cds/cds = 49C8 1628 2276 AK001313 Hs.73742 0 4 cDNA FLJ10451 fis, clone NT2RP1000959, highly 41D7 2760 3563 J03565 Hs.73792 0 1 Epstein-Barr virus complement receptor type ll(cr2) 121F8 2470 2815 AL136131 Hs.73793 1.00E−123 1 DNA sequence from clone RP1-261G23 on chromosome 6p12 482C7 2864 3199 NM_003005 Hs.73800 1.00E−165 3 selectin P (granule membrane protein 140 kD, an 153E12 160 778 D90144 Hs.73817 0 22 gene for LD78 alpha precursor, complete cds/c 489E12 161 776 NM_002983 Hs.73817 0 6 small inducible cytokine A3 (homologous to mo 177D7 112 388 BF673951 Hs.73818 1.00E−143 1 602137331F1 cDNA, 5′ end/clone = IMAGE: 4274094 587E10 5 387 NM_006004 Hs.73818 1.00E−155 6 ubiquinol-cytochrome c reductase hinge prote 142H11 119 436 AL110183 Hs.73851 1.00E−148 1 cDNA DKFZp566A221 (from clone DKFZp566A2 190G11 1 375 NM_001685 Hs.73851 0 6 ATP synthase, H+ transporting, mitochondrial 119D10 675 1700 BC001267 Hs.73957 0 4 RAB5A, member RAS oncogene family, clone MGC: 135H12 1244 1772 NM_003016 Hs.73965 0 2 splicing factor, arginine/serine-rich 2 (SFR 160E6 1811 2196 X75755 Hs.73965 0 5 PR264 gene/cds = (98,763)/gb = X75755/gi = 455418 175F9 791 1446 L29218 Hs.73986 0 2 clk2 mRNA, complete cds/cds = (129,1628)/gb = L2 516D9 782 1144 NM_003992 Hs.73987 0 1 CDC-like kinase 3 (CLK3), transcript variant p 469F3 1778 1956 NM_002286 Hs.74011 4.00E−78 1 lymphocyte-activation gene 3 (LAG3), mRNA/cd 481D6 1323 1805 Z22970 Hs.74076 1.00E−173 1 H. sapiens mRNA for M130 antigen cytoplasmic variant 2/cds = ( 193H9 813 1569 NM_007360 Hs.74085 1.00E−127 3 DNA segment on chromosome 12 (unique) 2489 expr 39D9 810 994 X54870 Hs.74085 1.00E−100 1 NKG2-D gene/cds = (338,988)/gb = X54870/gi = 3 71F3 3014 3858 NM_004430 Hs.74088 1.00E−114 4 early growth response 3 (EGR3), mRNA/cds = (357, 74B12 3651 4214 S40832 Hs.74088 1.00E−114 7 EGR3 = EGR3 protein mRNA, 105E11 2 142 AL050391 Hs.74122 6.00E−72 2 cDNA DKFZp586A181 (from clone DKFZp586A1 174A12 141 1072 NM_001225 Hs.74122 0 9 caspase 4, apoptosis-related cysteine protea 599E9 351 1864 AF279903 Hs.74267 0 6 60S ribosomal protein L15 (EC45) mRNA, complet 74F7 126 1867 AF283772 Hs.74267 0 8 clone TCBAP0781 mRNA sequence/cds = (40,654)/ 156G12 554 831 AF034607 Hs.74276 1.00E−156 1 chloride channel ABP mRNA, complete cds/cds = ( 118F4 1 148 BG112085 Hs.74313 7.00E−65 2 602283260F1 cDNA, 5′ end/clone = IMAGE: 4370727 70G10 1 2177 M16660 Hs.74335 0 26 90-kDa heat-shock protein gene, cDNA, complete cds/c 64D1 330 2219 NM_007355 Hs.74335 0 26 heat shock 90 kD protein 1, beta (HSPCB), mRNA/ 121E12 700 1033 NM_006826 Hs.74405 0 1 tyrosine 3-monooxygenase/tryptophan 5-monoo 177D3 480 1645 X57347 Hs.74405 0 2 HS1 protein/cds = (100,837)/gb = X57347/ 155A5 680 1176 U86602 Hs.74407 0 1 nucleolar protein p40 mRNA, complete cds/ cds = (142,10 181G10 1802 2302 NM_012381 Hs.74420 0 2 origin recognition complex, subunit 3 (yeast h 66D8 927 1490 X86691 Hs.74441 0 1 218 kD Mi-2 protein/cds = (89,5827)/gb = X 189D10 383 1102 NM_001749 Hs.74451 0 7 calpain 4, small subunit (30 K) (CAPN4), mRNA/ 171A3 721 1092 X04106 Hs.74451 1.00E−174 1 calcium dependent protease (small subunit)/ 173F3 1069 1468 NM_004559 Hs.74497 0 1 nuclease sensitive element binding protein 1 176B7 1592 1990 NM_001178 Hs.74515 0 1 aryl hydrocarbon receptor nuclear translocato 481A11 2012 2210 NM_000947 Hs.74519 2.00E−61 1 primase, polypeptide 2A (58 kD) (PRIM2A), mRNA 116G8 689 1417 NM_002537 Hs.74563 0 4 ornithine decarboxylase antizyme 2 (OAZ2), mR 526F6 185 1088 NM_003145 Hs.74564 0 3 signal sequence receptor, beta (translocon-as 104D3 713 1127 X79353 Hs.74576 0 1 XAP-4 mRNA for GDP-dissociation inhibitor/cds = ( 518G1 2725 2993 NM_001357 Hs.74578 1.00E−134 1 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 459H1 3093 3268 NM_014767 Hs.74583 3.00E−67 1 KIAA0275 gene product (KIAA0275), mRNA/cds = ( 69C5 2304 2781 M97287 Hs.74592 0 3 MAR/SAR DNA binding protein (SATB1) mRNA 587F12 930 2777 NM_002971 Hs.74592 0 6 special AT-rich sequence binding protein 1 (b 124H10 1240 1812 NM_002808 Hs.74619 0 2 proteasome (prosome, macropain) 26S subunit, 57F10 700 2310 NM_000311 Hs.74621 0 60 prion protein (p27-30) (Creutzfeld-Jakob dis 74A10 870 2252 U29185 Hs.74621 0 34 prion protein (PrP) gene, complete cds/cds = (24 176H10 465 923 NM_000108 Hs.74635 0 1 dihydrolipoamide dehydrogenase (E3 component 98F4 870 2566 NM_003217 Hs.74637 0 7 testis enhanced gene transcript (TEGT), mRNA 179H8 1 1210 X75861 Hs.74637 0 3 TEGT gene/cds = (40,753)/gb = X75861/gi = 456258/ 125C4 417 1425 NM_014280 Hs.74711 0 2 splicing factor similar to dnaJ (SPF31), mRNA 74C5 21 177 BE549137 Hs.74861 4.00E−65 1 601076443F1 cDNA, 5′ end/clone = IMAGE: 3462154 497B12 124 384 NM_006713 Hs.74861 1.00E−123 2 activated RNA polymerase II transcription cof 191E10 497 859 NM_022451 Hs.74899 0 1 hypothetical protein FLJ12820 (FLJ12820), mR 114A3 1032 1446 AY007131 Hs.75061 0 1 clone CDABP0045 mRNA sequence 117G3 279 799 NM_004622 Hs.75066 0 1 translin (TSN), mRNA/cds = (81,767)/gb = NM_004 483G2 3293 3639 NM_006148 Hs.75080 1.00E−180 1 LIM and SH3 protein 1 (LASP1),/cds = (75,860)/g 181E11 8314 8804 NM_000038 Hs.75081 0 1 adenomatosis polyposis coli (APC), mRNA/cds = 597G6 374 2361 NM_003406 Hs.75103 0 6 tyrosine 3-monooxygenase/tryptophan 5-monoo 596F11 684 1088 NM_002097 Hs.75113 0 1 general transcription factor IIIA (GTF3A), mR 69C9 995 1564 AF113702 Hs.75117 0 4 clone FLC1353 PRO3063 mRNA, complete cds/cds = 46E7 128 1519 NM_004515 Hs.75117 1.00E−164 2 interleukin enhancer binding factor 2, 45 kD ( 481B10 66 515 NM_003201 Hs.75133 0 1 transcription factor 6-like 1 (mitochondrial 469C5 368 969 NM_006708 Hs.75207 0 1 glyoxalase I (GLO1), mRNA/cds = (87,641)/gb = N 71B4 939 2049 NM_002539 Hs.75212 0 24 ornithine decarboxylase 1 (ODC1) mRNA/cds = (33 75E10 173 1991 X16277 Hs.75212 0 51 ornithine decarboxylase ODC (EC 4.1.1.17)/c 166G9 2077 2632 L36870 Hs.75217 0 1 MAP kinase kinase 4 (MKK4) mRNA, complete cds/ 167A12 2074 2619 NM_003010 Hs.75217 0 1 mitogen-activated protein kinase kinase 4 (M 105B12 3030 5207 D67029 Hs.75232 0 3 SEC14L mRNA, complete cds 125D1 4782 5209 NM_003003 Hs.75232 0 1 SEC14 (S. cerevisiae)-like 1 (SEC14L1), mRNA 184E4 2075 3174 D42040 Hs.75243 0 5 KIAA9001 gene, complete cds/cds = (1701,4106) 191E5 2071 3174 NM_005104 Hs.75243 0 2 bromodomain-containing 2 (BRD2), mRNA/cds = (1 186C12 4159 4866 NM_001068 Hs.75248 0 6 topoisomerase (DNA) II beta (180 kD) (TOP2B), m 177C9 4473 4866 X68060 Hs.75248 0 1 topIIb mRNA for topoisomerase IIb/cds = (0,4865) 39D8 743 1980 D31885 Hs.75249 0 6 KIAA0069 gene, partial cds/cds = (0,680)/gb = 127G2 1363 1769 NM_016166 Hs.75251 0 1 DEAD/H (Asp-Glu-Ala-Asp/His) box binding pro 64E5 4 1214 NM_002922 Hs.75256 0 6 regulator of G-protein signalling 1 (RGS1), mR 69G5 276 914 S59049 Hs.75256 0 6 BL34 = B cell activation gene [human, mRNA, 1398 nt] 101F6 315 758 AF054174 Hs.75258 0 1 histone macroH2A1.2 mRNA, complete cds/cds = ( 596E10 320 1667 NM_004893 Hs.75258 0 5 H2A histone family, member Y (H2AFY), mRNA/cds 587G10 639 953 NM_001628 Hs.75313 1.00E−147 1 aldo-keto reductase family 1, member B1 (aldo 128F7 181 933 X06956 Hs.75318 0 4 HALPHA44 gene for alpha-tubulin, exons 1-3 74A1 321 3290 D21262 Hs.75337 0 10 KIAA0035 gene, partial cds/cds = (0,2125)/gb 50D8 2 667 BF303895 Hs.75344 0 4 601886515F2 cDNA, 5′ end/clone = IMAGE: 4120514 179F7 379 720 L07633 Hs.75348 1.00E−179 4 (clone 1950.2) interferon-gamma IEF SSP 5111 m 191F3 158 872 NM_006263 Hs.75348 0 18 proteasome (prosome, macropain) activator su 463G4 1849 2394 NM_001873 Hs.75360 0 1 carboxypeptidase E (CPE), mRNA/cds = (290,1720 117D6 224 671 AB023200 Hs.75361 0 1 mRNA for KIAA0983 protein, complete cds/cds = ( 73E8 1 2339 D89077 Hs.75367 0 8 for Src-like adapter protein, complete cd 49H5 1 2388 NM_006748 Hs.75367 0 4 Src-like-adapter (SLA), mRNA/cds = (41,871)/ 134A3 550 1126 NM_005917 Hs.75375 0 1 malate dehydrogenase 1, NAD (soluble) (MDH1), 462F2 73 361 NM_004172 Hs.75379 1.00E−158 1 solute carrier family 1 (glial high affinity gl 477G6 769 2043 NM_004300 Hs.75393 0 3 acid phosphatase 1, soluble (ACP1), transcript 62A10 1028 2528 X87949 Hs.75410 0 7 BiP protein/cds = (222,2183)/gb = X87949 125H4 510 807 NM_006010 Hs.75412 1.00E−130 2 Arginine-rich protein (ARP), mRNA/cds = (132,8 70H1 29 2349 AK026463 Hs.75415 0 30 FLJ22810 fis, clone KAIA2933, highly sim 60D3 160 1666 D31767 Hs.75416 0 6 KIAA0058 gene, complete cds/cds = (69,575)/g 98D5 103 1233 NM_014764 Hs.75416 0 10 DAZ associated protein 2 (DAZAP2), mRNA/cds = ( 55H1 1183 1390 NM_016525 Hs.75425 2.00E−81 1 ubiquitin associated protein (UBAP), mRNA/cd 44B12 51 480 BF131654 Hs.75428 0 3 601820480F1 cDNA, 5′ end/clone = IMAGE: 4052586 64E11 1 177 NM_000454 Hs.75428 7.00E−94 1 superoxide dismutase 1, soluble (amyotrophic 65D3 387 969 L33842 Hs.75432 0 4 (clone FFE-7) type II inosine monophosphate de 58F9 379 672 NM_000884 Hs.75432 1.00E−149 1 IMP (inosine monophosphate) dehydrogenase 2 73B1 87 291 BE790474 Hs.75458 5.00E−71 2 601476059F1 cDNA, 5′ end/clone = IMAGE: 3878799 585G5 1 302 NM_000979 Hs.75458 1.00E−170 8 ribosomal protein L18 (RPL18), mRNA/cds = (15,5 173A1 1893 2653 NM_006763 Hs.75462 0 2 BTG family, member 2 (BTG2), mRNA/cds = (71,547) 166A10 601 1147 AB00015 Hs.75470 0 1 mRNA expressed in osteoblast, complete cds/cd 180D10 601 1045 NM_006820 Hs.75470 0 1 hypothetical protein, expressed in osteoblast 122D9 3322 5191 AB023173 Hs.75478 0 2 mRNA for KIAA0956 protein, partial cds/cds = (0 461E5 2484 2804 AL133074 Hs.75497 1.00E−144 1 mRNA; cDNA DKFZp434M1317 (from clone DKFZp434M 512D6 69 799 NM_004591 Hs.75498 0 12 small inducible cytokine subfamily A (Cys-Cys 146B12 54 783 U64197 Hs.75498 0 4 chemokine exodus-1 mRNA, complete cds/cds = (4 596H5 685 1952 NM_001157 Hs.75510 0 5 annexin A11 (ANXA11), mRNA/cds = (178,1695)/g 179D6 215 603 D23662 Hs.75512 1.00E−168 2 ubiquitin-like protein, complete cds 522G12 52 603 NM_006156 Hs.75512 0 2 neural precursor cell expressed, developmenta 46B6 1108 1418 NM_000270 Hs.75514 1.00E−166 1 nucleoside phosphorylase (NP), mRNA/cds = (109 73H11 83 1418 X00737 Hs.75514 1.00E−104 3 purine nucleoside phosphorylase (PNP; EC 2. 154F7 1279 2056 L05425 Hs.75528 0 3 nucleolar GTPase mRNA, complete cds/cds = (79,2 164C10 1268 1910 NM_013285 Hs.75528 0 2 nucleolar GTPase (HUMAUANTIG), mRNA/cds = (79, 106C8 76 322 Z25749 Hs.75538 1.00E−130 3 gene for ribosomal protein S7/cds = (81,665)/gb = 98E5 474 1188 NM_003405 Hs.75544 0 1 tyrosine 3-monooxygenase/tryptophan 5-monoo 459G10 2160 2717 NM_000418 Hs.75545 0 1 interleukin 4 receptor (IL4R), mRNA/cds = (175, 44B2 71 692 U03851 Hs.75546 0 1 capping protein alpha mRNA, partial cds/ cds = (16,870) 483F2 1207 1392 NM_004357 Hs.75564 1.00E−80 1 CD151 antigen (CD151), mRNA/cds = (84,845)/gb 596D6 1968 2392 NM_021975 Hs.75569 0 1 v-rel avian reticuloendotheliosis viral onco 466G10 679 896 NM_014763 Hs.75574 1.00E−120 2 mitochondrial ribosomal protein L19 (MRPL19), 524B3 6194 6477 NM_001759 Hs.75586 1.00E−147 1 cyclin D2 (CCND2), mRNA/cds = (269,1138)/gb = N 481B4 3423 3804 NM_000878 Hs.75596 1.00E−160 2 interleukin 2 receptor, beta (IL2RB), mRNA/cd 162B5 753 1694 M29064 Hs.75598 0 6 hnRNP B1 protein mRNA/cds = (149,1210)/ gb = M29064/gi 176F5 730 922 NM_002137 Hs.75598 1.00E−106 1 heterogeneous nuclear ribonucleoprotein A2/ 106C2 1654 2589 D10522 Hs.75607 0 8 for 80K-L protein, complete cds/cds = (369, 98C5 1538 2589 NM_002356 Hs.75607 0 20 myristoylated alanine-rich protein kinase C 192E5 1007 1416 NM_006819 Hs.75612 0 1 stress-induced-phosphoprotein 1 (Hsp70/Hsp9 40E12 836 1765 M98399 Hs.75613 0 2 antigen CD36 (clone 21) mRNA, complete cds/ cds(254,1 107C6 1491 1595 AF113676 Hs.75621 3.00E−51 1 clone FLB2803 PRO0684 mRNA, complete cds/cds = 117E9 149 1033 NM_001779 Hs.75626 0 2 CD58 antigen, (lymphocyte function-associate 482H10 740 1367 NM_000591 Hs.75627 0 1 CD14 antigen (CD14), mRNA/cds = (119,1246)/gb 482D4 1342 1659 NM_006163 Hs.75643 3.00E−82 1 nuclear factor (erythroid-derived 2), 45 kD (N 73F8 2864 3657 L49169 Hs.75678 0 20 G0S3 mRNA, complete cds/cds = (593,1609)/ gb = L49169/ 58G3 3222 3657 NM_006732 Hs.75678 0 6 FBJ murine osteosarcoma viral oncogene homolo 53A7 30 836 J04130 Hs.75703 0 138 activation (Act-2) mRNA, complete cds/cds = (108,386) 500E11 41 688 NM_002984 Hs.75703 0 128 small inducible cytokine A4 (homologous to mo 170E9 415 2376 M16985 Hs.75709 0 6 cation-dependent mannose 6-phosphate-specific rece 591E8 1759 2401 NM_002355 Hs.75709 0 3 mannose-6-phosphate receptor (cation depende 191A11 20 1900 NM_002575 Hs.75716 0 13 serine (or cysteine) proteinase inhibitor, cl 184F5 18 1900 Y00630 Hs.75716 0 8 Arg-Serpin (plasminogen activator-inhibito 593G8 238 747 NM_005022 Hs.75721 1.00E−110 2 profilin 1 (PFN1), mRNA/cds = (127,549)/gb = NM 178G9 504 2101 NM_002951 Hs.75722 0 2 ribophorin II (RPN2), mRNA/cds = (288,2183)/g 138F12 2341 2488 Y00282 Hs.75722 4.00E−60 1 ribophorin II/cds = (288,2183)/gb = Y00282/g 37F7 1328 1863 AK023290 Hs.75748 0 3 FLJ13228 fis, clone OVARC1000085, highly 119C7 3736 4103 NM_003137 Hs.75761 1.00E−172 1 SFRS protein kinase 1 (SRPK1), mRNA/cds = (108,2 52E8 574 1106 M36820 Hs.75765 0 2 cytokine (GRO-beta) mRNA, complete cds/ cds = (74,397) 74C8 2055 3026 M10901 Hs.75772 0 4 glucocorticoid receptor alpha mRNA, complete cds/cd 196C5 2600 4591 NM_000176 Hs.75772 0 5 nuclear receptor subfamily 3, group C, member 68E7 2194 2597 D87953 Hs.75789 0 1 RTP, complete cds/cds = (122,1306)/gb = D87953 116E3 289 621 NM_016470 Hs.75798 0 1 hypothetical protein (HSPC207), mRNA/cds = (0 107C10 650 1165 AK025732 Hs.75811 0 1 FLJ22079 fis, clone HEP13180, highly sim 123C12 459 969 NM_004315 Hs.75811 0 1 N-acylsphingosine amidohydrolase (acid cera 99E11 1007 2346 NM_014761 Hs.75824 0 2 KIAA0174 gene product (KIAA0174), mRNA/cds = ( 128C11 377 906 NM_006817 Hs.75841 0 2 endoplasmic reticulum lumenal protein (ERP28 175F5 455 843 X94910 Hs.75841 1.00E−173 1 ERp28 protein/cds = (11,796)/gb = X9491 182F12 4263 4842 D86550 Hs.75842 0 1 mRNA for serine/threonine protein kinase, complete c 175E3 3255 3787 AL110132 Hs.75875 0 1 mRNA; cDNA DKFZp564H192 (from clone DKFZp564H1 195G3 1435 2132 NM_003349 Hs.75875 0 2 ubiquitin-conjugating enzyme E2 variant 1 (U 184B12 17 282 BF698920 Hs.75879 1.00E−138 8 602126495F1 cDNA, 5′ end/clone = IMAGE: 4283350 67G6 1218 1605 AK000639 Hs.75884 1.00E−173 1 FLJ20632 fis, clone KAT03756, highly simi 516A11 721 1109 NM_015416 Hs.75884 0 2 DKFZP586A011 protein (DKFZP586A011), mRNA/c 44B1 1066 4914 NM_004371 Hs.75887 0 4 coatomer protein complex, subunit alpha (COPA 594D3 3971 4158 NM_003791 Hs.75890 1.00E−73 1 site-1 protease (subtilisin-like, sterol-reg 459H8 5291 5688 D87446 Hs.75912 1.00E−160 1 mRNA for KIAA0257 gene, partial cds/cds = (0,5418)/gb 113F6 2281 2807 NM_006842 Hs.75916 0 1 splicing factor 3b, subunit 2, 145 kD (SF382), m 104F9 2334 2804 U41371 Hs.75916 0 1 spliceosome associated protein (SAP 145) mRNA, compl 100F12 656 825 AK024890 Hs.75932 6.00E−83 1 FLJ21237 fis, clone COL01114/cds = UNKNOW 39E1 40 526 BF217687 Hs.75968 1.00E−124 2 601882510F1 cDNA, 5′ end/clone = IMAGE: 4094907 111G8 41 547 NM_021109 Hs.75968 1.00E−166 19 thymosin, beta 4, X chromosome (TMSB4X), mRNA 478A7 1335 1653 NM_006813 Hs.75969 1.00E−119 1 proline-rich protein with nuclear targeting s 70E9 652 1065 U03105 Hs.75969 0 1 B4-2 protein mRNA, complete cds/cds = (113,1096)/ gb = U 596B9 508 1461 NM_003133 Hs.75975 0 2 signal recognition particle 9 kD (SRP9), mRNA 513F12 1359 2169 NM_005151 Hs.75981 0 3 ubiquitin specific protease 14 (tRNA-guanine 74B3 1361 2166 U30888 Hs.75981 0 2 tRNA-guanine transglycosylase mRNA, complete cds/c 67B6 81 1457 X17025 Hs.76038 0 4 homolog of yeast IPP isomerase/cds = (50,736)/ gb = X170 586F2 1471 2197 NM_004396 Hs.76053 0 13 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 70B3 762 2211 X52104 Hs.76053 0 12 p68 protein/cds = (175,2019)/gb = X52104/gi = 3 73B2 32 494 BF214146 Hs.76064 0 1 601847762F1 cDNA, 5′ end/clone = IMAGE: 4078622 523E6 10 441 NM_000990 Hs.76064 0 2 ribosomal protein L27a (RPL27A), mRNA/cds = (1 38F7 6 372 Z23090 Hs.76067 0 2 28 kDa heat shock protein/cds = (491,1108) 59B6 916 1274 AF071596 Hs.76095 1.00E−174 1 apoptosis inhibitor (IEX-1L) gene, complete c 493B3 540 1206 NM_003897 Hs.76095 0 3 immediate early response 3 (IER3), mRNA/cds = ( 483D7 1399 2063 NM_005626 Hs.76122 0 1 splicing factor, arginine/serine-rich 4 (SFR 591C12 13412 13873 NM_003922 Hs.76127 0 3 hect (homologous to the E6-AP (UBE3A) carboxyl 65H7 12209 12580 U50078 Hs.76127 0 1 guanine nucleotide exchange factor p532 mRNA, complet 160B6 79 535 X77584 Hs.76136 1.00E−140 1 ATL-derived factor/thiredoxin/cds = (80 596A9 1 124 NM_001009 Hs.76194 3.00E−62 1 ribosomal protein S5 (RPS5), mRNA/cds = (37,651 51H5 2834 3174 AK025353 Hs.76230 1.00E−180 1 cDNA: FLJ21700 fis, clone COL09849, highly sim 115C8 1589 2005 NM_001748 Hs.76288 0 1 calpain 2, (m/II) large subunit (CAPN2), mRNA 588C5 4 336 NM_004492 Hs.76362 0 2 general transcription factor IIA, 2 (12 kD subu 111D9 732 1077 NM_004930 Hs.76368 1.00E−161 2 capping protein (actin filament) muscle Z-lin 192A11 1589 1995 NM_002462 Hs.76391 0 3 myxovirus (influenza) resistance 1, homolog o 39F5 8481 8730 Y00285 Hs.76473 1.00E−111 1 insuline-like growth factor II receptor/cds 98C4 487 3719 NM_002298 Hs.76506 0 38 lymphocyte cytosolic protein 1 (L-plastin) (L 124H12 611 1747 NM_004862 Hs.76507 0 5 LPS-induced TNF-alpha factor (PIG7), mRNA/cd 37A6 920 1524 U77396 Hs.76507 1.00E−162 2 LPS-Induced TNF-Alpha Factor (LITAF) mRNA, co 71E9 759 3362 D00099 Hs.76549 0 4 mRNA for Na,K-ATPase alpha-subunit, complete 73F5 951 1277 AK001361 Hs.76556 1.00E−168 1 FLJ10499 fis, clone NT2RP2000346, weakly 48H6 1097 1603 NM_014330 Hs.76556 0 2 growth arrest and DNA-damage-inducible 34 (G 160C8 74 181 BE730376 Hs.76572 2.00E−40 1 601563816F1 5′ end/clone = IMAGE: 3833690 589D11 86 455 NM_001697 Hs.76572 0 2 ATP synthase, H+ transporting, mitochondrial 38B1 227 886 NM_014059 Hs.76640 0 9 RGC32 protein (RGC32), mRNA/cds = (146,499)/g 174B12 3024 4628 D80005 Hs.76666 1.00E−136 4 mRNA for KIAA0183 gene, partial cds/cds = (0,3190)/gb 37A11 1788 3255 AF070673 Hs.76691 0 5 stannin mRNA, complete cds/cds = (175,441)/gb 58H11 1706 2088 AL136807 Hs.76698 0 2 mRNA; cDNA DKFZp434L1621 (from clone DKFZp434L 477F9 6930 7298 AB002299 Hs.76730 0 2 mRNA for KIAA0301 gene, partial cds/cds = (0,6144)/gb 40G7 293 819 NM_000118 Hs.76753 0 1 endoglin (Osler-Rendu-Weber syndrome 1) (EN 75C11 10 1113 J00194 Hs.76807 0 5 human hla-dr antigen alpha-chain mrna & ivs fragments/cds = 99F4 10 969 NM_019111 Hs.76807 0 6 major histocompatibility complex, class II, 61G12 1870 2511 AL133096 Hs.76853 0 1 cDNA DKFZp434N1728 (from clone DKFZp434N 599C2 41 346 NM_002790 Hs.76913 1.00E−124 1 proteasome (prosome, macropain) subunit, alp 155C2 508 870 X61970 Hs.76913 0 1 for macropain subunit zeta/cds = (21,746)/g 70C5 3398 3754 AF002020 Hs.76918 0 1 Niemann-Pick C disease protein (NPC1) mRNA, co 57A11 2173 2764 NM_000271 Hs.76918 0 1 Niemann-Pick disease, type C1 (NPC1), mRNA/cd 158C9 314 1233 NM_001679 Hs.76941 0 3 ATPase, Na+/K+ transporting, beta 3 polypeptid 520E1 4175 4502 NM_014757 Hs.76986 1.00E−158 1 mastermind (Drosophila), homolog of (MAML1), 587D8 22 869 NM_001006 Hs.77039 0 5 ribosomal protein S3A (RPS3A), mRNA/cds = (36,8 481F2 440 1488 NM_001731 Hs.77054 0 3 B-cell translocation gene 1, anti-proliferati 53G11 340 1490 X61123 Hs.77054 0 3 BTG1 mRNA/cds = (308,823)/gb = X61123/gi = 29508/ ug = Hs 521A6 147 1325 D55716 Hs.77152 0 2 mRNA for P1cdc47, complete cds/cds = (116,2275)/ gb = D 37H9 2109 2530 X07109 Hs.77202 0 1 protein kinase C (PKC) type/cds = (136,2157)/ 167H5 3915 4508 NM_006437 Hs.77225 0 1 ADP-ribosyltransferase (NAD+; poly (ADP-ribo 139G5 2183 2389 U61145 Hs.77256 1.00E−111 1 enhancer of zeste homolog 2 (EZH2) mRNA, complete cds 109H2 2502 2893 D38549 Hs.77257 0 1 KIAA0068 gene, partial cds/cds = (0,3816)/gb 184B7 619 1111 L25080 Hs.77273 0 1 GTP-binding protein (rhoA) mRNA, complete cds 587H1 614 1371 NM_001664 Hs.77273 0 9 ras homolog gene family, member A (ARHA), mRNA 99G10 1387 2219 NM_002658 Hs.77274 0 1 plasminogen activator, urokinase (PLAU), mRN 143C12 2403 2905 AL049332 Hs.77311 0 2 cDNA DKFZp564L176 (from clone DKFZp564L1 519B11 5248 5555 NM_000430 Hs.77318 1.00E−160 1 platelet-activating factor acetylhydrolase, 52F10 3249 3459 AF095901 Hs.77324 1.00E−114 2 eRF1 gene, complete cds/cds = (136,1449)/gb = A 494G1 3255 3453 NM_004730 Hs.77324 1.00E−109 2 eukaryotic translation termination factor 1 517E4 305 973 NM_014754 Hs.77329 0 2 phosphatidylserine synthase 1 (PTDSS1), mRNA 72F9 1934 4605 AF187320 Hs.77356 0 10 transferrin receptor (TFRC) gene, complete cd 46D6 241 4902 NM_003234 Hs.77356 0 2 transferrin receptor (p90, CD71) (TFRC), mRNA 113A12 1028 1290 NM_024033 Hs.77365 1.00E−145 1 hypothetical protein MGC5242 (MGC5242), mRNA 173A7 1142 1649 AK026164 Hs.77385 0 2 cDNA: FLJ22511 fis, clone HRC11837, highly sim 189E7 466 798 NM_002004 Hs.77393 0 1 farnesyl diphosphate synthase (farnesyl pyro 479B1 306 482 NM_000566 Hs.77424 8.00E−55 1 Fc fragment of IgG, high affinity Ia, receptor 41E12 351 898 X14356 Hs.77424 0 1 high affinity Fc receptor (FcRI)/cds = (36,116 122D3 562 855 NM_002664 Hs.77436 1.00E−145 1 pleckstrin (PLEK), mRNA/cds = (60,1112)/gb = N 59C11 1 2745 X07743 Hs.77436 0 5 pleckstrin (P47)/cds = (60,1112)/gb = X07743 590B1 5185 5274 NM_001379 Hs.77462 1.00E−44 1 DNA (cytosine-5-)-methyltransferase 1 (DNMT1 522D1 572 956 NM_001929 Hs.77494 0 1 deoxyguanosine kinase (DGUOK), mRNA/cds = (11, 109E12 723 2474 D87684 Hs.77495 1.00E−163 5 for KIAA0242 protein, partial cds/cds = (0, 148E2 61 271 BE737246 Hs.77496 1.00E−81 1 601305556F1 5′ end/clone = IMAGE: 3640165 586D4 1887 2362 NM_003363 Hs.77500 0 1 ubiquitin specific protease 4 (proto-oncogene 57E8 29 2808 BC001854 Hs.77502 0 30 methionine adenosyltransferase II, alpha, c 70H9 87 1283 X68836 Hs.77502 0 14 S-adenosylmethionine synthetase/cds = ( 69B2 778 3033 M20867 Hs.77508 0 2 glutamate dehydrogenase (GDH) mRNA, complete cds/cd 513F9 2694 2929 NM_005271 Hs.77508 1.00E−105 1 glutamate dehydrogenase 1 (GLUD1), mRNA/cds = 75A3 190 701 X62744 Hs.77522 0 1 RING6 mRNA for HLA class II alpha product/ cds = (45,830 105E10 72 597 BE673364 Hs.77542 0 3 7d34a03.x1 cDNA, 3′ end/clone = IMAGE: 3249100 124B2 85 683 BF508702 Hs.77542 0 8 UI-H-BI4-aop-g-05-0-UI.s1 cDNA, 3′ end/clon 524C9 829 1233 AK021563 Hs.77558 0 3 cDNA FLJ11501 fis, clone HEMBA1002100/cds = UNK 523B12 7580 8153 NM_004652 Hs.77578 0 2 ubiquitin specific protease 9, X chromosome (D 166F3 169 340 AL021546 Hs.77608 7.00E−63 1 DNA sequence from BAC 15E1 on chromosome 12. Contains 195A11 164 451 NM_003769 Hs.77608 1.00E−162 1 splicing factor, arginine/serine-rich 9 (SF 595E1 618 1461 AF056322 Hs.77617 0 7 SP100-HMG nuclear autoantigen (SP100) mRNA, c 115A6 2954 3541 AL137938 Hs.77646 0 2 mRNA; cDNA DKFZp761M0223 (from clone DKFZp761M 592H6 261 951 NM_014752 Hs.77665 0 3 KIAA0102 gene product (KIAA0102), mRNA/cds = ( 461F3 4657 4980 NM_014749 Hs.77724 1.00E−174 1 KIAA0586 gene product (KIAA0586), mRNA/cds = ( 98C8 27 1961 NM_002543 Hs.77729 0 4 oxidised low density lipoprotein (lectin-like 598A12 101 1396 NM_006759 Hs.77837 0 4 UDP-glucose pyrophosphorylase 2 (UGP2), mRNA 594H8 1 872 NM_006802 Hs.77897 1.00E−144 2 splicing factor 3a, subunit 3, 60 kD (SF3A3), mR 171E4 1140 1394 X81789 Hs.77897 1.00E−110 1 for splicing factor SF3a60/cds = (565,2070) 500F1 2185 2496 AK025736 Hs.77910 1.00E−160 1 cDNA: FLJ22083 fis, clone HEP14459, highly sim 525B10 1696 2060 NM_000122 Hs.77929 0 1 excision repair cross-complementing rodent r 53E1 877 1539 AK026595 Hs.77961 0 7 FLJ22942 fis, clone KAT08170, highly sim 521C6 631 1089 NM_005514 Hs.77961 1.00E−115 4 major histocompatibility complex, class I, B 588C3 300 653 NM_004792 Hs.77965 0 1 Clk-associating RS-cyclophilin (CYP), mRNA 523C6 277 582 NM_001912 Hs.78056 1.00E−143 1 cathepsin L (CTSL), mRNA/cds = (288,1289)/gb = 140D10 292 1549 X12451 Hs.78056 0 3 pro-cathepsin L (major excreted protein MEP) 463E5 129 552 NM_005969 Hs.78103 0 1 nucleosome assembly protein 1-like 4 (NAP1L4) 166H3 540 895 U77456 Hs.78103 0 1 nucleosome assembly protein 2 mRNA, complete cds/cd 40B10 2433 2543 M28526 Hs.78146 5.00E−29 1 platelet endothelial cell adhesion molecule (PECAM-1 114E5 1671 2029 NM_000442 Hs.78146 1.00E−162 1 platelet/endothelial cell adhesion molecule 513D11 28 1399 NM_000700 Hs.78225 0 5 annexin A1 (ANXA1), mRNA/cds = (74,1114)/gb = N 331B3 219 1370 X05908 Hs.78225 0 3 lipocortin/cds = (74,1114)/gb = X05908/gi = 34 56A12 1383 2379 X94232 Hs.78335 0 4 novel T-cell activation protein/cds = (14 465H1 386 904 NM_002812 Hs.78466 0 2 proteasome (prosome, macropain) 26S subunit, 108H7 2067 2486 L42572 Hs.78504 0 1 p87/89 gene, complete cds/cds = (92,2368)/gb = 187E9 729 1494 NM_006839 Hs.78504 0 2 inner membrane protein, mitochondrial (mitofi 102F2 672 2947 L14561 Hs.78546 0 2 plasma membrane calcium ATPase isoform 1 (ATP 591H12 42 1949 NM_004034 Hs.78637 0 3 annexin A7 (ANXA7), transcript variant 2, mRN 595H3 2775 3030 NM_003470 Hs.78683 3.00E−96 1 ubiquitin specific protease 7 (herpes virus-as 62F5 2775 3838 Z72499 Hs.78683 0 2 herpesvirus associated ubiquitin-speci 46G4 2632 3238 NM_003580 Hs.78687 0 1 neutral sphingomyelinase (N-SMase) activatio 513A11 342 1258 NM_002635 Hs.78713 0 10 solute carrier family 25 (mitochondrial carri 472A4 3018 3286 NM_024298 Hs.78768 1.00E−132 1 malignant cell expression-enhanced gene/tumo 177A3 377 1186 AL049589 Hs.78771 0 3 DNA sequence from clone 570L12 on chromosome Xq13.1-2 71E6 303 1767 NM_000291 Hs.78771 0 12 phosphoglycerate kinase 1 (PGK1), mRNA/cds = ( 181D8 2104 3677 NM_018834 Hs.78825 0 4 matrin 3 (MATR3), mRNA/cds = (254,2800)/gb = NM 126G6 2498 2959 AL162049 Hs.78829 0 1 mRNA; cDNA DKFZp762E1712 (from clone DKFZp762E 41C3 1743 2340 M31932 Hs.78864 0 2 IgG low affinity Fc fragment receptor (FcRIIa) mRNA, c 166D11 1696 2156 M81601 Hs.78869 0 1 transcription elongation factor (SII) mRNA, complete 517B3 565 1392 D42039 Hs.78871 0 3 mRNA for KIAA0081 gene, partial cds/cds = (0,702)/ gb = 180G11 59 517 NM_020548 Hs.78888 0 1 diazepam binding inhibitor (GABA receptor mod 99B7 2356 3329 U07802 Hs.78909 0 45 Tis11d gene, complete cds/cds = (291,1739)/ gb = U07802 54C4 557 1101 U13045 Hs.78915 0 1 nuclear respiratory factor-2 subunit beta 1 mRNA, com 44A5 634 1128 U29607 Hs.78935 0 2 methionine aminopeptidase mRNA, complete cds/ cds = (2 63A2 964 1050 X92106 Hs.78943 7.00E−31 1 bleomycin hydrolase/cds = (78,1445)/gb 163G9 228 877 L13463 Hs.78944 0 3 helix-loop-helix basic phosphoprotein (G0S8) mRNA, 119H6 472 877 NM_002923 Hs.78944 0 1 regulator of G-protein signalling 2,24 kD (RG 166E2 5629 5764 U51903 Hs.78993 2.00E−69 1 RasGAP-related protein (IQGAP2) mRNA, complete cds 40F9 66 603 M15796 Hs.78996 0 1 cyclin protein gene, complete cds/cds = (118,903)/gb 593E5 156 854 NM_012245 Hs.79008 0 5 SKI-INTERACTING PROTEIN (SNW1), mRNA/ cds = (2 485B7 276 599 AF063591 Hs.79015 1.00E−136 1 brain my033 protein mRNA, complete cds/cds = (5 61B4 125 732 X05323 Hs.79015 0 2 MRC OX-2 gene signal sequence/cds = (0,824)/ gb = X05323 71C8 330 1958 NM_005261 Hs.79022 0 24 GTP-binding protein overexpressed in skeletal 75G8 330 1957 U10550 Hs.79022 0 63 Gem GTPase (gem) mRNA, complete cds/ cds = (213,1103)/ 584G1 4424 5153 AF226044 Hs.79025 0 2 HSNFRK (HSNFRK) mRNA, complete cds/ cds = (641,2 117C5 358 933 NM_012413 Hs.79033 0 1 glutaminyl-peptide cyclotransferase (glutam 72B2 910 2015 AJ250915 Hs.79037 0 9 p10 gene for chaperonin 10 (Hsp10 protein) and 71G11 880 1981 NM_002156 Hs.79037 0 5 heat shock 60 kD protein 1 (chaperonin) (HSPD1) 193H12 1859 2474 NM_003243 Hs.79059 0 5 transforming growth factor, beta receptor III 460B4 846 1325 NM_001930 Hs.79064 0 1 deoxyhypusine synthase (DHPS), transcript va 75C4 1166 2087 K02276 Hs.79070 0 85 (Daudi) translocated t(8;14) c-myc oncogene mRNA, co 71G10 1274 2121 NM_002467 Hs.79070 0 12 v-myc avian myelocytomatosis viral oncogene h 183D8 385 741 NM_002710 Hs.79081 0 1 protein phosphatase 1, catalytic subunit, gam 170A12 741 1203 X74008 Hs.79081 0 1 protein phosphatase 1 gamma/cds = (154,11 121D9 2920 3385 NM_006378 Hs.79089 0 1 sema domain, immunoglobulin domain (Ig), tran 40C12 2933 4108 U60800 Hs.79089 0 4 semaphorin (CD100) mRNA, complete cds/ cds = (87,2675) 104E1 1708 1932 L35263 Hs.79107 1.00E−101 1 CSaids binding protein (CSBP1) mRNA, complete cds/cd 70B2 913 2497 AK000221 Hs.79110 0 9 FLJ20214 fis, clone COLF2014, highly simi 123B12 1929 2644 D42043 Hs.79123 0 3 mRNA for KIAA0084 gene, partial cds/cds = (0,1946)/gb 193G7 802 1425 NM_004379 Hs.79194 0 2 cAMP responsive element binding protein 1 (CR 75D5 158 2139 NM_004233 Hs.79197 0 16 CD83 antigen (activated B lymphocytes, immuno 74H2 98 1357 NM_001154 Hs.79274 0 2 annexin A5 (ANXA5), mRNA/cds = (192,1154)/gb = 519G7 5358 5496 D86985 Hs.79276 2.00E−69 1 mRNA for KIAA0232 protein, partial cds/cds = (0, 462C2 1477 2031 NM_003006 Hs.79283 0 1 selectin P ligand (SELPLG), mRNA/cds = (59,1267 65C6 23 1609 M15353 Hs.79306 0 6 cap-binding protein mRNA, complete cds/cds = (1 64H8 326 1610 NM_001968 Hs.79306 0 3 eukaryotic translation initiation factor 4E 52C3 1333 1904 X64318 Hs.79334 0 1 E4BP4 gene/cds = (213,1601)/gb = X64318/gi = 30955 39F7 1179 1740 AF109733 Hs.79335 0 1 SWI/SNF-related, matrix-associated, actin-d 194A7 1512 1803 NM_003076 Hs.79335 1.00E−118 1 SWI/SNF related, matrix associated, actin dep 463E12 4326 4831 NM_015148 Hs.79337 0 1 KIAA0135 protein (KIAA0135), mRNA/cds = (1803, 526B5 1420 1867 NM_002958 Hs.79350 0 2 RYK receptor-like tyrosine kinase (RYK), mRNA 460F3 1755 2242 NM_006285 Hs.79358 0 2 testis-specific kinase 1 (TESK1), mRNA/cds = ( 98B11 2076 4834 X76061 Hs.79362 0 11 H. sapiens p130 mRNA for 130K protein/ cds = (69,3488)/gb = X76 45F3 2286 2666 NM_001423 Hs.79368 0 1 epithelial membrane protein 1 (EMP1), mRNA/cd 50C10 2016 2666 Y07909 Hs.79368 0 2 Progression Associated Protein/cds = (21 118E3 549 1078 NM_012198 Hs.79381 0 1 grancalcin (GCL), mRNA/cds = (119,772)/gb = NM_(—) 181F4 657 1271 NM_002805 Hs.79387 0 2 proteasome (prosome, macropain) 26S subunit, 105H3 1114 1538 D83018 Hs.79389 0 1 for nel-related protein 2, complete cds/ 173B2 429 3009 NM_006159 Hs.79389 0 5 nel (chicken)-like 2 (NELL2), mRNA/cds = (96,25 177B3 662 991 AC004382 Hs.79402 0 1 Chromosome 16 BAC clone CIT987SK-A-152E5/cds 590H3 663 1002 NM_002694 Hs.79402 0 1 polymerase (RNA) II (DNA directed) polypeptide 523B7 223 582 NM_002946 Hs.79411 0 1 replication protein A2 (32 kD) (RPA2), mRNA/c 182B10 472 1024 U02019 Hs.79625 1.00E−121 2 AU-rich element RNA-binding protein AUF1 mRNA, comple 479F3 100 301 NM_001783 Hs.79630 2.00E−86 1 CD79A antigen (immunoglobulin-associated al 40H9 582 1107 U05259 Hs.79630 0 1 MB-1 gene, complete cds/cds = (36,716)/gb = U05259/gi 116A2 1003 1368 NM_006224 Hs.79709 1.00E−176 1 phosphotidylinositol transfer protein (PITPN 74G8 252 1297 D21853 Hs.79768 0 5 KIAA0111 gene, complete cds/cds = (214,1449) 525G2 830 1297 NM_014740 Hs.79768 0 2 KIAA0111 gene product (KIAA0111), mRNA/cds = ( 125G3 2757 3339 AF072928 Hs.79877 0 1 myotubularin related protein 6 mRNA, partial c 184A2 532 1102 AF135162 Hs.79933 0 1 cyclin I (CYC1) mRNA, complete cds/cds = (199,13 514C6 329 1256 NM_006835 Hs.79933 0 6 cyclin I (CCNI), mRNA/cds = (0,1133)/gb = NM_006 116G5 824 1058 NM_006875 Hs.80205 1.00E−121 1 pim-2 oncogene (PIM2), mRNA/cds = (185,1189)/ 106C11 1700 1995 U77735 Hs.80205 1.00E−125 1 pim-2 protooncogene homolog pim-2 h mRNA, complete cd 110E3 276 653 AL136139 Hs.80261 0 1 DNA sequence from clone RP4-76112 on chromosome 6 Con 478D1 1067 2761 NM_006403 Hs.80261 2.00E−70 2 enhancer of filamentation 1 (cas-like docking; 178C8 880 1226 AL050192 Hs.80285 0 1 mRNA; cDNA DKFZp586C1723 (from clone DKFZp586C 494F11 477 5535 NM_014739 Hs.80338 0 8 KIAA0164 gene product (KIAA0164), mRNA/cds = ( 190A1 1165 1540 NM_004156 Hs.80350 1.00E−166 2 protein phosphatase 2 (formerly 2A), catalytic 461A1 4639 4913 NM_004653 Hs.80358 1.00E−140 1 SMC (mouse) homolog, Y chromosome (SMCY), mRNA 158A8 2656 3229 L24498 Hs.80409 0 1 gadd45 gene, complete cds/cds = (2327,2824)/ gb = L2449 41E6 2385 2992 U84487 Hs.80420 0 2 CX3C chemokine precursor, mRNA, alternatively splice 40H4 2830 3605 NM_000129 Hs.80424 0 1 coagulation factor XIII, A1 polypeptide (F13A 464D3 214 835 NM_004899 Hs.80426 0 2 brain and reproductive organ-expressed (TNFR 75H8 1180 4930 U12767 Hs.80561 0 60 mitogen induced nuclear orphan receptor (MINOR) mRNA 593E10 1 510 NM_004552 Hs.80595 1.00E−158 5 NADH dehydrogenase (ubiquinone) Fe-S protein 113C5 1182 1583 NM_003336 Hs.80612 0 1 ubiquitin-conjugating enzyme E2A (RAD6 homol 515B7 268 538 NM_001020 Hs.80617 2.00E−91 3 ribosomal protein S16 (RPS16), mRNA/cds = (37,4 477F12 460 606 NM_018996 Hs.80618 1.00E−47 1 hypothetical protein (FLJ20015), mRNA/cds = ( 41A8 1331 1788 L78440 Hs.80642 0 1 STAT4 mRNA, complete cds/cds = (81,2327)/gb = L 594C1 1594 2586 NM_003151 Hs.80642 0 4 signal transducer and activator of transcripti 112C8 1802 1932 NM_002198 Hs.80645 2.00E−35 1 interferon regulatory factor 1 (IRF1), mRNA/ 522H8 1130 1533 NM_003355 Hs.80658 1.00E−135 4 uncoupling protein 2 (mitochondrial, proton c 123E4 259 757 NM_002129 Hs.80684 0 4 high-mobility group (nonhistone chromosomal) 109H1 263 754 X62534 Hs.80684 0 1 HMG-2 mRNA/cds = (214,843)/gb = X62534/gi = 32332 149G9 1020 1607 J05032 Hs.80758 0 2 aspartyl-tRNA synthetase alpha-2 subunit mRNA, compl 461F12 1702 2246 AL031600 Hs.80768 0 1 DNA sequence from clone 390E6 on chromosome 16. Contai 102B2 1486 2008 M16038 Hs.80887 0 1 lyn mRNA encoding a tyrosine kinase/cds = (297,1835)/ 125B11 1260 2013 NM_002350 Hs.80887 0 5 v-yes-1 Yamaguchi sarcoma viral related oncog 37C9 2901 5260 D79990 Hs.80905 0 8 KIAA0168 gene, complete cds/cds = (196,1176) 196D6 2949 5261 NM_014737 Hs.80905 0 9 Ras association (RalGDS/AF-6) domain family 2 584H1 4072 4296 NM_002693 Hs.80961 3.00E−91 1 polymerase (DNA directed), gamma (POLG), nucl 584F9 31 568 AF174605 Hs.81001 0 5 F-box protein Fbx25 (FBX25) mRNA, partial cds 102D11 1037 1632 J03459 Hs.81118 0 1 leukotriene A-4 hydrolase mRNA, complete cds/ cds = (68 193F8 1037 1643 NM_000895 Hs.81118 0 2 leukotriene A4 hydrolase (LTA4H), mRNA/cds = ( 118H7 354 1148 U65590 Hs.81134 0 5 IL-1 receptor antagonist IL-1Ra (IL-1RN) gene 41H1 2549 2936 X60992 Hs.81226 0 1 CD6 mRNA for T cell glycoprotein CD6/cds = (120,152 171B9 2070 2479 AF248648 Hs.81248 0 1 RNA-binding protein BRUNOL2 (BRUNOL2) mRNA, c 590A6 291 512 NM_002961 Hs.81256 3.00E−66 1 S100 calcium-binding protein A4 (calcium prot 73H2 389 1481 M69043 Hs.81328 0 14 MAD-3 mRNA encoding IkB-like activity, complet 513G1 637 1481 NM_020529 Hs.81328 0 13 nuclear factor of kappa light polypeptide gene 488F2 1065 1417 NM_004499 Hs.81361 1.00E−180 4 heterogeneous nuclear ribonucleoprotein A/B 151C8 1260 1423 U76713 Hs.81361 1.00E−61 1 apobec-1 binding protein 1 mRNA, complete cds/ cds = (15 593B9 41 954 NM_001688 Hs.81634 0 3 ATP synthase, H+ transporting, mitochondrial 104H12 352 912 X60221 Hs.81634 0 1 H+-ATP synthase subunit b/cds = (32,802) 141G8 1132 1642 AK001883 Hs.81648 0 1 FLJ11021 fis, clone PLACE1003704, weakly 41A1 4214 4395 X06182 Hs.81665 5.00E−67 1 c-kit proto-oncogene mRNA/cds = (21,2951)/ gb = X06182 102F5 3037 3646 D38551 Hs.81848 0 1 KIAA0078 gene, complete cds/cds = (184,2079) 111E11 1375 1752 NM_006265 Hs.81848 0 1 RAD21 (S. pombe) homolog (RAD21), mRNA/cds = (1 592F8 38 720 NM_014736 Hs.81892 0 1 KIAA0101 gene product (KIAA0101), mRNA/cds = ( 194F1 6886 7115 AF241785 Hs.81897 1.00E−117 1 NPD012 (NPD012) mRNA, complete cds/cds = (552,2 525C6 1 615 NM_005563 Hs.81915 0 4 leukemia-associated phosphoprotein p18 (sta 101D12 3249 3508 D38555 Hs.81964 1.00E−143 1 KIAA0079 gene, complete cds/cds = (114,3491) 176D11 2996 3168 NM_004922 Hs.81964 9.00E−94 2 SEC24 (S. cerevisiae) related gene family, mem 129B7 5068 5759 D50683 Hs.82028 0 4 for TGF-betallR alpha, complete cds/cds = 195H6 946 1208 NM_006023 Hs.82043 6.00E−74 1 D123 gene product (D123), mRNA/cds = (280,1290) 481D9 2709 3085 NM_002184 Hs.82065 1.00E−134 1 interleukin 6 signal transducer (gp130, oncos 129A5 1338 1802 M14083 Hs.82085 0 1 beta-migrating plasminogen activator inhibitor I mR 57G9 500 1561 AF220656 Hs.82101 1.00E−145 3 apoptosis-associated nuclear protein PHLDA1 40C11 3748 4497 M27492 Hs.82112 0 1 interleukin 1 receptor mRNA, complete cds/ cds = (82,17 481B6 3164 3609 NM_000877 Hs.82112 0 1 interleukin 1 receptor, type I (IL1R1), mRNA/ 40H6 161 557 AB049113 Hs.82113 0 1 DUT mRNA for dUTP pyrophosphatase, complete cd 592B7 184 568 NM_001948 Hs.82113 1.00E−111 2 dUTP pyrophosphatase (DUT), mRNA/cds = (29,523 114F1 465 720 U70451 Hs.82116 1.00E−135 1 myleoid differentiation primary response protein My 71H5 194 3415 NM_006186 Hs.82120 0 36 nuclear receptor subfamily 4, group A, member 75C1 1264 3422 X75918 Hs.82120 0 84 NOT/cds = (317,2113)/gb = X75918/gi = 4158 40D1 1621 2080 M90391 Hs.82127 0 1 putative IL-16 protein precursor, mRNA, comple 71C4 678 5065 NM_002460 Hs.82132 0 88 interferon regulatory factor 4 (IRF4), mRNA/ 75G12 3219 5316 U52682 Hs.82132 0 27 lymphocyte specific interferon regulatory factor/in 193G6 1118 2682 NM_006874 Hs.82143 1.00E−178 3 E74-like factor 2 (ets domain transcription fa 147F6 1484 1951 AK025643 Hs.82148 0 1 FLJ21990 fis, clone HEP06386/cds = (22,49 155E4 853 1264 M64992 Hs.82159 0 1 prosomal protein P30-33K (pros-30) mRNA, complete cd 595F1 30 614 NM_002786 Hs.82159 0 3 proteasome (prosome, macropain) subunit, alp 58A4 473 1715 NM_005655 Hs.82173 0 3 TGFB inducible early growth response (TIEG), m 67E6 784 2109 S81439 Hs.82173 0 7 EGR alpha = early growth response gene alpha [human, prostate 593H2 132 722 NM_000985 Hs.82202 0 2 ribosomal protein L17 (RPL17), mRNA/cds = (138, 40H5 283 1442 M37033 Hs.82212 0 12 CD53 glycoprotein mRNA, complete cds/ cds = (93,752)/ 592C4 1 1442 NM_000560 Hs.82212 0 11 CD53 antigen (CD53), mRNA/cds = (93,752)/gb = N 460D4 1519 1845 NM_002510 Hs.82226 1.00E−160 1 glycoprotein (transmembrane) nmb (GPNMB), mR 61A8 507 736 AF045229 Hs.82280 1.00E−116 1 regulator of G protein signaling 10 mRNA, compl 45F7 418 651 NM_002925 Hs.82280 1.00E−119 1 regulator of G-protein signalling 10 (RGS10), 49C2 416 1323 NM_006417 Hs.82316 0 7 interferon-induced, hepatitis C-associated 41C11 847 1716 X63717 Hs.82359 0 2 APO-1 cell surface antigen/cds = (220,122 71H4 15 1627 NM_001781 Hs.82401 0 21 CD69 antigen (p60, early T-cell activation ant 75B10 9 1627 Z22576 Hs.82401 0 33 CD69 gene/cds = (81,680)/gb = Z22576/gi = 397938/ 117B7 1441 1515 NM_022059 Hs.82407 7.00E−28 1 CXC chemokine ligand 16 (CXCL16), mRNA/cds = (4 110D6 1219 1721 AF006088 Hs.82425 0 1 Arp2/3 protein complex subunit p16-Arc (ARC16) 598F10 39 1497 NM_005717 Hs.82425 0 5 actin related protein 2/3 complex, subunit 5 ( 99A9 621 1214 D26018 Hs.82502 0 1 mRNA for KIAA0039 gene, partial cds/cds = (0,1475)/gb 183F6 222 2235 NM_001637 Hs.82542 0 2 acyloxyacyl hydrolase (neutrophil) (AOAH), m 459G4 5196 5801 NM_003682 Hs.82548 0 1 MAP-kinase activating death domain (MADD), mR 75A6 301 2231 D85429 Hs.82646 0 44 heat shock protein 40, complete cds/c 64A5 300 2008 NM_006145 Hs.82646 0 17 heat shock 40 kD protein 1 (HSPF1), mRNA/cds = (4 50E5 628 2399 AK025459 Hs.82689 0 2 FLJ21806 fis, clone HEP00829, highly sim 115C6 23 589 NM_005087 Hs.82712 0 1 fragile X mental retardation, autosomal homol 105H10 1017 1429 M61199 Hs.82767 0 1 cleavage signal 1 protein mRNA, complete cds/ cds = (97, 461A11 204 748 NM_006296 Hs.82771 0 1 vaccinia related kinase 2 (VRK2), mRNA/cds = (1 39B4 1049 1203 M25393 Hs.82829 8.00E−83 1 protein tyrosine phosphatase (PTPase) mRNA, complete 590F5 123 436 NM_002828 Hs.82829 1.00E−178 1 protein tyrosine phosphatase, non-receptor t 517F10 1038 2618 AK025583 Hs.82845 0 9 cDNA: FLJ21930 fis, clone HEP04301, highly sim 40B7 972 1933 M25280 Hs.82848 0 6 lymph node homing receptor mRNA, complete cds/ cds = (11 515B1 1 2322 NM_000655 Hs.82848 0 12 selectin L (lymphocyte adhesion molecule 1) ( 587A10 190 685 NM_001344 Hs.82890 0 1 defender against cell death 1 (DAD1), mRNA/cd 113G9 1 2812 AF208850 Hs.82911 0 7 BM-008 mRNA, complete cds/cds = (341,844)/gb = 127H6 1828 2501 NM_003591 Hs.82919 0 2 cullin 2 (CUL2), mRNA/cds = (146,2383)/gb = NM_0 477E3 931 1777 NM_006416 Hs.82921 0 2 solute carrier family 35 (CMP-sialic acid tran 184D2 1355 1773 AL049795 Hs.83004 1.00E−164 1 DNA sequence from clone RP4-622L5 on chromosome 1p34. 41F10 507 774 D49950 Hs.83077 1.00E−150 1 for interferon-gamma inducing factor(IGI 482E7 499 774 NM_001562 Hs.83077 5.00E−97 1 interleukin 18 (interferon-gamma-inducing f 515C6 111 1162 L38935 Hs.83086 1.00E−107 2 GT212 mRNA/cds = UNKNOWN/gb = L38935/ gi = 100884 479D3 1775 2028 NM_001760 Hs.83173 1.00E−122 1 cyclin D3 (CCND3), mRNA/cds = (165,1043)/gb = N 583H12 945 1655 NM_012151 Hs.83363 0 9 coagulation factor VIII-associated (intronic 47B3 2140 3625 M58603 Hs.83428 0 13 nuclear factor kappa-B DNA binding subunit (NF- kappa- 58G1 2538 3625 NM_003998 Hs.83428 0 4 nuclear factor of kappa light polypeptide gene 477C6 1628 2131 Z49995 Hs.83465 0 1 H. sapiens mRNA (non-coding; clone h2A)/ cds = UNKNOWN/gb = Z4 587D10 1576 1900 AF064839 Hs.83530 0 2 map 3p21; 3.15 cR from WI-9324 region, complete 516B9 1662 3296 X59405 Hs.83532 0 4 H. sapiens, gene for Membrane cofactor protein/ cds = UNKNOWN 459A5 120 298 NM_017459 Hs.83551 7.00E−42 1 microfibrillar-associated protein 2 (MFAP2), 591A12 321 1116 NM_005731 Hs.83583 0 17 actin related protein 2/3 complex, subunit 2 ( 102C1 554 1127 AK025198 Hs.83623 0 1 FLJ21545 fis, clone COL06195/cds = UNKNOW 458C8 1022 1831 NM_001619 Hs.83636 0 1 adrenergic, beta, receptor kinase 1 (ADRBK1), 107G1 303 1008 L20688 Hs.83656 0 4 GDP-dissociation inhibitor protein (Ly-GDI) mRNA, c 597F8 293 1180 NM_001175 Hs.83656 0 55 Rho GDP dissociation inhibitor (GDI) beta (AR 591G5 1 216 NM_003142 Hs.83715 1.00E−108 3 Sjogren syndrome antigen B (autoantigen La) ( 184H9 240 392 X69804 Hs.83715 4.00E−77 2 for La/SS-B protein/cds = UNKNOWN/gb = X69804 193C10 1 1605 BC000957 Hs.83724 1.00E−154 4 Similar to hypothetical protein MNCb-2146, c 40A2 1101 1294 U90904 Hs.83724 1.00E−72 1 clone 23773 mRNA sequence/cds = UNKNOWN/ gb = U90904/g 57H2 191 422 NM_001827 Hs.83758 1.00E−126 1 CDC28 protein kinase 2 (CKS2), mRNA/cds = (95,33 60E10 191 422 X54942 Hs.83758 1.00E−129 1 ckshs2 mRNA for Cks1 protein homologue/cds = (95,3 164F5 1896 2293 NM_016325 Hs.83761 0 1 zinc finger protein 274 (ZNF274), mRNA/cds = (4 463E6 555 1128 NM_000791 Hs.83765 0 1 dihydrofolate reductase (DHFR), mRNA/cds = (47 194F8 1806 2223 NM_002199 Hs.83795 1.00E−161 1 interferon regulatory factor 2 (IRF2), mRNA/ 520D11 180 1229 NM_000365 Hs.83848 0 5 triosephosphate isomerase 1 (TPI1), mRNA/cds 168B6 530 891 U47924 Hs.83848 0 1 chromosome 12p13 sequence/cds = (373,1122)/ gb = U4792 331E11 2591 3485 NM_000480 Hs.83918 0 8 adenosine monophosphate deaminase (isoform E 458A11 125 409 NM_000396 Hs.83942 1.00E−108 1 cathepsin K (pycnodysostosis) (CTSK), mRNA/ 185H2 2501 2690 NM_000195 Hs.83951 3.00E−85 1 Hermansky-Pudlak syndrome (HPS), mRNA/cds = (2 99D2 977 1191 NM_019006 Hs.83954 1.00E−97 1 protein associated with PRK1 (AWP1), mRNA/cds 167D5 2275 2755 NM_000211 Hs.83968 0 4 integrin, beta 2 (antigen CD18 (p95), lymphocyt 524B2 262 575 BF028896 Hs.83992 1.00E−155 1 601765270F1 cDNA, 5′ end/clone = lMAGE: 3997576 523B2 688 1065 NM_015937 Hs.84038 0 1 CGI-06 protein (LOC51604), mRNA/cds = (6,1730) 102F1 951 1416 M63180 Hs.84131 0 1 threonyl-tRNA synthetase mRNA, complete cds/ cds = (13 589D5 863 1700 NM_006400 Hs.84153 0 3 dynactin 2 (p50) (DCTN2), mRNA/cds = (136,1356) 108F6 448 704 U70439 Hs.84264 1.00E−117 1 silver-stainable protein SSP29 mRNA, complete cds/ 146D6 1022 1253 K01144 Hs.84298 6.00E−95 2 major histocompatibility class II antigen gamma chain 188B10 823 1302 NM_004355 Hs.84298 0 1 CD74 antigen (invariant polypeptide of major 175D2 1060 1479 M63488 Hs.84318 1.00E−158 1 replication protein A 70 kDa subunit mRNA complete cds 115F4 2305 2393 NM_002945 Hs.84318 2.00E−43 1 replication protein A1 (70 kD) (RPA1), mRNA/cd 595H4 5400 5649 NM_004239 Hs.85092 1.00E−131 1 thyroid hormone receptor interactor 11 (TRIP1 106F1 493 1371 NM_017491 Hs.85100 0 3 WD repeat domain 1 (WDR1), transcript variant 1 40C10 438 880 X57025 Hs.85112 0 1 IGF-I mRNA for insulin-like growth factor I/cds = (166, 44C5 2247 2430 AF017257 Hs.85146 5.00E−89 1 chromosome 21 derived BAC containing erythrobl 45D4 1962 3324 X79067 Hs.85155 0 6 H. sapiens ERF-1 mRNA 3′ end/cds = UNKNOWN/ gb = X79067/gi = 483 591B9 2378 2603 NM_002880 Hs.85181 1.00E−109 1 v-raf-1 murine leukemia viral oncogene homolo 39E2 67 2493 X76488 Hs.85226 0 3 lysosomal acid lipase/cds = (145,1344)/ 62H12 1249 1975 M12824 Hs.85258 0 3 T-cell differentiation antigen Leu-2/T8 mRNA, partia 40C8 4505 4856 X53587 Hs.85266 0 1 integrin beta 4/cds = UNKNOWN/gb = X53587/gi = 40E11 1983 2633 S53911 Hs.85289 0 1 CD34 = glycoprotein expressed in lymphohematopoietic proge 135A2 121 695 BC001646 Hs.85301 0 2 clone MGC: 2392, mRNA, complete cds/cds = (964, 459H4 33 244 AK027067 Hs.85567 2.00E−90 1 cDNA: FLJ23414 fis, clone HEP20704/cds = (37,10 479A4 5556 5974 AB040974 Hs.85752 1.00E−171 1 mRNA for KIAA1541 protein, partial cds/cds = (9 146C3 1610 2062 AL049796 Hs.85769 0 1 DNA sequence from clone RP4-561L24 on chromosome 1p22 463H11 871 1153 NM_006546 Hs.86088 5.00E−83 1 IGF-II mRNA-binding protein 1 (IMP-1), mRNA/ 480A12 2 165 NM_004876 Hs.86371 7.00E−84 1 zinc finger protein 254 (ZNF254), mRNA/cds = (1 192F7 2854 3462 AF198614 Hs.86386 0 3 McI-1 (MCL-1) and McI-1 delta S/TM (MCL-1) gene 459G3 12 577 AL049340 Hs.86405 0 1 mRNA; cDNA DKFZp564P056 (from clone DKFZp564P0 460E4 2361 2787 NM_000161 Hs.86724 0 2 GTP cyclohydrolase 1 (dopa-responsive dystoni 62F9 834 1282 M60724 Hs.86858 0 1 p70 ribosomal S6 kinase alpha-1 mRNA, complete cds/cd 187E7 84 766 NM_001695 Hs.86905 0 1 ATPase, H+ transporting, lysosomal (vacuolar 159D4 315 559 J03798 Hs.86948 1.00E−113 1 autoantigen small nuclear ribonucleoprotein Sm-D mR 459F9 1557 1619 NM_006938 Hs.86948 2.00E−25 1 small nuclear ribonucleoprotein D1 polypeptid 480G11 87 603 BG168139 Hs.87113 0 1 602341526F1 cDNA, 5′ end/clone = IMAGE: 4449343 41D6 2208 2320 M35999 Hs.87149 4.00E−39 1 platelet glycoprotein lll a (GPllla) mRNA, complete c 462H11 387 648 NM_003806 Hs.87247 1.00E−133 1 harakiri, BCL2-interacting protein (contains 99D7 614 5517 NM_003246 Hs.87409 0 62 thrombospondin 1 (THBS1), mRNA/cds = (111,3623 39B8 2130 5517 X14787 Hs.87409 0 33 thrombospondin/cds = (111,3623)/gb = X14787 525A2 329 560 NM_007047 Hs.87497 1.00E−129 2 butyrophilin, subfamily 3, member A2 (BTN3A2) 583F2 3303 3622 D63876 Hs.87726 1.00E−155 1 mRNA for KIAA0154 gene, partial cds/cds = (0,2080)/gb 184D7 2211 2556 M34181 Hs.87773 1.00E−165 1 testis-specific cAMP-dependent protein kinase catal 460A4 499 1074 AL117637 Hs.87794 0 1 mRNA; cDNA DKFZp4341225 (from clone DKFZp43412 459G2 258 452 AW967701 Hs.87912 8.00E−88 1 EST379776 cDNA/gb = AW967701/gi = 8157540/ug = 74H7 1660 2397 AK026960 Hs.88044 0 9 FLJ23307 fis, clone HEP11549, highly sim 463D12 351 568 AI184553 Hs.88130 1.00E−118 1 qd60a05.x1 cDNA, 3′ end/clone = IMAGE: 1733840 595B1 309 986 NM_003454 Hs.88219 0 1 zinc finger protein 200 (ZNF200), mRNA/cds = (2 458D3 1018 1285 NM_000487 Hs.88251 6.00E−74 1 arylsulfatase A (ARSA), mRNA/cds = (375,1898) 462F4 4272 4846 AJ271878 Hs.88414 0 1 mRNA for putative transcription factor (BACH2 460B12 1267 2022 NM_006800 Hs.88764 0 3 male-specific lethal-3 (Drosophila)-like 1 461A4 2039 2421 AL161659 Hs.88820 0 1 DNA sequence from clone RP11-526K24 on chromosome 20 460F9 3413 3654 NM_000397 Hs.88974 1.00E−133 1 cytochrome b-245, beta polypeptide (chronic g 459G9 790 1160 NM_006228 Hs.89040 1.00E−145 1 prepronociceptin (PNOC), mRNA/cds = (211,741) 70H12 1 661 AV716500 Hs.89104 0 274 AV716500 cDNA, 5′ end/clone = DCBAKA08/clone_(—) 469H5 1620 2142 AB040961 Hs.89135 0 1 mRNA for KIAA1528 protein, partial cds/cds = (4 175G6 2069 2501 D83243 Hs.89385 0 1 NPAT mRNA, complete cds/cds = (66,4349)/ gb = D83243/g 592B10 3703 3936 NM_002519 Hs.89385 1.00E−130 1 nuclear protein, ataxia-telangiectasia locu 120B7 337 630 NM_005176 Hs.89399 1.00E−114 1 ATP synthase, H+ transporting, mitochondrial 39D2 370 1892 AF147204 Hs.89414 0 68 chemokine receptor CXCR4-Lo (CXCR4) mRNA, alt 99H4 7 1625 NM_003467 Hs.89414 0 137 chemokine (C-X-C motif), receptor 4 (fusin) (C 106D2 2 266 U03644 Hs.89421 1.00E−143 1 recepin mRNA, complete cds/cds = (32,1387)/ gb = U03644 41F5 1203 1522 M16336 Hs.89476 1.00E−170 1 T-cell surface antigen CD2 (T11) mRNA, complete cds, c 463A3 876 1025 NM_000698 Hs.89499 1.00E−79 1 arachidonate 5-lipoxygenase (ALOX5), mRNA/c 47D12 1198 4887 AB028969 Hs.89519 0 2 for KIAA1046 protein, complete cds/cds = ( 498G2 4420 5265 NM_014928 Hs.89519 0 2 KIAA1046 protein (KIAA1046), mRNA/cds = (577,1 589G3 598 689 NM_002796 Hs.89545 4.00E−45 2 proteasome (prosome, macropain) subunit, bet 331B1 699 788 S71381 Hs.89545 1.00E−41 1 prosome beta-subunit = multicatalytic proteinase complex 110A2 1403 1739 AK026432 Hs.89555 1.00E−177 1 FLJ22779 fis, clone KAIA1741/cds = (234,1 118E4 780 1672 NM_002110 Hs.89555 0 5 hemopoietic cell kinase (HCK), mRNA/cds = (168, 41B8 570 1166 M89957 Hs.89575 0 1 immunoglobulin superfamily member B cell receptor co 44A11 2567 2808 L20814 Hs.89582 1.00E−115 1 glutamate receptor 2 (HBGR2) mRNA, complete cds/ cds = ( 191G11 309 596 NM_006284 Hs.89657 1.00E−162 11 TATA box binding protein (TBP)-associated fac 72G5 1172 1575 AX023367 Hs.89679 0 38 Sequence 38 from Patent WO0006605 71B12 40 559 NM_000586 Hs.89679 0 13 interleukin 2 (IL2), mRNA/cds = (47,517)/gb = N 179G12 158 737 M36821 Hs.89690 0 1 cytokine (GRO-gamma) mRNA, complete cds 193B5 680 1146 NM_002994 Hs.89714 0 17 small inducible cytokine subfamily B (Cys-X-Cy 182G10 681 1146 X78686 Hs.89714 0 7 ENA-78 mRNA/cds = (106,450)/gb = X78686/gi = 47124 191C6 617 1597 NM_021950 Hs.89751 0 2 membrane-spanning 4-domains, subfamily A, m 40H3 1347 1597 X07203 Hs.89751 3.00E−71 1 CD20 receptor (S7)/cds = (90,983)/gb = X07203 458H2 3524 4331 NM_002024 Hs.89764 0 2 fragile X mental retardation 1 (FMR1), mRNA/c 40F6 1665 2210 D38081 Hs.89887 0 1 thromboxane A2 receptor, complete cds/cds = (9 473E1 578 956 AL515381 Hs.89986 1.00E−172 1 AL515381 cDNA/clone = CLOBB017ZH06-(3-prime) 126A12 770 982 AL558028 Hs.90035 1.00E−102 1 AL558028 cDNA/clone = CS0DJ002YF02-(5-prime) 183E12 2203 2814 NM_001316 Hs.90073 0 1 chromosome segregation 1 (yeast homolog)-like 145H12 1602 1811 AK026766 Hs.90077 1.00E−113 2 FLJ23113 fis, clone LNG07875, highly sim 62C2 1472 2610 AB023420 Hs.90093 0 2 for heat shock protein apg-2, complete cds 46H6 3172 3411 D26488 Hs.90315 6.00E−86 1 mRNA for KIAA0007 gene, partial cds/cds = (0,2062)/gb 116E2 1637 2016 AK025800 Hs.90421 1.00E−118 1 cDNA: FLJ22147 fis, clone HEP22163, highly sim 525H3 6 1231 NM_004261 Hs.90606 0 2 15 kDa selenoprotein (SEP15), mRNA/cds = (4,492 184D8 287 387 BE888304 Hs.90654 1.00E−46 2 601514033F1 cDNA, 5′ end/clone = IMAGE: 3915177 99D4 1948 4309 D50918 Hs.90998 0 5 mRNA for KIAA0128 gene, partial cds/cds = (0,1276)/gb 72B9 571 1312 AK026954 Hs.91065 0 1 FLJ23301 fis, clone HEP11120/cds = (2,188 586H8 189 478 NM_000987 Hs.91379 2.00E−83 1 ribosomal protein L26 (RPL26), mRNA/cds = (6,44 160A12 1 132 X69392 Hs.91379 4.00E−69 5 ribosomal protein L26/cds = (6,443)/gb = 331H4 1632 2166 AK027210 Hs.91448 0 1 FLJ23557 fis, clone LNG09686, highly sim 473E6 915 1390 NM_004556 Hs.91640 0 2 nuclear factor of kappa light polypeptide gene 69E4 673 1328 A8007956 Hs.92381 1.00E−122 2 mRNA, chromosome 1 specific transcript KIAA04 182F10 117 781 AF070523 Hs.92384 0 1 JWA protein mRNA, complete cds/cds = (115,681) 585F10 77 1890 NM_006407 Hs.92384 0 13 vitamin A responsive; cytoskeleton related (J 469G3 2061 2293 AK025683 Hs.92414 1.00E−110 1 cDNA: FLJ22030 fis, clone HEP08669/cds = UNKNOW 472H4 247 671 AW978555 Hs.92448 0 1 EST390664 cDNA/gb = AW978555/gi = 8169822/ug = 193F11 2051 4721 NM_003103 Hs.92909 0 3 SON DNA binding protein (SON), mRNA/cds = (414,4 37E7 1287 1805 AK002059 Hs.92918 0 1 FLJ11197 fis, clone PLACE1007690/cds = (37 111D7 244 596 NM_016623 Hs.92918 1.00E−166 1 hypothetical protein (BM-009), mRNA/cds = (385 41B10 1216 1530 U24577 Hs.93304 1.00E−173 1 LDL-phospholipase A2 mRNA, complete cds/ cds = (216,15 48B4 76 723 NM_001417 Hs.93379 0 5 eukaryotic translation initiation factor 4B 39F8 76 876 X55733 Hs.93379 0 1 initiation factor 4B cDNA/cds = (0,1835)/gb = X557 471B10 660 886 NM_007020 Hs.93502 1.00E−125 1 U1-snRNP binding protein homolog (70 kD) (U1SN 467A3 1189 1284 X91348 Hs.93522 3.00E−36 1 H. sapiens predicted non coding cDNA (DGCR5)/ cds = UNKNOWN/ 461B5 652 874 NM_003367 Hs.93649 1.00E−104 1 upstream transcription factor 2, c-fos intera 62B8 1386 1739 J05016 Hs.93659 1.00E−170 1 (clone pA3) protein disulfide isomerase related prote 461E7 1931 2086 NM_004911 Hs.93659 1.00E−65 1 protein disulfide isomerase related protein ( 458G11 2423 3161 AB040959 Hs.93836 0 1 mRNA for KIAA1526 protein, partial cds/cds = 104E3 516 981 AK000967 Hs.93872 0 1 FLJ10105 fis, clone HEMBA 1002542/cds = UN 41B6 87 846 X04430 Hs.93913 0 2 IFN-beta 2a mRNA for interferon-beta-2/cds = (86,724) 179H7 1610 1682 AF009746 Hs.94395 9.00E−34 1 peroxisomal membrane protein 69 (PMP69) mRNA, 470G3 74 493 NM_007221 Hs.94446 0 1 polyamine-modulated factor 1 (PMF1), mRNA/c 472A5 2325 2429 AK022267 Hs.94576 2.00E−48 1 cDNA FLJ12205 fis, clone MAMMA1000931/ cds = UNK 459C9 5356 6120 NM_006421 Hs.94631 0 3 brefeldin A-inhibited guanine nucleotide-exc 465F8 3580 4049 NM_015125 Hs.94970 0 1 KIAA0306 protein (KIAA0306), mRNA/cds = (0,436 57B9 4145 4379 NM_005109 Hs.95220 1.00E−126 1 oxidative-stress responsive 1 (OSR1), mRNA/c 160D6 30 480 X01451 Hs.95327 0 2 gene for 20 K T3 glycoprotein (T3-delta-chain) of T-c 512G1 1 415 BF107010 Hs.95388 1.00E−175 2 601824367F1 cDNA, 5′ end/clone = IMAGE: 4043920 593E11 24 273 BG291649 Hs.95835 1.00E−79 10 602385778F1 cDNA, 5′ end/clone = IMAGE: 4514827 41H2 1011 1306 M28170 Hs.96023 1.00E−114 1 cell surface protein CD19 (CD19) gene, complete cds/c 149G8 213 435 BF222826 Hs.96487 1.00E−119 2 7q23f06.x1/clone = IMAGE/gb = BF222826/g 101G7 2266 3173 AL133227 Hs.96560 0 2 DNA sequence from clone RP11-394O2 on chromosome 20 C 103E6 2840 3451 BC000143 Hs.96560 0 1 Similar to hypothetical protein FLJ11656, cl 107G5 226 2349 BF673956 Hs.96566 7.00E−24 1 602137338F1 cDNA, 5′ end/clone = IMAGE: 4274048 461A12 3602 4135 AB014555 Hs.96731 0 2 mRNA for KIAA0655 protein, partial cds/cds = (0 595A8 82 1571 NM_000734 Hs.97087 1.00E−147 10 CD3Z antigen, zeta polypeptide (TiT3 complex) 479H8 883 1378 NM_014373 Hs.97101 0 3 putative G protein-coupled receptor (GPCR150) 466D12 2001 5732 NM_012072 Hs.97199 0 2 complement component C1q receptor (C1QR), mRN 194B3 1835 2898 NM_002990 Hs.97203 0 2 small inducible cytokine subfamily A (Cys-Cys) 109E9 2880 3536 AF083322 Hs.97437 0 1 centriole associated protein CEP110 mRNA, com 459H5 9 230 BF438062 Hs.97896 1.00E−116 1 7q66e08.x1 cDNA/clone = IMAGE/gb = BF438062/g 473A4 871 1327 NM_007015 Hs.97932 0 1 chondromodulin I precursor (CHM-I), mRNA/cds 466E9 1408 1808 AL442083 Hs.98026 1.00E−172 2 mRNA; cDNA DKFZp547D144 (from clone DKFZp547D1 460E3 1290 1687 AF038564 Hs.98074 0 1 atrophin-1 interacting protein 4 (AIP4) mRNA, 462E6 103 642 NM_016440 Hs.98289 0 1 VRK3 for vaccinia related kinase 3 (LOC51231), 460B8 114 546 AA418743 Hs.98306 1.00E−178 1 zv98f06.s1 cDNA, 3′ end/clone = IMAGE: 767843/ 124A8 1 157 NM_019044 Hs.98324 2.00E−69 1 hypothetical protein (FLJ10996), mRNA/cds = ( 71B10 79 520 AI761058 Hs.98531 1.00E−112 34 wi69b03.x1 cDNA, 3′ end/clone = IMAGE: 2398541 49F1 36 435 AA913840 Hs.98903 0 1 oI39d11.s1 cDNA, 3′ end/clone = IMAGE: 1525845 462F6 61 201 AC006276 Hs.99093 2.00E−74 1 chromosome.19, cosmid R28379/cds = (0,633)/gb 473A2 47 475 BE326857 Hs.99237 0 1 hr65h06.x1 cDNA, 3′ end/clone = IMAGE: 3133403 599D8 1468 1748 NM_005825 Hs.99491 1.00E−132 1 RAS guanyl releasing protein 2 (calcium and DA 459F8 300 541 AW444899 Hs.99665 1.00E−123 1 UI-H-BI3-ajz-d-07-0-UI.s1 cDNA, 3′ end/clon 163H9 8 141 AL049319 Hs.99821 2.00E−58 1 cDNA DKFZp564C046 (from clone DKFZp564C0 165H8 1176 1930 NM_015400 Hs.99843 0 2 DKFZP586N0721 protein (DKFZP586N0721), mRNA 188C9 543 998 NM_001436 Hs.99853 0 2 fibrillarin (FBL), mRNA/cds = (59,1024)/gb = N 37H2 759 2017 AC018755 Hs.99855 0 4 chromosome 19, BAC BC330783 (CIT-HSPC_470E3), 127H3 758 2183 NM_001462 Hs.99855 0 5 formyl peptide receptor-like 1 (FPRL1), mRNA 62F2 1 642 BF315159 Hs.99858 0 6 601899519F1 cDNA, 5′ end/clone = IMAGE: 4128749 599A7 26 838 NM_000972 Hs.99858 0 11 ribosomal protein L7a (RPL7A), mRNA/cds = (31,8 167B3 1994 2101 AB032251 Hs.99872 2.00E−37 1 BPTF mRNA for bromodomain PHD finger transcript 41G8 461 751 L08096 Hs.99899 1.00E−161 1 CD27 ligand mRNA, complete cds/cds = (150,731)/ gb = L08 479C10 327 738 NM_001252 Hs.99899 0 1 tumor necrosis factor (ligand) superfamily, m 36D8 1180 2315 AL162047 Hs.99908 0 7 cDNA DKFZp762E1112 (from clone DKFZp762E 593E2 62 435 NM_000983 Hs.99914 1.00E−145 1 ribosomal protein L22 (RPL22), mRNA/cds = (51,4 478C8 48 311 NM_000023 Hs.99931 1.00E−112 1 sarcoglycan, alpha (50 kD dystrophin-associat 61A1 827 1053 S62140 Hs.99969 1.00E−126 1 TLS = translocated in liposarcoma [human, mRNA, 1824 nt]/cd 40C7 971 1724 X69819 Hs.99995 0 1 ICAM-3 mRNA/cds = (8,1651)/gb = X69819/gi = 32627 116F8 109 376 NM_002964 Hs.100000 1.00E−123 5 S100 calcium-binding protein A8 (calgranulin 121F4 30 540 NM_001629 Hs.100194 1.00E−118 7 arachidonate 5-lipoxygenase-activating pro 46G10 5175 5624 NM_003605 Hs.100293 0 2 O-linked N-acetylglucosamine (GlcNAc) transf 49E4 1279 2585 NM_006773 Hs.100555 0 4 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 61E1 1279 1767 X98743 Hs.100555 0 2 RNA helicase (Myc-regulated dead box pro 460A10 824 1321 NM_018099 Hs.100895 0 1 hypothetical protein FLJ10462 (FLJ10462), mR 458F1 1 303 R18757 Hs.100896 1.00E−157 1 yg17e04.r1 cDNA, 5′ end/clone = IMAGE: 32522/c 64B8 2062 2711 AB007859 Hs.100955 0 1 mRNA for KIAA0399 protein, partial cds/cds = (0, 515H6 131 201 NM_001207 Hs.101025 6.00E−33 1 basic transcription factor 3 (BTF3), mRNA/cd 472H12 10 358 AW968686 Hs.101340 0 1 EST380762 cDNA/gb = AW968686/gi = 8158527/ug = 99G6 2427 4860 AB002384 Hs.101359 0 9 mRNA for KIAA0386 gene, complete cds/ cds = (177,3383) 62E12 193 573 AI936516 Hs.101370 1.00E−100 6 wd28h07.x1 cDNA, 3′ end/clone = IMAGE: 2329501 493B9 3 638 AL583391 Hs.101370 0 8 AL583391 cDNA/clone = CS0DL012YA12-(3-prime) 117D4 2812 2966 NM_006291 Hs.101382 7.00E−79 1 tumor necrosis factor, alpha-induced protein 462A9 382 620 BC000764 Hs.101514 1.00E−133 1 hypothetical protein FLJ10342, clone MGC: 27 193G3 3368 3659 AL139349 Hs.102178 3.00E−88 1 DNA sequence from clone RP11-261P9 on chromosome 20. 62H6 3035 4257 AF193339 Hs.102506 0 5 eukaryotic translation initiation factor 2 a 46E2 3223 4023 NM_004836 Hs.102506 0 2 eukaryotic translation initiation factor 2-a 460C4 151 635 AW978361 Hs.102630 0 2 EST390470 cDNA/gb = AW978361/gi = 8169626/ug = 58E4 1 321 BF970875 Hs.102647 1.00E−177 2 602271536F1 cDNA, 5′ end/clone = IMAGE: 4359609 189G9 5473 6137 NM_018489 Hs.102652 0 2 hypothetical protein ASH1 (ASH1), mRNA/cds = ( 111H5 3043 3331 AK000354 Hs.102669 1.00E−125 1 cDNA FLJ20347 fis, clone HEP13790/cds = (708,14 465B8 27 348 AI707589 Hs.102793 1.00E−164 1 as30b05.x1 cDNA, 3′ end/clone = IMAGE: 2318673 126G11 1069 1431 NM_016128 Hs.102950 0 2 coat protein gamma-cop (LOC51137), mRNA/cds = 165H5 326 564 BF698884 Hs.103180 4.00E−71 1 602126455F1 cDNA, 5′ end/clone = IMAGE: 4283340 108H6 2135 2505 AB023187 Hs.103329 1.00E−59 1 for KIAA0970 protein, complete cds/cds = ( 521C9 1440 1962 AL136885 Hs.103378 0 2 mRNA; cDNA DKFZp434P116 (from clone DKFZp434P1 458C9 3876 4415 AF254411 Hs.103521 0 1 ser/arg-rich pre-mRNA splicing factor SR-A1 ( 99F6 349 767 NM_018623 Hs.103657 0 5 hypothetical protein PRO2219 (PRO2219), mRNA 162G11 1745 2161 AF117829 Hs.103755 1.00E−151 1 8q21.3: RICK gene/cds = (224,1846)/gb = AF11782 188G1 1757 2566 NM_004501 Hs.103804 0 2 heterogeneous nuclear ribonucleoprotein U ( 470F7 56 302 NM_024056 Hs.103834 1.00E−137 1 hypothetical protein MGC5576 (MGC5576), mRNA 460A11 225 288 BG033732 Hs.103902 3.00E−29 1 602301101F1 cDNA, 5′ end/clone = IMAGE: 4402465 522H7 2157 2397 NM_006342 Hs.104019 1.00E−132 1 transforming, acidic coiled-coil containing 39E5 1007 2535 L12168 Hs.104125 0 10 adenylyl cyclase-associated protein (CAP) mRN 98C11 1023 2558 NM_006367 Hs.104125 0 29 adenylyl cyclase-associated protein (CAP), m 461B2 88 221 AW968823 Hs.104157 1.00E−38 1 EST380899 cDNA/gb = AW968823/gi = 8158664/ug = 110A4 4010 4306 AB023143 Hs.104305 1.00E−125 1 for KIAA0926 protein, complete cds/cds = ( 122H5 4634 5232 NM_014922 Hs.104305 0 2 KIAA0926 protein (KIAA0926), mRNA/cds = (522,4 105C2 1817 2174 AB020669 Hs.104315 0 1 for KIAA0862 protein, complete cds/cds = ( 37G4 1321 2886 AF016495 Hs.104624 0 46 small solute channel 1 (SSC1) mRNA, complete cd 98D4 1578 2946 NM_020980 Hs.104624 0 71 aquaporin 9 (AQP9), mRNA/cds = (286,1173)/gb = 458E6 1007 1399 NM_015898 Hs.104640 0 1 HIV-1 inducer of short transcripts binding pro 462C11 1037 1532 NM_018492 Hs.104741 0 1 PDZ-binding kinase; T-cell originated protein 118G4 1940 2513 BC002538 Hs.104879 0 2 serine (or cysteine) proteinase inhibitor, c 496A7 1 618 BG035120 Hs.104893 0 4 602324815F1 cDNA, 5′ end/clone = IMAGE: 4413099 112G4 3421 3933 NM_003633 Hs.104925 0 2 ectodermal-neural cortex (with BTB-like doma 460E2 16 460 AI479075 Hs.104985 0 1 tm30h01.x1 cDNA, 3′ end/clone = IMAGE: 2158129 461H4 1500 1781 NM_020979 Hs.105052 1.00E−148 1 adaptor protein with pleckstrin homology and 469C7 231 380 NM_018331 Hs.105216 1.00E−77 1 hypothetical protein FLJ11125 (FLJ11125), mR 461B6 84 489 AA489227 Hs.105230 0 1 aa57f07.s1 cDNA, 3′ end/clone = IMAGE: 825061/ 462D5 1735 2129 NM_015393 Hs.105460 0 1 DKFZP564O0823 protein (DKFZP564O0823), mRNA 465H7 1 624 NM_017780 Hs.105461 0 1 hypothetical protein FLJ20357 (FLJ20357), mR 471F3 819 1126 AY007243 Hs.105484 1.00E−160 1 regenerating gene type IV mRNA, complete cds/ 473C1 42 479 AW970759 Hs.105621 0 1 EST382842 cDNA/gb = AW970759/gi = 8160604/ug = 102A9 1 331 AK025947 Hs.105664 0 1 FLJ22294 fis, clone HRC04426/cds = (240,6 465G9 193 524 AI475680 Hs.105676 0 1 tc93d12.x1 cDNA, 3′ end/clone = IMAGE: 2073719 469G2 1528 1625 AK022481 Hs.105779 8.00E−38 1 cDNA FLJ12419 fis, clone MAMMA1003047, highly 482A9 289 839 NM_012483 Hs.105806 0 3 granulysin (GNLY), transcript variant 519, m 595B11 918 1300 NM_002343 Hs.105938 0 1 lactotransferrin (LTF), mRNA/cds = (294,2429) 69B3 3649 4226 Y13247 Hs.106019 0 1 fb19 mRNA/cds = (539,3361)/gb = Y13247/gi = 2117 459E8 106 563 NM_013322 Hs.106260 0 1 sorting nexin 10 (SNX10), mRNA/cds = (128,733) 459E2 1939 2361 NM_003171 Hs.106469 0 1 suppressor of var1 ( S. cerevisiae) 3-like 1 (S 98H12 658 1040 BC002748 Hs.106650 0 2 Similar to hypothetical protein FLJ20533, cl 594H5 1418 1501 NM_001568 Hs.106673 6.00E−36 1 eukaryotic translation initiation factor 3, 194H12 751 1233 NM_021626 Hs.106747 0 1 serine carboxypeptidase 1 precursor protein ( 138G6 2749 3214 AF189723 Hs.106778 0 3 calcium transport ATPase ATP2C1 (ATP2C1A) mRN 56A5 1 1089 AL355722 Hs.106875 0 2 EST from clone 35214, full insert/cds = UNKNOWN 67H8 844 1102 X71490 Hs.106876 1.00E−103 1 vacuolar proton ATPase, subunit D/cds = (2 463G10 538 725 AF035306 Hs.106890 1.00E−102 1 clone 23771 mRNA sequence/cds = UNKNOWN/ gb = AF 121H2 14 394 NM_016619 Hs.107139 0 1 hypothetical protein (LOC51316), mRNA/cds = ( 185D12 118 884 NM_001564 Hs.107153 0 3 inhibitor of growth family, member 1-like (ING 186D6 1140 1507 NM_017892 Hs.107213 0 1 hypothetical protein FLJ20585 (FLJ20585), mR 462B10 192 541 AI707896 Hs.107369 1.00E−168 1 as34a10.x1 cDNA, 3′ end/clone = IMAGE: 2319066 59A10 1694 2335 AJ270952 Hs.107393 0 3 for putative membrane protein (GENX-3745 499G1 2987 4266 AL035683 Hs.107526 1.00E−104 2 DNA sequence from clone RP5-1063B2 on chromosome 20q1 466F11 327 493 AI391443 Hs.107622 9.00E−90 1 tf96e06.x1 cDNA, 3′ end/clone = IMAGE: 2107138 182F9 153 649 AF265439 Hs.107707 0 1 DC37 mRNA, complete cds/cds = (5,856)/gb = AF26 481F9 1216 1609 NM_016270 Hs.107740 0 2 Kruppel-like factor (LOC51713), mRNA/cds = (84 184H4 189 576 AF081282 Hs.107979 0 1 small membrane protein 1 (SMP1) mRNA, complete 103E11 1006 2137 NM_014313 Hs.107979 0 4 small membrane protein 1 (SMP1), mRNA/cds = (99, 596H7 1265 1771 NM_004078 Hs.108080 0 3 cysteine and glycine-rich protein 1 (CSRP1), m 46H8 777 914 AF070640 Hs.108112 2.00E−47 1 clone 24781 mRNA sequence/cds = UNKNOWN/ gb = AF 53B4 1552 1967 U32986 Hs.108327 0 2 xeroderma pigmentosum group E UV-damaged DNA binding 124A10 1089 1733 AK001428 Hs.108332 0 3 cDNA FLJ10566 fis, clone NT2RP2002959, highly 127F8 428 746 AL136941 Hs.108338 0 1 mRNA; cDNA DKFZp586C1924 (from clone DKFZp586 191G10 518 883 AL136640 Hs.108548 0 2 mRNA; cDNA DKFZp564F163 (from clone DKFZp564F1 458G8 2374 5101 NM_016227 Hs.108636 0 2 membrane protein CH1 (CH1), mRNA/cds = (124,434 58F11 735 798 NM_006963 Hs.108642 2.00E−28 1 zinc finger protein 22 (KOX 15) (ZNF22), mRNA/ 118B5 2715 2797 AK022874 Hs.108779 2.00E−38 1 cDNA FLJ12812 fis, clone NT2RP2002498/cds = (3, 110H2 18 661 AF026292 Hs.108809 0 1 chaperonin containing t-complex polypeptide 181G4 1008 1142 NM_006429 Hs.108809 2.00E−71 1 chaperonin containing TCP1, subunit 7 (eta) (C 189F11 415 615 AK024569 Hs.108854 2.00E−79 1 cDNA: FLJ20916 fis, clone ADSE00738, highly s 596F8 5958 6097 AB011087 Hs.108945 8.00E−48 1 mRNA for KIAA0515 protein, partial cds/cds = (0, 157D8 399 830 NM_016145 Hs.108969 0 1 PTD008 protein (PTD008),/cds = (233,553) 175E7 712 1849 AL133111 Hs.109150 0 2 mRNA; cDNA DKFZp434H068 (from clone DKFZp434H0 514E1 66 613 NM_012417 Hs.109219 0 4 retinal degeneration B beta (RDGBB), mRNA/cd 106A4 1864 2220 AJ011895 Hs.109281 1.00E−111 1 for HIV-1, Nef-associated factor 1 alpha 169E1 938 1331 AK024297 Hs.109441 0 2 FLJ14235 fis, clone NT2RP4000167/cds = (82 100B8 1 191 NM_012456 Hs.109571 3.00E−85 1 translocase of inner mitochondrial membrane 1 115B7 983 1193 NM_007074 Hs.109606 1.00E−116 1 coronin, actin-binding protein, 1A (CORO1A), 62H11 1 626 BF245892 Hs.109641 1.00E−154 10 601864070F1 cDNA, 5′ end/clone = lMAGE: 4082465 595B2 4976 5286 AB040884 Hs.109694 1.00E−142 1 mRNA for KIAA1451 protein, partial cds/cds = (0 75H11 227 482 BF244603 Hs.109697 1.00E−129 1 601862620F1 cDNA, 5′ end/clone = IMAGE: 4080412 118G3 219 392 NM_024292 Hs.109701 2.00E−66 1 ubiquitin-like 5 (UBL5), mRNA/cds = (65,286)/ 105A5 3271 3532 AL117407 Hs.109727 1.00E−147 2 cDNA DKFZp434D2050 (from clone DKFZp434D 481B7 1101 1201 NM_006026 Hs.109804 9.00E−42 1 H1 histone family, member X (H1FX), mRNA/cds = ( 476H12 1018 1429 NM_004310 Hs.109918 0 3 ras homolog gene family, member H (ARHH), mRNA 144C8 1252 1429 Z35227 Hs.109918 7.00E−92 1 TTF for small G protein/cds = (579,1154)/gb = 141E10 630 1269 AK001779 Hs.110445 0 4 FLJ10917 fis, clone OVARC1000321/cds = (18 494D8 4102 4476 NM_014918 Hs.110488 0 1 KIAA0990 protein (KIAA0990), mRNA/cds = (494,2 47C3 2298 2431 D86974 Hs.110613 1.00E−60 1 KIAA0220 gene, partial cds/cds = (0,1661)/gb 194C10 1210 1704 AL157477 Hs.110702 0 1 mRNA; cDNA DKFZp761E212 (from clone DKFZp761E2 192F1 3254 3686 NM_015726 Hs.110707 1.00E−150 2 H326 (H326), mRNA/cds = (176,1969)/gb = NM_0157 595B8 1148 1414 NM_003472 Hs.110713 1.00E−147 1 DEK oncogene (DNA binding) (DEK), mRNA/cds = (3 459F3 3337 3915 NM_001046 Hs.110736 0 1 solute carrier family 12 (sodium/potassium/ch 195F5 1051 1482 AK025557 Hs.110771 0 2 cDNA: FLJ21904 fis, clone HEP03585/cds = UNKNOW 53B10 163 742 NM_020150 Hs.110796 0 1 SAR1 protein (SAR1), mRNA/cds = (100,696)/gb = 164B11 122 932 NM_016039 Hs.110803 0 5 CGI-99 protein (LOC51637), mRNA/cds = (161,895 594H4 982 1454 AK026528 Hs.111222 6.00E−95 3 cDNA: FLJ22875 fis, clone KAT02879/cds = (30,51 50A10 1688 2095 AF119897 Hs.111334 0 2 PRO2760 mRNA, complete cds/cds = UNKNOWN/ gb = A 102H11 175 498 AI436587 Hs.111377 1.00E−148 1 ti03d11.x1 cDNA, 3′ end/clone = IMAGE: 2129397 109G11 1324 1388 AB016811 Hs.111554 2.00E−29 1 for ADP ribosylation factor-like protein, 144E10 77 304 BF219474 Hs.111611 1.00E−122 2 601884269F1 5′ end/clone = IMAGE: 4102769 583C9 4 272 NM_000988 Hs.111611 1.00E−148 10 ribosomal protein L27 (RPL27), mRNA/cds = (17,4 111F4 31 380 NM_014463 Hs.111632 0 1 Lsm3 protein (LSM3), mRNA/cds = (29,337)/gb = N 106E6 2646 2892 AL096723 Hs.111801 1.00E−135 1 cDNA DKFZp564H2023 (from clone DKFZp564H 169A2 773 1015 D14696 Hs.111894 1.00E−135 2 KIAA0108 gene, complete cds/cds = (146,847)/ 182D6 264 748 NM_014713 Hs.111894 0 1 lysosomal-associated protein transmembrane 460D11 205 452 AI557431 Hs.111973 4.00E−60 1 PT2.1_7_C05.r cDNA, 3′ end/clone_end = 3′ /gb = 121A7 355 589 NM_020382 Hs.111988 1.00E−128 1 PR/SET domain containing protein 07 (SET07), m 476C12 254 463 AA442585 Hs.112071 1.00E−111 1 zv57f09.r1 cDNA, 5′ end/clone = IMAGE: 757769/ 172E7 469 736 AF228422 Hs.112242 1.00E−143 1 normal mucosa of esophagus specific 1 (NMES1) 108E10 4800 4901 AF071076 Hs.112255 6.00E−48 1 cell-line HeLa Nup98-Nup96 precursor, mRNA, c 47G12 1 301 BF237710 Hs.112318 1.00E−165 5 601842210F1 cDNA, 5′ end/clone = IMAGE: 4079930 599G7 38 455 NM_019059 Hs.112318 0 32 6.2 kd protein (LOC54543), mRNA/cds = (93,260) 469F9 226 546 NM_002638 Hs.112341 1.00E−107 1 protease inhibitor 3, skin-derived (SKALP) (P 589G11 482 1336 AK026396 Hs.112497 0 2 cDNA: FLJ22743 fis, clone HUV00901/ cds = UNKNOW 464F10 1686 1917 NM_002978 Hs.112842 1.00E−119 1 sodium channel, nonvoltage-gated 1, delta (SC 54B11 1 423 BF025727 Hs.113029 0 26 601670406F1 cDNA, 5′ end/clone = IMAGE: 3953425 591C5 31 469 NM_001028 Hs.113029 0 10 ribosomal protein S25 (RPS25), mRNA/cds = (71,4 585F4 1882 3918 AK027136 Hs.113205 1.00E−130 3 cDNA: FLJ23483 fis, clone KAIA04052/cds = UNKNO 61B12 1168 2386 AF105253 Hs.113368 0 5 neuroendocrine secretory protein 55 mRNA, com 163D9 3470 4109 Y08890 Hs.113503 0 1 mRNA for Ran_GTP binding protein 5 466C4 276 946 AL359916 Hs.113872 0 1 DNA sequence from clone RP11-550O8 on chromosome 20 C 592C12 2506 2696 AF323540 Hs.114309 2.00E−80 1 apolipoprotein L-I mRNA, splice variant B, co 476A11 121 528 AA702108 Hs.114931 0 1 zi85e01.s1 cDNA, 3′ end/clone = IMAGE: 447576/ 109F4 3123 3521 D30783 Hs.115263 0 1 for epiregulin, complete cds/cds = (166,67 123D1 3123 3526 NM_001432 Hs.115263 0 1 epiregulin (EREG), mRNA/cds = (166,675)/gb = N 465D7 1 175 BG288391 Hs.115467 1.00E−94 1 602388053F1 cDNA, 5′ end/clone = IMAGE: 4517076 74H9 346 602 AK027114 Hs.115659 1.00E−108 1 FLJ23461 fis, clone HSI07757/cds = UNKNOW 585E4 384 1146 NM_024061 Hs.115659 0 3 hypothetical protein MGC5521 (MGC5521), mRNA 462C1 945 1222 NM_024036 Hs.115960 1.00E−152 1 hypothetical protein MGC3103 (MGC3103), mRNA 464E4 1276 1635 AK023633 Hs.116278 1.00E−138 1 cDNA FLJ13571 fis, clone PLACE1008405/cds = UNK 43B10 1601 1798 AF283777 Hs.116481 9.00E−47 1 clone TCBAP0702 mRNA sequence/cds = UNKNOWN/g 465G1 374 654 NM_001782 Hs.116481 5.00E−85 2 CD72 antigen (CD72), mRNA/cds = (108,1187)/gb 51G8 29 203 BF341330 Hs.116567 6.00E−26 1 602013274F1 cDNA, 5′ end/clone = IMAGE: 4149066 40D10 2694 3430 X68742 Hs.116774 0 1 integrin, alpha subunit/cds = UNKNOWN/g 107D1 1778 1943 U71383 Hs.117005 1.00E−84 1 OB binding protein-2 (OB-BP2) mRNA, complete cds/ cds 459D4 2882 3522 AK025364 Hs.117268 0 1 cDNA: FLJ21711 fis, clone COL10156/cds = UNKNOW 473E8 2104 2233 AB029016 Hs.117333 2.00E−65 3 mRNA for KIAA1093 protein, partial cds/cds = (0 458E2 88 627 AI825645 Hs.117906 0 2 wb75b09.x1 cDNA, 3′ end/clone = IMAGE: 2311481 163A7 1160 1420 X53793 Hs.117950 1.00E−109 1 ADE2H1 mRNA showing homologies to SAICAR syntheta 123B8 18 740 NM_002799 Hs.118065 0 1 proteasome (prosome, macropain) subunit, bet 583G3 924 1199 AB011182 Hs.118087 1.00E−155 4 mRNA for KIAA0610 protein, partial cds/cds = (0, 127A1 263 557 NM_006441 Hs.118131 1.00E−141 1 5,10-methenyltetrahydrofolate synthetase ( 459A10 188 817 AL522477 Hs.118142 0 1 AL522477 cDNA/clone = CS0DB008YK14-(3-prime) 584A10 8484 8875 NM_003316 Hs.118174 0 1 tetratricopeptide repeat domain 3 (TTC3), mRN 52D4 1287 1752 AK026486 Hs.118183 0 1 FLJ22833 fis, clone KAIA4266/cds = (479,8 470B6 68 532 BF030930 Hs.118303 0 1 601558648F1 cDNA, 5′ end/clone = IMAGE: 3828706 41B3 5041 5669 M14648 Hs.118512 0 1 cell adhesion protein (vitronectin) receptor alpha s 125B8 999 1573 NM_003733 Hs.118633 0 1 2′-5′oligoadenylate synthetase-like (OASL), 459D3 3 427 AI052447 Hs.118659 0 1 oz07g04.x1 cDNA, 3′ end/clone = IMAGE: 1674678 112F11 191 387 NM_006923 Hs.118684 1.00E−103 1 stromal cell-derived factor 2 (SDF2), mRNA/c 129E4 1727 1891 AL050404 Hs.118695 2.00E−86 1 DNA sequence from clone 955M13 on chromosome 20. Conta 126H2 1512 2209 NM_000358 Hs.118787 0 2 transforming growth factor, beta-induced, 68 598D9 817 1106 NM_001155 Hs.118796 1.00E−108 1 annexin A6 (ANXA6), transcript variant 1, mRN 331E6 89 475 BE311727 Hs.118857 0 1 601143334F1 cDNA, 5′ end/clone = IMAGE: 3507009 521C1 700 1180 NM_006292 Hs.118910 0 2 tumor susceptibility gene 101 (TSG101), mRNA 139E8 463 1198 AJ012506 Hs.118958 0 1 activated in tumor suppression, clone TSA 69H2 578 1117 U05040 Hs.118962 0 1 FUSE binding protein mRNA, complete cds/ cds = (26,1960 461F1 1241 1715 AK024119 Hs.118990 0 1 cDNA FLJ14057 fis, clone HEMBB1000337/cds = UNK 481E1 1682 1969 NM_017544 Hs.119018 1.00E−129 1 transcription factor NRF (NRF), mRNA/cds = (653 479B4 45 203 AL109806 Hs.119057 5.00E−43 1 DNA sequence from clone RP5-1153D9 on chromosome 20 C 520F1 177 672 NM_012423 Hs.119122 1.00E−148 8 ribosomal protein L13a (RPL13A), mRNA/cds = (1 477E4 46 1565 AL109786 Hs.119155 0 3 mRNA full length insert cDNA clone EUROIMAGE 81 166F10 304 814 M37583 Hs.119192 0 3 histone (H2A.Z) mRNA, complete cds/cds = (106,492)/g 592E5 302 814 NM_002106 Hs.119192 0 7 H2A histone family, member Z (H2AFZ), mRNA/cd 54B1 47 1144 AJ400717 Hs.119252 0 9 TPT1 gene for translationally controlled tumo 594H9 609 1013 NM_000520 Hs.119403 0 1 hexosaminidase A (alpha polypeptide) (HEXA), 492D9 30 272 NM_001004 Hs.119500 1.00E−135 2 ribosomal protein, large P2 (RPLP2), mRNA/cd 59H8 14 1890 NM_016091 Hs.119503 0 12 HSPC025 (HSPC025), mRNA/cds = (33,1727)/gb = N 525E8 12 446 NM_006432 Hs.119529 0 2 epididymal secretory protein (19.5 kD) (HE1), 166G7 1323 2293 M88108 Hs.119537 0 3 p62 mRNA, complete cds/cds = (106,1437)/ gb = M88108/g 112D10 1054 1722 NM_006559 Hs.119537 0 1 GAP-associated tyrosine phosphoprotein p62 158E9 847 1273 AL022326 Hs.119598 0 1 DNA sequence from clone 333H23 on chromosome 22q12.1-1 161H7 738 1272 NM_000967 Hs.119598 0 1 ribosomal protein L3 (RPL3), mRNA/cds = (6,1217 168F8 284 778 M34671 Hs.119663 0 1 lymphocytic antigen CD59/MEM43 mRNA, complete cds/c 585C9 285 783 NM_000611 Hs.119663 0 1 CD59 antigen p18-20 (antigen identified by mo 143G12 753 1329 AK023975 Hs.119908 0 4 FLJ13913 fis, clone Y79AA1000231, highly 55D12 1107 1365 NM_015934 Hs.119908 1.00E−119 1 nucleolar protein NOP5/NOP58 (NOP5/NOP58), m 467E7 37 419 AI492066 Hs.119923 0 1 tg12b03.x1 cDNA, 3′ end/clone = IMAGE: 2108525 462C10 2669 3025 NM_012318 Hs.120165 0 1 leucine zipper-EF-hand containing transmembr 473F11 396 1006 AK025068 Hs.120170 0 1 cDNA: FLJ21415 fis, clone COL04030/cds = (138,7 98E11 211 458 AW081455 Hs.120219 1.00E−114 2 xc31c07.x1 cDNA, 3′ end/clone = IMAGE: 2585868 471C8 60 301 NM_014487 Hs.120766 1.00E−120 1 nucleolar cysteine-rich protein (HSA6591), m 134C4 284 529 AK000470 Hs.120769 9.00E−98 1 cDNA FLJ20463 fis, clone KAT06143/ cds = UNKNOWN 469C10 1 441 AA677952 Hs.120891 0 1 zi14a06.s1 cDNA, 3′ end/clone = IMAGE: 430738/ 60C9 1022 1615 AB011421 Hs.120996 0 1 for DRAK2, complete cds/cds = (261,1379)/ 461A7 738 1274 NM_014205 Hs.121025 0 1 chromosome 11 open reading frame 5 (C11ORF5), m 104A4 557 1942 D89974 Hs.121102 0 4 for glycosylphosphatidyl inositol-ancho 196C9 557 1463 NM_004665 Hs.121102 0 9 vanin 2 (VNN2), mRNA/cds = (11,1573)/gb = NM_004 467F4 4 328 AW972196 Hs.121210 1.00E−162 1 EST384285 cDNA/gb = AW972196/gi = 8162042/ug = 587A12 224 367 AW975541 Hs.121572 1.00E−62 1 EST387650 cDNA/gb = AW975541/gi = 8166755/ug = 36G5 13 604 AL008729 Hs.121591 0 1 DNA sequence from PAC 257A7 on chromosome 6p24. Contai 464C1 120 413 AA772692 Hs.121709 1.00E−120 1 ai35b09.s1 cDNA, 3′ end/clone = 1358969/clone 36E2 411 821 AK025556 Hs.121849 0 1 FLJ21903 fis, clone HEP03579/cds = (84,46 196A6 411 1113 NM_022818 Hs.121849 0 1 Microtubule-associated proteins 1A and 1B, I 471G2 176 333 AW469546 Hs.122116 2.00E−64 1 hd19e09.x1 cDNA, 3′ end/clone = IMAGE: 2909992 462F5 218 611 BF677944 Hs.122406 1.00E−166 1 602084766F1 cDNA, 5′ end/clone = IMAGE: 4248905 465A6 376 478 AV762642 Hs.122431 2.00E−28 1 AV762642 cDNA, 5′ end/clone = MDSEMB08/clone_(—) 467G10 603 803 AL040371 Hs.122487 9.00E−96 1 DKFZp434P0213_r1 cDNA, 5′ end/clone = DKFZp434 465C12 66 260 AI804629 Hs.122848 3.00E−83 1 tc81g03.x1 cDNA, 3′ end/clone = IMAGE: 2072596 98H6 442 591 AI081246 Hs.122983 5.00E−78 1 oy67b06.x1 cDNA, 3′ end/clone = IMAGE: 1670867 52B4 123 236 BE676541 Hs.123254 8.00E−46 1 7f31g03.x1 cDNA, 3′ end/clone = IMAGE: 3296308 128C7 4875 5186 AB020631 Hs.123654 1.00E−131 1 mRNA for KIAA0824 protein, partial cds/cds = (0 184B5 594 1187 AL109865 Hs.124186 0 1 DNA sequence from clone GS1-120K12 on chromosome 1q25 106A6 1135 1456 AK026776 Hs.124292 9.00E−99 1 FLJ23123 fis, clone LNG08039/cds = UNKNOW 525G12 314 503 BF996704 Hs.124344 1.00E−72 1 MR1-GN0173-071100-009-g10 cDNA/gb = BF996704 466C3 120 496 AA831838 Hs.124391 1.00E−172 1 oc85h06.s1 cDNA, 3′ end/clone = IMAGE: 1356539 48G4 1 568 AA203497 Hs.124601 0 1 zx58g05.r1 cDNA, 5′ end/clone = IMAGE: 446744/ 517G2 577 756 AA858297 Hs.124675 3.00E−61 1 ob13b08.s1 cDNA, 3′ end/clone = IMAGE: 1323543 107H3 913 1220 AK023013 Hs.124762 1.00E−174 1 FLJ12951 fis, clone NT2RP2005457, highly 473A7 729 929 NM_019062 Hs.124835 4.00E−82 1 hypothetical protein (FLJ20225), mRNA/cds = ( 108D12 3225 3531 AF023142 Hs.125134 1.00E−142 2 pre-mRNA splicing SR protein rA4 mRNA, partial 463E11 158 519 AI380443 Hs.125608 0 1 tg02f04.x1 cDNA, 3′ end/clone = IMAGE: 2107615 104F6 1581 2028 NM_019853 Hs.125682 0 1 protein phosphatase 4 regulatory subunit 2 (P 462A5 5 282 AW975851 Hs.125815 1.00E−149 1 EST387960 cDNA/gb = AW975851/gi = 8167072/ug = 462B1 534 702 AI378032 Hs.125892 1.00E−69 1 te67g08.x1 cDNA, 3′ end/clone = IMAGE: 2091806 121A6 3074 3494 AB028978 Hs.126084 1.00E−174 1 mRNA for KIAA1055 protein, partial cds/cds = (0 171G12 94 1240 M15330 Hs.126256 0 7 interleukin 1-beta (IL1B) mRNA, complete cds/ cds = (86 183D12 100 1275 NM_000576 Hs.126256 0 9 interleukin 1, beta (IL1B), mRNA/cds = (86,895) 458B2 6 415 AI393205 Hs.126265 0 1 tg14b07.x1 cDNA, 3′ end/clone = IMAGE: 2108725 102G6 885 1906 AJ271684 Hs.126355 1.00E−171 2 for myeloid DAP12-associating lectin (MD 463E4 847 1015 NM_013252 Hs.126355 2.00E−89 1 C-type (calcium dependent, carbohydrate-reco 167B2 2468 2721 AF195514 Hs.126550 1.00E−142 1 VPS4-2 ATPase (VPS42) mRNA, complete cds/cds = 473D8 19 397 BF445163 Hs.126594 0 1 nad21d12.x1 cDNA, 3′ end/clone = IMAGE: 3366191 143C9 333 551 BE250027 Hs.126701 1.00E−121 1 600943030F1 cDNA, 5′ end/clone = IMAGE: 2959639 471E10 806 945 AK021519 Hs.126707 2.00E−71 1 cDNA FLJ11457 fis, clone HEMBA1001522/cds = (1 462B4 159 572 NM_017762 Hs.126721 0 1 hypothetical protein FLJ20313 (FLJ20313), mR 41D8 1 2519 AK023275 Hs.126925 0 5 FLJ13213 fis, clone NT2RP4001126, weakly 463F5 2 563 NM_014464 Hs.127011 0 1 tubulointerstitial nephritis antigen (TIN-A 597C8 2662 2905 AB046765 Hs.127270 1.00E−136 1 mRNA for KIAA1545 protein, partial cds/cds = (0 458F11 15 212 BF508731 Hs.127311 8.00E−81 1 UI-H-BI4-aoq-b-08-0-UI.s1 cDNA, 3′ end/clon 462B3 76 389 AW978753 Hs.127327 1.00E−133 1 EST390862 cDNA/gb = AW978753/gi = 8170027/ug = 463E2 176 787 AI028267 Hs.127514 0 1 ow01d06.x1 cDNA, 3′ end/clone = IMAGE: 1645547 465G5 181 372 AA953396 Hs.127557 6.00E−78 1 on63h10.s1 cDNA, 3′ end/clone = IMAGE: 1561411 125B8 999 1573 NM_003733 Hs.118633 0 1 2′-5′oligoadenylate synthetase-like (OASL), 459D3 3 427 AI052447 Hs.118659 0 1 oz07g04.x1 cDNA, 3′ end/clone = IMAGE: 1674678 112F11 191 387 NM_006923 Hs.118684 1.00E−103 1 stromal cell-derived factor 2 (SDF2), mRNA/c 129E4 1727 1891 AL050404 Hs.118695 2.00E−86 1 DNA sequence from clone 955M13 on chromosome 20. Conta 126H2 1512 2209 NM_000358 Hs.118787 0 2 transforming growth factor, beta-induced, 68 598D9 817 1106 NM_001155 Hs.118796 1.00E−108 1 annexin A6 (ANXA6), transcript variant 1, mRN 331E6 89 475 BE311727 Hs.118857 0 1 601143334F1 cDNA, 5′ end/clone = IMAGE: 3507009 521C1 700 1180 NM_006292 Hs.118910 0 2 tumor susceptibility gene 101 (TSG101), mRNA 139E8 463 1198 AJ012506 Hs.118958 0 1 activated in tumor suppression, clone TSA 69H2 578 1117 U05040 Hs.118962 0 1 FUSE binding protein mRNA, complete cds/ cds = (26,1960 461F1 1241 1715 AK024119 Hs.118990 0 1 cDNA FLJ14057 fis, clone HEMBB1000337/cds = UNK 481E1 1682 1969 NM_017544 Hs.119018 1.00E−129 1 transcription factor NRF (NRF), mRNA/cds = (653 479B4 45 203 AL109806 Hs.119057 5.00E−43 1 DNA sequence from clone RP5-1153D9 on chromosome 20 C 520F1 177 672 NM_012423 Hs.119122 1.00E−148 8 ribosomal protein L13a (RPL13A), mRNA/cds = (1 477E4 46 1565 AL109786 Hs.119155 0 3 mRNA full length insert cDNA clone EUROIMAGE 81 166F10 304 814 M37583 Hs.119192 0 3 histone (H2A.Z) mRNA, complete cds/cds = (106,492)/g 592E5 302 814 NM_002106 Hs.119192 0 7 H2A histone family, member Z (H2AFZ), mRNA/cd 54B1 47 1144 AJ400717 Hs.119252 0 9 TPT1 gene for translationally controlled tumo 594H9 609 1013 NM_000520 Hs.119403 0 1 hexosaminidase A (alpha polypeptide) (HEXA), 492D9 30 272 NM_001004 Hs.119500 1.00E−135 2 ribosomal protein, large P2 (RPLP2), mRNA/cd 59H8 14 1890 NM_016091 Hs.119503 0 12 HSPC025 (HSPC025), mRNA/cds = (33,1727)/gb = N 525E8 12 446 NM_006432 Hs.119529 0 2 epididymal secretory protein (19.5 kD) (HE1), 166G7 1323 2293 M88108 Hs.119537 0 3 p62 mRNA, complete cds/cds = (106,1437)/ gb = M88108/g 112D10 1054 1722 NM_006559 Hs.119537 0 1 GAP-associated tyrosine phosphoprotein p62 158E9 847 1273 AL022326 Hs.119598 0 1 DNA sequence from clone 333H23 on chromosome 22q12.1-1 161H7 738 1272 NM_000967 Hs.119598 0 1 ribosomal protein L3 (RPL3), mRNA/cds = (6,1217 168F8 284 778 M34671 Hs.119663 0 1 lymphocytic antigen CD59/MEM43 mRNA, complete cds/c 585C9 285 783 NM_000611 Hs.119663 0 1 CD59 antigen p18-20 (antigen identified by mo 143G12 753 1329 AK023975 Hs.119908 0 4 FLJ13913 fis, clone Y79AA1000231, highly 55D12 1107 1365 NM_015934 Hs.119908 1.00E−119 1 nucleolar protein NOP5/NOP58 (NOP5/NOP58), m 467E7 37 419 AI492066 Hs.119923 0 1 tg12b03.x1 cDNA, 3′ end/clone = IMAGE: 2108525 462C10 2669 3025 NM_012318 Hs.120165 0 1 leucine zipper-EF-hand containing transmembr 473F11 396 1006 AK025068 Hs.120170 0 1 cDNA: FLJ21415 fis, clone COL04030/cds = (138,7 98E11 211 458 AW081455 Hs.120219 1.00E−114 2 xc31c07.x1 cDNA, 3′ end/clone = IMAGE: 2585868 471C8 60 301 NM_014487 Hs.120766 1.00E−120 1 nucleolar cysteine-rich protein (HSA6591), m 134C4 284 529 AK000470 Hs.120769 9.00E−98 1 cDNA FLJ20463 fis, clone KAT06143/ cds = UNKNOWN 469C10 1 441 AA677952 Hs.120891 0 1 zi14a06.s1 cDNA, 3′ end/clone = IMAGE: 430738/ 60C9 1022 1615 AB011421 Hs.120996 0 1 for DRAK2, complete cds/cds = (261,1379)/ 461A7 738 1274 NM_014205 Hs.121025 0 1 chromosome 11 open reading frame 5 (C11ORF5), m 104A4 557 1942 D89974 Hs.121102 0 4 for glycosylphosphatidyl inositol-ancho 196C9 557 1463 NM_004665 Hs.121102 0 9 vanin 2 (VNN2), mRNA/cds = (11,1573)/gb = NM_004 467F4 4 328 AW972196 Hs.121210 1.00E−162 1 EST384285 cDNA/gb = AW972196/gi = 8162042/ug = 587A12 224 367 AW975541 Hs.121572 1.00E−62 1 EST387650 cDNA/gb = AW975541/gi = 8166755/ug = 36G5 13 604 AL008729 Hs.121591 0 1 DNA sequence from PAC 257A7 on chromosome 6p24. Contai 464C1 120 413 AA772692 Hs.121709 1.00E−120 1 ai35b09.s1 cDNA, 3′ end/clone = 1358969/clone 36E2 411 821 AK025556 Hs.121849 0 1 FLJ21903 fis, clone HEP03579/cds = (84,46 196A6 411 1113 NM_022818 Hs.121849 0 1 Microtubule-associated proteins 1A and 1B, I 471G2 176 333 AW469546 Hs.122116 2.00E−64 1 hd19e09.x1 cDNA, 3′ end/clone = IMAGE: 2909992 462F5 218 611 BF677944 Hs.122406 1.00E−166 1 602084766F1 cDNA, 5′ end/clone = IMAGE: 4248905 465A6 376 478 AV762642 Hs.122431 2.00E−28 1 AV762642 cDNA, 5′ end/clone = MDSEMB08/clone_(—) 467G10 603 803 AL040371 Hs.122487 9.00E−96 1 DKFZp434P0213_r1 cDNA, 5′ end/clone = DKFZp434 465C12 66 260 AI804629 Hs.122848 3.00E−83 1 tc81g03.x1 cDNA, 3′ end/clone = IMAGE: 2072596 98H6 442 591 AI081246 Hs.122983 5.00E−78 1 oy67b06.x1 cDNA, 3′ end/clone = IMAGE: 1670867 52B4 123 236 BE676541 Hs.123254 8.00E−46 1 7f31g03.x1 cDNA, 3′ end/clone = IMAGE: 3296308 128C7 4875 5186 AB020631 Hs.123654 1.00E−131 1 mRNA for KIAA0824 protein, partial cds/cds = (0 184B5 594 1187 AL109865 Hs.124186 0 1 DNA sequence from clone GS1-120K12 on chromosome 1q25 106A6 1135 1456 AK026776 Hs.124292 9.00E−99 1 FLJ23123 fis, clone LNG08039/cds = UNKNOW 525G12 314 503 BF996704 Hs.124344 1.00E−72 1 MR1-GN0173-071100-009-g10 cDNA/gb = BF996704 466C3 120 496 AA831838 Hs.124391 1.00E−172 1 oc85h06.s1 cDNA, 3′ end/clone = IMAGE: 1356539 48G4 1 568 AA203497 Hs.124601 0 1 zx58g05.r1 cDNA, 5′ end/clone = IMAGE: 446744/ 517G2 577 756 AA858297 Hs.124675 3.00E−61 1 ob13b08.s1 cDNA, 3′ end/clone = IMAGE: 1323543 107H3 913 1220 AK023013 Hs.124762 1.00E−174 1 FLJ12951 fis, clone NT2RP2005457, highly 473A7 729 929 NM_019062 Hs.124835 4.00E−82 1 hypothetical protein (FLJ20225), mRNA/cds = ( 108D12 3225 3531 AF023142 Hs.125134 1.00E−142 2 pre-mRNA splicing SR protein rA4 mRNA, partial 463E11 158 519 AI380443 Hs.125608 0 1 tg02f04.x1 cDNA, 3′ end/clone = IMAGE: 2107615 104F6 1581 2028 NM_019853 Hs.125682 0 1 protein phosphatase 4 regulatory subunit 2 (P 462A5 5 282 AW975851 Hs.125815 1.00E−149 1 EST387960 cDNA/gb = AW975851/gi = 8167072/ug = 462B1 534 702 AI378032 Hs.125892 1.00E−69 1 te67g08.x1 cDNA, 3′ end/clone = IMAGE: 2091806 121A6 3074 3494 AB028978 Hs.126084 1.00E−174 1 mRNA for KIAA1055 protein, partial cds/cds = (0 171G12 94 1240 M15330 Hs.126256 0 7 interleukin 1-beta (IL1B) mRNA, complete cds/ cds = (86 183D12 100 1275 NM_000576 Hs.126256 0 9 interleukin 1, beta (IL1B), mRNA/cds = (86,895) 458B2 6 415 AI393205 Hs.126265 0 1 tg14b07.x1 cDNA, 3′ end/clone = IMAGE: 2108725 102G6 885 1906 AJ271684 Hs.126355 1.00E−171 2 for myeloid DAP12-associating lectin (MD 463E4 847 1015 NM_013252 Hs.126355 2.00E−89 1 C-type (calcium dependent, carbohydrate-reco 167B2 2468 2721 AF195514 Hs.126550 1.00E−142 1 VPS4-2 ATPase (VPS42) mRNA, complete cds/cds = 473D8 19 397 BF445163 Hs.126594 0 1 nad21d12.x1 cDNA, 3′ end/clone = IMAGE: 3366191 143C9 333 551 BE250027 Hs.126701 1.00E−121 1 600943030F1 cDNA, 5′ end/clone = IMAGE: 2959639 471E10 806 945 AK021519 Hs.126707 2.00E−71 1 cDNA FLJ11457 fis, clone HEMBA1001522/cds = (1 462B4 159 572 NM_017762 Hs.126721 0 1 hypothetical protein FLJ20313 (FLJ20313), mR 41D8 1 2519 AK023275 Hs.126925 0 5 FLJ13213 fis, clone NT2RP4001126, weakly 463F5 2 563 NM_014464 Hs.127011 0 1 tubulointerstitial nephritis antigen (TIN-A 597C8 2662 2905 AB046765 Hs.127270 1.00E−136 1 mRNA for KIAA1545 protein, partial cds/cds = (0 458F11 15 212 BF508731 Hs.127311 8.00E−81 1 UI-H-BI4-aoq-b-08-0-UI.s1 cDNA, 3′ end/clon 462B3 76 389 AW978753 Hs.127327 1.00E−133 1 EST390862 cDNA/gb = AW978753/gi = 8170027/ug = 463E2 176 787 AI028267 Hs.127514 0 1 ow01d06.x1 cDNA, 3′ end/clone = IMAGE: 1645547 465G5 181 372 AA953396 Hs.127557 6.00E−78 1 on63h10.s1 cDNA, 3′ end/clone = IMAGE: 1561411 463E10 11190 11634 NM_016239 Hs.127561 0 1 unconventional myosin-15 (LOC51168), mRNA/c 476A9 27 216 AW384918 Hs.127574 1.00E−101 1 PM1-HT0422-291299-002-d01 cDNA/gb = AW384918 111B10 1825 2463 NM_014007 Hs.127649 0 1 KIAA0414 protein (KIAA0414), mRNA/cds = (1132, 499A7 2134 5198 AF070674 Hs.127799 0 8 inhibitor of apoptosis protein-1 (MIHC) mRNA, 331F5 4 460 BF342439 Hs.127863 0 1 602013944F1 cDNA, 5′ end/clone = IMAGE: 4149562 176A12 796 1351 NM_022900 Hs.128003 0 1 hypothetical protein FLJ21213 (FLJ21213), mR 462B5 1766 1949 NM_014406 Hs.128342 5.00E−82 1 potassium large conductance calcium-activate 467D5 157 279 AI222805 Hs.128630 6.00E−62 1 qp39c07.x1 cDNA, 3′ end/clone = IMAGE: 1925388 465G3 1 529 BE222032 Hs.128675 0 1 hr61g11.x1 cDNA, 3′ end/clone = IMAGE: 3133028 467C7 1172 1726 AF118274 Hs.128740 0 1 DNb-5 mRNA, partial cds/cds = (0,1601)/gb = AF11 175G11 358 724 AL110151 Hs.128797 0 1 mRNA; cDNA DKFZp586D0824 (from clone DKFZp586 472A12 402 782 BE745645 Hs.129135 1.00E−153 1 601578727F1 cDNA, 5′ end/clone = IMAGE: 3927535 473C7 46 217 BE670584 Hs.129192 3.00E−37 1 7e36h08.x1 cDNA, 3′ end/clone = IMAGE: 3284607 463G11 7 397 AA746320 Hs.129572 0 1 ob08f01.s1 cDNA, 3′ end/clone = IMAGE: 1323097 63D8 18 1167 D13748 Hs.129673 0 4 eukaryotic initiation factor 4AI/cds = (16,12 57F3 19 1279 NM_001416 Hs.129673 0 4 eukaryotic translation initiation factor 4A, 144G5 1071 1192 AF064090 Hs.129708 3.00E−62 3 ligand for herpesvirus entry mediator (HVEM-L) 118A9 2684 3198 AB046805 Hs.129750 0 1 mRNA for KIAA1585 protein, partial cds/cds = (2 50G5 1119 1440 AK024068 Hs.129872 1.00E−172 1 FLJ14006 fis, clone Y79AA1002399, highly 469D6 376 603 D43968 Hs.129914 1.00E−126 1 AML1 mRNA for AML1b protein (alternatively spliced pr 590G11 823 1571 NM_003563 Hs.129951 0 3 speckle-type POZ protein (SPOP), mRNA/cds = (15 591C7 68 571 NM_005243 Hs.129953 0 1 Ewing sarcoma breakpoint region 1 (EWSR1), tra 459F5 579 768 AI763262 Hs.130059 1.00E−35 1 wi66c04.x1 cDNA, 3′ end/clone = IMAGE: 2398278 479A10 259 448 AI089359 Hs.130232 1.00E−103 1 qb05h03.x1 cDNA, 3′ end/clone = IMAGE: 1695413 461G5 193 347 AW898615 Hs.130729 2.00E−68 1 RC1-NN0073-090500-012-f02 cDNA/gb = AW898615 466B1 373 569 AI347054 Hs.130879 1.00E−76 1 qp60a04.x1 cDNA, 3′ end/clone = IMAGE: 1927374 463G3 3212 5430 AJ404611 Hs.130881 0 2 mRNA for B-cell lymphoma/leukaemia 11A extra 462C3 48 468 AI421806 Hs.131067 0 1 tf44h11.x1 cDNA, 3′ end/clone = IMAGE: 2099109 596G10 39 491 NM_006294 Hs.131255 0 3 ubiquinol-cytochrome c reductase binding pro 469G10 189 361 AI024984 Hs.131580 1.00E−81 1 ov39d11.x1 cDNA, 3′ end/clone = IMAGE: 1639701 458B7 169 659 AW978870 Hs.131828 0 1 EST390979 cDNA/gb = AW978870/gi = 8170147/ug = 63D1 185 500 AF176706 Hs.131859 1.00E−133 1 F-box protein FBX11 mRNA, partial cds/cds = (0, 58C10 4188 4313 NM_014913 Hs.131915 2.00E−65 1 KIAA0863 protein (KIAA0863), mRNA/cds = (185,3 117H2 282 569 NM_003608 Hs.131924 1.00E−143 1 G protein-coupled receptor 65 (GPR65), mRNA/ 462D11 441 683 AW976422 Hs.132064 1.00E−118 1 EST388531 cDNA/gb = AW976422/gi = 8167649/ug = 586F11 161 1094 NM_017830 Hs.132071 0 2 hypothetical protein FLJ20455 (FLJ20455), mR 466A8 118 224 AI042377 Hs.132156 2.00E−44 1 ox62c03.x1 cDNA, 3′ end/clone = IMAGE: 1660900 472F6 979 1431 AK022463 Hs.132221 0 1 cDNA FLJ12401 fis, clone MAMMA 1002796/cds = (3, 462E4 19 567 AI031656 Hs.132237 0 1 ow48e06.x1 cDNA, 3′ end/clone = IMAGE: 1650082 462E2 4 539 AI829569 Hs.132238 0 1 wf28e02.x1 cDNA, 3′ end/clone = IMAGE: 2356922 461H9 453 618 BG037042 Hs.132555 4.00E−57 1 602288311F1 cDNA, 5′ end/clone = IMAGE: 4374122 467D10 4518 4689 AK024449 Hs.132569 2.00E−55 1 mRNA for FLJ00041 protein, partial cds/cds = (0 463H7 162 438 AI346336 Hs.132594 1.00E−132 1 qp50b04.x1 cDNA, 3′ end/clone = IMAGE: 1926415 592B8 2415 2957 NM_005337 Hs.132834 0 1 hematopoietic protein 1 (HEM1), mRNA/cds = (158 70H2 6370 6718 AF047033 Hs.132904 1.00E−175 1 sodium bicarbonate cotransporter 3 (SLC4A7) m 50G10 1167 2041 AL121985 Hs.132906 0 4 DNA sequence from clone RP11-404F10 on chromosome 1q2 123C10 1323 1570 NM_015071 Hs.132942 1.00E−136 1 GTPase regulator associated with the focal adh 121B10 92 503 AA504269 Hs.133032 0 1 aa61c09.s1 cDNA, 3′ end/clone = IMAGE: 825424/ 171A12 696 909 AL050035 Hs.133130 6.00E−83 1 mRNA; cDNA DKFZp566H0124 (from clone DKFZp566 463B5 123 449 AI051673 Hs.133175 1.00E−176 1 oy77g06.x1 cDNA, 3′ end/clone = IMAGE: 1671898 463B7 966 1103 AL044498 Hs.133262 3.00E−46 1 DKFZp4341082_s1 cDNA, 3′ end/clone = DKFZp4341 463B8 1 322 AV661783 Hs.133333 1.00E−176 1 AV661783 cDNA, 3′ end/clone = GLCGXE12/clone_(—) 463A10 431 694 AW966876 Hs.133543 1.00E−110 1 EST378950 cDNA/gb = AW966876/gi = 8156712/ug = 464B10 63 547 BF965766 Hs.133864 0 1 602276890F1 cDNA, 5′ end/clone = IMAGE: 4364495 460C6 454 653 AW009671 Hs.134272 8.00E−70 1 ws85g09.x1 cDNA, 3′ end/clone = IMAGE: 2504800 459C12 3337 3745 AJ278245 Hs.134342 1.00E−121 1 mRNA for LanC-like protein 2 (lancl2 gene)/cds 462G1 33 454 AI074016 Hs.134473 0 1 oy66g02.x1 cDNA, 3′ end/clone = IMAGE: 1670834 462G6 260 597 BE676210 Hs.134648 1.00E−156 1 7f25c05.x1 cDNA, 3′ end/clone = IMAGE: 3295688 466H12 505 662 AV706481 Hs.134829 3.00E−65 1 AV706481 cDNA, 5′ end/clone = ADBBYF02 148H11 16 474 BE786820 Hs.135056 0 1 601477630F1 5′ end/clone = IMAGE: 3880471 462E1 139 487 BF109873 Hs.135106 0 1 7170e11.x1 cDNA, 3′ end/clone = IMAGE: 3526772 147E6 11 364 AV712376 Hs.135167 0 2 AV712376 cDNA, 5′ end/clone = DCAAND12/clone_(—) 465B4 1993 2237 AJ271326 Hs.135187 1.00E−92 1 mRNA for unc-93 related protein (UNC93 gene)/ 463B4 185 352 AI051664 Hs.135339 4.00E−48 1 oy77f06.x1 cDNA, 3′ end/clone = IMAGE: 1671875 478H4 2126 2458 AK024921 Hs.135570 1.00E−170 1 cDNA: FLJ21268 fis, clone COL01718/cds = UNKNOW 148B6 119 444 AI004582 Hs.135764 3.00E−82 8 ou04a11.x1 3′ end/clone = IMAGE: 1625276 598E9 1948 2184 NM_022117 Hs.136164 3.00E−93 1 cutaneous T-cell lymphoma-associated tumor a 514C10 398 840 AL049597 Hs.136309 0 2 DNA sequence from clone RP4-612B15 on chromosome 1p22 461C6 18 219 BF513274 Hs.136375 1.00E−101 1 UI-H-BW1-amo-d-11-0-UI.s1 cDNA, 3′ end/clon 482E4 291 699 BF526066 Hs.136537 1.00E−142 1 602071176F1 cDNA, 5′ end/clone = IMAGE: 4214059 461G7 43 466 NM_013378 Hs.136713 0 1 pre-B lymphocyte gene 3 (VPREB3), mRNA/cds = (4 119B10 10 677 NM_013269 Hs.136748 0 2 lectin-like NK cell receptor (LLT1), mRNA/cd 462A10 1233 1727 AK024426 Hs.137354 0 1 mRNA for FLJ00015 protein, partial cds/cds = (3 41F2 2684 3000 AJ223324 Hs.137548 1.00E−156 1 for MAX.3 cell surface antigen/cds = (44,10 74E8 16 2000 D10923 Hs.137555 0 15 HM74/cds = (60,1223)/gb = D10923/gi = 219866/ 58D10 8 2000 NM_006018 Hs.137555 0 9 putative chemokine receptor; GTP-binding pro 120E2 210 814 NM_002027 Hs.138381 0 1 farnesyltransferase, CAAX box, alpha (FNTA), 168E12 1953 2522 D38524 Hs.138593 0 1 5′-nucleotidase/cds = (83,1768)/gb = D38524 178F7 573 824 NM_006413 Hs.139120 1.00E−115 1 ribonuclease P (30 kD) (RPP30), mRNA/cds = (27,8 473D1 1635 1767 AL049942 Hs.139240 6.00E−50 1 mRNA; cDNA DKFZp564F1422 (from clone DKFZp564F 188A8 924 1038 NM_017523 Hs.139262 1.00E−56 2 XIAP associated factor-1 (HSXIAPAF1), mRNA/c 168F7 933 1038 X99699 Hs.139262 1.00E−53 1 for XIAP associated factor-1/cds = (0,953)/ 181B10 1556 2517 NM_005816 Hs.142023 0 3 T cell activation, increased late expression ( 514E7 2052 2339 NM_003150 Hs.142258 1.00E−114 1 signal transducer and activator of transcripti 196C7 355 524 NM_016123 Hs.142295 9.00E−92 1 putative protein kinase NY-REN-64 antigen (LO 585B10 3261 3465 AK023129 Hs.142442 1.00E−100 1 cDNA FLJ13067 fis, clone NT2RP3001712, highly 458F2 283 413 BE293343 Hs.142737 3.00E−68 1 601143756F1 cDNA, 5′ end/clone = IMAGE: 3051493 134C6 289 572 BE886127 Hs.142838 1.00E−160 1 601509912F1 cDNA, 5′ end/clone = IMAGE: 3911451 110A11 345 584 AI126688 Hs.143049 1.00E−102 1 qb94a06.x1 cDNA, 3′ end/clone = IMAGE: 1707730 472G7 127 452 AW976331 Hs.143254 0 1 EST388440 cDNA/gb = AW976331/gi = 8167557/ug = 464G11 425 547 AI357640 Hs.143314 1.00E−56 1 qy15b06.x1 cDNA, 3′ end/clone = IMAGE: 2012051 463F11 257 640 BF446017 Hs.143389 0 1 7p18a11.x1 cDNA, 3′ end/clone = IMAGE: 3646004 463H2 107 443 AA825245 Hs.143410 1.00E−151 1 oe59g09.s1 cDNA, 3′ end/clone = IMAGE: 1415968 48B7 1 3366 NM_005813 Hs.143460 0 2 protein kinase C, nu (PRKCN), mRNA/cds = (555,32 463C9 290 405 AW173163 Hs.143525 5.00E−41 1 xj84b08.x1 cDNA, 3′ end/clone = IMAGE: 2663895 463C8 330 473 AI095189 Hs.143534 5.00E−57 2 oy83b06.s1 cDNA, 3′ end/clone = IMAGE: 1672403 464G5 94 189 BG033028 Hs.143554 1.00E−38 1 602300135F1 cDNA, 5′ end/clone = IMAGE: 4401776 463D7 120 563 NM_006777 Hs.143604 0 1 Kaiso (ZNF-kaiso), mRNA/cds = (0,2018)/gb = NM 471A10 132 586 AK026372 Hs.143631 0 1 cDNA: FLJ22719 fis, clone HSI14307/cds = UNKNOW 74G2 5129 5285 AF073310 Hs.143648 2.00E−79 2 insulin receptor substrate-2 (IRS2) mRNA, com 471G11 7 320 AI568622 Hs.143951 1.00E−154 2 tn41e10.x1 cDNA, 3′ end/clone = IMAGE: 2170218 478H12 963 1532 NM_018270 Hs.143954 0 1 hypothetical protein FLJ10914 (FLJ10914), mR 462G3 100 529 AI074020 Hs.144114 0 1 oy66g06.x1 cDNA, 3′ end/clone = IMAGE: 1670842 463C1 52 151 AI090305 Hs.144119 1.00E−42 1 oy81b01.s1 cDNA, 3′ end/clone = IMAGE: 1672201 472H8 157 485 BF509758 Hs.144265 1.00E−178 1 UI-H-B14-apg-d-04-0-UI.s1 cDNA, 3′ end/clon 166E1 23 443 D63874 Hs.144321 0 1 HMG-1, complete cds/cds = (76,723)/gb = D63874 145G8 125 1606 NM_018548 Hs.144477 0 2 hypothetical protein PRO2975 (PRO2975), mRNA 191H8 46 624 BF036686 Hs.144559 0 1 601459771F1 cDNA, 5′ end/clone = IMAGE: 3863248 151B1 1983 2561 M93651 Hs.145279 0 2 set gene, complete cds/cds = (3,836)/gb = M93651/ gi = 33 514B2 115 1583 NM_003011 Hs.145279 0 4 SET translocation (myeloid leukemia-associat 596D4 89 734 AA631938 Hs.145668 0 8 fmfc5 cDNA/clone = CR6-21/gb = AA631938/gi = 25 492B3 512 2226 NM_004902 Hs.145696 0 2 splicing factor (CC1.3) (CC1.3), mRNA/cds = (14 192E4 1483 1837 AF246126 Hs.145956 0 1 zinc finger protein mRNA, complete cds/cds = (1 480B9 1094 1426 AL136874 Hs.146037 1.00E−111 1 mRNA; cDNA DKFZp434C135 (from clone DKFZp434C1 49H1 1761 2182 NM_022894 Hs.146123 0 1 hypothetical protein FLJ12972 (FLJ12972), mR 129C6 517 603 BE220959 Hs.146215 6.00E−21 1 hu02b06.x1 cDNA, 3′ end/clone = IMAGE: 3165395 583D9 249 646 NM_003641 Hs.146360 0 1 interferon induced transmembrane protein 1 ( 589D9 125 1866 NM_002139 Hs.146381 0 5 RNA binding motif protein, X chromosome (RBMX) 68H11 122 1567 Z23064 Hs.146381 0 2 mRNA gene for hnRNP G protein/cds = (11,1186)/gb = 174A8 461 1008 NM_004757 Hs.146401 0 1 small inducible cytokine subfamily E, member 1 171A6 461 686 U10117 Hs.146401 1.00E−100 1 endothelial-monocyte activating polypeptide II mRN 465C4 53 342 AI141004 Hs.146627 3.00E−89 1 oy68f02.x1 cDNA, 3′ end/clone = IMAGE: 1671003 190H7 1306 3107 AB033079 Hs.146668 0 3 mRNA for KIAA1253 protein, partial cds/cds = (0 102E9 412 1022 AF054187 Hs.146763 0 3 alpha NAC mRNA, complete cds/cds = (309,956)/g 179B1 364 843 D16481 Hs.146812 0 1 mitochondrial 3-ketoacyl-CoA thiolas 126H12 1 358 NM_000183 Hs.146812 0 1 hydroxyacyl-Coenzyme A dehydrogenase/3-keto 476C9 20 249 AI187423 Hs.147040 1.00E−128 2 qf31d04.x1 cDNA, 3′ end/clone = IMAGE: 1751623 70H11 47 1593 AF272148 Hs.147644 0 7 KRAB zinc finger protein (RITA) mRNA, complete 51F1 635 1039 NM_018555 Hs.147644 0 3 C2H2-like zinc finger protein (ZNF361), mRNA 72H1 948 5026 AF000982 Hs.147916 0 7 dead box, X isoform (DBX) mRNA, alternative tra 37F10 3128 3652 X63563 Hs.148027 0 1 RNA polymerase II 140 kDa/cds = (43,3567) 64C11 163 279 AA908367 Hs.148288 6.00E−29 1 og76c11.s1 cDNA, 3′ end/clone = IMAGE: 1454228 463G2 52 473 AI335004 Hs.148558 0 1 tb21e09.x1 cDNA, 3′ end/clone = IMAGE: 2055016 471F8 17 463 AI471866 Hs.149095 0 1 ti67d04.x1 cDNA, 3′ end/clone = IMAGE: 2137063 169C12 449 1711 L06132 Hs.149155 0 2 voltage-dependent anion channel isoform 1 (VDAC) mRN 189G6 1353 1711 NM_003374 Hs.149155 0 5 voltage-dependent anion channel 1 (VDAC1), mR 481E3 501 669 NM_007022 Hs.149443 5.00E−84 1 putative tumor suppressor (101F6), mRNA/cds = 472B3 93 182 BF029894 Hs.149595 6.00E−44 1 601557056F1 cDNA, 5′ end/clone = IMAGE: 3827172 173D1 3719 3877 AB037901 Hs.149918 3.00E−83 1 GASC-1 mRNA, complete cds/cds = (150,3320)/gb 153G12 1429 1787 M31627 Hs.149923 0 2 X box binding protein-1 (XBP-1) mRNA, complete cds/cd 116B10 1435 1787 NM_005080 Hs.149923 1.00E−180 1 X-box binding protein 1 (XBP1), mRNA/cds = (12,7 111G4 480 1891 L12052 Hs.150395 0 2 cAMP phosphodiesterase PDE7 (PDE7A1) mRNA, co 461D6 1407 1904 NM_000790 Hs.150403 0 1 dopa decarboxylase (aromatic L-amino acid dec 73B3 896 1779 AL050005 Hs.150580 0 23 cDNA DKFZp564A153 (from clone DKFZp564A1 465G12 1 549 AJ272212 Hs.150601 0 1 mRNA for protein serine kinase (PSKH1 gene)/c 140G12 2 195 BF028489 Hs.150675 1.00E−100 1 601763692F1 cDNA, 5′ end/clone = IMAGE: 3995950 496E10 17 1686 BC000167 Hs.151001 0 5 clone IMAGE: 2900671, mRNA, partial cds/cds = 597G7 623 1488 NM_005015 Hs.151134 0 2 oxidase (cytochrome c) assembly 1-like (OXA1L 50C9 1051 1467 X80695 Hs.151134 0 1 OXA1Hs mRNA/cds = (6,1313)/gb = X80695/ gi = 619490 125H7 3154 3957 NM_001421 Hs.151139 0 3 E74-like factor 4 (ets domain transcription fa 111F2 306 638 BG286500 Hs.151239 1.00E−149 1 602382992F1 cDNA, 5′ end/clone = IMAGE: 4500527 177A4 9686 10035 AF075587 Hs.151411 0 1 protein associated with Myc mRNA, complete cds 185C7 6934 13968 NM_015057 Hs.151411 0 3 KIAA0916 protein (KIAA0916), mRNA/cds = (146,1 115E7 3406 4005 NM_004124 Hs.151413 0 1 glia maturation factor, beta (GMFB), mRNA/cds 182H7 234 833 AF099032 Hs.151461 0 1 embryonic ectoderm development protein short 169C10 4247 4727 U38847 Hs.151518 0 1 TAR RNA loop binding protein (TRP-185) mRNA, complete 167D6 1013 1197 NM_002870 Hs.151536 6.00E−83 1 RAB13, member RAS oncogene family (RAB13), mRN 588G11 1249 1898 AK023362 Hs.151604 1.00E−157 9 cDNA FLJ13300 fis, clone OVARC1001342, highly 479G10 1 277 NM_007210 Hs.151678 1.00E−103 1 UDP-N-acetyl-alpha-D-galactosamine: polype 178B7 2664 3033 NM_004247 Hs.151787 0 4 U5 snRNP-specific protein, 116 kD (U5-116 KD), 59A6 382 860 D42054 Hs.151791 0 1 KIAA0092 gene, complete cds/cds = (53,1477)/ 521B6 2017 2205 NM_014679 Hs.151791 2.00E−93 1 KIAA0092 gene product (KIAA0092), mRNA/cds = ( 59C10 37 697 AF070525 Hs.151903 0 5 clone 24706 mRNA sequence/cds = UNKNOWN/ gb = AF 519A7 165 686 NM_005792 Hs.152720 0 1 M-phase phosphoprotein 6 (MPHOSPH6), mRNA/c 481E11 3990 4280 NM_005154 Hs.152818 1.00E−135 1 ubiquitin specific protease 8 (USP8), mRNA/cd 110F2 1210 1841 L25931 Hs.152931 0 2 lamin B receptor (LBR) mRNA, complete cds/ cds = (75,192 516F8 1217 1708 NM_002296 Hs.152931 0 1 lamin B receptor (LBR), mRNA/cds = (75,1922)/g 462B2 93 2385 AF244129 Hs.153042 0 2 cell-surface molecule Ly-9 mRNA, complete cds 41F4 617 905 X14046 Hs.153053 1.00E−162 1 leukocyte antigen CD37/cds = (63,908)/gb = X14 462G8 2312 2843 AF311312 Hs.153057 0 1 infertility-related sperm protein mRNA, comp 142H5 17 221 M94856 Hs.153179 1.00E−92 1 fatty acid binding protein homologue (PA-FABP) mRNA, 486G9 3 431 NM_001444 Hs.153179 0 1 fatty acid binding protein 5 (psoriasis-associ 40A1 2158 2716 X79201 Hs.153221 0 1 SYT/cds = (3,1178)/gb = X79201/gi = 531105 101D9 1524 2060 AB014601 Hs.153293 0 1 for KIAA0701 protein, partial cds/cds = (0 460F10 1457 6107 AB032972 Hs.153489 0 2 mRNA for KIAA1146 protein, partial cds/cds = (0 106A5 445 547 AI761622 Hs.153523 2.00E−37 1 wg66f05.x1 cDNA, 3′ end/clone = IMAGE: 2370081 482A6 49 369 AI859076 Hs.153551 1.00E−106 1 wl33b04.x1 cDNA, 3′ end/clone = IMAGE: 2426671 589B2 1054 1556 AF261091 Hs.153612 0 1 iron inhibited ABC transporter 2 mRNA, complet 57A3 1586 1757 NM_004073 Hs.153640 9.00E−87 1 cytokine-inducible kinase (CNK), mRNA/cds = (3 466H3 2 257 NM_003866 Hs.153687 1.00E−133 1 inositol polyphosphate-4-phosphatase, type 483B6 3337 3544 NM_002526 Hs.153952 2.00E−72 1 5′ nucleotidase (CD73) (NT5), mRNA/cds = (49,17 41F1 2749 3371 X55740 Hs.153952 0 1 placental cDNA coding for 5′ nucleotidase (EC 3.1.3.5) 44C3 1319 1574 X82206 Hs.153961 1.00E−130 1 alpha-centractin/cds = (66,1196)/gb = X8 64F12 2578 2713 NM_022790 Hs.154057 1.00E−26 1 matrix metalloproteinase 19 (MMP19), transcri 72E11 1886 2717 U38320 Hs.154057 0 15 clone rasi-3 matrix metalloproteinase RASI-1 165H12 414 663 AW970676 Hs.154172 2.00E−22 1 EST382759 cDNA/gb = AW970676/gi = 8160521/ug = 37A4 1151 2746 M31210 Hs.154210 0 2 endothelial differentiation protein (edg-1) gene mR 597F4 1125 2395 NM_001400 Hs.154210 0 11 endothelial differentiation, sphingolipid G 106F2 24 1657 U22897 Hs.154230 0 2 nuclear domain 10 protein (ndp52) mRNA, comple 466E2 116 373 AB023149 Hs.154296 1.00E−131 2 mRNA for KIAA0932 protein, partial cds/cds = (0 107F11 1386 1743 AL117566 Hs.154320 0 1 cDNA DKFZp566J164 (from clone DKFZp566J1 166E12 4490 4894 D86967 Hs.154332 0 1 KIAA0212 gene, complete cds/cds = (58,2031)/ 188D12 5148 5666 NM_014674 Hs.154332 0 2 KIAA0212 gene product (KIAA0212), mRNA/cds = ( 66A1 88 615 M82882 Hs.154365 0 1 cis-acting sequence/cds = UNKNOWN/gb = M82882/ gi = 180 37C1 4320 4776 AB028999 Hs.154525 0 1 for KIAA1076 protein, partial cds/cds = (0 98D2 2317 4907 NM_000104 Hs.154654 0 6 cytochrome P450, subfamily I (dioxin-inducibl 37C4 4445 4907 U03688 Hs.154654 0 3 dioxin-inducible cytochrome P450 (CYP1B1) mRNA, comp 464A5 1418 2027 NM_006636 Hs.154672 0 3 methylene tetrahydrofolate dehydrogenase (N 36C5 615 1689 X16396 Hs.154672 0 7 NAD-dependent methylene tetrahydrofolate d 67C8 1 397 U85773 Hs.154695 0 1 phosphomannomutase (PMM2) mRNA, complete cds/ cds = ( 525D3 2084 2533 NM_002651 Hs.154846 0 1 phosphatidylinositol 4-kinase, catalytic, b 109A7 1979 3148 D10040 Hs.154890 0 2 for long-chain acyl-CoA synthetase, compl 167F6 1817 3359 NM_021122 Hs.154890 0 8 fatty-acid-Coenzyme A ligase, long-chain 2 ( 182A1 344 793 NM_021825 Hs.154938 0 1 hypothetical protein MDS025 (MDS025), mRNA/ 104E2 1254 1762 D87450 Hs.154978 0 1 KIAA0261 gene, partial cds/cds = (0,3865)/gb 519G10 4912 5303 NM_003489 Hs.155017 0 1 nuclear receptor interacting protein 1 (NRIP1 595C6 4067 4631 NM_006526 Hs.155040 0 2 zinc finger protein 217 (ZNF217), mRNA/cds = (2 105D4 1768 2418 L42373 Hs.155079 0 1 phosphatase 2A B56-alpha (PP2A) mRNA, complete 174B7 1768 2320 NM_006243 Hs.155079 0 1 protein phosphatase 2, regulatory subunit B ( 75G4 920 1775 X59066 Hs.155101 0 2 mitochondrial ATP synthase (F1-ATPase) alpha 523G12 20 848 NM_004681 Hs.155103 0 3 eukaryotic translation initiation factor 1A, 74D7 292 1094 M16942 Hs.155122 0 3 MHC class II HLA-DRw53-associated glycoprotein beta- 137D4 2500 2822 AL049761 Hs.155140 1.00E−176 1 DNA sequence from clone RP5-863C7 on chromosome 20p12 471B5 908 1168 AK023379 Hs.155160 1.00E−141 1 cDNA FLJ13317 fis, clone OVARC1001577, highly 176C9 2104 2635 NM_003664 Hs.155172 0 1 adaptor-related protein complex 3, beta 1 sub 99F5 212 671 NM_005642 Hs.155188 0 1 TATA box binding protein (TBP)-associated fac 166E9 1215 1637 U18062 Hs.155188 0 1 TFIID subunit TAFII55 (TAFII55) mRNA, complete cds/c 163A11 60 3052 AL162086 Hs.155191 0 8 cDNA DKFZp762H157 (from clone DKFZp762H1 71E4 44 558 NM_003379 Hs.155191 1.00E−175 4 villin 2 (ezrin) (VIL2), mRNA/cds = (117,1877) 145D8 2135 2669 L47345 Hs.155202 0 1 elongin A mRNA, complete cds/cds = (32,2350)/g 477H9 357 2812 NM_014670 Hs.155291 0 2 KIAA0005 gene product (KIAA0005), mRNA/cds = ( 58D8 38 336 NM_000518 Hs.155376 1.00E−100 1 hemoglobin, beta (HBB), mRNA/cds = (50,493)/g 48F11 576 2131 NM_006164 Hs.155396 0 2 nuclear factor (erythroid-derived 2)-like 2 65G11 426 1179 S74017 Hs.155396 0 1 Nrf2 = NF-E2-like basic leucine zipper transcriptional act 480G12 852 1246 NM_001352 Hs.155402 0 1 D site of albumin promoter (albumin D-box) bind 182B12 245 592 NM_006899 Hs.155410 0 1 isocitrate dehydrogenase 3 (NAD+) beta (IDH3B 599C9 3188 3487 NM_021643 Hs.155418 1.00E−163 1 GS3955 protein (GS3955), mRNA/cds = (1225,2256 68H2 563 1749 AF037448 Hs.155489 0 2 RRM RNA binding protein Gry-rbp (GRY-RBP) mRNA 173F6 1243 1811 AF208043 Hs.155530 0 2 IFI16b (IFI16b) mRNA, complete cds/cds = (264,2 170B3 1061 1342 D50063 Hs.155543 1.00E−139 1 proteasome subunit p40_/Mov34 protein, comp 590E9 494 1323 NM_002811 Hs.155543 0 2 proteasome (prosome, macropain) 26S subunit, 522D11 1463 1710 AB029003 Hs.155546 1.00E−138 2 mRNA for KIAA1080 protein, partial cds/cds = (0 587A8 3514 3923 NM_001746 Hs.155560 0 1 calnexin (CANX), mRNA/cds = (89,1867)/gb = NM_0 39A6 830 1474 D63878 Hs.155595 0 1 KIAA0158 gene, complete cds/cds = (258,1343) 167F5 745 2735 NM_004404 Hs.155595 0 3 neural precursor cell expressed, developmenta 106E10 1922 2340 U15173 Hs.155596 1.00E−179 2 BCL2/adenovirus E1B 19 kD-interacting protein 524A8 1639 2229 NM_014666 Hs.155623 0 1 KIAA0171 gene product (KIAA0171), mRNA/cds = ( 166D6 12177 12974 U47077 Hs.155637 0 3 DNA-dependent protein kinase catalytic subuni 488A10 1961 2426 NM_002827 Hs.155894 0 3 protein tyrosine phosphatase, non-receptor t 65D6 696 1107 S68271 Hs.155924 0 3 cyclic AMP-responsive element modulator (CRE 113E8 682 1435 NM_004054 Hs.155935 0 1 complement component 3a receptor 1 (C3AR1), mR 105F10 119 1591 U62027 Hs.155935 0 3 anaphylatoxin C3a receptor (HNFAG09) mRNA, complete 111C1 4122 4779 NM_005541 Hs.155939 0 5 inositol polyphosphate-5-phosphatase, 145 kD 40A9 1727 2300 D76444 Hs.155968 0 1 hkf-1 mRNA, complete cds/cds = (922,2979)/gb = 124F1 1464 2121 NM_005667 Hs.155968 0 1 zinc finger protein homologous to Zfp103 in mo 481E12 2237 2691 NM_003588 Hs.155976 0 1 cullin 4B (CUL4B), mRNA/cds = (78,2231)/gb = NM 109H3 36 440 NM_020414 Hs.155986 0 1 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 193B10 1103 1892 AK024974 Hs.156110 1.00E−180 5 cDNA: FLJ21321 fis, clone COL02335, highly sim 463H6 26 149 AI337347 Hs.156339 5.00E−57 1 tb98e10.x1 cDNA, 3′ end/clone = IMAGE: 2062410 107H5 34 253 AI146787 Hs.156601 7.00E−93 1 qb83f02.x1 cDNA, 3′ end/clone = IMAGE: 1706715 517E8 209 822 NM_015646 Hs.156764 0 3 RAP1B, member of RAS oncogene family (RAP1B), 478H11 456 768 NM_005819 Hs.157144 1.00E−172 1 syntaxin 6 (STX6), mRNA/cds = (0,767)/gb = NM_0 463G12 44 283 AI351144 Hs157213 3.00E−95 1 qt23f10.x1 cDNA, 3′ end/clone = IMAGE: 1948459 520A2 2359 2565 BC001913 Hs.157236 1.00E−95 2 Similar to membrane protein of cholinergic sy 473A8 2944 3570 AK026394 Hs.157240 0 1 cDNA: FLJ22741 fis, clone HUV00774/ cds = UNKNOW 464D5 433 601 AW207701 Hs.157315 8.00E−37 1 UI-H-BI2-age-e-03-0-UI.s1 cDNA, 3′ end/clon 464B8 288 633 BF184881 Hs.157396 2.00E−99 1 601843756F1 cDNA, 5′ end/clone = IMAGE: 4064508 463A6 225 554 AW976630 Hs.157447 1.00E−169 1 EST388739 cDNA/gb = AW976630/gi = 8167861/ug = 464G10 423 661 AI356405 Hs.157556 1.00E−103 1 qz26g04.x1 cDNA, 3′ end/clone = IMAGE: 2028054 464H3 396 642 AI568755 Hs.157564 1.00E−123 1 th15f03.x1 cDNA, 3′ end/clone = IMAGE: 2118365 466C1 110 384 AI760026 Hs.157569 1.00E−135 1 wh83c05.x1 cDNA, 3′ end/clone = IMAGE: 2387336 465A2 11 178 AI823541 Hs.157710 1.00E−79 1 wh55c11.x1 cDNA, 3′ end/clone = IMAGE: 2384660 464A8 2000 2248 AK023779 Hs.157777 1.00E−134 1 cDNA FLJ13717 fis, clone PLACE2000425/cds = UNK 464G1 122 447 AI361761 Hs.157813 1.00E−163 2 qz19a07.x1 cDNA, 3′ end/clone = IMAGE: 2021940 464G7 293 395 AI361849 Hs.157815 4.00E−30 1 qz19h11.x1 cDNA, 3′ end/clone = IMAGE: 2022021 145B8 238 598 BF303931 Hs.157850 1.00E−179 3 601886564F2 cDNA, 5′ end/clone = IMAGE: 4120574 115D1 111 712 NM_000661 Hs.157850 1.00E−159 2 ribosomal protein L9 (RPL9), mRNA/cds = (29,607 102F8 4161 4818 AB023198 Hs.158135 0 1 for KIAA0981 protein, partial cds/cds = (0 597H12 1253 2625 NM_000593 Hs.158164 0 5 ATP-binding cassette, sub-family B (MDR/TAP), 465A3 172 342 T78173 Hs.158193 5.00E−64 1 yd79c05.r1 cDNA, 5′ end/clone = IMAGE: 114440/ 465H8 740 1171 NM_006354 Hs.158196 1.00E−149 1 transcriptional adaptor 3 (ADA3, yeast homolo 59H12 1646 6883 NM_002313 Hs.158203 0 4 actin-binding LIM protein (ABLIM), transcript 464A2 32 549 NM_004571 Hs.158225 0 1 PBX/knotted 1 hoemobox 1 (PKNOX1), mRNA/cds = ( 124F12 6603 6907 AB007915 Hs.158286 1.00E−172 1 mRNA for KIAA0446 protein, partial cds/cds = (3 519F5 80 268 AI199223 Hs.158289 1.00E−86 1 qi47c06.x1 cDNA, 3′ end/clone = IMAGE: 1859626 463F8 33 286 BF433857 Hs.158501 1.00E−123 1 7q71b07.x1 cDNA/clone = IMAGE/gb = BF433857/g 137A8 204 452 AI370965 Hs.158653 5.00E−32 1 ta29b11.x1 cDNA, 3′ end/clone = IMAGE: 2045469 466A11 1 565 BE676408 Hs.158714 0 1 7f29b11.x1 cDNA, 3′ end/clone = IMAGE: 3296061 73C2 5 396 AW362008 Hs.158794 0 1 PM2-CT0265-211099-002-d04/gb = AW362008 465C6 242 433 AI378113 Hs.158877 2.00E−95 1 tc80c12.x1 cDNA, 3′ end/clone = IMAGE: 2072470 465C2 29 153 AI378457 Hs.158894 4.00E−60 2 tc79d10.x1 cDNA, 3′ end/clone = IMAGE: 2072371 465C10 47 442 AI379953 Hs.158943 0 1 tc81a07.x1 cDNA, 3′ end/clone = IMAGE: 2072532 477B9 151 396 AI380220 Hs.158965 1.00E−109 2 tf94a04.x1 cDNA, 3′ end/clone = IMAGE: 2106894 477B10 1 414 AI380236 Hs.158966 0 2 tf94b10.x1 cDNA, 3′ end/clone = IMAGE: 2106907 466F8 128 233 AI380388 Hs.158975 4.00E−30 1 tf96a03.x1 cDNA, 3′ end/clone = IMAGE: 2107084 467E12 109 350 AI799909 Hs.158989 1.00E−82 1 wc46c08.x1 cDNA, 3′ end/clone = IMAGE: 2321678 469G6 169 470 AI631850 Hs.158992 1.00E−119 1 wa36h07.x1 cDNA, 3′ end/clone = IMAGE: 2300221 467H4 17 292 BF508694 Hs.158999 1.00E−117 1 UI-H-BI4-aop-f-09-0-UI.s1 cDNA, 3′ end/clon 469B2 179 388 AI568751 Hs.159014 4.00E−94 1 th15d09.x1 cDNA, 3′ end/clone = IMAGE: 2118353 464E8 742 945 AL538276 Hs.159065 1.00E−110 1 AL538276 cDNA/clone = CS0DF027YC09-(5-prime) 469D9 1 413 AI431873 Hs.159103 0 1 ti26b11.x1 cDNA, 3′ end/clone = IMAGE: 2131581 122C7 1916 2375 NM_003266 Hs.159239 0 1 toll-like receptor 4 (TLR4), mRNA/cds = (284,26 462H4 79 239 BF307871 Hs.159336 7.00E−66 1 601890687F1 cDNA, 5′ end/clone = IMAGE: 4132028 179C1 428 734 AJ225093 Hs.159386 3.00E−88 1 single-chain antibody, complete cds 473D11 267 339 AI380255 Hs.159424 5.00E−34 1 tf94d08.x1 cDNA, 3′ end/clone = IMAGE: 2106927 107B2 1 617 BE783628 Hs.159441 1.00E−160 2 601471696F1 cDNA, 5′ end/clone = IMAGE: 3874823 590E12 52 654 BG290141 Hs.159441 0 6 602385221F1 cDNA, 5′ end/clone = IMAGE: 4514380 70E1 2095 2333 AK027194 Hs.159483 1.00E−119 1 FLJ23541 fis, clone LNG08276, highly sim 58A5 10448 12675 AF193556 Hs.159492 0 10 sacsin (SACS) gene, complete cds/cds = (76,1156 482E11 2064 2559 NM_000061 Hs.159494 0 1 Bruton agammaglobulinemia tyrosine kinase (B 147A11 755 2415 AF001622 Hs.159523 0 7 class-I MHC-restricted T cell associated mole 486H6 1164 1382 NM_019604 Hs.159523 1.00E−117 2 class-I MHC-restricted T cell associated mole 465A5 2693 3039 NM_000033 Hs.159546 1.00E−148 1 ATP-binding cassette, sub-family D (ALD), mem 60C4 1102 1962 AK024833 Hs.159557 1.00E−147 4 FLJ21180 fis, clone CAS11176, highly sim 465B11 457 1126 NM_016952 Hs.159565 0 1 surface glycoprotein, Ig superfamily member ( 477A12 89 581 AI797788 Hs.159577 0 5 wh78b11.x1 cDNA, 3′ end/clone = IMAGE: 2386845 595H8 19 912 NM_004632 Hs.159627 0 2 death associated protein 3 (DAP3), mRNA/cds = ( 74D2 7 2119 AF153609 Hs.159640 0 9 serine/threonine protein kinase sgk mRNA, com 71B2 8 533 NM_005627 Hs.159640 0 1 serum/glucocorticoid regulated kinase (SGK) 467G8 310 488 AW006352 Hs.159643 2.00E−92 1 wt04d12.x1 cDNA, 3′ end/clone = IMAGE: 2506487 467B8 11 363 AI392893 Hs.159655 1.00E−173 1 tg05d07.x1 cDNA, 3′ end/clone = IMAGE: 2107885 471F11 16 303 AI827950 Hs.159659 1.00E−162 1 wk31a11.x1 cDNA, 3′ end/clone = IMAGE: 2413916 467C11 18 501 BF508053 Hs.159673 0 1 UI-H-B14-apx-b-11-0-UI.s1 cDNA, 3′ end/clon 477F4 3 405 AI394671 Hs.159678 0 2 tg24a07.x1 cDNA, 3′ end/clone = IMAGE: 2109684 472F5 194 366 NM_018490 Hs.160271 1.00E−93 1 G protein-coupled receptor 48 (GPR48), mRNA/ 468B11 72 481 AI393041 Hs.160273 0 1 tg25b10.x1 cDNA, 3′ end/clone = IMAGE: 2109787 477D3 5 484 AI393906 Hs.160401 0 2 tg05f08.x1 cDNA, 3′ end/clone = IMAGE: 2107911 477D12 11 389 AI393962 Hs.160405 1.00E−178 1 tg11d08.x1 cDNA, 3′ end/clone = IMAGE: 2108463 477D5 15 262 AI393992 Hs.160408 1.00E−138 1 tg06c05.x1 cDNA, 3′ end/clone = IMAGE: 2107976 65A9 4106 5547 AF137030 Hs.160417 0 5 transmembrane protein 2 (TMEM2) mRNA, complete 513A2 4109 5547 NM_013390 Hs.160417 0 5 transmembrane protein 2 (TMEM2), mRNA/cds = (14 463F12 688 1425 AF218032 Hs.160422 0 1 clone PP902 unknown mRNA/cds = (693,1706)/gb = 165C1 2625 2987 X85116 Hs.160483 0 1 H. sapiens epb72 gene exon 1/cds = (61,927)/ gb = X85116/gi = 1 469G4 145 550 AI634652 Hs.160795 0 1 wa07e10.x1 CDNA, 3′ end/clone = IMAGE: 2297418 472C7 343 565 AI760020 Hs.160951 1.00E−105 1 wh83b05.x1 cDNA, 3′ end/clone = IMAGE: 2387313 466F12 485 662 BF207290 Hs.160954 2.00E−62 1 601870777F1 cDNA, 5′ end/clone = IMAGE: 4100850 477C10 5 290 BF437585 Hs.160980 1.00E−149 1 7p74d12.x1 cDNA, 3′ end/clone = IMAGE: 3651526 61E8 4435 6593 U83115 Hs.161002 0 3 non-lens beta gamma-crystallin like protein (AIM1) m 458E5 1 462 R84314 Hs.161043 1.00E−159 1 yq23a02.r1 cDNA, 5′ end/clone = IMAGE: 274443/ 466E12 117 447 BF001821 Hs.161075 0 1 7g93g02.x1 cDNA, 3′ end/clone = IMAGE: 3314066 102H4 7 219 AW963155 Hs.161786 1.00E−111 1 EST375228/gb = AW963155/gi = 8152991/ug = 118B6 2050 2260 NM_022570 Hs.161786 2.00E−75 1 C-type (calcium dependent, carbohydrate-reco 593C4 3863 4092 U86453 Hs.162808 9.00E−92 1 phosphatidylinositol 3-kinase catalytic subunit p1 467B7 129 455 AI023714 Hs.163442 1.00E−164 1 ow91h05.x1 cDNA, 3′ end/clone = IMAGE: 1654233 107G8 592 1016 AK023670 Hs.163495 0 1 FLJ13608 fis, clone PLACE1010628/cds = UNK 74F3 229 449 AA627122 Hs.163787 4.00E−77 1 nq70g02.s1 cDNA, 3′ end/clone = IMAGE: 1157714 68B3 1094 1771 AK023494 Hs.164005 0 5 FLJ13432 fis, clone PLACE1002537/cds = UNK 469H10 420 850 NM_002993 Hs.164021 0 1 small inducible cytokine subfamily B (Cys-X-C 464E9 86 424 AA811244 Hs.164168 1.00E−166 1 ob58h11.s1 cDNA, 3′ end/clone = IMAGE: 1335621 467E11 788 1330 NM_007063 Hs.164170 0 1 vascular Rab-GAP/TBC-containing (VRP), mRNA 597C5 59 1251 AY007135 Hs.164280 1.00E−126 3 clone CDABP0051 mRNA sequence/cds = (89,985)/ 464H11 2 202 BF689700 Hs.164675 9.00E−65 1 602186609F1 cDNA, 5′ end/clone = IMAGE: 4298402 459D5 6 496 AI248204 Hs.165051 0 1 qh64h11.x1 cDNA, 3′ end/clone = IMAGE: 1849509 120F12 23 502 NM_001017 Hs.165590 1.00E−159 5 ribosomal protein S13 (RPS13), mRNA/cds = (32,4 469C11 301 613 AW364833 Hs.165681 1.00E−136 1 QV3-DT0043-211299-044-d03 cDNA/gb = AW364833 465D3 289 481 AI766638 Hs.165693 2.00E−62 1 wi02a10.x1 cDNA, 3′ end/clone = IMAGE: 2389050 465D6 107 238 AW850041 Hs.165695 3.00E−61 1 IL3-CT0216-170300-097-C07 cDNA/gb = AW850041 466C7 166 421 AI538546 Hs.165696 1.00E−122 1 td08b07.x1 cDNA, 3′ end/clone = IMAGE: 2075029 469C4 351 691 AI436561 Hs.165703 1.00E−148 1 ti03b03.x1 cDNA, 3′ end/clone = IMAGE: 2129357 62A12 32 256 AV727063 Hs.165980 1.00E−120 4 AV727063 cDNA, 5′ end/clone = HTCCED11/clone_(—) 107C2 2427 2613 AJ250865 Hs.165986 1.00E−82 1 for TESS 2 protein (TESS/cds = (128,1393)/ 461D5 1762 1935 NM_004031 Hs.166120 8.00E−81 1 interferon regulatory factor 7 (IRF7), transc 147D11 38 1283 AL022097 Hs.166203 0 5 DNA sequence from PAC 256G22 on chromosome 6p24 595H12 1321 1597 NM_002636 Hs.166204 1.00E−135 2 PHD finger protein 1 (PHF1), mRNA/cds = (56,1429 58H7 41 2036 AL136711 Hs.166254 0 2 mRNA; cDNA DKFZp566I133 (from clone DKFZp566I1 98D12 5559 6110 NM_014646 Hs.166318 0 1 lipin 2 (LPIN2), mRNA/cds = (239,2929)/gb = NM_0 468G1 146 509 AW873324 Hs.166338 1.00E−168 2 hl92a07.x1 cDNA, 3′ end/clone = IMAGE: 3009396 477D7 2900 3748 L14922 Hs.166563 0 1 DNA-binding protein (PO-GA) mRNA, complete cd 177E7 3265 3595 L23320 Hs.166563 0 1 replication factor C large subunit mRNA, complete cds 584H2 206 1613 NM_006925 Hs.166975 1.00E−112 5 splicing factor, arginine/serine-rich 5 (SFR 481F5 647 917 NM_002643 Hs.166982 1.00E−128 1 phosphatidylinositol glycan, class F (PIGF), 598E4 112 538 NM_002788 Hs.167106 1.00E−174 1 proteasome (prosome, macropain) subunit, alp 466D8 46 470 AI805131 Hs.167206 0 1 td11f04.x1 cDNA, 3′ end/clone = IMAGE:2075359 464C8 342 469 BE674762 Hs.167208 4.00E−50 1 7e98d05.x1 cDNA, 3′ end/clone = IMAGE: 3293193 468A6 1177 1417 NM_003658 Hs.167218 4.00E−85 1 BarH-like homeobox 2 (BARX2), mRNA/cds = (96,93 74H10 1 1271 AF107405 Hs.167460 0 12 pre-mRNA splicing factor (SFRS3) mRNA, comple 60E9 3154 3926 U43185 Hs.167503 1.00E−143 2 signal transducer and activator of transcription Sta 517G3 1129 2787 NM_006994 Hs.167741 0 3 butyrophilin, subfamily 3, member A3 (BTN3A3), 175H2 2261 2467 U90548 Hs.167741 2.00E−86 1 butyrophilin (BTF3) mRNA, complete cds/ cds = (171,192 588H5 1324 1735 NM_002901 Hs.167791 0 1 reticulocalbin 1, EF-hand calcium binding dom 331D7 53 625 AF116909 Hs.167827 4.00E−22 1 clone HH419 unknown mRNA/cds = (189,593)/gb = A 39C11 938 1672 AF026402 Hs.168103 0 1 U5 snRNP 100 kD protein mRNA, cds/cds = (39,2501 583C8 906 1669 NM_004818 Hs.168103 0 5 prp28, U5 snRNP 100 kd protein (U5-100K), mRNA 43B1 1156 1224 AF031167 Hs.168132 1.00E−22 1 interleukin 15 precursor (IL-15) mRNA, complet 479A7 424 801 NM_000585 Hs.168132 1.00E−149 1 interleukin 15 (IL15), mRNA/cds = (316,804)/g 67D6 1783 2336 AK024030 Hs.168232 0 1 FLJ13968 fis, clone Y79AA1001493, weakly 122H3 1646 2894 NM_023079 Hs.168232 0 2 hypothetical protein FLJ13855 (FLJ13855), mR 459H3 9 504 AI392830 Hs.168287 0 1 tg10b09.x1 cDNA, 3′ end/clone = IMAGE: 2108345 463G5 103 851 NM_003002 Hs.168289 0 1 succinate dehydrogenase complex, subunit D, 144G9 5588 5937 AL049935 Hs.168350 0 2 DKFZp564O1116 (from clone DKFZp564O 459A9 2293 2727 NM_000201 Hs.168383 0 2 intercellular adhesion molecule 1 (CD54), hum 123G3 2194 2675 AB046801 Hs.168640 0 2 mRNA for KIAA1581 protein, partial cds/cds = (0 112H10 505 864 AF007155 Hs.168694 1.00E−175 2 clone 23763 unknown mRNA, partial cds/cds = (0, 60H7 223 897 AF083420 Hs.168913 0 1 brain-specific STE20-like protein kinase 3 ( 105C12 1698 2052 AK026671 Hs.169078 1.00E−176 1 FLJ23018 fis, clone LNG00903/cds = (27,14 181B9 1148 1610 NM_003937 Hs.169139 0 1 kynureninase (L-kynurenine hydrolase) (KYNU) 462B7 13 478 AA977148 Hs.169168 0 1 oq24g08.s1 cDNA, 3′ end/clone = IMAGE: 1587326 41H5 197 624 U58913 Hs.169191 0 1 chemokine (hmrp-2a) mRNA, complete cds/ cds = (71,484) 69G6 11 552 BF214508 Hs.169248 1.00E−160 4 601845758F1 cDNA, 5′ end/clone = IMAGE: 4076510 460B2 904 2904 NM_003202 Hs.169294 1.00E−161 2 transcription factor 7 (T-cell specific, HMG- 464G12 543 994 D26121 Hs.169303 0 1 mRNA for ZFM1 protein alternatively spliced product, 464B5 163 762 NM_013259 Hs.169330 0 1 neuronal protein (NP25), mRNA/cds = (49,897)/ 593G4 787 1353 Z97989 Hs.169370 0 2 DNA sequence from PAC 66H14 on chromosome 6q21-22. Con 165F12 1177 1751 AK001725 Hs.169407 0 1 cDNA FLJ10863 fis, clone NT2RP4001575, highly 483B12 10871 11349 NM_004010 Hs.169470 0 1 dystrophin (muscular dystrophy, Duchenne and 518B3 22 1257 NM_002046 Hs.169476 0 5 glyceraldehyde-3-phosphate dehydrogenase ( 67E7 1289 1597 U34995 Hs.169476 3.00E−88 1 normal keratinocyte substraction library mRNA, clon 47E9 2148 2452 NM_005461 Hs.169487 1.00E−172 1 Kreisler (mouse) maf-related leucine zipper h 69C3 846 3195 U41387 Hs.169531 0 24 Gu protein mRNA, partial cds/cds = (0,2405)/ gb = U41387 468G7 73 450 AI523598 Hs.169541 1.00E−178 1 th08g11.x1 cDNA, 3′ end/clone = IMAGE: 2117732 72E12 490 3074 AJ251595 Hs.169610 0 29 for transmembrane glycoprotein (CD44 gen 471F2 97 533 AW172306 Hs.169738 0 1 xj37a08.x1 cDNA, 3′ end/clone = IMAGE: 2659382 589D4 96 488 NM_000994 Hs.169793 1.00E−163 2 ribosomal protein L32 (RPL32), mRNA/cds = (34,4 105B6 1590 2215 AK027212 Hs.169854 0 1 FLJ23559 fis, clone LNG09844/cds = UNKNOW 462A8 1043 1529 NM_000305 Hs.169857 0 1 paraoxonase 2 (PON2), mRNA/cds = (32,1096)/gb 175D11 390 929 AF061736 Hs.169895 1.00E−132 2 ubiquitin-conjugating enzyme RIG-B mRNA, com 149A2 2442 2942 U75686 Hs.169900 0 1 polyadenylate binding protein mRNA, complete 524B9 2484 2709 NM_007049 Hs.169963 1.00E−125 2 butyrophilin, subfamily 2, member A1 (BTN2A1), 169G8 1192 1684 U90543 Hs.169963 0 1 butyrophilin (BTF1) mRNA, complete cds/ cds = (210,179 129E9 686 1227 X70340 Hs.170009 0 1 transforming growth factor alpha/cds = (3 589C1 1893 3451 NM_004350 Hs.170019 0 5 runt-related transcription factor 3 (RUNX3), 331E1 5084 5496 NM_001621 Hs.170087 0 1 aryl hydrocarbon receptor (AHR) mRNA/cds = (643 595H7 659 4185 NM_002838 Hs.170121 0 34 protein tyrosine phosphatase, receptor type, 184G8 1083 3762 Y00062 Hs.170121 0 10 T200 leukocyte common antigen (CD45, LC-A)/c 109D4 4529 4876 AF032885 Hs.170133 0 1 forkhead protein (FKHR) mRNA, complete cds/cd 98A12 4529 4882 NM_002015 Hs.170133 1.00E−160 1 forkhead box O1A (rhabdomyosarcoma) (FOXO1A), 99E3 2098 2334 NM_004761 Hs.170160 1.00E−125 1 RAB2, member RAS oncogene family-like (RAB2L), 498F10 3472 4909 AL161952 Hs.170171 0 28 mRNA; cDNA DKFZp434M0813 (from clone DKFZp434M 465G7 390 462 AI475666 Hs.170288 2.00E−31 1 tc93c08.x1 cDNA, 3′ end/clone = IMAGE: 2073710 467E6 68 482 AK025743 Hs.170296 0 1 cDNA: FLJ22090 fis, clone HEP16084/cds = UNKNOW 459H9 4659 5168 NM_014636 Hs.170307 0 1 Ral guanine nucleotide exchange factor RalGPS 38D9 618 992 089678 Hs.170311 0 25 for A + U-rich element RNA binding factor, 589F11 1033 2022 NM_005463 Hs.170311 0 13 heterogeneous nuclear ribonucleoprotein D-I 469B9 127 573 AI436418 Hs.170326 0 1 ti01h02.x1 cDNA, 3′ end/clone = IMAGE: 2129235 183E4 2725 3777 NM_002444 Hs.170328 0 7 moesin (MSN), mRNA/cds = (100,1833)/gb = NM_002 170G2 1693 3305 Z98946 Hs.170328 0 4 DNA sequence from clone 376D21 on chromosome Xq11.1-12 464F6 162 534 AI492865 Hs.170331 1.00E−163 1 th78a05.x1 cDNA, 3′ end/clone = IMAGE: 2124752 472F8 412 554 AI373163 Hs.170333 1.00E−75 1 qz13a07.x1 cDNA, 3′ end/clone = IMAGE: 2021364 473C3 376 610 AW291507 Hs.170381 1.00E−123 1 UI-H-BI2-aga-g-11-0-UI.s1 cDNA, 3′ end/clon 465E5 421 547 BE676049 Hs.170584 3.00E−54 1 7f21a03.x1 cDNA, 3′ end/clone = IMAGE: 3295276 477A3 25 202 AI475884 Hs.170587 4.00E−92 2 tc95c12.x1 cDNA, 3′ end/clone = IMAGE: 2073910 477A4 34 489 AI475905 Hs.170588 0 1 tc95f06.x1 cDNA, 3′ end/clone = IMAGE: 2073923 469F2 238 490 AI478556 Hs.170777 2.00E−84 1 tm53e03.x1 cDNA, 3′ end/clone = IMAGE: 2161852 472C5 357 474 AI479022 Hs.170784 1.00E−53 1 tm30a05.x1 cDNA, 3′ end/clone = IMAGE: 2158064 477D6 23 407 AI492034 Hs.170909 0 2 tg06f12.x1 cDNA, 3′ end/clone = lMAGE: 2108015 471D4 187 416 AI492181 Hs.170913 1.00E−106 1 tg07e06.x1 cDNA, 3′ end/clone = IMAGE: 2108098 464F8 14 142 AI492651 Hs.170934 7.00E−53 1 qz18b10.x1 cDNA, 3′ end/clone = IMAGE: 2021851 466D3 173 461 AI540204 Hs.170935 1.00E−131 1 td10h12.x1 cDNA, 3′ end/clone = IMAGE: 2075303 478F10 314 461 AI761144 Hs.171004 4.00E−45 1 wh97h01.x1 cDNA, 3′ end/clone = IMAGE: 2388721 476E2 187 253 AI494612 Hs.171009 2.00E−30 2 qz17a03.x1 cDNA, 3′ end/clone = IMAGE: 2021740 107G12 2413 2929 AK024436 Hs.171118 0 1 for FLJ00026 protein, partial cds/cds = (0 478H3 1237 1509 AL161725 Hs.171118 1.00E−107 1 DNA sequence from clone RP11-165F24 on chromosome 9. 477H10 252 489 BE674709 Hs.171120 3.00E−87 1 7e94f05.x1 cDNA, 3′ end/clone = IMAGE: 3292833 477H11 18 521 AI524202 Hs.171122 0 1 th10d11.x1 cDNA, 3′ end/clone = IMAGE: 2117877 466C10 24 216 BE816212 Hs.171261 8.00E−81 1 MR1-BN0212-280600-001-c06 cDNA/gb = BE816212 470A4 22 562 AI628893 Hs.171262 0 1 ty95h02.x1 cDNA, 3′ end/clone = IMAGE: 2286867 477C4 216 464 AI540161 Hs.171264 1.00E−112 2 td10c10.x1 cDNA, 3′ end/clone = IMAGE: 2075250 519E12 1 321 NM_016468 Hs.171566 1.00E−167 2 hypothetical protein (LOC51241), mRNA/cds = ( 44C11 5363 5829 AF012872 Hs.171625 0 1 phosphatidylinositol 4-kinase 230 (pi4K230) 517D4 19 559 NM_003197 Hs.171626 0 3 transcription elongation factor B (SIII), pol 48E9 1563 1809 NM_004417 Hs.171695 1.00E−138 2 dual specificity phosphatase 1 (DUSP1), mRNA 520H5 941 3667 NM_002719 Hs.171734 0 2 protein phosphatase 2, regulatory subunit B ( 106G2 1 308 BF243010 Hs.171774 1.00E−167 2 601877795F1 cDNA, 5′ end/clone = IMAGE: 4106303 524A7 14 359 NM_015933 Hs.171774 0 14 hypothetical protein (HSPC016), mRNA/cds = (3 117A11 311 614 BF966361 Hs.171802 1.00E−143 2 602286929F1 cDNA, 5′ end/clone = IMAGE: 4375783 38H11 885 2087 M55543 Hs.171862 0 6 guanylate binding protein isoform II (GBP-2) mRNA, co 512F8 232 1971 NM_004120 Hs.171862 0 12 guanylate binding protein 2, interferon-induc 111B9 3748 4161 NM_004941 Hs.171872 0 1 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 192H11 5738 5903 NM_000937 Hs.171880 2.00E−68 1 polymerase (RNA) II (DNA directed) polypeptide 176F11 1322 4789 AL109935 Hs.171917 0 3 DNA sequence from clone RP5-1022P6 on chromosome 20 C 596G12 2472 3152 NM_001110 Hs.172028 0 5 a disintegrin and metalloproteinase domain 10 170A5 2438 2767 AK023154 Hs.172035 0 1 FLJ13092 fis, clone NT2RP3002147/cds = (34 469D11 71 535 AI474074 Hs.172070 0 1 ti68h11.x1 cDNA, 3′ end/clone = IMAGE: 2137221 100G4 5574 5662 U02882 Hs.172081 3.00E−24 1 rolipram-sensitive 3′,5′-cyclic AMP phosphodiester 524A11 1 2517 AL110202 Hs.172089 0 20 mRNA; cDNA DKFZp586I2022 (from clone DKFZp586 49A2 929 2845 NM_002568 Hs.172182 0 30 poly(A)-binding protein, cytoplasmic 1 (PABP 54C5 929 2484 Y00345 Hs.172182 0 9 polyA binding protein/cds = (502,2403)/gb = Y0 586B1 1042 1504 NM_002408 Hs.172195 0 1 mannosyl (alpha-1,6-)-glycoprotein beta-1,2 169H6 5576 5958 D25538 Hs.172199 0 1 KIAA0037 gene, complete cds/cds = (265,3507) 115G7 4531 4976 NM_001114 Hs.172199 0 1 adenylate cyclase 7 (ADCY7), mRNA/cds = (265,35 120F2 1 2496 NM_007363 Hs.172207 0 11 non-POU-domain-containing, octamer-binding 74A3 860 1364 Y11289 Hs.172207 0 1 p54nrb gene, exon 3 (and joined/cds = (136,1551) 60B7 695 1160 NM_000202 Hs.172458 0 1 iduronate 2-sulfatase (Hunter syndrome) (IDS 479D10 4059 4347 NM_000632 Hs.172631 1.00E−125 1 integrin, alpha M (complement component recep 167B10 1 389 NM_003761 Hs.172684 0 4 vesicle-associated membrane protein 8 (endob 189E11 1773 2038 NM_001345 Hs.172690 1.00E−149 2 diacylglycerol kinase, alpha (80 kD) (DGKA), m 177C2 983 1489 X62535 Hs.172690 0 1 diacylglycerol kinase/cds = (103,2310) 458B12 535 1002 NM_012326 Hs.172740 0 1 microtubule-associated protein, RP/EB family 53A11 69 430 W26908 Hs.172762 1.00E−180 1 16b3/gb = W26908/gi = 1306136/ug = Hs.17276 151H2 2016 2572 M80359 Hs.172766 0 1 protein p78 mRNA, complete cds/cds = (171,2312)/ gb = M8 100G10 3983 4302 AB037808 Hs.172789 1.00E−149 1 for KIAA1387 protein, partial cds/cds = (0 515D9 354 548 NM_004182 Hs.172791 3.00E−65 1 ubiquitously-expressed transcript (UXT), mR 193D9 2282 2757 AL109669 Hs.172803 0 3 mRNA full length insert cDNA clone EUROIMAGE 31 460H10 12 490 NM_016466 Hs.172918 0 1 hypothetical protein (LOC51239), mRNA/cds = ( 483D3 3473 3941 AB011102 Hs.173081 0 1 mRNA for KIAA0530 protein, partial cds/cds = (0, 195B9 380 854 NM_005729 Hs.173125 0 2 peptidylprolyl isomerase F (cyclophilin F) ( 173H6 6008 6412 NM_006283 Hs.173159 0 1 transforming, acidic coiled-coil containing 113E6 142 240 AI554733 Hs.173182 3.00E−49 1 tn27f08.x1 cDNA, 3′ end/clone = IMAGE: 2168871 56G8 140 630 AK002009 Hs.173203 0 2 FLJ11147 fis, clone PLACE1006678, weakly 69E6 1 463 BF131656 Hs.173205 1.00E−147 8 601820483F1 cDNA, 5′ end/clone = IMAGE: 4052348 44A2 6 196 X06347 Hs.173255 1.00E−94 1 U1 small nuclear RNP-specific A protein/cds = clone 149G1 79 498 AY007165 Hs.173274 1.00E−117 2 CDABP0163 mRNA sequence/cds = UNKNOWN/g 464F3 53 500 AW005376 Hs.173280 0 1 ws94a12.x1 cDNA, 3′ end/clone = IMAGE: 2505598 587H5 3299 4083 NM_014633 Hs.173288 0 2 KIAA0155 gene product (KIAA0155), mRNA/cds = ( 499B9 1032 1923 NM_012081 Hs.173334 0 2 ELL-RELATED RNA POLYMERASE II, ELONGATION FAC 54F11 368 1923 U88629 Hs.173334 0 2 RNA polymerase II elongation factor ELL2, complete cd 459A4 2170 2775 AK001362 Hs.173374 0 1 cDNA FLJ10500 fis, clone NT2RP2000369/cds = UNK 124B1 2566 3019 AB046825 Hs.173422 0 1 mRNA for KIAA1605 protein, partial cds/cds = (3 126H6 1080 1626 NM_006363 Hs.173497 0 1 Sec23 (S. cerevisiae) homolog B (SEC23B), mRNA 596D5 1233 1365 NM_004550 Hs.173611 8.00E−63 5 NADH dehydrogenase (ubiquinone) Fe-S protein 108C5 1709 1864 AK022681 Hs.173685 2.00E−83 1 FLJ12619 fis, clone NT2RM4001682/cds = (39 583D12 3 1960 AK025703 Hs.173705 0 4 cDNA: FLJ22050 fis, clone HEP09454/cds = UNKNOW 70B6 579 1140 AL049610 Hs.173714 0 2 DNA sequence from clone 1055C14 on chromosome Xq22.1- 46D7 590 1150 NM_012286 Hs.173714 0 1 MORF-related gene X (KIAA0026), mRNA/cds = (305 467G5 17 283 AA534537 Hs.173720 1.00E−104 1 nf80h10.s1 cDNA, 3′ end/clone = IMAGE: 926275/ 168H5 1 1066 D25274 Hs.173737 0 5 mRNA, clone: PO2ST9/cds = UNKNOWN/gb = D25274/ 471B8 5347 5922 NM_014832 Hs.173802 0 1 KIAA0603 gene product (KIAA0603), mRNA/cds = ( 177F4 1053 1622 U51166 Hs.173824 0 1 G/T mismatch-specific thymine DNA glycosylase mRNA, 471C3 396 719 AF277292 Hs.173840 1.00E−176 1 C4orf1 mRNA/cds = (0,281)/gb = AF277292/gi = 96 477F7 2053 2694 U80735 Hs.173854 0 3 CAGF28 mRNA, partial cds/cds = (0,2235)/gb = U80 41F3 3595 3890 M37435 Hs.173894 1.00E−143 1 macrophage-specific colony-stimulating factor (CSF 460C8 1542 1939 NM_014225 Hs.173902 0 1 protein phosphatase 2 (formerly 2A), regulator 458A9 292 414 AI763121 Hs.173904 4.00E−57 1 wi06d12.x1 cDNA, 3′ end/clone = IMAGE: 2389463 170B10 1230 3510 AL137681 Hs.173912 1.00E−176 5 cDNA DKFZp434M0326 (from clone DKFZp434M 126E10 1061 1795 Z17227 Hs.173936 1.00E−111 2 mRNA for transmebrane receptor protein/cds = (4 72H7 1210 1907 U08316 Hs.173965 0 2 insulin-stimulated protein kinase 1 (ISPK-1) mRNA, c 123G7 554 858 NM_005777 Hs.173993 1.00E−168 1 RNA binding motif protein 6 (RBM6), mRNA/cds = ( 469C8 261 528 BE674902 Hs.174010 1.00E−113 1 7e97a04.x1 cDNA, 3′ end/clone = IMAGE: 3293070 117G6 2450 2657 NM_003089 Hs.174051 1.00E−112 1 small nuclear ribonucleoprotein 70 kD polypept 103A5 4907 5011 NM_002209 Hs.174103 1.00E−48 1 integrin, alpha L (antigen CD11A (p180), lymph 159F4 333 925 AF261087 Hs.174131 0 7 DNA-binding protein TAXREB107 mRNA, complete 588F9 333 926 NM_000970 Hs.174131 0 8 ribosomal protein L6 (RPL6), mRNA/cds = (26,892 187A2 2993 3464 NM_001096 Hs.174140 0 2 ATP citrate lyase (ACLY), mRNA/cds = (84,3401) 41C6 3652 3992 X03663 Hs.174142 0 1 c-fms proto-oncogene/cds = (300,3218)/gb = X0 465G10 199 489 BE674951 Hs.174144 1.00E−152 1 7e97g10.x1 cDNA, 3′ end/clone = IMAGE: 3293154 468H10 28 159 AI524263 Hs.174193 6.00E−62 1 th11g07.x1 cDNA, 3′ end/clone = IMAGE: 2118012 99C7 402 733 NM_006435 Hs.174195 1.00E−179 2 interferon induced transmembrane protein 2 ( 467E4 162 516 BF062628 Hs.174215 1.00E−157 1 7h62h05.x1 cDNA, 3′ end/clone = IMAGE: 3320601 74E5 2 485 D63789 Hs.174228 0 15 DNA for SCM-1beta precursor, complete cds/cd 470F11 108 305 AI590337 Hs.174258 1.00E−104 1 tn49c03.x1 cDNA, 3′ end/clone = IMAGE: 2171716 463D2 1 194 AV734916 Hs.175971 1.00E−94 1 AV734916 cDNA, 5′ end/clone = cdAAHE11/clone_(—) 477E5 75 222 AI380955 Hs.176374 2.00E−33 1 tg18b08.x1 cDNA, 3′ end/clone = IMAGE: 2109111 473A9 1 296 AI708327 Hs.176430 1.00E−162 1 at04c02.x1 cDNA, 3′ end/clone = IMAGE: 2354114 468C3 24 235 AW081098 Hs.176498 6.00E−91 1 xc29a12.x1 cDNA, 3′ end/clone = IMAGE: 2585662 479D11 595 1810 J04162 Hs.176663 0 14 leukocyte IgG receptor (Fc-gamma-R) mRNA, complete c 108G2 388 579 AI638800 Hs.176920 6.00E−78 4 tt32e01.x1 cDNA, 3′ end/clone = IMAGE: 2242488 467A10 98 170 AI865603 Hs.177045 6.00E−27 1 wk47g03.x1 cDNA, 3′ end/clone = IMAGE: 2418580 117A6 1179 1403 AF116606 Hs.177415 1.00E−112 2 PRO0890 mRNA, complete cds/cds = (1020,1265)/ 73F2 236 919 NM_016406 Hs.177507 0 4 hypothetical protein (HSPC155), mRNA/cds = (2 516D8 24 340 NM_006886 Hs.177530 1.00E−179 1 ATP synthase, H+ transporting, mitochondrial 479F4 163 676 NM_002414 Hs.177543 0 1 antigen identified by monoclonal antibodies 1 126A9 906 2105 NM_005534 Hs.177559 0 35 interferon gamma receptor 2 (interferon gamma 41H6 905 1826 U05875 Hs.177559 0 10 clone pSK1 interferon gamma receptor accessory factor 37G1 1690 2420 U62961 Hs.177584 0 1 succinyl CoA: 3-oxoacid CoA transferase precursor (O 597H7 1764 2520 AF218002 Hs.177596 0 7 clone PP2464 unknown mRNA/cds = (675,2339)/gb 520B8 1036 1202 NM_006888 Hs.177656 4.00E−90 3 calmodulin 1 (phosphorylase kinase, delta) (C 151G7 2439 3048 J03473 Hs.177766 0 1 poly(ADP-ribose) synthetase mRNA, complete cds/ cds = clone 116C6 318 834 BC001980 Hs.177781 1.00E−144 4 MGC: 5618, mRNA, complete cds/cds = (156, 179C11 211 737 X07834 Hs.177781 0 3 manganese superoxide dismutase (EC 1.15.1.1) 98A9 213 648 M73547 Hs.178112 0 4 polyposis locus (DP1 gene) mRNA, complete cds/ cds = (82 459E10 149 789 AK023719 Hs.178357 0 1 cDNA FLJ13657 fis, clone PLACE1011563/cds = (8 120H6 137 404 NM_021029 Hs.178391 1.00E−136 1 ribosomal protein L44 (RPL44), mRNA/cds = (37,3 589E9 371 596 NM_000973 Hs.178551 1.00E−125 1 ribosomal protein L8 (RPL8), mRNA/cds = (43,816 142F5 1848 2210 D21090 Hs.178658 1.00E−179 1 XP-C repair complementing protein (p58/HHR23 120H11 402 532 AV716627 Hs.178703 9.00E−69 1 AV716627 cDNA, 5′ end/clone = DCBBCH05/clone_(—) 98G11 3287 6017 NM_004859 Hs.178710 0 5 clathrin, heavy polypeptide (Hc) (CLTC), mRNA 177H1 142 421 BF130300 Hs.178732 1.00E−139 1 601818357F1 cDNA, 5′ end/clone = IMAGE: 4041902 472A10 421 562 AI681868 Hs.178784 4.00E−63 1 tx50a12.x1 cDNA, 3′ end/clone = IMAGE: 2272990 467G6 194 292 AW138461 Hs.179003 1.00E−49 1 UI-H-BI1-adg-e-06-0-UI.s1 cDNA, 3′ end/clon 465C11 3312 3606 NM_016562 Hs.179152 1.00E−166 1 toll-like receptor 7 (LOC51284), mRNA/cds = (13 469F7 268 405 AI568459 Hs.179419 3.00E−45 1 tn39e07.x1 cDNA, 3′ end/clone = IMAGE: 2170020 99F11 750 2687 NM_006472 Hs.179526 0 73 upregulated by 1,25-dihydroxyvitamin D-3 (VD 39G9 526 2687 S73591 Hs.179526 0 17 brain-expressed HHCPA78 homolog VDUP1 (Gene) 102A1 2235 2659 AL034343 Hs.179565 0 1 DNA sequence from clone RP1-108C2 on chromosome 6p12. 492B2 1074 2126 NM_002717 Hs.179574 1.00E−131 3 protein phosphatase 2 (formerly 2A), regulator 143F2 242 457 NM_005771 Hs.179608 1.00E−117 1 retinol dehydrogenase homolog (RDHL]) mRNA/ 111G7 626 898 NM_002659 Hs.179657 1.00E−153 1 plasminogen activator, urokinase receptor (P 585D2 61 3189 AL162068 Hs.179662 0 6 mRNA; cDNA DKFZp762G106 (from clone DKFZp762G1 125G4 1159 1627 NM_000389 Hs.179665 1.00E−130 2 cyclin-dependent kinase inhibitor 1A (p21, Ci 331A1 51 377 AK026642 Hs.179666 1.00E−161 2 FLJ22989 fis, clone KAT11824, highly sim 516H12 19 362 NM_000997 Hs.179779 1.00E−180 3 ribosomal protein L37 (RPL37), mRNA/cds = (28,3 170A11 1390 2087 L20298 Hs.179881 0 1 transcription factor (CBFB) mRNA, 3′ end/cds = ( 195H8 1732 2110 NM_001755 Hs.179881 1.00E−173 1 core-binding factor, beta subunit (CBFB), tra 127G6 2406 2924 AK022499 Hs.179882 0 2 cDNA FLJ12437 fis, clone NT2RM1000118, weakly 461E6 610 1148 NM_014153 Hs.179898 0 1 HSPC055 protein (HSPC055), mRNA/cds = (1400,19 516B3 4 584 NM_000975 Hs.179943 1.00E−136 2 ribosomal protein L11 (RPL11), mRNA/cds = (0,53 62F8 24 537 X79234 Hs.179943 1.00E−175 1 ribosomal protein L11/cds = (0,536)/gb = tumor 471B11 1990 2496 NM_005802 Hs.179982 0 1 protein p53-binding protein (TP53BPL), 194B4 693 956 NM_004159 Hs.180062 1.00E−112 1 proteasome (prosome, macropain) subunit, bet 49D4 1002 1259 NM_002690 Hs.180107 1.00E−125 1 polymerase (DNA directed), beta (POLB), mRNA 184A11 26 515 AK024823 Hs.180139 0 2 FLJ21170 fis, clone CAS10946, highly sim 593A8 43 535 NM_006937 Hs.180139 0 13 SMT3 (suppressor of mif two 3, yeast) homolog 2 61D10 102 722 AF161415 Hs.180145 0 1 HSPC297 mRNA, partial cds/cds = (0,438)/gb = AF 178A4 131 628 NM_017924 Hs.180201 0 2 hypothetical protein FLJ20671 (FLJ20671), mR 463H9 54 171 NM_005507 Hs.180370 1.00E−60 1 cofilin 1 (non-muscle) (CFL1), mRNA/cds = (51,5 162B9 2139 2386 AB013382 Hs.180383 1.00E−124 1 for DUSP6, complete cds/cds = (351,1496)/ 190B7 1743 2386 NM_001946 Hs.180383 1.00E−124 2 dual specificity phosphatase 6 (DUSP6), trans 589B11 21 1566 NM_006597 Hs.180414 0 11 heat shock 70 kD protein 8 (HSPA8), mRNA/cds = (8 73G2 21 1567 Y00371 Hs.180414 0 16 hsc70 gene for 71 kd heat shock protein/ cds = (83,2023) 62G1 985 1559 X89602 Hs.180433 0 1 rTS beta protein/cds = (17,1267)/gb = X896 98F9 1479 3653 L38951 Hs.180446 0 9 importin beta subunit mRNA, complete cds/cds = ( 590F12 283 614 NM_001026 Hs.180450 0 1 ribosomal protein S24 (RPS24), mRNA/cds = (142, 597F2 2670 3046 AF187554 Hs.180532 0 47 sperm antigen-36 mRNA, complete cds/cds = (234, 482E2 85 366 AL571386 Hs.180546 1.00E−106 1 AL571386 cDNA/clone = CS0DI009YL09-(3-prime) 109C2 324 682 BE540238 Hs.180549 1.00E−143 1 601059809F1 cDNA, 5′ end/clone = IMAGE: 3446283 68G8 1447 3594 AF123094 Hs.180566 0 3 API2-MLT fusion protein (API2-MLT) mRNA, comp 180B9 1851 2142 NM_002087 Hs.180577 1.00E−160 2 granulin (GRN), mRNA/cds = (62,1843)/gb = NM_00 51E4 880 2466 NM_005066 Hs.180610 0 6 splicing factor proline/glutamine rich (poly 50G4 880 1280 X70944 Hs.180610 0 1 PTB-associated splicing factor/cds = (85 127C8 317 3175 AK023143 Hs.180638 0 5 cDNA FLJ13081 fis, clone NT2RP3002033/cds = (17 125E2 287 1692 AL117621 Hs.180777 0 2 mRNA; cDNA DKFZp564M0264 (from clone DKFZp564 521F11 1969 2431 AF126964 Hs.180799 0 1 C3HC4-type zinc finger protein (LZK1) mRNA, co 479C11 1186 2245 AK000271 Hs.180804 1.00E−155 2 cDNA FLJ20264 fis, clone COLF7912/ cds = UNKNOWN 479C2 732 911 NM_001242 Hs.180841 3.00E−62 1 tumor necrosis factor receptor superfamily, m 596D2 67 942 NM_000977 Hs.180842 0 11 ribosomal protein L13 (RPL13), mRNA/cds = (51,6 41E9 884 1779 AL050337 Hs.180866 0 2 DNA sequence from clone 503F13 on chromosome 6q24.1-25 196C10 679 1338 NM_000416 Hs.180866 0 2 interferon gamma receptor 1 (IFNGR1), mRNA/cd 99A10 1 1655 AF218029 Hs.180877 0 11 clone PP781 unknown mRNA/cds = (113,523)/gb = A 65H9 1 1320 Z48950 Hs.180877 0 6 hH3.3B gene for histone H3.3/cds = (10,420)/gb = Z 160G1 2065 2538 AF045555 Hs.180900 0 2 wbscr1 (WBSCR1) and wbscr5 (WBSCR5) genes, com 596B1 5 860 NM_001008 Hs.180911 0 5 ribosomal protein S4, Y-linked (RPS4Y), mRNA 192F11 1857 2521 AK000299 Hs.180952 0 1 cDNA FLJ20292 fis, clone HEP05374/cds = (21,140 75D10 94 1656 AY007118 Hs.181013 0 8 clone CDABP0006 mRNA sequence/cds = (20,784)/ 46H2 105 1661 NM_002629 Hs.181013 0 5 phosphoglycerate mutase 1 (brain) (PGAM1), mR 107G10 4869 5527 AK024391 Hs.181043 0 1 FLJ14329 fis, clone PLACE4000259, highly 179A1 22 908 AK001934 Hs.181112 0 2 FLJ11072 fis, clone PLACE1004982/cds = (2 118D5 610 1130 NM_014166 Hs.181112 0 1 HSPC126 protein (HSPC126), mRNA/cds = (25,837) 483D9 659 915 X57809 Hs.181125 1.00E−123 1 rearranged immunoglobulin lambda light chain mRNA/c 596B10 499 1198 NM_005517 Hs.181163 0 2 high-mobility group (nonhistone chromosomal) 74A12 34 1674 AK026650 Hs.181165 0 192 FLJ22997 fis, clone KAT11962, highly sim 99H8 1079 2742 BC001412 Hs.181165 0 260 eukaryotic translation elongation factor 1 70F10 144 840 AB015798 Hs.181195 0 1 HSJ2 mRNA for DnaJ homolog, complete cds/cds = MRJ 64E10 72 856 BC002446 Hs.181195 0 2 gene for a member of protein family, clone 597F6 1119 1767 NM_001675 Hs.181243 0 3 activating transcription factor 4 (tax-respon 109D8 825 1233 D32129 Hs.181244 0 1 HLA class-I (HLA-A26) heavy chain, complete c 593H10 465 1222 NM_016057 Hs.181271 0 3 CGI-120 protein (LOC51644), mRNA/cds = (37,570 127H10 4782 5154 AB020335 Hs.181300 0 1 Pancreas-specific TSA305 mRNA, complete cds 150F7 509 1238 M11353 Hs.181307 1.00E−175 5 H3.3 histone class C mRNA, complete cds/ cds = (374,784) 127F7 895 1057 NM_002107 Hs.181307 3.00E−85 2 H3 histone, family 3A (H3F3A), mRNA/cds = (374,7 39H10 6 416 BF676042 Hs.181357 0 7 602084011F1 cDNA, 5′ end/clone = IMAGE: 4248195 99G12 193 842 NM_002295 Hs.181357 0 28 laminin receptor 1 (67 kD, ribosomal protein SA 66A12 312 1084 M20430 Hs.181366 0 4 MHC class II HLA-DR-beta (DR2-DQw1/DR4 DQw3) mRNA, co 71H11 748 1096 NM_002125 Hs.181366 1.00E−176 1 major histocompatibility complex, class II, 56E4 272 521 AI827911 Hs.181400 1.00E−126 1 wf34e11.x1 cDNA, 3′ end/clone = IMAGE: 2357516 170F6 5255 5724 D63486 Hs.181418 0 1 KIAA0152 gene, complete cds/cds = (128,1006) 464A11 5981 6322 NM_014730 Hs.181418 1.00E−159 1 KIAA0152 gene product (KIAA0152), mRNA/cds = ( 514F6 1 232 AW955745 Hs.181426 1.00E−117 1 EST367815 cDNA/gb = AW955745/gi = 8145428/ug = TRAF4 177E2 690 947 U81002 Hs.181466 1.00E−130 2 associated factor 1 mRNA, partial cds/c 99B5 260 1660 NM_001549 Hs.181874 0 6 interferon-induced protein with tetratricope 595H9 104 645 M90356 Hs.181967 0 1 BTF3 protein homologue gene, complete cds/ cds = (0,644 67E2 1057 1782 AK026664 Hs.182225 4.00E−85 3 FLJ23011 fis, clone LNG00572/cds = (288,7 190A3 319 1615 NM_014052 Hs.182238 0 7 GW128 protein (GW128), mRNA/cds = (698,889)/g 140B10 1770 2034 U46751 Hs.182248 2.00E−92 1 phosphotyrosine independent ligand p62 for the Lck S 158H11 371 597 D50420 Hs.182255 1.00E−126 1 OTK27, complete cds/cds = (94,480)/gb 584A12 95 1397 NM_005008 Hs.182255 0 3 non-histone chromosome protein 2 (S. cerevisia 40G2 735 908 Y00503 Hs.182265 7.00E−41 1 keratin 19/cds = (32,1234)/gb = Y00503/gi = 340 596E7 1 886 NM_001743 Hs.182278 0 3 calmodulin 2 (phosphorylase kinase, delta) (C 129E10 36 350 L29348 Hs.182378 1.00E−174 2 granulocyte-macrophage colony-stimulating 487G1 184 934 NM_002952 Hs.182426 0 3 ribosomal protein S2 (RPS2), mRNA/cds = (240,90 517G6 126 1497 NM_005742 Hs.182429 0 4 protein disulfide isomerase-related protein 60E12 10 1329 M16342 Hs.182447 0 4 nuclear ribonucleoprotein particle (hnRNP) C protein 98E9 10 1184 NM_004500 Hs.182447 0 8 heterogeneous nuclear ribonucleoprotein C ( 496A4 87 1835 NM_014394 Hs.182470 0 2 PTD10 protein (PTD010), mRNA/cds = (129,1088) 110F11 947 1571 AF061738 Hs.182579 0 2 leucine aminopeptidase mRNA, complete cds/cd 124E1 1330 1889 NM_005739 Hs.182591 0 2 RAS guanyl releasing protein 1 (calcium and DA 143B2 32 565 Z47087 Hs.182643 0 1 RNA polymerase II elongation factor-like 103D2 161 538 NM_001015 Hs.182740 8.00E−97 5 ribosomal protein S11 (RPS11), mRNA/cds = (15,4 331C2 1310 1585 D64015 Hs.182741 1.00E−136 1 for T-cluster binding protein, complete c 59E9 27 269 BF245224 Hs.182825 1.00E−105 1 601863885F1 cDNA, 5′ end/clone = IMAGE: 4082396 525E3 12 261 NM_007209 Hs.182825 1.00E−135 2 ribosomal protein L35 (RPL35), mRNA/cds = (27,3 70C9 189 625 BE963551 Hs.182928 1.00E−129 1 601657346R1 cDNA, 3′ end/clone = IMAGE: 3866266 177B9 14 561 BF242969 Hs.182937 0 2 601877739F1 cDNA, 5′ end/clone = IMAGE: 4106289 519H3 34 526 NM_021130 Hs.182937 0 1 peptidylprolyl isomerase A (cyclophilin A) ( 159A5 3163 3579 AK026491 Hs.182979 1.00E−141 2 FLJ22838 fis, clone KAIA4494, highly sim 106G11 2956 3527 AF204231 Hs.182982 1.00E−138 2 88-kDa Golgi protein (GM88) mRNA, complete cds 169A3 2117 2495 M33336 Hs.183037 1.00E−105 3 cAMP-dependent protein kinase type I-alpha subunit ( 124H9 2767 2955 NM_002734 Hs.183037 7.00E−91 1 protein kinase, cAMP-dependent, regulatory, 107B3 2877 3182 U17989 Hs.183105 1.00E−170 1 nuclear autoantigen GS2NA mRNA, complete cds/ 476A6 538 893 NM_016523 Hs.183125 0 1 killer cell lectin-like receptor F1 (KLRF1), m 75A1 629 1222 AK001433 Hs.183297 0 1 FLJ10571 fis, clone NT2RP2003121, weakly 597E11 97 1656 AF248966 Hs.183434 0 5 HT028 mRNA, complete cds/cds = (107,1159)/gb = cDNA 124A2 2015 2756 AK024275 Hs.183506 0 1 FLJ14213 fis, clone NT2RP3003572/cds = (11 74F2 2082 2418 U53347 Hs.183556 1.00E−177 2 neutral amino acid transporter B mRNA, complete cds/ 482C5 1211 1688 NM_018399 Hs.183656 0 1 VNN3 protein (HSA238982), mRNA/cds = (45,1550) 594H12 1718 3458 NM_001418 Hs.183684 0 4 eukaryotic translation initiation factor 4 g 61H11 1457 2024 U73824 Hs.183684 0 2 p97 mRNA, complete cds/cds = (306,3029)/ gb = U73824/g 75H7 342 2258 M26880 Hs.183704 0 7 ubiquitin mRNA, complete cds/cds = (135,2192)/ gb = M26 599E7 2306 3111 D44640 Hs.183706 0 6 HUMSUPY040 cDNA/clone = 035-00-1/gb = D44640/ 518H4 1554 1973 NM_002078 Hs.183773 0 1 golgi autoantigen, golgin subfamily a, 4 (GOL 520C3 98 255 NM_018955 Hs.183842 3.00E−64 1 ubiquitin B (UBB), mRNA/cds = (94,783)/gb = NM_(—) 102C11 1730 1808 M15182 Hs.183868 8.00E−33 2 beta-glucuronidase mRNA, complete cds/ cds = (26,1981 523D3 1730 2183 NM_000181 Hs.183868 0 2 glucuronidase, beta (GUSB), mRNA/cds = (26,198 187A12 122 828 NM_003589 Hs.183874 0 1 cullin 4A (CUL4A), mRNA/cds = (160,2139)/gb = N 156F4 228 907 AF119665 Hs.184011 0 4 inorganic pyrophosphatase complete cds 525B8 225 791 NM_021129 Hs.184011 0 2 pyrophosphatase (inorganic) (PP), nuclear ge 589B1 3 394 NM_000993 Hs.184014 0 10 ribosomal protein L31 (RPL31), mRNA/cds = (7,38 99D6 3909 4308 NM_004985 Hs.184050 1.00E−145 1 v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene 166B3 12 345 BE964596 Hs.184052 1.00E−90 1 601658521R1 cDNA, 3′ end/clone = IMAGE: 3885796 591G6 1348 1958 NM_022152 Hs.184052 0 3 PP1201 protein (PP1201), mRNA/cds = (66,1001) 114E11 1780 1942 AK025645 Hs.184062 4.00E−59 1 cDNA: FLJ21992 fis, clone HEP06554/cds = (60,84 597E4 8 407 NM_000982 Hs.184108 1.00E−114 6 ribosomal protein L21 (gene or pseudogene) (RP 162C5 295 1062 L41887 Hs.184167 0 3 splicing factor, arginine/serine-rich 7 (SFR 109F6 151 749 AF054182 Hs.184211 0 1 mitochondrial processing peptidase beta-subu 462C6 4590 5087 NM_015001 Hs.184245 0 1 KIAA0929 protein Msx2 interacting nuclear tar 517D1 1510 1936 NM_004252 Hs.184276 1.00E−162 7 solute carrier family 9 (sodium/hydrogen exch 55E3 174 427 NM_018370 Hs.184465 1.00E−107 1 hypothetical protein FLJ11259 (FLJ11259), mR 50F9 2484 3108 AB023182 Hs.184523 0 1 for KIAA0965 protein, partial cds/cds = (0 100A4 297 1941 AK025730 Hs.184542 1.00E−149 3 FLJ22077 fis, clone HEP12728, highly sim 113D4 950 1623 NM_016061 Hs.184542 0 1 CGI-127 protein (LOC51646), mRNA/cds = (125,49 145D11 41 339 BE730026 Hs.184582 1.00E−111 1 601562642F1 cDNA, 5′ end/clone = IMAGE: 3832258 595F4 69 548 NM_000986 Hs.184582 0 1 ribosomal protein L24 (RPL24), mRNA/cds = (39,5 108H10 250 701 U00946 Hs.184592 0 1 clone A9A2BRB5 (CAC)n/(GTG)n repeat-containing mRN 43B5 4399 4488 AF104032 Hs.184601 3.00E−24 1 L-type amino acid transporter subunit LAT1 mRN 104F12 298 1713 NM_014999 Hs.184627 0 2 KIAA0118 protein (KIAA0118), mRNA/cds = (255,9 122E8 513 995 AF035307 Hs.184697 0 2 clone 23785 mRNA sequence/cds = UNKN0WN/ gb = AF 40H2 66 2605 M37197 Hs.184760 1.00E−177 4 CCAAT-box-binding factor (CBF) mRNA, complete cds/c 514E4 29 519 NM_000984 Hs.184776 0 3 ribosomal protein L23a (RPL23A), mRNA/cds = (2 589A7 736 983 AK025533 Hs.184793 1.00E−138 1 cDNA: FLJ21880 fis, clone HEP02743/cds = UNKNOW 142G5 1918 2157 AL049782 Hs.184938 8.00E−83 3 Novel human gene mapping to chomosome 13/ cds = UNKNOWN/gb = A 462G9 178 398 AI085568 Hs.185062 1.00E−76 1 oy68b05.x1 cDNA, 3′ end/clone = IMAGE: 1670961 470C12 81 333 T98171 Hs.185675 1.00E−105 1 ye56c12.s1 cDNA, 3′ end/clone = IMAGE: 121750/ 463F2 3175 3359 NM_014686 Hs.186840 1.00E−72 1 KIAA0355 gene product (KIAA0355), mRNA/cds = ( 461E4 907 1118 NM_018519 Hs.186874 4.00E−91 1 hypothetical protein PRO2266 (PRO2266), mRNA 155A1 53 379 AI619574 Hs.187362 1.00E−109 1 ty50c09.x1 cDNA, 3′ end/clone = IMAGE: 2282512 461C9 2948 3458 NM_014504 Hs.187660 0 1 putative Rab5 GDP/GTP exchange factor homologu 470F2 5 331 BE646499 Hs.187872 1.00E−156 1 7e87h02.x1 cDNA, 3′ end/clone = IMAGE: 3292179 68D12 590 740 AW963239 Hs.187908 4.00E−66 1 EST375312/gb = AW963239/gi = 8153075/ug = 75H12 2012 2585 AL110269 Hs.187991 0 1 cDNA DKFZp564A122 (from clone DKFZp564A1 167G4 1474 1958 NM_015626 Hs.187991 0 1 DKFZPS64A122 protein (DKFZP564A122), mRNA/c 137G3 54 197 AI625368 Hs.188365 2.00E−34 46 ts37c10.x1 cDNA, 3′ end/clone = IMAGE: 2230770 464C12 183 404 AA432364 Hs.188777 7.00E−94 1 zw76a09.s1 cDNA, 3′ end/clone = IMAGE: 782104/ 467E9 29 183 AA576947 Hs.188886 1.00E−63 1 nm82b04.s1 cDNA, 3′ end/clone = IMAGE: 1074703 467B4 349 459 AI392805 Hs.189031 2.00E−49 1 tg04h03.x1 cDNA, 3′ end/clone = IMAGE: 2107829 461E2 242 473 BE674964 Hs.190065 1.00E−109 1 7f11b09.x1 cDNA, 3′ end/clone = IMAGE: 3294329 466F4 58 295 BG326781 Hs.190219 1.00E−132 1 602425659F1 cDNA, 5′ end/clone = IMAGE: 4563471 465H4 111 558 AA582958 Hs.190229 0 1 nn80d08.s1 cDNA, 3′ end/clone = IMAGE: 1090191 470F9 26 529 AI763206 Hs.190453 0 1 wh95e09.x1 cDNA, 3′ end/clone = IMAGE: 2388520 66H12 1 3459 D00099 Hs.190703 0 5 for Na, K-ATPase alpha-subunit, complete 472E1 338 540 AW294083 Hs.190904 2.00E−46 1 UI-H-BI2-ahg-b-05-0-UI.s1 cDNA, 3′ end/clon 522G10 433 970 NM_003757 Hs.192023 0 2 eukaryotic translation initiation factor 3, 54GB 29 410 AW838827 Hs.192123 0 1 CM1-LT0059-280100-108-e02/gb = AW838827 465G4 261 515 BF224348 Hs.192463 1.00E−104 1 7q86c05.x1 cDNA/clone = IMAGE/gb = BF224348/g 468F9 392 487 AI524039 Hs.192524 2.00E−36 1 tg99h02.x1 cDNA, 3′ end/clone = IMAGE: 2116947 466C6 111 392 AW972048 Hs.192534 1.00E−153 1 EST384032 cDNA/gb = AW972048/gi = 8161789/ug = 184F12 1 677 AF090927 Hs.192705 0 1 clone HQ0457 PRO0457 mRNA, complete cds/cds = ( 464C11 1 65 BE298181 Hs.192755 3.00E−23 1 601118566F1 cDNA, 5′ end/clone = IMAGE: 3028193 465H3 108 706 BG036938 Hs.192965 0 1 602287708F1 cDNA, 5′ end/clone = IMAGE: 4375153 169F9 4138 4890 D87454 Hs.192966 0 1 KIAA0265 gene, partial cds/cds = (0,1205)/gb 118H10 1104 1858 AK024263 Hs.193063 1.00E−132 2 cDNA FLJ14201 fis, clone NT2RP3002955/cds = UNK 472F3 28 405 BF062295 Hs.193237 0 1 7k76b11.x1 cDNA, 3′ end/clone = IMAGE: 3481293 40A5 1933 2611 X12830 Hs.193400 0 1 interleukin-6 (IL-6) receptor/cds = (437,184 63B5 327 582 AW959162 Hs.193669 1.00E−103 1 EST371232/gb = AW959162/gi = 8148846/ug = 52G10 803 1173 M57627 Hs.193717 0 1 interleukin 10 (IL10) mRNA, complete cds/ cds = (30,566 469F5 2088 2438 AL110204 Hs.193784 1.00E−179 1 mRNA; cDNA DKFZp586K1922 (from clone DKFZp586K 598H7 1428 1715 NM_014828 Hs.194035 1.00E−119 1 KIAA0737 gene product (KIAA0737), mRNA/cds = ( 462B6 103 546 BE618004 Hs.194362 1.00E−165 1 601462354F1 cDNA, 5′ end/clone = IMAGE: 3865861 472F12 1177 1667 AB036737 Hs.194369 0 2 mRNA for RERE, complete cds/cds = (636,5336)/g 182E10 11785 13486 U82828 Hs.194382 0 5 ataxia telangiectasia (ATM) gene, complete cd 458F4 258 408 NM_022739 Hs.194477 2.00E−62 1 E3 ubiquitin ligase SMURF2 (SMURF2), mRNA/cd 583D2 1425 1732 NM_014232 Hs.194534 1.00E−136 1 vesicle-associated membrane protein 2 (synapt 38H8 1198 1620 U89387 Hs.194638 0 1 RNA polymerase II subunit hsRPB4 gene, complete cds/ 122H10 5292 5481 NM_023005 Hs.194688 4.00E−80 1 bromodomain adjacent to zinc finger domain, 1B 186G9 1 1908 AL136945 Hs.194718 0 2 mRNA; cDNA DKFZp586O012 (from clone DKFZp586O0 113F3 1852 2375 NM_000634 Hs.194778 0 1 interleukin 8 receptor, alpha (IL8RA), mRNA/ 106A3 35 404 U11870 Hs.194778 0 1 interleukin-8 receptor type A (IL8RBA) gene, promote 473B8 1001 1314 AF319438 Hs.194976 1.00E−172 1 SH2 domain-containing phosphatase anchor pro 57F9 442 1934 Y14039 Hs.195175 0 27 mRNA for CASH alpha protein/cds = (481,1923)/g 49E5 2314 2512 NM_018666 Hs.195292 2.00E−37 1 putative tumor antigen (SAGE), mRNA/cds = (167, 473B10 406 532 BE671815 Hs.195374 1.00E−54 1 7a47c12.x1 cDNA, 3′ end/clone = IMAGE: 3221878 595B5 59 311 AI653766 Hs.195378 6.00E−46 1 ty01b06.x1 cDNA, 3′ end/clone = IMAGE: 2277779 60G4 42 1554 D13642 Hs.195614 0 2 KIAA0017 gene, complete cds/cds = (136,1335) 473B9 739 927 AF241534 Hs.196015 2.00E−73 1 hydatidiform mole associated and imprinted (H 99C10 1075 1424 NM_000294 Hs.196177 1.00E−115 1 phosphorylase kinase, gamma 2 (testis) (PHKG2 45H9 956 1405 AF283645 Hs.196270 0 1 folate transporter/carrier mRNA, complete cd 54F9 2567 2954 U04636 Hs.196384 0 1 cyclooxygenase-2 (hCox-2) gene, complete cds/ cds = (1 38F12 401 606 AI984074 Hs.196398 1.00E−104 1 wz56c02.x1 cDNA, 3′ end/clone = IMAGE: 2562050 157G1 403 551 AJ006835 Hs.196769 7.00E−77 2 RNA transcript from U17 small nucleolar RNA ho 163F4 1 402 AI650871 Hs.197028 0 1 wa95f03.x1 cDNA, 3′end/clone = IMAGE: 2303933 160B3 408 476 AI832038 Hs.197091 5.00E−27 1 wj99e02.x1 3′end/clone = IMAGE: 2410970 105E8 1299 3674 AB020657 Hs.197298 0 6 for KIAA0850 protein, complete cds/cds = ( 178G12 2097 3593 AF205218 Hs.197298 0 8 NS1-binding protein-like protein mRNA, compl 585F1 284 1711 NM_001469 Hs.197345 0 4 thyroid autoantigen 70 kD (Ku antigen) (G22P1) 39C10 545 1984 Z83840 Hs.197345 0 2 DNA sequence from clone CTA-216E10 on chromosome 22 C 58E12 2162 3013 NM_001530 Hs.197540 0 2 hypoxia-inducible factor 1, alpha subunit (ba 125G11 3673 4059 D29805 Hs.198248 0 1 mRNA for beta-1,4-galactosyltransferase, complete 41H10 6 821 M33906 Hs.198253 1.00E−156 2 MHC class II HLA-DQA1 mRNA, complete cds/ cds = (43,810) 186A11 551 1031 NM_004544 Hs.198271 0 2 NADH dehydrogenase (ubiquinone) 1 alpha subco 126D8 993 1381 NM_021105 Hs.198282 0 1 phospholipid scramblase 1 (PLSCR1), mRNA/cds 174C12 4824 5257 NM_003070 Hs.198296 0 1 SWI/SNF related, matrix associated, actin dep 109C6 128 833 X04327 Hs.198365 0 1 erythrocyte 2,3-bisphosphoglycerate mutase mRNA EC 64B12 4383 5289 NM_000189 Hs.198427 0 2 hexokinase 2 (HK2), mRNA/cds = (1490,4243)/gd 70B4 3267 5289 Z46376 Hs.198427 0 4 HK2 mRNA for hexokinase II/cds = (1490,4243)/gb = Z 478H6 186 475 AI978581 Hs.198694 1.00E−129 1 wq72d08.x1 cDNA, 3′ end/clone = IMAGE: 2476815 587G1 767 1143 NM_006837 Hs.198767 1.00E−170 1 COP9 (constitutive photomorphogenic, Arabido 465F12 373 554 BE621611 Hs.198802 2.00E−77 1 601493754T1 cDNA, 3′ end/clone = IMAGE: 3895836 123B3 310 3608 AB011108 Hs.198891 0 3 mRNA for KIAA0536 protein, partial cds/cds = (0, 157H3 3457 5268 D50929 Hs.198899 0 2 KIAA0139 gene, complete cds/cds = (128,4276) 477H1 35 592 NM_002229 Hs.198951 0 1 jun B proto-oncogene (JUNB), mRNA/cds = (253,12 53C5 979 1296 X51345 Hs.198951 1.00E−160 1 jun-B mRNA for JUN-B protein/cds = (253,1296)/ gb = X513 54H8 350 501 AW450874 Hs.199014 5.00E−81 1 UI-H-BI3-all-a-11-0-UI.s1 cDNA, 3′ end/clon 520E12 3506 3878 L04731 Hs.199160 0 1 translocation T(4:11) of ALL-1 gene to chromoso 57F4 5941 6266 NM_006267 Hs.199179 1.00E−158 1 RAN binding protein 2 (RANBP2), mRNA/cds = (127, 50B10 5 3645 D86984 Hs.199243 0 2 KIAA0231 gene, partial cds/cds = (0,1430)/gb 68E12 1757 2052 L25124 Hs.199248 1.00E−156 2 prostaglandin E2 receptor mRNA, complete cds/ 484H3 1879 1958 NM_000958 Hs.199248 3.00E−33 1 prostaglandin E receptor 4 (subtype EP4) (PTGE 466G6 368 3287 NM_013233 Hs.199263 0 2 Ste-20 related kinase (SPAK), mRNA/cds = (173,1 464B9 633 1068 AF015041 Hs.199291 0 1 NUMB-R protein (NUMB-R) mRNA, complete cds/c 522F9 2 116 AI669591 Hs.200442 5.00E−59 1 tw34b09.x1 cDNA, 3′ end/clone = IMAGE: 2261561 60F11 4945 5114 AB040942 Hs.201500 7.00E−92 1 for KIAA1509 protein, partial cds/cds = (0 72D12 819 1293 AF104398 Hs.201673 0 1 comichon mRNA, complete cds/cds = (56,490)/g 105G5 1629 2130 AF091263 Hs.201675 0 1 RNA binding motif protein 5 (RBM5) mRNA, comple 116G3 1637 2854 NM_005778 Hs.201675 0 2 RNA binding motif protein 5 (RBM5), mRNA/cds = ( 40A10 254 431 AI693179 Hs.201789 5.00E−85 1 wd68d12.x1 cDNA, 3′ end/clone = IMAGE: 2336759 473D4 421 547 BE551203 Hs.201792 3.00E−49 1 7b55h12.x1 cDNA, 3′ end/clone = IMAGE: 3232199 472D8 313 623 AW390251 Hs.202402 1.00E−123 1 CM4-ST0182-051099-021-b06 cDNA/gb = AW390251 66H5 176 482 AI271437 Hs.203041 1.00E−173 1 qi19c05.x1 cDNA, 3′ end/clone = IMAGE: 1856936 594C2 35 368 AW131782 Hs.203606 1.00E−147 2 xf34e08.x1 cDNA, 3′ end/clone = IMAGE: 2619974 138B12 101 420 AW194379 Hs.203755 1.00E−93 3 xm08h07.x1 3′ end/clone = IMAGE: 2683645 473D3 1 234 AI538474 Hs.203784 1.00E−117 1 td06h08.x1 cDNA, 3′ end/clone = IMAGE: 2074911 471A5 113 442 AI393908 Hs.203829 1.00E−153 1 tg05f10.x1 cDNA, 3′ end/clone = IMAGE: 2107915 40A4 1621 2037 AF004230 Hs.204040 0 1 monocyte/macrophage Ig-related receptor MIR 463H1 7 319 AW977671 Hs.204214 1.00E−161 1 EST389900 cDNA/gb = AW977671/gi = 8169049/ug = 478E7 25 434 AI762023 Hs.204610 0 2 wh89f04.x1 cDNA, 3′ end/clone = IMAGE: 2387935 55E11 324 469 AI741246 Hs.204656 100E−58 12 wg26g09.x1 cDNA, 3′ end/clone = IMAGE: 2366272 478G10 345 476 AI760901 Hs.204703 9.00E−34 1 wi09h06.x1 cDNA, 3′ end/clone = IMAGE: 2389787 470E11 374 507 AI762741 Hs.204707 2.00E−49 1 wh93h02.x1 cDNA, 3′ end/clone = IMAGE: 2388339 478F5 179 437 AI086035 Hs.204873 1.00E−110 1 oy70h04.x1 cDNA, 3′ end/clone = IMAGE: 1671223 464G4 33 320 AI749444 Hs.204929 5.00E−50 1 at24c03.x1 cDNA, 3′ end/clone = IMAGE: 2356036 472D2 88 198 AI760018 Hs.205071 4.00E−54 1 wh83b02.x1 cDNA, 3′ end/clone = IMAGE: 2387307 470D9 5 422 AW976641 Hs.205079 0 1 EST388750 cDNA/gb = AW976641/gi = 8167872/ug = 470D4 122 500 AA885473 Hs.205175 0 1 am10c12.s1 cDNA, 3′ end/clone = IMAGE: 1466422 473C5 285 525 BF679831 Hs.205319 2.00E−96 1 602154415F1 cDNA, 5′ end/clone = IMAGE: 4295595 470E7 295 521 AI762557 Hs.205327 9.00E−95 2 wh92f07.x1 cDNA, 3′ end/clone = IMAGE: 2388229 478F11 11 447 AI761141 Hs.205452 0 3 wh97g08.x1 cDNA, 3′ end/clone = IMAGE: 2388734 459A12 111 323 N72600 Hs.205555 9.00E−96 1 za46f08.s1 cDNA, 3′ end/clone = IMAGE: 295623/ 470F4 214 481 AW977820 Hs.205675 1.00E−131 1 EST389824 cDNA/gb = AW977820/gi = 8168971/ug = 102G3 1 249 BF680988 Hs.205696 2.00E−78 1 602156272F1 cDNA, 5′ end/clone = IMAGE: 4297216 472B2 312 700 BF794256 Hs.206761 0 1 602255454F1 cDNA, 5′ end/clone = IMAGE: 4338949 470C1 1113 1643 AK024118 Hs.206868 0 1 cDNA FLJ14056 fis, clone HEMBB1000335/cds = UNK 469H7 1076 1215 U15177 Hs.206984 3.00E−69 1 cosmid CRI-JC2015 at D10S289 in 10sp13/ cds = (0,1214) 61F9 5 181 AW340421 Hs.207995 4.00E−94 1 hc96h02.x1 cDNA, 3′ end/clone = IMAGE: 2907891 473C2 239 551 BF439675 Hs.208854 1.00E−151 1 nab69e11.x1 cDNA/clone = IMAGE/gb = BF439675/ 62G11 159 292 BE781611 Hs.208985 1.00E−60 1 601467463F1 cDNA, 5′ end/clone = IMAGE: 3870902 472E2 258 554 AI343473 Hs.209203 1.00E−135 1 tb97a08.x1 cDNA, 3′ end/clone = IMAGE: 2062262 471C10 148 498 AI768880 Hs.209511 0 1 wh71e04.x1 cDNA, 3′ end/clone = IMAGE: 2386206 470G9 416 561 AI798144 Hs.209609 4.00E−63 1 wh81g12.x1 cDNA, 3′ end/clone = IMAGE: 2387206 478C10 120 447 AI809310 Hs.210385 1.00E−158 2 wh75h08.x1 cDNA, 3′ end/clone = IMAGE: 2386623 476B7 64 341 AI075288 Hs.210727 1.00E−151 2 oy69h10.x1 cDNA, 3′ end/clone = IMAGE: 1671139 477G4 915 1541 AB040919 Hs.210958 0 1 mRNA for KIAA1486 protein, partial cds/cds = (1 468C2 215 498 AI832182 Hs.210995 1.00E−145 1 td13h11.x1 cDNA, 3′ end/clone = IMAGE: 2075589 472D11 1 300 AI860120 Hs.211024 1.00E−126 1 wh39e01.x1 cDNA, 3′ end/clone = IMAGE: 2383128 470D3 30 317 AW362304 Hs.211194 1.00E−137 1 CM3-CT0275-031199-031-a08 cDNA/gb = AW362304 179F6 105 551 AI823649 Hs.211535 0 1 wi85g03.x1 3′ end/clone = IMAGE: 2400148 477G12 2439 4050 NM_020993 Hs.211563 0 4 B-cell CLL/lymphoma 7A (BCL7A), mRNA/cds = (953 39A11 5178 5792 L10717 Hs.211576 0 2 T cell-specific tyrosine kinase mRNA, complete 187B9 5365 5790 NM_005546 Hs.211576 0 1 IL2-inducible T-cell kinase (ITK), mRNA/cds = 152C2 3965 4297 Z22551 Hs.211577 1.00E−174 1 kinectin gene/cds = (69,4139)/gb = Z22551/gi = 296 120A2 2556 2917 NM_005955 Hs.211581 0 1 metal-regulatory transcription factor 1 (MTF 147A2 2915 4407 M59465 Hs.211600 0 6 tumor necrosis factor alpha inducible protein A20 mRN 583B12 2404 3981 NM_006290 Hs.211600 0 11 tumor necrosis factor, alpha-induced protein 589F3 1905 2274 AF090693 Hs.211610 0 1 apoptosis-related RNA binding protein (NAPOR- 470G11 277 462 AI862623 Hs.211744 5.00E−99 1 wh99h10.x1 cDNA, 3′ end/clone = IMAGE: 2388931 473F2 195 423 BE675092 Hs.211828 2.00E−95 1 7f02d07.x1 cDNA, 3′ end/clone = IMAGE: 3293485 517D2 1059 1366 BC000747 Hs.211973 1.00E−162 2 Similar to homolog of Yeast RRP4 (ribosomal RN 109D9 391 533 AI922921 Hs.212553 2.00E−68 1 wn81c05.x1 cDNA, 3′ end/clone = IMAGE: 2452232 494H12 172 549 AI912585 Hs.213385 0 3 we11d07.x1 cDNA, 3′ end/clone = IMAGE: 2340781 596G11 4740 5687 AB007916 Hs.214646 0 8 mRNA for KIAA0447 protein, partial cds/cds = (2 104C12 843 1787 AL031282 Hs.215595 0 2 DNA sequence from clone 283E3 on chromosome 1p36.21-36 124F8 1391 2913 NM_002074 Hs.215595 0 4 guanine nucleotide binding protein (G protein) 157E8 1264 1627 AK001548 Hs.215766 0 4 FLJ10686 fis, clone NT2RP3000252, highly 519G3 1729 2094 NM_012341 Hs.215766 0 1 GTP-binding protein (NGB), mRNA/cds = (23,1924 473E7 2278 2472 AB022663 Hs.215857 3.00E−52 1 HFB30 mRNA, complete cds/cds = (236,1660)/gb = 104F7 4 1324 D00017 Hs.217493 0 3 for lipocortin II, complete cds/cds = (49,1 58G2 11 1324 NM_004039 Hs.217493 0 7 annexin A2 (ANXA2), mRNA/cds = (49,1068)/gb = N 467D4 27 443 AI392814 Hs.221014 1.00E−180 1 tg10a02.x1 cDNA, 3′ end/clone = IMAGE: 2108330 463B1 69 457 AV686223 Hs.221642 0 1 AV686223 cDNA, 5′ end/clone = GKCGXH11/clone_(—) 464D10 295 552 BF058398 Hs.221695 1.00E−115 1 7k30d01.x1 cDNA, 3′ end/clone = IMAGE: 3476785 466C12 1 427 AI540165 Hs.222186 0 1 td10d05.x1 cDNA, 3′ end/clone = IMAGE: 2075241 125H10 2596 2917 AB046830 Hs.222746 0 1 mRNA for KIAA1610 protein, partial cds/cds = (0 473C4 1 193 BF435098 Hs.222833 9.00E−72 1 7p05g01.x1 cDNA, 3′ end/clone = IMAGE: 3645097 37B4 18 371 AW389509 Hs.223747 1.00E−147 1 CM3-ST0163-051099-019-b11/gb = AW389509 470H7 106 357 AI766706 Hs.223935 1.00E−116 1 wi02g11.x1 cDNA, 3′ end/clone = IMAGE: 2389124 472D12 1 370 AL133721 Hs.224680 0 1 DKFZp761H09121_r1 cDNA, 5′ end/clone = DKFZp76 124E4 53 208 AI874107 Hs.224760 7.00E−50 3 wm49b01.x1 cDNA, 3′ end/clone = IMAGE: 2439241 477G3 146 412 AI400714 Hs.225567 1.00E−141 1 tg93g12.x1 cDNA, 3′ end/clone = IMAGE: 2116390 112F12 2313 2799 AL163279 Hs.225674 0 1 chromosome 21 segment HS21C079/cds = (0,6888) 118D12 6187 6775 NM_015384 Hs.225767 0 1 IDN3 protein (IDN3), mRNA/cds = (706,7182)/gb 109B7 2208 3315 AF119417 Hs.225939 0 2 nonfunctional GM3 synthase mRNA, alternativel 125A8 2877 3381 NM_006999 Hs.225951 0 1 topoisomerase-related function protein 4-1 129C8 5510 5893 AF012108 Hs.225977 0 1 Amplified in Breast Cancer (AIB1) mRNA, comple 39G12 4498 4859 NM_014977 Hs.227133 1.00E−93 2 KIAA0670 protein/acinus (KIAA0670), mRNA/cd 153D10 1 286 AF000145 Hs.227400 1.00E−139 2 germinal center kinase related protein kinase 464B12 901 1425 AL050131 Hs.227429 0 1 mRNA; cDNA DKFZp586I111 (from clone DKFZp586I1 459D9 3828 4314 NM_004841 Hs.227806 0 1 ras GTPase activating protein-like (NGAP), mR 135E9 135 773 NM_004049 Hs.227817 0 1 BCL2-related protein A1 (BCL2A1), mRNA/cds = ( 59F10 123 808 Y09397 Hs.227817 0 12 GRS protein/cds = (102,629)/gb = Y09397/ 516H4 1901 2462 NM_014287 Hs.227823 0 1 pM5 protein (PM5), mRNA/cds = (0,3668)/gb = NM_0 107C12 2776 3390 Y15906 Hs.227913 0 1 for XAGL protein/cds = (132,1646)/gb = Y159 152C7 171 1390 AF052155 Hs.227949 0 2 clone 24761 mRNA sequence/cds = UNKNOWN/ gb = AF 522G8 108 293 AI917348 Hs.228486 2.00E−70 1 ts83d10.x1 cDNA, 3′ end/clone = IMAGE: 2237875 66C7 304 445 AI094726 Hs.228795 1.00E−26 1 qa08f05.x1 cDNA, 3′ end/clone = IMAGE: 1686177 585D1 51 294 AI199388 Hs.228817 5.00E−73 1 qs75e05.x1 cDNA, 3′ end/clone = IMAGE: 1943936 468E9 113 324 AI523873 Hs.228926 7.00E−77 2 tg97c12.x1 cDNA, 3′ end/clone = IMAGE: 2116726 466F1 44 139 AI380491 Hs.229374 3.00E−39 2 tf95b10.x1 cDNA, 3′ end/clone = IMAGE: 2107003 182F1 40 465 AI354231 Hs.229385 1.00E−138 4 qv12c04.x1 cDNA, 3′ end/clone = IMAGE: 1981350 465C1 237 318 AW812896 Hs.229868 3.00E−38 1 RC3-ST0186-250200-018-a11 cDNA/gb = AW812896 178H7 42 353 AI581732 Hs.229918 1.00E−68 5 ar74f03.x1 cDNA, 3′ end/clone = IMAGE: 2128349 72H6 48 534 AI818777 Hs.229990 1.00E−85 3 wl11f10.x1 cDNA, 3′ end/clone = IMAGE: 2424619 181E9 52 279 AI827451 Hs.229993 1.00E−66 1 wl17d11.x1 cDNA, 3′ end/clone = IMAGE: 2425173 38H1 225 311 AI579979 Hs.230430 1.00E−25 1 tq45a01.x1 cDNA, 3′ end/clone = IMAGE: 2211720 489G11 66 369 AI818596 Hs.230492 1.00E−112 5 wk74d04.x1 cDNA, 3′ end/clone = IMAGE: 2421127 118D6 40 161 AI025427 Hs.230752 6.00E−37 1 ow27g06.s1 cDNA, 3′ end/clone = IMAGE: 1648090 462H6 305 437 AI087055 Hs.230805 3.00E−67 1 oy70c09.x1 cDNA, 3′ end/clone = IMAGE: 1671184 107C11 93 240 AI796419 Hs.230939 1.00E−40 1 wj17f02.x1 cDNA, 3′ end/clone = IMAGE: 2403099 591A1 65 316 AA767883 Hs.231154 7.00E−59 4 oa30h07.s1 cDNA, 3′ end/clone = IMAGE: 1306525 471B3 177 519 BE407125 Hs.231510 1.00E−166 1 601301818F1 cDNA, 5′ end/clone = IMAGE: 3636412 64G11 609 950 AL542592 Hs.231816 1.00E−166 1 AL542592 cDNA/clone = CS0DE012YA05-(5-prime) 108G1 1 210 AW006867 Hs.231987 1.00E−109 1 ws15d07.x1 cDNA, 3′ end/clone = IMAGE: 2497261 115F3 44 185 AW016002 Hs.232000 7.00E−75 2 UI-H-BI0p-abh-h-06-0-UI.s1 cDNA, 3′ end/clo 138A6 4771 5194 D15050 Hs.232068 0 1 transcription factor AREB6, complete cds/cd 472A6 311 497 BF195579 Hs.232257 1.00E−78 1 7n85c03.x1 cDNA, 3′ end/clone = IMAGE: 3571205 111A7 285 463 AW026667 Hs.233261 1.00E−41 1 wv15d09.x1 cDNA, 3′ end/clone = IMAGE: 2529617 67G8 292 560 BE719483 Hs.233383 4.00E−94 3 MR1-HT0858-020800-001-c06/gb = BE719483 123B11 180 351 AW006045 Hs.233560 5.00E−82 1 wz81b09.x1 cDNA, 3′ end/clone = IMAGE: 2565209 472E3 1 319 AW027530 Hs.233564 1.00E−180 1 wv74c06.x1 cDNA, 3′ end/clone−IMAGE: 2535274 36F11 943 1896 Z85996 Hs.233750 0 6 DNA sequence from PAC 431A14 on chromosome 6p21. Conta 184G6 49 491 BF694761 Hs.233936 0 9 602080851F2 cDNA, 5′ end/clone = IMAGE: 4245133 599C7 12 540 NM_006471 Hs.233936 0 55 myosin, light polypeptide, regulatory, non-s 156B4 405 774 AF054185 Hs.233952 1.00E−164 1 proteasome subunit HSPC complete cds/c 595G5 85 315 NM_002792 Hs.233952 1.00E−126 1 proteasome (prosome, macropain) subunit, alp 67F5 108 556 AK000654 Hs.234149 0 1 FLJ20647 fis, clone KAT02147/cds = (90,836 591B6 1 555 NM_017918 Hs.234149 0 6 hypothetical protein FLJ20647 (FLJ20647), mR 111B7 1887 2217 AK023204 Hs.234265 1.00E−120 1 cDNA FLJ13142 fis, clone NT2RP3003212, modera 72F6 314 2581 AL035071 Hs.234279 0 2 DNA sequence from clone 1085F17 on chromosome 20q11.1 514H4 2105 2523 NM_012325 Hs.234279 0 1 microtubule-associated protein, RP/EB family 599A10 1 1163 NM_002300 Hs.234489 0 30 lactate dehydrogenase B (LDHB), mRNA/cds = (84 163A8 470 1153 X13794 Hs.234489 0 4 lactate dehydrogenase B gene exon 1 and (EC 1.1.1. 125E5 31 465 NM_000978 Hs.234518 1.00E−117 2 ribosomal protein L23 (RPL23), mRNA/cds = (25,4 471B1 1499 2033 L05148 Hs.234569 0 1 protein tyrosine kinase related mRNA sequence/ cds = UN 466D7 1050 1402 NM_013451 Hs.234680 0 1 fer-1 (C.elegans)-like 3 (myoferlin) (FER1L3) 108B11 407 742 X14008 Hs.234734 0 1 lysozyme gene (EC 3.2.1.17)/cds = (82,474)/ gb = X14008 476A12 3 440 AI076222 Hs.235042 0 2 oy65b09.x1 cDNA, 3′ end/clone = IMAGE: 1670681 464H7 994 2425 AL157426 Hs.235390 1.00E−22 1 mRNA; cDNA DKFZp761B101 (from clone DKFZp761B1 472F2 2203 2431 AK024137 Hs.235498 7.00E−97 1 cDNA FLJ14075 fis, clone HEMBB1001905, weakly 63C7 1159 1751 AK000260 Hs.235712 0 1 FLJ20253 fis, clone COLF6895/cds = UNKNOWN 73C8 39 485 AI379474 Hs.235823 0 1 tc57g08.x1 cDNA, 3′ end/clone = IMAGE: 2068766 590H8 182 449 AA020845 Hs.235883 1.00E−145 3 ze64a07.r1 cDNA, 5′ end/clone = IMAGE: 363732/ 182H3 468 2009 NM_001535 Hs.235887 1.00E−119 5 HMT1 (hnRNP methyltransferase, S. cerevisiae) 119B12 253 596 NM_003075 Hs.236030 0 1 SWI/SNF related, matrix associated, actin dep 461C5 654 1112 AK026410 Hs.236449 0 1 cDNA: FLJ22757 fis, clone KAIA0803/cds = (92,24 182G3 514 2817 AK023223 Hs.236494 0 2 FLJ13161 fis, clone NT2RP3003589, highly 469G7 857 1336 AK026359 Hs.236744 0 1 cDNA: FLJ22706 fis, clone HSI13163/cds = UNKNOW 592A9 1522 1888 NM_020135 Hs.236828 0 1 putative helicase RUVBL (LOC56897), mRNA/cds 177A1 1260 1704 AK001514 Hs.236844 1.00E−170 1 FLJ10652 fis, clone NT2RP2005886/cds = (50 594G2 916 1537 NM_018169 Hs.236844 0 2 hypothetical protein FLJ10652 (FLJ10652), mR 98D10 1881 1964 NM_006947 Hs.237825 9.00E−36 1 signal recognition particle 72 kD (SRP72), mRN 72C7 36 1214 M29696 Hs.237868 0 2 interleukin-7 receptor (IL-7) mRNA, complete cds/cd 591B10 577 1658 NM_002185 Hs.237868 0 9 interleukin 7 receptor (IL7R), mRNA/cds = (22,1 109G2 16 405 AF116682 Hs.238205 0 1 PRO2013 mRNA, complete cds/cds = (135,380)/gb 41E1 2163 2733 U60805 Hs.238648 0 1 oncostatin-M specific receptor beta subunit (OSMRB) 599C11 508 1734 AK026110 Hs.238707 0 5 cDNA: FLJ22457 fis, clone HRC09925/cds = (56,14 143E8 2 595 AV700542 Hs.238730 1.00E−177 6 AV700542 cDNA, 3′ end/clone = GKCAFD05/clone_(—) 596C11 77 658 AW955090 Hs.238954 0 5 EST367160 cDNA/gb = AW955090/gi = 8144773/ug = 169C7 1371 1634 AY004255 Hs.238990 1.00E−148 1 cdk inhibitor p27KIP1 mRNA, complete cds/cds = 173C1 1599 1859 BC001971 Hs.238990 1.00E−146 1 Similar to cyclin-dependent kinase inhibitor 458B5 1539 1809 AL136828 Hs.238996 1.00E−131 1 mRNA; cDNA DKFZp434K0427 (from clone DKFZp434K 591H9 6104 6559 AL157902 Hs.239114 0 1 DNA sequence from clone RP4-675C20 on chromosome 1p13 512G4 231 2376 NM_005746 Hs.239138 0 61 pre-B-cell colony-enhancing factor (PBEF), m 53D11 935 2053 U02020 Hs.239138 0 15 pre-B cell enhancing factor (PBEF) mRNA, complete cds 38B7 2187 2263 AK025021 Hs.239189 1.00E−36 1 FLJ21368 fis, clone COL03056, highly sim 458E10 90 622 NM_016533 Hs.239208 0 1 ninjurin 2 (NINJ2), mRNA/cds = (56,484)/gb = NM 184G10 1608 2056 AK026535 Hs.239307 0 1 FLJ22882 fis, clone KAT03587, highly sim 194D9 1544 1683 NM_003680 Hs.239307 4.00E−57 1 tyrosyl-tRNA synthetase (YARS), mRNA/cds = (0, 110C7 450 1216 AF246221 Hs.239625 0 4 transmembrane protein BRI mRNA, complete cds 599G9 446 1205 NM_021999 Hs.239625 0 13 integral membrane protein 2B (ITM2B), mRNA/cd 515E4 1404 1671 NM_014515 Hs.239720 1.00E−132 1 CCR4-NOT transcription complex, subunit 2 (C 115H10 1124 2079 BC000105 Hs.239760 0 2 Similar to CG14740 gene product, clone MGC: 25 466E3 605 923 NM_005301 Hs.239891 1.00E−164 2 G protein-coupled receptor 35 (GPR35), mRNA/ 52B5 993 1243 AJ223075 Hs.239894 1.00E−106 1 for TRIP protein/cds = (178,2532)/gb = AJ22 171E10 88 399 AW002624 Hs.240077 1.00E−145 1 wu60d10.x1 cDNA, 3′ end/clone = IMAGE: 990854/ 75C5 325 1604 AK027191 Hs.240443 0 8 FLJ23538 fis, clone LNG08010, highly sim 597D3 1134 1792 BC001255 Hs.240770 0 1 nuclear cap binding protein subunit 2, 20 kD, 98A11 596 6834 NM_005385 Hs.241493 0 10 natural killer-tumor recognition sequence (N 98C10 1580 2204 AK027187 Hs.241507 0 40 cDNA: FLJ23534 fis, clone LNG06974, highly sim 463E8 324 846 AF047002 Hs.241520 0 1 transcriptional coactivator ALY mRNA, partia 514G6 802 1238 NM_012392 Hs.241531 0 3 peflin (PEF), mRNA/cds = (12,866)/gb = NM_01239 177G4 1375 1887 AF099149 Hs.241558 0 1 TRIAD1 type I mRNA, complete cds/cds = (144,1625 110E4 1320 1937 AK021704 Hs.241567 0 1 FLJ11642 fis, clone HEMBA 1004356, highly 513B12 700 1447 NM_016839 Hs.241567 0 3 RNA binding motif, single stranded interacting 500G10 910 1249 NM_000594 Hs.241570 0 1 tumor necrosis factor (TNF superfamily, membe 514B6 735 1032 NM_018630 Hs.241576 1.00E−155 1 hypothetical protein PRO2577 (PRO2577), mRNA 590H9 61 251 NM_016200 Hs.241578 1.00E−104 1 U6 snRNA-associated Sm-like protein LSm8 (LOC 50A6 200 311 AK026704 Hs.242868 3.00E−57 3 FLJ23051 fis, clone LNG02642/cds = UNKNOW 104C10 199 353 AA424812 Hs.243029 2.00E−74 1 zw04b02.s1 cDNA, 3′ end/clone = IMAGE: 768267/ 72G4 182 415 AW081232 Hs.243321 1.00E−99 4 xc22e08.x1 cDNA, 3′ end/clone = IMAGE: 2585030 521D12 32 287 AW102836 Hs.243457 6.00E−96 1 xd38h12.x1 cDNA, 3′ end/clone = IMAGE: 2596103 102F3 79 157 W45562 Hs.243720 4.00E−26 1 zc26e07.s1 cDNA, 3′ end/clone = IMAGE: 323460/ 56D6 193 454 M97856 Hs.243886 1.00E−122 1 histone-binding protein mRNA, complete cds/c 595D8 25 495 NM_002482 Hs.243886 0 1 nuclear autoantigenic sperm protein (histone- 46G5 2137 2661 AK000745 Hs.243901 0 1 cDNA FLJ20738 fis, clone HEP08257/ cds = UNKNOWN 477D4 141 250 AI394001 Hs.244666 4.00E−51 1 tg06d04.x1 cDNA, 3′ end/clone = IMAGE: 2107975 139B7 50 235 AW078847 Hs.244816 4.00E−32 2 xb18g07.x1 cDNA, 3′ end/clone = IMAGE: 2576700 472C4 74 464 AW139918 Hs.245138 0 1 UI-H-BI1-aee-d-05-0-UI.s1 cDNA, 3′ end/clon 459F7 45 229 AW080951 Hs.245616 7.00E−58 1 xc28c10.x1 cDNA, 3′ end/clone = IMAGE: 2585586 100A6 41 1795 L22009 Hs.245710 1.00E−143 3 hnRNP H mRNA, complete cds/cds = (72,1421)/ gb = L22009 592G8 41 1798 NM_005520 Hs.245710 0 6 heterogeneous nuclear ribonucleoprotein H1 71G4 382 583 AL136607 Hs.245798 1.00E−104 1 mRNA; cDNA DKFZp564I0422 (from clone DKFZp564 118B9 4495 5528 AK024391 Hs.246112 0 4 cDNA FLJ14329 fis, clone PLACE4000259, highly 471E5 148 464 AI568725 Hs.246299 1.00E−177 1 th15a01.x1 cDNA, 3′ end/clone = IMAGE: 2118312 464D11 26 526 N28843 Hs.246358 0 1 yx59d10.r1 cDNA, 5′ end/clone = IMAGE: 266035/ 40H7 550 1108 S57235 Hs.246381 0 1 CD68 = 110 kda transmembrane glycoprotein [human, promonocy 471E12 152 507 AW117189 Hs.246494 1.00E−149 1 xd83f08.x1 cDNA, 3′ end/clone = IMAGE: 2604231 479C1 47 345 AV739961 Hs.246796 1.00E−140 1 AV739961 cDNA, 5′ end/clone = CBFBRA10/clone_(—) 472C9 43 400 BF796642 Hs.246818 0 1 602259846F1 cDNA, 5′ end/clone = IMAGE: 4343171 47F11 2 227 AB015856 Hs.247433 1.00E−123 1 for ATF6, complete cds/cds = (68,2080)/gb 179H9 12 379 AL031313 Hs.247783 1.00E−111 1 DNA sequence from clone 581F12 on chromosome Xq21. Co 167A9 5 352 Z00013 Hs.247792 1.00E−163 5 H. sapiens germilne gene for the leader peptide and variable 72B8 402 672 L15006 Hs.247824 1.00E−139 2 Ig superfamily CTLA-4 mRNA, complete cds/cds = 488H10 135 672 NM_005214 Hs.247824 1.00E−146 5 cytotoxic T-lymphocyte-associated protein 4 188G8 1 255 NM_002991 Hs.247838 1.00E−135 1 small inducible cytokine subfamily A (Cys-Cys 153D11 401 720 AL049545 Hs.247877 1.00E−133 2 DNA sequence from clone 263J7 on chromosome 6q14.3-15 44D2 42 448 AL035604 Hs.247894 1.00E−133 1 DNA sequence from clone 38C16 on chromosome 6q22.33-2 180B7 10 271 L21961 Hs.247947 4.00E−72 1 Ig rearranged lambda-chain mRNA, subgroup VL3, V- J re 110B11 311 803 U08626 Hs.247984 0 1 glutamine synthetase pseudogene/cds = (0,899)/gb = U 74G5 361 965 X14798 Hs.248109 0 1 DNA for c-ets-1 proto-oncogene/cds = (278,1603)/gb = 60H10 214 527 AW150084 Hs.248657 1.00E−99 3 xg36f03.x1 cDNA, 3′ end/clone = IMAGE: 2629661 64E2 329 536 BF512500 Hs.248689 1.00E−112 1 UI-H-BI3-alw-h-10-0-UI.s1 cDNA, 3′ end/clon 470C6 278 470 AI832183 Hs.249031 1.00E−103 1 wh80g09.x1 cDNA, 3′ end/clone = IMAGE: 2387104 146A9 1145 1422 S63912 Hs.249247 1.00E−113 1 D10S102 = FBRNP [human, fetal brain, mRNA, 3043 nt]/cds = (30, 519E8 37 628 NM_002136 Hs.249495 0 1 heterogeneous nuclear ribonucleoprotein A1 458C7 2232 2520 NM_000964 Hs.250505 1.00E−163 1 retinoic acid receptor, alpha (RARA), mRNA/cd 476A8 1060 1601 AF308285 Hs.250528 0 1 serologically defined breast cancer antigen N 123D7 436 2077 AL157499 Hs.250535 1.00E−153 3 mRNA; cDNA DKFZp434N2412 (from clone DKFZp434 477A10 285 370 AW291304 Hs.250600 2.00E−34 1 UI-H-BI2-agg-b-11-0-UI.s1 cDNA, 3′ end/clon 172G12 726 1598 AF182420 Hs.250619 0 6 MDS019 (MDS019) mRNA, complete cds/cds = (231,1 167E11 11633 13714 NM_016252 Hs.250646 1.00E−180 2 baculoviral IAP repeat-containing 6 (BIRC6), 591E4 198 714 NM_002823 Hs.250655 4.00E−99 3 prothymosin, alpha (gene sequence 28) (PTMA), 40D9 2289 3010 M95585 Hs.250692 0 1 hepatic leukemia factor (HLF) mRNA, complete cds/ cds 110D9 2336 3259 NM_003144 Hs.250773 0 3 signal sequence receptor, alpha (translocon-a 166A3 1 302 AF103458 Hs.250806 6.00E−93 2 isolate donor N clone N168K immunoglobulin kap 110C12 629 1228 M35416 Hs.250811 0 1 GTP-binding protein (RALB) mRNA, complete cds/ cds = (1 458D12 1136 1714 AY007158 Hs.250820 0 1 clone CDABP0113 mRNA sequence/cds = UNKNOWN/g 177C5 658 823 J02621 Hs.251064 3.00E−32 1 non-histone chromosomal protein HMG-14 mRNA, complet 126A2 658 1009 NM_004965 Hs.251064 0 3 high-mobility group (nonhistone chromosomal) 523G1 1 337 AE000660 Hs.251465 1.00E−178 2 T-cell receptor alpha delta locus from bases 5 40G1 4 781 X72308 Hs.251526 0 3 for monocyte chemotactic protein-3 (MCP- 188G7 1 1030 NM_002789 Hs.251531 0 3 proteasome (prosome, macropain) subunit, alp 61E12 578 2275 NM_006537 Hs.251636 0 2 ubiquitin specific protease 3 (USP3), mRNA/cd 38B10 995 1211 AK026594 Hs.251653 1.00E−107 1 FLJ22941 fis, clone KAT08078, highly sim 70C3 2022 2405 X52142 Hs.251871 0 1 CTP synthetase (EC 6.3.4.2)/cds = (75,1850)/ 177E9 49 406 S80990 Hs.252136 1.00E−125 2 ficolin [human, uterus, mRNA, 1736 nt]/ cds = (532,1512)/gb 50F8 1841 2048 AK026712 Hs.252259 1.00E−114 15 FLJ23059 fis, clone LNG03912/cds = (41,16 585E12 16 194 AI383340 Hs.252300 1.00E−63 1 tc76g05.x1 cDNA, 3′ end/clone = IMAGE: 2070584 181E12 22 99 BE963374 Hs.252338 4.00E−30 1 601657137R1 cDNA, 3′ end/clone = IMAGE: 3866193 477H4 290 451 AI524022 Hs.252359 8.00E−87 1 tg99f02.x1 cDNA, 3′ end/clone = IMAGE: 2116923 188G11 95 700 NM_007104 Hs.252574 0 2 ribosomal protein L10a (RPL10A), mRNA/cds = (1 471H9 1 285 AV706014 Hs.252580 1.00E−145 1 AV706014 cDNA, 5′ end/clone = ADBAOB12/clone_(—) 134F9 1358 1464 AL359626 Hs.252588 5.00E−50 1 mRNA; cDNA DKFZp564F172 (from clone DKFZp564F1 597B10 13 279 NM_000981 Hs.252723 1.00E−149 28 ribosomal protein L19 (RPL19), mRNA/cds = (28,6 120D7 962 1674 NM_006054 Hs.252831 0 5 reticulon 3 (RTN3), mRNA/cds = (124,834)/gb = N 593B10 102 467 AW191929 Hs.252989 7.00E−93 1 x177c10.x1 cDNA, 3′ end/clone = IMAGE: 2680722 482C11 32 122 AW195119 Hs.253151 3.00E−33 1 xn66b07.x1 cDNA, 3′ end/clone = IMAGE: 2699413 472C6 34 279 AW204029 Hs.253384 1.00E−137 1 UI-H-BI1-aen-d-02-0-UI.s1 cDNA, 3′ end/clon 472D4 27 440 AW205624 Hs.253502 0 1 UI-H-BI1-afr-e-01-0-UI.s1 cDNA, 3′ end/clon 472D1 120 362 BF750565 Hs.253550 1.00E−133 1 RC1-BN0410-261000-014-f11 cDNA/gb = BF750565 480F11 367 558 AW237483 Hs.253820 1.00E−105 1 xm72e01.x1 cDNA, 3′ end/clone = IMAGE: 2689752 472B5 35 363 AI432340 Hs.254006 1.00E−169 1 tg54e06.x1 cDNA, 3′ end/clone = IMAGE: 2112610 75E5 1 904 M14328 Hs.254105 0 5 alpha enolase mRNA, complete cds/cds = (94,1398)/ gb = 592A12 1 1100 NM_001428 Hs.254105 0 5 enolase 1, (alpha) (EN01), mRNA/cds = (94,1398) 472D10 183 414 AI364936 Hs.255100 1.00E−126 1 qz23c12.x1 cDNA, 3′ end/clone = IMAGE: 2027734 479H9 43 184 AW292772 Hs.255119 2.00E−70 1 UI-H-BW0-aij-d-03-0-UI.s1 cDNA, 3′ end/clon 480A2 18 523 AW293267 Hs.255178 0 1 UI-H-BW0-aii-e-10-0-UI.s1 cDNA, 3′ end/clon 480B7 16 298 AW293895 Hs.255249 1.00E−116 1 UI-H-BW0-ain-f-10-0-UI.s1 cDNA, 3′ end/clon 479H11 23 202 AW293955 Hs.255255 3.00E−79 1 UI-H-BW0-aik-d-05-0-UI.s1 cDNA, 3′ end/clon 480A4 415 598 AW294681 Hs.255336 5.00E−66 1 UI-H-BW0-ail-g-10-0-UI.s1 cDNA, 3′ end/clon 480A7 223 427 AW294695 Hs.255339 1.00E−103 1 UI-H-BW0-aim-a-02-0-UI.s1 cDNA, 3′ end/clon 480A8 26 338 BF514247 Hs.255340 1.00E−167 I UI-H-BW1-ani-h-09-0-UI.s1 cDNA, 3′ end/clon 480C12 239 483 AW295088 Hs.255389 1.00E−124 1 UI-H-BW0-ait-d-09-0-UI.s1 cDNA, 3′ end/clon 480F9 1 423 BF531016 Hs.255390 0 1 602072345F1 cDNA, 5′ end/clone = IMAGE: 4215251 480B3 68 377 AW295610 Hs.255446 1.00E−161 1 UI-H-BW0-aip-c-03-0-UI.s1 cDNA, 3′ end/clon 460H5 44 427 AA455707 Hs.255452 1.00E−161 1 aa22d09.r1 cDNA, 5′ end/clone = IMAGE: 814001/ 480B12 132 212 AW295664 Hs.255454 7.00E−39 1 UI-H-BW0-aip-g-12-0-UI.s1 cDNA, 3′ end/clon 472E7 163 489 AI439645 Hs.255490 1.00E−166 1 tc91e08.x1 cDNA, 3′ end/clone = IMAGE: 2073542 480D12 84 258 AW296005 Hs.255492 8.00E−90 1 UI-H-BW0-aiu-b-01-0-UI.s1 cDNA, 3′ end/clon 480F4 34 464 AW296063 Hs.255501 0 1 UI-H-BW0-aiu-g-08-0-UI.s1 cDNA, 3′ end/clon 480D5 18 404 AW296490 Hs.255554 0 2 UI-H-BW0-aiq-f-08-0-UI.s1 cDNA, 3′ end/clon 480E1 95 379 AW296532 Hs.255559 1.00E−101 1 UI-H-BW0-aiv-b-07-0-UI.s1 cDNA, 3′ end/clon 480E5 17 326 AW296545 Hs.255560 1.00E−128 1 UI-H-BW0-aiv-c-11-0-UI.s1 cDNA, 3′ end/clon 480F2 20 330 AW296730 Hs.255573 1.00E−160 1 UI-H-BW0-aix-f-12-0-UI.s1 cDNA, 3′ end/clon 480G7 38 479 AW296797 Hs.255579 0 1 UI-H-BW0-ajb-e-07-0-UI.s1 cDNA, 3′ end/clon 480C9 19 274 AW297339 Hs.255637 1.00E−117 1 UI-H-BW0-air-c-03-0-UI.s1 cDNA, 3′ end/clon 480C4 70 191 AW297400 Hs.255647 1.00E−49 1 UI-H-BW0-ais-a-05-0-UI.s1 cDNA, 3′ end/clon 480G5 17 242 AW297522 Hs.255661 2.00E−87 1 UI-H-BW0-aja-e-02-0-UI.s1 cDNA, 3′ end/clon 480F10 230 560 AW294654 Hs.255687 0 1 UI-H-BW0-ail-d-10-0-UI.s1 cDNA, 3′ end/clon 480G9 47 582 AW297813 Hs.255695 0 1 UI-H-BW0-aiy-g-09-0-UI.s1 cDNA, 3′ end/clon 480G10 31 453 AW297827 Hs.255697 0 1 UI-H-BW0-aiy-h-11-0-UI.s1 cDNA, 3′ end/clon 482G6 16 242 AW339651 Hs.255927 3.00E−78 1 he15g04.x1 cDNA, 3′ end/clone = IMAGE: 2919126 469B11 4 221 AW341086 Hs.256031 1.00E−99 1 xz92h04.x1 cDNA, 3′ end/clone = IMAGE: 2871703 140E7 2870 3589 M32315 Hs.256278 1.00E−84 2 tumor necrosis factor receptor mRNA, complete cds/cd 189H12 2839 3294 NM_001066 Hs.256278 0 2 tumor necrosis factor receptor superfamily, m 99H11 83 589 NM_005620 Hs.256290 0 4 S100 calcium-binding protein A11 (calgizzarin 58C7 1778 2264 AJ271747 Hs.256583 0 1 partial mRNA for double stranded RNA binding nu 482F4 373 628 AV719442 Hs.256959 1.00E−124 1 AV719442 cDNA, 5′ end/clone = GLCBNA01/clone_(—) 482F5 8 377 AW440866 Hs.256961 1.00E−179 1 he05f02.x1 cDNA, 3′ end/clone = IMAGE: 2918139 482F8 191 315 AW440974 Hs.256971 2.00E−62 1 he06e12.x1 cDNA, 3′ end/clone = IMAGE: 2918254 479E7 136 567 AW444482 Hs.256979 0 2 UI-H-BI3-akb-e-05-0-UI.s1 cDNA, 3′ end/clon 471H5 3 432 AI438957 Hs.257066 0 1 tc89b05.x1 cDNA, 3′ end/clone = IMAGE: 2073297 472G3 233 617 AW450350 Hs.257283 0 1 UI-H-B13-akn-c-01-0-UI.s1 cDNA, 3′ end/clon 472G11 112 338 AI809475 Hs.257466 1.00E−101 1 wh76d06.x1 cDNA, 3′ end/clone = IMAGE: 2386667 479F7 22 421 AW452467 Hs.257572 0 1 UI-H-BI3-als-e-09-0-UI.s1 cDNA, 3′ end/clon 479G9 95 304 AW452513 Hs.257579 1.00E−81 1 UI-H-BW1-ame-b-03-0-UI.s1 cDNA, 3′ end/clon 479F11 16 329 AW453021 Hs.257640 1.00E−163 1 UI-H-BW1-ama-c-02-0-UI.s1 cDNA, 3′ end/clon 479G4 45 441 AW453044 Hs.257646 0 1 UI-H-BW1-ama-e-01-0-UI.s1 cDNA, 3′ end/clon 482F9 11 256 AW467193 Hs.257667 1.00E−108 1 he07a04.x1 cDNA, 3′ end/clone = IMAGE: 2918286 482G2 9 271 AW467400 Hs.257680 1.00E−112 1 he10f11.x1 cDNA, 3′ end/clone = IMAGE: 2918637 482G8 108 428 AW467437 Hs.257682 1.00E−177 1 he17d05.x1 cDNA, 3′ end/clone = IMAGE: 2919273 482G12 1 417 AW467501 Hs.257687 0 1 he19e06.x1 cDNA, 3′ end/clone = IMAGE: 2919490 482H4 39 143 AW467746 Hs.257695 3.00E−51 1 he23d05.x1 cDNA, 3′ end/clone = IMAGE: 2919849 482H6 1 116 AW467863 Hs.257705 2.00E−59 1 he27c04.x1 cDNA, 3′ end/clone = IMAGE: 2920230 482H7 1 321 AW467864 Hs.257706 1.00E−156 1 he27c05.x1 cDNA, 3′ end/clone = IMAGE: 2920232 482H9 1 112 AW467992 Hs.257709 1.00E−47 1 he30b01.x1 cDNA, 3′ end/clone = IMAGE: 2920489 483A2 20 429 AW468207 Hs.257716 0 1 he34a12.x1 cDNA, 3′ end/clone = IMAGE: 2920894 483A9 11 373 AW468431 Hs.257727 0 1 he37h11.x1 cDNA, 3′ end/clone = IMAGE: 2921253 483B2 2 241 AW468621 Hs.257743 1.00E−119 1 he42e03.x1 cDNA, 3′ end/clone = IMAGE: 2921692 75B1 157 246 BE531180 Hs.258494 5.00E−44 1 601278313F1 cDNA, 5′ end/clone = IMAGE: 3610443 585F6 2200 4106 AL136549 Hs.258503 0 8 mRNA; cDNA DKFZp761I12121 (from clone DKFZP761 169E2 5186 5415 U20489 Hs.258609 1.00E−119 2 glomerular epithelial protein 1 (GLEPP1) comple 127A5 2142 2477 AB037790 Hs.258730 1.00E−177 1 mRNA for KIAA1369 protein, partial cds/cds = (0 171B12 4202 4314 Y10129 Hs.258742 4.00E−45 2 mybpc3 gene/cds = (33,3857)/gb = Y10129/gi = 20583 75B7 531 682 L14542 Hs.258850 3.00E−81 1 lectin-like type II integral membrane protein (NKG2-E 471G5 344 473 AI144328 Hs.259084 3.00E−61 1 oy84g04.x1 cDNA, 3′ end/clone = IMAGE: 1672566 479B7 73 307 AF161364 Hs.259683 1.00E−123 1 HSPC101 mRNA, partial cds/cds = (0,556)/gb = AF 146B11 1942 2174 AL136842 Hs.260024 8.00E−92 1 DKFZp434A0530 (from clone DKFZp434A 584A1 1085 1470 AL022398 Hs.261373 1.00E−166 1 DNA sequence from PAC 434O14 on chromosome 1q32 148B1 119 817 X60656 Hs.261802 0 2 elongation factor 1-beta/cds = (95,772) 60G3 203 3170 NM_001634 Hs.262476 0 15 S-adenosylmethionine decarboxylase 1 (AMD1) 462E7 292 374 AW300868 Hs.262789 8.00E−40 1 xk07d09.x1 eDNA, 3′ end/clone = IMAGE: 2666033 56F11 33 234 BF243724 Hs.263414 4.00E−82 1 601877832F1 cDNA, 5′ end/clone = IMAGE: 4106359 119C5 2414 2664 NM_002108 Hs.263435 1.00E−137 1 histidine ammonia-lyase (HAL), mRNA/cds(297 105A4 3225 3775 AK025774 Hs.264190 0 3 FLJ22121 fis, clone HEP18876, highly sim 469H1 369 576 AI380111 Hs.264298 1.00E−103 1 tf98a11.x1 cDNA, 3′ end/clone = IMAGE: 2107292 181A3 2434 2768 NM_002535 Hs.264981 1.00E−148 2 2′-5′oligoadenylate synthetase 2 (OAS2), tra 41B7 3209 3885 M59911 Hs.265829 0 1 integrin alpha-3 chain mRNA, complete cds/ cds = (73,32 75F9 264 452 AW150944 Hs.265838 2.00E−96 1 xg42e09.x1 cDNA, 3′ end/clone = IMAGE: 2630248 99C3 2684 3155 AK000680 Hs.266175 0 2 cDNA FLJ20673 fis, clone KAIA4464/cds = (104,14 598E12 2417 2894 AK026669 Hs.266940 0 2 cDNA: FLJ23016 fis, clone LNG00874/cds = UNKNOW 468B6 863 1515 NM_016569 Hs.267182 0 1 TBX3-iso protein (TBX3-iso), mRNA/cds = (116,1 115E11 1234 1713 AF271994 Hs.267288 0 1 dopamine responsive protein DRG-1 mRNA, compl 114A4 31 382 NM_024095 Hs.267400 1.00E−179 1 hypothetical protein MGC5540 (MGC5540), mRNA 166C7 1315 1919 AK001749 Hs.267604 0 2 FLJ10887 fis, clone NT2RP4002018, weakly 56A8 564 3624 AB033054 Hs.267690 0 3 for KIAA1228 protein, partial cds/cds = (0 70B10 229 2138 AK001471 Hs.268012 0 3 FLJ10609 fis, clone NT2RP2005276, highly 178D10 1831 2796 NM_012255 Hs.268555 0 2 5′-3′exoribonuclease 2 (XRN2), mRNA/cds = (68, 168B9 451 881 AF068235 Hs.268763 0 1 barrier-to-autointegration factor mRNA, com 465F2 91 433 AA613224 Hs.270264 0 1 no19d06.s1 cDNA, 3′ end/clone = IMAGE: 1101131 469E2 302 422 BE857296 Hs.270293 1.00E−57 1 7g27b01.x1 cDNA, 3′ end/clone = IMAGE: 3307657 465D10 284 405 AI270476 Hs.270341 4.00E−51 1 qu88e12.x1 cDNA, 3′ end/clone = IMAGE: 1979182 473F10 831 1096 AK021517 Hs.270557 1.00E−140 1 cDNA FLJ11455 fis, clone HEMBA1001497/cds = UNK 193A10 458 563 AI818951 Hs.270614 5.00E−31 1 wj89e12.x1 cDNA, 3′ end/clone = IMAGE: 2410030 458E11 44 264 W03955 Hs.270717 1.00E−118 1 za62d04.r1 cDNA, 5′end/clone = IMAGE: 297127/ 163C12 280 954 M30704 Hs.270833 1.00E−168 2 amphiregulin (AR) mRNA, complete cds, clones lambda-A 196F4 208 567 NM_001657 Hs.270833 1.00E−158 1 amphiregulin (schwannoma-derived growth fac 464G2 378 529 AW172850 Hs.270999 4.00E−77 1 xj04f02.x1 cDNA, 3′ end/clone = IMAGE: 2656251 464F5 131 476 AW572930 Hs.271264 0 1 hf17f07.x1 cDNA, 3′ end/clone = IMAGE: 2932165 41G6 458 880 Y16645 Hs.271387 0 1 for monocyte chemotactic protein-2/cds = 464F2 139 220 AW975086 Hs.271420 2.00E−34 1 EST387192 cDNA/gb = AW975086/gi = 8166291/ug = 178E10 961 1452 AK021715 Hs.271541 0 1 cDNA FLJ11653 fis, clone HEMBA1004538/cds = UNK 129E1 73 441 NM_016049 Hs.271614 1.00E−136 1 CGI-112 protein (LOC51016), mRNA/cds = (158,78 40C9 4195 4949 X17033 Hs.271986 0 1 integrin alpha-2 subunit/cds = (48,3593)/gb 108E1 917 1331 NM_006811 Hs.272168 0 2 tumor differentially expressed 1 (TDE1), mRNA 155H10 232 715 AL021395 Hs.272279 1.00E−164 1 DNA sequence from clone RP1-269M15 on chromosome 20q1 159D3 38 238 AL034343 Hs.272295 1.00E−106 4 DNA sequence from clone RP1-108C2 on chromosome 6p12. 477C3 744 1166 AL133015 Hs.272307 0 2 mRNA; cDNA DKFZp434O2417 (from clone DKFZp434O 173D12 228 594 AL121934 Hs.272340 1.00E−140 5 DNA sequence from clone RP11-209A2 on chromosome 6. C 472D9 27 418 NM_016135 Hs.272398 0 1 transcription factor ets (TEL2), mRNA/cds = (7 465F9 1885 2345 NM_013351 Hs.272409 0 1 T-box 21 (TBX21), mRNA/cds = (211,1818)/gb = NM 41E11 1 277 NM_004167 Hs.272493 1.00E−113 1 small inducible cytokine subfamily A (Cys-Cys 462E11 8 526 NM_001503 Hs.272529 0 1 glycosylphosphatidylinositol specific phos 104C6 210 327 AE000659 Hs.272550 5.00E−61 1 T-cell receptor alpha delta locus from bases 2 596A3 411 1208 NM_013392 Hs.272736 0 5 nuclear receptor binding protein (NRBP), mRNA 75C2 1892 2188 AK000316 Hs.272793 1.00E−165 1 FLJ20309 fis, clone HEP07296/cds = (41,127 58C6 1 956 NM_006009 Hs.272897 0 2 Tubulin, alpha, brain-specific (TUBA3), mRNA 190H8 3246 3771 AK024471 Hs.273230 1.00E−165 2 mRNA for FLJ00064 protein, partial cds/cds = (0 590E11 1512 1860 NM_014230 Hs.273307 1.00E−168 4 signal recognition particle 68 kD (SRP68), mRN 588H2 696 1454 NM_000516 Hs.273385 0 3 guanine nucleotide binding protein (G protein) 165E9 3186 3695 NM_014871 Hs.273397 0 1 KIAA0710 gene product (KIAA0710), mRNA/cds = ( 462A6 394 496 AA527312 Hs.273775 2.00E−42 1 ng36a08.s1 cDNA, 3′ end/clone = IMAGE: 936854/ 587F1 1763 1978 AL050353 Hs.274170 1.00E−112 1 mRNA; cDNA DKFZp564C0482 (from clone DKFZp564C 177E5 1448 1876 AK000765 Hs.274248 0 1 FLJ20758 fis, clone HEP01508/cds = (464,13 59E7 1 301 AF151049 Hs.274344 1.00E−159 3 HSPC215 mRNA, complete cds/cds = (92,451)/gb = 174A6 931 1352 NM_004301 Hs.274350 0 1 BAF53 (BAF53A), mRNA/cds = (136,1425)/gb = NM_0 99E2 718 1391 NM_018477 Hs.274369 0 4 uncharacterized hypothalamus protein HARP11 117F6 3046 3478 AB037844 Hs.274396 0 2 mRNA for KIAA1423 protein, partial cds/cds = (0 52F3 1724 2342 NM_005346 Hs.274402 1.00 E−149 48 heat shock 70 kD protein 1 (HSPA1B), mRNA/cds = ( 516B1 719 1026 NM_018975 Hs.274428 1.00E−161 2 TRF2-interacting telomeric RAP1 protein (RAP 104A1 1943 2396 AK002127 Hs.274439 0 1 FLJ11265 fis, clone PLACE1009158/cds = (30 137D6 1697 1817 NM_001403 Hs.274466 8.00E−49 1 eukaryotic translation elongation factor 1 a 108D11 321 646 X16863 Hs.274467 1.00E−160 1 Fc-gamma RIII-1 cDNA for Fc-gamma receptor III-1 (CD 107F1 567 895 AF283771 Hs.274472 1.00E−168 1 clone TCBAP0774 mRNA sequence/cds = UNKNOWN/g 517B9 4 480 NM_002128 Hs.274472 0 3 high-mobility group (nonhistone chromosomal) 514C8 254 539 M12888 Hs.274474 1.00E−144 2 T-cell receptor germline beta-chain gene C-region C- 460G5 602 775 M12679 Hs.274485 3.00E−94 1 Cw1 antigen mRNA, complete cds/cds = (0,617)/ gb = M1267 463G7 163 744 D90145 Hs.274535 0 4 LD78 beta gene/cds = (86,367)/gb = D90145/ gi = 219907/ 472E10 277 391 AI393960 Hs.274851 6.00E−59 1 tg11d04.x1 cDNA, 3′ end/clone = IMAGE: 2108455 115A11 156 446 NM_014624 Hs.275243 1.00E−157 8 S100 calcium-binding protein A6 (calcyclin) ( 102C6 23 448 AA610514 Hs.275611 1.00E−161 1 np93h02.s1/clone = IMAGE: 1133907/gb = AA6 160E3 24 304 AA757952 Hs.275773 1.00E−74 3 zg49e07.s1 3′ end/clone = IMAGE: 396708/ 500B8 26 536 NM_022551 Hs.275865 0 3 ribosomal protein S18 (RPS18), mRNA/cds = (46,5 522D9 184 593 NM_001959 Hs.275959 0 1 eukaryotic translation elongation factor 1 b 151H4 1 196 AA984890 Hs.276063 5.00E−58 1 am62e06.s1 cDNA, 3′ end/clone = IMAGE: 1576642 476B10 362 615 BF510670 Hs.276341 1.00E−116 1 UI-H-BI4-aof-b-08-0-UI.s1 cDNA, 3′ end/clon 144F10 73 279 Al318342 Hs.276662 8.00E−57 1 ta73c09.x1 3′ end/clone = IMAGE: 2049712 593G1 17 88 BE747210 Hs.276718 2.00E−26 1 601580926F1 cDNA, 5′ end/clone = IMAGE: 3929430 473E3 205 488 AI380791 Hs.276766 1.00E−144 1 tg04b12.x1 cDNA, 3′ end/clone = IMAGE: 2107775 598A2 72 427 NM_001803 Hs.276770 0 19 CDW52 antigen (CAMPATH-1 antigen) (CDW52), mR 170H2 83 432 X62466 Hs.276770 0 1 CAMPATH-1 (CDw52) antigen/cds = (33,218) 464F7 2 454 AI492640 Hs.276903 0 2 qz18a06.x1 cDNA, 3′ end/clone = IMAGE: 2021842 464E5 102 191 AI493726 Hs.276907 3.00E−44 2 qz12f08.x1 cDNA, 3′ end/clone = IMAGE: 2021319 50B5 42 308 AI581383 Hs.276988 5.00E−77 1 to71c02.x1 cDNA, 3′ end/clone = IMAGE: 2183714 468C6 40 279 AI740667 Hs.277201 1.00E−64 1 wg07b07.x1 cDNA, 3′ end/clone = IMAGE: 2364373 111D12 1 562 AI749435 Hs.277224 1.00E−118 9 at24b04.x1 cDNA, 3′ end/clone = IMAGE: 2356015 459B4 176 367 AI811065 Hs.277293 2.00E−38 1 tr03f05.x1 cDNA, 3′ end/clone = IMAGE: 2217249 477H3 6227 6584 NM_013449 Hs.277401 1.00E−132 1 bromodomain adjacent to zinc finger domain, 2A 54A8 34 301 AW050975 Hs.277672 3.00E−48 1 wz25f04.x1 cDNA, 3′ end/clone = IMAGE: 2559103 459E4 1532 2061 NM_006389 Hs.277704 0 1 oxygen regulated protein (150 kD) (ORP150), mR 109B6 3281 3721 U65785 Hs.277704 0 1 150 kDa oxygen-regulated protein ORP150 mRNA, complet 524H7 2979 3350 NM_005899 Hs.277721 0 1 membrane component, chromosome 17, surface ma 472F10 425 556 AW082714 Hs.277738 5.00E−69 1 xb61f07.x1 cDNA, 3′ end/clone = IMAGE: 2580805 176D1 113 269 AW262728 Hs.277994 6.00E−32 1 xq94a12.x1 cDNA, 3′ end/clone = IMAGE: 2758270 464H4 2138 3563 NM_016733 Hs.278027 0 9 LIM domain kinase 2 (LIMK2), transcript varian 145C9 533 1446 D13316 Hs.278238 0 3 transcription factor, E4TF1-47, complete cds 161C3 339 560 NM_002041 Hs.278238 1.00E−123 1 GA-binding protein transcription factor, bet 74C9 345 1048 AK026632 Hs.278242 0 3 FLJ22979 fis, clone KAT11379, highly sim 59E2 255 782 L24804 Hs.278270 0 2 (p23) mRNA, complete cds/cds = (232,714)/ gb = L24804/ 521H10 8 461 AI720536 Hs.278302 1.00E−114 4 as83c02.x1 cDNA, 3′ end/clone = IMAGE: 2335298 118C6 830 1104 NM_001995 Hs.278333 1.00E−148 1 fatty-acid-Coenzyme A ligase, long-chain 1 ( 104E9 248 417 AF151054 Hs.278429 2.00E−78 1 HSPC220 mRNA, complete cds/cds = (288,818)/gb 594F10 379 1760 NM_016520 Hs.278429 0 4 hepatocellular carcinoma-associated antigen 126D11 7374 7716 NM_006289 Hs.278559 0 1 talin (TLN), mRNA/cds = (126,7751)/gb = NM_0062 589E6 3078 5778 NM_003105 Hs.278571 0 3 sortilin-related receptor, L(DLR class) A re 102C10 669 1180 D14041 Hs.278573 0 1 for H-2K binding factor-2, complete cds/ 526H8 167 4709 NM_015874 Hs.278573 0 5 H-2K binding factor-2 (LOC51580), mRNA/cds = ( 120A12 732 1305 AB029031 Hs.278586 0 1 mRNA for KIAA1108 protein, partial cds/cds = (0 126F4 3138 3515 AF035737 Hs.278589 0 2 general transcription factor 2-I (GTF2I) mRNA 40A7 3179 3864 U24578 Hs.278625 0 1 RP1 and complement C4B precursor (C4B) genes, partial 50C4 4401 4581 AB002334 Hs.278671 2.00E−60 1 KIAA0336 gene, complete cds/cds = (253,5004) 106E12 104 1222 D50525 Hs.278693 0 11 TI-227H/cds = UNKNOWN/gb = D50525/gi = 1167502 467E10 168 542 BE973840 Hs.278704 1.00E−145 1 601680647F1 cDNA, 5′ end/clone = IMAGE: 3951154 75F2 1121 1772 J04755 Hs.278718 0 37 ferritin H processed pseudogene, complete cds/ cds = UN 170E12 204 843 AL121735 Hs.278736 0 2 Isoform of human GTP-binding protein G25K/ cds = (104,679)/ 103F4 589 926 NM_019597 Hs.278857 0 1 heterogeneous nuclear ribonucleoprotein H2 37F8 3 519 UO1923 Hs.278857 0 1 BTK region clone ftp-3 mRNA/cds = UNKNOWN/ gb = U01923/ 66B11 2195 2512 AB029027 Hs.279039 1.00E−172 1 for KIAA1104 protein, complete cds/cds = ( 171G3 219 815 AK027258 Hs.279040 0 2 FLJ23605 fis, clone LNG15982, highly sim 172E12 18 95 NM_014065 Hs.279040 4.00E−27 2 HT001 protein (HT001), mRNA/cds = (241,1203)/ 596A12 1 225 BE220869 Hs.279231 2.00E−78 1 hu01g02.x1 cDNA, 3′ end/clone = IMAGE: 3165362 61H2 20 220 BE279328 Hs.279429 2.00E−32 3 601157666F1 cDNA, 5′ end/clone = IMAGE: 3504328 458E12 1835 2473 NM_014160 Hs.279474 0 1 HSPC070 protein (HSPC070), mRNA/cds(331,158 110F3 983 1614 NM_016160 Hs.279518 0 1 amyloid precursor protein homolog HSD-2 (LOC5 37E5 39 732 AK001403 Hs.279521 0 1 FLJ10541 fis, clone NT2RP2001381/cds = (3 66D6 6 463 BE502919 Hs.279522 0 1 hz81b08.x1 cDNA, 3′ end/clone = IMAGE: 3214359 123A11 411 903 NM_013237 Hs.279529 0 2 px19-like protein (PX19), mRNA/cds = (176,835) 185A10 809 1324 NM_002817 Hs.279554 0 1 proteasome (prosome, macropain) 26S subunit, 472H9 88 543 AL582047 Hs.279555 0 1 AL582047 cDNA/clone = CS0DL003YD01-(3-prime) 41A2 1 326 AK000575 Hs.279581 1.00E−162 1 FLJ20568 fis, clone REC00775/cds = (6,422) 135F4 648 935 NM_016283 Hs.279586 1.00E−110 1 adrenal gland protein AD-004 (LOC51578), mRNA 69D9 841 935 D16217 Hs.279607 9.00E−40 1 calpastatin, complete cds/cds = (162,2288)/ 116B6 938 1562 NM_001750 Hs.279607 0 1 calpastatin (CAST), mRNA/cds = (66,1358)/gb = 473F4 6847 7401 NM_007329 Hs.279611 0 1 deleted in malignant brain tumors 1 (DMBT1), tr 123C7 2488 2684 NM_021644 Hs.279681 1.00E−105 1 heterogeneous nuclear ribonucleoprotein H3 586E2 357 633 NM_014169 Hs.279761 3.00E−97 1 HSPC134 protein (HSPC134), mRNA/cds = (45,716) 464D6 383 524 NM_016154 Hs.279771 1.00E−33 1 ras-related GTP-binding protein 4b (RAB4B), m 99G9 1375 1835 NM_013388 Hs.279784 0 1 prolactin regulatory element binding (PREB), 590F4 1045 1540 NM_003883 Hs.279789 0 2 histone deacetylase 3 (HDAC3), mRNA/cds = (55,1 163E1 59 564 NM_015932 Hs.279813 0 3 hypothetical protein (HSPC014), mRNA/cds = (8 525G5 3914 4160 NM_014819 Hs.279849 1.00E−138 1 KIAA0438 gene product (KIAA0438), mRNA/cds = ( 598A10 9 821 NM_003295 Hs.279860 0 19 tumor protein, translationally-controlled 1 526C8 734 1166 NM_016007 Hs.279867 0 1 CGI-59 protein (LOC51625), mRNA/cds = (2,1153) 183G12 758 1093 NM_017774 Hs.279893 0 1 hypothetical protein FLJ20342 (FLJ20342), mR 36B3 247 611 AK025623 Hs.279901 0 1 FLJ21970 fis, clone HEP05733, highly sim 592G3 479 1052 NM_016146 Hs.279901 0 4 PTD009 protein (PTD009), mRNA/cds = (257,916) 38F5 811 1256 AF151875 Hs.279918 0 4 CGI-117 protein mRNA, complete cds/cds = (456,9 161E3 542 862 NM_016391 Hs.279918 1.00E−151 1 hypothetical protein (HSPC111), mRNA/cds = (6 584F11 10 212 NM_014248 Hs.279919 1.00E−112 2 ring-box 1 (RBX1), mRNA/cds = (6,332)/gb = NM_0 588H7 400 1155 NM_003404 Hs.279920 0 12 tyrosine 3-monooxygenase/tryptophan 5-monoo 169C8 400 1155 X57346 Hs.279920 1.00E−131 2 HS1 protein/cds = (372,1112)/gb = X57346 147A1 209 1978 AK025927 Hs.279921 0 8 FLJ22274 fis, clone HRC03616, highly sim 591H11 48 1810 NM_016127 Hs.279921 1.00E−176 33 HSPC035 protein (LOC51669), mRNA/cds = (16,103 69D1 727 1776 NM_014366 Hs.279923 0 3 putative nucleotide binding protein, estradio 52C6 303 1151 V00522 Hs.279930 0 2 encoding major histocompatibility complex gene 158C11 2483 2785 D84224 Hs.279946 1.00E−166 2 methionyl tRNA synthetase, complete c 194E7 1525 1767 NM_004990 Hs.279946 1.00E−125 1 methionine- tRNA synthetase (MARS), mRNA/cds 62E5 215 701 U93243 Hs.279948 0 1 Ubc6p homolog mRNA, complete cds/cds = (27,983) 145G3 1 1882 AK024090 Hs.281434 1.00E−147 5 FLJ14028 fis, clone HEMBA1003838/cds = UN 473A6 1 310 BE552131 Hs.282091 1.00E−158 1 hw29b05.x1 cDNA, 3′ end/clone = IMAGE: 3184305 52C12 1 455 R67739 Hs.282401 0 1 yi28c06.r1 cDNA, 5′ end/clone = IMAGE: 140554/ 112A3 5072 5274 NM_006165 Hs.282441 3.00E−83 1 nuclear factor related to kappa B binding prote 61H3 443 577 AV648638 Hs.282867 2.00E−68 4 AV648638 cDNA, 3′ end/clone = GLCBLE12/clone_(—) 37D3 38 766 AF287008 Hs.283022 0 5 triggering receptor expressed on monocytes 1 125C5 32 748 NM_018643 Hs.283022 0 13 triggering receptor expressed on myeloid cell 41B1 597 1084 NM_018636 Hs.283106 0 2 hypothetical protein PRO2987 (PRO2987), mRNA 111E9 1111 1405 AB037802 Hs.283109 1.00E−152 1 mRNA for KIAA1381 protein, partial cds/cds = (0 169D7 5 175 BE672733 Hs.283216 2.00E−37 1 7b75g07.x1 3′ end/clone = IMAGE: 3234108 74G11 47 384 BE676472 Hs.283267 1.00E−151 1 7f30c05.x1 cDNA, 3′ end/clone = IMAGE: 3296168 191A5 256 890 NM_018507 Hs.283330 0 3 hypothetical protein PRO1843 (PRO1843), mRNA 465B7 114 638 AW979262 Hs.283410 0 2 EST391372 cDNA/gb = AW979262/gi = 8170550/ug = 143E1 1970 2258 NM_020217 Hs.283611 1.00E−110 1 hypothetical protein DKFZp547I014 (DKFZp547I 54E9 385 739 AF116620 Hs.283630 0 3 PRO1068 mRNA, complete cds/cds = UNKNOWN/ gb = A 462D10 63 279 NM_007220 Hs.283646 1.00E−119 1 carbonic anhydrase VB, mitochondrial (CA5B), 518B11 359 690 NM_016056 Hs.283670 1.00E−167 2 CGI-119 protein (LOC51643), mRNA/cds = (0,776) 36H5 1 226 BE778549 Hs.283674 8.00E−85 1 601466063F1 cDNA, 5′ end/clone = IMAGE: 3869391 126H10 907 1431 NM_017801 Hs.283685 0 1 hypothetical protein FLJ20396 (FLJ20396), mR 69B1 2288 3232 AF103803 Hs.283690 0 6 clone H41 unknown mRNA/cds = (323,1099)/gb = AF 98B1 162 489 NM_018476 Hs.283719 1.00E−110 1 uncharacterized hypothalamus protein HBEX2 39C3 997 3088 NM_020151 Hs.283722 0 2 GTT1 protein (GTT1), mRNA/cds = (553,1440)/gb 592E4 13 2219 NM_020357 Hs.283728 0 2 PEST-containing nuclear protein (pcnp), mRNA 142F11 138 371 AF173296 Hs.283740 1.00E−130 1 e(y)2 homolog mRNA, complete cds/cds = (216,521 592F3 480 858 NM_013234 Hs.283781 0 2 muscle specific gene (M9), mRNA/cds = (171,827) 159E5 3 281 AL121916 Hs.283838 1.00E−113 6 DNA sequence from clone RP1-189G13 on chromosome 20. 142H10 517 892 AL121585 Hs.283864 9.00E−70 2 DNA sequence from clone RP11-504H3 on chromosome 20 C 166D3 1 227 X72475 Hs.283972 6.00E−70 1 for rearranged lg kappa light chain variable 134E8 980 1302 NM_014110 Hs.284136 0 47 PRO2047 protein (PRO2047), mRNA/cds = (798,968 596C5 30 705 NM_006134 Hs.284142 0 2 chromosome 21 open reading frame 4 (C21ORF4), m 74A4 1944 2157 AL359585 Hs.284158 1.00E−110 3 cDNA DKFZp762B195 (from clone DKFZp762B1 159A4 159 1414 AF165521 Hs.284162 0 4 ribosomal protein L30 isolog (L30) mRNA, compl 597F9 836 1000 NM_016304 Hs.284162 1.00E−88 1 60S ribosomal protein L30 isolog (LOC51187), m 462D2 655 1306 NM_016301 Hs.284164 0 1 protein × 0004 (LOC51184), mRNA/cds = (31,885) 458C6 720 910 AP001753 Hs.284189 1.00E−102 1 genomic DNA, chromosome 21q, section 97/105/ 165D5 1482 2302 AB040120 Hs.284205 0 2 mRNA for BCG induced integral membrane protein 180C12 309 602 BF381953 Hs.284235 1.00E−148 2 601816251F1 cDNA, 5′ end/clone = IMAGE: 4050061 67D9 27 2026 AK024969 Hs.284249 0 10 FLJ21316 fis, clone COL02253, highly sim 39D1 307 2899 U90552 Hs.284283 0 5 butyrophilin (BTF5) mRNA, complete cds/ cds = (359,190 147C8 391 556 AF161451 Hs.284295 2.00E−58 1 HSPC333 mRNA, partial cds/cds = (0,443)/gb = AF 192C12 333 484 AV700210 Hs.284605 5.00E−57 1 AV700210 cDNA, 3′ end/clone = GKBALC03/clone_(—) 49G11 380 523 AV700636 Hs.284674 4.00E−33 1 AV700636 cDNA, 3′ end/clone = GKBAGH12/clone_(—) 115C11 375 1001 AK023291 Hs.285017 0 1 cDNA FLJ13229 fis, clone OVARC1000106/cds = (15 458H8 1544 2233 AK023459 Hs.285107 0 1 cDNA FLJ13397 fis, clone PLACE1001351/cds = (22 70F4 11 605 AV700298 Hs.285173 0 4 AV700298 cDNA, 3′ end/clone = GKCBVGO5/clone_(—) 66C6 684 1415 NM_001300 Hs.285313 0 5 core promoter element binding protein (COPEB), 169F2 4 460 BF684382 Hs.285555 0 2 602141836F1 5′ end/clone = IMAGE: 4302776 171F12 646 839 X58529 Hs.285823 6.00E−99 2 rearranged immunoglobulin mRNA for mu heavy chain enh 142F10 1438 1728 AK025788 Hs.285833 1.00E−152 1 FLJ22135 fis, clone HEP20858/cds = UNKNOW 171H2 1 2500 AL050376 Hs.285853 5.00E−21 1 mRNA; cDNA DKFZp586J101 (from clone DKFZp586J1 40C5 786 1163 AK026603 Hs.286124 0 2 FLJ22950 fis, clone KAT09618, highly sim 458D9 55 684 NM_016041 Hs.286131 0 1 CGI-101 protein (LOC51009), mRNA/cds = (6,635) 458D1 1 310 AK025886 Hs.286194 1.00E−151 1 cDNA: FLJ22233 fis, clone HRC02016/cds = (35,12 515C10 817 1136 AK021791 Hs.286212 1.00E−138 1 cDNA FLJ11729 fis, clone HEMBA1005394, modera 71C7 285 2441 AK026933 Hs.286236 0 7 cDNA: FLJ23280 fis, clone HEP07194/cds = (468,1 184B9 372 612 BE965319 Hs.286754 3.00E−66 2 601659229R1 cDNA, 3′ end/clone = IMAGE: 3895783 586C12 18 381 NM_000996 Hs.287361 0 3 ribosomal protein L35a (RPL35A), mRNA/cds = (6 36C6 152 685 AJ277247 Hs.287369 0 37 for interleukin 21 (IL-21 gene)/cds = (71, 513H8 17 690 NM_020525 Hs.287369 0 510 interleukin 22 (IL22), mRNA/cds = (71,610)/gb 586G2 3978 4107 NM_021621 Hs.287387 3.00E−68 1 caspase recruitment domain protein 7 (CARD7), 99D12 2330 2851 NM_015906 Hs.287414 0 1 transcriptional intermediary factor 1 gamma ( 182A2 284 576 AK024331 Hs.287631 1.00E−156 1 cDNA FLJ14269 fis, clone PLACE1003864/cds = UN 465A11 2226 2321 AK024372 Hs.287634 1.00E−42 1 cDNA FLJ14310 fis, clone PLACE3000271/cds = (40 190A11 679 1126 AK026769 Hs.287725 0 1 cDNA: FLJ23116 fis, clone LNG07945, highly sim 75E2 479 837 AL390738 Hs.287788 1.00E−146 3 DNA sequence from clone RP11-438F9 on chromosome 13 C 59B7 488 1071 AK022537 Hs.287863 0 1 FLJ12475 fis, clone NT2RM1000962/cds = (16 460E8 1611 1979 AK024092 Hs.287864 0 1 cDNA FLJ14030 fis, clone HEMBA1004086/cds = UNK 465F11 5714 6271 NM_006312 Hs.287994 0 1 nuclear receptor co-repressor 2 (NCOR2), mRNA 150E12 2041 2720 AK026834 Hs.287995 0 3 FLJ23181 fis, clone LNG11094/cds = UNKNOW 52D9 703 1482 AB016247 Hs.288031 0 1 for sterol-C5-desaturase, complete cds 37F4 1091 1655 AK025375 Hs.288061 1.00E−141 20 FLJ21722 fis, clone COLF0522, highly sim 188G5 1081 1753 NM_001101 Hs.288061 0 69 actin, beta (ACTB), mRNA/cds = (73,1200)/gb = N 171C12 2103 2426 AB046857 Hs.288140 1.00E−158 1 KIAA1637 protein, partial cds/cds = (0 104E8 1354 1790 AK023078 Hs.288141 0 1 FLJ13016 fis, clone NT2RP3000624, modera 181A4 1890 2507 AK022030 Hs.288178 0 2 cDNA FLJ11968 fis, clone HEMBB1001133/cds = UNK 129A1 3522 3748 J04144 Hs.288204 1.00E−125 1 angiotensin I-converting enzyme mRNA, complete cds/ 598D12 1464 1947 AK025643 Hs.288224 0 3 cDNA: FLJ21990 fis, clone HEP06386/cds = (22,49 52E6 920 1388 AK023402 Hs.288416 0 2 FLJ13340 fis, clone OVARC1001942, weakly 165E3 303 640 NM_020666 Hs.288417 0 1 protein serine threonine kinase Clk4 (CLK4), 53D3 1 153 AK022280 Hs.288435 6.00E−76 1 FLJ12218 fis, clone MAMMA1001075, modera 586C2 223 448 BF110312 Hs.288443 1.00E−63 3 7n36d08.x1 cDNA, 3′ end/clone = IMAGE: 3566654 521F12 1922 2248 AK026923 Hs.288455 0 1 cDNA: FLJ23270 fis, clone COL10309, highly sim 120A11 825 1855 AK026078 Hs.288555 0 2 cDNA: FLJ22425 fis, clone HRC08686/ cds = UNKNOW 129D11 1723 1984 AK023470 Hs.288673 1.00E−143 2 FLJ13408 fis, clone PLACE1001672, weakly 109B12 1686 2086 AK025215 Hs.288708 1.00E−121 8 FLJ21562 fis, clone COL06420/cds = (238,2 178F11 387 558 NM_005402 Hs.288757 3.00E−93 1 v-ral simian leukemia viral oncogene homolog 58F8 1262 1604 AK022735 Hs.288836 0 1 cDNA FLJ12673 fis, clone NT2RM4002344/cds = (2, 163E11 360 1687 AK024094 Hs.288856 1.00E−25 2 FLJ14032 fis, clone HEMBA1004353, highly 105B4 741 1243 AK025092 Hs.288872 0 1 FLJ21439 fis, clone COL04352/cds = (206,1 106D10 1598 2291 AB014515 Hs.288891 0 3 for KIAA0615 protein, complete cds/cds = ( 460F8 154 2487 NM_021818 Hs.288906 1.00E−150 2 WW Domain-Containing Gene (WW45), mRNA/cds = ( 48A6 560 1258 NM_017644 Hs.288922 0 1 hypothetical protein FLJ20059 (FLJ20059), mR 168B10 1271 1747 AK023320 Hs.288929 0 1 FLJ13258 fis, clone OVARC1000862, modera 114E2 2395 2849 AK023256 Hs.288932 0 1 cDNA FLJ13194 fis, clone NT2RP3004378, weakly 586F9 368 730 AK026363 Hs.288936 1.00E−162 4 cDNA: FLJ22710 fis, clone HSI13340/cds = UNKNOW 180B4 831 959 NM_000344 Hs.288986 1.00E−32 1 survival of motor neuron 1, telomeric (SMN1), 149A12 10 1958 AK025467 Hs.289008 0 5 FLJ21814 fis, clone HEP01068/cds = UNKNOW 117B5 5160 5611 NM_012231 Hs.289024 1.00E−141 1 PR domain containing 2, with ZNF domain (PRDM2) 469A5 3132 3365 AK024456 Hs.289034 1.00E−106 1 mRNA for FLJ00048 protein, partial cds/cds = (2 461F6 396 473 AK024197 Hs.289037 7.00E−37 1 cDNA FLJ14135 fis, clone MAMMA1002728/cds = UN 176G11 1049 1811 AK024669 Hs.289069 0 4 cDNA: FLJ21016 fis, clone CAE05735/cds = (90,11 473A5 1343 1937 NM_013326 Hs.289080 0 1 colon cancer-associated protein Mic1 (MIC1), 591G2 14 2259 NM_005348 Hs.289088 0 14 heat shock 90 kD protein 1, alpha (HSPCA), mRNA 70D3 21 2912 X15183 Hs.289088 0 17 90-kDa heat-shock protein/cds = (60,2258)/g 37E8 780 1509 AK026033 Hs.289092 0 5 FLJ22380 fis, clone HRC07453, highly sim 74B10 408 791 X00453 Hs.289095 1.00E−153 2 gene fragment for DX alpha-chain signal peptide, 518B5 870 1128 NM_005313 Hs.289101 1.00E−119 1 glucose regulated protein, 58 kD (GRP58), mRNA 472A3 116 304 X83300 Hs.289103 4.00E−84 1 H. sapiens SMA4 mRNA/cds = (66,488)/gb = X83300/ gi = 603028/ 112G6 1703 2550 NM_001166 Hs.289107 0 5 baculoviral IAP repeat-containing 2 (BIRC2), 37F11 1996 2580 U37547 Hs.289107 0 2 IAP homolog B (MIHB) mRNA, complete cds/ cds = (1159,301 169A12 371 588 X57812 Hs.289110 2.00E−84 1 rearranged immunoglobulin lambda light chain/c 472D6 2102 2424 AF294900 Hs.289118 1.00E−121 1 beta, beta-carotene 15, 15′-dioxygenase (BCD 151D1 2214 2294 AK025846 Hs.289721 1.00E−38 2 FLJ22193 fis, clone HRC01108/cds = UNKNOW 40A8 160 346 AI761924 Hs.289834 2.00E−94 1 wg68h03.x1 cDNA, 3′ end/clone = IMAGE: 2370293 468D5 42 105 AA719103 Hs.290535 5.00E−29 1 zh33d10.s1 cDNA, 3′ end/clone = IMAGE: 413875/ 515B6 7 249 AA837754 Hs.291129 2.00E−61 1 oe10d02.s1 cDNA/clone = IMAGE: 1385475/gb = AA 594C9 16 319 NM_005745 Hs.291904 1.00E−150 1 accessory proteins BAP31/BAP29 (DXS1357E), m 476C10 180 311 AI184710 Hs.292276 8.00E−62 1 qd64a01.x1 cDNA, 3′ end/clone = IMAGE: 1734216 466G5 65 431 AA461604 Hs.292451 0 1 zx51d08.r1 cDNA, 5′ end/clone = IMAGE: 795759/ 331F12 142 314 BF310166 Hs.292457 3.00E−85 1 601894826F1 cDNA, 5′ end/clone = IMAGE: 4124119 590D6 1 406 BG339050 Hs.292457 0 2 602436875F1 cDNA, 5′ end/clone = IMAGE: 4554643 150G5 160 431 AI440234 Hs.292490 6.00E−66 1 ti99h12.x1 cDNA, 3′ end/clone = IMAGE: 2140199 594F8 319 447 AA761571 Hs.292519 1.00E−57 1 nz23d06.s1 cDNA, 3′ end/clone = lMAGE: 1288619 122E2 91 307 AI582954 Hs.292553 4.00E−47 1 tr98e07.x1 cDNA, 3′ end/clone = IMAGE: 2227140 41E5 363 463 D59502 Hs.292590 3.00E−48 1 HUM041H11A cDNA, 3′ end/clone = GEN-041H11/cl 99B8 215 378 AI672433 Hs.292615 6.00E−62 4 wa03b05.x1 cDNA, 3′ end/clone = IMAGE: 2296977 72C6 198 484 AA719537 Hs.292877 1.00E−112 3 zh40g12.s1 cDNA, 3′ end/clone = IMAGE: 414598/ 157H5 49 447 AI962127 Hs.292901 1.00E−126 1 wx77f07.x1 3′ end/clone = IMAGE: 2549701 115C2 2052 2613 NM_006310 Hs.293007 0 1 aminopeptidase puromycin sensitive (NPEPPS), 463F3 14 445 AW629485 Hs.293352 0 2 hi59b07.x1 cDNA, 3′ end/clone = IMAGE: 2976565 193H8 94 333 AI263141 Hs.293444 7.00E−58 1 qw90c01.x1 cDNA, 3′ end/clone = IMAGE: 1998336 170G9 46 713 AI452611 Hs.293473 9.00E−21 1 tj27g07.x1 cDNA, 3′ end/clone = lMAGE: 2142780 100F9 554 666 BE905040 Hs.293515 2.00E−43 1 601496859F1 cDNA, 5′ end/clone = IMAGE: 3898767 588G9 153 507 BF794089 Hs.293658 1.00E−143 1 602255649F1 cDNA, 5′ end/clone = IMAGE: 4338732 142G8 2 231 AV701332 Hs.293689 1.00E−79 1 AV701332 cDNA, 5′ end/clone = ADAABD03/clone_(—) 137A4 1 557 BF029654 Hs.293777 0 1 601765621F1 cDNA, 5′ end/clone = IMAGE: 3997900 478C6 442 622 BE748123 Hs.293842 3.00E−63 1 601571679F1 cDNA, 5′ end/clone = lMAGE: 3838675 100E7 198 488 BE748663 Hs.293842 1.00E−145 1 601571679T1 cDNA, 3′ end/clone = lMAGE: 3838675 110B4 246 469 NM_016398 Hs.293905 1.00E−122 1 hypothetical protein (HSPC131), mRNA/cds = (1 466D2 198 543 AW972477 Hs.294083 1.00E−180 1 EST384568 cDNA/gb = AW972477/gi = 8162323/ug = 100C10 1 398 AW963235 Hs.294092 0 2 EST375308/gb = AW963235/gi = 8153071/ug = 118F10 418 552 BF245076 Hs.294110 1.00E−48 1 601863910F1 cDNA, 5′ end/clone = IMAGE: 4082235 596H2 1150 2308 BC002450 Hs.294135 0 20 ribosomal protein L4, clone MGC: 776, mRNA, co 596B4 139 414 BE621121 Hs.294309 7.00E−73 3 601493943F1 cDNA, 5′ end/clone = IMAGE: 3896051 114D4 600 738 BE961923 Hs.294348 8.00E−33 1 601655335R1 cDNA, 3′ end/clone = IMAGE: 3845768 66D11 185 625 BE963811 Hs.294578 1.00E−127 6 601657462R1 cDNA, 3′ end/clone = IMAGE: 3875846 53E11 433 701 BE964149 Hs.294612 5.00E−81 1 601657833R1 cDNA, 3′ end/clone = IMAGE: 3875984 179A11 442 776 BF313856 Hs.294754 9.00E−79 1 601902261F1 5′ end/clone = IMAGE: 4134998 102B9 146 347 H71236 Hs.295055 7.00E−90 2 ys12f10.s1 cDNA, 3′ end/clone = IMAGE: 214603/ 110F4 136 358 H80108 Hs.295107 1.00E−118 1 yu09f02.s1 cDNA, 3′ end/clone = IMAGE: 233307/ 593F2 78 381 AF212224 Hs.295231 1.00E−172 3 CLK4 mRNA, complete cds/cds = (153,1514)/gb = A 50G9 355 415 AI052431 Hs.295451 1.00E−26 2 oz07e08.x1 cDNA, 3′ end/clone = IMAGE: 1674662 102E4 99 413 AI560651 Hs.295682 1.00E−146 8 tq60f01.x1 cDNA, 3′ end/clone = IMAGE: 2213209 486F7 263 489 BF572855 Hs.295806 1.00E−100 1 602079424F2 cDNA, 5′ end/clone = lMAGE: 4254172 39C1 2054 2315 AL050141 Hs.295833 1.00E−144 6 cDNA DKFZp586O031 (from clone DKFZp586O0 192D3 48 551 AW081320 Hs.295945 1.00E−158 4 xc30f12.x1 cDNA, 3′ end/clone = IMAGE: 2585807 102B7 753 850 AL117536 Hs.295969 5.00E−39 1 cDNA DKFZp434G012 (from clone DKFZp434G0 168D1 73 1193 AL360190 Hs.295978 1.00E−134 3 mRNA full length insert cDNA clone EUROIMAGE 74 47D6 103 331 AW150085 Hs.295997 3.00E−79 8 xg36f04.x1 cDNA, 3′ end/clone = lMAGE: 2629663 151H9 197 507 AW264291 Hs.296057 1.00E−113 1 xq97g08.x1 cDNA, 3′ end/clone = IMAGE: 2758622 56A1 1034 1220 AJ012504 Hs.296151 3.00E−74 1 activated in tumor suppression, clone TSA 525D12 42 545 AI922889 Hs.296159 1.00E−148 42 wn64g11.x1 cDNA, 3′ end/clone = IMAGE: 2450276 72C12 280 545 AW166001 Hs.296159 1.00E−84 10 xf43e11.x1 cDNA, 3′ end/clone = IMAGE: 2620844 99B1 21 286 BE259480 Hs.296183 4.00E−81 3 601106571F1 cDNA, 5′ end/clone = IMAGE: 3342929 143F5 18 178 BE962588 Hs.296183 1.00E−55 1 601655929R1 cDNA, 3′ end/clone = IMAGE: 3855823 110A10 2115 2237 AL096752 Hs.296243 1.00E−61 1 cDNA DKFZp434A012 (from clone DKFZp434A0 170G1 16 304 BE964134 Hs.296246 4.00E−96 1 601657818R1 CDNA, 3′ end/clone = IMAGE: 3876028 597G5 168 1564 NM_014456 Hs.296251 0 18 programmed cell death 4 (PDCD4), mRNA/cds = (84 184A12 686 1564 U96628 Hs.296251 0 2 nuclear antigen H731-like protein mRNA, compl 479H10 247 540 NM_002072 Hs.296261 1.00E−117 1 guanine nucleotide binding protein (G protein 179H11 48 250 BF315059 Hs.296266 3.00E−56 1 601899090F1 5′ end/clone = IMAGE: 4128334 182E9 1576 2251 AK023460 Hs.296275 0 2 FLJ13398 fis, clone PLACE1001377, highly 459B11 305 545 BF340402 Hs.296317 1.00E−79 1 602036746F1 cDNA, 5′ end/clone = IMAGE: 4184602 459B12 349 721 AK001838 Hs.296323 0 1 cDNA FLJ10976 fis, clone PLACE1001399/cds = UN 179F8 1 756 BF342246 Hs.296333 0 2 602013019F1 5′ end/clone = IMAGE: 4148741 171D1 12 330 AV693913 Hs.296339 1.00E−100 1 AV693913 cDNA, 5′ end/clone = GKCDVG04/clone_(—) 39B9 1 297 AB046771 Hs.296350 1.00E−167 1 for KIAA1551 protein, partial cds/cds = (0 36H12 547 1089 M96995 Hs.296381 0 2 epidermal growth factor receptor-binding pro 459F1 867 1020 NM_014499 Hs.296433 4.00E−76 1 putative purinergic receptor (P2Y10), mRNA/c 584A11 615 1287 NM_006392 Hs.296585 0 4 nucleolar protein (KKE/D repeat) (NOP56), mRN 593F7 209 752 NM_005678 Hs.296948 0 2 SNRPN upstream reading frame (SNURF), transcr 174F7 493 681 BE253125 Hs.297095 2.00E−60 5 601116648F1 cDNA, 5′ end/clone = IMAGE: 3357178 123H9 132 413 BE965554 Hs.297190 9.00E−88 1 601659486R1 cDNA, 3′ end/clone = IMAGE: 3896204 123D6 1105 1595 AF113676 Hs.297681 0 1 clone FLB2803 PRO0684 mRNA, complete cds/cds = 71C6 1076 1630 NM_003380 Hs.297753 0 2 vimentin (VIM), mRNA/cds = (122,1522)/gb = NM_0 586G5 1179 1452 NM_001908 Hs.297939 1.00E−142 1 cathepsin B (CTSB), mRNA/cds = (177,1196)/gb = 521E7 1 220 NM_001022 Hs.298262 1.00E−119 4 ribosomal protein S19 (RPS19), mRNA/cds = (22,4 466H7 9 339 AW614181 Hs.298654 1.00E−153 1 hg77d03.x1 cDNA, 3′ end/clone = IMAGE.2951621 464A4 675 1232 BC001077 Hs.299214 0 1 clone IMAGE: 2822295, mRNA, partial cds/cds = 466F3 49 337 AA132448 Hs.299416 1.00E−141 1 zo20a03.s1 cDNA, 3′ end/clone = IMAGE: 587404/ 589B10 123 339 AW073707 Hs.299581 1.00E−55 30 xb01h03.x1 cDNA, 3′ end/clone = IMAGE: 2575061 521H4 3 371 NM_001000 Hs.300141 1.00E−125 4 ribosomal protein L39 (RPL39), mRNA/cds = (37,1 599F12 36 328 AW243795 Hs.300220 2.00E−67 1 xo56f02.x1 cDNA, 3′ end/clone = IMAGE: 2707995 479A6 173 356 AW262077 Hs.300229 3.00E−64 1 xq61e07.x1 cDNA, 3′ end/clone = IMAGE: 2755140 111C8 806 1350 NM_018579 Hs.300496 1.00E−147 6 mitochondrial solute carrier (LOC51312), mRN 459D8 1 679 NM_014478 Hs.300684 0 1 calcitonin gene-related peptide-receptor co 522C5 98 1360 NM_001154 Hs.300711 0 10 annexin A5 (ANXA5), mRNA/cds = (192,1154)/gb = 596B7 407 750 NM_003130 Hs.300741 2.00E−83 1 sorcin (SRI), mRNA/cds = (12,608)/gb = NM_00313 191A3 210 440 AA788623 Hs.301104 4.00E−34 9 ah29f09.s1 cDNA, 3′ end/clone = 1240265/clone 123E1 15 267 BE963194 Hs.301110 1.00E−60 11 601656811R1 cDNA, 3′ end/clone = IMAGE: 3865731 116F11 346 650 NM_014029 Hs.301175 2.00E−71 2 HSPC022 protein (HSPC022), mRNA/cds = (18,623) 58D4 489 611 AW863111 Hs.301183 8.00E−50 1 MR3-SN0009-010400-101-f02 cDNA/gb = AW863111 122D8 3644 4034 AB037808 Hs.301434 0 1 mRNA for KIAA1387 protein, partial cds/cds = (0 520F11 276 553 BE886472 Hs.301486 1.00E−111 1 601509688F1 cDNA, 5′ end/clone = IMAGE: 3911301 512E5 71 687 NM_001011 Hs.301547 0 8 ribosomal protein S7 (RPS7), mRNA/cds = (81,665 463F9 168 689 AV702152 Hs.301570 0 1 AV702152 cDNA, 5′ end/clone = ADBBFH05/clone_(—) 117A12 2239 2395 NM_007167 Hs.301637 5.00E−78 1 zinc finger protein 258 (ZNF258), mRNA/cds = (9 190A6 12942 13156 AF155238 Hs.301698 1.00E−114 1 BAC 180i23 chromosome 8 map 8q24.3 beta-galacto 594F12 1409 1841 NM_005442 Hs.301704 0 1 eomesodermin (Xenopus laevis) homolog (EOMES) 116G12 5477 5571 AB033081 Hs.301721 6.00E−47 1 mRNA for KIAA1255 protein, partial cds/cds = (0 123C4 23 579 BE260041 Hs.301809 1.00E−129 4 601150579F1 cDNA, 5′ end/clone = IMAGE: 3503419 192E12 1458 1854 NM_007145 Hs.301819 0 1 zinc finger protein 146 (ZNF146), mRNA/cds = (8 590G8 1100 1307 AF132197 Hs.301824 3.00E−57 1 PRO1331 mRNA, complete cds/cds = (422,616)/gb 482E5 1764 2139 NM_001295 Hs.301921 0 1 chemokine (C-C motif) receptor 1 (CCR1), mRNA 583C5 4283 4684 NM_014415 Hs.301956 0 1 zinc finger protein (ZNF-U69274), mRNA/cds = ( 173G11 645 839 X58529 Hs.302063 1.00E−104 4 rearranged immunoglobulin mRNA for mu heavy chain enh 597D11 30 369 AL137162 Hs.302114 1.00E−150 5 DNA sequence from clone RP5-843L14 on chromosome 20. 191G9 182 353 AC004079 Hs.302183 9.00E−60 1 PAC clone RP1-167F23 from 7p15/cds = (0,569)/g 473D2 102 333 BF477640 Hs.302447 1.00E−126 1 7r01c05.x1 cDNA/clone = IMAGE/gb = BF477640/g 479A9 18 267 BE964028 Hs.302585 7.00E−79 1 601657601R1 cDNA, 3′ end/clone = IMAGE: 3875617 180A5 894 1325 NM_018295 Hs.302981 0 2 hypothetical protein FLJ11000 (FLJ11000), mR 593H6 950 1151 X00437 Hs.303157 1.00E−104 1 mRNA for T-cell specific protein/cds = (37,975)/gb = XC 51G12 274 533 BG054649 Hs.303214 1.00E−138 4 7o45b01.x1 cDNA, 3′ end/clone = IMAGE: 3576912 189B10 785 1024 NM_002138 Hs.303627 1.00E−133 2 heterogeneous nuclear ribonucleoprotein D ( 99B11 1 529 NM_002982 Hs.303649 0 51 small inducible cytokine A2 (monocyte chemota 461E1 397 496 AI472078 Hs.303662 2.00E−28 1 tj85h03.x1 cDNA, 3′ end/clone = IMAGE: 2148341 103A1 359 687 AF130085 Hs.304177 1.00E−151 1 clone FLB8503 PRO2286 mRNA, complete cds/cds 180B11 52 240 AI824522 Hs.304477 4.00E−57 1 tx71d03.x1 cDNA, 3′ end/clone = lMAGE: 2275013 519A10 1 104 AI880542 Hs.304620 3.00E−26 1 at80h05.x1 cDNA, 3′ end/clone = IMAGE: 2378361 479F6 331 582 AA873734 Hs.304886 1.00E−131 1 oh55h07.s1 cDNA, 3′ end/clone = IMAGE: 1470589 176G3 61 324 AI904802 Hs.304919 2.00E−74 1 IL-BT067-190199-037 cDNA/gb = AI904802/gi = 6 471G6 169 397 AW592876 Hs.304925 1.00E−122 1 hg04d05.x1 cDNA, 3′ end/clone = IMAGE: 2944617 119D11 3 348 AL049282 Hs.306030 1.00E−179 1 mRNA; cDNA DKFZp564M113 (from clone DKFZp564M1 112F7 2398 3008 U80743 Hs.306094 0 1 CAGH32 mRNA, partial cds/cds = (0,1671)/gb = U80 460C1 243 533 NM_001353 Hs.306098 5.00E−71 1 aldo-keto reductase family 1, member C1 (dihy 126A4 469 543 L08048 Hs.306192 2.00E−28 1 non-histone chromosomal protein (HMG-1) retropseudo 119F3 2113 2237 AL096752 Hs.306327 3.00E−60 1 mRNA; cDNA DKFZp434A012 (from clone DKFZp434A0 467F8 1860 2406 AL390039 Hs.307106 0 1 DNA sequence from clone RP13-383K5 on chromosome Xq22 192B12 1 454 X72475 Hs.307183 0 6 H. sapiens mRNA for rearranged Ig kappa light chain variable 116H11 60 402 AF067519 Hs.307357 1.00E−160 1 PITSLRE protein kinase beta SV1 isoform (CDC2L 472D3 150 478 AW975895 Hs.307486 1 .00E−124 1 EST388004 cDNA/gb = AW975895/gi = 8167117/ug = 458B4 87 354 AW206977 Hs.307542 1.00E−143 1 UI-H-BI1-afs-h-11-0-UI.s1 cDNA, 3′ end/clon 463A11 181 397 AI057025 Hs.307879 1.00E−69 1 oy75a12.x1 cDNA, 3′ end/clone = IMAGE: 1671646 479C6 138 403 BE264564 Hs.308154 1.00E−144 1 601192330F1 cDNA, 5′ end/clone = IMAGE: 3536383 468G10 118 446 AI361642 Hs.309028 0 1 qy86d04.x1 cDNA, 3′ end/clone = IMAGE: 2018887 461G12 64 466 AI379735 Hs.309117 7.00E−25 1 tc41c11.x1 cDNA, 3′ end/clone = IMAGE: 2067188 466H8 15 487 AI380278 Hs.309120 0 1 tf99f08.x1 cDNA, 3′ end/clone = IMAGE: 2107431 477C8 28 187 AI380449 Hs.309122 7.00E−84 1 tg02f12.x1 cDNA, 3′ end/clone = IMAGE: 2107631 477C9 47 537 AI380687 Hs.309127 0 1 tg03e04.x1 cDNA, 3′ end/clone = IMAGE: 2107710 465F4 68 631 AI440337 Hs.309279 0 1 tc88b03.x1 cDNA, 3′ end/clone = IMAGE: 2073197 465G6 313 404 AI475653 Hs.309347 9.00E−31 1 tc93b04.x1 cDNA, 3′ end/clone = IMAGE: 2073679 465E7 1 340 AI475827 Hs.309349 1.00E−171 2 tc87a05.x1 cDNA, 3′ end/clone = IMAGE: 2073104 517G11 62 516 AI707809 Hs.309433 1.00E−115 2 as28g09.x1 cDNA, 3′ end/clone = IMAGE: 2318560 468D11 290 497 AI523766 Hs.309484 1.00E−103 1 tg94f07.x1 cDNA, 3′ end/clone = IMAGE: 2116453 186F5 77 418 AI569898 Hs.309629 1.00E−81 1 tr57c12.x1 cDNA, 3′ end/clone = IMAGE: 2222422 116A12 8 158 AI735206 Hs.310333 2.00E−43 1 at07f03.x1 cDNA, 3′ end/clone = IMAGE: 2354429 126G12 35 170 AI866194 Hs.310948 1.00E−54 1 wl27a03.x1 cDNA, 3′ end/clone = IMAGE: 2426092 172G8 86 227 AI926251 Hs.311137 3.00E−44 1 wo41h05.x1 cDNA, 3′ end/clone = IMAGE: 2457945 477D8 1 115 AI968387 Hs.311448 4.00E−42 2 wu02e08.x1 cDNA, 3′ end/clone = IMAGE: 2515814 462F10 13 220 AW043857 Hs.311783 1.00E−107 1 wy81g04.x1 cDNA, 3′ end/clone = IMAGE: 2554998 185A9 46 423 AW130007 Hs.312182 1.00E−130 2 xf26f10.x1 cDNA, 3′ end/clone = IMAGE: 2619211 515F6 34 181 AW148618 Hs.312412 3.00E−58 2 xe99f02.x1 cDNA, 3′ end/clone = IMAGE: 2616699 583E12 5945 6393 AL133572 Hs.312840 0 1 mRNA; cDNA DKFZp434I0535 (from clone DKFZp434I 471D5 306 411 AW298430 Hs.313413 1.00E−46 1 UI-H-BW0-ajI-c-09-0-UI.s1 cDNA, 3′ end/clon 482F7 1 449 AW440965 Hs.313578 0 1 he06d07.x1 cDNA, 3′ end/clone = IMAGE: 2918221 473B3 179 463 BG150461 Hs.313610 1.00E−135 1 7k01d08.x1 cDNA, 3′ end/clone = IMAGE: 3443006 479E9 138 434 AW450835 Hs.313715 1.00E−127 1 UI-H-BI3-alf-f-06-0-UI.s1 cDNA, 3′ end/clon 71B9 344 577 AI733018 Hs.313929 1.00E−115 1 oh60h01.x5 cDNA, 3′ end/clone = IMAGE: 1471441 479B6 217 443 AW629176 Hs.314085 2.00E−70 1 hi52a04.x1 cDNA, 3′ end/clone = IMAGE: 2975886 191F11 55 123 BE255377 Hs.314898 1.00E−26 1 601115405F1 cDNA, 5′ end/clone = IMAGE: 3355872 522F11 14 204 BE962883 Hs.314941 9.00E−83 3 601656423R1 cDNA, 3′ end/clone = IMAGE: 3856325 195F12 120 363 BE351010 Hs.315050 2.00E−77 1 ht22g04.x1 cDNA, 3′ end/clone = IMAGE: 3147510 173A5 429 824 BE410105 Hs.315263 1.00E−133 1 601302278F1 cDNA, 5′ end/clone = IMAGE: 3637002 481B2 1063 1283 NM_006255 Hs.315366 3.00E−72 1 protein kinase C, eta (PRKCH), mRNA/cds = (166,2 459G1 1428 1700 NM_006850 Hs.315463 1.00E−124 1 suppression of tumorigenicity 16 (melanoma di 113H4 22 359 BE901218 Hs.315633 1.00E−127 2 601676034F1 cDNA, 5′ end/clone = IMAGE: 3958617 583B7 510 754 BE963666 Hs.316047 2.00E−55 2 601656685R1 cDNA, 3′ end/clone = IMAGE: 3865820 466E10 488 644 AV729160 Hs.316771 1.00E−54 1 AV729160 cDNA, 5′ end/clone = HTCCAB04/clone_(—) 597A6 50 249 AV710763 Hs.316785 4.00E−31 2 AV710763 cDNA, 5′ end/clone = CuAAJH09/clone_(—) 123C3 41 529 BF183507 Hs.318215 1.00E−158 1 601809991R1 cDNA, 3′ end/clone = IMAGE: 4040470 193E12 15 2274 NM_006074 Hs.318501 0 7 stimulated trans-acting factor (50 kDa) (STAF 165D8 727 1344 BC002867 Hs.318693 0 1 clone IMAGE: 3940519, mRNA, partial cds/cds = 49F8 520 1094 M16942 Hs.318720 0 1 MHC class II HLA-DRw53-associated glycoprotein beta- 172E10 310 944 NM_016018 Hs.318725 0 1 CGI-72 protein (LOC51105), mRNA/cds = (69,1400 585B1 51 296 BF696330 Hs.318782 6.00E−90 4 602125273F1 cDNA, 5′ end/clone = IMAGE: 4281906 45E12 208 737 NM_000636 Hs.318885 0 7 superoxide dismutase 2, mitochondrial (SOD2) 460G2 409 663 BG106948 Hs.318893 5.00E−96 1 602291361F1 cDNA, 5′ end/clone = IMAGE: 4386159 480C1 155 325 BF889206 Hs.319926 4.00E−74 1 RC6-TN0073-041200-013-H02 cDNA/gb = BF889206 178F1 1 387 BG112503 Hs.320972 1.00E−133 3 602282105F1 cDNA, 5′ end/clone = IMAGE: 4369633 176G4 1092 1339 AL110236 Hs.321022 1.00E−136 1 mRNA; cDNA DKFZp566P1124 (from clone DKFZp566P 461H6 1701 2239 NM_024101 Hs.321130 0 1 hypothetical protein MGC2771 (MGC2771), mRNA 513F2 605 1614 AK001111 Hs.321245 0 2 cDNA FLJ10249 fis, clone HEMBB1000725, highly 525B4 9 251 BE871962 Hs.321262 6.00E−98 15 601448005F1 cDNA, 5′ end/clone = IMAGE: 3852001 467A4 1974 2223 AK026270 Hs.321454 6.00E−87 1 cDNA: FLJ22617 fis, clone HSI05379, highly sim 589F10 39 276 BF970928 Hs.321477 5.00E−77 1 602270204F1 cDNA, 5′ end/clone = IMAGE: 4358425 125A7 1102 1584 BC000627 Hs.321677 0 1 Signal transducer and activator of transcript 597H3 2786 2920 AL136542 Hs.322456 4.00E−46 2 mRNA; cDNA DKFZp761D0211 (from clone DKFZp761D 465E2 40 107 BE747224 Hs.322643 7.00E−22 1 601580941F1 cDNA, 5′ end/clone = IMAGE: 3929386 515A12 1 698 AL050376 Hs.322645 0 2 mRNA; cDNA DKFZp586J101 (from clone DKFZp586J1 589H11 26 265 BG283132 Hs.322653 4.00E−79 6 602406784F1 cDNA, 5′ end/clone = IMAGE: 4518957 586E5 1939 2162 AK025200 Hs.322680 1.00E−120 3 cDNA: FLJ21547 fis, clone COL06206/cds = UNKNOW 595A2 1 306 BG311130 Hs.322804 2.00E−70 2 ia55a08.y1 cDNA, 5′ end/clone_end = 5′/gb = BG3 459H11 742 951 BC002746 Hs.322824 1.00E−111 1 Similar to dodecenoyl-Coenzyme A delta isome 64C3 655 887 NM_020368 Hs.322901 1.00E−112 1 disrupter of silencing 10 (SAS10), mRNA/cds = ( 591B8 3626 4574 D80006 Hs.322903 0 3 mRNA for KIAA0184 gene, partial cds/cds = (0,2591)/gb 458C3 5106 5198 NM_003035 Hs.323032 3.00E−43 1 TAL1 (SCL) interrupting locus (SIL), mRNA/cds 526B7 2132 2750 NM_024334 Hs.323193 0 2 hypothetical protein MGC3222 (MGC3222), mRNA 167F4 467 731 NM_014953 Hs.323346 1.00E−136 2 KIAA1008 protein (KIAA1008), mRNA/cds = (93,28 194B8 1913 3596 AB051480 Hs.323463 0 9 mRNA for KIAA1693 protein, partial cds/cds = (0 478H9 75 564 BF700502 Hs.323662 0 1 602128860F1 cDNA, 5′ end/clone = IMAGE: 4285502 119B1 1598 2284 NM_014664 Hs.323712 0 2 KIAA0615 gene product (KIAA0615), mRNA/cds = ( 167H2 1410 3683 AB046771 Hs.323822 0 4 mRNA for KIAA1551 protein, partial cds/cds = (0 595C12 1 528 NM_021998 Hs.323950 0 6 zinc finger protein 6 (CMPX1) (ZNF6), mRNA/cd 462F1 1 356 AK026836 Hs.324060 1.00E−176 1 cDNA: FLJ23183 fis, clone LNG11477/cds = (226,7 122D10 217 424 AK026091 Hs.324187 2.00E−83 1 cDNA: FLJ22438 fis, clone HRC09232, highly sim 525B2 1028 3282 AL136739 Hs.324275 0 2 mRNA; cDNA DKFZp434D2111 (from clone DKFZp434D 459B6 3 482 BF668584 Hs.324342 0 1 602123634F1 cDNA, 5′ end/clone = IMAGE: 4280408 583D10 232 466 NM_021104 Hs.324406 1.00E−130 2 ribosomal protein L41 (RPL41), mRNA/cds = (83,1 118F8 2262 2819 NM_016824 Hs.324470 0 1 adducin 3 (gamma) (ADD3), transcript variant 1 461A5 46 391 AW968541 Hs.324481 1.00E−111 1 EST380617 cDNA/gb = AW968541/gi = 8158382/ug = 467F11 927 1189 NM_000817 Hs.324784 1.00E−147 1 glutamate decarboxylase 1 (brain, 67 kD) (GAD1 103E12 1686 1771 AK024863 Hs.325093 9.00E−42 1 cDNA: FLJ21210 fis, clone COL00479/cds = UNKNOW 521E11 4276 4689 AB028990 Hs.325530 0 1 mRNA for KIAA1067 protein, partial cds/cds = (0 480A9 112 333 AA760848 Hs.325874 1.00E−108 1 nz14f06.s1 cDNA, 3′ end/clone = IMAGE: 1287779 71G8 2619 2868 NM_001964 Hs.326035 1.00E−116 1 early growth response 1 (EGR1), mRNA/cds = (270, 593D6 742 3372 NM_004735 Hs.326159 0 4 leucine rich repeat (in FLII) interacting prot 463G9 42 608 AW975482 Hs.326165 0 1 EST387591 cDNA/gb = AW975482/gi = 8166696/ug = 526B12 2380 2639 U83857 Hs.326247 1.00E−143 2 Aac11 (aac11) mRNA, complete cds/cds = (77,1663)/ gb = 36A1 63 338 AA010282 NA 1.00E−116 1 zi08h07.r1 Soares_fetal_liver_spleen_1NFLS_S1 cDNA 459D10 67 164 AA044450 NA 3.00E−47 1 zk55a02.r1 Soares_pregnant_uterus_NbHPU cDNA clone 469E6 1 216 AA069335 NA 1.00E−104 1 zf74e10.r1 Soares_pineal_gland_N3HPG cDNA clone 463B2 4 205 AA077131 NA 4.00E−88 1 Brain cDNA Library cDNA clone 7B08E10 68H9 17 383 AA101212 NA 0 1 endothelial cell 937223 cDNA clone IMAGE: 549605 3′ 458F3 120 498 AA115345 NA 0 1 zl09f11.r1 Soares_pregnant_uterus_NbHPU cDNA clone 459E6 36 532 AA122297 NA 0 1 zk97a11.r1 Soares_pregnant_uterus_NbHPU cDNA clone 462C5 1 122 AA136584 NA 2.00E−59 1 fetal retina 937202 cDNA clone IMAGE: 565899 3′ 594A1 60 412 AA149078 NA 0 1 zl45e09.r1 Soares_pregnant_uterus_NbHPU cDNA clone 515A9 329 449 AA182528 NA 2.00E−46 1 NT2 neuronal precursor 937230 cDNA clone 75H4 7 371 AA187234 NA 1.00E−119 1 endothelial cell 937223 cDNA clone IMAGE: 624540 3′ 73F10 1 544 AA210786 NA 0 1 cDNA clone IMAGE: 682976 5′ 525D8 1 119 AA214691 NA 6.00E−60 1 Express cDNA library cDNA 5′ 37H4 250 401 AA243144 NA 3.00E−48 1 cDNA clone IMAGE: 685113 5′ 463B10 145 408 AA250809 NA 1.00E−123 1 cDNA clone IMAGE: 684374 5′ 464E10 1 303 AA251184 NA 1.00E−119 1 cDNA clone IMAGE: 684046 5′ 477H8 1 123 AA252909 NA 4.00E−58 3 cDNA clone IMAGE: 669292 5′ 465C3 1 279 AA258979 NA 1.00E−129 1 cDNA clone IMAGE: 687151 5′ 588G6 275 529 AA280051 NA 2.00E−94 1 cDNA clone IMAGE: 705062 5′ 465E9 74 429 AA282774 NA 0 1 cDNA clone IMAGE: 713136 5′ 459E7 49 466 AA283061 NA 0 1 cDNA clone IMAGE: 713078 5′ 164B4 41 329 AA284232 NA 1.00E−148 2 zc39c01.T7 Soares_senescent_fibroblasts_NbHSF cDNA 461G8 289 532 AA290921 NA 1.00E−123 1 cDNA clone IMAGE: 700335 5′ 470G7 29 441 AA290993 NA 0 1 cDNA clone IMAGE: 700425 5′ 500A12 1 519 AA307854 NA 1.00E−174 1 (HCC) cell line cDNA 5′ end similar to 471F4 9 326 AA309188 NA 1.00E−153 1 cDNA 194B6 134 467 AA312681 NA 1.00E−163 1 cDNA 5′ end 69F3 5 321 AA314369 NA 1.00E−176 1 (HCC) cell line II cDNA 5′ end similar 67G10 1 171 AA319163 NA 3.00E−64 2 cDNA 5′ end 99A5 1 287 AA322158 NA 1.00E−136 1 cDNA 5′ end similar to similar to tropomyosin 171B1 13 310 AA332553 NA 1.00E−135 1 cDNA 5′ end 485D11 46 210 AA360634 NA 2.00E−75 1 cDNA 5′ end 462G2 1 183 AA377352 NA 4.00E−89 2 cDNA 5′ end 523A8 1 407 AA397592 NA 0 1 cDNA clone IMAGE: 728546 5′ 171G10 1 409 AA401648 NA 0 2 cDNA clone IMAGE: 726936 5′ 100F5 42 172 AA402069 NA 4.00E−60 1 cDNA clone IMAGE: 727161 5′ 459H7 48 375 AA412436 NA 1.00E−163 1 cDNA clone IMAGE: 731446 5′ 102A8 25 120 AA418765 NA 1.00E−46 1 cDNA clone IMAGE: 767795 5′ 73A3 1 424 AA426506 NA 0 1 cDNA clone IMAGE: 768117 5′ 72E10 1 442 AA427653 NA 0 11 tumor NbHOT cDNA clone IMAGE: 770045 5′ 72A1 1 261 AA429783 NA 1.00E−142 1 zw57b01.r1 Soares_total_fetus_Nb2HF8_9w cDNA clone 460D12 126 388 AA431959 NA 1.00E−93 1 cDNA clone IMAGE: 782188 3′ 450B11 1 437 AA454987 NA 0 1 cDNA clone IMAGE: 811916 5′ 518A8 1 329 AA457757 NA 1.00E−177 1 fetal retina 937202 cDNA clone IMAGE: 838756 5′ 460F7 47 490 AA460876 NA 0 1 zx69d04.r1 Soares_total_fetus_Nb2HF8_9w cDNA clone 118H12 1 304 AA476568 NA 1.00E−163 1 zx02f11.r1 Soares_total_fetus_Nb2HF8_9w cDNA clone 40F11 1 533 AA479163 NA 0 1 cDNA clone IMAGE: 754246 5′ similar to gb: X15606 470F3 76 356 AA482019 NA 1.00E−142 1 cDNA clone IMAGE: 746046 3′ 466C2 1 354 AA490796 NA 1.00E−148 1 cDNA clone IMAGE: 82101 5′ 464A9 228 364 AA496483 NA 7.00E−71 1 tumor NbHOT cDNA clone IMAGE: 755690 5′ similar to 123D11 99 297 AA501725 NA 1.00E−103 1 cDNA clone IMAGE: 929806 similar to contains Alu 119G10 128 374 AA501934 NA 1.00E−134 1 cDNA clone IMAGE: 956346 166A11 19 140 AA516406 NA 1.00E−48 1 cDNA clone IMAGE: 923858 3′ 36G1 5 480 AA524720 NA 0 1 cDNA clone IMAGE: 937468 3′ 109H9 37 286 AA573427 NA 1.00E−130 2 cDNA clone IMAGE: 1028913 3′ 477B2 8 273 AA579400 NA 1.00E−143 1 cDNA clone IMAGE: 915561 similar to contains Alu 178C10 1 354 AA588755 NA 1.00E−177 1 cDNA clone IMAGE: 1084243 3′ 486G7 35 99 AA613460 NA 6.00E−28 1 cDNA clone IMAGE: 1144571 similar to contains 472E9 27 389 AA628833 NA 1 .00E−119 1 af37g04.s1 Soares_total_fetus_Nb2HF8_9w cDNA clone 100C3 122 505 AA639796 NA 0 1 cDNA clone IMAGE: 1159029 3′ 518A7 39 226 AA665359 NA 4.00E−83 1 cDNA clone IMAGE: 1205697 similar to 473D9 377 446 AA683244 NA 1.00E−30 1 schizo brain S11 cDNA clone IMAGE: 971252 3′ 523D7 80 502 AA701667 NA 1.00E−158 1 zi43g09.s1 Soares_fetal_liver_spleen_1NFLS_S1 cDNA 472B1 37 130 AA744774 NA 1.00E−35 1 cDNA clone IMAGE: 1283731 3′ 98C9 10 254 AA748714 NA 1.00E−111 1 cDNA clone IMAGE: 1270595 3′ 196D7 3 442 AA806222 NA 0 1 cDNA clone IMAGE: 1409989 3′ 118A8 10 381 AA806766 NA 0 1 cDNA clone IMAGE: 1338727 3′ 98B3 56 159 AA826572 NA 7.00E−47 1 cDNA clone IMAGE: 1416447 3′ 154D9 38 405 AA846378 NA 1.00E−164 1 cDNA clone IMAGE: 1394232 3′ 459C2 1 491 AA909983 NA 0 2 Soares_NFL_T_GBC_S1 cDNA clone IMAGE: 1523142 3′ 486A7 1 176 AA916990 NA 1.00E−72 1 Soares_NFL_T_GBC_S1 cDNA clone IMAGE: 1527333 3′ 460D2 78 537 AA923567 NA 0 1 cDNA clone IMAGE: 1536231 3′ 105F4 86 390 AA974839 NA 4.00E−94 1 cDNA clone IMAGE: 1567639 3′ 461H7 295 383 AA974991 NA 2.00E−30 1 Soares_NFL_T_GBC_S1 cDNA clone IMAGE: 1560953 3′ 162B1 398 470 AA976045 NA 9.00E−28 1 cDNA clone IMAGE: 1558392 3′ 53D8 1 422 AA984245 NA 1.00E−162 1 schizo brain S11 cDNA clone IMAGE: 1629672 3′ 524A5 3568 4037 AB020681 NA 0 1 mRNA for KIAA0874 protein, partial cds Length = 4440 174H3 81 271 AB021288 NA 1.00E−101 1 mRNA for beta 2-microglobulin, complete cds Length = 925 115A2 1920 2309 AB034747 NA 0 4 SIMPLE mRNA for small integral membrane protein of lysosome/late endos 39G7 1578 1920 AB040875 NA 1 .00E−135 3 hxCT mRNA for cystine/glutamate exchanger, complete cds Length = 2000 149H2 430 713 AB044971 NA 1.00E−158 1 mRNA for nucleolar phosphoprotein Nopp34, complete cds Length = 1005 458F6 780 1235 AB045118 NA 0 1 FRAT2 mRNA, complete cds Length = 2164 459D12 2694 3564 AB045278 NA 0 2 beta3GnT5 mRNA for beta1,3-N- acetylglucosaminyltransferase 5, complete 103H7 1294 1933 AB049881 NA 1.00E−139 1 similar to Macaca fascicularis brain cDNA, clone: QnpA 18828 Length = 2517 102E11 1142 1772 AB050511 NA 0 1 similar to Macaca fascicularis brain cDNA, clone: QnpA- 18828 Length = 2518 460C3 798 930 AB050514 NA 9.00E−54 1 similar to Macaca fascicularis brain cDNA, clone: QnpA- 18828 Length = 2519 480A10 4649 5183 AB058677 NA 0 1 mRNA for MEGF11 protein (KIAA1781), complete cds Length = 5702 142G10 2251 2430 AB060884 NA 6.00E−44 1 similar to Macaca fascicularis brain cDNA clone: QtrA- 13024, full insert sequence 494G5 1585 1998 AF005213 NA 0 1 ankyrin 1 (ANK1) mRNA, complete cds Length = 2651 154C6 520 826 AF005775 NA 1.00E−150 3 caspase-like apoptosis regulatory protein 2 (clarp) mRNA, alternativel 186B6 772 1248 AF039575 NA 0 1 heterogeneous nuclear ribonucleoprotein D0B mRNA partial cds 471A4 395 611 AF061944 NA 6.00E−84 1 kinase deficient protein KDP mRNA, partial cds Length = 2653 37G5 277 525 AF067529 NA 1.00E−129 1 PITSLRE protein kinase beta SV18 isoform (CDC2L2) mRNA, partial cds 479D1 1270 1570 AF070635 NA 1.00E−144 1 clone 24818 mRNA sequence Length = 1643 491E2 38 226 AF086214 NA 9.00E−74 1 full length insert cDNA clone ZD64D04 Length = 691 517C2 230 465 AF086431 NA 1.00E−113 1 full length insert cDNA clone ZD79H10 Length = 530 593C6 1 359 AF113210 NA 0 5 MSTP030 mRNA, complete cds Length = 1024 191A8 135 1169 AF113213 NA 0 3 MSTP033 mRNA, complete cds Length = 1281 144E9 799 943 AF116679 NA 9.00E−29 1 PRO2003 mRNA, complete cds Length = 1222 106E3 583 1187 AF116702 NA 0 2 PRO2446 mRNA, complete cds Length = 1356 72F8 878 1205 AF130094 NA 1.00E−175 1 clone FLC0165 mRNA sequence Length = 1548 458G9 730 1463 AF157116 NA 0 1 clone 274512, mRNA sequence Length = 2172 139F11 18 229 AF161430 NA 1.00E−115 1 HSPC312 mRNA, partial cds Length = 360 149H10 406 621 AF161455 NA 3.00E−95 2 HSPC337 mRNA, partial cds Length = 1033 68A9 19 243 AF173954 NA 2.00E−27 1 Cloning vector pGEM-URA3, complete sequence Length = 4350 165B7 65 418 AF202092 NA 0 1 PC3-96 mRNA, complete cds Length = 1068 52H1 361 594 AF212226 NA 1.00E−34 1 RPL24 mRNA, complete cds Length = 1474 162H8 52 404 AF212233 NA 1.00E−179 1 microsomal signal peptidase subunit mRNA, complete cds Length = 794 54E10 680 1316 AF212241 NA 0 3 CDA02 mRNA, complete cds Length = 2179 117D8 2052 2482 AF248648 NA 0 3 RNA-binding protein BRUNOL2 mRNA, complete cds Length = 2615 75E3 326 662 AF249845 NA 0 2 isolate Siddi 10 hypervariable region 1, mitochondrial sequence 459G12 791 1267 AF260237 NA 0 1 hairy/enhancer of split 6 (HES6) mRNA, complete cds Length = 1286 177F6 1968 2423 AF267856 NA 0 1 HT033 mRNA, complete cds Length = 2972 115G8 996 1399 AF267863 NA 0 1 DC43 mRNA, complete cds Length = 2493 501H3 426 1152 AF279437 NA 0 107 interleukin 22 (IL22) mRNA, complete cds Length = 1167 174B4 900 1332 AF283771 NA 0 2 clone TCBAP0774 mRNA sequence Length = 1814 126C7 454 843 AF332864 NA 1.00E−116 2 similar to Mus Ras association domain family 3 protein (Rassf3) mRNA 105A9 232 624 AF333025 NA 1.00E−140 1 prokineticin 2 precursor (PROK2) mRNA, complete cds Length = 1406 186F1 4543 5058 AF347010 NA 0 3 mitochondrion, complete genome Length = 16570 590B12 4684 5053 AF347013 NA 0 1 mitochondrion, complete genome Length = 16566 517H7 4669 5058 AF347015 NA 0 1 mitochondrion, complete genome Length = 16571 596E9 220 295 AI027844 NA 3.00E−34 1 cDNA clone IMAGE: 1671612 3′ 599B3 608 609 AI039890 NA 1.00E−45 1 ox97d11.x1 Soares_senescent_fibroblasts_NbHSF cDNA 189H9 22 524 AI041828 NA 0 1 oy34b08.x1 Soares_parathyroid_tumor_NbHPA cDNA clone 471F6 63 526 AI084224 NA 0 1 cDNA clone IMAGE: 1671418 3′ 142E9 6 372 AI091533 NA 1.00E−179 1 oo23d05.x1 Soares_NSF_F8_9W_OT_PA_P_S1 cDNA clone 72D2 65 529 AI131018 NA 0 6 qb82e07.x1 Soares_fetal_heart_NbHH19W cDNA clone 468F6 9 428 AI223400 NA 0 1 cDNA clone IMAGE: 1838447 3′ similar to TR: O15383 185H1 94 199 AI267714 NA 5.00E−50 1 SB pool 1 cDNA clone IMAGE: 2038526 166A9 1 480 AI275205 NA 0 1 cDNA clone IMAGE: 1990616 3′ 499F2 4 395 AI281442 NA 0 2 cDNA clone IMAGE: 1967452 3′ 517H5 155 457 AI298509 NA 1.00E−158 1 cDNA clone IMAGE: 1896546 3′ 144F7 24 364 AI299573 NA 0 1 cDNA clone IMAGE: 1900105 3′ 519E9 52 408 AI352690 NA 1.00E−180 1 cDNA clone IMAGE: 1946884 3′ 466F9 172 440 AI361839 NA 1.00E−109 1 cDNA clone IMAGE: 2022012 3′ 144C9 118 373 AI362793 NA 7.00E−63 1 cDNA clone IMAGE: 2018948 3′ similar to gb: M60854 464B11 19 455 AI363001 NA 0 1 cDNA clone IMAGE: 2018452 3′ similar to contains 127B6 40 257 AI370412 NA 6.00E−96 1 cDNA clone IMAGE: 1987587 3′ 166C4 58 271 AI371227 NA 1.00E−62 1 cDNA clone IMAGE: 1987633 3′ similar to 467G7 1 450 AI380016 NA 0 1 cDNA clone IMAGE: 2109169 3′ similar to 466C5 316 497 AI380390 NA 8.00E−44 1 cDNA clone IMAGE: 2107088 3′ 466B5 200 477 AI381586 NA 1.00E−126 1 cDNA clone IMAGE: 2074796 3′ 458G10 347 444 AI384128 NA 2.00E−40 1 cDNA clone IMAGE: 2088819 3′ similar to contains 467A8 415 522 AI391500 NA 1.00E−41 1 cDNA clone IMAGE: 2107686 3′ 477D1 14 269 AI392705 NA 1.00E−137 2 cDNA clone IMAGE: 2109581 3′ 467B11 1 293 AI393970 NA 1.00E−122 1 cDNA clone IMAGE: 2107950 3′ 522D3 250 526 AI419082 NA 1.00E−127 1 cDNA clone IMAGE: 2103029 3′ 149A11 25 313 AI440491 NA 1.00E−132 1 cDNA clone IMAGE: 2073277 3′ 471C1 77 215 AI458739 NA 1.00E−50 1 cDNA clone IMAGE: 2149471 3′ similar to gb: S85655 116E10 162 503 AI469584 NA 1.00E−171 1 cDNA clone IMAGE: 2156522 3′ 472C8 1 369 AI498316 NA 0 1 cDNA clone IMAGE: 2160886 3′ similar to TR: Q62717 468E8 2 451 AI523854 NA 3.00E−92 1 cDNA clone IMAGE: 2116683 3′ 477B5 23 295 AI524624 NA 2.00E−86 1 cDNA clone IMAGE: 2075323 3′ 193H3 368 489 AI525644 NA 4.00E−34 1 cDNA 5′ 66F1 277 436 AI571519 NA 7.00E−84 2 cDNA clone IMAGE: 2225079 3′ similar to gb: J03909 171A11 225 429 AI581199 NA 1.00E−101 3 cDNA clone IMAGE: 2154787 3′ similar to 116F2 337 429 AI597917 NA 4.00E−42 1 cDNA clone IMAGE: 2258495 3′ similar to contains 461G10 9 398 AI627495 NA 1.00E−179 1 cDNA clone IMAGE: 2285386 3′ 594D11 206 434 AI628930 NA 1.00E−110 1 cDNA clone IMAGE: 2281541 3′ similar to 489H9 1 507 AI633798 NA 0 4 cDNA clone IMAGE: 2242115 3′ 171G7 212 431 AI634972 NA 1.00E−103 1 cDNA clone IMAGE: 2284157 3′ 165C12 270 581 AI651212 NA 1.00E−175 1 cDNA clone IMAGE: 2304186 3′ 64B3 1 529 AI678099 NA 0 1 Soares_NFL_T_GBC_S1 cDNA clone IMAGE: 2330166 3′ 134H3 186 289 AI684022 NA 1.00E−34 1 cDNA clone IMAGE: 2267411 3′ 110B8 169 496 AI688560 NA 1.00E−132 1 Soares_NFL_T_GBC_S1 cDNA clone IMAGE: 2330535 3′ 459F2 160 542 AI697756 NA 0 1 cDNA clone IMAGE: 2341330 3′ 481F11 21 340 AI700738 NA 1.00E−167 1 cDNA clone IMAGE: 2343628 3′ 488C5 37 533 AI701165 NA 0 4 cDNA clone IMAGE: 2340734 3′ 104D9 116 241 AI709236 NA 4.00E−60 1 HPLRB6 cDNA clone IMAGE: 2353865 3′ similar to 112E1 18 576 AI742850 NA 0 1 wg47a05.x1 Soares_NSF_F8_9W_OT_PA_P_S1 cDNA clone 113H12 5 140 AI748827 NA 1.00E−63 1 HPLRB6 cDNA clone IMAGE: 2356401 3′ 458B8 150 474 AI760353 NA 0 1 cDNA clone IMAGE: 2387703 3′ 461H11 334 578 AI762870 NA 1.00E−111 1 cDNA clone IMAGE: 2397996 3′ 458D10 1 465 AI765153 NA 0 1 cDNA clone IMAGE: 2393531 3′ 38B5 2 295 AI766963 NA 1.00E−140 1 cDNA clone IMAGE: 2400693 3′ 471A2 320 394 AI796317 NA 2.00E−31 1 cDNA clone IMAGE: 2384100 3′ 74D10 15 377 AI802547 NA 1.00E−124 2 cDNA clone IMAGE: 2186739 3′similar to TR: O15510 482C9 117 409 AI803065 NA 1.00E−164 1 tj47a07.x1 Soares_NSF_F8_9W_OT_PA_P_S1 cDNA clone 480C5 177 517 AI807278 NA 0 1 Soares_NFL_T_GBC_S1 cDNA clone IMAGE: 2357909 3′ 175B12 228 513 AI817153 NA 1.00E−132 1 cDNA clone IMAGE: 2413005 3′ 66E10 14 268 AI858771 NA 1.00E−119 1 cDNA clone IMAGE: 2429769 3′ 470H6 65 500 AI880607 NA 0 1 HPLRB6 cDNA clone IMAGE: 2355013 3′ 181D12 7 512 AI884548 NA 0 1 cDNA clone IMAGE: 2437818 3′similar to gb: L06797 468H6 52 528 AI884671 NA 0 1 cDNA clone IMAGE: 2431488 3′ 597C9 284 383 AI904071 NA 1.00E−48 1 cDNA 467C2 206 351 AI917642 NA 2.00E−59 1 cDNA clone IMAGE: 2392330 3′ 459D1 25 575 AI948513 NA 0 1 cDNA clone IMAGE: 2470532 3′ 166E11 152 280 AI954499 NA 4.00E−54 1 cDNA clone IMAGE: 2550263 3′ 493D7 2032 2171 AJ001235 NA 4.00E−29 1 similar to Papio hamadryas ERV-9 like LTR insertion Length = 2240 116B1 1169 1744 AJ009771 NA 0 1 mRNA for putative RING finger protein, partial Length = 3038 137B9 296 407 AJ271637 NA 4.00E−32 1 similar to Elaeis guineensis microsatellite DNA, clone mEgCIR0219 483E6 4250 4492 AJ278191 NA 1.00E−95 1 similar to Mus musculus mRNA for putative mc7 protein (mc7 gene) 144A8 988 1152 AK001163 NA 1.00E−75 1 cDNA FLJ10301 fis, clone NT2RM2000032 Length = 1298 525C11 49 496 AK001451 NA 0 1 cDNA FLJ10589 fis, clone NT2RP2004389 177D9 707 980 AK004265 NA 7.00E−76 1 similar to Mus 18 days embryo cDNA, RIKEN full- length enriched library, 111E10 777 1121 AK004400 NA 1.00E−112 1 similar to Mus 18 days embryo cDNA, RIKEN full- length enriched library, 458G4 650 1259 AK008020 NA 8.00E−86 1 similar to Mus adult male small intestine cDNA, RIKEN full-length enrich 47G7 31 328 AK009988 NA 1.00E−111 1 similar to Mus adult male tongue cDNA, RIKEN full- length enriched librar 69G7 1801 1987 AK012426 NA 5.00E−68 3 similar to Mus 11 days embryo cDNA, RIKEN full- length enriched library, 62C10 1092 1267 AK013164 NA 6.00E−46 2 similar to Mus 10, 11 days embryo cDNA, RIKEN full- length enriched libra 46D9 3243 3564 AK014408 NA 1.00E−104 1 similar to Mus 12 days embryo embryonic body below diaphragm region 1078C11 2069 2326 AK016683 NA 9.00E−83 1 similar to Mus adult male testis cDNA, RIKEN full- length enriched librar 102C12 698 1339 AK018758 NA 0 1 similar to Mus adult male liver cDNA, RIKEN full- length enriched library 585B3 1278 1873 AK021925 NA 0 1 cDNA FLJ11863 fis, clone HEMBA1006926 Length = 2029 46F3 1377 2006 AK022057 NA 0 1 cDNA FLJ11995 fis, clone HEMBB1001443, highly similar to Rattus norveg 73E7 344 1112 AK023512 NA 0 9 cDNA FLJ13450 fis, clone PLACE1003027, highly similar to Homo sapiens 465B12 681 1338 AK024202 NA 0 1 cDNA FLJ14140 fis, clone MAMMA1002858, highly similar to Rat cMG1 142D12 254 358 AK024740 NA 9.00E−27 1 cDNA: FLJ21087 fis, clone CAS03323 Length = 826 472F7 1330 1623 AK024764 NA 1.00E−164 1 cDNA: FLJ21111 fis, clone CAS05384, highly similar to AF144700 Homo sa 521A3 26 195 AK024976 NA 2.00E−90 1 cDNA: FLJ21323 fis, clone COL02374 Length = 1348 465D1 2091 2255 AK025769 NA 1.00E−74 1 cDNA: FLJ22116 fis, clone HEP18520 Length = 2271 595E9 16 546 AK026264 NA 0 1 cDNA: FLJ22611 fis, clone HSI04961 Length = 1426 103E1 1353 1866 AK026334 NA 1.00E−126 1 cDNA: FLJ22681 fis, clone HSI10693 Length = 1903 524F3 1635 1742 AK026443 NA 9.00E−51 2 cDNA: FLJ22790 fis, clone KAIA2176, highly similar to HUMPMCA 196H10 938 1286 AK026819 NA 6.00E−82 1 cDNA: FLJ23166 fis, clone LNG09880 Length = 1941 172F7 349 738 AK027258 NA 0 1 cDNA: FLJ23605 fis, clone LNG15982, highly similar to AF113539 Homo sa 187B10 1583 2142 AK027260 NA 1.00E−129 1 cDNA: FLJ23607 fis, clone LNG16050 Length = 2560 190F11 76 636 AL042081 NA 0 1 (synonym: htes3) cDNA clone DKFZp434P171 3′ 525A9 1 653 AL042370 NA 0 1 (synonym: htes3) cDNA clone DKFZp434A1821 5′ 464G8 59 686 AL042376 NA 0 1 (synonym: htes3) cDNA clone DKFZp434A2421 5′ 172B12 380 624 AL047171 NA 1.00E−131 1 (synonym: hute1) cDNA clone DKFZp586F2018 5′ 193F3 915 1309 AL049305 NA 1.00E−133 1 mRNA; cDNA DKFZp564A186 (from clone DKFZp564A186) Length = 1669 111H8 102 660 AL049356 NA 1.00E−146 1 mRNA; cDNA DKFZp566E233 (from clone DKFZp566E233) Length = 808 526E6 118 551 AL049932 NA 1.00E−147 2 mRNA; cDNA DKFZp564H2416 (from clone DKFZp564H2416) Length = 1865 37C8 707 996 AL050218 NA 1.00E−156 1 mRNA; cDNA DKFZp586I0923 (from clone DKFZp58610923) Length = 1282 72A9 1235 1391 AL110164 NA 2.00E−70 1 mRNA; cDNA DKFZp586I0324 (from clone DKFZp586I0324) Length = 1705 107C8 1042 1398 AL117644 NA 0 2 mRNA; cDNA DKFZp434M095 (from clone DKFZp434M095) Length = 1455 62E7 1 475 AL120453 NA 1.00E−117 1 (synonym: hamy2) cDNA clone DKFZp761I208 5′ 492A7 77 390 AL121406 NA 1.00E−101 1 (synonym: hmel2) cDNA clone DKFZp762G117 5′ 598B1 443 812 AL133879 NA 1.00E−172 1 (synonym: hamy2) cDNA clone DKFZp761J0114 5′ 458C10 47 351 AL133913 NA 5.00E−76 1 (synonym: hamy2) cDNA clone DKFZp761M2014 5′ 98E7 922 2284 AL136558 NA 0 6 mRNA; cDNA DKFZp761B1514 (from clone DKFZp761B1514) Length = 3453 157F6 3511 3847 AL136797 NA 0 1 mRNA; cDNA DKFZp434N031 (from clone DKFZp434N031); complete cds 68B4 1009 1595 AL136932 NA 0 1 mRNA; cDNA DKFZp586H1322 (from clone DKFZp586H1322); complete cds 458B6 278 955 AL137601 NA 0 1 mRNA; cDNA DKFZp434E0811 (from clone DKFZp434E0811); partial cds 172C9 1866 2423 AL137608 NA 0 1 mRNA; cDNA DKFZp434J1111 (from clone DKFZp434J1111); partial cds 72G1 194 474 AL138429 NA 1.00E−151 1 (synonym: htes3) cDNA clone DKFZp434E0629 3′ 463H12 12 356 AL513780 NA 1.00E−124 1 cDNA clone CL0BA003ZF07 5 prime 181B6 43 638 AL520535 NA 0 1 cDNA clone CS0DB006YD20 3 prime 69B6 352 858 AL520892 NA 0 1 cDNA clone CS0DB002YG16 5 prime 182A5 119 617 AL521097 NA 0 1 cDNA clone CS0DB001YA13 3 prime 458E9 3 865 AL528020 NA 0 2 cDNA clone CS0DC028YO09 3 prime 485C11 1 431 AL532303 NA 0 1 cDNA clone CS0DM014YJ04 5 prime 196G3 78 698 AL532406 NA 0 1 cDNA clone CS0DM014YL03 5 prime 105H4 154 486 AL533737 NA 1.00E−156 1 cDNA clone CS0DF002YH09 5 prime 594G1 337 756 AL534564 NA 0 1 cDNA clone CS0DF004YI09 5 prime 524A9 403 906 AL540260 NA 0 1 cDNA clone CS0DF032YF03 3 prime 118H5 433 532 AL540399 NA 4.00E−39 1 cDNA clone CS0DE001YM08 5 prime 124C2 270 815 AL543900 NA 0 1 cDNA clone CS0DI005YK13 3 prime 471D3 216 403 AL550229 NA 9.00E−49 1 cDNA clone CS0DI039YD11 5 prime 191F2 324 844 AL554506 NA 0 1 cDNA clone CS0DI083YJ17 5 prime 166F6 64 576 AL556016 NA 0 1 cDNA clone CS0DK010YH04 5 prime 467G9 61 401 AL556919 NA 1.00E−138 1 cDNA clone CS0DK012YI02 5 prime 37D7 149 685 AL559029 NA 0 1 cDNA clone CS0DJ010YJ11 5 prime 590B3 76 287 AL559422 NA 1.00E−111 2 cDNA clone CS0DJ013YN07 5 prime 181H2 168 780 AL559555 NA 0 1 cDNA clone CS0DJ013YP21 5 prime 589E3 28 447 AL561074 NA 0 1 cDNA clone CS0DL001YN01 5 prime 487F9 326 739 AL561892 NA 1.00E−149 1 cDNA clone CS0DB006YL04 3 prime 68F10 12 658 AL562895 NA 0 1 cDNA clone CS0DC021YO20 3 prime 157D7 2 108 AL565736 NA 1.00E−28 1 cDNA clone CS0DF007YC06 3 prime 177B1 231 505 AL567986 NA 1.00E−128 1 cDNA clone CS0DF036YI04 3 prime 512E3 627 815 AL575666 NA 1.00E−94 1 cDNA clone CS0DI069YD02 3 prime 112E10 193 623 AL575755 NA 0 1 cDNA clone CS0DI070YG17 3 prime 70H7 197 757 AL576149 NA 0 1 cDNA clone CS0DI072YK21 3 prime 37F1 275 411 AL577970 NA 1.00E−43 1 cDNA clone CS0DK008YK22 3 prime 65D4 278 828 AL578975 NA 0 1 cDNA clone CS0DK012YN01 3 prime 182G2 70 684 AL579745 NA 0 1 cDNA clone CS0DJ003YG20 5 prime 194F9 450 669 AL582354 NA 3.00E−94 1 cDNA clone CS0DL006YH05 3 prime 184F2 27 501 AL583322 NA 2.00E−37 1 cDNA clone CS0DL012YI10 5 prime 40A3 432 638 AL583391 NA 4.00E−83 1 cDNA clone CS0DL012YA12 3 prime 53G7 6 462 AU117298 NA 0 1 sapiens cDNA clone HEMBA1001091 5′ 37G7 218 706 AU118159 NA 0 1 sapiens cDNA clone HEMBA1002998 5′ 180F9 174 698 AU120731 NA 0 1 sapiens cDNA clone HEMBB1001298 5′ 191F1 298 608 AU135154 NA 1.00E−137 1 sapiens cDNA clone PLACE1001348 5′ 466G7 11 125 AU158636 NA 1.00E−53 1 sapiens cDNA clone PLACE4000063 3′ 67F9 1 453 AV648670 NA 0 2 cDNA clone GLCBLH08 3′ 155D6 97 337 AV650434 NA 1.00E−104 1 cDNA clone GLCCEG06 3′ 596H6 1 397 AV651615 NA 0 1 cDNA clone GLCCRF09 3′ 99D5 41 232 AV653169 NA 6.00E−78 1 cDNA clone GLCDIB01 3′ 331C10 33 365 AV654188 NA 1.00E−103 6 cDNA clone GLCDTC01 3′ 121A12 70 188 AV659358 NA 3.00E−47 1 cDNA clone GLCFWC05 3′ 460G9 69 476 AV687530 NA 0 1 cDNA clone GKCATH08 5′ 470F5 1 174 AV689330 NA 2.00E−50 1 cDNA clone GKCDJE03 5′ 109E8 71 471 AV705900 NA 0 1 cDNA clone ADBBFE11 5′ 166C9 121 226 AV709955 NA 2.00E−26 1 cDNA clone ADCABF08 5′ 117F1 69 582 AV710415 NA 0 1 cDNA clone CuAAND10 5′ 523C9 41 536 AV716565 NA 0 6 cDNA clone DCBCAF01 5′ 103D7 1 164 AV716644 NA 3.00E−77 2 cDNA clone DCBAUG10 5′ 195F11 232 459 AV716791 NA 1.00E−113 2 cDNA clone DCBAZC04 5′ 63C4 208 421 AV719659 NA 1.00E−101 1 cDNA clone GLCGRA09 5′ 496C4 156 563 AV719938 NA 0 1 cDNA clone GLCFUC08 5′ 479A1 120 469 AV720984 NA 1.00E−162 1 cDNA clone HTBBIC02 5′ 499D6 70 406 AV721008 NA 1.00E−112 4 cDNA clone HTBBHG03 5′ 461C8 182 676 AV723437 NA 0 1 cDNA clone HTBBUE10 5′ 585G1 173 552 AV724531 NA 0 1 cDNA clone HTBARD04 5′ 113B8 1 149 AV724559 NA 3.00E−40 1 cDNA clone HTBCFB08 5′ 111H4 497 498 AV724665 NA 0 1 cDNA clone HTBAYG03 5′ 458F5 1 534 AV730135 NA 0 1 cDNA clone HTFAHA06 5′ 589F6 21 226 AV735258 NA 6.00E−70 1 cDNA clone cdAAIF03 5′ 172C8 209 426 AV738173 NA 9.00E−98 1 cDNA clone CBMAHC04 5′ 464G3 43 498 AV743635 NA 0 1 cDNA clone CBLBAC03 5′ 72D4 43 384 AV745692 NA 1.00E−178 2 cDNA clone NPAACB06 5′ 592G12 175 571 AV749844 NA 1.00E−176 1 cDNA clone NPCBVG08 5′ 169F6 110 250 AV755117 NA 3.00E−28 1 cDNA cloneTPAABA12 5′ 99H3 200 513 AV755367 NA 1.00E−131 2 cDNA clone BMFAIB02 5′ 595G9 399 549 AV756188 NA 2.00E−31 1 cDNA clone BMFABD08 5′ 595A12 8 572 AW002985 NA 0 2 cDNA clone IMAGE: 2475831 3′ 586B7 184 330 AW004905 NA 8.00E−50 1 cDNA clone IMAGE: 2565317 3′ similar to 591D6 15 436 AW021037 NA 0 1 Cochlea cDNA clone IMAGE: 2483601 5′ 188F1 135 476 AW021551 NA 0 1 Cochlea cDNA clone IMAGE: 2484414 5′ 467E8 73 474 AW027160 NA 1.00E−162 1 Soares_thymus_NHFTh cDNA clone IMAGE: 2512983 3′ similar to 472G2 11 110 AW064187 NA 9.00E−38 1 CD4 intrathymic T-cell cDNA library cDNA 3′ 598F3 43 453 AW071894 NA 0 1 cDNA clone IMAGE: 2501169 3′ 181C7 10 96 AW131768 NA 8.00E−41 1 cDNA clone IMAGE: 2619947 3′ 181D1 69 216 AW134512 NA 2.00E−77 1 UI-H-BI1-abv-e-05-0-UI.s1 NCI_CGAP_Sub3 cDNA clone IMAGE: 2713065 3′ 472B10 339 458 AW136717 NA 4.00E−54 1 UI-H-BI1-adm-a-03-0-UI.s1 NCI_CGAP_Sub3 cDNA clone IMAGE: 2717092 3′ 166B9 240 408 AW137104 NA 6.00E−88 1 UI-H-BI1-acp-e-02-0-UI.s1 NCI_CGAP_Sub3 cDNA clone IMAGE: 2714979 3′ 188C1 323 461 AW137149 NA 2.00E−72 1 UI-H-BI1-acq-a-05-0-UI.s1 NCI_CGAP_Sub3 cDNA clone IMAGE: 2715152 3′ 65B2 106 298 AW148765 NA 7.00E−75 1 cDNA clone IMAGE: 2616915 3′ 524C3 234 429 AW151854 NA 1.00E−76 2 cDNA clone IMAGE: 2623546 3′ similar to 479A8 6 327 AW161820 NA 1.00E−151 1 brain 00004 cDNA clone IMAGE: 2781653 3′ 585E10 7 391 AW166442 NA 0 1 Soares_NHCe_cervix cDNA clone IMAGE: 269740 3′ 482C6 9 329 AW188398 NA 1.00E−133 1 cDNA clone IMAGE: 2665252 3′ 522G11 39 516 AW248322 NA 0 1 cDNA clone IMAGE: 2820662 5′ 473D5 283 416 AW274156 NA 4.00E−69 1 Soares_NFL_T_GBC_S1 cDNA clone IMAGE: 2814367 3′ 71C12 20 530 AW293159 NA 0 2 UI-H-BW0-aii-b-08-0-UI.s1 NCI_CGAP_Sub6 cDNA clone IMAGE: 2729414 3′ 472H11 205 501 AW293424 NA 1.00E−151 1 UI-H-BI2-ahm-a-12-0-UI.s1 NCI_CGAP_Sub4 cDNA clone IMAGE: 2727094 3′ 465H11 17 124 AW293426 NA 1.00E−48 1 UI-H-BI2-ahm-b-02-0-UI.s1 NCI_CGAP_Sub4 cDNA clone IMAGE: 2727122 3′ 461H8 19 452 AW295965 NA 0 1 UI-H-BI2-ahh-f-07-0-UI.s1 NCI_CGAP_Sub4 cDNA clone IMAGE: 2726917 3′ 464B7 250 551 AW300500 NA 3.00E−95 1 cDNA clone IMAGE: 2774602 3′ 465C7 1 322 AW338115 NA 0 1 cDNA clone IMAGE: 2833029 3′ 466H5 10 523 AW341449 NA 0 1 Soares_NFL_T_GBC_S1 cDNA clone IMAGE: 2909026 3′ similar to 461D9 12 325 AW379049 NA 1.00E−134 1 HT0230 cDNA 186E8 51 277 AW380881 NA 1.00E−103 1 HT0283 cDNA 180D4 260 348 AW384988 NA 2.00E−30 1 HT0427 cDNA 472C1 13 404 AW390233 NA 1.00E−122 1 ST0181 cDNA 462G12 236 321 AW402007 NA 3.00E−40 1 UI-HF-BK0-aao-g-02-0-UI.r1 NIH_MGC_36 cDNA clone IMAGE: 3054530 5′ 177H2 18 338 AW405863 NA 9.00E−52 1 UI-HF-BL0-acf-e-06-0-UI.r1 NIH_MGC_37 cDNA clone IMAGE: 3059026 5′ 140G10 6 308 AW440517 NA 1.00E−152 1 cDNA clone IMAGE: 2890615 3′ 482A10 1 231 AW440869 NA 1.00E−114 1 cDNA clone IMAGE: 2918151 3′ similar to contains 40B2 18 353 AW444632 NA 4.00E−45 1 UI-H-BI3-ajw-b-11-0-UI.s1 NCI_CGAP_Sub5 cDNA clone IMAGE: 2733260 3′ 61C2 21 392 AW444812 NA 0 1 UI-H-BI3-ajy-d-11-0-UI.s1 NCI_CGAP_Sub5 cDNA clone IMAGE: 2733380 3′ 461H10 151 248 AW449610 NA 8.00E−48 1 UI-H-BI3-aku-g-11-0-UI.s1 NCI_CGAP_Sub5 cDNA clone IMAGE: 2735804 3′ 479E10 9 425 AW451293 NA 0 1 UI-H-BI3-alh-f-06-0-UI.s1 NCI_CGAP_Sub5 cDNA clone IMAGE: 2736899 3′ 489G6 16 303 AW452023 NA 1.00E−125 1 UI-H-BI3-alm-f-06-0-UI.s1 NCI_CGAP_Sub5 cDNA clone IMAGE: 2737306 3′ 463H8 99 289 AW452096 NA 1.00E−103 1 UI-H-BI3-alo-d-02-0-UI.s1 NCI_CGAP_Sub5 cDNA clone IMAGE: 3068186 3′ 459B8 71 535 AW499658 NA 0 1 UI-HF-BR0p-ajj-c-07-0-UI.r1 NIH_MGC_52 cDNA clone IMAGE: 3074677 5′ 37A2 128 395 AW499828 NA 1.00E9−110 I UI-HF-BN0-ake-c-06-0-UI.rl NIH_MGC_50 cDNA clone IMAGE: 3076619 5′ 112E5 88 557 AW499829 NA 0 1 UI-HF-BN0-ake-c-07-0-UI.r1 NIH_MGC_50 cDNA clone IMAGE: 3076621 5′ 523F5 435 517 AW500534 NA 4.00E−36 1 UI-HF-BN0-akj-d-04-0-UI.r1 NIH_MGC_50 cDNA clone IMAGE: 3077406 5′ 476E10 152 450 AW501528 NA 1.00E−129 1 UI-HF-BP0p-ajf-c-02-0-UI.r1 NIH_MGC_51 cDNA clone IMAGE: 3073923 5′ 67D10 36 413 AW504212 NA 0 1 UI-HF-BN0-alp-a-11-0-UI.r1 NIH_MGC_50 cDNA clone IMAGE: 3080348 5′ 100E10 29 364 AW504293 NA 1.00E−159 1 UI-HF-BN0-alg-b-10-0-UI.r1 NIH_MGC_50 cDNA clone IMAGE: 3079267 5′ 484D12 35 353 AW510795 NA 1.00E−167 1 Soares_NFL_T_GBC_S1 cDNA clone IMAGE: 2911933 3′ similar to 480B2 109 446 AW572538 NA 1.00E−162 1 cDNA clone IMAGE: 2832030 3′ 465D2 272 464 AW573211 NA 2.00E−49 1 Soares_NFL_T_GBC_S1 cDNA clone IMAGE: 2933767 3′ similar to 47G6 125 126 AW614193 NA 1.00E−51 1 cDNA clone IMAGE: 2951662 3′ 499D7 1 341 AW630825 NA 0 2 cDNA clone IMAGE: 2969854 5′ 62H5 10 423 AW651682 NA 0 2 cDNA clone IMAGE: 2901099 5′ 104A7 3 461 AW778854 NA 0 1 cDNA clone IMAGE: 3037337 3′ 484H1 9 453 AW780057 NA 0 1 cDNA clone IMAGE: 3036046 3′ 491E8 18 348 AW792856 NA 1.00E−164 2 UM0001 cDNA 65D11 64 648 AW810442 NA 0 3 ST0125 cDNA 596F6 49 623 AW813133 NA 0 1 ST0189 cDNA 518H1 131 386 AW819894 NA 1.00E−133 1 ST0294 cDNA 115A7 1 315 AW836389 NA 1.00E−169 3 LT0030 cDNA 486D9 32 237 AW837717 NA 1.00E−65 1 LT0042 cDNA 477B12 84 253 AW837808 NA 4.00E−67 1 LT0042 cDNA 121A11 253 444 AW842489 NA 1.00E−98 1 CN0032 cDNA 472E6 132 447 AW846856 NA 1.00E−149 1 CT0195 cDNA 164F9 1 462 AW856490 NA 0 1 CT0290 cDNA 103C4 23 366 AW859565 NA 0 1 CT0355 cDNA 129D3 81 295 AW866426 NA 1.00E−108 1 SN0024 cDNA 501F9 88 421 AW873028 NA 1.00E−170 3 cDNA clone IMAGE: 3120038 3′ 98G4 1 294 AW873326 NA 1.00E−107 1 cDNA clone IMAGE: 3009400 3′ 72D5 55 648 AW886511 NA 0 1 OT0083 cDNA 460A5 101 294 AW891344 NA 1.00E−102 1 NT0079 cDNA 459E9 196 260 AW945538 NA 8.00E−28 1 EN0024 cDNA 479H5 17 224 AW948395 NA 1.00E−102 1 FN0040 cDNA 165E7 2 599 AW949461 NA 0 1 MAGA cDNA 123G9 104 715 AW954112 NA 0 2 MAGC cDNA 183F3 84 503 AW954476 NA 1.00E−159 1 MAGC cDNA 196C6 8 189 AW954580 NA 5.00E−98 1 MAGC cDNA 515H10 1 512 AW955265 NA 0 1 MAGC cDNA 41E8 16 671 AW957139 NA 1.00E−145 2 MAGD cDNA 66A7 335 503 AW958538 NA 4.00E−85 1 MAGE cDNA 465G8 169 615 AW960484 NA 0 1 MAGF cDNA 519E6 44 290 AW960593 NA 1.00E−134 1 MAGF cDNA 594F4 306 571 AW963171 NA 1.00E−112 1 MAGH cDNA 155B2 30 673 AW964218 NA 0 3 MAGH cDNA 173B5 1 553 AW965078 NA 0 1 MAGI cDNA 176A6 7 312 AW965490 NA 1.00E−136 1 MAGI cDNA 498H9 1 456 AW965987 NA 0 2 MAGI cDNA 517D11 105 484 AW966098 NA 0 2 MAGI cDNA 166H7 63 559 AW967388 NA 0 1 MAGJ cDNA 462C8 69 212 AW967948 NA 2.00E−72 1 MAGJ cDNA 189C5 8 566 AW968561 NA 0 1 MAGJ cDNA 459C3 129 587 AW969359 NA 0 2 MAGK cDNA 174C1 155 527 AW969546 NA 1.00E−170 1 MAGK cDNA 191F6 158 543 AW973953 NA 1.00E−152 2 MAGM cDNA 461G9 311 437 AW974749 NA 7.00E−47 1 MAGN cDNA 104D1 182 594 AW993791 NA 0 1 BN0034 cDNA 188F5 734 1292 AY007110 NA 0 4 clone TCCCTA00084 mRNA sequence Length = 1656 48D7 692 1169 AY029066 NA 1.00E−76 4 Humanin (HN1) mRNA, complete cds Length = 1567 55B8 1802 2045 BC000141 NA 3.00E−96 1 Similar to myelocytomatosis oncogene, clone MGC: 5183, mRNA 37A8 34 301 BC000374 NA 1.00E−101 1 ribosomal protein L18, clone MGC: 8373, mRNA, complete cds 178E5 20 551 BC000408 NA 5.00E−53 1 acetyl-Coenzyme A acetyltransferase 2 (acetoacetyl Coenzyme A thiolase 596G2 27 263 BC000449 NA 3.00E−43 2 Similar to ubiquitin C, clone MGC: 8448, mRNA, complete cds 179A3 693 1002 BC000514 NA 1.00E−160 3 ribosomal protein L13a, clone MGC: 8547, mRNA, complete cds 158F10 169 522 BC000523 NA 1.00E−157 1 Similar to ribosomal protein S24, clone MGC: 8595, mRNA, complete cds 515G5 34 270 BC000530 NA 7.00E−38 1 ribosomal protein L19, clone MGC: 8653, mRNA, complete cds 39B6 286 1073 BC000590 NA 0 9 actin related protein 2/3 complex, subunit 2 (34 kD), clone MGC: 1416, 169A4 929 1314 BC000672 NA 0 1 guanine nucleotide binding protein (G protein), beta polypeptide 2-lik 166H4 1350 1745 BC000771 NA 1.00E−169 8 Similar to tropomyosin 4, clone MGC: 3261, mRNA, complete cds 331F9 482 949 BC000967 NA 0 1 clone IMAGE: 3449287, mRNA, partial cds Length = 2156 526C6 633 829 BC001169 NA 1.00E−100 1 Similar to esterase 10, clone MGC: 1873, mRNA, complete cds 135G12 1598 1766 BC001303 NA 6.00E−42 1 Similar to splicing factor, arginine/serine-rich 2 (SC- 35), clone MGC: 491C6 613 714 BC001385 NA 3.00E−34 1 Similar to leucine rich repeat (in FLII) interacting protein 1, clone 108D10 234 641 BC001399 NA 2.00E−79 1 ferritin, heavy polypeptide 1, clone MGC: 1749, mRNA, complete cds 196H5 1387 1899 BC001412 NA 6.00E−55 4 eukaryotic translation elongation factor 1 alpha 1, clone MGC: 1332, mR 460F5 973 1350 BC001413 NA 0 1 clone IMAGE: 3140866, mRNA Length = 1634 520C5 348 472 BC001632 NA 5.00E−34 1 Similar to NADH dehydrogenase (ubiquinone) flavoprotein 2 (24 kD), clon 520D10 1729 2205 BC001637 NA 0 2 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 524A1 564 922 BC001660 NA 1.00E−94 2 ribonuclease 6 precursor, clone MGC: 1360, mRNA, complete cds 121E7 275 381 BC001697 NA 2.00E−26 1 Similar to ribosomal protein S15a, clone MGC: 2466, mRNA, complete cds 109D1 2441 2835 BC001798 NA 1.00E−123 1 clone MGC: 3157, mRNA, complete cds Length = 3041 180D9 741 921 BC001819 NA 5.00E−85 2 ribonuclease 6 precursor, clone MGC: 3554, mRNA, complete cds 72H5 1264 2808 BC001854 NA 0 8 methionine adenosyltransferase II, alpha, clone MGC: 4537, mRNA, comple 167H8 1099 1436 BC002409 NA 1.00E−49 1 actin, beta, clone MGC: 8647, mRNA, complete cds Length = 1858 53H1 2398 2513 BC002538 NA 3.00E−41 1 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 125B3 246 585 BC002711 NA 1.00E−40 1 cell division cycle 42 (GTP-binding protein, 25 kD), clone MGC: 3497, mR 331H8 201 557 BC002837 NA 0 1 clone MGC: 4175, mRNA, complete cds Length = 1092 150C4 1699 2040 BC002845 NA 8.00E−29 1 eukaryotic translation elongation factor 1 alpha 1, clone MGC: 3711, mR 70D7 345 850 BC002900 NA 0 1 Similar to proteasome (prosome, macropain) subunit, alpha type, 2, clo 476B5 1431 1761 BC002929 NA 1.00E−141 1 clone IMAGE: 3954899, mRNA, partial cds Length = 2467 38D7 200 688 BC002971 NA 0 2 clone IMAGE: 3543711, mRNA, partial cds Length = 1934 74A11 652 1724 BC003063 NA 0 5 Similar to likely ortholog of yeast ARV1, clone IMAGE: 3506392, mRNA 105H12 1148 1370 BC003090 NA 1.00E−105 1 COP9 homolog, clone MGC: 1297, mRNA, complete cds Length = 1637 50F4 8 301 BC003137 NA 1.00E−115 1 ribosomal protein S3, clone MGC: 3657, mRNA, complete cds 175G9 93 216 BC003352 NA 1.00E−33 1 tumor protein, translationally-controlled 1, clone MGC: 5308, mRNA, com 587E9 72 554 BC003358 NA 4.00E−60 2 ribosomal protein L10, clone MGC: 5189, mRNA, complete cds 71F8 491 911 BC003406 NA 0 1 cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMP-N-acet 512E11 308 372 BC003563 NA 2.00E−27 1 guanine nucleotide binding protein (G protein), gamma 5, clone MGC: 196 118B11 76 343 BC003577 NA 1.00E−111 1 clone IMAGE: 3544292, mRNA, partial cds Length = 826 107E3 9 634 BC003697 NA 0 1 clone MGC: 5564, mRNA, complete cds Length = 2145 128D4 1408 1550 BC004186 NA 1.00E−34 1 guanine nucleotide binding protein, beta 1, clone MGC: 2819, mRNA, comp 58H6 554 859 BC004245 NA 1.00E−171 2 ferritin, light polypeptide, clone MGC: 10465, mRNA, complete cds 481D8 134 460 BC004258 NA 6.00E−73 1 hypothetical protein PRO1741, clone MGC: 10753, mRNA, complete cds 520F6 160 1400 BC004317 NA 0 3 clone MGC: 10924, mRNA, complete cds Length = 1837 489G7 511 787 BC004458 NA 2.00E−60 1 enolase 1, (alpha), clone MGC: 4315, mRNA, complete cds 115B8 1162 1640 BC004521 NA 0 2 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 118A2 1126 1369 BC004805 NA 4.00E−38 1 similar to Mus musculus, clone IMAGE: 3584831, mRNA Length = 1910 73D2 1174 1751 BC004872 NA 0 1 clone MGC: 11034, mRNA, complete cds Length = 2471 522E3 681 993 BC004900 NA 1.00E−175 10 ribosomal protein L13a, clone IMAGE: 3545758, mRNA, partial cds 55G12 1 232 BC004928 NA 3.00E−68 1 clone MGC: 10493, mRNA, complete cds Length = 2567 520C2 3 139 BC004994 NA 1.00E−31 1 myosin regulatory light chain, clone MGC: 4405, mRNA, complete cds 460H4 1577 1923 BC005101 NA 0 1 clone IMAGE: 3618561, mRNA Length = 2113 154F12 122 283 BC005128 NA 2.00E−46 1 ribosomal protein L7a, clone MGC: 10607, mRNA, complete cds 592C8 647 925 BC005187 NA 2.00E−32 1 Similar to hypothetical protein, clone MGC: 12182, mRNA, complete cds 591D1 726 837 BC005361 NA 5.00E−31 1 proteasome (prosome, macropain) subunit, alpha type, 4, clone MGC: 1246 458A7 1307 1568 BC005816 NA 4.00E−98 1 Similar to deltex (Drosophila) homolog 1, clone IMAGE: 3688330, mRNA, p 122C6 263 378 BC005928 NA 1.00E−29 1 S100 calcium-binding protein A8 (calgranulin A), clone MGC: 14536, mRNA 47H11 273 854 BC006008 NA 0 1 clone IMAGE: 4285740, mRNA Length = 1040 598E1 850 1226 BC006176 NA 0 2 clone IMAGE: 4054156, mRNA, partial cds Length = 1423 175A1 570 887 BC006282 NA 1.00E−161 1 Similar to RIKEN cDNA 1110020N13 gene, clone MGC: 10540 150H12 543 1098 BC006464 NA 0 1 calmodulin 2 (phosphorylase kinase, delta), clone MGC: 2168 583E5 980 1246 BC006849 NA 1.00E−127 1 Similar to RIKEN cDNA 2410044K02 gene, clone MGC: 5469 41H7 619 1308 BC007004 NA 0 2 Similar to oxysterol-binding protein-related protein 1, clone IMAGE: 40 56C12 13 187 BC007063 NA 6.00E−27 1 peroxiredoxin 1, clone MGC: 12514, mRNA, complete cds Length = 973 183C11 2986 3328 BC007203 NA 1.00E−169 1 hypothetical protein MGC10823, clone MGC: 12957, mRNA, complete cds 109H10 1343 1627 BC007277 NA 1.00E−156 1 Similar to RIKEN cDNA 0610039P13 gene, clone MGC: 15619, mRNA 588E11 423 1324 BC007299 NA 0 3 Similar to ATP synthase, H+ transporting, mitochondrial F1 complex, al 164F12 72 336 BE002854 NA 1.00E−147 1 BN0090 cDNA 106A12 22 608 BE005703 NA 0 1 BN0120 cDNA 472E11 168 297 BE044364 NA 1.00E−66 1 Soares_NFL_T_GBC_S1 cDNA clone IMAGE: 3040218 3′ 458H11 2 510 BE049439 NA 0 1 cDNA clone IMAGE: 2834924 3′ 46F7 18 527 BE061115 NA 0 1 BT0041 cDNA 105A8 1 166 BE085539 NA 3.00E−74 1 BT0669 cDNA 467F5 27 247 BE086076 NA 1.00E−115 1 BT0672 cDNA 469B6 5 188 BE091932 NA 6.00E−87 1 BT0733 cDNA 66D7 18 568 BE160822 NA 0 1 HT0422 cDNA 593F8 110 451 BE163106 NA 1.00E−165 1 HT0457 cDNA 468B10 1 461 BE168334 NA 0 1 HT0514 cDNA 192E1 1 602 BE176373 NA 0 1 HT0585 cDNA 109A9 100 377 BE177661 NA 1.00E−129 1 HT0598 cDNA 468B9 27 145 BE178880 NA 3.00E−31 1 HT0609 cDNA 526E11 6 222 BE217848 NA 1.00E−118 3 cDNA clone IMAGE: 3174941 3′ 115H2 226 227 BE218938 NA 2.00E−97 1 cDNA clone IMAGE: 3176478 3′ 126B3 1 509 BE222301 NA 1.00E−151 1 cDNA clone IMAGE: 3166180 3′ 195F2 123 470 BE222392 NA 4.00E−91 1 cDNA clone IMAGE: 3166335 3′ 170F7 1 375 BE242649 NA 0 1 acute myelogenous leukemia cell (FAB M1) Baylor- HGSC 459F10 35 432 BE247056 NA 5.00E−84 1 cell acute lymphoblastic leukemia Baylor-HGSC project = TCBA 491G11 269 516 BE253336 NA 1.00E−116 1 cDNA clone IMAGE: 3357826 5′ 471H10 140 202 BE254064 NA 2.00E−26 1 cDNA clone IMAGE: 3354554 5′ 521H9 22 605 BE292793 NA 0 2 cDNA clone IMAGE: 2987838 5′ 472A9 33 436 BE297329 NA 0 1 cDNA clone IMAGE: 3532809 5′ 99E10 59 423 BE328818 NA 0 1 cDNA clone IMAGE: 3181355 3′ 192C3 4 335 BE348809 NA 0 1 cDNA clone IMAGE: 3152438 3′ 140G6 206 405 BE348955 NA 3.00E−85 1 cDNA clone IMAGE: 3144625 3′ 483D12 1 534 BE349148 NA 1.00E−160 1 cDNA clone IMAGE: 3150275 3′ 491H12 1 526 BE379820 NA 0 1 cDNA clone IMAGE: 3510960 5′ 481D5 212 333 BE464239 NA 3.00E−45 1 cDNA clone IMAGE: 3194693 3′ 469H8 31 179 BE466500 NA 2.00E−71 1 cDNA clone IMAGE: 3195395 3′ 56D11 72 353 BE467470 NA 1.00E−113 1 cDNA clone IMAGE: 3212950 3′ 471D10 1 249 BE502246 NA 1.00E−119 2 cDNA clone IMAGE: 3197344 3′ 471C2 255 486 BE502992 NA 1.00E−128 1 cDNA clone IMAGE: 3214462 3′ 56A2 291 669 BE538333 NA 1.00E−164 1 cDNA clone IMAGE: 3454710 5′ 191F12 488 587 BE547584 NA 9.00E−28 1 cDNA clone IMAGE: 3461312 5′ 525F3 5 236 BE550944 NA 1.00E−125 1 cDNA clone IMAGE: 3233200 3′ 473B7 46 228 BE551867 NA 4.00E−86 1 cDNA clone IMAGE: 3195555 3′ 467C6 48 404 BE569141 NA 1.00E−162 1 cDNA clone IMAGE: 3681180 5′ 110D3 193 473 BE613237 NA 1.00E−157 2 cDNA clone IMAGE: 3856357 3′ 140F9 20 344 BE614297 NA 1.00E−84 1 cDNA clone IMAGE: 3906037 3′ 473B12 63 216 BE645630 NA 3.00E−51 1 cDNA clone IMAGE: 3288143 3′ similar to contains 460C2 156 594 BE646470 NA 0 1 cDNA clone IMAGE: 3292133 3′ 172E5 329 491 BE670804 NA 7.00E−72 8 cDNA clone IMAGE: 3285031 3′ similar to gb: J04130 469D4 50 553 BE674685 NA 0 1 cDNA clone IMAGE: 3292800 3′ similar to TR: O60688 171F2 10 280 BE676054 NA 1.00E−96 1 cDNA clone IMAGE: 3295273 3′ 102E12 102 357 BE737348 NA 2.00E−93 1 cDNA clone IMAGE: 3640772 5′ 121C11 198 488 BE748663 NA 1.00E−150 1 cDNA clone IMAGE: 3838675 3′ 126D1 208 449 BE763412 NA 1.00E−122 1 NT0036 cDNA 172H5 52 581 BE768647 NA 0 1 FT0010 cDNA 176F12 178 646 BE792125 NA 0 1 cDNA clone IMAGE: 3936215 5′ 71A6 16 437 BE825187 NA 0 1 CN0028 cDNA 115F11 14 132 BE858152 NA 4.00E−60 1 cDNA clone IMAGE: 3306735 3′ 61A11 1 448 BE872245 NA 0 1 cDNA clone IMAGE: 3850435 5′ 171B8 155 377 BE875145 NA 8.00E−88 1 cDNA clone IMAGE: 3891244 5′ 108A6 370 539 BE876375 NA 7.00E−72 2 cDNA clone IMAGE: 3889033 5′ 166B1 1 472 BE877115 NA 1.00E−153 1 cDNA clone IMAGE: 3887598 5′ 63D11 208 496 BE878973 NA 1.00E−141 1 cDNA clone IMAGE: 3895002 5′ 525C3 208 400 BE879482 NA 7.00E−88 1 cDNA clone IMAGE: 3894277 5′ 526F7 335 603 BE881113 NA 1.00E−126 1 cDNA clone IMAGE: 3894306 5′ 152G12 122 659 BE881351 NA 0 2 cDNA clone IMAGE: 3892808 5′ 589H4 118 510 BE882335 NA 0 2 cDNA clone IMAGE: 3907044 5′ 51B12 199 631 BE884898 NA 3.00E−56 1 cDNA clone IMAGE: 3908551 5′ 114C1 286 530 BE887646 NA 1.00E−121 1 cDNA clone IMAGE: 3913468 5′ 120H2 282 706 BE888744 NA 0 1 cDNA clone IMAGE: 3915133 5′ 107D11 172 497 BE891242 NA 0 1 cDNA clone IMAGE: 3917201 5′ 513G4 263 662 BE891269 NA 0 1 cDNA clone IMAGE: 3917064 5′ 166B8 7 453 BE891928 NA 0 1 cDNA clone IMAGE: 3920185 5′ 185G9 23 390 BE894437 NA 1.00E−145 1 cDNA clone IMAGE: 3918224 5′ 189A8 211 485 BE896691 NA 1.00E−82 1 cDNA clone IMAGE: 3925062 5′ 598A7 78 301 BE897669 NA 1.00E−83 1 cDNA clone IMAGE: 3923346 5′ 191D9 189 575 BE899595 NA 0 3 cDNA clone IMAGE: 3952215 5′ 331F2 109 287 BF001438 NA 3.00E−96 2 cDNA clone IMAGE: 3313517 3′ 192C9 57 419 BF033741 NA 0 1 cDNA clone IMAGE: 3857635 5′ 117H4 73 454 BF056055 NA 0 1 cDNA clone IMAGE: 3443950 3′ similar to contains 104B10 6 412 BF058599 NA 1.00E−177 1 cDNA clone IMAGE: 3477311 3′ 331A12 13 164 BF059133 NA 1.00E−72 1 cDNA clone IMAGE: 3480249 3′ 40H1 81 507 BF060725 NA 0 1 7j59h07.x1 Soares_NSF_F8_9W_OT_PA_P_S1 cDNA clone 464F1 1 510 BF061421 NA 0 1 7j52c11.x1 Soares_NSF_F8_9W_OT_PA_P_S1 cDNA clone 71E11 1 441 BF105172 NA 0 1 cDNA clone IMAGE: 4042560 5′ 129D7 92 561 BF116224 NA 0 2 cDNA clone IMAGE: 3570793 3′ 145E10 83 624 BF131060 NA 0 1 cDNA done IMAGE: 4051731 5′ 113B6 105 410 BF194880 NA 1.00E−157 1 cDNA clone IMAGE: 3643600 3′ 157E9 102 308 BF197153 NA 1.00E−108 2 cDNA clone IMAGE: 3561933 3′ 127H8 1 173 BF197762 NA 3.00E−92 1 cDNA clone IMAGE: 3653139 3′ 462D1 29 177 BF221780 NA 7.00E−78 1 cDNA clone IMAGE: 3578603 3′ 472B8 7 229 BF306204 NA 9.00E−70 1 cDNA clone IMAGE: 4138980 5′ 62A3 187 612 BF309911 NA 1.00E−162 1 cDNA clone IMAGE: 4138171 5′ 476G4 316 487 BF330908 NA 5.00E−66 1 BT0333 cDNA 524D1 86 258 BF339088 NA 8.00E−88 1 cDNA clone IMAGE: 4182956 5′ 58G4 13 606 BF341359 NA 0 2 cDNA clone IMAGE: 4149195 5′ 480E7 68 288 BF357523 NA 4.00E−97 1 HT0945 cDNA 116C9 8 170 BF364413 NA 2.00E−81 1 NN1068 cDNA 168F4 11 595 BF369763 NA 0 1 GN0120 cDNA 495F1 1 318 BF373638 NA 1.00E−108 2 FT0176 cDNA 98E1 81 499 BF377518 NA 0 2 TN0115 cDNA 169C5 17 500 BF380732 NA 0 1 UT0073 cDNA 464E11 12 272 BF432643 NA 1.00E−129 1 cDNA clone IMAGE: 3406531 3′ 183G2 119 548 BF433058 NA 1.00E−112 1 cDNA clone IMAGE: 3565500 3′ 473F9 21 411 BF433353 NA 0 1 cDNA clone IMAGE: 3703678 3′ 117C9 179 462 BF433657 NA 2.00E−99 1 cDNA clone IMAGE: 3702965 3′ similar to contains 514A3 170 245 BF435621 NA 2.00E−34 2 Lupski_sciatic_nerve cDNA clone IMAGE: 3394901 3′ similar to 459G8 78 417 BF445405 NA 1.00E−179 1 cDNA clone IMAGE: 3699337 3′ 483D10 12 474 BF447885 NA 0 1 cDNA clone IMAGE: 3706147 3′ 519H12 319 394 BF449068 NA 3.00E−27 1 cDNA clone IMAGE: 3579069 3′ 584H11 78 487 BF475501 NA 7.00E−50 1 Lupski_sciatic_nerve cDNA clone IMAGE: 3396242 3′ 471G8 214 400 BF478238 NA 9.00E−61 1 cDNA clone IMAGE: 3700476 3′ similar to contains 109F10 20 329 BF507849 NA 1.00E−172 1 UI-H-BI4-apv-h-02-0-UI.s1 NCI_CGAP_Sub8 cDNA clone IMAGE: 3088755 3′ 173E10 147 231 BE510393 NA 1.00E−39 1 UI-H-BI4-aon-h-07-0-UI.s1 NCI_CGAP_Sub8 cDNA clone IMAGE: 3085669 3′ 464D1 32 460 BF513602 NA 1.00E−106 1 UI-H-BW1-amt-a-11-0-UI.s1 NCI_CGAP_Sub7 cDNA clone IMAGE: 3070773 3′ 118D9 106 248 BF514341 NA 4.00E−46 1 UI-H-BW1-and-h-10-0-UI.s1 NCI_CGAP_Sub7 cDNA clone IMAGE: 3082218 3′ 462E3 29 197 BF515538 NA 1.00E−87 1 UI-H-BW1-anq-b-09-0-UI.s1 NCI_CGAP_Sub7 cDNA clone IMAGE: 3083081 3′ 459C7 70 661 BF525720 NA 0 1 cDNA clone IMAGE: 4212877 5′ 462F8 151 684 BF526421 NA 0 1 cDNA clone IMAGE: 4213536 5′ 174H6 1 367 BF530382 NA 0 1 cDNA clone IMAGE: 4214327 5′ 477C5 183 689 BF569545 NA 0 1 cDNA clone IMAGE: 4310435 5′ 46C3 2 626 BF571362 NA 0 1 cDNA clone IMAGE: 4252059 5′ 465B1 350 508 BF591040 NA 3.00E−39 1 cDNA clone IMAGE: 3319177 3′ 477G7 6 127 BF592138 NA 2.00E−57 1 cDNA clone IMAGE: 3573334 3′ 180B2 53 264 BF593930 NA 1.00E−114 1 nab48e03.x1 Soares_NSF_F8_9W_OT_PA_P_S1 cDNA clone 185F12 139 578 BF663116 NA 0 1 cDNA clone IMAGE: 4308392 5′ 471F9 77 590 BF667621 NA 0 1 cDNA clone IMAGE: 4278888 5′ 41D10 16 664 BF668050 NA 0 2 cDNA clone IMAGE: 4279827 5′ 491G6 87 275 BF670567 NA 1.00E−97 1 cDNA clone IMAGE: 4290961 5′ 112B4 17 303 BF671020 NA 1.00E−120 1 cDNA clone IMAGE: 4292143 5′ 194H6 6 196 BF678298 NA 1.00E−100 1 cDNA clone IMAGE: 4248916 5′ 514H9 96 179 BF691178 NA 2.00E−32 1 cDNA clone IMAGE: 4332544 5′ 99H1 146 327 BF691895 NA 2.00E−69 1 cDNA clone IMAGE: 4333460 5′ 465E12 29 681 BF725383 NA 0 1 cDNA (Un-normalized, unamplified): BX cDNA clone 69B10 17 96 BF726114 NA 3.00E−37 1 cDNA (Un-normalized, unamplified): BY cDNA clone 151H10 18 366 BF732404 NA 0 1 cDNA clone IMAGE: 3434918 3′ 124D2 36 378 BF736784 NA 1.00E−179 1 KT0018 cDNA 463H5 30 152 BF740663 NA 3.00E−56 1 HB0031 cDNA 469D2 164 398 BF744387 NA 6.00E−74 1 BT0636 cDNA 72E1 17 128 BF749089 NA 1.00E−44 3 BN0386 cDNA 98C3 9 515 BF758480 NA 0 1 CT0539 cDNA 46E11 26 162 BF773126 NA 5.00E−57 1 IT0048 cDNA 124C8 32 257 BF773393 NA 1.00E−115 1 IT0039 cDNA 166G8 312 549 BF797348 NA 1.00E−108 1 cDNA clone IMAGE: 4340490 5′ 146D8 222 288 BF805164 NA 5.00E−29 1 CI0173 cDNA 49G4 99 460 BF813798 NA 0 5 CI0084 cDNA 469F8 31 455 BF816700 NA 4.00E−88 1 CI0128 cDNA 98C1 37 375 BF818594 NA 1.00E−163 1 CI0184 cDNA 62C9 166 359 BF821451 NA 3.00E−28 1 RT0038 cDNA 51F8 28 367 BF827734 NA 1.00E−175 1 HN0025 cDNA 56F7 15 429 BF845167 NA 9.00E−84 1 HT1035 cDNA 476D11 1 303 BF869167 NA 1.00E−165 2 ET0119 cDNA 476H4 12 262 BF875575 NA 1.00E−131 2 ET0100 cDNA 68D6 242 452 BF877979 NA 3.00E−98 1 ET0109 cDNA 37C10 1 381 BF897042 NA 0 3 MT0179 cDNA 465B3 63 193 BF898285 NA 5.00E−60 1 MT0229 cDNA 331C7 274 485 BF899464 NA 3.00E−83 1 MT0211 cDNA 72D8 50 334 BF904425 NA 1.00E−152 1 MT0245 cDNA 159F6 333 417 BF906114 NA 2.00E−35 1 MT0267 cDNA 108H5 6 409 BF926187 NA 0 1 NT0193 cDNA 71F9 192 286 BF928644 NA 1.00E−43 1 NT0216 cDNA 481D4 27 334 BF938959 NA 1.00E−102 1 cDNA clone IMAGE: 3706689 3′ 189B11 69 183 BF939014 NA 4.00E−29 1 cDNA clone IMAGE: 3706658 3′ 115G2 85 399 BF940103 NA 1.00E−177 1 cDNA clone IMAGE: 3439383 3′ 463B3 304 449 BF940291 NA 8.00E−62 1 cDNA clone IMAGE: 3577096 3′ 122G1 8 339 BF950968 NA 1.00E−170 1 NN1186 cDNA 470B4 251 320 BF962743 NA 2.00E−28 1 NN0045 cDNA 516D5 39 208 BF962934 NA 5.00E−69 1 NN0045 cDNA 593G10 242 597 BF965068 NA 1.00E−177 2 cDNA clone IMAGE: 4356776 5′ 101A1 6 356 BF965438 NA 1.00E−132 1 cDNA clone IMAGE: 4356453 5′ 477F3 25 653 BF965960 NA 0 1 cDNA clone IMAGE: 4365102 5′ 588E4 67 562 BF966028 NA 1.00E−134 1 cDNA clone IMAGE: 4364887 5′ 467F10 11 282 BF966049 NA 1.00E−122 1 cDNA clone IMAGE: 4364941 5′ 59E12 81 355 BF966269 NA 1.00E−144 1 cDNA clone IMAGE: 4375212 5′ 480E11 416 755 BF968628 NA 8.00E−41 1 cDNA clone IMAGE: 4359351 5′ 37H8 200 500 BF968963 NA 1.00E−148 1 cDNA clone IMAGE: 4358390 5′ 98H5 396 397 BF969990 NA 1.00E−133 1 cDNA clone IMAGE: 4360614 5′ 597C3 15 571 BF971075 NA 0 1 cDNA clone IMAGE: 4358911 5′ 101F1 188 305 BF971984 NA 6.00E−42 1 cDNA clone IMAGE: 4329095 5′ 464H5 246 602 BF980139 NA 0 1 cDNA clone IMAGE: 4373963 3′ 63B6 130 597 BF981080 NA 0 1 cDNA clone IMAGE: 4401411 5′ 167A3 223 418 BF981263 NA 1.00E−101 1 cDNA clone IMAGE: 4400757 5′ 512C12 1 494 BF981634 NA 0 1 cDNA clone IMAGE: 4397101 5′ 187H7 26 433 BF997765 NA 1.00E−180 2 GN0127 cDNA 458E4 54 242 BG006820 NA 3.00E−62 1 GN0227 cDNA 106A7 1 604 BG024761 NA 0 1 cDNA clone IMAGE: 4363858 5′ 459H6 1 524 BG026279 NA 0 1 cDNA clone IMAGE: 4386607 5′ 460B9 264 512 BG028577 NA 1.00E−105 1 cDNA clone IMAGE: 4387518 5′ 49E9 100 537 BG033909 NA 0 1 cDNA clone IMAGE: 4402729 5′ 54C10 1 582 BG033953 NA 0 2 cDNA clone IMAGE: 4402647 5′ 182B3 1 489 BG034799 NA 0 1 cDNA clone IMAGE: 4413514 5′ 166F8 13 586 BG036101 NA 0 1 cDNA clone IMAGE: 4414135 5′ 104A12 56 240 BG054966 NA 1.00E−100 1 cDNA clone IMAGE: 3441756 3′ 171H10 4 269 BG056668 NA 3.00E−85 1 cDNA clone IMAGE: 4169714 3′ 146G11 13 522 BG057282 NA 0 5 cDNA clone IMAGE: 4140477 3′ similar to contains 472A11 69 358 BG057892 NA 1.00E−145 1 7f76e08.x1 Lupski_dorsal_root_ganglion cDNA clone 513B4 2 418 BG058599 NA 0 1 cDNA clone IMAGE: 4141266 3′ 134B4 201 519 BG058739 NA 1.00E−75 4 cDNA clone IMAGE: 4140551 3′ 163E7 83 327 BG110599 NA 1.00E−126 1 cDNA clone IMAGE: 4368492 5′ 118A7 180 577 BG110835 NA 0 1 cDNA clone IMAGE: 4366502 5′ 37F12 38 649 BG111212 NA 0 5 cDNA clone IMAGE: 4369233 5′ 464A10 57 673 BG111773 NA 0 1 cDNA clone IMAGE: 4372861 5′ 464A7 56 411 BG118529 NA 1.00E−167 1 cDNA clone IMAGE: 4443519 5′ 458D8 186 715 BG121288 NA 0 1 cDNA clone IMAGE: 4450407 5′ 166H12 25 339 BG149747 NA 1.00E−177 1 cDNA clone IMAGE: 3367325 3′ 51H4 4 224 BG149986 NA 1.00E−121 1 cDNA clone IMAGE: 3406766 3′ 75G3 70 280 BG150273 NA 1.00E−115 4 cDNA clone IMAGE: 3442930 3′ 500F10 18 677 BG163237 NA 0 3 cDNA clone IMAGE: 4446802 5′ 519E4 39 575 BG164898 NA 0 3 cDNA clone IMAGE: 4453661 5′ 119E5 21 276 BG165998 NA 1.00E−120 1 cDNA clone IMAGE: 4456017 5′ 519B8 29 214 BG166279 NA 5.00E−86 1 cDNA clone IMAGE: 4455496 5′ 103B8 377 499 BG170647 NA 1.00E−45 1 cDNA clone IMAGE: 4426826 5′ 470F8 184 307 BG180098 NA 4.00E−63 1 cDNA clone IMAGE: 4430875 5′ 585C4 4 98 BG230563 NA 5.00E−46 1 cDNA clone IMAGE: 4143330 3′ similar to contains 48G7 2 298 BG231557 NA 1.00E−119 1 cDNA clone IMAGE: 4142471 3′ 73C4 188 430 BG231805 NA 1.00E−130 1 cDNA clone IMAGE: 4142814 3′ 148H4 2 525 BG231961 NA 1.00E−133 12 cDNA clone IMAGE: 4143104 3′ 484B5 364 533 BG235942 NA 5.00E−81 1 cDNA clone IMAGE: 4141389 3′ 137B5 97 523 BG236015 NA 6.00E−87 1 cDNA clone IMAGE: 4141365 3′ 489B11 12 294 BG236084 NA 4.00E−75 2 cDNA clone IMAGE: 4141856 3′ similar to 45H2 1 492 BG249224 NA 1.00E−139 1 cDNA clone IMAGE: 4470038 5′ 172F1 1 562 BG254117 NA 0 1 cDNA clone IMAGE: 4475233 5′ 588F3 66 202 BG254292 NA 9.00E−43 1 cDNA clone IMAGE: 4477042 5′ 583B5 8 183 BG272304 NA 7.00E−45 1 cDNA clone IMAGE: 4257371 73A4 119 311 BG282346 NA 3.00E−42 1 cDNA clone IMAGE: 4545131 5′ 586A2 99 511 BG283706 NA 1.00E−160 1 cDNA clone IMAGE: 4519866 5′ 152F12 1 676 BG286649 NA 0 5 cDNA clone IMAGE: 4499224 5′ 479A12 228 601 BG286817 NA 1.00E−142 1 cDNA clone IMAGE: 4500259 5′ 99B4 1 449 BG288308 NA 0 2 cDNA clone IMAGE: 4512706 5′ 584G2 54 468 BG288554 NA 0 1 cDNA clone IMAGE: 4517068 5′ 464E2 244 549 BG289048 NA 1.00E−159 2 cDNA clone IMAGE: 4512868 5′ 113H1 149 436 BG289347 NA 1.00E−161 1 cDNA clone IMAGE: 4516241 5′ 39G6 1 503 BG290577 NA 0 1 cDNA clone IMAGE: 4517986 5′ 48D8 38 440 BG291970 NA 0 1 cDNA clone IMAGE: 4517457 5′ 60E7 1 398 BG319445 NA 0 4 Keratinocyte Subtraction Library-Downregulated Transcripts Homo 168C2 3 221 BG319498 NA 1.00E−111 2 Keratinocyte Subtraction Library-Downregulated Transcripts Homo 461B12 1 393 BG387694 NA 0 2 cDNA clone IMAGE: 4521084 5′ 174G11 3 542 BG391695 NA 0 1 cDNA clone IMAGE: 4537243 5′ 597A4 164 612 BG396292 NA 0 2 cDNA clone IMAGE: 4581548 5′ 190B10 469 667 BG397564 NA 3.00E−62 2 cDNA clone IMAGE: 4564968 5′ 593C3 35 461 BG403635 NA 0 1 cDNA clone IMAGE: 4526364 5′ 57H10 121 495 BG413494 NA 0 1 7j54e06.x1 Soares_NSF_F8_9W_OT_PA_P_S1 cDNA clone 155G11 119 347 BG424974 NA 3.00E−52 1 cDNA clone IMAGE: 4591378 5′ 45G3 17 332 BG427404 NA 1.00E−159 1 cDNA clone IMAGE: 4612518 5′ 185C9 16 185 BG432194 NA 3.00E−62 1 cDNA clone IMAGE: 4610035 5′ 331D4 60 386 BG434865 NA 1.00E−179 1 cDNA clone IMAGE: 4605025 5′ 464H12 97 295 BG438232 NA 1.00E−105 1 cDNA clone IMAGE: 4622433 5′ 521F2 280 534 BG468330 NA 1.00E−111 1 cDNA clone IMAGE: 4644153 5′ 56F6 167 582 BG473228 NA 0 2 cDNA clone IMAGE: 4646938 5′ 61G3 8 185 BG473813 NA 2.00E−95 1 cDNA clone IMAGE: 4647416 5′ 119E9 7 377 BG482798 NA 1.00E−178 3 cDNA clone IMAGE: 4616253 5′ 125F8 47 318 BG489375 NA 1.00E−149 1 cDNA clone IMAGE: 4636634 5′ 73H3 55 154 BG493253 NA 5.00E−49 1 cDNA clone IMAGE: 4672787 5′ 111H9 79 754 BG497765 NA 0 1 cDNA clone IMAGE: 4665582 5′ 171A10 74 476 BG501063 NA 0 1 cDNA clone IMAGE: 4668643 5′ 471G1 65 197 BG501895 NA 1.00E−63 1 cDNA clone IMAGE: 4654344 5′ 111E1 16 181 BG503693 NA 4.00E−85 2 cDNA clone IMAGE: 4657381 5′ 121B6 77 553 BG505271 NA 0 2 cDNA clone IMAGE: 4664028 5′ 599F2 379 484 BG505379 NA 3.00E−45 1 cDNA clone IMAGE: 4657121 5′ 105C1 208 646 BG505961 NA 0 1 cDNA clone IMAGE: 4072795 5′ 521E10 23 440 BG506168 NA 0 4 cDNA clone IMAGE: 4072226 5′ 119A5 188 596 BG506472 NA 1.00E−103 1 cDNA clone IMAGE: 4070820 5′ 479D7 34 308 BG527060 NA 1.00E−121 1 cDNA clone IMAGE: 4685209 5′ 71H3 27 542 BG527658 NA 0 1 cDNA clone IMAGE: 4685854 5′ 186A7 2 336 BG531486 NA 5.00E−96 1 cDNA clone IMAGE: 4699409 5′ 187H11 186 662 BG532345 NA 0 1 cDNA clone IMAGE: 4699954 5′ 64G4 166 650 BG532470 NA 0 1 cDNA clone IMAGE: 4699923 5′ 486E6 224 561 BG533994 NA 1.00E−168 5 cDNA clone IMAGE: 4663102 5′ 116F9 188 392 BG536394 NA 7.00E−67 1 cDNA clone IMAGE: 4689645 5′ 75C7 1 452 BG536641 NA 0 2 cDNA clone IMAGE: 4691078 5′ 175D10 3 114 BG537502 NA 2.00E−49 1 cDNA clone IMAGE: 4690780 5′ 599E1 356 659 BG538731 NA 1.00E−111 1 cDNA clone IMAGE: 4691392 5′ 191H9 80 631 BG541679 NA 0 1 cDNA clone IMAGE: 4695805 5′ 466A4 1 408 BG542394 NA 0 1 cDNA clone IMAGE: 4696046 5′ 67G12 29 698 BG547561 NA 0 3 cDNA clone IMAGE: 4703738 5′ 467B6 60 234 BG547627 NA 3.00E−93 2 cDNA clone IMAGE: 4703608 5′ 488F8 2041 2132 D10495 NA 9.00E−31 1 mRNA for protein kinase C delta-type, complete cds Length = 2163 525B6 21 222 D17042 NA 1.00E−100 2 HepG2 partial cDNA, clone hmd3f07m5 Length = 222 471E4 2287 2877 D17391 NA 0 2 mRNA for alpha 4(IV) collagen, C-terminal Length = 3558 134D8 561 694 D28589 NA 2.00E−59 1 mRNA (KIAA00167), partial sequence Length = 792 112D1 1614 2159 D30036 NA 0 1 mRNA for phosphatidylinositol transfer protein (PI- TPalpha), complete 98H4 1 357 F11941 NA 1.00E−180 1 brain cDNA cDNA clone c-33f05 585G7 15 264 F13765 NA 1.00E−136 1 (1992) cDNA clone FII112 3′ 47D11 1 296 F35665 NA 1.00E−146 1 cDNA clone sH5-000005-0/E06 465F5 34 225 H03298 NA 1.00E−70 1 cDNA clone IMAGE: 151865 5′ 481A6 43 362 H51796 NA 1.00E−123 1 spleen 1NFLS cDNA clone IMAGE: 194250 5′ 100E3 116 205 H56344 NA 1.00E−37 1 spleen 1NFLS cDNA clone IMAGE: 203711 5′ similar to 464F9 10 398 H57221 NA 5.00E−45 2 spleen 1NFLS cDNA clone IMAGE: 204710 5′ 66C3 10 77 H78395 NA 8.00E−28 1 liver spleen 1NFLS cDNA clone IMAGE: 233597 3′ 105D11 63 365 H81660 NA 1.00E−154 1 2NbHM cDNA clone IMAGE: 249138 5′ 60G10 1 189 H86841 NA 1.00E−100 1 cDNA clone IMAGE: 220310 5′ similar to SP: S44265 470D6 1 314 H92914 NA 1.00E−146 1 Soares_pineal_gland_N3HPG cDNA clone IMAGE: 231988 3′ 483E5 839 944 K02885 NA 1.00E−26 1 T-cell receptor active beta-chain V-D-J-beta-1.2-C- beta-1 (TCRB) mRNA, 516F5 1753 2047 L11284 NA 1.00E−131 1 Homo sapiens ERK activator kinase (MEK1) mRNA Length = 2222 525E11 105 738 L40557 NA 1.00E−112 1 perforin (PRF1) mRNA, 3′ end Length = 818 74F1 661 826 M11124 NA 5.00E−41 1 MHC HLA DQ alpha-chain mRNA from DRw9 cell line Length = 835 121E3 1323 1870 M12824 NA 0 4 T-cell differentiation antigen Leu-2/T8 mRNA, partial cds Length = 197 66H2 713 1190 M17783 NA 0 1 glia-derived nexin (GDN) mRNA, 5′ end Length = 1191 41A9 698 883 M32577 NA 4.00E−28 1 MHC HLA-DQ beta mRNA, complete cds Length = 1104 478D10 436 605 M55674 NA 4.00E−33 1 (clone M212) phosphoglycerate mutase 2 (muscle specific isozyme) (PGAM 469B8 5 377 N20190 NA 0 1 2NbHM cDNA clone IMAGE: 264340 3′ 109E4 21 449 N23307 NA 0 2 2NbHM cDNA clone IMAGE: 267836 3′ 171D9 80 381 N25486 NA 1.00E−147 1 2NbHM cDNA clone IMAGE: 264068 5′ 73H12 1 398 N27575 NA 1.00E−144 2 2NbHM cDNA clone IMAGE: 264499 5′ 490A11 25 475 N31700 NA 0 1 2NbHM cDNA clone IMAGE: 267025 5′ 599D6 185 483 N34261 NA 1.00E−150 1 2NbHM cDNA clone IMAGE: 267967 5′ 188F3 112 357 N36787 NA 1.00E−107 1 2NbHM cDNA clone IMAGE: 273145 3′ 465B10 7 558 N49836 NA 0 1 yz08a11.s1 Soares_multiple_sclerosis_2NbHMSP cDNA 40D4 199 575 N58136 NA 1.00E−153 1 spleen 1NFLS cDNA clone IMAGE: 247587 3′ 183E2 227 366 N80578 NA 2.00E−53 1 Soares_fetal_lung_NbHL19W cDNA clone IMAGE: 300873 3′ similar to 139G6 9 269 N94511 NA 1.00E−125 1 zb80g04.s1 Soares_senescent_fibroblasts_NbHSF cDNA 126B8 1 256 N99577 NA 1.00E−137 2 spleen 1NFLS cDNA clone IMAGE: 295067 5′ 118A10 893 5056 NC_001807 NA 0 7 mitochondrion, complete genome Length = 16568 41B2 1 471 NM_000873 NA 0 1 intercellular adhesion molecule 2 (ICAM2), mRNA Length = 1035 62A8 1877 1958 NM_000958 NA 1.00E−37 4 prostaglandin E receptor 4 (subtype EP4) (PTGER4), mRNA 179H10 53 265 NM_000983 NA 1.00E−44 1 ribosomal protein L22 (RPL22), mRNA Length = 602 331D3 71 343 NM_001024 NA 1.00E−144 5 ribosomal protein S21 (RPS21), mRNA Length = 343 41G10 3162 3565 NM_001243 NA 3.00E−47 1 tumor necrosis factor receptor superfamily, member 8 (TNFRSF8), mRNA 591E9 1027 1483 NM_002211 NA 0 2 integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 497C6 4946 5064 NM_002460 NA 9.00E−36 2 interferon regulatory factor 4 (IRF4), mRNA Length = 5065 597D8 1232 1461 NM_005356 NA 2.00E−48 1 lymphocyte-specific protein tyrosine kinase (LCK), mRNA Length = 2032 166G2 50 319 NM_005745 NA 2.00E−90 1 accessory proteins BAP31/BAP29 (DXS1357E), mRNA Length = 1314 468D2 3245 3480 NM_011086 NA 8.00E−63 1 similar to Mus phosphoinositide kinase, fyve- containing (Pikfyve), mRNA 599A4 1335 1630 NM_014644 NA 2.00E−69 1 KIAA0477 gene product (KIAA0477), mRNA Length = 5676 69C2 818 1361 NM_014905 NA 0 3 glutaminase (GLS), mRNA Length = 4606 495C6 622 838 NM_015435 NA 1.00E−104 1 double ring-finger protein, Dorfin (DORFIN), mRNA Length = 1640 463D11 480 632 NM_015995 NA 1.00E−77 1 Kruppel-like factor 13 (KLF13), mRNA Length = 1079 49C10 817 964 NM_019604 NA 3.00E−28 1 class-I MHC-restricted T cell associated molecule (CRTAM), mRNA 188E4 390 643 NM_019997 NA 6.00E−79 1 similar to Mus musculus cDNA sequence AB041581 (AB041581) 103H2 1421 1662 NM_021432 NA 3.00E−66 1 similar to Mus RIKEN cDNA 1110020M21 gene (1110020M21Rik) 465G11 1685 1761 NM_021777 NA 1.00E−34 1 a disintegrin and metalloproteinase domain 28 (ADAM28), transcirpt var 166D8 1265 1951 NM_022152 NA 0 1 PP1201 protein (PP1201), mRNA Length = 2309 459G6 1 123 NM_024567 NA 2.00E−36 1 hypothetical protein (FLJ21616), mRNA Length = 1858 461G2 667 1182 NM_025977 NA 1.00E−28 1 similar to Mus RIKEN cDNA 2510048L02 gene (2510048L02Rik) 62A5 759 1200 NM_030780 NA 0 1 folate transporter/carrier (LOC81034), mRNA Length = 2534 52C11 1277 1954 NM_030788 NA 0 1 DC-specific transmembrane protein (LOC81501), mRNA Length = 1974 108A7 910 3014 NM_031419 NA 0 4 molecule possessing ankyrin repeats induced by lipopolysaccharide 74E11 47 464 NM_031435 NA 0 1 hypothetical protein DKFZp56410422 (DKFZP56410422), mRNA 56B3 1518 1962 NM_031453 NA 1.00E−176 1 hypothetical protein MGC11034 (MGC11034), mRNA Length = 3301 46F2 118 663 NM_031480 NA 1.00E−105 1 hypothetical protein AD034 (AD034), mRNA Length = 2495 192B3 51 290 R11456 NA 1.00E−105 1 spleen 1NFLS cDNA clone IMAGE: 129880 5′ similar to 458B9 43 359 R64054 NA 1.00E−159 1 cDNA clone IMAGE: 139969 5′ 169F11 1 429 R85137 NA 0 1 brain N2b4HB55Y cDNA clone IMAGE: 180492 5′ 465B5 16 392 R88126 NA 1.00E−164 1 cDNA clone IMAGE: 186850 5′ 477F8 1 525 T77017 NA 0 1 1NIB cDNA clone IMAGE: 23326 5′ 39G11 162 455 T80378 NA 1.00E−145 1 1NIB cDNA clone IMAGE: 24693 5′ 107D7 1 371 T80654 NA 0 1 spleen 1NFLS cDNA clone IMAGE: 108950 5′ 465A1 6 314 T85880 NA 1.00E−114 1 spleen 1NFLS cDNA clone IMAGE: 112441 5′ 48D12 2300 2533 U08015 NA 1.00E−128 1 NF-ATc mRNA, complete cds Length = 2743 121F1 13 380 U46388 NA 1.00E−150 1 cell line Patu 8988t cDNA clone xs425 127B12 3 330 U52054 NA 0 4 S6 H-8 mRNA expressed in chromosome 6- suppressed melanoma cells 487C2 4054 4187 U52682 NA 2.00E−28 1 lymphocyte specific interferon regulatory factor/interferon regulatory 110B3 1404 2081 U53530 NA 0 1 cytoplasmic dynein 1 heavy chain mRNA, partial cds Length = 2694 466C8 34 175 U75805 NA 3.00E−47 1 cDNA clone f46 148G12 1513 1639 U87954 NA 1.00E−27 1 erbB3 binding protein EBP1 mRNA, complete cds Length = 1648 70A4 564 1381 U94359 NA 0 2 glycogenin-2 like mRNA sequence Length = 4066 158E4 843 945 U97075 NA 1.00E−33 1 FLICE-like inhibitory protein short form mRNA, complete cds 459A1 227 446 W00466 NA 1.00E−60 1 2NbHM cDNA clone IMAGE: 291193 5′ 459A2 60 350 W00491 NA 1.00E−126 1 2NbHM cDNA clone IMAGE: 291255 5′ similar to 459B1 76 551 W02600 NA 0 1 spleen 1NFLS cDNA clone IMAGE: 296099 5′ 166C10 10 415 W16552 NA 0 1 Soares_fetal_lung_NbHL19W cDNA clone IMAGE: 301703 5′ 471C6 3 383 W19201 NA 1.00E−149 1 Soares_fetal_lung _NbHL19W cDNA clone IMAGE: 303118 5′ similar to 520A8 75 382 W19487 NA 1.00E−154 1 zb36f09.r1 Soares_parathyroid_tumor_NbHPA cDNA clone 459B7 57 158 W25068 NA 9.00E−50 1 Soares_fetal_lung _NbHL19W cDNA clone IMAGE: 308696 5′ 188D3 39 283 W26193 NA 2.00E−91 1 randomly primed sublibrary cDNA 75B12 8 386 W27656 NA 1.00E−166 1 randomly primed sublibrary cDNA 163F8 74 330 W47229 NA 1.00E−117 1 zc39c01.r1 Soares_senescent_fibroblasts_NbHSF cDNA 478E6 2 322 W56487 NA 3.00E−51 1 zc59c07.r1 Soares_parathyroid _tumor_NbHPA cDNA clone 73H4 76 297 W72392 NA 1.00E−121 1 Soares_fetal_heart_NbHH19W cDNA clone IMAGE: 345661 3′ 66D5 1 457 W74397 NA 0 3 Soares_fetal_heart_NbHH19W cDNA clone IMAGE: 345236 5′ 496D4 85 450 W79598 NA 0 1 Soares_fetal_heart_NbHH1 9W cDNA clone IMAGE: 347020 5′ 165D1 108 287 W80882 NA 4.00E−94 1 Soares_fetal_heart_NbHH19W cDNA clone IMAGE: 347240 5′ 463G1 5 406 W86427 NA 0 1 zh61c11.s1 Soares_fetal_liver spleen_1NFLS_S1 cDNA 469G11 1276 1621 X06180 NA 0 1 mRNA for CD7 antigen (gp40) Length = 1656 113E11 126 885 X65318 NA 0 1 Cloning vector pGEMEX-2 Length = 3995 482E1 921 1168 X79536 NA 1.00E−102 1 mRNA for hnRNPcore protein A1 Length = 1198 123G8 408 848 XM_002068 NA 8.00E−73 1 glutamate-ammonia ligase (glutamine synthase) (GLUL), mRNA 185E1 508 734 XM_002158 NA 1.00E−27 1 proteasome (prosome, macropain) subunit, alpha type, 5 (PSMA5), mRNA 71A9 1131 1252 XM_002269 NA 4.00E−29 1 ARP3 (actin-related protein 3, yeast) homolog (ACTR3), mRNA 49G7 1 257 XM_003189 NA 1.00E−142 3 similar to eukaryotic translation initiation factor 4A, isoform 2 (H. 128B5 783 980 XM_003304 NA 6.00E−41 1 toll-like receptor 2 (TLR2), mRNA Length = 2600 185G10 853 1057 XM_003507 NA 2.00E−26 1 small inducible cytokine subfamily B (Cys-X-CyS), member 5 (epithelial 41C9 588 1221 XM_003593 NA 0 1 CD38 antigen (p45) (CD38), mRNA Length = 1227 156C4 127 270 XM_004020 NA 6.00E−71 1 ribosomal protein S23 (RPS23), mRNA Length = 488 66E2 1344 1577 XM_004500 NA 1.00E−46 1 CD83 antigen (activated B lymphocytes, immunoglobulin superfamily) (CD 61C6 474 987 XM_004611 NA 2.00E−80 1 Ras homolog enriched in brain 2 (RHEB2), mRNA Length = 987 184A7 971 1361 XM_004720 NA 0 1 hypothetical protein FLJ11000 (FLJ11000), mRNA Length = 1680 128E6 580 741 XM_004839 NA 5.00E−38 1 pre-B-cell colony-enhancing factor (PBEF), mRNA Length = 2377 55A11 1096 1305 XM_005162 NA 1.00E−60 1 GTP-binding protein overexpressed in skeletal muscle (GEM), mRNA 519C4 1307 1441 XM_005543 NA 1.00E−69 1 aquaporin 3 (AQP3), mRNA Length = 1441 129F1 1854 2367 XM_005693 NA 0 1 inositol polyphosphate-5-phosphatase, 40 kD (INPP5A), mRNA 522C10 700 916 XM_005698 NA 7.00E−53 1 programmed cell death 4 (PDCD4), mRNA Length = 1622 180G6 1884 2290 XM_005799 NA 1.00E−166 1 integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 55F4 2573 2748 XM_005883 NA 4.00E−73 1 early growth response 2 (Krox-20 (Drosophila) homolog) (EGR2), mRNA 492H7 976 1176 XM_005980 NA 4.00E−33 1 proteoglycan 1, secretory granule (PRG1), mRNA Length = 1176 476B4 1541 1918 XM_006741 NA 0 1 hypothetical protein FLJ10701 (FLJ10701), mRNA Length = 2299 493H5 145 379 XM_006881 NA 2.00E−56 1 interleukin 22 (IL22), mRNA Length = 676 499B4 11117 11410 XM_007156 NA 3.00E−34 1 spastic ataxia of Charlevoix-Saguenay (sacsin) (SACS), mRNA 183D7 4270 4376 XM_007189 NA 5.00E−37 1 forkhead box O1A (rhabdomyosarcoma) (FOXO1A), mRNA Length = 5037 115B6 4151 4408 XM_007606 NA 2.00E−50 2 thrombospondin 1 (THBS1), mRNA Length = 5719 587B4 31 264 XM_007650 NA 1.00E−114 3 beta-2-microglobulin (B2M), mRNA Length = 918 598H5 206 300 XM_008062 NA 1.00E−31 1 ribosomal protein S15a (RPS15A), mRNA Length = 435 73E4 3252 3505 XM_008082 NA 1.00E−119 1 adaptor-related protein complex 1, gamma 1 subunit (AP1G1), mRNA 64F7 186 334 XM_008449 NA 1.00E−47 1 small inducible cytokine A4 (homologous to mouse Mip-1b) (SCYA4) 585E1 904 1020 XM_009533 NA 1.00E−26 1 CGI-06 protein (LOC51604), mRNA Length = 2146 75B8 710 1406 XM_009574 NA 0 1 nucleolar protein (KKE/D repeat) (NOP56), mRNA Length = 1910 467A5 210 620 XM_009641 NA 0 1 v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (SRC), 44A3 480 854 XM_009917 NA 0 1 splicing factor 3a, subunit 1, 120 kD (SF3A1), mRNA Length = 2614 114D12 2269 2491 XM_009929 NA 7.00E−56 1 LIM domain kinase 2 (LIMK2), mRNA Length = 3699 52F6 1 230 XM_010593 NA 2.00E−36 1 signaling lymphocytic activation molecule (SLAM), mRNA Length = 1791 185E5 1576 1695 XM_010897 NA 3.00E−32 1 neural precursor cell expressed, developmentally down-regulated 5 (NED 106C3 1359 1824 XM_011080 NA 0 1 T cell activation, increased late expression (TACTILE), mRNA 56H11 40 617 XM_011082 NA 0 1 interleukin 21 (IL21), mRNA Length = 617 53B2 2711 2839 XM_011714 NA 3.00E−29 1 neutral sphingomyelinase (N-SMase) activation associated factor (NSMAF 47A3 896 1231 XM_011865 NA 1.00E−55 1 isopentenyl-diphosphate delta isomerase (IDI1), mRNA Length = 1835 159E9 17 178 XM_011914 NA 1.00E−73 1 ribosomal protein S24 (RPS24), mRNA Length = 515 39E6 339 535 XM_012059 NA 1.00E−44 1 hypothetical protein MDS025 (MDS025), mRNA Length = 1225 142F6 623 745 XM_012328 NA 2.00E−40 1 granzyme B (granzyme 2, cytotoxic T-lymphocyte- associated serine ester 118D4 329 765 XM_012649 NA 1.00E−114 1 small inducible cytokine A7 (monocyte chemotactic protein 3) (SCYA7), 168H9 2502 2616 XM_015180 NA 2.00E−33 1 apolipoprotein L, 6 (APOL6), mRNA Length = 2915 58D2 1582 1742 XM_015921 NA 2.00E−30 1 putative chemokine receptor; GTP-binding protein (HM74), mRNA 466H9 86 440 XM_016138 NA 2.00E−45 1 hypothetical protein FLJ12439 (FLJ12439), mRNA Length = 1614 184G1 2651 3584 XM_016481 NA 0 3 hypothetical protein (DJ328E19.C1.1), mRNA Length = 3603 107G9 8199 8786 XM_016721 NA 0 1 zinc finger protein 106 (ZFP106), mRNA Length = 10462 39F11 2719 3671 XM_016972 NA 0 2 similar to hypothetical protein (H. sapiens) (LOC82646), mRNA 159A7 19 561 XM_018498 NA 1.00E−167 3 ribosomal protein L5 (RPL5), mRNA Length = 984 459H2 2956 3450 Y16414 NA 0 1 mRNA for exportin (tRNA) Length = 3497

[0823] TABLE 3B Identified Genomic Regions that code for novel human mRNA's Example Genome Number Clone Start End Accession Probability Clones Genbank Description 172H5 12457 13616 AC000015 0 2 chromosome 4 clone B271E1 map 4q25, complete sequence L 464A9 21144 21280 AC000068 2.00E−70 1 Chromosome 22q11.2 Cosmid Clone 102g9 In DGCR Region, c 472B10 20340 20745 AC000087 2.00E−67 1 Chromosome 22q11.2 Cosmid Clone 83c5 In DGCR Region, co 103C4 93389 93611 AC000119 0 5 BAC clone RG104I04 from 7q21-7q22, 119111 119521 AC000119 complete sequence [H 119522 119890 AC000119 119989 121059 AC000119 514A3 201218 201293 AC000353 5.00E−34 2 Chromosome 11q13 BAC Clone 18h3, complete sequence Leng 524A9 24315 24820 AC002073 0 3 PAC clone RP3-515N1 from 22q11.2-q22, 24879 25274 AC002073 complete sequence 458D10 28080 28625 AC002297 0 1 Genomic sequence from 9q34, complete sequence [Homo sap 476D3 106080 106289 AC002302 1.00E−86 1 Chromosome 16 BAC clone CIT987-SKA- 345G4-complete geno 471D10 34638 34885 AC002306 1.00E−118 2 DNA from chromosome 19-cosmid R33799, genomic sequence, 596F6 75526 76327 AC002467 0 1 BAC clone CTA-364P16 from 7q31, complete sequence [Homo 473F3 74912 75540 AC002549 0 2 Xp22 BAC GS-377014 (Genome Systems BAC library) complet 111E12 24581 24992 AC003086 0 1 BAC clone CTB-104F4 from 7q21-q22, complete sequence Le 471E9 39706 40014 AC003103 1.00E−151 1 chromosome 17, clone HCIT268N12, complete sequence Leng 526B9 39477 39615 AC003695 3.00E−29 1 chromosome 17, clone hRPC.859_O_20, complete sequence L 331A3 47793 48492 AC003976 1.00E−164 5 chromosome 17, clone hCIT.91_J_4, complete sequence Len 105C1 115642 116079 AC004067 0 1 chromosome 4 clone B366O24 map 4q25, complete sequence 469H8 35828 35976 AC004080 5.00E−71 1 PAC clone RP1-170O19 from 7p15-p21, complete sequence L 55F9 114263 114415 AC004169 3.00E−46 1 chromosome 4 clone C0236G06 map 4p16, complete sequence 487F9 35319 35718 AC004187 0 1 clone UWGC: y17c131 from 6p21, complete sequence Length 459H7 13409 13739 AC004190 1.00E−166 1 from UWGC: y18c282 from 6p21, complete sequence Length = 464D1 28530 29042 AC004221 1.00E−106 1 DNA from chromosome 19, cosmid R29144 (LLNLR-252D12) an 468A7 53111 53416 AC004386 5.00E−80 2 Homo Sapiens Chromosome X clone bWXD691, complete seque 188F1 859 1200 AC004520 0 1 BAC clone CTB-119C2 from 7p15, complete sequence Length 523F5 38269 38756 AC004644 3.00E−38 1 chromosome 16, cosmid clone 367E12 (LANL), complete seq 142E4 113118 114014 AC004686 0 14 chromosome 17, clone hRPC.1073_F_15, 117050 117275 AC004686 complete sequence 135F10 39469 39637 AC004762 3.00E−75 1 chromosome 20, P1 clone 28 (LBNL H134), complete sequen 472C8 120427 120603 AC004838 6.00E−92 1 PAC clone RP4-589D8 from 7q31.1-q31.3, complete sequenc 464F11 64853 65242 AC004849 5.00E−59 2 PAC clone RP4-659J6 from 7q33-q35, complete sequence Le 460D2 54796 55320 AC004854 0 1 PAC clone RP4-673M15 from 7p13-p11.2, complete sequence 513B4 94866 95147 AC004858 2.00E−57 1 PAC clone RP4-687K1 from 14, complete sequence Length = 463C7 53959 54083 AC004906 1.00E−44 1 PAC clone RP5-852O24 from 7p22, complete sequence Lengt 584D3 56155 56311 AC004913 5.00E−36 1 clone DJ0876A24, complete sequence Length = 98870 171B1 23796 24098 AC004918 1.00E−145 1 PAC clone RP5-894A10 from 7q32-q32, complete sequence L 463B10 33758 34061 AC004923 1.00E−135 1 PAC clone RP5-901A4, complete sequence Length = 94851 101A1 50075 50425 AC004997 1.00E−129 1 PAC clone RP1-130H16 from 22q12.1-qter, complete sequen 465G8 28181 28635 AC005014 0 1 BAC clone GS1-166A23 from 7p21, complete sequence Lengt 470C3 93162 93469 AC005068 1.00E−160 1 BAC clone CTB-137N13 from 7, complete sequence Length = 119E5 28806 29061 AC005156 1.00E−119 1 PAC clone RP5-1099C19 from 7q21-q22, complete sequence 98C3 24385 25049 AC005192 0 1 BAC clone CTB-163K11 from 7q31, complete sequence Lengt 140G6 37679 37878 AC005280 6.00E−85 1 PAC clone RP1-240K6 from 14, complete sequence Length = 476A10 12753 12826 AC005306 8.00E−33 1 chromosome 19, cosmid R27216 (LLNLR- 232D4) and 3′ overl 331A12 34177 34328 AC005391 2.00E−72 1 chromosome 19, cosmid R29942, complete sequence Length 111H11 85156 86081 AC005488 0 2 clone NH0313P13, complete sequence Length = 185737 472H11 22517 22813 AC005531 1.00E−150 1 PAC clone RP4-701O16 from 7q33-q36, complete sequence L 139G6 96577 97117 AC005540 0 3 clone RP11-533I8, complete sequence 116180 116836 AC005540 Length = 133761 472F4 70951 71038 AC005593 3.00E−41 1 chromosome 5, P1 clone 1369f10 (LBNL H28), complete seq 469D4 27949 28457 AC005667 0 1 chromosome 17, clone hRPK.329_E_11, complete sequence L 463A7 127455 127799 AC005740 1.00E−154 1 chromosome 5p, BAC clone 50g21 (LBNL H154), complete se 126B8 27782 28073 AC005837 1.00E−160 2 chromosome 17, clone hRPK.318_A_15, complete sequence L 479D2 202167 202536 AC005859 2.00E−46 1 Xp22-83 BAC GSHB-324M7 (Genome Systems BAC Library) com 39G6 62582 63099 AC005920 0 1 chromosome 17, clone hRPK.700_H_6, complete sequence Le 63E1 39129 39250 AC006006 3.00E−59 1 PAC clone RP4-813F11 from 7q32-q34, complete sequence L 461B11 140287 140770 AC006010 1.00E−154 2 clone DJ0935K16 119G10 81312 81740 AC006033 0 1 BAC clone RP11-121A8 from 7p14-p13, complete sequence L 64A2 109063 109613 AC006050 0 2 chromosome 17, clone hRPK.268_F_2, complete sequence Le 459B7 13630 14294 AC006077 0 1 chromosome 5, P1 clone 254f11 (LBNL H62), complete sequ 37H4 58820 59068 AC006111 1.00E−67 1 chromosome 16 clone RP11-461A8, complete sequence Lengt 512E3 39935 40123 AC006139 3.00E−94 1 clone UWGC: y55c068 from 6p21, complete sequence Length 171H10 33704 33969 AC006165 8.00E−78 1 clone UWGC: y54c125 from 6p21, complete sequence Length 72A1 106659 106958 AC006207 1.00E−149 1 12p13.3 BAC RPCI3-488H23 (Roswell Park Cancer Institute 195H12 38763 38930 AC006323 2.00E−61 1 clone RP5-1151M5, complete sequence Length = 86267 113B6 36330 36635 AC006344 1.00E−157 1 PAC clone RP4-726N20 from 7q32-q34, complete sequence L 588G6 174012 174265 AC006449 2.00E−93 1 chromosome 17, clone hCIT.58_E_17, complete sequence Le 463B2 65534 66031 AC006483 0 1 BAC clone CTB-161C1 from 7, complete sequence Length = 115F11 71976 72094 AC006511 8.00E−60 1 12p13.1 (17.1-21.3 cM) BAC RPCI11-69M1 (Roswell Park Ca 187H11 34068 34544 AC006536 0 1 chromosome 14 clone BAC257P13 map 14q31, complete seque 477E6 106567 106656 AC007009 6.00E−30 1 BAC clone RP11-560C1 from 7p22-p21, complete sequence L 53E10 123408 123785 AC007040 0 1 BAC clone RP11-298H3 from 2, complete sequence Length = 462C8 164080 164223 AC007068 4.00E−72 2 12p BAC RPCI11-75L1 (Roswell Park 174303 174379 AC007068 Cancer Institute BAC 478C7 27207 27305 AC007097 4.00E−43 1 BAC clone RP11-332E22 from 7q35-q36, complete sequence 181A8 4600 4798 AC007201 5.00E−59 2 chromosome 19, cosmid R34383, complete sequence Length 159F6 111852 112188 AC007263 1.00E−151 1 chromosome 14 clone RP11-79J20 containing gene for chec 163F10 94927 95303 AC007283 1.00E−126 2 BAC clone RP11-536I18 from 2, complete sequence Length 124G4 192082 192785 AC007318 0 3 clone RP11-420C9, complete sequence Length = 204230 331A5 117939 118047 AC007383 3.00E−51 1 BAC clone RP11-310K15 from 2, complete sequence Length 463C5 101528 101815 AC007444 9.00E−41 1 clone RP11-340F1 from 7p14-15, complete sequence Length 485D5 94681 95267 AC007458 1.00E−152 8 12q15 BAC RPCI11-444B24 (Roswell Park 95517 95826 AC007458 Cancer Institute 95858 96487 AC007458 96742 96838 AC007458 187608 187732 AC007458 181B6 95554 96149 AC007488 0 2 3q27 BAC RPCI11-246B7 (Roswell Park Cancer Institute BA 102E12 12533 12977 AC007540 4.00E−93 1 12q24.1 BAC RPCI11-128P10 (Roswell Park Cancer Institut 471C6 9877 10401 AC007561 1.00E−160 1 clone RP11-394E1, complete sequence Length = 106093 471C1 27629 27769 AC007676 1.00E−27 1 clone RP11-9B17, complete sequence Length = 152138 40D4 120766 121349 AC007882 0 1 BAC clone RP11-499D5 from 7p11.2-q11.2, complete sequen 166C10 90374 90790 AC007899 0 1 BAC clone RP11-531C11 from 2, complete sequence Length 492A7 11200 11376 AC007911 7.00E−57 1 chromosome 18, clone RP11-520K18, complete sequence Len 459B3 65768 66232 AC008009 0 2 3q26.2-27 BAC RPCI11-436A20 (Roswell Park Cancer Instit 463F10 127622 127783 AC008083 3.00E−85 1 12 BAC RP11-493L12 (Roswell Park Cancer Institute BAC L 585C4 176255 176348 AC008124 6.00E−38 1 Chromosome 12q13-62.7-72 BAC RPCI11- 352M15 (Roswell Par 468E6 134033 134685 AC008279 0 2 BAC clone RP11-427F22 from 2, complete sequence Length 112E9 37565 37926 AC008408 0 4 chromosome 5 clone CTC-278H1, complete 37996 38360 AC008408 sequence Length 145C5 131866 132484 AC008592 1.00E−141 8 chromosome 5 clone CTC-576H9, complete 134190 134862 AC008592 sequence Length 458D8 82521 83080 AC008623 0 1 chromosome 19 clone CTB-14D10, complete sequence Length 584G2 44371 44929 AC008723 0 2 chromosome 5 clone CTB-95B16, complete sequence Length 144F7 73662 74295 AC008750 2.00E−54 2 chromosome 19 clone CTD-2616J11, complete sequence Leng 149G2 99171 99875 AC008760 1.00E−121 6 chromosome 19 clone CTD-3128G10, complete sequence Leng 194H6 52930 53250 AC008795 5.00E−89 2 chromosome 5 clone CTD-2052F19, 57088 57263 AC008795 complete sequence Lengt 117H9 101321 102169 AC008860 0 11 chromosome 5 clone CTD-2185A1, complete 102715 102980 AC008860 sequence Length 103113 103402 AC008860 155D6 34277 34517 AC008982 1.00E−103 1 chromosome 19 clone LLNLF-172E10, complete sequence Len 458E4 33802 34039 AC008985 8.00E−77 1 chromosome 19 clone LLNLF-198H7, complete sequence Leng 176A6 170428 170746 AC009073 1.00E−138 1 chromosome 16 clone RP11-31O11, complete sequence Lengt 146D8 11633 11699 AC009086 1.00E−28 1 chromosome 16 clone RP11-368N21, complete sequence Leng 458B8 176406 176888 AC009120 0 1 chromosome 16 clone RP11-484E3, complete sequence Lengt 73C4 136885 137479 AC009299 0 1 BAC clone RP11-26B22 from 2, Complete sequence Length = 54F4 202039 202564 AC009312 0 1 clone RP11-425F6, complete sequence Length = 204834 480E2 143559 143986 AC009313 0 1 BAC clone RP11-440P12 from 2, complete sequence Length 519E9 13492 13848 AC009404 1.00E−178 1 BAC clone RP11-28H22 from 2, complete sequence Length = 129D12 81260 81769 AC009466 1.00E−151 1 chromosome 11, clone RP11-87N22, complete sequence Leng 37E10 124522 125457 AC009477 0 3 BAC clone RP11-209H16 from 2, complete sequence Length 129A12 6750 7331 AC009506 0 1 clone RP11-542H1, complete sequence Length = 191764 515H10 5494 5990 AC009812 3.00E−69 4 chromosome 3, clone RP11-48B3, complete 74019 74540 AC009812 sequence Length 165D1 53879 54343 AC009951 0 1 clone RP11-107E5, complete sequence Length = 159791 53D8 30308 30860 AC010132 1.00E−159 1 BAC clone RP11-111K18 from 7p11.2-p2, complete sequence 487F11 16839 17267 AC010480 1.00E−130 3 chromosome 5 clone CTD-2315M5, complete sequence Length 461G10 8988 9327 AC010677 1.00E−163 1 BAC clone CTD-2304L4 from 7, complete sequence Length = 115H2 19073 19679 AC010789 4.00E−97 2 chromosome 10, clone RP11-190J1, 126247 126428 AC010789 complete sequence Leng 168A9 78976 79540 AC010877 0 2 BAC clone RP11-218F6 from Y, complete sequence Length = 468G6 98034 98744 AC010878 1.00E−107 3 clone RP11-230E20, complete sequence Length = 154115 477B12 167367 167895 AC010913 0 1 BAC clone RP11-44N22 from 2, complete sequence Length = 192E1 10683 11328 AC011245 0 1 clone RP11-498O5, complete sequence Length = 56793 467C2 4521 4890 AC011462 1.00E−178 1 chromosome 19 clone CTC-435M10, complete sequence Lengt 189F3 12090 12208 AC011495 8.00E−60 1 chromosome 19 clone CTB-33G10, complete sequence Length 144C9 38166 38421 AC011500 1.00E−62 1 chromosome 19 clone CTB-60E11, complete sequence Length 162E8 41387 41499 AC012005 8.00E−30 1 clone RP11-533E23, complete sequence Length = 189557 158G6 70285 70462 AC012170 3.00E−95 1 chromosome 15 clone RP11-562A8 map 15q21.1, complete se 189B11 19127 19241 AC013436 8.00E−29 3 BAC clone RP11-105B9 from 7, complete 23196 23655 AC013436 sequence Length = 98C9 178883 179326 AC015651 1.00E−107 1 chromosome 17, clone RP11-55A13, complete sequence Leng 69F8 57839 58168 AC015819 0 1 chromosome 18, clone RP11-405M12, complete sequence Len 47F9 3198 3826 AC016395 0 1 chromosome 10 clone RP11-153K11, complete sequence Leng 480E3 39766 40155 AC016623 2.00E−35 1 chromosome 5 clone CTD-2345N17, complete sequence Lengt 196G12 59552 60523 AC016637 0 2 chromosome 5 clone RP11-34J15, complete sequence Length 518A8 61011 61433 AC016751 0 1 BAC clone RP11-504O20 from 2, complete sequence Length 36C11 54765 54868 AC017002 2.00E−30 2 clone RP11-68E19, complete sequence Length = 205662 489H9 108513 109049 AC017003 0 2 clone RP11-78C11, complete sequence Length = 118385 479H6 142657 142930 AC017020 8.00E−45 1 BAC clone RP11-185K15 from Y, complete sequence Length 483D10 99413 99875 AC017101 0 1 clone RP11-556A11, complete sequence Length = 195635 112B4 87464 88155 AC018511 1.00E−129 2 chromosome 10 clone RP11-77G23, 117653 117940 AC018511 complete sequence Lengt 171F2 157933 158203 AC018673 2.00E−96 1 clone RP11-145A4, complete sequence Length = 187099 166H12 116351 116665 AC018682 1.00E−177 1 clone RP11-417F21, complete sequence Length = 181405 123F8 140561 141314 AC018904 0 3 chromosome 15 clone RP11-50C13 map 15q21.3, complete se 116C9 191414 191866 AC019206 0 1 BAC clone RP11-401N16 from 2, complete sequence Length 472E9 148765 149172 AC020550 1.00E−140 1 BAC clone RP11-198M19 from 2, complete sequence Length 129D1 66284 67154 AC020595 0 3 BAC clone RP11-358M9 from 2, complete sequence Length = 465H10 82476 83166 AC020629 0 2 12q BAC RP11-76E16 (Roswell Park Cancer Institute BAC L 182E2 83346 83465 AC020716 1.00E−33 2 clone RP11-449G13, complete sequence 84373 84451 AC020716 Length = 171805 37G8 35257 35957 AC020750 0 1 chromosome 3 clone RP11-105H19 map 3p, complete sequenc 125F8 43854 44125 AC022007 1.00E−149 1 chromosome 3 clone RP11-481H17 map 3p, complete sequenc 523A8 2991 3475 AC022149 0 1 chromosome 19 clone CTD-3093B17, complete sequence Leng 459E7 90726 91104 AC022173 0 1 chromosome 7 clone RP11-29B3, complete sequence Length 469F8 53281 53724 AC022336 6.00E−92 1 3 BAC RP11-71H17 (Roswell Park Cancer Institute BAC Lib 463H5 75118 75256 AC022382 5.00E−72 1 chromosome 3 clone RP11-266J6 map 3p, complete sequence 466G7 20276 20522 AC023058 2.00E−53 2 3 BAC CTB-187G23 (CalTech BAC Library 21327 21875 AC023058 B) complete seque 470B8 127894 128301 AC024568 1.00E−169 1 chromosome 5 clone CTD-2179L22, complete sequence Lengt 473E11 21558 21818 AC024939 1.00E−117 1 12 BAC RP11-485K18 (Roswell Park Cancer institute BAC L 470E1 150190 150573 AC025165 1.00E−171 1 12 BAC RP11-571M6 (Roswell Park Cancer Institute BAC Li 480B5 107499 107766 AC025253 9.00E−66 1 12 BAC RP11-499A10 (Roswell Park Cancer Institute BAC L 583B5 27783 27958 AC025257 1.00E−44 1 12 BAC RP11-56G10 (Roswell Park Cancer Institute BAC Li 37H8 86118 86418 AC026425 1.00E−148 1 chromosome 5 clone CTD-2183D23, complete sequence Lengt 166A9 119110 119797 AC026794 0 1 chromosome 5 clone CTD-2276B5, complete sequence Length 103D4 105697 105794 AC034240 5.00E−40 2 chromosome 5 clone CTD-2335C11, complete sequence Lengt 117H4 49581 49962 AC053513 0 1 clone RP11-359J14, complete sequence Length = 155958 459B8 64143 64709 AC066580 0 1 chromosome 3 clone RP11-109J15 map 3p, complete sequenc 174D1 41807 42055 AC067945 2.00E−69 2 clone RP11-629B4, complete sequence 115078 115365 AC067945 Length = 162471 178F5 105048 105223 AC068492 7.00E−37 1 BAC clone RP11-809C23 from 2, complete sequence Length 66E6 2116 2578 AC068499 1.00E−135 2 chromosome 19, cosmid R26574 (LLNL- R_225F10), complete 178C12 15618 15959 AC068789 0 1 12 BAC RP11-1049A21 (Roswell Park Cancer Institute BAC 145F12 110468 110647 AC069298 3.00E−89 4 chromosome 3 clone RP11-56K23, complete 110779 111202 AC069298 sequence Length 141211 141790 AC069298 519F3 159763 160355 AC069304 0 1 BAC clone RP11-632K21 from 7, complete sequence Length 464B11 52608 53051 AC073347 0 1 BAC clone RP11-775L16 from 7, complete sequence Length 469E12 85540 85930 AC073917 0 2 12q BAC RP11-415D21 (Roswell Park Cancer Institute BAC 118C12 141407 141495 AC083868 6.00E−70 3 chromosome 7 clone RP11-148L5, complete 142293 142607 AC083868 sequence Length 168G5 6632 7097 AC087065 0 2 chromosome 22q11 clone cos6, complete sequence Length = 479G12 127024 127342 AC090942 1.00E−119 1 chromosome 3 clone RP11-220D14 map 3p, complete sequenc 122G1 41957 42383 AC091118 0 1 chromosome 16 clone CTC-510K1, complete sequence Length 479D7 153992 154141 AF001549 6.00E−29 1 Chromosome 16 BAC clone CIT987SK-A- 270G1, complete sequ 461H7 21977 22331 AF015262 2.00E−69 1 chromosome 21 clone Pac 255P7 map 21q- AML, complete seq 463E9 27006 27615 AF015725 0 1 chromosome 21 clone cosmid clone D68F9 map 21q22.2, com 480D9 15848 16252 AF027207 1.00E−123 1 chromosome 21 clone cosmid D13C2 map 21q22.2, complete 465E9 296143 296800 AF131216 0 1 chromosome 8 map 8p23-p22 clones CTB- 164D9, CTB-169o5, 469D2 23811 24045 AF161800 2.00E−78 1 chromosome 8q21.2 BAC 189m5, complete sequence Length = 37G7 200214 200755 AJ003147 0 2 complete genomic sequence between 201078 201309 AJ003147 D16S3070 and D16S3275 459A1 36969 37402 AL008730 8.00E−82 2 DNA sequence from PAC 487J7 on chromosome 6q21-22.1. Co 480C8 37929 38457 AL008733 0 1 DNA sequence from clone RP1-163G9 on chromosome 1p36.2- 462D9 36712 37037 AL021878 0 2 DNA sequence from clone RP1-257I20 on 40603 40772 AL021878 chromosome 22q13. 182H1 30506 30760 AL022238 3.00E−96 2 DNA sequence from clone RP5-1042K10 on chromosome 22q13 166F6 75035 75547 AL022240 0 1 DNA sequence from clone 328E19 on chromosome 1q12-21.2 165C12 179455 179766 AL022329 1.00E−175 1 DNA sequence from clone CTA-407F11 on chromosome 22q12 465A12 26329 26834 AL022331 0 1 DNA sequence from clone CTA-440B3 on chromosome 22q12.1 524D1 70719 70891 AL022394 2.00E−87 1 DNA sequence from clone RP3-511B24 on chromosome 20q11. 53E3 129077 129538 AL022396 0 1 DNA sequence from PAC 380E11 on chromosome 6p22.3-p24. 126D1 69809 70220 AL031178 0 1 DNA sequence from clone RP3-341E18 on chromosome 6p11.2 466A9 103757 104346 AL031277 0 1 DNA sequence from clone 1177E19 on chromosome 1p36.12-3 472E11 41594 41778 AL031595 9.00E−97 1 DNA sequence from clone RP4-671O14 on chromosome 22q13. 462E8 72042 72629 AL031672 0 1 DNA sequence from clone RP4-691N24 on chromosome 20p11. 478C2 29633 29708 AL031708 9.00E−28 1 DNA sequence from clone LA16-315G5 on chromosome 16, co 53B1 30963 31311 AL031729 1.00E−163 1 DNA sequence from clone RP1-159A19 on chromosome 1p36.1 178B2 38674 38800 AL033383 3.00E−27 1 DNA sequence from clone RP5-1013A10 on chromosome 6p24. 104A7 40604 41062 AL033397 0 1 DNA sequence from clone 27K12 on chromosome 6p11.2-12.3 190F11 77693 78285 AL033519 0 1 DNA sequence from clone RP3-340B19 on chromosome 6p21.2 121A11 15252 15679 AL034344 9.00E−52 1 DNA sequence from clone RP1-118B18 on chromosome 6p24.1 173B5 102500 102752 AL034384 7.00E−58 1 chromosome Xq28, cosmid clones 7H3, 14D7, C1230, 11E7, 121A12 34566 34684 AL034397 6.00E−47 1 DNA sequence from clone 159A1 on chromosome Xq12-13.3. 104B10 73639 74045 AL034418 1.00E−176 1 DNA sequence from clone RP5-1049G16 on chromosome 20q12 471F1 37083 37364 AL034553 1.00E−150 1 DNA sequence from clone RP5-914P20 on chromosome 20q13. 463H8 97563 97753 AL035405 1.00E−102 1 DNA sequence from clone 21O18 on chromosome 1p35.1-36.2 472E6 20949 21271 AL035413 1.00E−155 1 DNA sequence from clone RP4-657E11 on chromosome 1p35.1 121F1 65029 65503 AL035455 0 1 DNA sequence from clone RP5-1018E9 on chromosome 20q13. 465B1 37269 37445 AL035530 2.00E−47 1 DNA sequence from clone RP1-111C20 on chromosome 6q25.3 482C9 64837 65129 AL035662 1.00E−163 1 DNA sequence from clone RP4-599F21 on chromosome 20q12- 166B9 39808 39976 AL049715 1.00E−87 1 DNA sequence from clone RP4-646P11 on chromosome 1, com 591D6 65470 65892 AL049795 0 1 DNA sequence from clone RP4-622L5 on chromosome 1p34.2- 72G1 82160 82440 AL049829 1.00E−148 1 chromosome 14 DNA sequence *** IN PROGRESS *** BAC R-12 112H3 2111 2535 AL050330 0 2 DNA sequence from clone RP1-3E1 on chromosome 6p21.23-2 479G5 18853 19244 AL096712 1.00E−125 1 DNA sequence from clone RP4-744I24 on chromosome 6p12.1 464C10 80145 80583 AL096773 4.00E−85 1 DNA sequence from clone 1000E10 on chromosome 1p12-13.3 123D11 34999 35510 AL096808 1.00E−166 1 genomic region containing hypervariable minisatellites 129F10 1148 2507 AL109616 0 95 chromosome 21 Cosmid LLNLc116L1110, complete sequence L 469B8 13155 13527 AL109755 0 1 DNA sequence from clone RP3-340H11 on chromosome 6q24.1 105F4 57995 58306 AL109758 5.00E−98 1 chromosome 14 DNA sequence *** IN PROGRESS *** BAC R-87 465H5 136248 136356 AL109847 7.00E−29 1 chromosome 14 DNA sequence BAC R- 603H7 of library RPCI- 60G8 84706 84959 AL109914 1.00E−135 1 DNA sequence from clone RP11-27F12 on chromosome 6p22.3 102A8 169378 169473 AL109918 2.00E−34 1 DNA sequence from clone RP1-152L7 on chromosome 6p11.2- 471D6 63862 64021 AL117186 4.00E−80 1 chromosome 14 DNA sequence *** IN PROGRESS *** BAC R-29 176E10 145991 146554 AL117258 3.00E−63 1 chromosome 14 DNA sequence BAC R- 244E17 of library RPCI 480E7 2975 3356 AL117352 1.00E−153 1 DNA sequence from clone RP5-876B10 on chromosome 1q42.1 110D3 48631 48886 AL121573 3.00E−65 2 DNA sequence from clone RP1-306F2 on chromosome 6p12.1- 40B2 106788 107123 AL121657 2.00E−42 1 BAC sequence from the SPG4 candidate region at 2p21-2p2 52B9 56473 56690 AL121899 1.00E−104 2 DNA sequence from clone RP11-128M1 on chromosome 20. Co 485A6 5475 7084 AL121985 1.00E−138 7 DNA sequence from clone RP11-404F10 on 15867 16574 AL121985 chromosome 1q23. 17098 17504 AL121985 24037 24292 AL121985 40E4 54176 54528 AL121998 1.00E−179 1 DNA sequence from clone RP5-1103B4 on chromosome 1 Cont 118H12 21398 21744 AL132838 0 1 chromosome 14 DNA sequence BAC R- 85G20 of library RPCI- 599F11 153822 154345 AL133153 0 1 chromosome 14 DNA sequence BAC R- 895M11 of library RPCI 478G8 115784 116115 AL133243 1.00E−120 1 BAC sequence from the SPG4 candidate region at 2p21-2p2 107H8 119760 120729 AL133330 0 22 DNA sequence from clone RP1-68D18 on 121182 121863 AL133330 chromosome 11p12-1 122773 122940 AL133330 143751 144379 AL133330 146057 147016 AL133330 159262 159639 AL133330 471E7 127891 128013 AL133340 6.00E−46 1 DNA sequence from clone RP11-204H22 on chromosome 20. C 118H5 3922 4021 AL133392 1.00E−38 2 DNA sequence from clone CITF22-45C1 on 4557 5184 AL133392 chromosome 22 Co 40A3 96202 96785 AL133412 0 3 DNA sequence from clone RP11-131A5 on 97177 97568 AL133412 chromosome 9q22.1 482A5 28668 29037 AL133415 3.00E−34 4 DNA sequence from clone RP11-124N14 on 51083 51210 chromosome 10. C 54G9 54866 55153 AL135783 1.00E−154 1 DNA sequence from clone RP3-527F8 on chromosome Xq25-27 515C12 72222 72601 AL135818 1.00E−146 2 chromosome 14 DNA sequence BAC C- 2547L24 of library Cal 109A9 53171 53447 AL136320 1.00E−137 1 DNA sequence from clone RP3-323N1 on chromosome 10. Con 476H10 127150 127680 AL137017 0 1 DNA sequence from clone RP11-120J1 on chromosome 9 Cont 192C3 122511 122837 AL137100 1.00E−117 1 chromosome 14 DNA sequence BAC R- 108M12 of library RPCl 55G3 38923 39058 AL137142 7.00E−44 2 DNA sequence from clone RP11-173P16 on 42456 42686 AL137142 chromosome 13q12 466G2 24290 24402 AL137144 9.00E−42 1 DNA sequence from clone RP11-210E23 on chromosome 13q31 140F9 27354 27715 AL137798 8.00E−82 1 DNA sequence from clone RP5-1182A14 on chromosome 1 Con 37A2 134590 134750 AL137800 3.00E−69 1 DNA sequence from clone RP1 -127C7 on chromosome 1q25.1- 493C2 734 1052 AL138714 1.00E−157 1 DNA sequence from clone RP11-121J7 on chromosome 13q32. 468B9 1911 2509 AL138717 9.00E−70 1 DNA sequence from clone RP11-11D8 on chromosome 6 Conta 194F9 46595 46814 AL138755 6.00E−94 1 DNA sequence from clone RP11-48M17 on chromosome 9p24.1 483D12 80220 80755 AL138776 1.00E−157 1 DNA sequence from clone RP11-20H6 on chromosome 1q25.1- 464G9 14032 14659 AL139020 0 1 chromosome 14 DNA sequence BAC R- 164H13 of library RPCI 59G1 34476 34936 AL139274 0 1 DNA sequence from clone RP11-393l2 on chromosome 6, com 129D3 65447 65661 AL139289 1.00E−107 2 DNA sequence from clone RP1-92O14 on 66950 67158 AL139289 chromosome 1p33-34 464C2 55616 56289 AL139328 0 1 DNA sequence from clone RP11-84N7 on chromosome 13. Con 57H10 155342 155810 AL139330 0 2 DNA sequence from clone RP11-266C7 on chromosome 6q25.2 470G6 44695 44978 AL139399 1.00E−130 1 DNA sequence from clone RP11-574A21 on chromosome Xq2l. 476F5 42969 43159 AL139801 5.00E−98 1 DNA sequence from clone RP11-247M1 on chromosome 13, co 107G11 139776 140378 AL157402 0 2 DNA sequence from clone RP11-553K8 on chromosome 1q31.2 172B12 136072 136492 AL157768 1.00E−155 1 DNA sequence from clone RP11-481A22 on chromosome 13 Co 149A11 438 663 AL157776 1.00E−123 1 DNA sequence from clone RP11-68J15 on chromosome 6, com 165E7 66361 67034 AL157789 0 1 chromosome 14 DNA sequence BAC R- 880O3 of library RPCI- 192B3 51907 52253 AL157938 1.00E−176 1 DNA sequence from clone RP11-544A12 on chromosome 9q34. 50A11 5753 5886 AL158136 1.00E−59 1 DNA sequence from clone RP1-44N23 on chromosome 6 Conta 472F9 84638 85232 AL158159 0 1 DNA sequence from clone RP11-498N2 on chromosome 9, com 462G12 132520 132708 AL160155 2.00E−95 1 DNA sequence from clone RP11-461N23 on chromosome 13, c 117H6 1976 2518 AL160233 0 1 chromosome 14 DNA sequence BAC C- 2373J19 of library Cal 460B9 207 739 AL160408 1.00E−104 2 DNA sequence from clone RP4-781K5 on 2023 2537 AL160408 chromosome 1q42.1- 467F10 8461 8829 AL161627 1.00E−122 1 DNA sequence from clone RP11-287A8 on chromosome 9, com 469A10 81966 82313 AL161781 1.00E−175 1 DNA sequence from clone RP11-297B17 on chromosome 9, co 598H2 222231 222679 AL162151 0 1 chromosome 14 DNA sequence*** IN PROGRESSss*** BAC C-31 466C5 147064 147687 AL162578 0 1 DNA sequence from clone RP11-2J18 on chromosome 6, comp 467C9 216403 216544 AL163303 3.00E−38 1 chromosome 21 segment HS21C103 Length = 340000 462H9 63385 63502 AL163853 6.00E−59 1 chromosome 14 DNA sequence BAC R- 248B10 of library RPCI 464A10 63421 63807 AL353744 2.00E−55 1 clone RP13-100-A9 on chromosome X 99E10 6789 7153 AL353804 0 1 DNA sequence from clone RP13-216E22 on chromosome Xq13. 477D10 49708 50171 AL354716 4.00E−96 1 DNA sequence from clone RP11-86F4 on chromosome 6, comp 518F10 3379 3602 AL354891 2.00E−94 1 DNA sequence from clone RP11-44I7 on chromosome 13, com 464D8 122494 122702 AL354977 1.00E−87 2 DNA sequence from clone RP11-509J21 on chromosome 9, co 459H6 109525 109864 AL355520 1.00E−179 1 DNA sequence from clone RP4-595C2 on chromosome 1q24.1- 196C6 21603 21783 AL355615 7.00E−96 2 DNA sequence from clone RP11-33E24 on chromosome 6, com 110B8 11907 12312 AL355797 1.00E−145 1 DNA sequence from clone RP1-9E2 on chromosome 6, comple 180B2 142517 142726 AL355871 1.00E−72 1 DNA sequence from clone RP11-47K11 on chromosome 1, com 464H5 50106 50463 AL356276 0 2 DNA sequence from clone RP11-367J7 on chromosome 1. Con 105H4 32156 32236 AL356379 2.00E−27 2 DNA sequence from clone RP1-63P18 on 32440 32804 AL356379 chromosome 1. Cont 113H1 22550 22837 AL356481 1.00E−160 1 DNA sequence from clone RP11-216B9 on chromosome 9, com 170F7 46442 46855 AL357374 0 1 DNA sequence from clone RP11-353C18 on chromosome 20 Co 522D3 113148 113424 AL360182 1.00E−127 1 DNA sequence from clone RP11-549L6 on chromosome 10, co 36E9 38157 38346 AL390196 4.00E−47 9 clone RP11-60E24 on chromosome 6 587E3 15704 16062 AL442128 1.00E−173 2 DNA sequence from clone RP11 -365P13 on chromosome 13, c 468E8 52779 53344 AL445201 1.00E−123 1 DNA sequence from clone RP11-358L16 on chromosome 10, c 39G11 106047 106169 AL445687 2.00E−26 1 clone RP11-567B20 on chromosome 1 101F1 1538 1656 AL449244 5.00E−44 2 Novel human gene mapping to chomosome 1676 2096 AL449244 22 Length = 2315 466D1 56761 56929 AL450344 5.00E−85 1 DNA sequence from clone RP11-136K14 on chromosome 6 Con 142E9 116227 116568 AL590763 0 8 chromosome X sequence from 6 PACs 1 116669 117358 AL590763 BAC and 1 cosmid, r 154792 155165 AL590763 459E9 26826 26890 AP000471 2.00E−27 1 genomic DNA, chromosome 21q22.3, clone: B2308H15 Length 472C1 95646 96035 AP000501 1.00E−101 1 genomic DNA, chromosome 8p11.2, clone: 91h23 to 9-41 Len 464A7 7930 8285 AP000526 1.00E−178 1 genomic DNA, chromosome 22q11.2, Cat Eye Syndrome regio 165E11 643 1244 AP000554 1.00E−147 2 genomic DNA, chromosome 22q11.2, BCRL2 region, clone: KB 72D8 27091 27486 AP000555 0 1 genomic DNA, chromosome 22q11.2, BCRL2 region, clone: KB 470B4 15634 15703 AP001429 5.00E−28 1 genomic DNA, chromosome 21q22.2, clone: T1212, LB7T-ERG 59E12 59103 59520 AP001574 1.00E−144 2 genomic DNA, chromosome 8q23, clone: 60671 61189 AP001574 KB1991G8 Length = 138G5 313261 313931 AP001693 1.00E−31 27 genomic DNA, chromosome 21q, section 315877 315967 AP001693 37/105 Length = 34 319062 319564 AP001693 319957 320293 AP001693 320563 321212 AP001693 328757 329184 AP001693 158G11 107888 108375 AP001721 0 1 genomic DNA, chromosome 21q, section 65/105 Length = 34 462F9 330129 330645 AP001728 1.00E−133 1 genomic DNA, chromosome 21q, section 72/105 Length = 34 479A12 74529 74902 AP002907 1.00E−141 1 genomic DNA, chromosome 8q23, clone: KB431C1 Length = 9 470B2 123506 123689 AP003117 4.00E−72 2 genomic DNA, chromosome 8q23, clone: KB1958F4 Length = 46D1 79174 79657 AP003471 1.00E−164 2 genomic DNA, chromosome 8q23, clone: 83490 84099 AP003471 KB1552D7 Length = 496C4 745790 746197 NT_004406 0 1 chromosome 1 working draft sequence segment 468E10 2015 2118 NT_004452 2.00E−32 2 chromosome 1 working draft sequence segment 479H12 394087 394676 NT_004480 0 1 chromosome 1 working draft sequence segment 472G2 268543 268642 NT_004525 3.00E−42 1 chromosome 1 working draft sequence segment 477D9 231154 231469 NT_004531 1.00E−177 1 chromosome 1 working draft sequence segment 460F7 786014 786511 NT_004623 0 1 chromosome 1 working draft sequence segment 171F11 1E+06 1036701 NT_004658 1.00E−26 1 chromosome 1 working draft sequence segment 184H1 2E+06 1770512 NT_004698 0 4 chromosome 1 working draft sequence 2E+06 1822054 NT_004698 segment 2E+06 1832854 NT_004698 514H9 289858 289941 NT_004705 1.00E−29 1 chromosome 1 working draft sequence segment 463G1 175158 175615 NT_004725 0 1 chromosome 1 working draft sequence segment 466C9 543567 544240 NT_004753 0 1 chromosome 1 working draft sequence segment 496D7 2E+06 1515549 NT_004754 0 1 chromosome 1 working draft sequence segment 583G8 733247 733667 NT_004771 1.00E−128 1 chromosome 1 working draft sequence segment 124D2 107397 107739 NT_004916 1.00E−178 1 chromosome 1 working draft sequence segment 479A8 285973 286345 NT_005130 1.00E−165 1 chromosome 2 working draft sequence segment 165F7 1E+06 1435537 NT_005151 1.00E−125 1 chromosome 2 working draft sequence segment 465F7 773772 774502 NT_005166 0 2 chromosome 2 working draft sequence segment 73A3 80919 81448 NT_005182 0 2 chromosome 2 working draft sequence 81502 81742 NT_005182 segment 124G7 2E+06 1859389 NT_005204 1.00E−180 1 chromosome 2 working draft sequence segment 479G6 552674 553005 NT_005229 1.00E−141 5 chromosome 2 working draft sequence 1E+06 1122605 NT_005229 segment 194C2 481052 481444 NT_005230 1.00E−101 1 chromosome 2 working draft sequence segment 159F11 795978 796616 NT_005275 0 1 chromosome 2 working draft sequence segment 472B1 1013 1410 NT_005311 0 1 chromosome 2 working draft sequence segment 470G7 375182 375594 NT_005399 0 1 chromosome 2 working draft sequence segment 100C3 803712 804094 NT_005420 0 2 chromosome 2 working draft sequence 970577 971108 NT_005420 segment 98H4 2E+06 1829143 NT_005423 0 1 chromosome 2 working draft sequence segment 105A10 1E+06 1144092 NT_005435 1.00E−167 2 chromosome 2 working draft sequence segment 465C3 13444 13890 NT_005471 0 1 chromosome 2 working draft sequence segment 112E5 3169 3793 NT_005485 0 1 chromosome 2 working draft sequence segment 111H6 146878 146999 NT_005499 2.00E−55 1 chromosome 3 working draft sequence segment 467G7 198880 199329 NT_005505 0 1 chromosome 3 working draft sequence segment 182F12 140059 140193 NT_005516 1.00E−144 3 chromosome 3 working draft sequence 140754 141039 NT_005516 segment 112B5 137689 138300 NT_005529 0 4 chromosome 3 working draft sequence segment 64B3 55213 55793 NT_005535 0 1 chromosome 3 working draft sequence segment 465E12 866776 867258 NT_005769 0 2 chromosome 3 working draft sequence 1E+06 1021292 NT_005769 segment 470D5 1E+06 1395364 NT_005795 1.00E−147 3 chromosome 3 working draft sequence 2E+06 1749621 NT_005795 segment 479G2 294179 294607 NT_005910 0 1 chromosome 3 working draft sequence segment 112E1 392884 393490 NT_005973 0 1 chromosome 3 working draft sequence segment 466H5 339511 340153 NT_005985 0 2 chromosome 3 working draft sequence segment 189A8 22414 22869 NT_005991 1.00E−110 1 chromosome 3 working draft sequence segment 45H8 1E+06 1012040 NT_006098 1.00E−113 1 chromosome 4 working draft sequence segment 104D1 282259 282753 NT_006102 0 2 chromosome 4 working draft sequence segment 459G8 367701 368248 NT_006111 0 1 chromosome 4 working draft sequence segment 480E11 486179 486804 NT_006114 0 1 chromosome 4 working draft sequence segment 115G2 4E+06 3514655 NT_006204 1.00E−177 1 chromosome 4 working draft sequence segment 479G3 71744 72258 NT_006258 0 1 chromosome 4 working draft sequence segment 461H11 378023 378482 NT_006397 0 1 chromosome 4 working draft sequence segment 462F11 80360 81081 NT_006410 0 1 chromosome 4 working draft sequence segment 463A5 2E+06 1609976 NT_006489 1.00E−138 1 chromosome 5 working draft sequence segment 464C5 190095 190533 NT_006611 0 2 chromosome 5 working draft sequence segment 109H9 89260 89769 NT_006946 0 3 chromosome 5 working draft sequence segment 137B5 2E+06 1613357 NT_006951 1.00E−86 4 chromosome 5 working draft sequence segment 73H4 992358 992685 NT_007288 0 1 chromosome 6 working draft sequence segment 174H6 431672 432054 NT_007308 0 1 chromosome 6 working draft sequence segment 124C8 282413 283138 NT_007951 0 1 chromosome 7 working draft sequence segment 174G11 829762 830370 NT_007972 0 1 chromosome 8 working draft sequence segment 471H11 613132 613314 NT_007978 9.00E−96 1 chromosome 8 working draft sequence segment 471G8 189279 189630 NT_008012 1.00E−147 1 chromosome 8 working draft sequence segment 67C5 287017 287563 NT_008037 0 2 chromosome 8 working draft sequence segment 479H4 90555 90944 NT_008047 1.00E−174 1 chromosome 8 working draft sequence segment 100D7 64180 64371 NT_008050 1.00E−134 6 chromosome 8 working draft sequence 331150 331412 NT_008050 segment 45B9 479878 480193 NT_008060 1.00E−165 12 chromosome 8 working draft sequence 489788 490607 NT_008060 segment 169F11 291836 292284 NT_008081 0 1 chromosome 8 working draft sequence segment 468H11 106661 106897 NT_008128 1.00E−121 2 chromosome 8 working draft sequence 110374 110691 NT_008128 segment 470H6 520107 520754 NT_008139 0 1 chromosome 8 working draft sequence segment 471F9 392744 393279 NT_008157 0 1 chromosome 8 working draft sequence segment 469G8 433686 434156 NT_008338 0 1 chromosome 9 working draft sequence segment 193E6 1E+06 1228306 NT_008445 6.00E−56 1 chromosome 9 working draft sequence segment 480D2 90407 90990 NT_008484 0 1 chromosome 9 working draft sequence segment 58G4 1E+06 1055972 NT_008513 1.00E−139 1 chromosome 9 working draft sequence segment 490F10 669853 669980 NT_008653 5.00E−39 2 chromosome 10 working draft sequence 743459 744217 NT_008653 segment 463B3 1E+06 1369815 NT_008682 0 1 chromosome 10 working draft sequence segment 116E10 1E+06 1462064 NT_008769 0 5 chromosome 10 working draft sequence 2E+06 2026887 NT_008769 segment 2E+06 2027460 NT_008769 2E+06 2028265 NT_008769 190A9 806672 807345 NT_008774 0 4 chromosome 10 working draft sequence segment 473B7 75339 75524 NT_008783 4.00E−72 2 chromosome 10 working draft sequence 75869 76181 NT_008783 segment 490A11 484304 484753 NT_008921 0 1 chromosome 10 working draft sequence segment 585E10 328767 329151 NT_008978 0 1 chromosome 11 working draft sequence segment 458B9 955258 955846 NT_009073 0 1 chromosome 11 working draft sequence segment 471F4 288811 289312 NT_009107 0 1 chromosome 11 working draft sequence segment 478H7 1E+06 1255050 NT_009184 1.00E−92 1 chromosome 11 working draft sequence segment 109F10 1E+06 1136705 NT_009314 1.00E−171 1 chromosome 11 working draft sequence segment 117F1 401530 402043 NT_009334 0 2 chromosome 11 working draft sequence 2E+06 1600694 NT_009334 segment 467B6 3E+06 3011938 NT_009338 5.00E−93 2 chromosome 11 working draft sequence segment 158H6 351515 351940 NT_009438 0 2 chromosome 12 working draft sequence segment 471C2 977560 977791 NT_009452 1.00E−127 1 chromosome 12 working draft sequence segment 182G2 21455 21913 NT_009458 0 3 chromosome 12 working draft sequence 167133 167630 NT_009458 segment 462B12 518389 518876 NT_009464 0 1 chromosome 12 working draft sequence segment 458A3 2E+06 1890445 NT_009471 0 1 chromosome 12 working draft sequence segment 470D7 9540 10050 NT_009540 0 1 chromosome 12 working draft sequence segment 525F3 163261 163590 NT_009616 1.00E−125 1 chromosome 12 working draft sequence segment 186E8 2E+06 1502030 NT_009714 0 1 chromosome 12 working draft sequence segment 465G2 2E+06 1787964 NT_009759 1.00E−130 2 chromosome 12 working draft sequence segment 476C1 321714 322118 NT_009763 1.00E−170 1 chromosome 12 working draft sequence segment 476G8 2E+06 1609230 NT_009770 6.00E−26 1 chromosome 12 working draft sequence segment 588E4 1E+06 1136791 NT_010036 1.00E−134 1 chromosome 14 working draft sequence segment 479H5 2E+06 2151529 NT_010062 0 1 chromosome 14 working draft sequence segment 178C10 6E+06 6026576 NT_010113 0 1 chromosome 14 working draft sequence segment 192C9 5E+06 5344032 NT_010194 0 1 chromosome 15 working draft sequence segment 119F12 3E+06 2680702 NT_010204 1.00E−128 1 chromosome 15 working draft sequence segment 67G10 112609 112890 NT_010222 1.00E−132 2 chromosome 15 working draft sequence segment 98C1 6684 7232 NT_010237 0 1 chromosome 15 working draft sequence segment 458G10 478693 479052 NT_010253 1.00E−120 1 chromosome 15 working draft sequence segment 459D1 2E+06 2123962 NT_010289 0 1 chromosome 15 working draft sequence segment 110G1 303146 303706 NT_010308 0 1 chromosome 15 working draft sequence segment 73A4 758542 758734 NT_010310 6.00E−42 1 chromosome 15 working draft sequence segment 470F5 495497 496038 NT_010360 0 1 chromosome 15 working draft sequence segment 469B6 1E+06 1095404 NT_010419 1.00E−123 1 chromosome 16 working draft sequence segment 479E10 468259 468674 NT_010432 0 1 chromosome 16 working draft sequence segment 100F5 177425 177795 NT_010505 1.00E−169 1 chromosome 16 working draft sequence segment 462C5 22345 22727 NT_010523 0 1 chromosome 16 working draft sequence segment 71H3 125549 125838 NT_010530 5.00E−77 1 chromosome 16 working draft sequence segment 161E8 1E+06 1067677 NT_010641 1.00E−123 1 chromosome 17 working draft sequence segment 464D9 120516 121079 NT_010657 0 1 chromosome 17 working draft sequence segment 114G3 385825 386329 NT_010672 1.00E−152 3 chromosome 17 working draft sequence 387069 387398 NT_010672 segment 424808 425286 NT_010672 459E6 262663 263161 NT_010757 0 1 chromosome 17 working draft sequence segment 134H3 583781 583868 NT_010799 7.00E−32 1 chromosome 17 working draft sequence segment 467E5 1E+06 1376833 NT_010808 0 1 chromosome 17 working draft sequence segment 462A11 436300 437040 NT_010816 0 2 chromosome 17 working draft sequence segment 460C2 168998 169554 NT_010833 0 1 chromosome 17 working draft sequence segment 467A8 480458 480865 NT_010986 0 1 chromosome 18 working draft sequence segment 480F8 137902 138430 NT_011029 0 1 chromosome 18 working draft sequence segment 470F8 472324 472740 NT_011141 0 1 chromosome 19 working draft sequence segment 100E3 445588 445677 NT_011145 2.00E−37 2 chromosome 19 working draft sequence 445757 446041 NT_011145 segment 104A12 169627 169811 NT_011240 2.00E−99 1 chromosome 19 working draft sequence segment 69B10 358921 359000 NT_011245 6.00E−37 1 chromosome 19 working draft sequence segment 465C7 243467 243788 NT_011269 0 1 chromosome 19 working draft sequence segment 464E7 1E+06 1182829 NT_011597 1.00E−107 1 chromosome X working draft sequence segment 61A11 67055 67582 NT_011724 0 1 chromosome X working draft sequence segment 140G10 761394 761693 NT_015805 1.00E−138 3 chromosome 2 working draft sequence 761753 762151 NT_015805 segment 486C4 503899 504524 NT_016354 0 2 chromosome 4 working draft sequence segment 480G4 260275 260648 NT_016355 0 1 chromosome 4 working draft sequence segment 461G8 276786 277233 NT_016593 0 1 chromosome 4 working draft sequence segment 118D9 413201 413343 NT_016968 7.00E−46 1 chromosome 6 working draft sequence segment 68C9 2E+06 2193260 NT_017568 1.00E−169 1 chromosome 9 working draft sequence segment 470E5 526603 527148 NT_017582 1.00E−131 2 chromosome 9 working draft sequence segment 127H8 248872 249411 NT_019390 0 1 chromosome 5 working draft sequence segment 47G6 204946 205445 NT_019447 0 1 chromosome 7 working draft sequence segment 467E8 210239 210638 NT_021889 1.00E−170 1 chromosome 1 working draft sequence segment 480C6 210001 210545 NT_021897 0 1 chromosome 1 working draft sequence segment 69H11 94439 94993 NT_021903 1.00E−104 1 chromosome 1 working draft sequence segment 107D7 466791 467280 NT_021918 0 1 chromosome 1 working draft sequence segment 471E11 418049 418124 NT_021967 8.00E−32 1 chromosome 1 working draft sequence segment 468F11 370984 371480 NT_022103 0 1 chromosome 1 working draft sequence segment 464H12 1E+06 1024449 NT_022171 1.00E−155 1 chromosome 2 working draft sequence segment 462B11 242113 242753 NT_022174 0 1 chromosome 2 working draft sequence segment 196D7 65778 66218 NT_022315 0 5 chromosome 2 working draft sequence 66514 66886 NT_022315 segment 100E10 148157 148338 NT_022358 4.00E−95 1 chromosome 2 working draft sequence segment 142F9 193054 193433 NT_022457 0 6 chromosome 3 working draft sequence 240726 241196 NT_022457 segment 286545 287198 NT_022457 595A12 40034 40650 NT_022488 0 2 chromosome 3 working draft sequence segment 75A2 24792 25256 NT_022555 1.00E−133 1 chromosome 3 working draft sequence segment 468G12 276616 277068 NT_022751 0 1 chromosome 4 working draft sequence segment 471F6 403620 404200 NT_022765 6.00E−89 1 chromosome 4 working draft sequence segment 463H12 197991 198185 NT_022795 2.00E−88 1 chromosome 4 working draft sequence segment 473E4 408745 409322 NT_022840 1.00E−123 2 chromosome 4 working draft sequence segment 461C8 544633 545127 NT_022844 0 1 chromosome 4 working draft sequence segment 470G10 148269 148781 NT_022855 0 1 chromosome 4 working draft sequence segment 480F3 471820 472173 NT_023178 1.00E−138 1 chromosome 5 working draft sequence segment 176G2 98388 98683 NT_023529 1.00E−153 1 chromosome 7 working draft sequence segment 71F2 62180 62604 NT_023654 0 1 chromosome 8 working draft sequence segment 459F2 324390 324869 NT_023660 0 1 chromosome 8 working draft sequence segment 124F9 275971 276413 NT_023666 0 1 chromosome 8 working draft sequence segment 111H9 388593 389283 NT_023676 0 1 chromosome 8 working draft sequence segment 460D12 527418 527528 NT_023703 3.00E−43 1 chromosome 8 working draft sequence segment 129D7 104058 104672 NT_023833 1.00E−170 1 chromosome 8 working draft sequence segment 183G2 183398 183840 NT_023923 1.00E−112 1 chromosome 9 working draft sequence segment 478G6 41677 41996 NT_023945 1.00E−137 1 chromosome 9 working draft sequence segment 163E7 1E+06 1455953 NT_023959 1.00E−126 1 chromosome 9 working draft sequence segment 472G12 21182 21574 NT_024016 0 1 chromosome 9 working draft sequence segment 466B7 471195 471690 NT_024040 1.00E−138 1 chromosome 10 working draft sequence segment 459D2 315088 315482 NT_024091 0 1 chromosome 10 working draft sequence segment 468B10 791272 792086 NT_024101 0 2 chromosome 10 working draft sequence segment 175D1 270651 271264 NT_024115 0 2 chromosome 10 working draft sequence segment 472D7 16139 16549 NT_024223 0 1 chromosome 11 working draft sequence segment 476G3 71426 71803 NT_024498 1.00E−144 1 chromosome 13 working draft sequence segment 138B6 2E+06 1638986 NT_024680 0 2 chromosome 15 working draft sequence segment 466A4 308514 309137 NT_024767 0 1 chromosome 16 working draft sequence segment 583D6 551386 551654 NT_024781 1.00E−133 1 chromosome 16 working draft sequence segment 468F10 91355 92043 NT_024815 1.00E−132 2 chromosome 16 working draft sequence segment 461D9 406470 406916 NT_024897 0 2 chromosome 17 working draft sequence 440400 440720 NT_024897 segment 520A8 168514 168868 NT_024997 0 1 chromosome 18 working draft sequence segment 128F5 113027 113221 NT_025378 6.00E−82 1 chromosome X working draft sequence segment 467B11 519341 519633 NT_025635 1.00E−113 1 chromosome 1 working draft sequence segment 464E11 8932 9161 NT_025657 1.00E−126 1 chromosome 2 working draft sequence segment 188C1 1E+06 1221531 NT_025823 4.00E−72 1 chromosome 10 working draft sequence segment 468B2 156035 156630 NT_025900 1.00E−150 2 chromosome 16 working draft sequence segment 470F3 427484 428029 NT_026379 0 2 chromosome 10 working draft sequence segment 36G1 483362 484059 NT_026443 0 1 chromosome 15 working draft sequence segment 466B5 19929 20420 NT_026455 1 .00E−123 1 chromosome 16 working draft sequence segment 105A8 3431 3518 U12202 6.00E−34 1 ribosomal protein S24 (rps24) gene, complete cds Length 175D10 18139 18285 U18671 8.00E−45 2 Stat2 gene, complete cds Length = 18648 BAC956, complete sequence Length = 116F9 68889 69093 U85199 6.00E−69 1 105232 598F3 22246 22656 U91318 0 1 chromosome 16 BAC clone CIT987SK-A- 962B4, complete sequ 471G1 1 109 Z56926 9.00E−54 1 CpG island DNA genomic Mse1 fragment, clone 153c6, forw 516D5 1 143 Z62429 4.00E−53 1 CpG island DNA genomic Mse1 fragment, clone 69a1, forwa 107D11 81 292 Z63603 1.00E−104 1 CpG island DNA genomic Mse1 fragment, clone 87h3, forwa 481D4 12379 12686 Z69304 1.00E−101 1 DNA sequence from cosmid V311G7, between markers DXS366 461G6 23967 24497 Z69715 1.00E−173 2 DNA sequence from clone LL22NC03-74G7 on chromosome 22 465F5 15468 15659 Z77852 3.00E−70 1 DNA sequence from cosmid LUCA2 on chromosome 3p21.3 con 459B2 26193 26772 Z82248 0 2 DNA sequence from clone LL22NC03-44A4 on chromosome 22 478E5 49480 49615 Z83847 6.00E−50 1 DNA sequence from clone RP3-496C20 on chromosome 22 Con 469E6 4705 5229 Z83851 0 1 DNA sequence from clone 989H11 on chromosome 22q13.1-13 517H5 128852 129155 Z85986 1.00E−156 1 DNA sequence from clone 108K11 on chromosome 6p21 Conta 114C1 15995 16486 Z93016 1.00E−121 3 DNA sequence from clone RP1-211D12 on 77940 78185 Z93016 chromosome 20q12- 118A8 117801 118272 Z97989 0 2 DNA sequence from PAC 66H14 on 132708 132773 Z97989 chromosome 6q21-22. Cont

[0824] TABLE 3C Table of novel human nucleotide sequences compared to assembled human sequences, depicting putative exon-intron structure Exon Exon Clone Genome Clone Genome Clone Accession Start Stop Start Stop Start Stop Start Stop 47D11 NT_008060 90 407 480193 479876 406 586 478843 478662 53G7 NT_008060 4 204 478642 478842 204 459 479917 480171 62C9 NT_015169 29 224 220269 220464 321 384 220540 220603 62G9 NT_006328 1 145 566357 566213 144 219 565724 565649 65B1 NT_006098 243 454 2418134 2418345 303 462 2421648 2421807 65D10 NT_025892 218 401 369301 369483 404 541 370290 370427 65D11 NT_025892 98 241 367311 367453 240 425 369301 369486 65D12 NT_025892 98 219 367333 367453 218 399 369301 369483 72D4 NT_008060 1 198 478646 478843 197 489 479876 480168 73A7 NT_008060 1 197 478646 478842 197 538 479917 480259 75B12 NT_010265 1 171 309301 309471 169 267 315278 315376 NT_010265 587 658 319041 319112 100B5 NT_006098 16 142 556012 556138 143 336 560579 560772 105B11 NT_022315 2 226 66662 66886 429 491 89124 89186 170F9 NT_010194 4 324 6405068 6405386 323 465 6407864 6408006 144F5 NT_011595 1 280 125097 124818 345 491 120524 120378 166H7 NT_009729 59 130 537939 537868 127 281 537177 537023 NT_009729 579 672 491513 491419 171A10 NT_009151 2 244 6556227 6556469 245 396 6556693 6556846 98E1 NT_006098 12 138 556012 556138 139 328 560579 560768 134B4 NT_011512 3 251 12517461 12517709 252 338 12519881 12519967 172E5 NT_009935 5 449 1427508 1427952 448 551 1434457 1434560 176F12 NT_011520 48 309 6163505 6163766 308 409 6163866 6163967 51B9 NT_021980 75 578 120596 121099 3 79 120203 120279 51B12 NT_007140 1 85 309298 309214 79 609 300215 299684 191F6 NT_010194 7 330 6405063 6405386 329 473 6407864 6408008 459F10 NT_008982 1 121 92783 92903 116 314 93005 93202 461H12 NT_023539 19 94 332693 332768 92 166 334220 334294 463C3 NT_010478 1 186 1307774 1307960 183 314 1308993 1309124 465B3 NT_010222 41 227 700806 700992 227 414 701556 701743 513G4 NT_005130 1 134 384702 384569 133 204 383722 383651 515E10 NT_023563 1 169 9743 9575 169 309 8111 7971 466B10 NT_006292 1 331 936306 935977 244 745 935875 935374 466F9 NT_024872 17 186 64694 64525 184 295 61751 61640 121B6 NT_023169 2 98 183171 183075 258 455 164976 164779 462D1 NT_023923 139 298 191231 191072 297 528 190168 189937 64G9 NT_025892 68 210 367311 367453 209 394 369301 369486 467C6 NT_010101 1 73 1265999 1266071 218 330 1295695 1295807 NT_010101 546 687 1334907 1335047 467G9 NT_011157 69 142 917117 917044 142 253 916090 915979 476G4 NT_007592 58 121 2382380 2382443 120 362 2382598 2382840 477E1 NT_008680 1 116 1185208 1185323 116 472 1186107 1186462 477A11 NT_006292 1 325 936300 935977 238 851 935875 935262 480A3 NT_010478 1 99 2220394 2220492 181 525 2221546 2221890 518H1 NT_005337 1 73 2383056 2383128 125 229 2386650 2386754 519A9 NT_016632 64 193 172305 172434 191 279 176990 177078 521F2 NT_023563 3 107 7651 7756 110 254 7968 8111 597A4 NT_023563 1 109 7647 7755 109 256 7964 8111 491G11 NT_010265 1 127 284740 284866 123 242 288529 288648 494B11 NT_007343 25 246 3168142 3167921 244 334 3162477 3162387 479A1 NT_015169 1 109 293941 293833 112 217 289082 288977 47D11 NT_008060 53G7 NT_008060 62C9 NT_015169 449 518 220668 220737 517 774 220958 221215 62G9 NT_006328 217 315 563987 563889 315 418 563775 563672 65B1 NT_006098 65D10 NT_025892 65D11 NT_025892 423 562 370288 370427 561 690 376519 376648 65D12 NT_025892 402 541 370290 370427 72D4 NT_008060 491 585 489271 489365 73A7 NT_008060 75B12 NT_010265 264 441 316976 317153 440 588 317239 317387 NT_010265 100B5 NT_006098 331 416 561268 561353 105B11 NT_022315 170F9 NT_010194 144F5 NT_011595 279 347 123833 123765 490 559 118816 118747 166H7 NT_009729 282 362 529971 529891 363 581 495632 495414 NT_009729 171A10 NT_009151 98E1 NT_006098 330 506 561271 561447 134B4 NT_011512 336 448 12523936 12524048 172E5 NT_009935 176F12 NT_011520 51B9 NT_021980 51B12 NT_007140 191F6 NT_010194 459F10 NT_008982 461H12 NT_023539 164 298 334438 334572 300 470 335340 335510 463C3 NT_010478 315 429 1309210 1309324 427 559 1309492 1309625 465B3 NT_010222 513G4 NT_005130 202 281 378695 378616 287 346 299615 299556 515E10 NT_023563 466B10 NT_006292 466F9 NT_024872 294 626 59515 59185 121B6 NT_023169 460 576 163071 162955 462D1 NT_023923 64G9 NT_025892 392 531 370288 370427 467C6 NT_010101 330 468 1315073 1315211 467 547 1315798 1315878 NT_010101 467G9 NT_011157 476G4 NT_007592 477E1 NT_008680 477A11 NT_006292 480A3 NT_010478 518H1 NT_005337 227 366 2393104 2393243 519A9 NT_016632 521F2 NT_023563 597A4 NT_023563 256 452 9575 9771 491G11 NT_010265 494B11 NT_007343 479A1 NT_015169 218 338 285931 285811

[0825] TABLE 4 The Library Browser at the NCBI UniGene web site was used to identify genes that are specifically expressed in leukocyte cell populations. Sequences before Library Library Name Category reduction Sequences on array* Lib. 2228 Human_leukocyte_MATCHMAKER_cDNA_Library other/unclassified 4 3 Lib. 238 RA-MO-III (activated monocytes from RA patient) Blood 2 1 Lib. 242 Human_peripheral_blood_(Whole)_(Steve_Elledge) Blood 4 2 Lib. 2439 Subtracted_cDNA_libraries_from_human_Jurkat_cells other/unclassified 4 1 Lib. 323 Activated_T-cells_I other/unclassified 19 3 Lib. 327 Monocytes,_stimulated_II Blood 92 35 Lib. 387 Macrophage_I other/unclassified 84 24 Lib. 409 Activated_T-cells_IV other/unclassified 37 10 Lib. 410 Activated_T-cells_VIII other/unclassified 27 10 Lib. 411 Activated_T-cells_V other/unclassified 41 9 Lib. 412 Activated_T-cells_XII other/unclassified 29 12 Lib. 413 Activated_T-cells_XI other/unclassified 13 6 Lib. 414 Activated_T-cells_II other/unclassified 69 30 Lib. 429 Macrophage_II other/unclassified 56 24 Lib. 4480 Homo_sapiens_rheumatoid_arthritis_fibroblast-like_synovial other/unclassified 7 6 Lib. 476 Macrophage,_subtracted_(total_cDNA) other/unclassified 11 1 Lib. 490 Activated_T-cells_III other/unclassified 9 5 Lib. 491 Activated_T-cells_VII other/unclassified 27 8 Lib. 492 Activated_T-cells_IX other/unclassified 16 5 Lib. 493 Activated_T-cells_VI other/unclassified 31 15 Lib. 494 Activated_T-cells_X other/unclassified 18 5 Lib. 498 RA-MO-I (activated peripheral blood monocytes from RA patient) Blood 2 1 Lib. 5009 Homo_Sapiens_cDNA_Library_from_Periph- other/unclassified 3 3 eral_White_Blood_Cell Lib. 6338 human_activated_B_lymphocyte Tonsils 9 8 Lib. 6342 Human_lymphocytes other/unclassified 2 2 Lib. 646 Human_leukocyte_(M. L. Markelov) other/unclassified 1 1 Lib. 689 Subtracted_cDNA_library_of_activated_B_lymphocyte Tonsil 1 1 Lib. 773 PMA-induced_HL60_cell_subtraction_library (leukemia) other/unclassified 6 3 Lib. 1367 cDNA_Library_from_rIL-2_activated_lymphocytes other/unclassified 3 2 Lib. 5018 Homo_sapiens_CD4+_T-cell_clone_HA1.7 other/unclassified 6 3 Lib. 376 Activated_T-cells_XX other/unclassified 999 119 Lib. 669 NCI_CGAP_CLL1 (Lymphocyte) Blood 353 81♯ Lib. 1395 NCI_CGAP_Sub6 (germinal center b-cells) B cells germinal 389 100♯ Lib. 2217 NCI_CGAP_Sub7 (germinal center b-cells) B cells germinal 605 200♯ Lib. 289 NCI_CGAP_GCB1 (germinal center b-cells) Tonsil 935 200♯ Total 3914 939

[0826] TABLE 5 Nucleotide sequence databases used for analysis Threshold of Significance Database Version Description Location of file Used nr Release GenBank + EMBL + DDBJ + P ftp:/ncbi.nlm.nih.gov/ Expect value 123.0 DB sequences (but no EST, blast/nt.Z (e) < 10⁻²⁵ STS, GSS, or HTGS sequences). No longer “non- redundant”. dbEST Apr. 10, 2001 Non-redundant Database of ftp:/ncbi.nlm.nih.gov/ Expect value GenBank + EMBL + DDBJ blast/est_human.Z (e) < 10⁻²⁵ EST Division UniGene_unique Build 132 One sequence selected from ftp:/ncbi.nlm.nih.gov/ Expect value each UniGene cluster (the pub/shuler/unigene/ (e) < 10⁻²⁵ one with the longest region of Hs.seq.uniq.Z high-quality sequence data). Human Genome Build 22 Sequence data of all contigs ftp:/ncbi.nlm.nih.gov/ Expect value used to assemble the human genomes/H_sapiens/ (e) < 10⁻²⁵ genome CHR_#/hs_chr#.fa.gz

[0827] TABLE 6 Algorithms used for exon and polypeptide prediction Algorithm Description Web address Genscan Predicts the locations and exon-intron http://genes.mit.edu/GENSCAN.html structures of genes in genomic sequences. Genomescan Incorporates protein homology http://genes.mit.edu/genomescan.html information when predicting genes. GrailEXP Predicts exons, genes, promoters, http://grail.lsd.ornl.gov/grailexp/ polyAs, CpG islands, EST similarities, and repetitive elements within a DNA sequence. G-Known Predicts genes and features of a DNA http://www.cse.ucsc.edu/research/compbio/pgf/ sequence at user-specified levels of complexity. Can incorporate extra information supplied by user including gene predictions from other gene finding programs, EST hits, similarities to known proteins, synteny between corresponding genomic regions in related organisms, methylation of the bases, regulatory binding sites, and topology information. FGENES Uses linear and hidden Markov models http://genomic.sanger.ac.uk/gf/gf.shtml for exon prediction

[0828] TABLE 7 Databases and algorithms used for Protein Analysis Algorithm Description Web address BLASTP, version 2.0 Identification of unknown protein or http://www.ncbi.nlm.nih.gov/BLAST/ subunit based on similarity to known proteins or subunits. BLASTX Algorithm for translating a nucleotide http://www.ncbi.nlm.nih.gov/BLAST/ query sequence and aligning the translation to sequences in protein databases TBLASTN Algorithm for aligning an unidentified http://www.ncbi.nlm.nih.gov/BLAST/ peptide sequence to predicted translations of nucleotide sequences SWISS-PROT, Protein sequence database http://www.expasy.ch/cgi-bin/ release 39.0 sprot-search-de Protein International Protein sequence database http://www-nbrf.georgetown.edu/ Resource (PIR) pirwww/ GenPept Amino acid translations from ftp://ncbi.nlm.nih.gov/genbank/ GenBank/EMBL/DDBJ records that are genpept.fsa.gz annotated with one or more CDS features TrEMBL Contains the translations of all coding http://www.ebi.ac.uk/swissprot/ sequences present in the EMBL Nucleotide Sequence Database, which are not yet integrated into SWISS-PROT Prosite, release 16.39 Database of protein families and http://www.expasy.Ch/prosite/ domains. Consists of biologically significant sites, patterns and profiles. Pfam, version 6.2 Collection of multiple sequence http://www.sanger.ac.uk/Software/ alignments and hidden Markov models Pfam/ covering many common protein domains ProDom, version 2001.1 Domain arrangements of proteins and http://protein.toulouse.inra.fr/ protein families prodom.html TMpred Prediction of transmembrane regions to http://www.ch.embnet.org/software/ aid in subcellular localization and TMPRED_form.html function predictions

[0829]

TABLE 9 Viral genomes were used to design oligonucleotides for the microarrays. The accession numbers for the viral genomes used are given, along with the gene name and location of the region used for oligonucleotide design. Virus Gene Name Genome Location Adenovirus, E1a 1226.1542 type 2 E1b_1 3270 . . . 3503 Accession E2a_2 complement(24089 . . . 25885) #J01917 E3-1 27609 . . . 29792 E4 (last exon complement(33193 . . . 32802) at 3′-end) IX 3576 . . . 4034 Iva2 complement(4081 . . . 5417) DNA Polymerase complement(5187 . . . 5418) Cytomega- HCMVTRL2 1893 . . . 2240 lovirus (IRL2) (CMV) HCMVTRL7 complement(6595 . . . 6843) Accession (IRL7) #X17403 HCMVUL21 complement(26497 . . . 27024) HCMVUL27 complement(32831 . . . 34657) HCMVUL33 43251 . . . 44423 HCMVUL54 complement(76903 . . . 80631) HCMVUL75 complement(107901 . . . 110132) HCMVUL83 complement(119352 . . . 121037) HCMVUL106 complement(154947 . . . 155324) HCMVUL109 complement(157514 . . . 157810) HCMVUL113 161503 . . . 162800 HCMVUL122 complement(169364 . . . 170599) HCMVUL123 complement(171006 . . . 172225) (last exon at 3′-end) HCMVUS28 219200 . . . 220171 Epstein- Exon in EBNA-1 RNA 67477 . . . 67649 Barr virus Exon in EBNA-1 RNA 98364 . . . 98730 (EBV) BRLF1 complement(103366 . . . 105183) Accession BZLF1 (first of complement(102655 . . . 103155) # 3 exons) NC_001345 BMLF1 complement(82743 . . . 84059) BALF2 complement(161384 . . . 164770) Human U16/U17 complement(26259 . . . 27349) Herpesvirus U89 complement(133091 . . . 135610) (HHV6) U90 complement(135664 . . . 135948) 6 U86 complement(125989 . . . 128136) Accession U83 123528 . . . 123821 # U22 complement(33739 . . . 34347) NC_001664 DR2 (DR2L) 791 . . . 2653 DR7 (DR7L) 5629 . . . 6720 U95 142941 . . . 146306 U94 complement(141394 . . . 142866) U39 complement(59588 . . . 62080) U42 complement(69054 . . . 70598) U81 complement(121810 . . . 122577) U91 136485 . . . 136829

[0830] TABLE 10A Lupus gene expression markers SEQ Oligo/ ID SEQ ID Source Unigene Acc GI (Acc) Name Strand SAM FDR CART 41 cDNA Hs.166120 NM_004031 4809287 8845 interferon regulatory factor 7 (IRF7) 1 1.1 NA T-cells 328 Tabel 3A NA NA NA 8846 53G7 1 NA surrogate 668 Table 3A Hs.169895 NM_004223 4759281 8847 ubiquitin-conjugating enzyme E2L 6 1 1.6 NA 855 Table 3A Hs.135187 NM_030930 13569892 8848 unc93 (C.elegans) homolog B 1 1.1 NA 981 Table 3A Hs.17448 AK023680 10435678 8849 cDNA FLJ13618 fis 1 1.6 NA 1001 Table 3A Hs.85155 NM_004926 15812179 8850 zinc finger protein 36, C3H type-like 1 1 NA Model II (5 gene) 3rd Splitter 1003 Table 3A Hs.24115 AK024240 10436567 8851 cDNA FLJ14178 fis 1 NA Model II (5 gene) Secondary Splitter 1025 Table 3A Hs.12293 NM_024556 13375720 8852 hypothetical protein FLJ21103 1 NA Model II (3 gene) Secondary Splitter 1035 Table 3A Hs.166254 NM_030938 20070348 8853 VMP1 ortholog of rat vacuole protein 1 1 NA surrogate 1227 Table 3A Hs.322456 NM_032039 14042969 8854 hypothetical protein DKFZp761D0211 1 NA surrogate 1341 Table 3A Hs.181165 AV756188 10914036 8855 eukaryotic translation elongation factor 1 1.6 NA 1390 Table 3A Hs.238990 NM_004064 17978497 8856 EST IMAGE: 3458141, 1 1.1 NA Similar to p27, Kip1, 1436 Table 3A Hs.288061 NM_001101 5016088 8857 actin, beta (ACTB) 1 NA Model I (3 gene) Secondary Splitter 1535 Table 3A Hs.356755 BE868389 10317165 8858 tripartite motif protein 14 (TRIM14) 1 1.6 NA 1750 Table 3A Hs.198253 NM_002122 18426974 8859 HLA-DQA1 1 1.1 NA 2102 Table 3A Hs.301921 NM_001295 4502630 8860 chemokine (C-C motif) 1 1.6 NA receptor 1 (CCR1) 2331 Table 3A Hs.172182 NM_002568 4505574 8861 poly(A)-binding protein, cytoplasmic 1 1 1.6 NA 2386 Table 3A Hs.63489 NM_002831 18104988 8862 protein tyrosine phosphatase, PTPN6 1 1.6 NA 2412 Table 3A Hs.79411 NM_002946 4506584 8863 replication protein A2 1 1.1 Model I (2 gene) Primary Splitter 2560 literature Hs.1524 NM_003811 4507608 8864 TNF (ligand) superfamily, 1 1.6 NA member 9 (TNFSF9) 2648 Table 3A Hs.38125 NM_080424 17986253 8865 SP110 nuclear body protein 1 1.6 Model I (2 gene) Primary Splitter 2895 Table 3A Hs.18420 NM_006289 16753232 8866 talin 1 (TLN1) 1 1.1 NA 3249 Table 3A Hs.7104 NM_015995 7706289 8867 cDNA DKFZp761P06121 1 NA surrogate 3305 Table 3A Hs.183125 NM_016523 7705573 8868 killer cell lectin-like receptor 1 1.6 NA subfamily F 3541 literature Hs.170222 R14692 768965 8869 Na+/H+ exchanger NHE-1 isoform 1 1.6 NA 3692 Table 3A Hs.173334 W47229 1331869 8870 ELL-RELATED RNA 1 1.1 NA POLYMERASE II 3701 Table 3A Hs.1103 NM_000660 10863872 8871 transforming growth factor, 1 1.6 NA beta 1 (TGFB1) 3741 Table 3A Hs.198951 NM_002229 4504808 8872 jun B proto-oncogene (JUNB) 1 1.1 NA 3825 Table 3A Hs.3416 NM_001122 4557260 8873 adipose differentiation-related 1 1.1 NA protein (ADFP) 3827 Table 3A Hs.139262 NM_017523 8923794 8874 XIAP associated factor-1 1 2.67 NA (HSXIAPAF1) 3832 Table 3A Hs.172182 NM_002568 4505574 8875 poly(A)-binding protein, cytoplasmic 1 1 1.6 NA 4149 Literature Hs.74621 NM_000311 4506112 8876 prion protein (p27-30) (PRNP) 1 1.6 NA 4400 db mining NA AF073705 3335589 8877 immunoglobulin lambda light chain 1 1.1 NA variable region 4a 4601 literature Hs.149609 NM_002205 4504750 8878 integrin, alpha 5 (fibronectin receptor) 1 1.6 NA 4604 db mining Hs.169824 NM_002258 4504878 8879 killer cell lectin-like receptor 1 1.1 NA subfamily B, member 1 4631 literature Hs.73839 NM_002935 4506550 8880 ribonuclease, RNase A family, 3 1 1.1 NA 4637 db mining Hs.301698 NM_003033 4506950 8881 beta-galactoside alpha-2,3- 1 NA NA sialyltransferase (SIAT4A) 5067 Table 3B Hs.356291 W16552 1290934 8882 capicua protein (CIC) mRNA 1 0 Model II (1 gene) Primary Splitter 5074 db mining NA AA701193 2704358 8883 EST Soares_fetal_liver_spleen −1 1.6 NA IMAGE: 461188 3′ 5468 Table 3A Hs.229990 AI818777 5437856 8884 EST IMAGE: 2424619 −1 1.6 NA 5531 Table 3A Hs.77393 AL567986 12921892 8885 famesyl diphosphate synthase −1 1.6 NA 5607 db mining Hs.279105 AW063509 8887446 8886 TN1012 cDNA −1 1.6 NA 6382 Table 3A Hs.179665 NM_078467 17978494 8887 cyclin-dependent kinase 1 1.6 NA inhibitor 1A (p21, Cip1) 6956 Table 3B NA BM852711 19209110 8888 ESTT (Negative stand probe 1 1.1 NA to Hs.17481) 7238 db mining Hs.56009 NM_006187 5453823 8889 2′-5′-oligoadenylate synthetase 3 1 1.1 NA 7330 db mining Hs.226307 NM_004900 4758159 8890 phorbolin 1 0.25 NA 7641 db mining Hs.100217 NM_005892 5174400 8891 formin-like (FMNL) 1 1.6 NA 8015 HUVEC Hs.198281 NM_002654 4505838 8892 pyruvate kinase, muscle (PKM2) 1 1.6 NA cDNA 8095 HUVEC Hs.251653 NM_006088 20127490 8893 tubulin, beta, 2 (TUBB2) 1 1.6 NA cDNA

[0831] TABLE 10B PCR Primers for lupus marker genes SEQ ID PRIMER SET 1 Tm SEQ ID Primer Set 2 Tm SEQ ID 41 FORWARD GAAGAGCCTGGTCCTGGTGA 62.74 8894 TGACGACATCGAGTGCTTCC 62.41 8895 REVERSE AGAGGCTGAGGCTGCTGCTA 62.82 8896 CAGCTCTAGGTGGGCTGCTC 62.56 8897 328 FORWARD GCCCAAGGGTGAAAACTGTG 62.77 8898 TGGGTCTGCTGCTGTCTGTC 62.67 8899 REVERSE TCCGTCGTTGACTTGTGTCC 62.15 8900 AGGACGGGGATGGACGTATC 63.32 8901 668 FORWARD TACATTCCCCAGAGCCAAGG 62.28 8902 GCCTGCTTGCAGGAAATGAA 63.63 8903 REVERSE GCCTGCAAGGTGACCTGTCT 62.79 8904 CTCCCACCCATATGCTCCAC 62.63 8905 855 FORWARD TACATTCCCCAGAGCCAAGG 62.28 8906 GCCTGCTTGCAGGAAATGAA 63.63 8907 REVERSE GCCTGCAAGGTGACCTGTCT 62.79 8908 CTCCCACCCATATGCTCCAC 62.63 8909 981 FORWARD CCGTAATCTTAAAGAGAAAATCTTTGGA 62.24 8910 CCCGTAATCTTAAAGAGAAAATCTTTGG 63.41 8911 REVERSE TCACTCAGAAATGGAACTTTTACCTG 61.95 8912 TCACTCAGAAATGGAACTTTTACCTGT 62.55 8913 1001 FORWARD TGGATTCCAGGTCTGGAGTTTT 62.09 8914 CACGTGCCCATCTCAAGACA 63.3 8915 REVERSE CGACGGTAGTGACCAGCAAG 61.84 8916 ATGTGTGTGTGCCAGTTCTGTTT 61.82 8917 1003 FORWARD GCCTCTCAACTGAGCAGTAAAGGT 62.42 8918 GCAGTAAAGGTAAGGAGAGCTCAATC 62.1 8919 REVERSE TGAAGTCTCAAGTGGGCATGA 61.79 8920 TGAAGTCTCAAGTGGGCATGA 61.79 8921 1025 FORWARD AACCCACTCCCCAGGCTAGA 63.2 8922 GCCGCCTGTTCAAGTTCAAG 63.16 8923 REVERSE ATCCAGACCCCGAGTCCTTC 62.71 8924 CACATTGGTGTGCTGTGTGG 62.16 8925 1035 FORWARD ATGGCAGCCTTGCCTAATCC 63.58 8926 TGCATGAGAGAGCCACTACCA 61.95 8927 REVERSE TATGCAGCAGCCCAGTTTCA 62.83 8928 AGGTAGGCCAATCCCAGAGG 62.62 8929 1227 FORWARD ACCTCTGTGCCTTGCTGCTC 63.06 8930 ATCCCAAGGAACTGGCTGTG 62.4 8931 REVERSE ATCAGGCTGCTTTGGCTACG 62.72 8932 GCCTCTTCAGGGACAGAGCA 63.01 8933 1341 FORWARD AAGGATTGATCGCCGTTTTG 62.22 8934 CTGAACCATCCAGGCCAAAT 62.17 8935 REVERSE TGGGCCTGACAAGAACCATT 62.76 8936 ACGGCGATCAATCCTTTCCT 63.1 8937 1390 FORWARD TGGCATGTTTTGTGCATTTGT 62.27 8938 AAGCCAAAGTGGCATGTTTTG 62.27 8939 REVERSE CTTGGCTCAGTATGCAACCTTTT 61.81 8940 GGCTCAGTATGCAACCTTTTAAGC 62.48 8941 1436 FORWARD GCCGAGGACTTTGATTGCAC 63.04 8942 GAACGGTGAAGGTGACAGCA 62.29 8943 REVERSE GAAGTGGGGTGGCTTTTAGGA 62.55 8944 AATCAAAGTCCTCGGCCACA 62.89 8945 1535 FORWARD TCCACACCATGGGCAGAAC 63.02 8946 CAGGGCCTGGGTTTGAATAA 62.08 8947 REVERSE GGCCCTGCAATTATTCAAACC 62.69 8948 TTGATTGCTGAATGGGAGAGG 62.41 8949 1750 FORWARD CCCTTGGTGTCTGGAAGCAC 63.01 8950 TTAGGTAGCTGGGCGGCTTA 62.06 8951 REVERSE GTCTGTGCCTTGGGGTTGTC 62.89 8952 GGTGCTTCCAGACACCAAGG 63.01 8953 2102 FORWARD AGGAAGCAGGGTTGGTTTCC 62.63 8954 CCCAGAGCCAATCAGTAGCC 62.07 8955 REVERSE CCAAGATGGCAGTCGGAACT 62.53 8956 TGTTCCCCAGGATTCCAAGA 62.71 8957 2331 FORWARD GGCTGCCCAGAAAGCAGTTA 62.7 8958 AAAGAGGCTGCCCAGAAAGC 63.13 8959 REVERSE TTCTTCGGTGAAGCACAAGTTTC 62.83 8960 TGAAGCACAAGTTTCTTTTCATGG 62.63 8961 2386 FORWARD AAGTGAGCGGTGCTGTCCTC 62.92 8962 AGCGGTCAGCAGACAAGGAG 63.04 8963 REVERSE TGGGGCACTCCTAGGTTCAG 62.51 8964 AATGCTTCCACAGGGTCAGG 62.4 8965 2412 FORWARD TGGCCTCTGCCTGTTTTCAT 63.02 8966 AGGACCAGGGCGTTATAGGC 62.56 8967 REVERSE CGTCATGGCAAGTGTGTCAA 61.78 8968 ATGCCACACAACCAAAGTCG 61.81 8969 2560 FORWARD GGGTCCCTGCTGCTTTCTCT 63.11 8970 GGCGTCCATCTTCACACTGA 62.27 8971 REVERSE TCCAACTTGGGGAAGGAGTG 62.36 8972 ACCCGGAAGAGTCCCAAGAC 62.72 8973 2648 FORWARD AGCATCCCCACCTCAGGATT 63.08 8974 TTACGGTGAGCCCTTTCAGG 62.43 8975 REVERSE GTGTCTGGGTTTGGGTCCTG 62.74 8976 GCATGTCTCGCACAAACCAT 62.09 8977 2895 FORWARD CCAAGTGCCTTCATGCCCTA 63.37 8978 TCTGCCTTCAGAGCTTCGAGA 62.79 8979 REVERSE CGGCAGATTCAGATCGAGGT 62.65 8980 CAGCCCAGAAGGCTTTGGTA 62.56 8981 3249 FORWARD CTGGCAGGACTGCAACAAGA 62.55 8982 GCTCCCTCAGCGACTACAGC 62.58 8983 REVERSE CAGATGGGGCAGCTGAACTT 62.66 8984 AGGAAAGGCCAGGGACTCAC 62.85 8985 3305 FORWARD TCCCTCCATCATCGACACTG 62.09 8986 GTCTAGCCTCAGAGTAACCCCTGTT 62.42 8987 REVERSE TTGGCATAAAATAAGCGACGAA 61.72 8988 TTGGCATAAAATAAGCGACGAA 61.72 8989 3541 FORWARD CTGCTGACCCACCAAGGTCT 62.64 8990 GAGCAGGGGTGGTTTCTACG 61.96 8991 REVERSE CCCGCAGCTCTGAGTAAGGA 62.9 8992 TCCTTCCCCTAGCAGCTTCC 62.98 8993 3692 FORWARD TGGTTGCCTTAAGGTGTTTGC 62.27 8994 ACATTAAATCCGCCCTGCAA 62.58 8995 REVERSE GCCACAGTATGCTTCCCATTG 62.7 8996 TGCTCTAATCAAGTGGGAAGCAG 62.93 8997 3701 FORWARD TTGACTTCCGCAAGGACCTC 62.65 8998 GCCTTTCCTGCTTCTCATGG 62.19 8999 REVERSE TCCAGGCTCCAAATGTAGGG 62.28 9000 CTCCGTGGAGCTGAAGCAAT 62.79 9001 3741 FORWARD TCCACCTCGACGTTTACAAGC 62.48 9002 CCTGCCCCTTTACGGACAC 62.76 9003 REVERSE CCCTCTTCCCCTCCCTGTTA 62.59 9004 GCCGGAGTCCAGTGTGGT 62.21 9005 3825 FORWARD ACCCTCCTGTCCAACATCCA 62.73 9006 TGTTAACAACACGCCCCTCA 62.45 9007 REVERSE CAGCATTGCGGAACACTGAG 62.95 9008 TGTCCATCTCTGCACCTTGG 62.26 9009 3827 FORWARD TTTTGATGTCAGAGCCCAAGC 62.57 9010 TCAGTGTGGCATCCTGCTTC 62.41 9011 REVERSE GAAGCAGGATGCCACACTGA 62.41 9012 TGAAGCTAACCACCGGCATT 62.81 9013 3832 FORWARD TGGCATGTTGTTGGAGATTGA 62.43 9014 GGCTGCCCAGAAAGCAGTTA 62.7 9015 REVERSE TGGGCAGCCTCTTTAGCTTG 62.81 9016 TTCTTCGGTGAAGCACAAGTTTC 62.83 9017 4149 FORWARD AAACCCTTTTGCGTGGTCCT 63 9018 TTAATATGTGGGAAACCCTTTTGC 62.25 9019 REVERSE CCTGTTAATGGTGTCCACTTTGG 62.79 9020 CCTGTTAATGGTGTCCACTTTGG 62.7 9021 4400 FORWARD ACATCATCGCATGGCATCAG 63.06 9022 ACAACAAGGGGAGCGGAGTT 63.23 9023 REVERSE AACTCCGCTCCCCTTGTTGT 63.23 9024 TCAGCCTCATCCTCAAACTGG 62.65 9025 4601 FORWARD CAGCTCCAAGGGGAATCAGA 62.61 9026 AGCCAGGAATTTCCCAGGAC 62.62 9027 REVERSE CTGGATCTGCCTGGATTGGT 62.38 9028 ACAGTGGGCTCCCCTTTCTC 62.85 9029 4604 FORWARD GGCAGCAACTCCGAGAGAAA 62.91 9030 TGCAGTGTGGACATTCAACAGA 62.71 9031 REVERSE GCAGGCTGGATTCTTTGGTG 63.02 9032 TCTCGGAGTTGCTGCCAATA 61.85 9033 4631 FORWARD CTCACAGGAGCCACAGCTCA 62.79 9034 CCACGGTATCCTGTGGTTCC 62.51 9035 REVERSE CACCCATAAGCCCCAACAGA 63.12 9036 TGATTGAGGAGCTTGGCAGA 62.03 9037 4637 FORWARD ATGCTCCCCTTCTTTTGCAC 62.59 9038 GGCAAGCTTGGGAATGAATG 62.78 9039 REVERSE GGAGCCTCTGGTGGCTCATA 62.65 9040 TGCTGGAGGTAATCGCCACT 63.04 9041 5067 FORWARD TCGACATGGTGAGGTAGAGCA 61.81 9042 TTTGGTGACAGTGAGCTTGAGG 62.69 9043 REVERSE TGTTCTGGCAGCACCTCAAG 62.55 9044 TGGATGGCCGTTTAGAGAGAA 61.99 9045 5074 FORWARD GGCTTARCCCAGGCATCCTC 63.1 9046 TGTCTGGAAGCCACAACTGG 62.27 9047 REVERSE GAGGCCTGCTTCCAGTTGTG 63.27 9048 GGGTTTTCTGTGGCCCTCTT 62.63 9049 5468 FORWARD CCCACTTCCCCATGTTTGTC 62.5 9050 TAAAACAGCCCAGCGCTCAC 63.65 9051 REVERSE CGGCAGATCCCTGAAATGAC 62.88 9052 GCTGGAAACCTGGCAGTGAT 62.55 9053 5531 FORWARD CCATGGGGTCTTGCCCTAC 62.62 9054 TGCTCCTTCTCGCCATCAAT 63.14 9055 REVERSE AGGCTGGACCATCAGTCAGG 62.62 9056 AGGAAGCAGCCAGGAAGATG 61.82 9057 5607 FORWARD AAACTCGGCATGTCCTCCAG 62.53 9058 CGGTCAGATCGTTGCGTAGA 62.33 9059 REVERSE CAAGGATGAGGACGGTGCTT 62.53 9060 TGGGCTTAGCCTTGATCCAC 62.43 9061 6382 FORWARD TGGGGCTGGGAGTAGTTGTC 62.4 9062 CATCCCTCCCCAGTTCATTG 62.6 9063 REVERSE GGAAGGTGTTTGGGGTCAGA 62.25 9064 GTGGCATGCCCTGTCCATA 62.91 9065 6956 FORWARD TCTTGGAGATTCGAGCAGCA 62.17 9066 AGGCAGCAGTGCAAGTGACA 63.23 9067 REVERSE CTGCGACCAGAGTCAGTGGA 62.65 9068 TGGCTATTGCTGGCCTCCTA 63.03 9069 7238 FORWARD CTCTGCCAAGTTGTCCAGCA 62.55 9070 GGACCCCAAACTCCACCTCT 62.59 9071 REVERSE AGGTACCCAACTGCGACCTG 62.43 9072 TGGACAACTTGGCAGAGCAG 62.55 9073 7330 FORWARD CCTGGGTTGAGCAGCAGAAT 62.66 9074 CAGCCCTGGGATGGACTAGA 62.5 9075 REVERSE AGCACATTGCTTTGCTGGTG 62.36 9076 AGGCCCATCCTTCAGTTTCC 62.62 9077 7641 FORWARD CAGGCTGAGGCTCAAGGAAG 62.53 9078 CCTCCGACCTCTCGCTGTAG 62.41 9079 REVERSE CCAAGAGGAGGATGCACCAG 63.11 9080 GCTGAGGACCACCTTCCTTG 62.15 9081 8015 FORWARD CCCTGGCCCTTACTTGCTTC 63.22 9082 GCAAGAGGGTGACAGCTTCC 62.3 9083 REVERSE GGTGGAGGGTGGAGTCTTTG 62.74 9084 GCTGTTTCTTGACCCCAAGC 62.09 9085

[0832] TABLE 10 C Surrogates for lupus gene expression markers SEQ Hierarchical (Oligo) Clustering ID Acc Name CART Surogates Surrogates 41 NM_004031 interferon regulatory factor 7 (IRF7) 328 unknown 53G7 668 AF061736 ubiquitin-conjugating enzyme E2L 6 855 AJ271326 unc93 (C elegans) homolog B 171 981 AK023680 cDNA FLJ13618 fis 1001 NM_004926 zinc finger protein 36, C3H type-like 1 1015, 1019, 1036, 1037, 1013, 2401, 209, 8004, 578 1003 AK024240 cDNA FLJ14178 fis 10, 100, 1005, 1004, 1001 6074 1025 AK024756 hypothetical protein FLJ21103 103, 1041, 1042, 1046, 1003 1035 NM_030938 VMP1 ortholog of rat vacuole protein 1 1227 NM_032039 hypothetical protein DKFZp761D0211 1341 AV756188 eukaryotic translation elongation factor 1390 AY004255 EST IMAGE.3458141, Similar to p27, Kip1, 1436 NM_001101 actin, beta (ACTB) 5067, 7330, 3692, 1052 1535 BE868389 tripartite motif protein 14 (TRIM14) 1750 M11124 HLA-DQA1 1770, 1769 2102 NM_001295 chemokine (C-C motif) receptor 1 (CCR1) 2331 NM_002568 poly(A)-binding protein, cytoplasmic 1 3832 2386 NM_002831 protein tyrosine phosphatase, PTPN6 2412 NM_002946 replication protein A2 855, 7330, 2331, 2895, 3741, 3692 2560 NM_303811 TNF (ligand) superfamily, member 9 (TNFSF9) 2648 NM_080424 SP110 nuclear body protein 2412, 855, 7330, 2331, 2895, 3328, 824, 2969, 371, 8016, 7238, 3827, 4 2895 NM_006289 talin 1 (TLN1) 8095, 2386 3249 NM_015995 cDNA DKFZp761P06121 3305 NM_016523 killer cell lectin-like receptor subfamily F 3541 R14692 Na⁺/H⁺ exchanger NHE-1 isoform 3692 W47229 ELL-RELATED RNA POLYMERASE II 3701 X02812 transforming growth factor, beta 1 (T6FB1) 3741 X51345 jun B proto-oncogene (JUNB) 3825 X97324 adipose differentiation-related protein (ADFP) 3827 X99699 XIAP associated factor-1 (HSXIAPAF1) 3832 Y00345 poly(A)-binding protein, cytoplasmic 1 2331 4149 NM_000311 prion protein (p27-30) (PRNP) 4444 4400 AF073705 immunoglobulin lambda light chain variable region 4a 4601 NM_002205 integrin, alpha 5 (fibronectin receptor) 4604 NM_002258 killer cell lectin-like receptor subfamily B, member 1 1991 4631 NM_002935 ribonuclease, RNase A family, 3 4637 NM_003033 beta-galactoside alpha-2,3-sialyltransferase (SIAT4A) 5067 W16552 capicua protein (CIC) mRNA 328, 2412, 1227, 3249, 2331, 7242 5074 AA701193 EST Soares_fetal_liver_spleen IMAGE.461188 3′ 5468 AI818777 EST IMAGE 2424619 5531 AL567986 farnesyl diphosphate synthase 5607 AW063509 TN1012 cDNA 6382 NM_078467 cyclin-dependent kinase inhibitor 1A (p21, Cip1) 6956 BM852711 ESTT (Negative stand probe to Hs 17481) 5278 7238 NM_006187 2′-5′-oligoadenylate synthetase 3 3328, 824, 2969, 371, 8016, 1785, 3827, 41 7330 NM_004900 phorbolin 7641 NM_005892 formin-like (FMNL) 8015 M26252 pyruvate kinase, muscle (PKM2) 8095 AK026594 tubulin, beta, 2 (TUBB2)

[0833]

0 SEQUENCE LISTING The patent application contains a lengthy “Sequence Listing” section. A copy of the “Sequence Listing” is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/sequence.html?DocID=20040009479). An electronic copy of the “Sequence Listing” will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3). 

We claim:
 1. A method of diagnosing or monitoring an autoimmune or chronic inflammatory disease in a patient, comprising detecting the expression level of one or more genes or surrogates derived therefrom in said patient to diagnose or monitor said autoimmune or chronic inflammatory disease in said patient wherein said genes comprise a nucleotide sequence selected from the group consisting of SEQ ID NO: 41; SEQ ID NO:328; SEQ ID NO:668; SEQ ID NO:855; SEQ ID NO:981; SEQ ID NO:1001; SEQ ID NO:1003; SEQ ID NO:1025; SEQ ID NO:1035; SEQ ID NO:1227; SEQ ID NO:1341; SEQ ID NO:1390; SEQ ID NO:1436; SEQ ID NO:1535; SEQ ID NO:1750; SEQ ID NO:2102; SEQ ID NO:2331; SEQ ID NO:2386; SEQ ID NO:2412; SEQ ID NO:2560; SEQ ID NO:2648; SEQ ID NO:2895, SEQ ID NO:3249; SEQ ID NO:3305; SEQ ID NO:3541;SEQ ID NO:3692; SEQ ID NO:3701; SEQ ID NO:3741; SEQ ID NO:3825; SEQ ID NO:3827; SEQ ID NO:3832; SEQ ID NO:4149; SEQ ID NO:4400; SEQ ID NO:4601; SEQ ID NO:4604; SEQ ID NO:4631; SEQ ID NO:4637; SEQ ID NO:5067; SEQ ID NO:5074; SEQ ID NO:5468; SEQ ID NO:5531; SEQ ID NO:5607; SEQ ID NO:6382; SEQ ID NO:6956; SEQ ID NO:7238; SEQ ID NO:7330; SEQ ID NO:7641; SEQ ID NO:8015 and SEQ ID NO:8095.
 2. The method of claim 1 wherein said chronic inflammatory disease is systemic lupus erythematosis (SLE). 3 The method of claim 1 wherein said expression level is detecting by measuring the RNA level expressed by said gene.
 4. The method of claim 3 further including isolating RNA from said patient prior to detecting the RNA level expressed by said gene.
 5. The method of claim 4 wherein said RNA level is detected by PCR.
 6. The method of claim 4 wherein said RNA level is detected by hybridization.
 7. The method of claim 4 wherein said RNA level is detected by hybridization to an oligonucleotide.
 8. The method of claim 7 wherein said oligonucleotide has a nucleotide sequence consisting of SEQ ID NO:
 4637. 9. The method of claim 8 wherein the nucleotide sequence comprises DNA, RNA, cDNA, PNA, genomic DNA, or synthetic oligonucleotides.
 10. The method of claim 1 wherein said expression is detecting by measuring protein levels of said gene.
 11. A diagnostic oligonucleotide for diagnosing or monitoring an autoimmune or chronic inflammatory disease in a patient wherein the oligonucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 41; SEQ ID NO: 328; SEQ ID NO:668; SEQ ID NO:855; SEQ ID NO:981; SEQ ID NO:1001; SEQ ID NO:1003; SEQ ID NO:1025; SEQ ID NO:1035; SEQ ID NO:1227; SEQ ID NO:1341; SEQ ID NO:1390; SEQ ID NO:1436; SEQ ID NO:1535; SEQ ID NO:1750; SEQ ID NO:2102; SEQ ID NO:2331; SEQ ID NO:2386; SEQ ID NO:2412; SEQ ID NO:2560; SEQ ID NO:2648; SEQ ID NO:2895, SEQ ID NO:3249; SEQ ID NO:3305; SEQ ID NO:3541;SEQ ID NO:3692; SEQ ID NO:3701; SEQ ID NO:3741; SEQ ID NO:3825; SEQ ID NO:3827; SEQ ID NO:3832; SEQ ID NO:4149; SEQ ID NO:4400; SEQ ID NO:4601; SEQ ID NO:4604; SEQ ID NO:4631; SEQ ID NO:4637; SEQ ID NO:5067; SEQ ID NO:5074; SEQ ID NO:5468; SEQ ID NO:5531; SEQ ID NO:5607; SEQ ID NO:6382; SEQ ID NO:6956; SEQ ID NO:7238; SEQ ID NO:7330; SEQ ID NO:7641; SEQ ID NO:8015 and SEQ ID NO:8095.
 12. The diagnostic oligonucleotide of claim 111, wherein said chronic inflammatory disease is systemic lupus erythematosis (SLE).
 13. The diagnostic oligonucleotide of claim 12, wherein the nucleotide sequence comprises DNA, cDNA, PNA, genomic DNA, or synthetic oligonucleotides.
 14. A system or kit for diagnosing or monitoring chronic inflammatory disease in a patient comprising an isolated nucleic acid wherein said isolated nucleic acid detects the expression level of a gene wherein said gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 41; SEQ ID NO: 328; SEQ ID NO:668; SEQ ID NO:855; SEQ ID NO:981; SEQ ID NO:1001; SEQ ID NO:1003; SEQ ID NO:1025; SEQ ID NO:1035; SEQ ID NO:1227; SEQ ID NO:1341; SEQ ID NO:1390; SEQ ID NO:1436; SEQ ID NO:1535; SEQ ID NO:1750; SEQ ID NO:2102; SEQ ID NO:2331; SEQ ID NO:2386; SEQ ID NO:2412; SEQ ID NO:2560; SEQ ID NO:2648; SEQ ID NO:2895, SEQ ID NO:3249; SEQ ID NO:3305; SEQ ID NO:3541;SEQ ID NO:3692; SEQ ID NO:3701; SEQ ID NO:3741; SEQ ID NO:3825; SEQ ID NO:3827; SEQ ID NO:3832; SEQ ID NO:4149; SEQ ID NO:4400; SEQ ID NO:4601; SEQ ID NO:4604; SEQ ID NO:4631; SEQ ID NO:4637; SEQ ID NO:5067; SEQ ID NO:5074; SEQ ID NO:5468; SEQ ID NO:5531; SEQ ID NO:5607; SEQ ID NO:6382; SEQ ID NO:6956; SEQ ID NO:7238; SEQ ID NO:7330; SEQ ID NO:7641; SEQ ID NO:8015 and SEQ ID NO:8095.
 15. The kit of claim 14 wherein said chronic inflammatory disease is systemic lupus erythematosis (SLE).
 16. The system of claim 14 wherein the nucleic acid is synthetic DNA, genomic DNA, RNA, PNA or cDNA.
 17. The system of claim 14 wherein the isolated DNA molecule is immobilized on an array.
 18. The system of claim 17 wherein the array is selected from the group consisting of a chip array, a plate array, a bead array, a pin array, a membrane array, a solid surface array, a liquid array, an oligonucleotide array, polynucleotide array or a cDNA array, a microtiter plate, a membrane and a chip.
 19. The system of claim 14 wherein and said isolated nucleic acid is at least 14 nucleotides in length. 